|
(11) | EP 4 682 145 A1 |
| (12) | EUROPEAN PATENT APPLICATION |
| published in accordance with Art. 153(4) EPC |
|
|
|
|
|||||||||||||||||||||||||||
| (54) | BENZOHETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF |
| (57) Disclosed in the present invention are a benzoheterocyclic compound, and a preparation
method therefor and the use thereof. The compound has the general formula of formula
I. The compound of the present invention has a good GPR40 agonistic activity and has
good drug development prospects.
|
[0001] The present application claims the right of the priorities of Chinese patent application 2023102432757 filed on March 14, 2023 and Chinese patent application 2024102637408 filed on March 7, 2024. The contents of the above Chinese patent applications are incorporated herein by reference in their entireties.
TECHNICAL FIELD
[0002] The present disclosure relates to a benzoheterocyclic compound, a preparation method therefor, and a use thereof.
BACKGROUND
[0003] GPR40 is a member of the GPCR family, also known as the FFA1 receptor, and is a class A G protein-coupled receptor. It can be activated by endogenous medium- and long-chain fatty acids (such as capric acid, palmitic acid, oleic acid, and docosahexaenoic acid) in vivo. GPR40 is predominantly expressed at high levels in pancreatic β-cells, intestinal endocrine cells, and the brain, while also being expressed in tissues such as the gastrointestinal tract, liver, heart, skeletal muscle, and taste buds. When activated by its endogenous ligand, GPR40 induces insulin secretion only at higher blood glucose levels (activation of GPR40 promotes Ca2+ influx in pancreatic β-cells, leading to insulin secretion), thereby eliminating the risk of hypoglycemia. Partial agonists of GPR40 activate the Gq/IP3 pathway to promote insulin secretion; full agonists additionally activate the Gs/cAMP pathway, stimulating the release of GLP-1 and GIP, thereby achieving a more potent glucose-lowering effect. These make GPR40 an important therapeutic target for diseases such as diabetes, obesity, cardiovascular disease, and dyslipidemia. The distribution of GPR40 in the brain may be related to pain regulation, neuroprotection, behavior regulation, and the like, and is a potential target for treating nervous system diseases.
[0004] Given the importance of GPR40, the development of drugs that can activate GPR40 is of great significance.
SUMMARY
[0005] The technical problem to be solved by the present disclosure is to overcome the limited types of drugs with GPR40 agonistic activity in the prior art. To this end, the present disclosure provides a benzoheterocyclic compound, a preparation method therefor, and a use thereof. The compounds of the present disclosure have good GPR40 agonistic activity, and further have the advantages of good pharmacokinetics and low toxicity.
[0006] The present disclosure solves the above technical problem through the following technical solutions.
[0007] The present disclosure provides a compound of formula I or a pharmaceutically acceptable salt thereof:
wherein X is O or NR3, R3 is H or C1-C6 alkyl; Q is C or N;
Z and Y are independently C or N;
G1 is H, C1-C6 alkyl, C1-C6 alkyl substituted by one or more G1-1, C6-C14 aryl, C6-C14 aryl substituted by one or more G1-2, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryl substituted by one or more G1-3, C1-C6 alkoxy, C1-C6 alkoxy substituted by one or more G1-4, C2-C6 alkenyl, C2-C6 alkenyl substituted by one or more G1-5, C2-C6 alkynyl, C2-C6 alkynyl substituted by one or more G1-6, C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by one or more G1-7, C3-C8 cycloalkenyl, C3-C8 cycloalkenyl substituted by one or more G1-8, 3- to 8-membered heterocycloalkyl, 3- to 8-membered heterocycloalkyl substituted by one or more G1-9, 3- to 8-membered heterocycloalkenyl, or 3- to 8-membered heterocycloalkenyl substituted by one or more G1-10;
the 5- to 10-membered heteroaryl, the 5- to 10-membered heteroaryl substituted by one or more G1-3, the 3- to 8-membered heterocycloalkyl, the 3- to 8-membered heterocycloalkyl substituted by one or more G1-9, the 3- to 8-membered heterocycloalkenyl, and the 3- to 8-membered heterocycloalkenyl substituted by one or more G1-10 have 1, 2, 3, or 4 heteroatoms selected from one or more types of N, S, and O;
each G1-1, each G1-2, each G1-3, each G1-4, each G1-5, each G1-6, each G1-7 , each G1-8, each G1-9, and each G1-10 is independently deuterium, halogen, cyano, -NG1-1-1G1-1-2, -NC(=O)G1-1-3G1-1-4, hydroxyl, -S(=O)2-C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkyl substituted by one or more G1-1-5, C1-C6 alkoxy, C1-C6 alkoxy substituted by one or more G1-1-6, -S-C1-C6 alkyl, -S-C1-C6 alkyl substituted by one or more G1-1-7, C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by one or more G1-1-8, -O-C3-C8 cycloalkyl, -O-C3-C8 cycloalkyl substituted by one or more G1-1-9, or -C(=O)NG1-1-11G1-1-12;
alternatively, any two adjacent G1-2, together with the carbon atom to which they are attached, form a 3- to 8-membered heterocycloalkyl, a 3- to 8-membered heterocycloalkyl substituted by one or more G1-1-9, a C3-C8 cycloalkyl, or a C3-C8 cycloalkyl substituted by one or more G1-1-10;
G1-1-1, G1-1-2, G1-1-3, G1-1-4, G1-1-11, and G1-1-12 are independently H, C1-C6 alkyl, C3-C8 cycloalkyl, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryl substituted by one or more 01-1-10-1, C6-C14 aryl, or C6-C14 aryl substituted by one or more G1-1-10-2;
each G1-1-10-1 and each G1-1-10-2 is independently C1-C6 alkyl;
each G1-1-5, each G1-1-6, each G1-1-7, each G1-1-8, each G1-1-9, and each G1-1-10 is independently halogen, oxo, C1-C6 alkyl, C3-C8 cycloalkyl, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl substituted by one or more C1-C6 alkyl groups;
the 3- to 8-membered heterocycloalkyl, the 3- to 8-membered heterocycloalkyl substituted by one or more G1-1-9, the 5- to 10-membered heteroaryl, the 5- to 10-membered heteroaryl substituted by one or more G1-1-10-1, and the 5- to 10-membered heteroaryl substituted by one or more C1-C6 alkyl groups have 1, 2, 3, or 4 heteroatoms independently selected from one or more types of N, S, and O;
L1 is a bond or C1-C6 alkylene;
ring A is C4-C6 cycloalkyl, C4-C6 cycloalkyl substituted by one or more A1, C4-C6 cycloalkenyl, C4-C6 cycloalkenyl substituted by one or more A2, 4- to 8-membered heterocycloalkyl, 4- to 8-membered heterocycloalkyl substituted by one or more A3, 4-to 6-membered heterocycloalkenyl, or 4- to 6-membered heterocycloalkenyl substituted by one or more A4;
the 4- to 8-membered heterocycloalkyl, the 4- to 8-membered heterocycloalkyl substituted by one or more A3, the 4- to 6-membered heterocycloalkenyl, and the 4- to 6-membered heterocycloalkenyl substituted by one or more A4 have 1 or 2 heteroatoms independently selected from one or more types of N, S, and O;
each A1, each A2, each A3, and each A4 is independently deuterium, halogen, cyano, -NA1-1A1-2, -NC(=O)A1-3A1-4, hydroxyl, C1-C6 alkyl, C1-C6 alkyl substituted by one or more A1-5, C1-C6 alkoxy, or C1-C6 alkoxy substituted by one or more A1-6;
A1-1, A1-2, A1-3, and A1-4 are independently deuterium, halogen, cyano, C1-C6 alkyl, or C1-C6 alkoxy;
each A1-5 and each A1-6 is independently hydrogen, deuterium, halogen, cyano, C1-C6 alkyl, or C1-C6 alkoxy;
R1 is -C(=O)NR1-1R1-2, C1-C6 alkyl, C1-C6 alkyl substituted by one or more R1-3 C2-C6 alkenyl, C2-C6 alkenyl substituted by one or more R1-10, -C(=O)R1-11, or ring B;
R1-1, R1-2, and R1-11 are independently H, -S(=O)2C1-C12 alkyl, C1-C12 alkyl, C1-C12 alkyl substituted by one or more R1-1-1, C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-1-2, C6-C14 aryl, C6-C14 aryl substituted by one or more R1-1-3, 5- to 14-membered heteroaryl, or 5- to 14-membered heteroaryl substituted by one or more R1-1-4,
alternatively, R1-1 and R1-2, together with the N atom to which they are attached, form a 3- to 14-membered heterocycloalkyl or a 3- to 14-membered heterocycloalkyl substituted by one or more R1-1-5 (wherein the heterocycloalkyl contains at least one N atom);
each R1-1-1, each R1-1-2, each R1-1-3, R1-1-4, and each R1-1-5 is independently halogen, cyano, nitro, hydroxyl, amino, -NH(C1-C12 alkyl), -N(C1-C12 alkyl)2, -C(=O)-C1-C12 alkyl, -NHC(=O)-C1-C12 alkyl, C1-C12 alkyl, C1-C12 alkyl substituted by one or more R1-1-1-1, C1-C12 alkoxy, C1-C12 alkoxy substituted by one or more R1-1-1-2, C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-1-1-3, C6-C14 aryl, 3- to 12-membered heterocycloalkyl, or 5- to 14-membered heteroaryl;
each R1-1-1-1, each R1-1-1-2, and each R1-1-1-3 is independently halogen, C1-C12 alkyl, C3-C12 cycloalkyl, or C1-C12 alkoxy;
each R1-3 and each R1-10 is independently deuterium, halogen, cyano, hydroxyl, - NR1-3-1R1-3-2, -C(=O)NR1-3-3R1-3-4, -C(=O)R1-3-5, -S(=O)2-C1-C12 alkyl, -S-C1-C12 alkyl, C1-C12 alkyl, C1-C12 alkyl substituted by one or more R1-3-6, C1-C12 alkoxy, C1-C12 alkoxy substituted by one or more R1-3-7, 5- to 14-membered heteroaryl, 5- to 14-membered heteroaryl substituted by one or more R1-3-8, C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-3-9, C2-C6 alkenyl, C2-C6 alkenyl substituted by one or more R1-3-10, C6-C14 aryl, C6-C14 aryl substituted by one or more R1-3-11, -O-C6-C14 aryl, -O-C(=O)C6-C14 aryl, -O-5- to 14-membered heteroaryl, C3-C8 cycloalkenyl, C3-C8 cycloalkenyl substituted by one or more R1-3-12, 3- to 12-membered heterocycloalkyl, or 3- to 12-membered heterocycloalkyl substituted by one or more R1-3-13;
R1-3-1, R1-3-2, R1-3-3, and R1-3-4 are independently H, hydroxyl, C1-C6 alkyl, -C1-C6 alkyl-C6-C14 aryl, C1-C6 alkoxy, -C(=O)R1-3-1-1, C3-C8 cycloalkyl, C6-C14 aryl, or C6-C14 aryl substituted by one or more R1-3-1-4
alternatively, R1-3-1 and R1-3-2, together with the N atom to which they are attached, form a 3- to 8-membered heterocycloalkyl or a 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-1-2,
alternatively, R1-3-3 and R1-3-4, together with the N atom to which they are attached, form a 3- to 8-membered heterocycloalkyl or a 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-3-1,
each R1-3-1-1, each R1-3-1-2, each R1-3-1-4, and each R1-3-3-1 is independently halogen or C1-C6 alkyl;
R1-3-5 is independently H, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, or C3-C8 cycloalkyl;
each R1-3-6, each R1-3-7, each R1-3-9, each R1-3-10, each R1-3-12, and each R1-3-13 is independently halogen, hydroxyl, carboxyl, cyano, -C(=O)-O-C1-C6 alkyl, -C(=O)-N(C1-C6 alkyl)2, -C(=O)-N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C2-C6 alkenyl, C6-C14 aryl, C6-C14 aryl substituted by one or more C1-C6 alkyl groups, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl substituted by one or more C1-C6 alkyl groups;
each R1-3-8 and each R1-3-11 is independently halogen, hydroxyl, carboxyl, cyano, -C(=O)-O-C1-C6 alkyl, -C(=O)-N(C1-C6 alkyl)2, -C(=O)-N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, or C2-C6 alkenyl;
the 5- to 14-membered heteroaryl, the 5- to 14-membered heteroaryl substituted by one or more R1-1-4, the 3- to 14-membered heterocycloalkyl, the 3- to 14-membered heterocycloalkyl substituted by one or more R1-1-5, the 3- to 12-membered heterocycloalkyl, the 3- to 8-membered heterocycloalkyl, the 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-1-2, the 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-3-1, the 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-3-1, and the 5- to 10-membered heteroaryl substituted by one or more C1-C6 alkyl groups have 1, 2, 3, or 4 heteroatoms independently selected from one or more types of N, S, and O;
ring B is C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-4, C3-C12 cycloalkenyl, C3-C12 cycloalkenyl substituted by one or more R1-5, 3- to 12-membered heterocycloalkyl, 3- to 12-membered heterocycloalkyl substituted by one or more R1-6, 3- to 12-membered heterocycloalkenyl, 3- to 12-membered heterocycloalkenyl substituted by one or more R1-7, C6-C14 aryl, C6-C14 aryl substituted by one or more R1-8 5- to 14-membered heteroaryl, or 5- to 14-membered heteroaryl substituted by one or more R1-9;
each R1-4, each R1-5, each R1-6, each R1-7, each R1-8, and each R1-9 is independently deuterium, halogen, cyano, hydroxyl, -NR1-3-1aR1-3-2a, -C(=O)NR1-3-3aR1-3-4a, -C(=O)R1-3-5a, -S(=O)2-C1-C12 alkyl, -S-C1-C12 alkyl, C1-C12 alkyl, C1-C12 alkyl substituted by one or more R1-3-6a, C1-C12 alkoxy, C1-C12 alkoxy substituted by one or more R1-3-7a, 5- to 14-membered heteroaryl, 5- to 14-membered heteroaryl substituted by one or more R1-3-8a, C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-3-9a, C2-C6 alkenyl, C2-C6 alkenyl substituted by one or more R1-3-10a, C6-C14 aryl, C6-C14 aryl substituted by one or more R1-3-11a, -O-C6-C14 aryl, -O-C(=O)C6-C14 aryl, -O-5- to 10-membered heteroaryl, C3-C8 cycloalkenyl, C3-C8 cycloalkenyl substituted by one or more R1-3-12a, 3-to 12-membered heterocycloalkyl, or 3- to 12-membered heterocycloalkyl substituted by one or more R1-3-13a;
alternatively, any two adjacent R1-8, together with the carbon atom to which they are attached, form a 3- to 8-membered heterocycloalkyl, a 3- to 8-membered heterocycloalkyl substituted by one or more R1-8-1, or a C3-C14 cycloalkyl;
R1-3-1a, R1-3-2a, R1-3-3a, and R1-3-4a are independently H, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, -C(=O)R1-3-1-1a, or C3-C8 cycloalkyl,
alternatively, R1-3-1a and R1-3-2a, together with the N atom to which they are attached, form a 3- to 8-membered heterocycloalkyl or a 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-1-2a,
alternatively, R1-3-3a and R1-3-4a, together with the N atom to which they are attached, form a 3- to 8-membered heterocycloalkyl or a 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-3-1a,
each R1-3-1-1a, each R1-3-1-2a, and each R1-3-3-1a is independently halogen or C1-C6 alkyl;
R1-3-5a is independently H, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or 3- to 8-membered heterocycloalkyl;
each R1-3-6a, each R1-3-7a, each R1-3-8a, each R1-3-9a, each R1-3-10a, each R1-3-11a, each R1-3-12a, each R1-3-13a, and each R1-8-1 is independently halogen, hydroxyl, carboxyl, cyano, -C(=O)-O-C1-C6 alkyl, -C(=O)-NH-C1-C6 alkyl, -C(=O)-N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 3- to 12-membered heterocycloalkyl, C2-C6 alkenyl, or - O-C(=O)-C1-C6 alkyl-3- to 12-membered heterocycloalkyl;
the 3- to 8-membered heterocycloalkyl, the 3- to 12-membered heterocycloalkyl, the 3- to 12-membered heterocycloalkenyl, the 5- to 10-membered heteroaryl, the 5- to 14-membered heteroaryl, the 3- to 12-membered heterocycloalkyl substituted by one or more R1-6, the 3- to 12-membered heterocycloalkenyl substituted by one or more R1-7, the 5- to 14-membered heteroaryl substituted by one or more R1-9, the 5- to 14-membered heteroaryl substituted by one or more R1-3-8a, the 3- to 12-membered heterocycloalkyl substituted by one or more R1-3-13a, the 3- to 8-membered heterocycloalkyl substituted by one or more R1-8-1, the 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-1-2a, the 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-3-1a, the 3-to 8-membered heterocycloalkyl substituted by one or more R1-3-3-1a, the -O-5- to 10-membered heteroaryl, and the -O-C(=O)-C1-C6 alkyl-3- to 12-membered heterocycloalkyl have 1, 2, 3, or 4 heteroatoms independently selected from one or more types of N, S, and O;
R2 is hydrogen, deuterium, halogen, cyano, C1-C6 alkyl, or C1-C6 alkoxy;
L2 is a bond, C1-C6 alkylene, C1-C6 alkylene substituted by one or more L2-1, C3-C8 cycloalkylene, C3-C8 cycloalkylene substituted by one or more L2-2, -O-C1-C6 alkylene, -NH-C1-C6 alkylene, or -N(C1-C6 alkyl)-C1-C6 alkylene;
each L2-1 and each L2-2 is independently halogen, C1-C6 alkyl, C1-C6 alkyl substituted by one or more L2-1-1, C1-C6 alkoxy, C1-C6 alkoxy substituted by one or more L2-1-2, C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by one or more L2-1-3, C2-C6 alkynyl, or C2-C6 alkynyl substituted by one or more L2-1-4;
each L2-1-1, each L2-1-2, each L2-1-3, and each L2-1-4 is independently C3-C8 cycloalkyl or C3-C8 cycloalkyl substituted by one or more L2-1-1-1;
each L2-1-1-1 is independently halogen or C1-C6 alkyl;
G2 is H, -C(=O)G2-1, -C(=O)NG2-2G2-3, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryl substituted by one or more G2-4, -S(=O)2-OH, -P(=O)-(OH)2, - P(=O)-(OC1-C6 alkyl)(OH), 3- to 8-membered heterocycloalkenyl, or 3- to 8-membered heterocycloalkenyl substituted by one or more G2-5;
G2-1 is hydroxyl, C1-C6 alkyl, or -O-NH2;
G2-2 and G2-3 are independently H, -S(=O)2-C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkyl substituted by one or more G2-2-1, or -NH(=O)-5- to 10-membered heteroaryl;
each G2-2-1 is independently carboxyl or -S(=O)2OH;
each G2-4 and each G2-5 is independently hydroxyl or oxo;
the 5- to 10-membered heteroaryl, the 5- to 10-membered heteroaryl substituted by one or more G2-4, the 3- to 8-membered heterocycloalkenyl, the 3- to 8-membered heterocycloalkenyl substituted by one or more G2-5, and the -NH(=O)-5- to 10-membered heteroaryl have 1, 2, 3, or 4 heteroatoms independently selected from one or more types of N, S, and O.
the above heteroaryl, heterocycloalkenyl, and heterocycloalkyl may have 1, 2, 3, or 4 heteroatoms independently selected from one or more types of N, S, and O.
The definitions of some groups in the compound of formula I or the pharmaceutically acceptable salt thereof are as described below, while the definitions of the remaining groups are as described in any other embodiment.
[0008] In one embodiment, the compound of formula I or the pharmaceutically acceptable salt thereof:
wherein X is O or NR3, and R3 is H or C1-C6 alkyl;
Z and Y are independently C or N;
G1 is H, C1-C6 alkyl, C1-C6 alkyl substituted by one or more G1-1, C6-C14 aryl, C6-C14 aryl substituted by one or more G1-2, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryl substituted by one or more G1-3, C1-C6 alkoxy, C1-C6 alkoxy substituted by one or more G1-4, C2-C6 alkenyl, C2-C6 alkenyl substituted by one or more G1-5, C2-C6 alkynyl, C2-C6 alkynyl substituted by one or more G1-6, C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by one or more G1-7, C3-C8 cycloalkenyl, C3-C8 cycloalkenyl substituted by one or more G1-8, 3- to 8-membered heterocycloalkyl, 3- to 8-membered heterocycloalkyl substituted by one or more G1-9, 3- to 8-membered heterocycloalkenyl, or 3- to 8-membered heterocycloalkenyl substituted by one or more G1-10;
each G1-1, each G1-2, each G1-3, each G1-4, each G1-5, each G1-6, each G1-7, each G1-8, each G1-9, and each G1-10 is independently deuterium, halogen, cyano, -NG1-1-1G1-1-2, -NC(=O)G1-1-3G1-1-4, hydroxyl, -S(=O)2-C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkyl substituted by one or more G1-1-5, C1-C6 alkoxy, C1-C6 alkoxy substituted by one or more G1-1-6, -S-C1-C6 alkyl, -S-C1-C6 alkyl substituted by one or more G1-1-7, C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by one or more G1-1-8, -O-C3-C8 cycloalkyl, -O-C3-C8 cycloalkyl substituted by one or more G1-1-9, or -C(=O)NG1-1-11G1-1-12;
alternatively, any two adjacent G1-2, together with the carbon atom to which they are attached, form a 3- to 8-membered heterocycloalkyl, a 3- to 8-membered heterocycloalkyl substituted by one or more G1-1-9, a C3-C8 cycloalkyl, or a C3-C8 cycloalkyl substituted by one or more G1-1-10;
G1-1-1, G1-1-2, G1-1-3, G1-1-4, G1-1-11, and G1-1-12 are independently H, C1-C6 alkyl, C3-C8 cycloalkyl, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl substituted by one or more G1-1-10-1;
each G1-1-10-1 is independently C1-C6 alkyl;
each G1-1-5, each G1-1-6, each G1-1-7, each G1-1-8, each G1-1-9, and each G1-1-10 is independently halogen, oxo, C1-C6 alkyl, or C3-C8 cycloalkyl;
L1 is a bond or C1-C6 alkylene;
ring A is C4-C6 cycloalkyl, C4-C6 cycloalkyl substituted by one or more A1, C4-C6 cycloalkenyl, C4-C6 cycloalkenyl substituted by one or more A2, 4- to 6-membered heterocycloalkyl, 4- to 6-membered heterocycloalkyl substituted by one or more A1, 4-to 6-membered heterocycloalkenyl, or 4- to 6-membered heterocycloalkenyl substituted by one or more A4; the 4- to 6-membered heterocycloalkyl, the 4- to 6-membered heterocycloalkyl substituted by one or more A1, the 4- to 6-membered heterocycloalkenyl, and the 4- to 6-membered heterocycloalkenyl substituted by one or more A4 have 1 or 2 heteroatoms independently selected from one or more types of N, S, and O;
each A1, each A2, each A3, and each A4 is independently deuterium, halogen, cyano, -NA1-1A1-2, -NC(=O)A1-3A1-4, hydroxyl, C1-C6 alkyl, C1-C6 alkyl substituted by one or more A1-5, C1-C6 alkoxy, or C1-C6 alkoxy substituted by one or more A1-6;
A1-1, A1-2, A1-3, and A1-4 are independently deuterium, halogen, cyano, C1-C6 alkyl, or C1-C6 alkoxy;
each A1-5 and each A1-6 is independently hydrogen, deuterium, halogen, cyano, C1-C6 alkyl, or C1-C6 alkoxy;
R1 is -C(=O)NR1-1R1-2, C1-C6 alkyl substituted by one or more R1-3, or ring B;
R1-1 and R1-2 are independently H, C1-C6 alkyl, C1-C6 alkyl substituted by one or more R1-1-1, C3-C10 cycloalkyl, C3-C10 cycloalkyl substituted by one or more R1-1-2, C6-C14 aryl, C6-C14 aryl substituted by one or more R1-1-3, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl substituted by one or more R1-1-4;
each R1-1-1, each R1-1-2, each R1-1-3, and R1-1-4 is independently halogen, C1-C6 alkyl, or C3-C8 cycloalkyl;
ring B is C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by one or more R1-4, C3-C8 cycloalkenyl, C3-C8 cycloalkenyl substituted by one or more R1-5, 3- to 8-membered heterocycloalkyl, 3- to 8-membered heterocycloalkyl substituted by one or more R1-6, 3-to 8-membered heterocycloalkenyl, 3- to 8-membered heterocycloalkenyl substituted by one or more R1-7, C6-C14 aryl, C6-C14 aryl substituted by one or more R1-8, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl substituted by one or more R1-9;
each R1-3, each R1-4, each R1-5, each R1-6, each R1-7, each R1-8, and each R1-9 is independently deuterium, halogen, cyano, hydroxyl, -NR1-3-1R1-3-2, -C(=O)NR1-3-3R1-3-4, -C(=O)R1-3-5, -S(-O)2-C1-C6 alkyl, -S-C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkyl substituted by one or more R1-3-6, C1-C6 alkoxy, C1-C6 alkoxy substituted by one or more R1-3-7, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryl substituted by one or more R1-3-8, C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by one or more R1-3-9, C2-C6 alkenyl, or C2-C6 alkenyl substituted by one or more R1-3-10;
alternatively, any two adjacent R1-8, together with the carbon atom to which they are attached, form a 3- to 8-membered heterocycloalkyl or a 3- to 8-membered heterocycloalkyl substituted by one or more R1-8-1;
R1-3-1, R1-3-2, R1-3-3, and R1-3-4 are independently H, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, -C(=O)R1-3-1-1, or C3-C8 cycloalkyl,
alternatively, R1-3-1 and R1-3-2, together with the N atom to which they are attached, form a 3- to 8-membered heterocycloalkyl or a 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-1-2,
alternatively, R1-3-3 and R1-3-4, together with the N atom to which they are attached, form a 3- to 8-membered heterocycloalkyl or a 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-3-1,
R1-3-1-1 and each R1-3-1-1 is independently C1-C6 alkyl or 5- to 10-membered heteroaryl;
R1-3-5 is independently H, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, or C3-C8 cycloalkyl;
each R1-3-6, each R1-3-7, each R1-3-8, each R1-3-9, and each R1-3-10 is independently halogen, hydroxyl, carboxyl, -C(=O)-O-C1-C6 alkyl, -C(=O)-NH-C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or 3- to 8-membered heterocycloalkyl;
R2 is hydrogen, deuterium, halogen, cyano, C1-C6 alkyl, or C1-C6 alkoxy;
L2 is C1-C6 alkylene, C1-C6 alkylene substituted by one or more L2-1, C3-C8 cycloalkylene, or C3-C8 cycloalkylene substituted by one or more L2-2;
each L2-1 and each L2-2 is independently halogen, C1-C6 alkyl, C1-C6 alkyl substituted by one or more L2-1-1, C1-C6 alkoxy, C1-C6 alkoxy substituted by one or more L2-1-2, C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by one or more L2-1-3, C2-C6 alkynyl, or C2-C6 alkynyl substituted by one or more L2-1-4;
each L2-1-1, each L2-1-2, each L2-1-3, and each L2-1-4 is independently C3-C8 cycloalkyl or C3-C8 cycloalkyl substituted by one or more L2-1-1-1;
G2 is -C(=O)G2-1, -C(=O)NG2-2G2-3, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl substituted by one or more G2-4;
G2-1 is hydroxyl, C1-C6 alkyl, or -O-NH2;
G2-2 and G2-3 are independently H, -S(=O)2-C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkyl, or C1-C6 alkyl substituted by one or more G2-2-1;
each G2-2-1 is independently carboxyl or -S(=O)2OH;
each 5- to 10-membered heteroaryl, each 3- to 8-membered heterocycloalkenyl, and each 3- to 8-membered heterocycloalkyl has 1, 2, 3, or 4 heteroatoms independently selected from one or more types of N, S, and O.
In one embodiment, in R3 and G1, the "C1-C6 alkyl" in the C1-C6 alkyl and the C1-C6 alkyl substituted by one or more G1-1 may independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as methyl.
In one embodiment, in G1, the "C6-C14 aryl" in the C6-C14 aryl and the C6-C14 aryl substituted by one or more G1-2 may independently be phenyl or naphthyl.
[0009] In one embodiment, in G1, the "5- to 10-membered heteroaryl" in the 5- to 10-membered heteroaryl and the 5- to 10-membered heteroaryl substituted by one or more G1-3 may independently be 5-, 6-, 9-, or 10-membered monocyclic or bicyclic heteroaryl with 1 or 2 heteroatoms independently selected from one or more types of N, S, and O, and may further be pyridyl (
), thiazolyl (
), furanophenyl (
), or oxazolophenyl (
).
[0010] In one embodiment, in each G1-1, each G1-2, each G1-3, each G1-4, each G1-5, each G1-6, each G1-7 , each G1-8, each G1-9, each G1-10 , and each G1-11, the halogen may independently be fluorine, chlorine, or bromine, such as fluorine or chlorine.
[0011] In one embodiment, in each G1-1, each G1-2, each G1-3, each G1-4, each G1-5, each G1-6, each G1-7, each G1-8, each G1-9, and each G1-10, the "C1-C6 alkyl" in the -S(=O)2-C1-C6 alkyl, the C1-C6 alkyl, the C1-C6 alkyl substituted by one or more G1-1-5, the -S-C1-C6 alkyl, and the -S-C1-C6 alkyl substituted by one or more G1-1-7 may independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as methyl or ethyl.
[0012] In one embodiment, in each G1-1, each G1-2, each G1-3, each G1-4, each G1-5, each G1-6, each G1-7, each G1-8, each G1-9, and each G1-10, the "C1-C6 alkoxy" in the C1-C6 alkoxy and the C1-C6 alkoxy substituted by one or more G1-1-6 may independently be methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, or tert-butoxy, such as methoxy or ethoxy.
[0013] In one embodiment, in each G1-1, each G1-2, each G1-3, each G1-4, each G1-5, each G1-6, each G1-7, each G1-8, each G1-9, and each G1-10, the "C3-C8 cycloalkyl" in the C3-C8 cycloalkyl, the C3-C8 cycloalkyl substituted by one or more G1-1-8, the -O-C3-C8 cycloalkyl, and the -O-C3-C8 cycloalkyl substituted by one or more G1-9 may independently be cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, such as cyclopropyl.
[0014] In one embodiment, the "3- to 8-membered heterocycloalkyl" formed by any two adjacent G1-2 together with the carbon atom to which they are attached and the "3- to 8-membered heterocycloalkyl" in the 3- to 8-membered heterocycloalkyl substituted by one or more G1-1-9 may independently be 5- to 6-membered heterocycloalkyl with 1 or 2 heteroatoms independently being N and/or O, such as
where
indicates that the group forms a fused ring with the C6-C14 aryl through this bond.
[0015] In one embodiment, the "C3-C8 cycloalkyl" formed by any two adjacent G1-2 together with the carbon atom to which they are attached and the "C3-C8 cycloalkyl" in the C3-C8 cycloalkyl substituted by one or more G1-1-10 may independently be C3-C6 cycloalkyl, such as
where
indicates that the group forms a fused ring with the C6-C14 aryl through this bond.
[0016] In one embodiment, in G1-1-1, G1-1-2, G1-1-3, G1-1-4, G1-1-11, and G1-1-12, the C1-C6 alkyl may independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, or n-hexyl, such as methyl, tert-butyl, or n-hexyl.
[0017] In one embodiment, in G1-1-1, G1-1-2, G1-1-3, G1-1-4, G1-1-11, and G1-1-12, the C3-C8 cycloalkyl may independently be cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
[0018] In one embodiment, in G1-1-1, G1-1-2, G1-1-3, G1-1-4, G1-1-11, and G1-1-12, the "5- to 10-membered heteroaryl" in the 5- to 10-membered heteroaryl and the 5- to 10-membered heteroaryl substituted by one or more G1-1-10-1 may independently be 5- to 6-membered heteroaryl with 1 or 2 heteroatoms being N, such as pyridyl.
[0019] In one embodiment, in each G1-1-10-1 and each G1-1-10-2, the "C1-C6 alkyl" in the C1-C6 alkyl may independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as methyl.
[0020] In one embodiment, in each G1-1-5, each G1-1-6, each G1-1-7, each G1-1-8, each G1-1-9, and each G1-1-10, the halogen may independently be fluorine, chlorine, or bromine, such as fluorine.
[0021] In one embodiment, in each G1-1-5, each G1-1-6, each G1-1-7, each G1-1-8, each G1-1-9, and each G1-1-10, the C3-C8 cycloalkyl may independently be cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, such as cyclopropyl.
[0022] In one embodiment, in each G1-1-5, each G1-1-6, each G1-1-7, each G1-1-8, each G1-1-9, and each G1-1-10, the "5- to 10-membered heteroaryl" in the 5- to 10-membered heteroaryl and the 5- to 10-membered heteroaryl substituted by one or more C1-C6 alkyl groups may be 5-, 6-, 9-, or 10-membered monocyclic or bicyclic heteroaryl with 1, 2, or 3 heteroatoms being N, such as triazolyl (e.g.,
).
[0023] In one embodiment, in G1, the "C1-C6 alkyl" in the C1-C6 alkyl substituted by one or more G1-1 may be
[0024] In one embodiment, in G1, the C6-C14 aryl substituted by one or more G1-2 may be phenyl substituted by 1 or 2 G1-2, or may be any one of the following groups:
such as
[0025] In one embodiment, in G1, the 5- to 10-membered heteroaryl substituted by one or more G1-3 may be 5- to 6-membered monocyclic heterocycloalkyl substituted by 1 or 2 G1-3, and may further be
[0026] In one embodiment, in L1, the C1-C6 alkylene may be methylene, ethylene (
), or propylene (
), such as methylene.
[0027] In one embodiment, in ring A, the "C4-C6 cycloalkyl" in the C4-C6 cycloalkyl and the C4-C6 cycloalkyl substituted by one or more A1 is independently cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, such as cyclohexyl (
where the left end is connected to L1).
[0028] In one embodiment, in ring A, the "C4-C6 cycloalkenyl" in the C4-C6 cycloalkenyl and the C4-C6 cycloalkenyl substituted by one or more A2 may be cyclohexenyl containing one double bond, such as
where the left end is connected to L.
[0029] In one embodiment, in ring A, the "4- to 8-membered heterocycloalkyl" in the 4-to 8-membered heterocycloalkyl and the 4- to 8-membered heterocycloalkyl substituted by one or more A3 may independently be 4- to 6-membered heterocycloalkyl (e.g., monocyclic) with 1 or 2 heteroatoms being N or 7- to 8-membered bridged heterocycloalkyl with 1 or 2 heteroatoms being N; the 4- to 6-membered heterocycloalkyl may be azetidinyl, pyrrolidinyl, or piperidinyl, such as
or
the 7- to 8-membered bridged heterocycloalkyl may be azabicyclo[3.2.1]octanyl, such as
where the left end is connected to L1 via N, and the right end is connected to
via C.
[0030] In one embodiment, in ring A, the "4- to 6-membered heterocycloalkenyl" in the 4- to 6-membered heterocycloalkenyl and the 4- to 6-membered heterocycloalkenyl substituted by one or more A4 is independently 6-membered heterocycloalkenyl with 1 heteroatom being N, containing 1 double bond.
[0031] In one embodiment, in each A1, each A2, each A3, and each A4, the halogen may independently be fluorine, chlorine, or bromine, such as fluorine.
[0032] In one embodiment, in each A1, each A2, each A3, and each A4, the "C1-C6 alkyl" in the C1-C6 alkyl and the C1-C6 alkyl substituted by one or more A1-5 may independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as methyl.
[0033] In one embodiment, in ring A, the 4- to 8-membered heterocycloalkyl substituted by one or more A3 may be 4- to 6-membered heterocycloalkyl substituted by one or more A1 or 7- to 8-membered bridged heterocycloalkyl substituted by one or more A1; the 4-to 6-membered heterocycloalkyl substituted by one or more A1 may be
or
the 7- to 8-membered bridged heterocycloalkyl substituted by one or more A1 or
[0034] In one embodiment, in R1, the "C1-C6 alkyl" in the C1-C6 alkyl and the C1-C6 alkyl substituted by one or more R1-3 may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl,
[0035] In one embodiment, in R1, the "C2-C6 alkenyl" in the C2-C6 alkenyl and the C2-C6 alkenyl substituted by one or more R1-10 may be vinyl, propenyl (
), pentenyl (
), or hexenyl (
).
[0036] In one embodiment, in R1-1, R1-2, and R1-11, the "C1-C12 alkyl" in the C1-C12 alkyl, the C1-C12 alkyl substituted by one or more R1-1-1, and the -S(=O)2C1-C12 alkyl may independently be C1-C6 alkyl or C7-C12 alkyl; the "C1-C6 alkyl" in the C1-C6 alkyl, the C1-C6 alkyl substituted by one or more R1-1-1, and the -S(=O)2C1-C6 alkyl may independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, see-butyl, tert-butyl, or
such as methyl, ethyl, or isopropyl.
[0037] In one embodiment, in R1-1, R1-2, and R1-11, the "C3-C12 cycloalkyl" in the C3-C12 cycloalkyl and the C3-C12 cycloalkyl substituted by one or more R1-1-2 may independently be C3-C10 cycloalkyl or C11-C12 cycloalkyl; the "C3-C10 cycloalkyl" in the C3-C10 cycloalkyl and the C3-C10 cycloalkyl substituted by one or more R1-1-2 may independently be C3-C6 monocyclic cycloalkyl, C5-C7 bridged cycloalkyl, or adamantyl, and may further be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentyl (
), bicyclo[2.2.1]heptyl (
), or adamantyl (
).
[0038] In one embodiment, R1-1 and R1-2, together with the N atom to which they are attached, form a 3- to 14-membered heterocycloalkyl, wherein the 3- to 14-membered heterocycloalkyl may be 4- to 6-membered monocyclic heterocycloalkyl with 1 or 2 heteroatoms being N or 6- to 14-membered bicyclic spirocycloalkyl with 1 or 2 heteroatoms being N, such as pyrrolidinyl or 2-azaspiro[3.3]heptyl.
[0039] In one embodiment, in R1-1, R1-2, and R1-11, the "C6-C14 aryl" in the C6-C14 aryl and the C6-C14 aryl substituted by one or more R1-1-3 may independently be phenyl or naphthyl.
[0040] In one embodiment, in R1-1, R1-2, and R1-11, the "5- to 14-membered heteroaryl" in the 5- to 14-membered heteroaryl and the 5- to 14-membered heteroaryl substituted by one or more G1-1-10-1 may independently be 5- to 10-membered heteroaryl or 11- to 14-membered heteroaryl, wherein the "5- to 10-membered heteroaryl" in the 5- to 10-membered heteroaryl and the 5- to 10-membered heteroaryl substituted by one or more G1-1-10-1 may independently be 5- to 6-membered heteroaryl (monocyclic) or 8- to 10-membered bicyclic heteroaryl (e.g., with 1 or 2 heteroatoms being N), and may further be thiazolyl (
), oxazolyl (
), imidazolyl (
), pyrazolyl (
), thiadiazolyl (
), triazolyl (
), tetrazolyl (
), pyridyl, benzo[d]isoxazolyl (
), or benzo[d]thiazolyl (
).
[0041] In one embodiment, in each R1-1-1, each R1-1-2, each R1-1-3, R1-1-4, and each R1-1-5, the halogen may independently be fluorine, chlorine, or bromine, such as fluorine.
[0042] In one embodiment, in each R1-1-1, each R1-1-2, each R1-1-3, R1-1-4, and each R1-1-5, the "C1-C12 alkyl" in the -NH(C1-C12 alkyl), the -N(C1-C12 alkyl)2, the -C(=O)-C1-C12 alkyl, the -NHC(=O)-C1-C12 alkyl, the C1-C12 alkyl, and the C1-C12 alkyl substituted by one or more R1-1-1-1 may independently be C1-C6 alkyl or C7-C12 alkyl; the C1-C6 alkyl may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as methyl.
[0043] In one embodiment, in each R1-1-1, each R1-1-2, each R1-1-3, R1-1-4, and each R1-1-5, the "C3-C12 cycloalkyl" in the C3-C12 cycloalkyl and the C3-C12 cycloalkyl substituted by one or more R1-1-1-3 may independently be C3-C8 cycloalkyl or C9-C10 cycloalkyl; the C3-C8 cycloalkyl may be cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, such as cyclopropyl.
[0044] In one embodiment, in each R1-1-1, each R1-1-2, each R1-1-3, R1-1-4, and each R1-1-5, the C6-C14 aryl may be phenyl or naphthyl.
[0045] In one embodiment, in each R1-1-1, each R1-1-2, each R1-1-3, R1-1-4, and each R1-1-5, the 3- to 12-membered heterocycloalkyl may be 3- to 6-membered heterocycloalkyl with 1 or 2 heteroatoms being N and/or O, and may further be piperidinyl (
) or morpholinyl (
).
[0046] In one embodiment, in R1-1, R1-2, and R1-11, the C1-C12 alkyl substituted by one or more R1-1-1 may be C1-C6 alkyl substituted by one or more R1-1-1, and may further be
such as
[0047] In one embodiment, in R1-1, R1-2, and R1-11, the C3-C12 cycloalkyl substituted by one or more R1-1-2 may be C3-C8 cycloalkyl substituted by one or more (e.g., 2 or 3) R1-1-2, or may further be
[0048] In one embodiment, in R1-1, R1-2, and R1-11, the C6-C14 aryl substituted by one or more R1-1-3 may be phenyl substituted by 1, 2, or 3 R1-1-3, and may further be
such as
[0049] In one embodiment, in R1-1, R1-2, and R1-11, the 5- to 14-membered heteroaryl substituted by one or more R1-1-4 may be 5- to 6-membered monocyclic heteroaryl substituted by 1 or 2 R1-1-3 or 9- to 10-membered fused heteroaryl substituted by 1 or 2 R1-1-3, and may further be
[0050] In one embodiment, in each R1-3 and each R1-10, the halogen may independently be fluorine, chlorine, or bromine, such as fluorine or chlorine.
[0051] In one embodiment, in each R1-3 and each R1-10, the "C1-C12 alkyl" in the -S(=O)2-C1-C12 alkyl, the -S-C1-C12 alkyl, the C1-C12 alkyl, and the C1-C12 alkyl substituted by one or more R1-3-6 may independently be C1-C6 alkyl or C7-C12 alkyl;
[0052] the "C1-C6 alkyl" in the -S(=O)2-C1-C6 alkyl, the -S-C1-C6 alkyl, the C1-C6 alkyl, and the C1-C6 alkyl substituted by one or more R1-3-6 may independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as isopropyl; the C7-C12 alkyl may be pentyl, hexyl, or heptyl.
[0053] In one embodiment, in each R1-3 and each R1-10, the "C1-C12 alkoxy" in the C1-C12 alkoxy and the C1-C12 alkoxy substituted by one or more R1-3-7 may independently be C1-C6 alkoxy; the "C1-C6 alkoxy" in the C1-C6 alkoxy and the C1-C6 alkoxy substituted by one or more R1-3-7 may independently be methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, or tert-butoxy.
[0054] In one embodiment, in each R1-3 and each R1-10, the "5- to 14-membered heteroaryl" in the 5- to 14-membered heteroaryl, the 5- to 14-membered heteroaryl substituted by one or more R1-3-8, and the -O-5- to 14-membered heteroaryl may independently be 5- to 10-membered heteroaryl; the "5- to 10-membered heteroaryl" in the 5- to 10-membered heteroaryl and the 5- to 10-membered heteroaryl substituted by one or more R1-3-8 may independently be 5- to 6-membered monocyclic heteroaryl with 1, 2, or 3 heteroatoms independently selected from one or two types of N, S, and O, such as 1H-pyrazolyl (
), pyridyl (
), or oxadiazolyl (
).
[0055] In one embodiment, in each R1-3 and each R1-10, the "C3-C12 cycloalkyl" in the C3-C12 cycloalkyl and the C3-C12 cycloalkyl substituted by one or more R1-3-9 may independently be C3-C8 cycloalkyl or C9-C12 cycloalkyl; the "C3-C8 cycloalkyl" in the C3-C8 cycloalkyl and the C3-C8 cycloalkyl substituted by one or more R1-3-9 may independently be cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, such as cyclopropyl or cyclobutyl; the C9-C12 cycloalkyl may be adamantyl.
[0056] In one embodiment, in each R1-3 and each R1-10, the "C2-C6 alkenyl" in the C2-C6 alkenyl and the C2-C6 alkenyl substituted by one or more R1-3-10 may independently be vinyl or propenyl, such as
[0057] In one embodiment, in each R1-3 and each R1-10, the "C6-C14 aryl" in the C6-C14 aryl, the C6-C14 aryl substituted by one or more R1-3-11, the -O-C6-C14 aryl, and the -O-C(=O)C6-C14 aryl is independently phenyl.
[0058] In one embodiment, in each R1-3 and each R1-10, the "C3-C8 cycloalkenyl" in the C3-C8 cycloalkenyl and the C3-C8 cycloalkenyl substituted by one or more R1-3-12 may be cyclopentenyl containing one double bond or cyclohexenyl containing one double bond.
[0059] In one embodiment, in each R1-3 and each R1-10, the "3- to 12-membered heterocycloalkyl" in the 3- to 12-membered heterocycloalkyl and the 3- to 12-membered heterocycloalkyl substituted by one or more R1-3-13 may be 3- to 6-membered monocyclic heterocycloalkyl with 1 or 2 heteroatoms being O, such as
[0060] In one embodiment, in R1-3-1, R1-3-2, R1-3-3, R1-3-4, R1-3-1a, R1-3-2a , R1-3-3a, and R1-3-4a, the C1-C6 alkyl may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl.
[0061] In one embodiment, in each R1-3 and each R1-10, the "C6-C14 aryl" in the C6-C14 aryl and the C6-C14 aryl substituted by one or more R1-3-1-4 is independently phenyl.
[0062] In one embodiment, in each R1-3-1-1, each R1-3-1-2, each R1-3-1-4, and each R1-3-3-1, the C1-C6 alkyl may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl.
[0063] In one embodiment, in R1-3-5, the C1-C6 alkyl may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl.
[0064] In one embodiment, in each R1-3-6, each R1-3-7, each R1-3-8, each R1-3-9, each R1-3-10, each R1-3-11, each R1-3-12, and each R1-3-13, the "C1-C6 alkyl" in the -C(=O)-O-C1-C6 alkyl, the -C(=O)-N(C1-C6 alkyl)2, the -C(=O)-N(C1-C6 alkyl)2, and the C1-C6 alkyl may independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl.
[0065] In one embodiment, in each R1-3-6, R1-3-7, R1-3-8, R1-3-9, R1-3-10, R1-3-11, R1-3-12, and R1-3-13, the C3-C8 cycloalkyl may be cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl.
[0066] In one embodiment, in each R1-3-6, each R1-3-7, each R1-3-8, each R1-3-9, each R1-3-10, each R1-3-11, each R1-3-12, and each R1-3-13, the "5- to 10-membered heteroaryl" in the 5- to 10-membered heteroaryl and the 5- to 10-membered heteroaryl substituted by one or more C1-C6 alkyl groups may be 5- to 6-membered heteroaryl with 1 or 2 heteroatoms selected from one or two types of N, S, and O, and may further be furanyl or thienyl.
[0067] In one embodiment, in R1, in -C(=O)NR1-1R1-2, one of R1-1 and R1-2 may be H or C1-C12 alkyl, and the other may be -S(=O)2C1-C12 alkyl, C1-C12 alkyl, C1-C12 alkyl substituted by one or more R1-1-1, C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-1-2, C6-C14 aryl, C6-C14 aryl substituted by one or more R1-1-3, 5- to 14-membered heteroaryl, or 5- to 14-membered heteroaryl substituted by one or more R1-1-4;
[0069] In one embodiment, in R1, the C1-C6 alkyl substituted by one or more R1-3 may be any one of the following groups:
.
[0072] In one embodiment, in ring B, the "C3-C12 cycloalkyl" in the C3-C12 cycloalkyl and the C3-C12 cycloalkyl substituted by one or more R1-4 may independently be C3-C8 cycloalkyl or C9-C12 cycloalkyl; the "C3-C8 cycloalkyl" in the C3-C8 cycloalkyl and the C3-C8 cycloalkyl substituted by one or more R1-4 may independently be cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, such as cyclohexyl.
[0073] In one embodiment, in ring B, the "C3-C12 cycloalkenyl" in the C3-C12 cycloalkenyl and the C3-C12 cycloalkenyl substituted by one or more R1-5 may independently be C3-C8 cycloalkenyl or C9-C12 cycloalkenyl; the "C3-C8 cycloalkenyl" in the C3-C8 cycloalkenyl and the C3-C8 cycloalkenyl substituted by one or more R1-5 may be cyclopropenyl containing one double bond, cyclobutenyl containing one double bond, cyclopentenyl containing one double bond, or cyclohexenyl containing one double bond, such as cyclopentenyl or cyclohexenyl.
[0074] In one embodiment, in ring B, the "3- to 12-membered heterocycloalkyl" in the 3- to 12-membered heterocycloalkyl and the 3- to 12-membered heterocycloalkyl substituted by one or more R1-6 may independently be 3- to 8-membered heterocycloalkyl or 9- to 12-membered heterocycloalkyl; the "3- to 8-membered heterocycloalkyl" in the 3- to 8-membered heterocycloalkyl and the 3- to 8-membered heterocycloalkyl substituted by one or more R1-6 may independently be 5- to 6-membered heterocycloalkyl with 1 or 2 heteroatoms independently being O and/or N, and the number is 1 or 2, such as piperidinyl, dioxolanyl, or dioxanyl.
[0075] In one embodiment, in ring B, the "3- to 12-membered heterocycloalkenyl" in the 3- to 12-membered heterocycloalkenyl and the 3- to 12-membered heterocycloalkenyl substituted by one or more R1-7 may independently be 3- to 8-membered heterocycloalkenyl or 9- to 12-membered heterocycloalkenyl; the "3- to 8-membered heterocycloalkenyl" in the 3- to 8-membered heterocycloalkenyl and the 3- to 8-membered heterocycloalkenyl substituted by one or more R1-7 may independently be 5-to 6-membered heterocycloalkenyl (e.g., monocyclic) with 1 or 2 heteroatoms independently being N and containing one double bond, such as 1,2,3,6-tetrahydropyridyl.
[0076] In one embodiment, in ring B, the "C6-C14 aryl" in the C6-C14 aryl and the C6-C14 aryl substituted by one or more R1-8 may independently be phenyl or naphthyl.
[0077] Preferably, when the "C6-C14 aryl" in the C6-C14 aryl substituted by one or more R1-8 is phenyl, then the number of R1-8 is 1, and the substitution position is at the ortho, meta, or para position of the phenyl, such as the para position.
[0078] In one embodiment, in ring B, the "5- to 14-membered heteroaryl" in the 5- to 14-membered heteroaryl and the 5- to 14-membered heteroaryl substituted by one or more R1-9 may independently be 5- to 10-membered heteroaryl or 11- to 14-membered heteroaryl; the "5- to 10-membered heteroaryl" in the the 5- to 10-membered heteroaryl and the 5- to 10-membered heteroaryl substituted by one or more R1-9 may independently be 5-, 6-, or 9-membered monocyclic or bicyclic heteroaryl with 1, 2, 3, or 4 heteroatoms selected from one or more types of N, S, and O, and may further be pyrrolyl, imidazolyl, 1H-pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, 1,3,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl, thienyl, thiazolyl, pyridyl, pyrimidinyl, indolyl, indazolyl, thiazolophenyl, or triazolopyridyl; or may further be 1H-pyrazolyl, 1,3,4-oxadiazolyl, thienyl, thiazolyl, pyridyl, pyrimidinyl, indolyl, indazolyl, thiazolophenyl, or triazolopyridyl.
[0079] In one embodiment, in each R1-4, each R1-5, each R1-6, each R1-7 , each R1-8, and each R1-9, the halogen may independently be fluorine, chlorine, or bromine, such as fluorine or chlorine.
[0080] In one embodiment, in each R1-4, each R1-5, each R1-6, each R1-7, each R1-8, and each R1-9, the "C1-C12 alkyl" in the -S(=O)2-C1-C12 alkyl, the -S-C1-C12 alkyl, the C1-C12 alkyl, and the C1-C12 alkyl substituted by one or more R1-3-6a may independently be C1-C6 alkyl or C7-C12 alkyl; the "C1-C6 alkyl" in the -S(=O)2-C1-C6 alkyl, the -S-C1-C6 alkyl, the C1-C6 alkyl, and the C1-C6 alkyl substituted by one or more R1-3-6a may independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as isopropyl; the C7-C12 alkyl may be pentyl, hexyl, or heptyl.
[0081] In one embodiment, in each R1-4, each R1-5, each R1-6, each R1-7, each R1-8, and each R1-9, the "C1-C12 alkoxy" in the C1-C12 alkoxy and the C1-C12 alkoxy substituted by one or more R1-3-7a may independently be C1-C6 alkoxy; the "C1-C6 alkoxy" in the C1-C6 alkoxy and the C1-C6 alkoxy substituted by one or more R1-3-7a may independently be methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, or tert-butoxy.
[0082] In one embodiment, in each R1-4, each R1-5, each R1-6, each R1-7, each R1-8, and each R1-9, the "5- to 14-membered heteroaryl" in the 5- to 14-membered heteroaryl and the 5- to 14-membered heteroaryl substituted by one or more R1-3-8a may independently be 5- to 10-membered heteroaryl; the "5- to 10-membered heteroaryl" in the 5- to 10-membered heteroaryl and the 5- to 10-membered heteroaryl substituted by one or more R1-3-8a may independently be 5- to 6-membered monocyclic heteroaryl with 1 or 2 heteroatoms independently being N, and may further be 1H-pyrazolyl or pyridyl.
[0083] In one embodiment, in each R1-4, each R1-5, each R1-6, each R1-7, each R1-8, and each R1-9, the "C3-C12 cycloalkyl" in the C3-C12 cycloalkyl and the C3-C12 cycloalkyl substituted by one or more R1-3-9a may independently be C3-C8 cycloalkyl or C9-C12 cycloalkyl; the "C3-C8 cycloalkyl" in the C3-C8 cycloalkyl and the C3-C8 cycloalkyl substituted by one or more R1-3-9a may independently be cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, such as cyclopropyl or cyclobutyl; the C9-C12 cycloalkyl may be adamantyl.
[0084] In one embodiment, in each R1-4, each R1-5, each R1-6, each R1-7, each R1-8, and each R1-9, the "C2-C6 alkenyl" in the C2-C6 alkenyl and the C2-C6 alkenyl substituted by one or more R1-3-10a may independently be vinyl or propenyl, such as
[0085] In one embodiment, the "3- to 8-membered heterocycloalkyl" formed by any two adjacent R1-8 together with the carbon atom to which they are attached and the "3- to 8-membered heterocycloalkyl" in the 3- to 8-membered heterocycloalkyl substituted by one or more R1-8-1 may independently be 5- to 6-membered heterocycloalkyl with 1 or 2 heteroatoms independently being N and/or O, such as
where
indicates that the group forms a fused ring with the C6-C14 aryl through this bond.
[0086] In one embodiment, the "C1-C14 cycloalkyl" formed by any two adjacent R1-8 together with the carbon atom to which they are attached may be C11-C14 tricyclic cycloalkyl, such as
where
indicates that the group forms a fused ring with the C6-C14 aryl through this bond.
[0087] In one embodiment, in R1-3-1a, R1-3-2a, R1-3-3a, R1-3-4a, and R1-3-5a, the C1-C6 alkyl may independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl,
[0088] In one embodiment, in R1-3-1a, R1-3-2a, R1-3-3a, R1-3-4a, and R1-3-5a, the C1-C6 alkoxy may independently be methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, or tert-butoxy.
[0089] In one embodiment, in R1-3-1a, R1-3-2a, R1-3-3a, R1-3-4a, and R1-3-5a, the C3-C8 cycloalkyl may independently be cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, such as cyclopropyl or cyclopentyl.
[0090] In one embodiment, the "3- to 8-membered heterocycloalkyl" formed by R1-3-1a and R1-3-2a together with the N atom to which they are attached and the "3- to 8-membered heterocycloalkyl" in the 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-1-2a may independently be 5- to 6-membered heterocycloalkyl with 1 or 2 heteroatoms independently being N, and may further be pyrrolidinyl.
[0091] In one embodiment, the "3- to 8-membered heterocycloalkyl" formed by R1-3-3a and R1-3-4a together with the N atom to which they are attached and the "3- to 8-membered heterocycloalkyl" in the 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-3-1a may independently be 5- to 6-membered heterocycloalkyl with 1 or 2 heteroatoms independently being N or 6- to 7-membered dispiro heterocycloalkyl with 1 or 2 heteroatoms independently being N, and may further be pyrrolidinyl or 2-azaspiro[3.3]heptyl.
[0092] In one embodiment, in each R1-3-1-1a, each R1-3-1-2a, and each R1-3-3-1a, the halogen may independently be fluorine, chlorine, or bromine, such as fluorine.
[0093] In one embodiment, in each R1-3-1-1a, each R1-3-1-2a, and each R1-3-3-1a, the C1-C6 alkyl may independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as methyl.
[0094] In one embodiment, in each R1-3-6a, each R1-3-7a, each R1-3-8a, each R1-3-9a, each R1-3-10a, each R1-3-11a, each R1-3-12a, and each R1-8-1, the "C1-C6 alkyl" in the C1-C6 alkyl, the -C(=O)-O-C1-C6 alkyl, the -C(=O)-NH-C1-C6 alkyl, and the -C(=O)-N(C1-C6 alkyl)2 may independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as methyl or tert-butyl.
[0095] In one embodiment, in each R1-3-6a, each R1-3-7a, each R1-3-8a, each R1-3-9a, each R1-3-10a, each R1-3-11a, each R1-3-12a, and each R1-8-1, the "3- to 12-membered heterocycloalkyl" in the 3- to 12-membered heterocycloalkyl and the -O-C(=O)-C1-C6 alkyl-3- to 12-membered heterocycloalkyl may independently be 5- to 6-membered monocyclic heterocycloalkyl with 1 or 2 heteroatoms being N, such as pyrrolidinyl.
[0096] In one embodiment, in ring B, the C3-C12 cycloalkyl substituted by one or more R1-4 may be C3-C8 cycloalkyl substituted by one or more R1-4, and may further be
[0097] In one embodiment, in ring B, the C3-C12 cycloalkenyl substituted by one or more R1-5 may be C3-C8 cycloalkenyl substituted by one or more R1-5, and may further be
[0098] In one embodiment, in ring B, the 3- to 12-membered heterocycloalkyl substituted by one or more R1-6 may be 3- to 8-membered heterocycloalkyl substituted by one or more R1-6, and may further be
[0099] In one embodiment, in ring B, the 3- to 12-membered heterocycloalkenyl substituted by one or more R1-7 may be 3- to 8-membered heterocycloalkenyl substituted by one or more R1-7, and may further be
[0100] In one embodiment, in ring B, the C6-C14 aryl substituted by one or more R1-8 may be any one of the following groups:
such as
or
[0101] In one embodiment, in ring B, the 5- to 10-membered heteroaryl substituted by one or more R1-9 may be any one of the following groups:
such as
[0102] In one embodiment, in L2, the "C1-C6 alkylene" in the C1-C6 alkylene, the C1-C6 alkylene substituted by one or more L2-1, the -O-C1-C6 alkylene, and the -N-C1-C6 alkylene may independently be methylene, ethylene, n-propylene, isopropylene, n-butylene, isobutylene, sec-butylene, or tert-butylene, such as methyl, ethyl, n-propyl, or isopropyl, for example, methylene or ethylene.
[0103] In one embodiment, when L2 is C1-C6 alkylene, the C atom in the C1-C6 alkylene connected to
may be a non-chiral C, an S-configuration C, or an R-configuration C, preferably an S-configuration C.
[0104] In one embodiment, in L2, the "C3-C8 cycloalkylene" in the C3-C8 cycloalkylene and the C3-C8 cycloalkylene substituted by one or more L2-2 may independently be cyclopropylene, cyclobutylene, cyclopentylene, or cyclohexylene, such as cyclopropylene. In one embodiment, in each L2-1 and each L2-2, the halogen may independently be fluorine, chlorine, or bromine, such as fluorine.
[0105] In one embodiment, in each L2-1 and each L2-2, the "C1-C6 alkyl" in the C1-C6 alkyl and the C1-C6 alkyl substituted by one or more L2-1-1 may independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as methyl, ethyl, n-propyl, or isopropyl.
[0106] In one embodiment, in each L2-1 and each L2-2, the "C1-C6 alkoxy" in the C1-C6 alkoxy and the C1-C6 alkoxy substituted by one or more L2-1-2 may independently be methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, or tert-butoxy, such as methoxy or ethoxy.
[0107] In one embodiment, in each L2-1 and each L2-2, the "C3-C8 cycloalkyl" in the C3-C8 cycloalkyl and the C3-C8 cycloalkyl substituted by one or more L2-1-3 may independently be cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, such as cyclopropyl or cyclobutyl.
[0108] In one embodiment, in each L2-1 and each L2-2, the "C2-C6 alkynyl" in the C2-C6 alkynyl and the C2-C6 alkynyl substituted by one or more L2-1-4 may independently be ethynyl.
[0109] In one embodiment, in each L2-1-1, each L2-1-2, each L2-1-3, and each L2-1-4, the "C3-C8 cycloalkyl" in the C3-C8 cycloalkyl and the C3-C8 cycloalkyl substituted by one or more L2-1-1-1 may independently be cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, such as cyclopropyl.
[0110] In one embodiment, in G2, the "5- to 10-membered heteroaryl" in the 5- to 10-membered heteroaryl and the 5- to 10-membered heteroaryl substituted by one or more G2-4 may independently be 5- to 6-membered heteroaryl with 2, 3, or 4 heteroatoms selected from one or more types of N, O, and S, and may further be 5- to 6-membered heteroaryl with 3 or 4 heteroatoms being N and/or O, such as tetrazolyl,
oxazolyl (
), or
[0111] In one embodiment, in G2, the "3- to 8-membered heterocycloalkenyl" in the 3-to 8-membered heterocycloalkenyl and the 3- to 8-membered heterocycloalkenyl substituted by one or more G2-5 may independently be 3- to 5-membered heterocycloalkenyl with 2 or 3 heteroatoms being N and/or S, such as
[0112] In one embodiment, in G2-1, G2-2, and G2-3, the "C1-C6 alkyl" in the -S(=O)2-C1-C6 alkyl, C3-C8 cycloalkyl, the C1-C6 alkyl, and the C1-C6 alkyl substituted by one or more G2-2-1 may independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as methyl or ethyl.
[0113] In one embodiment, in G2-1, G2-2, and G2-3, the C3-C8 cycloalkyl may independently be cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, such as cyclopropyl.
[0114] In one embodiment, in G2-2 and G2-3, the "5- to 10-membered heteroaryl" in the -NH(=O)-5- to 10-membered heteroaryl is 5- to 6-membered heteroaryl with 1 or 2 heteroatoms being N, such as pyridyl.
[0118] In one embodiment, G1 may be C1-C6 alkyl, C6-C14 aryl, C6-C14 aryl substituted by one or more G1-2, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl substituted by one or more G1-3.
[0119] In one embodiment, each G1-2 may independently be halogen, cyano, -NG1-1-1G1-1-2, -S(=O)2-C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkyl substituted by one or more G1-1-5, C1-C6 alkoxy, C1-C6 alkoxy substituted by one or more G1-1-6, -S-C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by one or more G1-1-8, or -O-C3-C8 cycloalkyl.
[0121] In one embodiment, ring A may be 4- to 6-membered heterocycloalkyl or 4- to 6-membered heterocycloalkyl substituted by one or more A1; the "4- to 6-membered heterocycloalkyl" in the 4- to 6-membered heterocycloalkyl and the 4- to 6-membered heterocycloalkyl substituted by one or more A1 has 1 heteroatom being N.
[0122] Preferably, when ring A is 4- to 6-membered heterocycloalkyl or 4- to 6-membered heterocycloalkyl substituted by one or more A3, then L1 is a bond, and G1 is connected to ring A through a heteroatom.
[0124] In one embodiment, L2 may be C1-C6 alkylene or C1-C6 alkylene substituted by one or more L2-1
[0127] In one embodiment, the compound of formula I may be the following general formula I-1:
in formula I-1, the N in ring A represents a nitrogen atom, and all other definitions are as described above.
[0129] More preferably, L2 is C1-C6 alkylene substituted by one or more L2-1, at least one L2-1 is C3-C8 cycloalkyl, and L2-1 is substituted at the terminal group of L2.
[0130] In one embodiment, the compound of formula I may be the following general formulas I-2 to I-14:
in formula I-3, n1 is 0, 1, or 2;
in formula I-11, R1 is C1-C6 alkyl, C1-C6 alkyl substituted by one or more R1-3, C2-C6 alkenyl, or C2-C6 alkenyl substituted by one or more R1-10;
in formula I-12, n2 is 0, 1, or 2; R4 is C1-C6 alkyl, or R4 and G1-2 together form - (CH2)n3-, wherein n3 is 1, 2, or 3, and 1 or 2 of the -(CH2)n3- in -(CH2)n3- are optionally replaced by a group selected from: -CHR4a-, -CR4bR4c-, -NH-, -O-, and -C(=O)-; R4a, R4b, and R4c are independently C1-C6 alkyl or halogen (e.g.,
);
in formula I-13, n2 is 0, 1, or 2; (e.g., R4 is C1-C6 alkyl; G1-2 is halogen; R4 is C1-C6 alkyl);
in formula I-14, n2 is 0, 1, or 2 (e.g., R2 is hydrogen or halogen);
the definitions of other groups in formulas I-1 to I-14 are as described above (e.g., the definitions of groups G1-2, A1, G1, G2, L1, L2, R1, R2, R3, R1-1, R1-2, and ring B in I-1 to I-10 are as described above).
[0131] Preferably:
in formula I-9, ring B is C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-4, C3-C12 cycloalkenyl, C3-C12 cycloalkenyl substituted by one or more R1-5, 3- to 12-membered heterocycloalkyl, 3- to 12-membered heterocycloalkyl substituted by one or more R1-6, 3- to 12-membered heterocycloalkenyl, 3- to 12-membered heterocycloalkenyl substituted by one or more R1-7, C6-C14 aryl, C6-C14 aryl substituted by one or more R1-8, 5- to 14-membered heteroaryl, or 5- to 14-membered heteroaryl substituted by one or more R1-9;
each R1-4, each R1-5, each R1-6, each R1-7, each R1-8, and each R1-9 is independently halogen, cyano, hydroxyl, -NR1-3-1aR1-3-2a, -C(=O)NR1-3-3aR1-3-4a, -C(=O)R1-3-5a, -S(=O)2-C1-C12 alkyl, -S-C1-C12 alkyl, C1-C12 alkyl, C1-C12 alkyl substituted by one or more R1-3-6a, C1-C12 alkoxy, C1-C12 alkoxy substituted by one or more R1-3-7a, 5- to 14-membered heteroaryl, 5- to 14-membered heteroaryl substituted by one or more R1-3-8a, C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-3-9a, C2-C6 alkenyl, C2-C6 alkenyl substituted by one or more R1-3-10a, C6-C14 aryl, C6-C14 aryl substituted by one or more R1-3-11a, -O-C6-C14 aryl, -O-C(=O)C6-C14 aryl, -O-5- to 10-membered heteroaryl, 3-to 12-membered heterocycloalkyl, or 3- to 12-membered heterocycloalkyl substituted by one or more R1-3-13a; alternatively, any two adjacent R1-8, together with the carbon atom to which they are attached, form a C3-C14 cycloalkyl;
R1-3-1a, R1-3-2a, R1-3-3a, and R1-3-4a are independently H, C1-C6 alkyl, -C(=O)R1-3-1-1a, or C3-C8 cycloalkyl;
R1-3-1-1a is C1-C6 alkyl;
R1-3-5a is C3-C8 cycloalkyl or 3- to 8-membered heterocycloalkyl;
each R1-3-6a and each R1-3-7a is independently halogen, hydroxyl, carboxyl, cyano, C1-C6 alkoxy, C3-C8 cycloalkyl, 3- to 12-membered heterocycloalkyl, or -O-C(=O)-C1-C6 alkyl-3- to 12-membered heterocycloalkyl;
each R1-3-8a, each R1-3-9a, each R1-3-10a, each R1-3-11a, and each R1-3-12a is independently C1-C6 alkyl.
[0132] Preferably,
in formula I-10, R1-1 and R1-2 are independently H, -S(=O)2C1-C12 alkyl, C1-C12 alkyl, C1-C12 alkyl substituted by one or more R1-1-1, C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-1-2, C6-C14 aryl, C6-C14 aryl substituted by one or more R1-1-3, 5- to 14-membered heteroaryl, or 5- to 14-membered heteroaryl substituted by one or more R1-1-4,
alternatively, R1-1 and R1-2, together with the N atom to which they are attached, form a 3- to 14-membered heterocycloalkyl or a 3- to 14-membered heterocycloalkyl substituted by one or more R1-1-5;
each R1-1-1 and each R1-1-2 is independently halogen, cyano, nitro, hydroxyl, amino, -NH(C1-C12 alkyl), -N(C1-C12 alkyl)2, C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-1-1-3, C6-C14 aryl, 3- to 12-membered heterocycloalkyl, or 5- to 14-membered heteroaryl;
each R1-1-3, R1-1-4, and each R1-1-5 is independently halogen, cyano, nitro, hydroxyl, amino, -NH(C1-C12 alkyl), -N(C1-C12 alkyl)2, -C(=O)-C1-C12 alkyl, -NHC(=O)-C1-C12 alkyl, C1-C12 alkyl, C1-C12 alkyl substituted by one or more R1-1-1-1, C1-C12 alkoxy, C1-C12 alkoxy substituted by one or more R1-1-1-2, C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-1-1-3, C6-C14 aryl, 3- to 12-membered heterocycloalkyl, or 5- to 14-membered heteroaryl;
each R1-1-1-1, each R1-1-1-2, and each R1-1-1-3 is independently halogen, C1-C12 alkyl, or C3-C12 cycloalkyl.
[0133] Preferably,
in formula I-11, each R1-3 and each R1-10 is independently deuterium, halogen, cyano, hydroxyl, -NR1-3-1R1-3-2, -C(=O)NR1-3-3R1-3-4, -C(=O)R1-3-5, -S(=O)2-C1-C12 alkyl, -S-C1-C12 alkyl, C1-C12 alkyl, C1-C12 alkyl substituted by one or more R1-3-6, C1-C12 alkoxy, C1-C12 alkoxy substituted by one or more R1-3-7, 5- to 14-membered heteroaryl, 5- to 14-membered heteroaryl substituted by one or more R1-3-8, C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-3-9, C2-C6 alkenyl, C6-C14 aryl, C6-C14 aryl substituted by one or more R1-3-11, -O-C6-C14 aryl, -O-C(=O)C6-C14 aryl, -O-5- to 14-membered heteroaryl, C3-C8 cycloalkenyl, C3-C8 cycloalkenyl substituted by one or more R1-3-12, 3- to 12-membered heterocycloalkyl, or 3- to 12-membered heterocycloalkyl substituted by one or more R1-3-13
R1-3-1, R1-3-2, R1-3-3, and R1-3-4 are independently H, C1-C6 alkyl, -C1-C6 alkyl-C6-C14 aryl, -C(=O)R1-3-1-1, C6-C14 aryl, or C6-C14 aryl substituted by one or more R1-3-1-4,
each R1-3-6 and each R1-3-7 is independently C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C2-C6 alkenyl, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl substituted by one or more C1-C6 alkyl groups;
each R1-3-8, each R1-3-9, each R1-3-10, each R1-3-11, each R1-3-12, and each R1-3-13 is independently halogen, hydroxyl, carboxyl, cyano, C1-C6 alkyl, or C1-C6 alkoxy.
[0134] In one embodiment, the compound of formula I is preferably any one of the following compounds:
[0135] The present disclosure also provides a preparation method for the compound of formula I, wherein the method is method 1 or 2:
when G2 is -C(=O)OH, the method is method 1; method 1 comprises the following step: subjecting
compound II-1 to a hydrolysis reaction in a solvent in the presence of a base to obtain
the compound of formula I;
wherein R4 is C1-C6 alkyl; the definitions of X, Y, Z, R1, R2, L, G1, G2, and ring A are as described above;
when G2 is 5- to 10-membered heteroaryl, the method is method 2; method 2 comprises the following step: subjecting compound II-2 and trimethylsilyl azide to a cyclization reaction in a solvent in the presence of a catalyst to obtain the compound of formula I;
alternatively, subjecting compound II-2 and N,N'-carbonyldiimidazole to a cyclization reaction in a solvent in the presence of a catalyst
to obtain the compound of formula I;
wherein R5 is
or cyano; R5 is an amino protecting group or a hydroxyl protecting group; and the definitions
of X, Y, Z, R1, R2, L, G1, G2, and ring A are as described above.
[0136] The present disclosure also provides a compound II-1, II-2, II-1a, or II-2a:
wherein the definitions of Q, X, Y, Z, R1, R2, R3, R4, R5, L1, L2, G1, and ring A are as described above.
[0139] The present disclosure also provides a pharmaceutical composition comprising the compound of formula I or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
[0140] The present disclosure also provides a use of the compound of formula I or the pharmaceutically acceptable salt thereof in the manufacture of a GPR40 agonist (in vivo or in vitro).
[0141] The present disclosure also provides a use of the compound of formula I or the pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing a GPR40-related disease.
[0143] The present disclosure also provides a use of the compound of formula I or the pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating or preventing diabetes, wherein the disease is diabetes.
[0144] The present disclosure also provides a method for treating a GPR40-related disease (preferably diabetes), comprising administering to a patient an effective amount of the compound of formula I or the pharmaceutically acceptable salt thereof.
[0145] The present disclosure also provides a method for treating diabetes, comprising administering to a patient an effective amount of the compound of formula I or the pharmaceutically acceptable salt thereof.
[0146] The more than one in the expression "group B substituted by one or more group A" refers to 2, 3, 4, or 5. The "group B substituted by one or more group A" means that 1, 2, 3, 4, or 5 hydrogen atoms in group B are independently substituted by group A. When more than one group A appears simultaneously, unless otherwise specified, their definitions are independent of and do not affect each other. For example, "C6-C10 aryl substituted by 3 halogens" refers to the C6-C10 aryl substituted by 3 halogens, where the definitions of the 3 halogens are independent of and do not affect each other, including but not limited to:
etc.
[0147] The term "pharmaceutically acceptable salt" refers to a salt obtained by reacting a compound with a pharmaceutically acceptable acid or base. When the compound contains a relatively acidic functional group, a base addition salt can be obtained by contacting the compound with a sufficient amount of a pharmaceutically acceptable base in a suitable inert solvent. When the compound contains a relatively basic functional group, an acid addition salt can be obtained by contacting the compound with a sufficient amount of a pharmaceutically acceptable acid in a suitable inert solvent. For details, please refer to the "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" (P. Heinrich Stahl, Camille G. Wermuth, 2011, 2nd Revised Edition).
[0148] The "
" in a structural moiety means that the structural moiety is connected to other moieties in the molecule through this site. For example,
refers to cyclohexyl.
[0149] The "-" at the terminus of a group indicates that the group is connected to the rest of the molecule through this site. For example, CH3-C(=O)- refers to acetyl.
[0151] The term "alkyl" refers to a straight or branched, saturated monovalent hydrocarbon group having a specified number of carbon atoms (e.g., C1-C12 or C1-C6). The alkyl includes, but is not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl, etc.
[0152] The term "alkenyl" refers to a straight or branched, unsaturated monovalent hydrocarbon group having a specified number of carbon atoms (e.g., C2-C6) with one or more (e.g., 1, 2, or 3) carbon-carbon sp2 double bonds. The alkenyl includes, but is not limited to, vinyl,
etc.
[0153] The term "heterocycloalkenyl" refers to a cyclic, unsaturated monovalent hydrocarbon group having a specified number of ring atoms (e.g., 5- to 14-membered or 5- to 10-membered), a specified number of heteroatoms (e.g., 1, 2, or 3), and a specified type of heteroatoms (one or more types of N, O, and S), which has one or more (e.g., 1, 2, or 3) carbon-carbon sp2 double bonds and is not aromatic. (Monocyclic) heterocycloalkenyl is connected to the molecule via a carbon atom or a heteroatom.
[0154] The term "heterocycloalkyl" refers to a cyclic group having a specified number of ring atoms (e.g., 5- to 14-membered, 5- to 10-membered, or 5- to 6-membered), a specified number of heteroatoms (e.g., 1, 2, 3, or 4), and a specified type of heteroatoms (one or more types of N, O, and S), which is a monocyclic ring, a bridged ring, or a spiro ring (the bridged ring and the spiro ring may be a bicyclic ring or a tricyclic ring), and each ring is saturated. The heterocycloalkyl includes, but is not limited to, azetidinyl, tetrahydropyrrolyl, tetrahydrofuryl, morpholinyl, piperidinyl, etc.
[0155] The term "alkoxy" refers to the group RX-O-, where the definition of RX is the same as that in the term "alkyl". The alkoxy includes, but is not limited to: methoxy, ethoxy, n-propoxy, isopropoxy, etc.
[0156] The term "alkylene" refers to a divalent group connected to the rest of the molecule via two single bonds, with the remaining definition being the same as the term "alkyl".
[0157] The term "cycloalkyl" refers to a cyclic, saturated monovalent hydrocarbon group having a specified number of carbon atoms (e.g., C3-C12, C3-C8, or C3-C6), which is a monocyclic ring, a bridged ring, or a spiro ring (the bridged ring and the spiro ring may be a bicyclic ring or a tricyclic ring). The cycloalkyl includes, but is not limited to:
etc.
[0158] The term "aryl" refers to a cyclic, unsaturated monovalent hydrocarbon group having a specified number of carbon atoms (e.g., C6-C10), which is a monocyclic ring or a polycyclic ring (e.g., 2 or 3 rings). When the aryl is a polycyclic ring, the monocyclic rings share two atoms and one bond, and each ring is aromatic. The aryl includes, but is not limited to, phenyl, naphthyl, etc.
[0159] The term "heterocycloalkyl" refers to a cyclic, saturated monovalent group having a specified number of ring atoms (e.g., 5- to 14-membered, 5- to 10-membered, or 5- to 6-membered), a specified number of heteroatoms (e.g., 1, 2, 3, or 4), and a specified type of heteroatoms (one or more types of P, N, O, and S), which is a monocyclic heterocycloalkyl, or a bicyclic or tricyclic fused, bridged, or spiro heterocycloalkyl. The heterocycloalkyl includes, but is not limited to:
etc.
[0160] The term "heteroaryl" refers to a cyclic, unsaturated monovalent group having a specified number of ring atoms (e.g., 5- to 14-membered, 5- to 10-membered, or 5- to 6-membered), a specified number of heteroatoms (e.g., 1, 2, or 3), and a specified type of heteroatoms (one or more types of P, N, O, and S), which is a monocyclic ring or a polycyclic ring (e.g., 2 or 3 rings), where the monocyclic rings share two atoms and one bond, and each ring is aromatic. The heteroaryl is connected to the rest of the molecule via a carbon atom or a heteroatom; the heteroaryl is connected to the rest of the molecule through a ring with heteroatoms or a ring without heteroatoms. The heteroaryl includes, but is not limited to:
etc.
[0161] The term "pharmaceutical excipient" refers to all substances contained in a pharmaceutical preparation other than the active pharmaceutical ingredient, generally classified into two categories: vehicles and additives. For details, please refer to the "Pharmacopoeia of the People's Republic of China (2020 Edition)" and the "Handbook of Pharmaceutical Excipients" (Paul J Sheskey, Bruno C Hancock, Gary P Moss, David J Goldfarb, 2020, 9th Edition).
[0162] On the basis of not violating the common sense in the field, the preferred conditions above can be arbitrarily combined to obtain the preferred examples of the present disclosure.
[0164] The positive and progressive effects of the present disclosure are that the compounds of the present disclosure have good GPR40 agonistic activity, and further have good pharmacokinetics and low toxicity.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
[0165] The present disclosure is further described below by the way of examples, but the present disclosure is not thereby limited to the scope of the described examples. Experimental methods without specific conditions in the following examples are selected according to conventional methods and conditions, or according to the commercial specification.
Synthesis of Intermediate M1
Synthetic Route:
[0167] To a 500 mL three-necked flask, compound M1-1 (17 g, 0.139 mol) and water (300 mL) were added separately and stirred to dissolve and carry out the reaction under an 80°C oil bath. Then, the pre-weighed compound M1-2 (0.167 mol, 24 g) was slowly added to the reaction system. The reaction was continued at this temperature for 40 minutes, followed by hot filtration to obtain compound M1-3 (31 g, yield: 90%). MS (ESI, m/z): 249.2 [M+H]+.
[0168] In a 500 mL three-necked flask under a nitrogen atmosphere, compound M1-3 (11 g, 44.31 mmol) and anhydrous tetrahydrofuran (20 mL) were added separately and stirred to dissolve. Cyclopropylmagnesium bromide M1-4 (352 mL, 265.88 mmol) was slowly added dropwise under an ice bath. After the dropwise addition was completed, the reaction was gradually warmed to room temperature and continued for 2 hours, and then quenched with saturated ammonium chloride aqueous solution (20 mL). The reaction mixture was extracted with dichloromethane (20 mL × 3), and the combined organic phases were dried over anhydrous sodium sulfate and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound M1-5 (8.7 g, yield: 68%) as a pale yellow solid. MS (ESI, m/z): 291.3 [M+H]+.
[0169] In a 250 mL three-necked flask, compound M1-5 (8.7 g, 29.97 mol) was added, and then N,N-dimethylformamide (50 mL) and water (5 mL) were added and stirred to dissolve. The reaction mixture was then placed in a 100°C oil bath and reacted overnight. The reaction was stopped after TLC monitoring confirmed the complete consumption of the starting material. Ethyl acetate (150 mL × 3) was added for extraction. The combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain crude compound M1-6 (7.48 g) as a yellow solid, which was directly used in the next step. MS (ESI, m/z): 207.2 [M+H]+.
[0170] At room temperature, in a 100 mL three-necked flask, compound M1-6 (7.48 g, 36.27 mmol) and methanol (10 mL) were added and stirred to dissolve. Concentrated sulfuric acid (2 mL, 37.5 mmol) was then added, and the reaction was stirred for an additional 2 hours until TLC monitoring confirmed the complete consumption of the starting material. Ethyl acetate (20 mL × 3) and water (20 mL) were added to the reaction mixture for extraction. The combined organic phases were washed with saturated sodium bicarbonate aqueous solution (50 mL × 3), dried, and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound M1-7 (4 g, yield: 50%) as a pale yellow solid. MS (ESI, m/z): 221.2 [M+H]+.
[0171] Under an ice-water bath, in a 100 mL three-necked flask, compound M1-7 (4 g, 18.16 mmol) and dichloromethane (50 mL) were added and stirred to dissolve. Then, N-iodosuccinimide (4.9 g, 21.79 mmol) was slowly added. After reacting for 1 hour, LCMS monitoring confirmed the complete consumption of the starting material. Dichloromethane (50 mL) and water (50 mL) were added for extraction. The organic phase was washed with saturated ammonium chloride (50 mL × 3), dried, and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound M1-8 (2.87 g, yield: 46%) as a brown solid. MS (ESI, m/z): 347.2 [M+H]+.
[0172] In a 25 mL three-necked flask under a nitrogen atmosphere, compound M1-8 (1.47 g, 4.247 mmol), copper(I) iodide (0.08 g, 0.425 mmol), and bis(triphenylphosphine)palladium(II) chloride (0.17 g, 0.212 mmol) were added, followed by the addition of acetonitrile (20 mL) with stirring. Triethylamine (0.590 mL, 4.247 mmol) was then added, and the stirring was continued. The reaction mixture was stirred at 80°C for 2 minutes, and then compound M1-9 (0.89 g, 4.247 mmol) was added. After the addition was completed, the reaction was continued at 80°C for 90 minutes. After the reaction was completed, the reaction mixture was cooled to room temperature, and dichloromethane (50 mL) and water (50 mL) were added to the resulting suspension for extraction. The combined organic phases were dried and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound M1 (1.2 g, yield: 66%) as a brown solid. MS (ESI, m/z): 428.3 [M+H]+.
Synthesis of Intermediate M2
Synthetic Route:
[0174] Referring to the synthetic route of intermediate M1, compound M1-7 was replaced with commercially available starting material compound M2-1: methyl (S)-3-cyclopropyl-3-(3-hydroxyphenyl)propanoate to obtain compound M2 (565 mg, yield: 93%) as a yellow oil. MS (ESI, m/z): 428.3 [M+H]+.
Example 1:
Synthetic Route:
[0176] To a solution of compound M1 (1.69 g, 3.953 mmol) in anhydrous dichloromethane (20 mL), N-bromosuccinimide (0.845 g, 4.748 mmol) was slowly added under an ice-water bath. The reaction mixture was stirred in the ice-water bath for 2 hours. After the reaction was completed, water (50 mL) was added to the reaction system, followed by extraction with dichloromethane (30 mL × 3). The combined organic phases were dried and concentrated, then purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 1-1 (1.48 g, yield: 74%) as a brownish-red solid. MS (ESI, m/z): 506.3 [M+H]+.
[0177] At room temperature, in a 100 mL three-necked flask under a nitrogen atmosphere, compound 1-1 (200 mg, 0.396 mmol), potassium carbonate (120 mg, 0.871 mmol), bis(triphenylphosphine)palladium(II) chloride (57.4 mg, 0.081 mmol), and 3-tert-butylbenzeneboronic acid 1-2 (144.2 mg, 0.81 mmol) were added. Then, 1,4-dioxane (10 mL) and water (2 mL) were added and stirred. The reaction mixture was placed in a 100°C oil bath and reacted for 3 hours. LCMS monitoring confirmed the complete consumption of the starting material. After the reaction was stopped, the reaction mixture was cooled to room temperature and rotary evaporated to dryness. Water (10 mL) was added, and the mixture was extracted with ethyl acetate (10 mL × 3). The combined organic phases were dried, concentrated, and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 10%) to obtain compound 1-3 (168 mg, yield: 74%) as a yellow oil. MS (ESI, m/z): 582.4 [M+Na]+.
[0178] To a solution of compound 1-3 (168 mg, 0.3 mmol) and dichloromethane (2 mL), trifluoroacetic acid (137 mg, 1.2 mmol) was added at room temperature. The reaction was carried out at room temperature for 2 hours. LCMS monitoring confirmed the complete consumption of the starting material. The pH of the reaction system was adjusted to neutral with saturated sodium bicarbonate solution, followed by extraction with dichloromethane (5 mL × 3). The combined organic phases were dried and concentrated, then purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 1-4 (150 mg, yield: 96%) as a yellow oil. MS (ESI, m/z): 460.3 [M+H]+.
[0179] To a solution of compound 1-4 (100 mg, 0.22 mmol), anhydrous magnesium sulfate (637 mg, 5.30 mmol), dichloroethane (5 mL), methanol (5 mL), and 40% formaldehyde (5 mL), acetic acid (0.1 mL) was added at room temperature. The reaction was carried out at room temperature for 4 hours, followed by the addition of sodium triacetoxyborohydride (92 mg, 0.44 mmol). The reaction was continued at room temperature for 16 hours. LCMS monitoring confirmed the complete consumption of the starting material. The reaction was quenched with 5 M sodium hydroxide solution (20 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic phases were dried and concentrated, then purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 20%) to obtain compound 1-6 (70 mg, yield: 67%) as a yellow oil. MS (ESI, m/z): 474.4 [M+H]+.
[0180] At room temperature, compound 1-6 (70 mg, 0.14 mmol) and methanol (5 mL) were stirred to dissolve. Lithium hydroxide (3 mg, 0.14 mmol) was then slowly added, and the reaction mixture was reacted at room temperature for 16 hours. LCMS monitoring confirmed the complete consumption of the starting material. The resulting crude product obtained after direct concentration was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 1 (14 mg, yield: 22%). MS (ESI, m/z): 460.3 [M+H]+. 1H NMR (400 MHz, DMSO-d6) δ 7.51 (s, 1H), 7.48 - 7.38 (m, 4H), 7.33 - 7.27 (m, 1H), 7.16 (d, J = 8.0 Hz, 1H), 2.93 - 2.77 (m, 3H), 2.73 - 2.65 (m, 2H), 2.43 - 2.34 (m, 1H), 2.18 (s, 3H), 2.03 - 1.75 (m, 6H), 1.34 (s, 9H), 1.12 - 1.04 (m, 1H), 0.55 - 0.49 (m, 1H), 0.34 - 0.24 (m, 2H), 0.18 - 0.11(m, 1H).
Example 2:
Synthetic Route:
[0182] To a solution of compound M1-8 (200 mg, 0.58 mmol) in triethylamine (5 mL), compound 2-1 (65 mg, 0.64 mmol), copper(I) iodide (5.5 mg, 0.03 mmol), and bis(triphenylphosphine)palladium(II) chloride (20 mg, 0.03 mmol) were added. The reaction was stirred at 90°C for 12 hours. LCMS monitoring confirmed the complete consumption of the starting material. The reaction mixture was directly concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 2-2 (120 mg, yield: 65%) as a pale yellow oil. MS (ESI, m/z): 321.2 [M+H]+.
[0183] To a solution of compound 2-2 (120 mg, 0.38 mmol) in dichloromethane (5 mL) at 0°C, N-bromosuccinimide (68 mg, 0.38 mmol) was added, and the reaction was stirred at room temperature for 4 hours. LCMS monitoring confirmed the complete consumption of the starting material. The reaction mixture was directly concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 2-3 (148 mg, yield: 98%) as a pale yellow oil. MS (ESI, m/z): 421.0 [M+Na]+.
[0184] To a mixture of compound 2-3 (148 mg, 0.37 mmol) in 1,4-dioxane (6 mL) and water (2 mL), compound 1-2 (66 mg, 0.37 mmol), potassium phosphate (235 mg, 1.11 mmol), and [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (29 mg, 0.04 mmol) were added. The reaction was stirred at 90°C for 5 hours. LCMS monitoring confirmed the complete consumption of the starting material. The reaction mixture was directly concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 2-4 (137 mg, yield: 82%) as a pale yellow oil. MS (ESI, m/z): 453.2 [M+H]+.
[0185] To a mixture of compound 2-4 (137 mg, 0.30 mmol) in tetrahydrofuran (2 mL), methanol (2 mL), and water (2 mL), lithium hydroxide (22 mg, 0.91 mmol) was added. The reaction was stirred at room temperature for 4 hours. LCMS monitoring confirmed the complete consumption of the starting material. The reaction mixture was directly concentrated, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 2 (46 mg, yield: 35%) as a white solid. MS (ESI, m/z): 439.2 [M+H]+.
[0186] 1H NMR (400 MHz, DMSO-d6) δ 7.58 (dd, J = 8.0, 1.6 Hz, 2H), 7.53 (s, 1H), 7.48 - 7.42 (m, 3H), 7.42 - 7.26 (m, 5H), 7.20 (d, J = 8.0 Hz, 1H), 2.60 - 2.41 (m, 3H), 1.25 (s, 9H), 1.02 - 0.98 (m, 1H), 0.47 - 0.45 (m, 1H), 0.34 - 0.22 (m, 2H), 0.16 - 0.08 (m, 1H).
Example 3:
Synthetic Route:
[0188] In a 25 mL single-necked flask, compound 1-4 (68.9 mg, 0.15 mmol), 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl (3.1 mg, 0.006 mmol), tris(dibenzylideneacetone)dipalladium (3.2 mg, 0.003 mmol), compound 3-1 (65.4 mg, 0.3 mmol), and cesium carbonate (146.6 mg, 0.45 mmol) were added. Toluene (5 mL) was then added and stirred. The reaction mixture was placed at 100°C and reacted overnight. LCMS monitoring confirmed the complete consumption of the starting material. After the reaction was stopped, dichloromethane (20 mL) and water (20 mL) were added to the reaction mixture for extraction. The organic phase was dried and concentrated, and the resulting crude compound 3-2 (160 mg) was directly used in the next step. MS (ESI, m/z): 550.3 [M+H]+.
[0189] Referring to the synthetic route of compound 1, the synthesis was carried out, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 3 (17 mg, yield: 8%) as a white solid. MS (ESI, m/z): 536.3 [M+H]+.
[0190] 1H NMR (400 MHz, MeOD) δ 7.50 (s, 1H), 7.47 - 7.37 (m, 4H), 7.31 - 7.29 (m, 1H), 7.16 (d, J = 8.4 Hz, 1H), 7.01 (d, J = 9.2 Hz, 2H), 6.85 (d, J = 9.2 Hz, 2H), 3.76 - 3.66 (m, 2H), 3.13 - 3.04 (m, 1H), 2.82 - 2.64 (m, 4H), 2.49 - 2.47 (m, 1H), 2.32 - 2.17 (m, 5H), 2.01 - 1.93 (m, 2H), 1.39 (s, 9H), 1.14 - 1.11 (m, 1H), 0.62 - 0.59 (m, 1H), 0.42 - 0.33 (m, 2H), 0.21 - 0.16 (m, 1H).
Example 4:
Synthetic Route:
[0192] Referring to the synthetic route of compound 3, compound 3-1 was replaced with compound 4-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 4 (15 mg, yield: 7%) as a white solid. MS (ESI, m/z): 536.3 [M+H]+.
[0193] 1H NMR (400 MHz, MeOD) δ 7.51 (s, 1H), 7.46 - 7.35 (m, 4H), 7.32 - 7.28 (m, 1H), 7.17 - 7.09 (m, 2H), 6.87 - 6.80 (m, 2H), 6.69 (d, J = 7.6 Hz, 1H), 3.82 - 3.73 (m, 2H), 3.13 - 3.04 (m, 1H), 2.87 - 2.67 (m, 4H), 2.51 - 2.42 (m, 1H), 2.31 - 2.17 (m, 5H), 2.01 - 1.91 (m, 2H), 1.39 (s, 9H), 1.17 - 1.07 (m, 1H), 0.65 - 0.56 (m, 1H), 0.46 - 0.30 (m, 2H), 0.22 - 0.13 (m, 1H).
Example 5:
Synthetic Route:
[0195] Referring to the synthetic route of compound 3, compound 3-1 was replaced with compound 5-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 5 (11 mg, yield: 19%) as a white solid. MS (ESI, m/z): 536.3 [M+H]+.
[0196] 1H NMR (400 MHz, CDCl3) δ 7.49 (s, 1H), 7.47-7.45 (m, 3H), 7.38 (d, J = 8.0 Hz, 1H), 7.33 (d, J = 6.8 Hz, 1H), 7.20-7.11 (m, 3H), 7.03 (d, J =7.6 Hz, 1H), 6.96-6.94 (m, 1H), 3.16-3.14 (m, 2H), 3.04-3.00 (m, 1H), 2.69-2.66 (m, 2H), 2.50-2.26 (m, 6H), 2.16-2.14 (m, 2H), 1.94-1.91 (m, 2H), 1.35 (s, 9H), 1.05-0.95 (s, 1H), 0.47-0.41 (m, 1H), 0.31-0.23 (m, 2H), 0.11-0.05 (m, 1H).
Example 6:
Synthetic Route:
[0198] Referring to the synthetic route of compound 1, compound 1-2 was replaced with compound 6-1 to carry out the synthesis and obtain compound 6-3. Then, referring to the synthetic route of compound 3, compound 3-1 was replaced with compound 6-4 to carry out the synthesis, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 6 (16 mg, yield: 50%) as a white solid. MS (ESI, m/z): 550.3 [M+H]+.
[0199] 1H NMR (400 MHz, DMSO-d6) δ 7.55 (d, J = 8.4 Hz, 2H), 7.46 - 7.43 (m, 3H), 7.38 (d, J = 8.0 Hz, 1H), 7.14 - 7.10 (m, 2H), 6.86 - 6.72 (m, 2H), 6.63 (d, J = 7.6 Hz, 1H), 3.85 - 3.74 (m, 2H), 3.12 - 3.05 (m, 1H), 2.81 - 2.75 (m, 2H), 2.58 - 2.35 (m, 5H), 2.31 - 2.03 (m, 2H), 1.89 - 1.86 (m, 2H), 1.35 (s, 9H), 1.21 - 1.14 (m, 3H), 1.06 - 0.92 (m, 1H), 0.47 - 0.43 (m, 1H), 0.31 - 0.20 (m, 2H), 0.14 - 0.03 (m, 1H).
Example 7:
Synthetic Route:
[0201] Referring to the synthetic route of compound 3, compound 3-1 was replaced with compound 7-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 57 (5 mg, yield: 32%) as a white solid. MS (ESI, m/z): 540.4 [M+H]+.
[0202] 1H NMR (400 MHz, DMSO-d6) δ 7.53 - 7.43 (m, 4H), 7.41 (d, J = 8.0 Hz, 1H), 7.37 - 7.33 (m, 1H), 7.20 - 7.15 (m, 1H), 7.12 - 6.96 (m, 4H), 3.80 - 3.71 (m, 2H), 3.12 - 3.02 (m, 1H), 2.80 - 2.70 (m, 2H), 2.56 - 2.38 (m, 3H), 2.16 - 2.04 (m, 2H), 1.98 - 1.88 (m, 2H), 1.37 (s, 9H), 1.06 - 0.98 (m, 1H), 0.52 - 0.44 (m, 1H), 0.32 - 0.24 (m, 2H), 0.15 - 0.07 (m, 1H).
Example 8:
Synthetic Route:
[0204] Referring to the synthetic route of compound 3, compound 3-1 was replaced with compound 8-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 8 (33 mg, yield: 51%) as a white solid. MS (ESI, m/z): 540.2 [M+H]+.
[0205] 1H NMR (400 MHz, DMSO-d6) δ 7.50 - 7.29 (m, 6H), 7.25 - 7.12 (m, 2H), 6.82 - 6.73 (m, 2H), 6.55 - 6.48 (m, 1H), 3.90 - 3.87 (m, 2H), 3.15 - 3.12 (m, 1H), 2.88 - 2.74 (m, 2H), 2.52 - 2.36 (m, 3H), 2.07 - 1.96 (m, 2H), 1.90 - 1.87 (m, 2H), 1.34 (s, 9H), 0.98 - 0.95 (m, 1H), 0.46 - 0.44 (m, 1H), 0.30 - 0.20 (m, 2H), 0.08 - 0.06 (m, 1H).
Example 9:
Synthetic Route:
[0207] Referring to the synthetic route of compound 3, compound 3-1 was replaced with compound 9-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 9 (6 mg, yield: 29%) as a white solid. MS (ESI, m/z): 540.3 [M+H]+.
[0208] 1H NMR (400 MHz, MeOD) δ 7.51 (s, 1H), 7.45 - 7.39 (m, 3H), 7.32 - 7.29 (m, 1H), 7.16 (d, J = 9.2 Hz, 1H), 7.09 - 6.95 (m, 5H), 3.57 - 3.53 (m, 2H), 3.13 - 3.12 (m, 1H), 2.82 - 2.73 (m, 4H), 2.51 - 2.46 (m, 1H), 2.33 - 2.28 (m, 2H), 1.99 - 1.95 (m, 2H), 1.39 (s, 9H), 1.16 - 1.12 (m, 1H), 0.63 - 0.60 (m, 1H), 0.44 - 0.33 (m, 2H), 0.20 - 0.17 (m, 1H).
Example 10:
Synthetic Route:
[0210] Referring to the synthetic route of compound 3, compound 3-1 was replaced with compound 10-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 10 (4 mg, yield: 12%) as a white solid. MS (ESI, m/z): 552.3 [M+H]+.
[0211] 1H NMR (400 MHz, MeOD) δ 7.50 (s, 1H), 7.47 - 7.37 (m, 4H), 7.31 - 7.29 (m, 1H), 7.16 (d, J = 8.4 Hz, 1H), 7.01 (d, J = 9.2 Hz, 2H), 6.85 (d, J = 9.2 Hz, 2H), 3.75 (s, 3H), 3.62 - 3.59 (m, 2H), 3.13 - 3.06 (m, 1H), 2.82 - 2.64 (m, 4H), 2.49 - 2.47 (m, 1H), 2.29 - 2.25 (m, 2H), 1.99 - 1.95 (m, 2H), 1.39 (s, 9H), 1.14 - 1.11 (m, 1H),0.62 - 0.59 (m, 1H), 0.42 - 0.33 (m, 2H), 0.21 - 0.16 (m, 1H).
Example 11:
Synthetic Route:
[0213] Referring to the synthetic route of compound 3, compound 3-1 was replaced with compound 11-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 11 (18 mg, yield: 32%) as a white solid. MS (ESI, m/z): 552.3 [M+H]+.
[0214] 1H NMR (400 MHz, MeOD) δ 7.50 (s, 1H), 7.45-7.39 (m, 3H), 7.38 (s, 1H), 7.32-7.28 (m, 1H), 7.18-7.10 (m, 2H), 6.61 (dd, J = 8.0, 2.0 Hz, 1H), 6.56-6.52 (m, 1H), 6.43 (dd, J = 8.0, 2.0 Hz, 1H), 3.84-3.74 (m, 5H), 3.15-3.05 (m, 1H), 2.85-2.69 (m, 4H), 2.51-2.42 (m, 1H), 2.30-2.15 (m, 2H), 2.00-1.90 (m, 2H), 1.38 (s, 9H), 1.18-1.06 (m, 1H), 0.65-0.56 (m, 1H), 0.46-0.28 (m, 2H), 0.22-0.11 (m, 1H).
Example 12:
Synthetic Route:
[0216] Referring to the synthetic route of intermediate M1, intermediate M2 was obtained. Referring to the synthetic route of compound 11, the synthesis was carried out, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 12 (13 mg, yield: 33%) as a white solid. MS (ESI, m/z): 552.3 [M+H]+.
[0217] 1H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 8.8 Hz, 1H), 7.44 (d, J = 6.4 Hz, 1H), 7.38 (s, 1H), 7.32 (d, J = 6.0 Hz, 1H), 7.20 (t, J = 8.0 Hz, 2H), 7.14 (d, J = 8.0 Hz, 2H), 6.62 (d, J = 8.0 Hz, 1H), 6.54 (s, 1H), 6.44 (d, J = 8.0 Hz, 1H), 3.84 - 3.81 (m, 5H), 3.18 - 3.05 (m, 1H), 2.93 - 2.84 (m, 2H), 2.84 - 2.73 (m, 2H), 2.57 - 2.44 (m, 1H), 2.36 - 2.21 (m, 2H), 1.96 (d, J = 13.2 Hz, 2H), 1.40 (s, 9H), 1.15 - 1.02 (m, 1H), 0.63 (s, 1H), 0.52 - 0.39 (m, 1H), 0.39 - 0.27 (m, 1H), 0.28 - 0.15 (m, 1H).
Example 13:
Synthetic Route:
[0219] Referring to the synthetic route of compound 6, compound 6-4 was replaced with compound 11-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 13 (2 mg, yield: 8%) as a white solid. MS (ESI, m/z): 552.3 [M+H]+.
[0220] 1H NMR (400 MHz, DMSO-d6) δ 7.55 (d, J = 8.4 Hz, 2H), 7.46 - 7.41 (m, 3H), 7.37 (d, J = 8.0 Hz, 1H), 7.13 - 7.09 (m, 2H), 6.59 - 6.54 (m, 1H), 6.50 - 6.47 (d, J = 2.4 Hz, 1H), 6.37 - 6.34 (m, 1H), 3.86 - 3.77 (m, 2H), 3.72 (s, 3H), 3.13 - 3.07 (m, 1H), 2.84 - 2.77 (m, 2H), 2.55 - 2.36 (m, 3H), 2.08 - 1.99 (m, 2H), 1.88 - 1.84 (m, 2H), 1.35 (s, 9H), 1.01 - 0.95 (m, 1H), 0.46 - 0.41 (m, 1H), 0.28 - 0.21 (m, 2H), 0.08 - 0.04 (m, 1H).
Example 14:
Synthetic Route:
[0222] Referring to the synthetic route of compound 12, compound 1-2 was replaced with compound 6-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 14 (20 mg, yield: 36%) as a white solid. MS (ESI, m/z): 552.3 [M+H]+.
[0223] 1H NMR (400 MHz, DMSO-d6) δ 7.51 (t, J = 8.0 Hz, 3H), 7.41 (d, J = 7.6 Hz, 2H), 7.37 (s, 1H), 7.20 (t, J = 8.0 Hz, 1H), 7.12 (d, J = 8.0 Hz, 1H), 6.61 (d, J = 8.0 Hz, 1H), 6.53 (s, 1H), 6.46 - 6.41 (m, 1H),3.83 - 3.79 (m, 5H), 3.13 - 3.08 (m, 1H), 2.90 - 2.75 (m, 4H), 2.56 - 2.45 (m, 1H), 2.32 - 2.22 (m, 2H), 1.96 - 1.89 (m, 2H), 1.41 (s, 9H), 1.15 - 1.06 (m, 1H), 0.68 - 0.58 (m, 1H), 0.50 - 0.40 (m, 1H), 0.40 - 0.30 (m, 1H), 0.26 - 0.15 (m, 1H).
Example 15:
Synthetic Route:
[0225] Referring to the synthetic route of compound 14, compound 11-1 was replaced with compound 15-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 15 (19 mg, yield: 39%) as a white solid. MS (ESI, m/z): 566.3 [M+H]+.
[0226] 1H NMR (400 MHz, DMSO-d6) δ 7. 55 (d, J = 8.4 Hz, 2H), 7.47 - 7.41 (m, 3H), 7.38 (d, J = 8.0 Hz, 1H), 7.14 - 7.07 (m, 2H), 6.56 - 6.53 (m, 1H), 6.48 - 6.44 (m, 1H), 6.35 - 6.32 (m, 1H), 3.99 (d, J = 6.8 Hz, 2H), 3.82 - 3.79 (m, 2H), 3.13 - 3.07 (m, 1H), 2.84 - 2.77 (m, 2H), 2.68 - 2.38 (m, 3H), 2.06 - 1.97 (m, 2H), 1.85 - 1.82 (m, 2H), 1.35 (s, 9H), 1.31 (t, J = 6.8 Hz, 3H), 1.03 - 0.98 (m, 1H), 0.47 - 0.42 (m, 1H), 0.30 - 0.23 (m, 2H), 0.09 - 0.05 (m, 1H).
Example 16:
Synthetic Route:
[0228] Referring to the synthetic route of compound 14, compound 11-1 was replaced with compound 16-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 16 (6 mg, yield: 30%) as a white solid. MS (ESI, m/z): 578.7 [M+H]+.
[0229] 1H NMR (400 MHz, DMSO-d6) δ 7.54 (d, J = 8.4 Hz, 2H), 7.43 (d, J = 8.4 Hz, 2H), 7.39 (s, 1H), 7.35 (d, J = 8.0 Hz, 1H), 7.14 - 7.07 (m, 2H), 6.61 - 6.55 (m, 2H), 6.51 - 6.46 (m, 1H), 3.85 - 3.74 (m, 3H), 3.13 - 3.04 (m, 1H), 2.85 - 2.73 (m, 2H), 2.45 - 2.30 (m, 3H), 2.08 - 1.94 (m, 2H), 1.90 - 1.79 (m, 2H), 1.33 (s, 9H), 1.01 - 0.90 (m, 1H), 0.76 - 0.69 (m, 2H), 0.65 - 0.57 (m, 2H), 0.45 - 0.38 (m, 1H), 0.28 - 0.17 (m, 2H), 0.08 - 0.03 (m, 1H).
Example 17:
Synthetic Route:
[0231] Referring to the synthetic route of compound 14, compound 11-1 was replaced with compound 17-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 17 (12 mg, yield: 38%) as a white solid. MS (ESI, m/z): 592.7 [M+H]+.
[0232] 1H NMR (400 MHz, DMSO-d6) δ 7.53 (d, J = 8.4 Hz, 2H), 7.41 (d, J = 8.4 Hz, 2H), 7.37 (s, 1H), 7.34 (d, J = 8.0 Hz, 1H), 7.12 - 7.02 (m, 2H), 6.51 (dd, J = 8.4, 2.0 Hz, 1H), 6.44 (s, 1H), 6.30 (dd, J = 8.0, 2.0 Hz, 1H), 3.83 - 3.71 (m, 4H), 3.12 - 3.03 (m, 1H), 2.81 - 2.72 (m, 2H), 2.45 - 2.31 (m, 3H), 2.09 - 1.92 (m, 2H), 1.87 - 1.78 (m, 2H), 1.32 (s, 9H), 1.21 - 1.12 (m, 1H), 1.01 - 0.89 (m, 1H), 0.57 - 0.49 (m, 2H), 0.45 - 0.36 (m, 1H), 0.31 - 0.19 (m, 4H), 0.07 - 0.00 (m, 1H).
Example 18:
Synthetic Route:
[0234] Referring to the synthetic route of compound 14, compound 11-1 was replaced with compound 18-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 18 (23 mg, yield: 46%) as a white solid. MS (ESI, m/z): 606.2 [M+H]+.
[0235] 1H NMR (400 MHz, CDCl3) δ 7.52 - 7.47 (m, 3H), 7.41 -7.36 (m, 3H), 7.23 (d,J = 8.4 Hz, 1H), 7.13 - 7.09 (m, 1H), 6.86 (dd, J = 8.4, 2.4 Hz, 1H), 6.75 (s, 1H), 6.70 - 6.65 (m, 1H), 3.86 - 3.75 (m, 2H), 3.15 - 3.07 (m, 1H), 2.92 - 2.80 (m, 4H), 2.55 - 2.45 (m, 1H), 2.30 - 2.16 (m, 2H), 1.99 - 1.89 (m, 2H), 1.39 (s, 9H), 1.15 - 1.04 (m, 1H), 0.67 - 0.57 (m, 1H), 0.49 - 0.41 (m, 1H), 0.37 - 0.29 (m, 1H), 0.27 - 0.16 (m, 1H).
Example 19:
Synthetic Route:
[0237] Referring to the synthetic route of compound 3, compound 3-1 was replaced with compound 19-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 19 (19 mg, yield: 39%) as a white solid. MS (ESI, m/z): 547.3 [M+H]+.
[0238] 1H NMR (400 MHz, CDCl3) δ 7.50-7.28 (m, 9H), 7.17-7.11 (m, 2H), 3.96-3.94 (m, 2H), 3.18-3.10 (m, 1H), 2.89-2.86 (m, 2H), 2.50-2.35 (m, 3H), 2.03-1.99 (m, 2H), 1.91-1.88 (m,2H), 1.34 (s, 9H), 1.05-0.97 (m,1H), 0.51-0.40 (m, 1H), 0.30-0.21 (m, 2H), 0.13-0.05 (m, 1H).
Example 20:
Synthetic Route:
[0240] Referring to the synthetic route of compound 3, compound 3-1 was replaced with compound 20-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 20 (15 mg, yield: 39%) as a white solid. MS (ESI, m/z): 590.3 [M+H]+.
[0241] 1H NMR (400 MHz, DMSO-d6) δ 7.50 - 7.36 (m, 6H), 7.35 - 7.31 (m, 1H), 7.29 - 7.24 (m, 1H), 7.23 - 7.22(m, 1H), 7.17 - 7.12 (m, 1H), 7.07 - 7.69 (m, 1H), 3.98 - 3.89 (m, 2H), 3.16 - 3.09 (m, 1H), 2.92 - 2.77 (m, 2H), 2.60 - 2.33 (m, 3H), 2.12 - 1.88 (m, 4H), 1.34 (s, 9H), 1.05 - 0.97 (m, 1H), 0.51 - 0.41 (m, 1H), 0.31 - 0.21 (m, 2H), 0.12 - 0.05 (m, 1H).
Example 21:
Synthetic Route:
[0243] Referring to the synthetic route of compound 3, compound 3-1 was replaced with compound 21-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 71 (18 mg, yield: 32%) as a white solid. MS (ESI, m/z): 552.3 [M+H]+.
[0244] 1H NMR (400 MHz, DMSO-d6) δ 7.50 - 7.41 (m, 4H), 7.38 - 7.34 (m, 1H), 7.33 - 7.31 (m, 1H), 7.16 (d, J = 8.4 Hz, 1H), 6.95 - 6.86 (m, 4H), 3.81 (s, 3H), 3.49 - 3.46 (m, 2H), 3.03 - 2.99 (m, 1H), 2.64 - 2.56 (m, 2H), 2.50 - 2.33 (m, 3H), 2.14 - 2.11(m, 2H), 1.91 - 1.88 (m, 2H), 1.35 (s, 9H), 1.05 - 0.95 (m, 1H), 0.44 - 0.42 (m, 1H), 0.32 - 0.21 (m, 2H), 0.09 - 0.08 (m, 1H).
Example 22:
Synthetic Route:
[0246] Referring to the synthetic route of compound 3, compound 3-1 was replaced with compound 22-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 22 (9 mg, yield: 59%) as a white solid. MS (ESI, m/z): 556.6 [M+H]+.
[0247] 1H NMR (400 MHz, DMSO-d6) δ 7.52 - 7.37 (m, 6H), 7.35 - 7.26 (m, 2H), 7.21 - 7.14 (m, 2H), 7.07 - 7.00 (m, 1H), 3.42 - 3.30 (m, 2H), 3.11 - 3.00 (m, 1H), 2.80 - 2.69 (m, 2H), 2.57 - 2.38 (m, 3H), 2.24 - 2.09 (m, 2H), 2.01 - 1.89 (m, 2H), 1.35 (s, 9H), 1.10 - 0.97 (m, 1H), 0.53 - 0.44 (m, 1H), 0.34 - 0.23 (m, 2H), 0.16 - 0.07 (m, 1H).
Example 23:
Synthetic Route:
[0249] Referring to the synthetic route of compound 3, compound 3-1 was replaced with compound 23-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 23 (33 mg, yield: 55%) as a white solid. MS (ESI, m/z): 606.3 [M+H]+.
[0250] 1H NMR (400 MHz, MeOD) δ 7.51 (s, 1H), 7.47 - 7.41 (m, 3H), 7.40 - 7.37 (m, 1H), 7.31 - 7.13 (m, 5H), 7.05 - 7.00 (m, 1H), 3.52 - 3.46 (m, 2H), 3.14 - 3.04 (m, 1H), 2.79 - 2.65 (m, 4H), 2.55 - 2.45 (m, 1H), 2.34 - 2.20 (m, 2H), 1.99 - 1.89 (m, 2H), 1.39 (s, 9H), 1.18 - 1.04 (m, 1H), 0.64 - 0.55 (m, 1H), 0.45 - 0.33 (m, 2H), 0.21 - 0.12 (m, 1H).
Example 24:
Synthetic Route:
[0252] Referring to the synthetic route of compound 6, compound 6-4 was replaced with compound 24-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 24 (22 mg, yield: 41%) as a white solid. MS (ESI, m/z): 551.3 [M+H]+.
[0253] 1H NMR (400 MHz, MeOD) δ 7.54 (d, J = 8.4 Hz, 2H), 7.44 - 7.34 (m, 4H), 7.18 - 7.14 (m, 1H), 7.05 - 6.99 (m, 1H), 6.42 - 6.33 (m, 1H), 6.35 - 6.31 (m, 1H), 6.25 - 6.18 (m, 1H), 3.78 - 3.69 (m, 2H), 3.12 - 3.04 (m, 1H), 2.78 - 2.47 (m, 8H), 2.29 - 2.14 (m, 2H), 1.95 - 1.88 (m, 2H), 1.39 (s, 9H), 1.13 - 1.03 (m, 1H), 0.60 - 0.53 (m, 1H), 0.42 - 0.32 (m, 2H), 0.14 - 0.07 (m, 1H).
Example 25:
Synthetic Route:
[0255] Referring to the synthetic route of compound 6, compound 6-4 was replaced with compound 25-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 25 (13 mg, yield: 61%) as a white solid. MS (ESI, m/z): 565.3 [M+H]+.
[0256] 1H NMR (400 MHz, DMSO-d6) δ 7.60 - 7.51 (m, 2H), 7.47 - 7.42 (m, 2H), 7.40 (s, 1H), 7.37 - 7.32 (m, 1H), 7.12 (d, J = 8.0 Hz, 1H), 7.05 - 6.97 (m, 1H), 6.35 - 6.28 (m, 1H), 6.27 (s, 1H), 6.24 - 6.16 (m, 1H), 3.83 - 3.73 (m, 2H), 3.12 - 3.00 (m, 1H), 2.87 (s, 6H), 2.81 - 2.71 (m, 2H), 2.46 - 2.28 (m, 3H), 2.10 - 1.98 (m, 2H), 1.92 - 1.81 (m, 2H), 1.35 (s, 9H), 1.03 - 0.93 (m, 1H), 0.48 - 0.38 (m, 1H), 0.31 - 0.19 (m, 2H), 0.11 - 0.02 (m, 1H).
Example 26:
Synthetic Route:
[0258] Referring to the synthetic route of compound 6, compound 6-4 was replaced with compound 26-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 26 (13 mg, yield: 61%) as a white solid. MS (ESI, m/z): 568.3 [M+H]+.
[0259] 1H NMR (400 MHz, CDCl3) δ 7.55 - 7.43 (m, 3H), 7.44 - 7.34 (m, 3H), 7.22 - 7.17 (m, 1H), 7.10 (d, J = 8.0 Hz, 1H), 7.01 - 6.96 (m, 1H), 6.88 (s, 1H), 6.79 - 6.73 (m, 1H), 3.82 - 3.77 (m, 2H), 3.19 - 3.01 (m, 1H), 2.87 - 2.79 (m, 4H), 2.49 (s, 3H), 2.27 - 2.19 (m, 2H), 1.97 - 1.89 (m, 2H), 1.39 (s, 9H), 1.26 (s, 1H), 1.08 (s, 1H), 0.62 (s, 1H), 0.46 (s, 1H), 0.32 (s, 1H), 0.20 (s, 1H).
Example 27:
Synthetic Route:
[0261] Referring to the synthetic route of compound 6, compound 6-4 was replaced with compound 27-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 27 (47 mg, yield: 47%) as a white solid. MS (ESI, m/z): 600.3 [M+H]+.
[0262] 1H NMR (400 MHz, CDCl3) δ 7.53 - 7.45 (m, 4H), 7.43 - 7.34 (m, 5H), 7.20 (d, J = 8.0 Hz, 1H), 7.11 (d, J = 8.0 Hz, 1H), 3.92 - 3.87 (m, 2H), 3.19 - 3.15 (m, 1H), 3.05 (s, 3H), 2.97 - 2.91 (m, 2H), 2.97 - 2.91 (m, 2H), 2.52 - 2.46 (m, 1H), 2.26 - 2.21 (m, 2H), 2.00 - 1.95 (m, 2H), 1.39 (s, 9H), 1.09 (s, 1H), 0.61 (s, 1H), 0.44 (s, 1H), 0.36 - 0.29 (m, 1H), 0.23 - 0.15 (m, 1H).
Example 28:
Synthetic Route:
[0264] Referring to the synthetic route of compound 12, compound 1-2 was replaced with compound 28-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 28 (50 mg, yield: 71%) as a white solid. MS (ESI, m/z): 510.3 [M+H]+.
[0265] 1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 8.0 Hz, 1H), 7.41 - 7.37 (m, 2H), 7.30 (s, 1H), 7.26 - 7.17 (m, 3H), 7.12 (d, J = 8.0 Hz, 1H), 6.65 - 6.58 (m, 1H), 6.53 (s, 1H), 6.46 - 6.42 (m, 1H), 3.83 - 3.79 (m, 5H), 3.14 - 3.04 (m, 1H), 2.89 - 2.78 (m, 4H), 2.54 - 2.47 (m, 1H), 2.45 (s, 3H), 2.28 - 2.17 (m, 2H), 1.95 - 1.89 (m, 2H), 1.16 - 1.06 (m, 1H), 0.69 - 0.57 (m, 1H), 0.50 - 0.41 (m, 1H), 0.39 - 0.31 (m, 1H), 0.25 - 0.16 (m, 1H).
Example 29:
Synthetic Route:
[0267] Referring to the synthetic route of compound 6, compound 6-1 was replaced with compound 29-1 and compound 6-4 was replaced with compound 11-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 29 (48.9 mg, yield: 13%) as a white solid. MS (ESI, m/z): 526.1 [M+H]+.
[0268] 1H NMR (400 MHz, MeOD) δ 7.44 - 7.36 (m, 3H), 7.18 - 7.10 (m, 2H), 7.05 (d, J= 7.6 Hz, 1H), 7.00 (s, 1H), 6.99 - 6.94 (m, 1H), 6.63 - 6.58 (m, 1H), 6.56 - 6.53 (m, 1H), 6.45 - 6.40 (m, 1H), 3.85 (s, 3H), 3.82 - 3.72 (m, 5H), 3.18 - 3.06 (m, 1H), 2.83 - 2.69 (m, 4H), 2.52 - 2.43 (m, 1H), 2.28 - 2.13 (m, 2H), 1.98-1.88 (m, 2H), 1.17 - 1.05 (m, 1H), 0.64 - 0.55 (m, 1H), 0.45 - 0.30 (m, 2H), 0.20 - 0.13 (m, 1H).
Example 30:
Synthetic Route:
[0270] Referring to the synthetic route of compound 6, compound 6-1 was replaced with compound 30-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 30 (15 mg, yield: 19%) as a white solid. MS (ESI, m/z): 536.2 [M+H]+.
[0271] 1H NMR (400 MHz, MeOD) δ 7.63 (d, J = 8.4 Hz, 2H), 7.45 (d, J = 8.4 Hz, 2H), 7.41-7.41 (m, 2H), 7.20 - 7.09 (m, 2H), 6.63 - 6.60 (m, 1H), 6.56 - 6.54 (m, 1H), 6.44 - 6.41 (m, 1H), 5.46 (s, 1H), 5.13 - 5.11 (m, 1H), 3.82 - 3.71 (s, 5H), 3.14 - 3.11 (m, 1H), 2.84 - 2.47 (m, 5H), 2.30 - 2.13 (m, 5H),1.95 - 1.92 (m, 2H), 1.09 - 1.06 (m, 1H), 0.58 - 0.54 (m, 1H), 0.39 - 0.35 (m, 2H), 0.15 - 0.12 (m, 1H).
Example 31:
Synthetic Route:
[0273] Referring to the synthetic route of compound 26, compound 6-3 was replaced with compound 1-4 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 31 (11 mg, yield: 47%) as a white solid. MS (ESI, m/z): 568.3 [M+H]+.
[0274] 1H NMR (400 MHz, CDCl3) δ 7.50 (s, 1H), 7.47 - 7.40 (m, 3H), 7.39 - 7.36 (m, 1H), 7.35 - 7.31 (m, 1H), 7.15 (d, J = 8.0 Hz, 1H), 6.96 - 6.90 (m, 3H), 6.89 - 6.86 (m, 1H), 3.51 - 3.47 (m, 2H), 3.02 (s, 1H), 2.71 - 2.59 (m, 2H), 2.57 (s, 1H), 2.50 (s, 3H), 2.33 (s, 2H), 2.18 - 2.12 (m, 2H), 1.95 - 1.88 (m, 2H), 1.35 (s, 9H), 0.99 (s, 1H), 0.45 - 0.40 (m, 1H), 0.31 - 0.22 (m, 2H), 0.12 - 0.06 (m, 1H).
Example 32:
Synthetic Route:
[0276] Referring to the synthetic route of compound 6, compound 6-4 was replaced with compound 32-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 32 (20 mg, yield: 42%) as a white solid. MS (ESI, m/z): 553.3 [M+H]+.
[0277] 1H NMR (400 MHz, MeOD) δ 7.94 - 7.88 (m, 1H), 7.58 - 7.51 (m, 2H), 7.45 - 7.32 (m, 4H), 7.20 - 7.14 (m, 1H), 6.35 - 6.29 (m, 2H), 4.38 - 4.26 (m, 2H), 3.83 (s, 3H), 3.30 - 3.14 (m, 1H), 2.99 - 2.86 (m, 2H), 2.72 - 2.45 (m, 3H), 2.15 - 2.01 (m, 2H), 1.95 - 1.84 (m, 2H), 1.39 (s, 9H), 1.11 - 1.00 (m, 1H), 0.61 - 0.50 (m, 1H), 0.43 - 0.31 (m, 2H), 0.16 - 0.07 (m, 1H).
Example 33:
Synthetic Route:
[0279] Referring to the synthetic route of compound 12, compound 1-2 was replaced with compound 33-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 33 (49 mg, yield: 79%) as a white solid. MS (ESI, m/z): 554.2 [M+H]+.
[0280] 1H NMR (400 MHz, CDCl3) δ 7.48 - 7.42 (m, 1H), 7.38 - 7.33 (m, 3H), 7.28 - 7.25 (m, 1H), 7.23 - 7.15 (m, 1H), 7.13 - 7.07 (m, 1H), 7.04 - 6.96 (m, 2H), 6.64 - 6.40 (m, 2H), 4.69 - 4.55 (m, 1H), 3.85 - 3.75 (m, 5H), 3.13 - 3.01 (m, 1H), 2.98 - 2.78 (m, 4H), 2.52 - 2.47 (m, 1H), 2.35 - 2.15 (m, 2H), 1.95 - 1.85 (m, 2H), 1.45 - 1.35 (m, 6H), 1.15 - 1.05 (m, 1H), 0.66 - 0.55 (m, 1H), 0.48 - 0.40 (m, 1H), 0.38 - 0.29 (m, 1H), 0.25 - 0.15 (m, 1H).
Example 34:
Synthetic Route:
[0282] Referring to the synthetic route of compound 12, compound 1-2 was replaced with compound 34-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 34 (27 mg, yield: 39%) as a white solid. MS (ESI, m/z): 553.2 [M+H]+.
[0283] 1H NMR (400 MHz, CDCl3) δ 7.51 - 7.44 (m, 1H), 7.37 - 7.32 (m, 1H), 7.31 - 7.27 (m, 1H), 7.22 - 7.15 (m, 1H), 7.13 - 7.05 (m, 1H), 6.90 - 6.36 (m, 6H), 3.86 - 3.74 (m, 4H), 3.70 - 3.60 (m, 1H), 3.21 - 3.05 (m, 1H), 2.92 - 2.76 (m, 3H), 2.54 - 2.42 (m, 1H), 2.35 - 2.16 (m, 2H), 1.96 - 1.83 (m, 2H), 1.36 - 1.20 (m, 7H), 1.13 - 1.02 (m, 1H), 0.96 - 0.80 (m, 1H), 0.68 - 0.56 (m, 1H), 0.48 - 0.40 (m, 1H), 0.38 - 0.28 (m, 1H), 0.24 - 0.14 (m, 1H).
Example 35:
Synthetic Route:
[0285] Referring to the synthetic route of compound 6, compound 6-1 was replaced with compound 35-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 35 (2 mg, yield: 12%) as a white solid. MS (ESI, m/z): 516.2 [M+H]+.
[0286] 1H NMR (400 MHz, MeOD) δ 7.46 (d, J = 8.0 Hz, 1H), 7.35 (s, 1H), 7.20 - 7.19 (m, 1H), 7.17 - 7.11 (m, 2H), 6.98 (s, 1H), 6.65 - 6.60 (m, 1H), 6.57 - 6.54 (m, 1H), 6.46 - 6.41 (m, 1H), 3.83 - 3.74 (m, 5H), 3.22 - 3.13 (m, 1H), 2.87 - 2.69 (m, 4H), 2.56 (s, 3H), 2.50 - 2.41 (m, 1H), 2.25 - 2.12 (m, 2H), 1.98 - 1.90 (m, 2H), 1.17 - 1.05 (m, 1H), 0.64 - 0.55 (m, 1H), 0.44 - 0.27 (m, 2H), 0.20 - 0.13 (m, 1H).
Example 36:
Synthetic Route:
[0288] Referring to the synthetic route of compound 6, compound 6-1 was replaced with compound 36-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 36 (8 mg, yield: 14%) as a white solid. MS (ESI, m/z): 500.2 [M+H]+.
[0289] 1H NMR (400 MHz, DMSO-d6) δ 8.07 (s, 1H), 7.73 (s, 1H), 7.52 - 7.44 (m, 1H), 7.38 (s, 1H), 7.15 - 7.09 (m, 2H), 6.61 - 6.54 (m, 1H), 6.51 - 6.47 (m, 1H), 6.38 - 6.32 (m, 1H), 3.93 (s, 3H), 3.86 - 3.78 (m, 2H), 3.73 (s, 3H), 3.23 - 3.13 (m, 1H), 2.93 - 2.80 (m, 2H), 2.47 - 2.31 (m, 3H), 2.05 - 1.80 (m, 4H), 1.02 - 0.94 (m, 1H), 0.47 - 0.40 (m, 1H), 0.29 - 0.19 (m, 2H), 0.10 - 0.03 (m, 1H).
Example 37:
Synthetic Route:
[0291] Referring to the synthetic route of compound 6, compound 6-1 was replaced with compound 37-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 37 (7 mg, yield: 16%) as a white solid. MS (ESI, m/z): 514.2 [M+H]+.
[0292] 1H NMR (400 MHz, MeOD) δ 7.93 (s, 1H), 7.71 (s, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.35 (s, 1H), 7.18 - 7.11 (m, 2H), 6.65 - 6.60 (m, 1H), 6.58 - 6.54 (m, 1H), 6.48 - 6.39 (m, 1H), 4.35 - 4.25 (m, 2H), 3.84 - 3.74 (m, 5H), 3.19 - 3.10 (m, 1H), 2.90 - 2.69 (m, 4H), 2.50 - 2.40 (m, 1H), 2.26 - 2.11 (m, 2H), 1.99 - 1.89 (m, 2H), 1.56 - 1.37 (m, 3H), 1.16 - 1.07 (m, 1H), 0.65 - 0.56 (m, 1H), 0.45 - 0.28 (m, 2H), 0.22 - 0.12 (m, 1H).
Example 38:
Synthetic Route:
[0294] Referring to the synthetic route of compound 12, compound 1-2 was replaced with compound 38-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 38 (13 mg, yield: 33%) as a white solid. MS (ESI, m/z): 542.2 [M+H]+.
[0295] 1H NMR (400 MHz, CDCl3) δ 7.70 (s, 2H), 7.48 (d, J = 8.0 Hz, 1H), 7.36 (s, 1H), 7.24 - 7.10 (m, 2H), 6.67 - 6.58 (m, 1H), 6.57 - 6.50 (m, 1H), 6.49 - 6.39 (m, 1H), 3.87 - 3.78 (m, 5H), 3.15 - 3.05 (m, 1H), 2.94 - 2.78 (m, 4H), 2.55 - 2.44 (m, 1H), 2.31 - 2.15 (m, 2H), 2.00 - 1.88 (m, 2H), 1.68 (s, 9H), 1.16 - 1.03 (m, 1H), 0.68 - 0.56 (m, 1H), 0.51 - 0.39 (m, 1H), 0.38 - 0.29 (m, 1H), 0.26 - 0.15 (m, 1H).
Example 39:
Synthetic Route:
[0297] Referring to the synthetic route of compound 6, compound 6-1 was replaced with compound 38-1 and compound 6-4 was replaced with compound 39-4 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 39 (17 mg, yield: 40%) as a white solid. MS (ESI, m/z): 512.2 [M+H]+.
[0298] 1H NMR (400 MHz, CDCl3) δ 7.72 - 7.68 (m, 2H), 7.48 (d, J = 8.0 Hz, 1H), 7.36 (s, 1H), 7.35 - 7.29 (m, 2H), 7.29 - 7.28 (m, 1H), 7.14 (d, J = 8.0 Hz, 1H), 7.05 - 7.00 (m, 1H), 6.96 - 6.85 (m, 1H), 3.89 - 3.79 (m, 2H), 3.19 - 3.02 (m, 1H), 2.93 - 2.82 (m, 4H), 2.56 - 2.46 (m, 1H), 2.37 - 2.17 (m, 2H), 1.98 - 1.90 (m, 2H), 1.68 (s, 9H), 1.16 - 1.05 (m, 1H), 0.67 - 0.58 (m, 1H), 0.49 - 0.42 (m, 1H), 0.39 - 0.31 (m, 1H), 0.26 - 0.15 (m, 1H).
Example 40:
Synthetic Route:
[0300] Referring to the synthetic route of compound 39, compound 39-4 was replaced with compound 4-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 40 (30 mg, yield: 61%) as a white solid. MS (ESI, m/z): 526.3 [M+H]+.
[0301] 1H NMR (400 MHz, CDCl3) δ 7.72 - 7.69 (m, 2H), 7.48 (d, J = 8.0 Hz, 1H), 7.36 (s, 1H), 7.22 - 7.12 (m, 2H), 6.87 - 6.79 (m, 2H), 6.74 - 6.69 (m, 1H), 3.85 - 3.79 (m, 2H), 3.15 - 3.05 (m, 1H), 2.92 - 2.81 (m, 4H), 2.54 - 2.47 (m, 1H), 2.35 (s, 3H), 2.29 - 2.20 (m, 2H), 1.98 - 1.92 (m, 2H), 1.68 (s, 9H), 1.13 - 1.06 (m, 1H), 0.65 - 0.58 (m, 1H), 0.46 - 0.41 (m, 1H), 0.37 - 0.31 (m, 1H), 0.24 - 0.17 (m, 1H).
Example 41:
Synthetic Route:
[0303] Referring to the synthetic route of compound 39, compound 39-4 was replaced with compound 41-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 50% to 70%] to obtain compound 41 (25 mg, yield: 71%) as a white solid. MS (ESI, m/z): 530.3 [M+H]+.
[0304] 1H NMR (400 MHz, CDCl3) δ 7.72 - 7.68 (m, 2H), 7.48 (d, J = 8.0 Hz, 1H), 7.36 (s, 1H), 7.26 - 7.17 (m, 1H), 7.14 (d, J = 8.0 Hz, 1H), 6.79 - 6.72 (m, 1H), 6.71 - 6.63 (m, 1H), 6.59 - 6.51 (m, 1H), 3.90 - 3.78 (m, 2H), 3.20 - 3.09 (m, 1H), 2.95 - 2.80 (m, 4H), 2.54 - 2.44 (m, 1H), 2.28 - 2.15 (m, 2H), 2.00 - 1.91 (m, 2H), 1.68 (s, 9H), 1.19 - 1.04 (m, 1H), 0.67 - 0.58 (m, 1H), 0.49 - 0.40 (m, 1H), 0.38 - 0.30 (m, 1H), 0.24 - 0.15 (m, 1H).
Example 42:
Synthetic Route:
[0306] Referring to the synthetic route of compound 39, compound 39-4 was replaced with compound 42-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 50% to 70%] to obtain compound 42 (36 mg, yield: 72%) as a white solid. MS (ESI, m/z): 596.3 [M+H]+.
[0307] 1H NMR (400 MHz, CDCl3) δ 7.72 - 7.67 (m, 2H), 7.48 (d, J = 8.0 Hz, 1H), 7.36 (s, 1H), 7.31 - 7.28 (m, 1H), 7.14 (d, J = 8.0 Hz, 1H), 6.99 - 6.88 (m, 1H), 6.87 - 6.78 (m, 1H), 6.78 - 6.68 (m, 1H), 3.90 - 3.79 (m, 2H), 3.20 - 3.08 (m, 1H), 2.99 - 2.84 (m, 4H), 2.55 - 2.46 (m, 1H), 2.33 - 2.16 (m, 2H), 2.02 - 1.93 (m, 2H), 1.68 (s, 9H), 1.15 - 1.05 (m, 1H), 0.70 - 0.60 (m, 1H), 0.49 - 0.40 (m, 1H), 0.37 - 0.30 (m, 1H), 0.23 - 0.17 (m, 1H).
Example 43:
Synthetic Route:
[0309] Referring to the synthetic route of compound 39, compound 39-4 was replaced with compound 43-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 50% to 70%] to obtain compound 43 (9.6 mg, yield: 47%) as a white solid. MS (ESI, m/z): 578.3 [M+H]+.
[0310] 1H NMR (400 MHz, DMSO-d6) δ 8.10 (s, 1H), 7.75 (s, 1H), 7.54 (d, J = 8.0 Hz, 1H), 7.41 (s, 1H), .27 - 7.21 (m, 1H), 7.23 (t, J = 74.6 Hz, 1H), 7.14 (d, J = 8.0 Hz, 1H), 6.88 - 6.82 (m, 1H), 6.75 - 6.71 (m, 1H), 6.56 - 6.51 (m, 1H), 3.94 - 3.82 (m, 2H), 3.25 - 3.16 (m, 1H), 2.99 - 2.88 (m, 2H), 2.64 - 2.50 (m, 2H), 2.44 - 2.37 (m, 1H), 2.07 - 1.77 (m, 4H), 1.60 (s, 9H), 1.07 - 0.95 (m, 1H), 0.52 - 0.41 (m, 1H), 0.33 - 0.19 (m, 2H), 0.12 - 0.08 (m, 1H).
Example 44:
Synthetic Route:
[0312] Referring to the synthetic route of compound 39, compound 39-4 was replaced with compound 44-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 50% to 70%] to obtain compound 44 (15 mg, yield: 47%) as a white solid. MS (ESI, m/z): 567.3 [M+H]+.
[0313] 1H NMR (400 MHz, CDCl3) δ 7.73 - 7.69 (m, 2H), 7.55 - 7.47 (m, 2H), 7.38 (s, 1H), 7.15 (d, J = 8.0 Hz, 1H), 6.57 - 6.51 (m, 2H), 3.86 (s, 3H), 3.79 - 3.72 (m, 2H), 3.17 - 3.08 (m, 1H), 2.95 - 2.86 (m, 4H), 2.57 - 2.49 (m, 1H), 2.42 - 2.31 (m, 2H), 2.01 - 1.96 (m, 2H), 1.69 (s, 9H), 1.15 - 1.09 (m, 1H), 0.70 - 0.60 (m, 1H), 0.50 - 0.43 (m, 1H), 0.39 - 0.32 (m, 1H), 0.27 - 0.19 (m, 1H).
Example 45:
Synthetic Route:
[0315] Referring to the synthetic route of compound 39, compound 39-4 was replaced with compound 45-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 40 (6 mg, yield: 30%) as a white solid. MS (ESI, m/z): 552.3 [M+H]+.
[0316] 1H NMR (400 MHz, DMSO-d6) δ 8.12 (s, 1H), 7.77 (s, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.44 (s, 1H), 7.18 (d, J = 8.0 Hz, 1H), 7.15 -7.08 (m, 1H), 6.85 - 6.75 (m, 1H), 6.74 (s, 1H), 6.53 - 6.45 (m, 1H), 3.90 - 3.80 (m, 2H), 3.24 - 3.15 (m, 1H), 2.93 - 2.82 (m, 2H), 2.64 - 2.56 (m, 2H), 2.49 - 2.40 (m, 1H), 2.08 - 1.98 (m, 2H), 1.96 - 1.85 (m, 3H), 1.63 (s, 9H), 1.10 - 1.00 (m, 1H), 0.96 - 0.90 (m, 2H), 0.72 - 0.65 (m, 2H), 0.55 - 0.45 (m, 1H), 0.33 - 0.26 (m, 2H), 0.18 - 0.08 (m, 1H).
Example 46:
Synthetic Route:
[0318] The synthesis route of intermediate M1 was referred to obtain intermediate M3. Then, referring to the synthetic route of compound 38, compound 12-1 was replaced with compound 46-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 46 (60 mg, yield: 42%) as a white solid. MS (ESI, m/z): 542.3 [M+H]+.
[0319] 1H NMR (400 MHz, CDCl3) δ 7.79 - 7.61 (m, 2H), 7.55 - 7.45 (m, 1H), 7.36 (s, 1H), 7.17 - 7.09 (m, 2H), 6.61 - 6.34 (m, 3H), 3.80 - 3.75 (m, 5H), 3.41 - 3.29 (m, 1H), 3.21 - 3.11 (m, 1H), 2.91 - 2.81 (m, 3H), 2.54 - 2.48 (m, 1H), 2.07 - 1.94 (m, 2H), 1.89 - 1.77 (m, 2H), 1.66 (s, 9H), 1.15 - 1.06 (m, 1H), 0.65 - 0.58 (m, 1H), 0.48 - 0.42 (m, 1H), 0.36 - 0.30 (m, 1H), 0.25 - 0.16 (m, 1H).
Example 47:
Synthetic Route:
[0321] Referring to the synthetic route of compound 6, compound 6-1 was replaced with compound 47-1 to synthesize compound 47-4 (29 mg, 0.0507 mmol). To compound 47-4 (29 mg, 0.0507 mmol), dichloromethane (2 mL) and diethylaminosulfur trifluoride (11 mg, 0.066) were added at 0°C, and the reaction was carried out at room temperature for 2 hours. Water (10 mL) was added, and the mixture was extracted with ethyl acetate (10 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and rotary evaporated to dryness to remove the solvent. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 20%) to obtain compound 47-5 (15 mg, yield: 52%) as a white solid. MS (ESI, m/z): 574.3 [M+H]+.
[0322] Then, referring to the synthetic route of compound 6, the synthesis was carried out, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 47 (3 mg, yield: 21%) as a white solid. MS (ESI, m/z): 560.3 [M+H]+.
[0323] 1H NMR (400 MHz, CDCl3) δ 7.73 - 7.65 (m, 2H), 7.48 (d, J = 8.0 Hz, 1H), 7.36 (s, 1H), 7.23 - 7.17 (m, 1H), 7.16 - 7.12 (m, 1H), 6.64 - 6.58 (m, 1H), 6.57 - 6.51 (m, 1H), 6.47 - 6.41 (m, 1H), 4.37 (d, J = 22.0 Hz, 2H), 3.88 - 3.77 (m, 5H), 3.17 - 3.00 (m, 1H), 2.92 - 2.79 (m, 4H), 2.56 - 2.46 (m, 1H), 2.28 - 2.17 (m, 2H), 1.97 - 1.90 (m, 2H), 1.42 (s, 3H), 1.37 (s, 3H), 1.13 - 1.07 (m, 1H), 0.67 - 0.60 (m, 1H), 0.51 - 0.42 (m, 1H), 0.39 - 0.31 (m, 1H), 0.25 - 0.17 (m, 1H).
Example 48:
Synthetic Route:
[0325] Referring to the synthetic route of compound 6, compound 6-1 was replaced with compound 48-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 48 (27 mg, yield: 46%) as a white solid. MS (ESI, m/z): 572.3 [M+H]+.
[0326] 1H NMR (400 MHz, CDCl3) δ 7.79 - 7.64 (m, 2H), 7.49 (d, J = 8.0 Hz, 1H), 7.35 (s, 1H), 7.24 - 7.17 (m, 2H), 7.14 (d, J = 8.0 Hz, 1H), 6.67 - 6.58 (m, 1H), 6.57 - 6.51 (m, 1H), 6.50 - 6.40 (m, 1H), 3.97 - 3.83 (m, 2H), 3.82 (s, 3H), 3.70 - 3.59 (m, 2H), 3.31 (s, 3H), 3.16 - 3.04 (m, 1H), 2.93 - 2.76 (m, 4H), 2.55 - 2.45 (m, 1H), 2.28 - 2.19 (m, 2H), 1.99 - 1.86 (m, 2H), 1.67 (s, 6H), 1.17 - 1.02 (m, 1H), 0.70 - 0.56 (m, 1H), 0.51 - 0.39 (m, 1H), 0.39 - 0.28 (m, 1H), 0.22 -0.17 (m, 1H).
Example 49:
Synthetic Route:
[0328] A mixture of compound 12-1 (7.6 g, 15.0 mmol), trifluoroacetic acid (5.13 g, 45.0 mmol), and dichloromethane (100 mL) was stirred at room temperature for 2 hours. After the reaction was completed, saturated sodium bicarbonate solution (100 mL) was added, followed by extraction with dichloromethane (200 mL × 3). The organic phase was concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 50%) to obtain compound 49-1 (5.65 g, yield: 93%) as a yellow oil. MS (ESI, m/z): 406.2 [M+H]+.
[0329] Compound 49-1 (5.65 g, 13.9 mmol), 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (1.21 g, 1.9 mmol), palladium acetate (400 mg, 1.9 mmol), compound 11-1 (4.28 g, 20.8 mmol), and cesium carbonate (18.12 g, 55.6 mol) were added to toluene (100 mL) and stirred at 100°C overnight. LCMS monitoring confirmed the complete consumption of the starting material. After the reaction was stopped, dichloromethane (200 mL) and water (200 mL) were added to the reaction mixture. The reaction mixture was extracted, and the organic phase was concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 50%) to obtain compound 49-2 (949 mg, yield: 13%) as a white solid. MS (ESI, m/z): 512.1 [M+H]+.
[0330] Compound 49-2 (525 mg, 1.0 mmol), compound 49-3 (385 mg, 2.5 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) chloride dichloromethane complex (40 mg, 0.5 mmol), and cesium carbonate (975 mg, 3 mmol) were added to a mixture of 1,4-dioxane: water = 5:1 (25 mL). The reaction mixture was stirred at 80°C for 16 hours. LCMS monitoring confirmed the complete consumption of the starting material. The reaction mixture was extracted with ethyl acetate (50 mL) and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 20%) to obtain compound 49-4 (390 mg, yield: 97%) as a yellow oil. MS (ESI, m/z): 460.2 [M+H]+.
[0331] Compound 49-4 (390 mg, 0.85 mmol) and 2,6-dimethylpyridine (182 mg, 1.7 mmol) were added to a mixture of 1,4-dioxane: water = 3:1 (40 mL). Potassium osmate dihydrate (15.5 mg, 0.0425 mmol) and sodium periodate (910 mg, 4.25 mmol) were added at 0°C, and the reaction mixture was stirred at 0°C for 4 hours. LCMS monitoring confirmed the complete consumption of the starting material. Saturated sodium thiosulfate aqueous solution (25 mL) was added at 0°C, and the reaction mixture was extracted with ethyl acetate (50 mL) and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 20%) to obtain compound 49-5 (195 mg, yield: 49%) as a yellow oil. MS (ESI, m/z): 462.2 [M+H]+.
[0332] Compound 49-5 (195 mg, 0.425 mmol) and 2-methyl-2-butene (600 mg, 8.5 mmol) were added to a mixture of tetrahydrofuran: tert-butanol = 1:1 (20 mL). An aqueous solution (10 mL) containing sodium dihydrogen phosphate (700 mg, 5.1 mmol) and sodium chlorite (192 mg, 2.15 mmol) was added dropwise at 25°C. The reaction mixture was stirred at 25°C for 4 hours. LCMS monitoring confirmed the complete consumption of the starting material. The reaction mixture was extracted with ethyl acetate (30 mL) and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 50%) to obtain compound 49-6 (128 mg, yield: 63%) as a yellow oil. MS (ESI, m/z): 478.2 [M+H]+.
[0333] Compound 49-6 (120 mg, 0.25 mmol), triethylamine (76 mg, 0.75 mmol), and 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (191 mg, 0.50 mmol) were added to N,N-dimethylformamide (5 mL) and stirred. Then, tert-butyl carbazate (66 mg, 0.50 mmol) was added, and the reaction mixture was stirred at room temperature for 16 hours. After the reaction was completed, ethyl acetate (80 mL) was added for dilution, and the organic phase was washed with water (40 mL × 3), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 50%) to obtain compound 49-7 (145 mg, yield: 97%) as a yellow oil. MS (ESI, m/z): 592.2 [M+H]+.
[0334] Compound 49-7 (145 mg, 0.25 mmol) was added to 1,4-dioxane (2 mL) and stirred. Then, hydrochloric acid in 1,4-dioxane (4 M, 4 mL) was added, and the reaction mixture was stirred at room temperature for 4 hours. After the reaction was completed, the reaction mixture was concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 50%) to obtain compound 49-8 (128 mg, yield: 99%) as a yellow oil. MS (ESI, m/z): 492.2 [M+H]+.
[0335] Compound 49-8 (64 mg, 0.12 mmol), triethylamine (37 mg, 0.36 mmol), and 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (92 mg, 0.24 mmol) were added to N,N-dimethylformamide (10 mL) and stirred. Then, 3,3,3-trifluoro-2,2-dimethylpropanoic acid (38 mg, 0.36 mmol) was added, and the reaction mixture was stirred at room temperature for 16 hours. After the reaction was completed, ethyl acetate (200 mL) was added for dilution, and the organic phase was washed with water (40 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 50%) to obtain compound 49-9 (72 mg, yield: 95%) as a yellow oil. MS (ESI, m/z): 630.2 [M+H]+.
[0336] Compound 49-9 (72 mg, 0.11 mmol) and p-toluenesulfonyl chloride (33 mg, 0.17 mmol) were added to dichloromethane (5 mL), and triethylamine (35 mg, 0.34 mmol) was added at 0°C. The reaction mixture was reacted at room temperature for 2 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product. The resulting crude product was then purified by normal-phase column chromatography (petroleum ether: ethyl acetate = 8:2) to obtain compound 49-10 (65 mg, yield: 93%) as a yellow oil. MS (ESI, m/z): 612.2 [M+H]+.
[0337] Compound 49-10 (65 mg, 0.11 mmol) was added to methanol (2 mL) and stirred. 4 M sodium hydroxide solution (2 mL) was added, and the reaction mixture was stirred at 60°C for 16 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product. The resulting crude product was then purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 49 (21.05 mg, yield: 33%) as a yellow solid. MS (ESI, m/z): 598.3 [M+H]+.
[0338] 1H NMR (400 MHz, CDCl3) δ 7.98 - 7.87 (m, 1H), 7.42 (s, 1H), 7.32 - 7.27 (m, 1H), 7.24 - 7.15 (m, 1H), 6.66 - 6.59 (m, 1H), 6.55 (s, 1H), 6.49 - 6.41 (m, 1H), 3.91 - 3.73 (m, 6H), 2.98 - 2.80 (m, 4H), 2.55 - 2.46 (m, 1H), 2.26 - 2.16 (m, 2H), 2.08 - 2.02 (m, 2H), 1.77 (s, 6H), 1.16 - 1.03 (m, 1H), 0.69 - 0.59 (m, 1H), 0.48-0.42 (m, 1H), 0.39 - 0.30 (m, 1H), 0.21-0.16 (m, 1H).
Example 50:
Synthetic Route:
[0340] Referring to the synthetic route of compound 49, 3,3,3-trifluoro-2,2-dimethylpropionic acid was replaced with 2,2-dimethylbutyric acid to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 50 (11 mg, yield: 19%) as a white solid. MS (ESI, m/z): 558.3 [M+H]+.
[0341] 1H NMR (400 MHz, CDCl3) δ 7.95 - 7.90 (m, 1H), 7.41 (s, 1H), 7.27 - 7.16 (m, 2H), 6.68 - 6.60 (m, 1H), 6.56 (s, 1H), 6.50 - 6.42 (m, 1H), 3.93 - 3.68 (m, 6H), 3.00 - 2.75 (m, 4H), 2.58 - 2.43 (m, 1H), 2.31 - 2.15 (m, 2H), 2.07 -2.04 (m, 2H), 1.90 - 1.83 (m, 2H), 1.49 (s, 6H), 1.14 - 1.04 (m, 1H), 0.92 (t, J = 7.6 Hz, 3H), 0.69 - 0.59 (m, 1H), 0.51 - 0.40 (m, 1H), 0.40 - 0.30 (m, 1H), 0.25 - 0.13 (m, 1H).
Example 51:
Synthetic Route:
[0344] Referring to the synthetic route of compound 6, compound 6-1 was replaced with compound 51-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 51 (5 mg, yield: 15%) as a white solid. MS (ESI, m/z): 572.3 [M+H]+.
[0345] 1H NMR (400 MHz, CDCl3) δ 7.80 - 7.70 (m, 2H), 7.41 (d, J = 8.0 Hz, 1H), 7.35 (s, 1H), 7.23 - 7.17 (m, 1H), 7.09 (d, J = 8.0 Hz, 1H), 6.67 - 6.60 (m, 1H), 6.56 (s, 1H), 6.48 - 6.42 (m, 1H), 3.83 - 3.77 (m, 5H), 3.13 - 3.00 (m, 1H), 2.90 - 2.80 (m, 4H), 2.49 - 2.40 (m, 1H), 2.27 - 2.12 (m, 2H), 1.95 (s, 6H), 1.92 - 1.87 (m, 2H), 1.12 - 1.01 (m, 1H), 0.66 - 0.57 (m, 1H), 0.48 - 0.39 (m, 1H), 0.36 - 0.26 (m, 1H), 0.25 - 0.16 (m, 1H).
Example 52:
Synthetic Route:
[0347] Referring to the synthetic route of compound 51, compound 51-4 (100 mg, 0.172 mol) was obtained. Compound 51-4 (100 mg, 0.172 mol), methylamine hydrochloride (14 mg, 0.207 mmol), HATU (79 mg, 0.207 mmol), and TEA (52 mg, 0.517 mmol) were added to dichloromethane (5 mL), and the reaction was carried out at room temperature for 16 hours. After the reaction was completed, the reaction mixture was directly concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 52-1 (109 mg, yield: 99%) as a white solid. MS (ESI, m/z): 599.2 [M+H]+.
[0348] Referring to the synthetic route of compound 51, the synthesis was carried out, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 52 (30 mg, yield: 38%) as a white solid. MS (ESI, m/z): 585.3 [M+H]+.
[0349] 1H NMR (400 MHz, CDCl3) δ 7.84 - 7.77 (m, 2H), 7.45 (d, J = 8.0 Hz, 1H), 7.37 (s, 1H), 7.25 - 7.12 (m, 2H), 6.67 - 6.59 (m, 1H), 6.55 (s, 1H), 6.49 - 6.43 (m, 1H),6.42 - 6.35 (m, 1H), 3.87 - 3.81 (m, 5H), 3.14 - 3.00 (m, 1H), 2.90 - 2.82 (m, 4H), 2.81 - 2.74 (m, 3H), 2.57 - 2.46 (m, 1H), 2.33 - 2.16 (m, 2H), 1.97 - 1.91 (m, 8H), 1.16 - 0.98 (m, 1H), 0.70 - 0.59 (m, 1H), 0.50 - 0.41 (m, 1H), 0.40 - 0.29 (m, 1H), 0.26 - 0.14 (m, 1H).
Example 53:
Synthetic Route:
[0351] Referring to the synthetic route of compound 52, methylamine hydrochloride was replaced with dimethylamine hydrochloride to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 53 (22 mg, yield: 41%) as a white solid. MS (ESI, m/z): 599.3 [M+H]+.
[0352] 1H NMR (400 MHz, DMSO-d6) δ 8.18 - 8.12 (m, 1H), 7.84 - 7.78 (m, 1H), 7.54 - 7.48 (m, 1H), 7.44 (s, 1H), 7.17 - 7.09 (m, 2H), 6.67 - 6.59 (m, 1H), 6.55 (s, 1H), 6.49 - 6.43 (m, 1H), 3.84 - 3.76 (m, 2H), 3.72 (s, 3H), 3.20 - 3.16 (m, 1H), 2.89 - 2.79 (m, 4H), 2.71 - 2.59 (m, 3H), 2.40 - 2.32 (m, 3H), 1.97 - 1.93 (m, 1H), 1.89 - 1.83 (m, 2H), 1.76 (s, 6H), 1.07 - 1.00 (m, 1H), 0.53 - 0.45 (m, 1H), 0.28 - 0.21 (m, 2H), 0.15 - 0.08 (m, 1H).
Example 54:
Synthetic Route:
[0354] Referring to the synthetic route of compound 38, compound 38-4 (210 mg, 0.382 mmol) was obtained and dissolved in tetrahydrofuran (5 mL). Lithium bis(trimethylsilyl)amide (0.77 mL, 2 M in THF) was added at -78°C, and the reaction was transferred to room temperature and carried out for 1 hour. After cooling back to -78°C, N-fluorobenzenesulfonimide (240 mg, 7.64 mmol) was added, and the reaction was carried out at room temperature overnight. The reaction was quenched with saturated ammonium chloride solution (20 mL) and extracted with ethyl acetate (20 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 5%) to obtain compound 54-1 (41 mg, yield: 19%) as a white solid. MS (ESI, m/z): 574.3 [M+H]+.
[0355] Compound 54-1 (41 mg, 0.0897 mmol) and lithium hydroxide (9.0 mg, 0.358 mmol) were dissolved in THF (2 mL), methanol (2 mL), and water (2 mL). The reaction was carried out at 50°C for 2 hours. After concentration, the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 50% to 70%] to obtain compound 54 (8.0 mg, yield: 20%) as a white solid. MS (ESI, m/z): 560.3 [M+H]+.
[0356] 1H NMR (400 MHz, CDCl3) δ 7.75 - 7.68 (m, 2H), 7.54 - 7.48 (m, 2H), 7.25 - 7.20 (m, 2H), 6.70 - 6.58 (m, 2H), 6.51 - 6.45 (m, 1H), 5.22 (d, J = 48.1 Hz, 1H), 3.86 - 3.79 (m, 5H), 3.15 - 3.08 (m, 1H), 2.92 - 2.86 (m, 2H), 2.67 - 2.61 (m, 1H), 2.32 - 2.23 (m, 2H), 1.99 - 1.90 (m, 2H), 1.69 (s, 9H), 1.56 - 1.50 (m, 1H), 0.77 - 0.70 (m, 1H), 0.63 - 0.56 (m, 1H), 0.52 - 0.45 (m, 1H), 0.17 - 0.10 (m, 1H).
Example 55:
Synthetic Route:
[0358] Referring to the synthetic route of compound 38, compound 38-4 (253 mg, 0.46 mmol) was obtained and dissolved in tetrahydrofuran (5 mL). Lithium bis(trimethylsilyl)amide (1.0 mL, 2 M in THF) was added at -40°C, and the reaction was carried out for 1 hour. Then iodomethane (196 mg, 1.4 mmol) was added. The reaction was carried out at room temperature overnight. The reaction was quenched with saturated ammonium chloride solution (20 mL) and extracted with ethyl acetate (20 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 5%) to obtain compound 55-1 (192 mg, yield: 74%) as a white solid. MS (ESI, m/z): 570.3 [M+H]+.
[0359] Referring to the synthetic route of compound 6, compound 6-5 was replaced with compound 55-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 55 (122 mg, yield: 64%) as a white solid. MS (ESI, m/z): 556.3 [M+H]+.
[0360] 1H NMR (400 MHz, CDCl3) δ 7.73 - 7.63 (m, 2H), 7.50 - 7.40 (m, 1H), 7.34 (s, 1H), 7.23 - 7.06 (m, 2H), 6.65 - 6.36 (m, 3H), 3.81 (s, 5H), 3.16 - 3.02 (m, 1H), 3.06 - 2.94 (m, 1H), 2.88 - 2.79 (m, 2H), 2.40 - 2.30 (m, 1H), 2.26 - 2.15 (m, 2H), 1.97 - 1.88 (m, 2H), 1.66 (s, 9H), 1.31 (d, J = 7.2 Hz, 3H), 1.19 - 1.06 (m, 1H), 0.74 - 0.67 (m, 1H), 0.45 - 0.31 (m, 2H), 0.09 - 0.03 (m, 1H).
Example 56:
Synthetic Route:
[0362] Referring to the synthetic route of compound 38, compound 12-1 was replaced with compound 1-1 to synthesize compound 56-3 (560 mg, 1.0 mmol) as a white solid. Compound 56-3 (560 mg, 1.0 mmol) was added to tetrahydrofuran (10 mL), and lithium aluminum hydride (84 mg, 2.22 mmol) was slowly added to the reaction mixture under an ice bath. The reaction mixture was then stirred at room temperature for 1 hour. After the reaction was completed, the system was quenched sequentially with 0.1 mL of water, 0.1 mL of 15% sodium hydroxide solution, and 0.3 mL of water. Anhydrous sodium sulfate was added, and the mixture was filtered. The filtrate was concentrated to obtain a crude product, which was then purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 56 (377 mg, yield: 71%) as a white solid. MS (ESI, m/z): 528.1 [M+H]+.
[0363] 1H NMR (400 MHz, DMSO-d6) δ 8.13 - 8.06 (m, 1H), 7.76 - 7.71 (m, 1H), 7.59 - 7.53 (m, 1H), 7.41 - 7.37 (m, 1H), 7.16 - 7.08 (m, 2H), 6.61 - 6.54 (m, 1H), 6.51 - 6.46 (m, 1H), 6.40 - 6.33 (m, 1H), 4.33 - 4.28 (m, 1H), 3.84 (d, J = 12.0 Hz, 2H), 3.74 (s, 3H), 3.28 - 3.16 (m, 1H), 2.95 - 2.85 (m, 2H), 2.06 - 1.81 (m, 8H), 1.61 (s, 9H), 1.10 - 0.95 (m, 1H), 0.59 - 0.49 (m, 1H), 0.30 - 0.19 (m, 2H), 0.06 - 0.03 (m, 1H).
Example 57:
Synthetic Route:
[0365] Compound 56 (45 mg, 0.085 mmol) was added to dichloromethane (5 mL). Diethylaminosulfur trifluoride (27 mg, 0.17 mmol) was slowly added to the reaction mixture under an ice bath, and the reaction mixture was stirred at room temperature for 2 hours. After the reaction was completed, the reaction mixture was directly concentrated and purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 57 (7 mg, yield: 16%) as a white solid. MS (ESI, m/z): 530.1 [M+H]+.
[0366] 1H NMR (400 MHz, DMSO-d6) δ 8.10 (s, 1H), 7.75 (s, 1H), 7.63 - 7.54 (m, 1H), 7.45 (s, 1H), 7.14 - 7.10 (m, 2H), 6.63 - 6.54 (m, 1H), 6.49 (s, 1H), 6.39 - 6.31 (m, 1H), 4.54 - 4.18 (m, 1H), 3.89 - 3.78 (m, 2H), 3.73 (s, 3H), 3.22 - 3.18 (m, 1H), 2.95 - 2.81 (m, 2H), 2.26 - 1.82 (m, 8H), 1.60 (s, 9H), 1.15 - 1.02 (m, 1H), 0.62 - 0.53 (m, 1H), 0.33 - 0.19 (m, 2H), 0.11 - 0.02 (m, 1H).
Example 58:
Synthetic Route:
[0368] Compound 56 (300 mg, 0.57 mmol) was added to dichloromethane (15 mL). Under an ice bath, Dess-Martin periodinane (483 mg, 1.14 mmol) was slowly added to the reaction mixture and stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was directly concentrated and purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 58-1 (53 mg, yield: 18%) as a white solid. MS (ESI, m/z): 526.1 [M+H]+.
[0369] Compound 58-1 (53 mg, 0.1 mmol) was added to dichloromethane (15 mL). Diethylaminosulfur trifluoride (33 mg, 0.2 mmol) was slowly added to the reaction mixture under an ice bath, and the reaction mixture was stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was directly concentrated and purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 58 (6 mg, yield: 11%) as a yellow solid. MS (ESI, m/z): 548.1 [M+H]+.
[0370] 1H NMR (400 MHz, DMSO-d6) δ 7.76 - 7.65 (m, 2H), 7.54 - 7.46 (m, 1H), 7.38 - 7.31 (m, 1H), 7.26 - 7.17 (m, 2H), 7.15 - 7.08 (m, 1H), 6.69 - 6.38 (m, 2H), 5.91 - 5.57 (m, 1H), 3.89 - 3.76 (m, 5H), 3.13 - 2.83 (m, 1H), 2.42 - 2.09 (m, 5H), 2.05 - 1.89 (m, 2H), 1.69 (s, 9H), 1.57 - 1.49 (m, 2H), 1.10 - 1.06 (m, 1H), 0.75 - 0.64 (m, 1H), 0.50 - 0.39 (m, 1H), 0.38 - 0.29 (m, 1H), 0.22 - 0.13 (m, 1H).
Example 59:
Synthetic Route:
[0372] Compound 58-1 (94 mg, 0.18 mmol), propylene glycol (82 mg, 1.07 mmol), and a catalytic amount of p-toluenesulfonic acid were added to toluene (5 mL). The reaction mixture was heated to 120°C and stirred overnight. After the reaction was completed, the reaction mixture was directly concentrated and purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 59 (5 mg, yield: 5%) as a white solid. MS (ESI, m/z): 584.2 [M+H]+.
[0373] 1H NMR (400 MHz, DMSO-d6) δ 7.71 (s, 2H), 7.53 - 7.45 (m, 1H), 7.35 (s, 1H), 7.25 - 7.18 (m, 1H), 7.17 - 7.10 (m, 1H), 6.67 - 6.59 (m, 1H), 6.55 (s, 1H), 6.49 - 6.38 (m, 1H), 4.84 - 4.76 (m, 1H), 4.14 - 4.03 (m, 1H), 3.92 - 3.74 (m, 6H), 3.40 - 3.31 (m, 1H), 3.17 - 3.06 (m, 1H), 2.92 - 2.71 (m, 2H), 2.30 - 2.10 (m, 5H), 1.97 - 1.89 (m, 2H), 1.69 (s, 9H), 1.32 - 1.28 (m, 3H), 1.08 - 1.01 (m, 1H), 0.68 - 0.59 (m, 1H), 0.43 - 0.31 (m, 2H), 0.21 - 0.11 (m, 1H).
Example 60:
Synthetic Route:
[0375] Intermediate M4 was synthesized by referring to the synthetic route of intermediate M1. Then, referring to the synthetic route of compound 38 and replacing compound 12-1 with compound 60-1, compound 60-4 (3.42 g, 7.02 mmol) was obtained. Compound 60-4 (3.42 g, 7.02 mmol) was added to tetrahydrofuran (20 mL), and lithium aluminum hydride (293 mg, 7.72 mmol) was added under an ice bath. The reaction mixture was stirred at 0°C for 1 hour, then quenched with water (0.3 mL), followed by the addition of 15% sodium hydroxide (0.3 mL) and water (0.9 mL). The mixture was dried over magnesium sulfate, filtered, and the filtrate was concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 60-5 (2.5 g, yield: 77%) as a yellow solid. MS (ESI, m/z): 460.2 [M+H]+.
[0376] Compound 60-5 (1.5 g, 3.27 mmol), phosphorus tribromide (1.5 mL), and dichloromethane (25 mL) were stirred and reacted at room temperature for 2 hours. The reaction mixture was directly concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 60-6 (1.2 g, yield: 70%) as a yellow oil. MS (ESI, m/z): 522.2 [M+H]+.
[0377] Compound 60-6 (1.2 g, 2.3 mmol), compound 60-7 (3.08 g, 323 mmol), potassium carbonate (634 mg, 4.6 mmol), and N,N-dimethylformamide (10 mL) were stirred at 80°C for 3 hours. The reaction mixture was directly concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 60-8 (0.9 g, yield: 65%) as a yellow oil. MS (ESI, m/z): 602.2 [M+H]+.
[0378] Compound 60-8 (20 mg, 0.0333 mmol), iodomethane (14 mg, 0.0998 mmol), cesium carbonate (33 mg, 0.0999 mmol), and N,N-dimethylformamide (2 mL) were stirred at room temperature for 2 hours. The reaction mixture was directly concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 60-9 (15 mg, yield: 73%) as a yellow oil. MS (ESI, m/z): 616.3 [M+H]+.
[0379] Compound 60-9 (15 mg, 0.0244 mmol), water (1 mL), and N,N-dimethylformamide (2 mL) were stirred at room temperature for 2 hours. The reaction mixture was directly concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 60-10 (10 mg, yield: 75%) as a white solid. MS (ESI, m/z): 544.2 [M+H]+.
[0380] Compound 60-10 (15 mg, 0.0184 mmol), lithium hydroxide (22 mg, 0.921 mmol), water (1 mL), tetrahydrofuran (2 mL), and methanol (2 mL) were stirred at 60°C for 2 hours. The reaction mixture was directly concentrated, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 60 (8.85 mg, yield: 93%) as a white solid. MS (ESI, m/z): 516.3 [M+H]+.
[0381] 1H NMR (400 MHz, CDCl3) δ 7.71 (s, 2H), 7.48 - 7.42 (m, 1H), 7.29 (s, 1H), 7.23 - 7.16 (m, 1H), 7.11 - 7.05 (m, 1H), 6.64 - 6.58 (m, 1H), 6.54 (s, 1H), 6.46 - 6.40 (m, 1H), 3.86 - 3.78 (m, 5H), 3.25 - 3.15 (m, 1H), 3.15 - 3.04 (m, 1H), 2.90 - 2.76 (m, 4H), 2.27 - 2.18 (m, 2H), 1.98 - 1.89 (m, 2H), 1.68 (s, 9H), 1.24 - 1.17 (m, 2H).
Example 61:
Synthetic Route:
[0383] Referring to the synthetic route of compound 60, iodomethane was replaced with iodoethane to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 51 (7 mg, yield: 22%) as a white solid. MS (ESI, m/z): 530.3 [M+H]+.
[0384] 1H NMR (400 MHz, CDCl3) δ 7.76 - 7.60 (m, 3H), 7.50 - 7.42 (m, 1H), 7.33 - 7.29 (m, 1H), 7.24 - 7.20 (m, 1H), 7.12 - 7.06 (m, 1H), 6.72 - 6.37 (m, 2H), 3.83 (s, 3H), 3.82 - 3.78 (m, 2H), 3.16 - 3.11 (m, 1H), 3.11 - 3.07 (m, 1H), 2.93 - 2.86 (m, 2H), 2.79 - 2.60 (m, 2H), 2.34 - 2.12 (m, 2H), 1.98 - 1.89 (m, 2H), 1.68 (s, 9H), 1.64 - 1.62 (m, 2H), 0.99 (t, J = 7.2 Hz, 3H).
Example 62:
Synthetic Route:
[0386] Referring to the synthetic route of compound 60, compound 60-6 (116 mg, 0.222 mmol) and compound 62-1 (46 mg, 0.444 mmol) were synthesized and added to tetrahydrofuran (5 mL). Sodium bis(trimethylsilyl)amide (444 µL, 0.444 mmol) was added at -70°C, and the reaction was stirred at -70°C for 1 hour, followed by stirring at room temperature overnight. The reaction mixture was quenched with water at 0°C. The organic phase was dried over sodium sulfate and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 62-2 (42 mg, yield: 35%) as a yellow oil. MS (ESI, m/z): 546.3 [M+H]+.
[0387] Referring to the synthetic route of compound 60, the synthesis was carried out, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 62 (15 mg, yield: 38%) as a yellow solid. MS (ESI, m/z): 532.3 [M+H]+.
[0388] 1H NMR (400 MHz, CDCl3) δ 7.76 (s, 1H), 7.73 (s, 1H), 7.49 (d, J = 8.0 Hz, 1H), 7.40 (s, 1H), 7.26 - 7.16 (m, 2H), 6.72 - 6.64 (m, 1H), 6.61 (s, 1H), 6.53 - 6.45 (m, 1H), 4.13 - 4.05 (m, 1H), 3.86 - 3.80 (m, 5H), 3.44 (s, 3H), 3.34 - 3.24 (m, 1H), 3.23 - 3.07 (m, 2H), 2.96 - 2.83 (m, 2H), 2.35 - 2.20 (m, 2H), 2.02 - 1.91 (m, 2H), 1.71 (s, 9H).
Example 63:
Synthetic Route:
[0390] Referring to the synthetic route of compound 60, compound 60-4 (1.7 g, 3.5 mmol) was synthesized. Compound 60-4 (1.7 g, 3.5 mmol) and lithium hydroxide (170 mg, 7.0 mmol) were added to tetrahydrofuran (16 mL) and water (4 mL). The reaction was carried out at room temperature for 16 hours, followed by dilution with water (20 mL) and extraction with ethyl acetate (20 mL × 3). The organic phase was dried over sodium sulfate and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 63-1 (1.7 g, yield: 91%) as a yellow solid. MS (ESI, m/z): 474.2 [M+H]+.
[0391] Compound 63-2 (327 mg, 2.38 mmol) was dissolved in ethyl acetate (8 mL). Triethylamine (421 mg, 4.06 mmol) and magnesium chloride (217 mg, 2.28 mmol) were added at 0°C, and the reaction was carried out at room temperature for 3 hours to obtain system 1. Compound 63-1 (600 mg, 1.27 mmol) and N,N'-carbonyldiimidazole (272 mg, 1.65 mmol) were dissolved in THF (8 mL) and reacted at room temperature for 2 hours. The resulting mixture was added to system 1 and reacted at 45°C for 8 hours. Water (30 mL) was added for dilution, followed by extraction with ethyl acetate (30 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 5% to 10%) to obtain compound 63-3 (450 mg, yield: 65%) as a white solid. MS (ESI, m/z): 544.2 [M+H]+.
[0392] Compound 63-3 (450 mg, 0.829 mmol) was dissolved in ethanol (4 mL), and sodium borohydride (35 mg, 0.912 mmol) was added at 0°C. The reaction was carried out at room temperature for 2 hours, then diluted with 1 N hydrochloric acid aqueous solution (30 mL) and extracted with ethyl acetate (30 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 30% to 100%) to obtain compound 63-4 (400 mg, yield: 89%) as a white solid. MS (ESI, m/z): 546.2 [M+H]+.
[0393] Compound 63-4 (200 mg, 0.366 mmol) was dissolved in dichloromethane (3 mL), followed by the addition of trimethyloxonium tetrafluoroborate (108 mg, 0.733 mmol), proton sponge (156 mg, 0.733 mmol), and molecular sieves (200 mg). The reaction was carried out at room temperature overnight. Water (30 mL) was added for dilution, followed by extraction with ethyl acetate (30 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 30% to 100%) to obtain compound 63-5 (180 mg, yield: 91%) as a white solid. MS (ESI, m/z): 560.2 [M+H]+.
[0394] To a reaction tube, compound 63-5 (180 mg, 0.330 mmol), lithium hydroxide (40 mg, 1.65 mmol), tetrahydrofuran (3 mL), methanol (3 mL), and water (3 mL) were added. The reaction was carried out at 50°C for 2 hours. After the reaction mixture was rotary evaporated to remove the solvent, the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 63 (110 mg, yield: 61%) as a white solid. MS (ESI, m/z): 532.2 [M+H]+.
[0395] 1H NMR (400 MHz, DMSO-d6) δ 8.15 (s, 1H), 7.81 (s, 1H), 7.73 - 7.66 (m, 1H), 7.61 - 7.56 (m, 3H), 7.36 (s, 1H), 7.30 - 7.26 (m, 1H), 7.24 - 7.20 (m, 1H), 4.82 - 4.70 (m, 3H), 4.15 - 4.02 (m, 2H), 3.92 (s, 3H), 3.47 (s, 3H),2.27 - 2.20 (m, 1H), 2.19 - 2.11 (m, 2H), 2.07 - 1.92 (m, 4H), 1.64 (s, 9H).
Example 64:
Synthetic Route:
[0397] Intermediate M5 was synthesized by referring to the synthetic route of intermediate M1. Then, referring to the synthetic route of compound 38, compound 12-1 was replaced with compound 64-1 to obtain compound 64-2 (60 mg, 1.32 mmol). Compound 64-2 (60 mg, 1.32 mmol) was added to boron tribromide (4 mL), and the reaction mixture was stirred at 0°C for 2 hours, and then quenched with saturated sodium bicarbonate (20 mL). The mixture was extracted with ethyl acetate (20 mL × 3), dried over magnesium sulfate, filtered, and the organic phase was concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 5% to 20%) to obtain compound 64-3 (40 mg, yield: 89%) as a yellow oil. MS (ESI, m/z): 340.2 [M+H]+.
[0398] Compound 64-3 (30 mg, 0.09 mmol), di-tert-butyl dicarbonate (39 mg, 0.18 mmol), 4-dimethylaminopyridine (2.16 mg, 0.02 mmol), and dichloromethane (5 mL) were stirred at room temperature for 16 hours. The reaction mixture was directly concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 64-4 (40 mg, yield: 84%) as a yellow oil. MS (ESI, m/z): 484.2 [M-55]+.
[0399] Compound 64-4 (40 mg, 0.074 mmol), sodium hydroxide (6 mg, 0.15 mmol), and methanol (10 mL) were stirred at room temperature for 16 hours. The reaction mixture was directly concentrated, and the resulting crude product was purified by normal -phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 64-5 (30 mg, yield: 92%) as a yellow oil. MS (ESI, m/z): 384.2 [M-55]+.
[0400] Compound 64-5 (30 mg, 0.068 mmol), compound 64-6 (12.5 mg, 0.082 mmol), potassium carbonate (28.3 mg, 0.205 mmol), and N,N-dimethylformamide (2 mL) were stirred at room temperature for 16 hours. The reaction mixture was directly concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 64-7 (32 mg, yield: 91%) as a yellow oil. MS (ESI, m/z): 456.2 [M-55]+.
[0401] Compound 64-7 (32 mg, 0.063 mmol), trifluoroacetic acid (14.3 mg, 0.125 mmol), and dichloromethane (2 mL) were stirred at room temperature for 16 hours. The reaction mixture was directly concentrated, and the resulting crude product was purified by normal-phase column chromatography (methanol: dichloromethane = 5% to 30%) to obtain compound 64-8 (23 mg, yield: 89%) as a yellow oil. MS (ESI, m/z): 412.2 [M+H]+.
[0402] Referring to the synthetic route of compound 38, compound 38-3 was replaced with compound 64-8 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 64 (14 mg, yield: 20%) as a white solid. MS (ESI, m/z): 504.3 [M+H]+.
[0403] 1H NMR (400 MHz, MeOD) δ 8.01 - 7.91 (m, 1H), 7.71 (s, 1H), 7.43 (d, J = 8.8Hz, 1H), 7.17 (t, J = 8.0Hz, 1H), 7.06 (d, J = 2.0Hz, 1H), 6.99 - 6.90 (m, 1H), 6.69 - 6.63 (m, 1H), 6.61 - 6.56 (m, 1H), 6.49 - 6.43 (m, 1H), 4.58 (s, 2H), 3.86 - 3.77 (m, 5H), 3.17 - 3.07 (m, 1H), 2.90 - 2.80 (m, 2H), 2.26 - 2.12 (m, 2H), 2.01 - 1.90 (m, 2H), 1.68 (s, 9H).
Example 65:
Synthetic Route:
[0405] Referring to the synthetic route of compound 64, compound 64-6 was replaced with compound 65-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 65 (2.4 mg, yield: 8%) as a white solid. MS (ESI, m/z): 518.3 [M+H]+.
[0406] 1H NMR (400 MHz, CDCl3) δ 7.72 - 7.67 (m, 2H), 7.46 - 7.41 (m, 1H), 7.24 - 7.18 (m, 1H), 7.02 (s, 1H), 6.96 - 6.90 (m, 1H), 6.67 - 6.60 (m, 1H), 6.56 (s, 1H), 6.49 - 6.42 (m, 1H), 4.90 - 4.82 (m, 1H), 3.86 - 3.78 (m, 5H), 3.13 - 3.03 (m, 1H), 2.92 - 2.81 (m, 2H), 2.26 - 2.20 (m, 2H), 1.97 - 1.90 (m, 2H), 1.73 - 1.67 (m, 12H).
Example 66:
Synthetic Route:
[0408] The synthesis route of intermediate M1 was referred to obtain intermediate M6. Then, referring to the synthetic route of compound 38, compound 12-1 was replaced with compound 66-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 66 (65 mg, yield: 79%) as a white solid. MS (ESI, m/z): 530.3 [M+H]+.
[0409] 1H NMR (400 MHz, CDCl3) δ 7.71 (s, 2H), 7.47 (d, J = 8.0 Hz, 1H), 7.29 (s, 1H), 7.24 - 7.17 (m, 1H), 7.13 - 7.07 (m, 1H), 6.66 - 6.59 (m, 1H), 6.58 - 6.52 (m, 1H), 6.48 - 6.42 (m, 1H), 3.86 - 3.80 (m, 5H), 3.20 - 3.02 (m, 2H), 2.92 - 2.79 (m, 2H), 2.77 - 2.64 (m, 2H), 2.33 - 2.15 (m, 2H), 2.01 - 1.88 (m, 2H), 1.87 - 1.73 (m, 2H), 1.68 (s, 9H), 0.82 (t, J = 7.2 Hz, 3H).
Example 67:
Synthetic Route:
[0411] Referring to the synthetic route of intermediate M1, intermediate M7 was synthesized. Then, referring to the synthetic route of compound 38, N-bromosuccinimide was replaced with N-iodosuccinimide to synthesize compound 67-4 (40 mg, 0.08 mmol). Compound 67-4 (40 mg, 0.08 mmol) and tert-butyl carbamate (19 mg, 0.16 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (9 mg, 0.02 mmol), and cesium carbonate (51 mg, 0.16 mmol) were added to 1,4-dioxane (10 mL). The reaction mixture was stirred at 90°C for 4 hours and then directly concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 67-5 (40 mg, yield: 93%) as a yellow solid. MS (ESI, m/z): 545.2 [M+H]+.
[0412] Under an ice bath, compound 67-5 (40 mg, 0.07 mmol), sodium hydride (2 mg, 0.09 mmol), and iodoethane (14 mg, 0.09 mmol) were added to tetrahydrofuran (5 mL), and the reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was directly concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 67-6 (40 mg, yield: 95%) as a colorless oil. MS (ESI, m/z): 573.3 [M+H]+.
[0413] Compound 67-6 (40 mg, 0.07 mmol), trifluoroacetic acid (40 mg, 0.35 mmol), and dichloromethane (5 mL) were stirred at room temperature for 6 hours. The reaction mixture was directly concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 67-7 (30 mg, yield: 91%) as a yellow oil. MS (ESI, m/z): 473.3 [M+H]+.
[0414] Compound 67-7 (30 mg, 0.06 mmol), ethyl bromoacetate (21 mg, 0.13 mmol), sodium carbonate (20 mg, 0.19 mmol), and N,N-dimethylformamide (5 mL) were stirred at room temperature for 6 hours. The reaction mixture was diluted with water (20 mL) and extracted with ethyl acetate (20 mL × 3). The organic phase was dried over magnesium sulfate, filtered, and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 67-8 (20 mg, yield: 56%) as a yellow solid. MS (ESI, m/z): 559.3 [M+H]+.
[0415] Then, referring to the synthetic route of compound 38, the synthesis was carried out, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 67 (4 mg, yield: 19%) as a white solid. MS (ESI, m/z): 531.2 [M+H]+.
[0416] 1H NMR (400 MHz, DMSO-d6) δ 8.02 (s, 1H), 7.70 (s, 1H), 7.34 (d, J = 8.4 Hz, 1H), 7.15 - 7.08 (m, 1H), 6.60 - 6.52 (m, 3H), 6.50 - 6.47 (m, 1H), 6.38 - 6.32 (m, 1H), 3.86 - 3.77 (m, 2H), 3.73 (s, 3H), 3.56 (s, 2H), 3.40 (q, J = 7.2 Hz, 2H), 3.16 - 3.06 (m, 1H), 2.91 - 2.81 (m, 2H), 2.02 - 1.89 (m, 2H), 1.88 - 1.79 (m, 2H), 1.59 (s, 9H), 1.10 (t, J = 7.2 Hz, 3H).
Example 68:
Synthetic Route:
[0418] Referring to the synthetic route of compound 63, compound 63-1 (2.6 g, 5.50 mmol) was synthesized. Compound 63-1 (2.6 g, 5.50 mmol), triethylamine (2.78 g, 27.48 mmol), and 2-(7-azabenzotriazol-1-yl)-N,N,N,N'-tetramethyluronium hexafluorophosphate (4.18 g, 10.99 mmol) were added to N,N-dimethylformamide (80 mL) and stirred. Dimethylhydroxylamine hydrochloride (808 mg, 8.25 mmol) was then added, and the reaction mixture was stirred at room temperature for 8 hours. After the reaction was completed, the reaction mixture was diluted with ethyl acetate (600 mL), and the organic phase was washed with water (180 mL × 6), dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 68-1 (2.6 g, yield: 92%) as a yellow solid. MS (ESI, m/z): 517.2 [M+H]+.
[0419] Under an ice bath, compound 68-1 (2.6 g, 5.04 mmol) was added to anhydrous tetrahydrofuran (50 mL) and stirred. Cyclopropylmagnesium bromide (1.0 M in tetrahydrofuran, 10.1 mL, 10.08 mmol) was then added, and the reaction mixture was stirred at room temperature for 3 hours. After the reaction was completed, the reaction was quenched with saturated sodium bicarbonate solution (2 mL), and a crude product was obtained by concentration. The resulting crude product was then purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 5% to 30%) to obtain compound 68-2 (2.1 g, yield: 84%) as a yellow oil. MS (ESI, m/z): 498.3 [M+H]+.
[0420] Methyltriphenylphosphonium bromide (4.31 g, 12.07 mmol) was added to anhydrous tetrahydrofuran (40 mL) and stirred. Under a nitrogen atmosphere at 0°C, n-butyllithium solution (2.5 M in tetrahydrofuran, 4.83 mL, 12.07 mmol) was added and reacted for 0.5 hours. Then, a solution of compound 68-2 (2.0 g, 4.0 mmol) in tetrahydrofuran (10 mL) was slowly added. The reaction was carried out at room temperature for 14 hours, quenched with water (1.5 mL), and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 68-3 (1.8 g, yield: 90%) as a yellow oil. MS (ESI, m/z): 496.3 [M+H]+.
[0421] Compound 68-3 (800 mg, 1.62 mmol) was added to tetrahydrofuran (40 mL) and stirred. At 0°C, borane-dimethyl sulfide complex (2.0 M in tetrahydrofuran, 2.43 mL, 4.85 mmol) was added, and the reaction was carried out at room temperature for 16 hours. Then, 6 M sodium hydroxide solution (1.62 mL, 9.70 mmol) and hydrogen peroxide (30% in water, 3.12 mL, 32.32 mmol) were slowly added, and the mixture was stirred at room temperature for 16 hours. After the reaction was completed, the reaction was quenched with saturated sodium thiosulfate solution (100 mL) and extracted with ethyl acetate (80 mL × 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 68-4 (670 mg, yield: 80%) as a colorless oil. MS (ESI, m/z): 514.3 [M+H]+.
[0422] Compound 68-4 (98 mg, 0.19 mmol), triphenylphosphine (75 mg, 0.29 mmol), and imidazole (19 mg, 0.29 mmol) were added to anhydrous tetrahydrofuran (10 mL) and stirred. Iodine (73 mg, 0.29 mmol) was added, and the reaction was carried out at room temperature for 16 hours. After the reaction was completed, the reaction mixture was concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 68-5 (52 mg, yield: 44%) as a yellow oil. MS (ESI, m/z): 624.3 [M+H]+.
[0423] Compound 68-5 (52 mg, 0.08 mmol) was added to ethanol (10 mL)/water (1 mL) and stirred. Sodium sulfite (158 mg, 1.25 mmol) was added, and the reaction mixture was stirred at 90°C for 72 hours. After the reaction was completed, the reaction mixture was concentrated, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 68 (6 mg, yield: 13%) as a yellow solid. MS (ESI, m/z): 578.2 [M+H]+.
[0424] 1H NMR (400 MHz, CDCl3) δ 7.74 (s, 1H), 7.72 - 7.65 (m, 1H), 7.58 (s, 1H), 7.54 - 7.33 (m, 3H), 7.29 - 7.25 (m, 1H), 7.17 - 7.05 (m, 1H), 6.97 - 6.93 (m, 1H), 3.94 (s, 3H), 3.79 - 3.47 (m, 4H), 3.39 - 3.02 (m, 3H), 2.95 - 2.84 (m, 1H), 2.53 - 2.34 (m, 2H), 2.00 - 1.86 (m, 2H), 1.69 (s, 9H), 1.38 - 1.33 (m, 1H), 0.70 - 0.60 (m, 1H), 0.60 - 0.50 (m, 1H), 0.50 - 0.41 (m, 1H), 0.30 - 0.19 (m, 1H).
Example 69:
Synthetic Route:
[0426] Referring to the synthetic route of compound 68, compound 68-5 (300 mg, 0.48 mmol) was synthesized and added to trimethyl phosphite (2 mL) with stirring. The reaction was carried out in a sealed tube at 100°C under a nitrogen atmosphere for 18 hours. After the reaction was completed, the reaction mixture was concentrated, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 69-1 (40 mg, yield: 14%) as a yellow oil. MS (ESI, m/z): 606.2 [M+H]+.
[0427] Compound 69-1 (40 mg, 0.07 mmol) was added to dichloromethane (10 mL) and stirred. Trimethylbromosilane (0.5 mL) was added, and the reaction mixture was stirred at room temperature for 16 hours. After the reaction was completed, the reaction mixture was concentrated, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 69 (1 mg, yield: 2%) as a white solid. MS (ESI, m/z): 578.2 [M+H]+.
[0428] 1H NMR (400 MHz, CDCl3) δ 7.75 - 7.60 (m, 2H), 7.45 - 7.37 (m, 1H), 7.27 - 7.04 (m, 3H), 6.80 - 6.47 (m, 3H), 3.90 - 3.81 (m, 4H), 3.74 - 3.66 (m, 2H), 3.14 - 3.06 (m, 1H), 2.99 - 2.77 (m, 4H), 2.09 - 2.03 (m, 2H), 1.95 - 1.87 (m, 2H), 1.66 (s, 9H), 1.17 - 1.04 (m, 1H), 0.63 - 0.51 (m, 1H), 0.45 - 0.27 (m, 2H), 0.20 - 0.07 (m, 1H).
Example 70:
Synthetic Route:
[0430] Referring to the synthetic route of compound 69, compound 69-1 (25 mg, 0.04 mmol) was synthesized and stirred in a mixture of tetrahydrofuran (1 mL)/methanol (1 mL)/water (1 mL). Lithium hydroxide (30 mg, 1.24 mmol) was added, and the reaction was stirred at 70°C under a nitrogen atmosphere for 16 hours. After the reaction was completed, the reaction mixture was concentrated, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 70 (9 mg, yield: 38%) as a white solid. MS (ESI, m/z): 592.2 [M+H]+.
[0431] 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 5.6 Hz, 2H), 7.50 - 7.43 (m, 1H), 7.33 (s, 1H), 7.25 - 7.16 (m, 1H), 7.15 - 7.06 (m, 1H), 6.65 - 6.59 (m, 1H), 6.55 (s, 1H), 6.50 - 6.41 (m, 1H), 3.82 - 3.78 (m, 5H), 3.47 - 3.34 (m, 3H), 3.12 - 3.07 (m, 1H), 2.89 - 2.79 (m, 2H), 2.45 - 2.39 (m, 1H), 2.30 - 2.17 (m, 4H), 1.99 - 1.87 (m, 2H), 1.68 (s, 9H), 1.18 - 1.04 (m, 1H), 0.66 - 0.51 (m, 1H), 0.46 - 0.29 (m, 2H), 0.16 - 0.09 (m, 1H).
Example 71:
Synthetic Route:
[0433] Compound 38 (304 mg, 0.56 mmol), HATU (426 mg, 1.12 mmol, 2.0 eq), ammonium chloride (90 mg, 1.68 mmol, 3.0 eq), and triethylamine (329 mg, 3.36 mmol, 6.0 eq) were added to dichloromethane (10 mL). The reaction was carried out at room temperature overnight. After the reaction was completed, water (10 mL) was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 71-1 (263 mg, yield: 87%) as a white solid. MS (ESI, m/z): 541.3 [M+H]+.
[0434] To a reaction tube, compound 71-1 (263 mg, 0.49 mmol), triethylamine (303 mg, 3.0 mmol), and dry dichloromethane (10 mL) were added. Trifluoroacetic anhydride (315 mg, 1.5 mmol) was slowly added dropwise at room temperature, and the reaction was carried out at room temperature for 4 hours. After the reaction was completed, water (10 mL) was added, and the reaction mixture was extracted with ethyl acetate (20 mL × 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 71-2 (217 mg, yield: 86%) as a white solid. MS (ESI, m/z): 523.3 [M+H]+.
[0435] To a reaction tube, compound 71-2 (217 mg, 0.41 mmol) and tetrahydrofuran (6 mL) were added under a nitrogen atmosphere. After cooling to -80°C, 1 M solution of lithium bis(trimethylsilyl)amide (1 mg, 1.0 mmol, 2.5 eq) was slowly added dropwise. The reaction mixture was stirred for 1 hour, and then iodomethane (233 mg, 1.64 mmol, 4.0 eq) was added. The reaction was carried out at room temperature for 24 hours. The reaction mixture was directly concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 71-3 (118 mg, yield: 52%) as a white solid. MS (ESI, m/z): 551.4 [M+H]+.
[0436] To a reaction tube, compound 71-3 (41 mg, 0.075 mmol), dioxane (2 mL), and water (2 mL) were added. Then, KOH (84 mg, 1.5 mmol) was added. The reaction was carried out at 140°C overnight. Dilute hydrochloric acid was added to adjust the pH to 3, and the mixture was extracted with ethyl acetate (20 mL × 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 71 (8 mg, yield: 19%) as a white solid. MS (ESI, m/z): 569.3 [M+H]+.
[0437] 1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 8.0 Hz, 2H), 7.43 (d, J = 7.6 Hz, 1H), 7.33 (s, 1H), 7.25 - 7.16 (m, 1H), 7.14 - 7.08 (m, 1H), 6.67 - 6.57 (m, 1H), 6.53 (s, 1H), 6.47 - 6.37 (m, 1H), 5.50 (s, 1H), 5.33 (s, 1H), 3.88 - 3.76 (m, 5H), 3.17 - 3.05 (m, 1H), 2.91 - 2.79 (m, 2H), 2.40 - 2.33 (m, 1H), 2.28 - 2.15 (m, 2H), 1.98 - 1.87 (m, 2H), 1.67 (s, 9H), 1.33 (s, 3H), 1.35 - 1.24 (m, 1H), 1.16 (s, 3H), 0.80 -0.72 (m, 1H), 0.57 - 0.49 (m, 1H), 0.46 - 0.35 (m, 1H), -0.09 - -0.18 (m, 1H).
Example 72:
Synthetic Route:
[0439] Referring to the synthetic route of compound 63, compound 63-3 (50 mg, 0.094 mmol) was synthesized. Compound 63-3 (50 mg, 0.094 mmol) and hydroxylamine hydrochloride (32 mg, 0.47 mmol) were added to 2 N sodium hydroxide aqueous solution (20 mL). The reaction was carried out at room temperature for 1 hour. After the reaction was completed, the reaction mixture was concentrated to obtain crude compound 72-1 (50 mg, yield: 99%). MS (ESI, m/z): 531.2 [M+H]+.
[0440] Compound 72-1 (50 mg, 0.094 mmol) was added to concentrated hydrochloric acid (2 mL) and reacted at room temperature for 16 hours. After the reaction was completed, the reaction mixture was concentrated, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 72 (6 mg, yield: 3%) as a white solid. MS (ESI, m/z): 513.2 [M+H]+.
[0441] 1H NMR (400 MHz, DMSO-d6) δ 8.21 (s, 1H), 8.13 (s, 1H), 7.76 (s, 1H), 7.68 - 7.59 (m, 2H), 7.54 (d, J = 8.0 Hz, 1H), 7.16 - 7.09 (m, 1H), 6.63 - 6.55 (m, 1H), 6.50 (s, 1H), 6.39 - 6.32 (m, 1H), 3.88 - 3.80 (m, 2H), 3.73 (s, 3H), 3.24 - 3.18 (m, 1H), 2.94 - 2.84 (m, 2H), 2.04 - 1.88 (m, 4H), 1.61 (s, 9H).
Example 73:
Synthetic Route:
[0443] Referring to the synthetic route of compound 72, hydroxylamine hydrochloride was replaced with O-(tetrahydro-2H-pyran-2-yl)hydroxylamine to synthesize compound 73-1 (200 mg, 0.33 mmol). Compound 73-1 (200 mg, 0.33 mmol) was added to 2 N hydrochloric acid (1 mL) and methanol (10 mL). The reaction was carried out at room temperature for 1 hour. After the reaction was completed, the reaction mixture was concentrated, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 73 (7 mg, yield: 3%) as a white solid. MS (ESI, m/z): 513.2 [M+H]+.
[0444] 1H NMR (400 MHz, DMSO-d6) δ 11.37 (s, 1H), 8.17 (s, 1H), 8.04 (s, 1H), 7.82 - 7.77 (m, 2H), 7.73 - 7.67 (m, 1H), 7.16 - 7.09 (m, 1H), 6.63 - 6.56 (m, 2H), 6.52 - 6.48 (m, 1H), 6.40 - 6.32 (m, 1H), 3.89 - 3.80 (m, 2H), 3.73 (s, 3H), 3.32 - 3.22 (m, 1H), 2.95 - 2.86 (m, 2H), 2.03 - 1.89 (m, 4H), 1.62 (s, 9H).
Example 73:
Synthetic Route:
[0446] Referring to the synthetic route of compound 67, compound 67-4 (360 mg, 0.70 mmol) was synthesized. Compound 67-4 (360 mg, 0.70 mmol), bis(pinacolato)diboron (198 mg, 0.77 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane complex (102.75 mg, 0.14 mmol), and potassium acetate (208.45 mg, 2.12 mmol) were added to 1,4-dioxane (10 mL). The reaction was carried out at 90°C for 16 hours. After the reaction was completed, the reaction mixture was concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 74-1 (220 mg, yield: 50%) as a yellow oil. MS (ESI, m/z): 556.3 [M+H]+.
[0447] Compound 74-1 (90 mg, 0.16 mmol), compound 74-2 (36.6 mg, 0.16 mmol), and potassium carbonate (67.2 mg, 0.48 mmol) were added to 1,4-dioxane (5 mL). The reaction was carried out at 80°C for 12 hours. After the reaction was completed, the reaction mixture was concentrated, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 74 (3 mg, yield: 3%) as a white solid. MS (ESI, m/z): 617.3 [M+H]+.
[0448] 1H NMR (400 MHz, DMSO-d6) δ 8.20 (s, 1H), 8.15 - 8.12 (m, 1H), 7.95 - 7.91 (m, 1H), 7.82 (s, 1H), 7.80 - 7.76 (m, 1H), 7.51 (s, 1H), 7.15 - 7.10 (m, 1H), 6.61 - 6.56 (m, 1H), 6.52 - 6.49 (m, 1H), 6.39 - 6.35 (m, 1H), 3.88 - 3.80 (m, 2H), 3.73 (s, 3H), 3.30 - 3.26 (m, 1H), 2.95 - 2.86 (m, 2H), 2.03 - 1.91 (m, 4H), 1.66 (s, 9H), 1.62 (s, 9H).
Example 75:
Synthetic Route:
[0450] Compound 74 (20 mg, 0.03 mmol) was added to trifluoroacetic acid (3 mL) and reacted at 100°C for 12 hours. After the reaction was completed, the reaction mixture was concentrated, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 75 (6 mg, yield: 31%) as a white solid. MS (ESI, m/z): 561.2 [M+H]+.
[0451] 1H NMR (400 MHz, DMSO-d6) δ 8.18 (s, 1H), 8.08 - 8.03 (m, 1H), 7.85 - 7.76 (m, 3H), 7.18 - 7.12 (m, 1H), 7.01 (s, 1H), 6.65 - 6.60 (m, 1H), 6.55 (s, 1H), 6.43 - 6.37 (m, 1H), 3.88 - 3.80 (m, 2H), 3.74 (s, 3H), 3.30 - 3.27 (m, 1H), 2.99 - 2.91 (m, 2H), 2.06 - 1.94 (m, 4H), 1.62 (s, 9H).
Example 76:
Synthetic Route:
[0453] Compound 38 (325 mg, 0.6 mmol), compound 76-1 (123 mg, 0.9 mmol), 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (456 mg, 1.2 mmol), and triethylamine (182 mg, 1.8 eq) were added to N,N-dimethylformamide (10 mL). The reaction was carried out at room temperature for 12 hours. After the reaction was completed, the reaction mixture was concentrated, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 75 (187 mg, yield: 47%) as a white solid. MS (ESI, m/z): 661.2 [M+H]+.
[0454] 1H NMR (400 MHz, CDCl3) δ 9.91 (s, 1H), 9.06 (s, 1H), 8.99 (s, 1H), 8.68 (d, J = 3.6 Hz, 1H), 8.10 - 8.01 (m, 1H), 7.73 (s, 1H), 7.70 (s, 1H), 7.49 - 7.42 (m, 1H), 7.33 (s, 1H), 7.32 - 7.28 (m, 1H), 7.26 - 7.17 (m, 1H), 7.14 - 7.08 (m, 1H), 6.71 - 6.65 (m, 1H), 6.64 - 6.61 (m, 1H), 6.53 - 6.49 (m, 1H), 3.85 - 3.77 (m, 5H), 3.19 - 3.07 (m, 1H), 2.98 - 2.71 (m, 4H), 2.59 - 2.52 (m, 1H), 2.33 - 2.18 (m, 2H), 1.99 - 1.89 (m, 2H), 1.69 (s, 9H), 1.15 - 1.02 (m, 1H), 0.70 - 0.57 (m, 1H), 0.50 - 0.39 (m, 1H), 0.38 - 0.27 (m, 1H), 0.24 - 0.14 (m, 1H).
Example 77:
Synthetic Route:
[0456] Referring to the synthetic route of compound 76, compound 76-1 was replaced with compound 77-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 77 (118 mg, yield: 65%) as a white solid. MS (ESI, m/z): 661.2 [M+H]+.
[0457] 1H NMR (400 MHz, CDCl3) δ 9.67 (s, 1H), 8.73 - 8.63 (m, 3H), 7.72 (s, 1H), 7.70 (s, 1H), 7.58 (d, J = 5.6 Hz, 2H), 7.50 - 7.44 (m, 1H), 7.34 (s, 1H), 7.26 - 7.19 (m, 1H), 7.15 -7.09 (m, 1H), 6.71 - 6.65 (m, 1H), 6.63 - 6.57 (m, 1H), 6.54 - 6.47 (m, 1H), 3.84 - 3.79 (m, 5H), 3.18 - 3.08 (m, 1H), 2.95 - 2.69 (m, 4H), 2.60 - 2.51 (m, 1H), 2.33 - 2.18 (m, 2H), 1.96 - 1.91 (m, 2H), 1.69 (s, 9H), 1.15 - 1.04 (m, 1H), 0.71 - 0.60 (m, 1H), 0.52 - 0.41 (m, 1H), 0.39 - 0.30 (m, 1H), 0.26 - 0.16 (m, 1H).
Example 78:
Synthetic Route:
[0459] To a reaction flask, compound 78-1 (5.53 g, 16.2 mmol), compound 78-2 (3.91 g, 16.2 mmol), bis(triphenylphosphine)palladium(II) chloride (562 mg, 0.8 mmol), copper(I) iodide (309 mg, 1.6 mmol), triethylamine (4.9 g, 48.6 mmol), and dry acetonitrile (60 mL) were added. The reaction was then carried out at 85°C overnight. After the reaction was completed, saturated ammonium chloride solution (10 mL) was added to quench the reaction, and the mixture was extracted with ethyl acetate (50 mL × 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 78-3 (5.65 g, yield: 76%) as a white solid. MS (ESI, m/z): 460.2 [M+H]+.
[0460] To a 100 mL reaction flask, compound 78-3 (5.65 g, 12.3 mmol), 10% palladium hydroxide on carbon (200 mg), Raney nickel (400 mg), tetrahydrofuran (25 mL), and isopropanol (25 mL) were added. The reaction was then carried out at 60°C overnight. After the reaction was completed, the reaction mixture was quenched with saturated ammonium chloride solution (10 mL) at 0°C and directly concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 78-4 (4.14 g, yield: 91%) as a white solid. MS (ESI, m/z): 370.3 [M+H]+.
[0461] To a reaction flask, compound 78-4 (4.14 g, 11.3 mmol), triethylamine (2.3 g, 22.6 mmol), and dichloromethane (50 mL) were added. Di-tert-butyl dicarbonate (4.9 g, 22.6 mmol) was slowly added, and the reaction was carried out at room temperature overnight. After the reaction was completed, saturated ammonium chloride solution (10 mL) was added to quench the reaction, and the mixture was extracted with ethyl acetate (50 mL × 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 78-5 (4.87 g, yield: 92%) as a white solid. MS (ESI, m/z): 470.2 [M+H]+.
[0462] To a reaction flask, compound 78-5 (4.37 g, 9.3 mmol) and acetonitrile (50 mL) were added. N-Bromosuccinimide (2.5 g, 14 mmol) was then rapidly added, and the reaction was carried out at room temperature for 30 minutes. After the reaction was completed, saturated ammonium chloride solution (10 mL) was added to quench the reaction, and the mixture was extracted with ethyl acetate (50 mL × 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 78-6 (4.25 g, yield: 83%) as a white solid. MS (ESI, m/z): 548.3 [M+H]+.
[0463] To a reaction flask, compound 78-6 (1.94 g, 3.5 mmol), compound 38-1 (1.1 g, 4.2 mmol), tetrakis(triphenylphosphine)palladium (202 mg, 0.18 mmol), potassium phosphate (2.23 g, 10.5 mmol), dioxane (30 mL), and water (10 mL) were added under a nitrogen atmosphere. The reaction mixture was stirred at 100°C for 24 hours, then cooled to room temperature and diluted with ethyl acetate (100 mL). The organic phase was washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 78-7 (4.25 g, yield: 83%) as a white solid. MS (ESI, m/z): 592.3 [M+H]+.
[0464] To a reaction flask, compound 78-7 (1.16 g, 1.96 mmol) and dichloromethane (30 mL) were added, followed by the addition of trifluoroacetic acid (3 mL). The reaction mixture was stirred overnight at room temperature, and the pH was adjusted to approximately 8 with saturated sodium bicarbonate aqueous solution. The mixture was then extracted with dichloromethane (50 mL × 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 78-8 (876 mg, yield: 91%) as a white solid. MS (ESI, m/z): 492.3 [M+H]+.
[0465] To a reaction flask, compound 78-8 (536 mg, 1.1 mmol), [dicyclohexyl[3-(1-methylethoxy)-2',4',6'-tris(1-methylethyl)[1,1'-biphenyl]-2-yl]phosphine-κP](methanesulfonato-κO)[2'-(methylamino-κN)[1,1'-biphenyl]-2-yl-κC]palladium (EPhos Pd G4) (10 mg, 0.011 mmol), dicyclohexyl(3-isopropoxy-2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphine (11.8 mg, 0.022 mmol), 3-iodoanisole 78-9 (309 mg, 1.3 mmol), cesium carbonate (1.1 g, 3.3 mmol), and dioxane (10 mL) were added. The reaction was then carried out at 100°C overnight. After the reaction was completed, saturated ammonium chloride solution (10 mL) was added to quench the reaction, and the mixture was extracted with ethyl acetate (20 mL × 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 78-10 (96 mg, yield: 45%) as a white solid. MS (ESI, m/z): 598.3 [M+H]+.
[0466] To a reaction flask, compound 78-10 (96 mg, 0.16 mmol), tetrahydrofuran (3 mL), and methanol (3 mL) were added. 1 mL of sodium hydroxide (64 mg, 1.6 mmol, 10.0 eq) aqueous solution was then added dropwise to the reaction. The reaction was carried out at room temperature overnight. Dilute hydrochloric acid was added to adjust the pH to 3, followed by extraction with ethyl acetate (10 mL × 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 78 (32 mg, yield: 34%) as a white solid. MS (ESI, m/z): 584.3 [M+H]+.
[0467] 1H NMR (400 MHz, CDCl3) δ 7.95 (s, 1H), 7.85 (s, 1H), 7.52 - 7.44 (m, 1H), 7.35 (s, 1H), 7.20 - 7.11 (m, 2H), 6.55 - 6.47 (m, 1H), 6.42 (s, 1H), 6.38 - 6.30 (m, 1H), 3.80 (s, 3H), 3.47 - 3.37 (m, 3H), 2.86 - 2.76 (m, 4H), 2.52 - 2.42 (m, 1H), 1.70 - 1.55 (m, 15H), 1.12 - 1.02 (m, 1H), 0.64 - 0.56 (m, 1H), 0.46 - 0.38 (m, 1H), 0.35 - 0.27 (m, 1H), 0.21 - 0.13 (m, 1H).
Example 79:
Synthetic Route:
[0469] Referring to the synthetic route of compound 39, compound 39-4 was replaced with compound 79-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 79 (8 mg, yield: 41%) as a white solid. MS (ESI, m/z): 543.2 [M+H]+.
[0470] 1H NMR (400 MHz, CDCl3) δ 7.74 - 7.69 (m, 2H), 7.50 - 7.41 (m, 2H), 7.34 (s, 1H), 7.16 - 7.11 (m, 1H), 6.27 - 6.21 (m, 1H), 6.12 - 6.06 (m, 1H), 4.51 - 4.41 (m, 2H), 3.90 (s, 3H), 3.25 - 3.15 (m, 1H), 3.01 - 2.83 (m, 4H), 2.55 - 2.45 (m, 1H), 2.19 - 2.06 (m, 2H), 1.93 - 1.88 (m, 2H), 1.68 (s, 9H), 1.16 - 1.05 (m, 1H), 0.65 - 0.57 (m, 1H), 0.49 - 0.42 (m, 1H), 0.39 - 0.32 (m, 1H), 0.23 - 0.15 (m, 1H).
Example 80:
Synthetic Route:
[0472] Referring to the synthetic route of compound 39, compound 39-4 was replaced with compound 80-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 80 (80 mg, yield: 73%) as a white solid. MS (ESI, m/z): 543.2 [M+H]+.
[0473] 1H NMR (400 MHz, CDCl3) δ 7.94 - 7.89 (m, 1H), 7.72 - 7.65 (m, 2H), 7.50 - 7.43 (m, 1H), 7.34 (s, 1H), 7.17 - 7.10 (m, 1H), 6.49 - 6.42 (m, 1H), 6.11 (s, 1H), 4.01 - 3.95 (m, 2H), 3.92 (s, 3H), 3.26 - 3.16 (m, 1H), 3.05 - 2.97 (m, 2H), 2.90 - 2.81 (m, 2H), 2.55 - 2.46 (m, 1H), 2.19 - 2.07 (m, 2H), 1.93 - 1.87 (m, 2H), 1.68 (s, 9H), 1.15 - 1.05 (m, 1H), 0.66 - 0.60 (m, 1H), 0.47 - 0.40 (m, 1H), 0.38 - 0.31 (m, 1H), 0.23 - 0.15 (m, 1H).
Example 81:
Synthetic Route:
[0475] Referring to the synthetic route of compound 49, compound 49-2 (358 mg, 0.70 mmol) was synthesized. Compound 49-2 (358 mg, 0.70 mmol), bis(pinacolato)diboron (198 mg, 0.77 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane complex (102.75 mg, 0.14 mmol), and potassium acetate (208.45 mg, 2.12 mmol) were added to 1,4-dioxane (10 mL). The reaction was carried out at 90°C for 16 hours. After the reaction was completed, the reaction mixture was concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 81-1 (196 mg, yield: 50%) as a yellow oil. MS (ESI, m/z): 560.3 [M+H]+.
[0476] Compound 81-1 (196 mg, 0.35 mmol), compound 81-2 (110 mg, 0.35 mmol), tetrakis(triphenylphosphine)palladium (40 mg, 0.0035 mmol), and potassium carbonate (223 mg, 1.05 mmol) were added to 1,4-dioxane (5 mL). The reaction was carried out at 100°C for 16 hours. After the reaction was completed, the reaction mixture was cooled to room temperature and diluted with ethyl acetate (50 mL). The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 81-3 (137 mg, yield: 59%) as a white solid. MS (ESI, m/z): 666.3 [M+H]+.
[0477] To a reaction tube, compound 81-3 (137 mg, 0.21 mmol), methanol (3 mL), and THF (3 mL) were added. Then, 1 mL of NaOH (84 mg, 1.0 mmol) aqueous solution was added dropwise to the reaction, and the reaction mixture was stirred at room temperature overnight. The pH was adjusted to 3 with dilute hydrochloric acid, and the mixture was extracted with ethyl acetate (10 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 81 (107 mg, yield: 79%) as a white solid. MS (ESI, m/z): 652.3 [M+H]+.
[0478] 1H NMR (400 MHz, CDCl3) δ 7.88 - 7.83 (m, 1H), 7.82 - 7.74 (m, 2H), 7.65 (d, J = 8.0 Hz, 1H), 7.57 - 7.51 (m, 1H), 7.49 - 7.44 (m, 1H), 7.43 - 7.27 (m, 4H), 7.24 - 7.12 (m, 2H), 6.82 - 6.26 (m, 2H), 3.88 - 3.75 (m, 5H), 3.25 - 3.13 (m, 1H), 2.94 - 2.81 (m, 3H), 2.55 - 2.48 (m, 1H), 2.38 - 2.21 (m, 2H), 2.04 - 1.90 (m, 6H), 1.88 - 1.71 (m, 7H), 1.14 - 1.06 (m, 1H), 0.66 - 0.59 (m, 1H), 0.50 - 0.42 (m, 1H), 0.41 - 0.32 (m, 1H), 0.26 - 0.18 (m, 1H).
Example 82:
Synthetic Route:
[0480] Referring to the synthetic route of compound 49, compound 12-1 was replaced with compound 1-1 to synthesize compound 82-1. Then, referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 82-4 to carry out the synthesis, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 82 (14 mg, yield: 27%) as a white solid. MS (ESI, m/z): 556.2 [M+H]+.
[0481] 1H NMR (400 MHz, DMSO-d6) δ 8.14 - 8.06 (m, 1H), 7.61 (d, J = 8.0 Hz, 1H), 7.44 (s, 1H), 7.24 (d, J = 1.6 Hz, 1H), 7.17 - 7.10 (m, 2H), 7.02 (d, J = 1.6 Hz, 1H), 6.61 - 6.57 (m, 1H), 6.52 - 6.49 (m, 1H), 6.38 - 6.34 (m, 1H), 3.93 (s, 3H), 3.88 - 3.81 (m, 2H), 3.73 (s, 3H), 3.30 - 3.19 (m, 1H), 2.91 (m, 2H), 2.75 (d, J = 4.4 Hz, 3H), 2.72 - 2.67 (m, 2H), 2.42 - 2.32 (m, 1H), 2.06 - 1.93 (m, 2H), 1.91 - 1.81 (m, 2H), 1.12 - 1.01 (m, 1H), 0.56 - 0.46 (m, 1H), 0.33 - 0.23 (m, 2H), 0.18 - 0.11 (m, 1H).
Example 83:
Synthetic Route:
[0483] Referring to the synthetic route of compound 39, compound 39-4 was replaced with compound 83-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 83 (11 mg, yield: 61%) as a white solid. MS (ESI, m/z): 543.2 [M+H]+.
[0484] 1H NMR (400 MHz, CDCl3) δ 8.07 (d, J = 6.0 Hz, 1H), 7.69 (s, 2H), 7.48 (d, J = 8.0 Hz, 1H), 7.34 (s, 1H), 7.14 (d, J = 8.0 Hz, 1H), 6.30 - 6.26 (m, 1H), 6.20 - 6.14 (m, 1H), 4.42 - 4.32 (m, 2H), 3.85 (s, 3H), 3.24 - 3.11 (m, 1H), 2.98 - 2.82 (m, 4H), 2.55 - 2.46 (m, 1H), 2.14 - 2.05 (m, 2H), 1.93 - 1.88 (m, 2H), 1.68 (s, 9H), 1.13 - 1.05 (m, 1H), 0.66 - 0.58 (m, 1H), 0.48 - 0.41 (m, 1H), 0.37 - 0.31 (m, 1H), 0.23 - 0.16 (m, 1H).
Example 84:
Synthetic Route:
[0486] Referring to the synthetic route of compound 39, compound 39-4 was replaced with compound 84-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 84 (22 mg, yield: 49%) as a white solid. MS (ESI, m/z): 556.3 [M+H]+.
[0487] 1H NMR (400 MHz, CDCl3) δ 7.74 - 7.69 (m, 2H), 7.49 (d, J= 8.0 Hz, 1H), 7.40 (s, 1H), 7.17 - 7.10 (m, 2H), 6.66 - 6.63 (m, 1H), 6.59 - 6.54 (m, 1H), 3.81 (s, 3H), 3.31 - 3.25 (m, 2H), 3.13 - 3.03 (m, 1H), 2.91 - 2.82 (m, 2H), 2.78 - 2.70 (m, 2H), 2.58 - 2.50 (m, 1H), 2.31 - 2.24 (m, 5H), 1.96 - 1.89 (m, 2H), 1.69 (s, 9H), 1.16 - 1.08 (m, 1H), 0.66 - 0.59 (m, 1H), 0.47 - 0.41 (m, 1H), 0.37 - 0.32 (m, 1H), 0.23 - 0.18 (m, 1H).
Example 85:
Synthetic Route:
[0489] Referring to the synthetic route of compound 39, compound 39-4 was replaced with compound 85-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 85 (13 mg, yield: 33%) as a white solid. MS (ESI, m/z): 572.3 [M+H]+.
[0490] 1H NMR (400 MHz, CDCl3) δ 7.74 - 7.68 (m, 2H), 7.48 (d, J= 8.0 Hz, 1H), 7.36 (s, 1H), 7.14 (d, J = 8.0 Hz, 1H), 6.85 - 6.75 (m, 1H), 6.64 - 6.57 (m, 1H), 6.53 - 6.46 (m, 1H), 3.87 (s, 3H), 3.79 (s, 3H), 3.70 - 3.63 (m, 2H), 3.12 - 3.05 (m, 1H), 2.90 - 2.85 (m, 2H), 2.72 - 2.64 (m, 2H), 2.54 - 2.47 (m, 1H), 2.40 - 2.31 (m, 2H), 1.96 - 1.90 (m, 2H), 1.69 (s, 9H), 1.15 - 1.05 (m, 1H), 0.66 - 0.57 (m, 1H), 0.49 - 0.42 (m, 1H), 0.39 - 0.32 (m, 1H), 0.28 - 0.16 (m, 1H).
Example 86:
Synthetic Route:
[0492] Referring to the synthetic route of compound 39, compound 39-4 was replaced with compound 86-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 86 (4 mg, yield: 13%) as a white solid. MS (ESI, m/z): 560.3 [M+H]+.
[0493] 1H NMR (400 MHz, CDCl3) δ 7.72 - 7.69 (m, 2H), 7.48 (d, J= 8.0 Hz, 1H), 7.37 (s, 1H), 7.14 (d, J= 8.0 Hz, 1H), 7.03 - 6.96 (m, 1H), 6.69 - 6.62 (m, 2H), 3.90 (s, 3H), 3.64 - 3.56 (m, 2H), 3.14 - 3.03 (m, 1H), 2.92 - 2.79 (m, 4H), 2.55 - 2.47 (m, 1H), 2.38 - 2.26 (m, 2H), 1.97 - 1.90 (m, 2H), 1.68 (s, 9H), 1.14 - 1.06 (m, 1H), 0.66 - 0.57 (m, 1H), 0.50 - 0.41 (m, 1H), 0.38 - 0.28 (m, 1H), 0.24 - 0.15 (m, 1H).
Example 87:
Synthetic Route:
[0495] Referring to the synthetic route of compound 86, compound 6-3 was replaced with compound 38-3 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 87 (13 mg, yield: 15%) as a white solid. MS (ESI, m/z): 560.3 [M+H]+.
[0496] 1H NMR (400 MHz, CDCl3) δ 7.73 - 7.67 (m, 2H), 7.48 (d, J= 8.0 Hz, 1H), 7.37 (s, 1H), 7.14 (d, J= 8.4 Hz, 1H), 7.05 - 6.96 (m, 1H), 6.73 - 6.61 (m, 2H), 3.90 (s, 3H), 3.65 - 3.56 (m, 2H), 3.16 - 3.01 (m, 1H), 2.94 - 2.80 (m, 4H), 2.57 - 2.46 (m, 1H), 2.39 - 2.29 (m, 2H), 1.99 - 1.91 (m, 2H), 1.69 (s, 9H), 1.15 - 1.06 (m, 1H), 0.69 - 0.61 (m, 1H), 0.47 - 0.43 (m, 1H), 0.36 - 0.32 (m, 1H), 0.23 - 0.19 (m, 1H).
Example 88:
Synthetic Route:
[0498] Referring to the synthetic route of compound 39, compound 39-4 was replaced with compound 88-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 88 (8 mg, yield: 36%) as a white solid. MS (ESI, m/z): 576.3 [M+H]+.
[0499] 1H NMR (400 MHz, CDCl3) δ 7.74 - 7.69 (m, 2H), 7.48 (d, J = 8.0 Hz, 1H), 7.39 (s, 1H), 7.22 - 7.16 (m, 1H), 7.14 (d, J= 8.0 Hz, 1H), 6.79 - 6.73 (m, 1H), 6.72 - 6.66 (m, 1H), 3.92 (s, 3H), 3.57 - 3.48 (m, 2H), 3.15 - 3.05 (m, 1H), 2.91 - 2.75 (m, 4H), 2.57 - 2.48 (m, 1H), 2.42 - 2.29 (m, 2H), 1.98 - 1.90 (m, 2H), 1.69 (s, 9H), 1.19 - 1.07 (m, 1H), 0.68 - 0.60 (m, 1H), 0.48 - 0.42 (m, 1H), 0.39 - 0.31 (m, 1H), 0.24 - 0.17 (m, 1H).
Example 89:
Synthetic Route:
[0502] Referring to the synthetic route of compound 38, compound 11-1 was replaced with compound 89-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 89 (19 mg, yield: 33%) as a white solid. MS (ESI, m/z): 560.3 [M+H]+.
[0503] 1H NMR (400 MHz, CDCl3) δ 7.71 (s, 2H), 7.52 - 7.44 (m, 1H), 7.36 (s, 1H), 7.20 - 7.08 (m, 1H), 7.03 - 6.88 (m, 1H), 6.63 - 6.50 (m, 1H), 6.48 - 6.38 (m, 1H), 3.79 (s, 3H), 3.68 - 3.54 (m, 2H), 3.16 - 3.03 (m, 1H), 2.96 - 2.71 (m, 4H), 2.58 - 2.44 (m, 1H), 2.40 - 2.24 (m, 2H), 2.01 - 1.86 (m, 2H), 1.68 (s, 9H), 1.16 - 1.04 (m, 1H), 0.70 - 0.57 (m, 1H), 0.50 - 0.40 (m, 1H), 0.39 - 0.30 (m, 1H), 0.26 - 0.14 (m, 1H).
Example 90:
Synthetic Route:
[0505] Referring to the synthetic route of compound 39, compound 39-4 was replaced with compound 90-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 90 (8 mg, yield: 53%) as a white solid. MS (ESI, m/z): 576.3 [M+H]+.
[0506] 1H NMR (400 MHz, CDCl3) δ 7.74 - 7.69 (m, 2H), 7.48 (d, J= 8.0 Hz, 1H), 7.39 (s, 1H), 7.27 (d, J= 2.4 Hz, 1H), 7.18 - 7.12 (m, 1H), 6.69 - 6.62 (m, 1H), 6.58 - 6.51 (m, 1H), 3.81 (s, 3H), 3.58 - 3.50 (m, 2H), 3.15 - 3.05 (m, 1H), 2.92 - 2.72 (m, 4H), 2.58 - 2.48 (m, 1H), 2.42 - 2.29 (m, 2H), 2.00 - 1.91 (m, 2H), 1.69 (s, 9H), 1.17 - 1.08 (m, 1H), 0.67 - 0.60 (m, 1H), 0.48 - 0.41 (m, 1H), 0.38 - 0.31 (m, 1H), 0.25 - 0.18 (m, 1H).
Example 91:
Synthetic Route:
[0508] Referring to the synthetic route of compound 39, compound 39-4 was replaced with compound 91-1 to synthesize compound 91-2 (184 mg, 0.27 mmol) as a yellow oil. Compound 91-2 (184 mg, 0.27 mmol) and palladium hydroxide (20 mg, 10%) were added to a mixture of methanol (10 mL) and ethyl acetate (10 mL), and the reaction mixture was heated to 60°C and stirred overnight. After the reaction was completed, the reaction mixture was concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 91-3 (69 mg, yield: 43%) as a white solid. MS (ESI, m/z): 600.1 [M+H]+.
[0509] Compound 91-3 (47 mg, 0.078 mmol), methylamine hydrochloride (26 mg, 0.39 mmol), 2-(7-azabenzotriazol-1-yl)-N,N,N',N-tetramethyluronium hexafluorophosphate (45 mg, 0.12 mmol), and N,N-diisopropylethylamine (81 mg, 0.63 mmol) were added to N,N-dimethylformamide (3 mL) and stirred at room temperature overnight. After the reaction was completed, ethyl acetate (50 mL) was added, and the organic phase was washed with saturated brine. The combined organic phases were concentrated to obtain a crude product. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 91-4 (30 mg, yield: 63%) as a yellow oil. MS (ESI, m/z): 613.1 [M+H]+.
[0510] Compound 91-4 (30 mg, 0.049 mmol) was added to a mixture of tetrahydrofuran (4 mL) and methanol (4 mL). Then, an aqueous solution (1.5 mL) of lithium hydroxide (24 mg, 0.98 mmol) was added to the reaction mixture, and the reaction mixture was heated to 60°C and stirred for 1 hour. The reaction mixture was then purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 91 (8.8 mg, yield: 30%) as a white solid. MS (ESI, m/z): 599.1 [M+H]+.
[0511] 1H NMR (400 MHz, DMSO-d6) δ 9.63 (s, 1H), 8.17 (d, J = 8.4 Hz, 1H), 7.76 - 7.64 (m, 2H), 7.48 (d, J = 8.0 Hz, 1H), 7.41 (s, 1H), 7.17 (d, J= 8.0 Hz, 1H), 6.79 - 6.68 (m, 2H), 3.86 (m, 3H), 3.36 - 3.22 (m, 2H), 3.15 - 3.07 (m, 4H), 2.94 - 2.81 (m, 4H), 2.56 - 2.50 (m, 1H), 2.27 - 2.14 (m, 2H), 2.08 - 1.99 (m, 2H), 1.69 (s, 9H), 1.16 - 1.07 (m, 1H), 0.67 - 0.59 (m, 1H), 0.50 - 0.42 (m, 1H), 0.39 - 0.32 (m, 1H), 0.24 - 0.18 (m, 1H).
Example 92:
Synthetic Route:
[0513] Referring to the synthetic route of compound 91, compound 39-3 was replaced with compound 38-3, and methylamine hydrochloride was replaced with N,2,2-trimethylpropan-1-amine to carry out the synthesis. The reaction mixture was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 92 (8 mg, yield: 28%) as a white solid. MS (ESI, m/z): 669.4 [M+H]+.
[0514] 1H NMR (400 MHz, CDCl3) δ 7.70 - 7.62 (m, 2H), 7.46 (d, J= 8.0 Hz, 1H), 7.41 - 7.32 (m, 1H), 7.30 - 7.26 (m, 1H), 7.18 - 7.10 (m, 1H), 6.64 - 6.45 (m, 2H), 3.82 (s, 3H), 3.69 - 3.49 (m, 2H), 3.43 - 3.27 (m, 1H), 3.25 - 3.16 (m, 2H), 3.09 - 2.91 (m, 4H), 2.89 - 2.78 (m, 2H), 2.67 - 2.56 (m, 1H), 2.54 - 2.46 (m, 1H), 2.23 - 2.06 (m, 2H), 2.04 - 1.88 (m, 2H), 1.87 - 1.79 (m, 1H), 1.66 (s, 9H), 1.15 - 1.02 (m, 6H), 0.82 - 0.72 (m, 3H), 0.65 - 0.57 (m, 1H), 0.47 - 0.38 (m, 1H), 0.36 - 0.29 (m, 1H), 0.23 - 0.15 (m 1H).
Example 93:
Synthetic Route:
[0516] Referring to the synthetic route of compound 92, N,2,2-trimethylpropan-1-amine was replaced with N-methylaniline to carry out the synthesis. The reaction mixture was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 93 (12 mg, yield: 36%) as a white solid. MS (ESI, m/z): 675.3 [M+H]+.
[0517] 1H NMR (400 MHz, CDCl3) δ 7.70 - 7.62 (m, 2H), 7.47 (d, J= 8.4 Hz, 1H), 7.42 (s, 1H), 7.34 (d, J= 8.4 Hz, 1H), 7.25 - 6.85 (m, 6H), 6.60 - 6.45 (m, 1H), 6.28 - 6.08 (m, 1H), 3.75 (s, 3H), 3.54 (s, 3H), 3.04 - 2.81 (m, 4H), 2.69 - 2.46 (m, 3H), 2.23 - 2.09 (m, 2H), 1.90 - 1.72 (m, 3H), 1.66 (s, 9H), 1.16 - 1.05 (m, 1H), 0.66 - 0.57 (m, 1H), 0.49 - 0.40 (m, 1H), 0.38 - 0.30 (m, 1H), 0.25 - 0.16 (m, 1H).
Example 94:
Synthetic Route:
[0519] Referring to the synthetic route of compound 91, methylamine hydrochloride was replaced with 2-amino-6-methylpyridine to carry out the synthesis. The reaction mixture was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 94 (5 mg, yield: 49%) as a white solid. MS (ESI, m/z): 676.3 [M+H]+.
[0520] 1H NMR (400 MHz, DMSO-d6) δ 12.86 (s, 1H), 8.29 - 8.25 (m, 1H), 8.24 - 8.18 (m, 1H),7.74 - 7.69 (m, 2H), 7.66 - 7.59 (m, 1H), 7.50 (d, J= 7.6 Hz, 1H), 7.36 (s, 1H), 7.16 (d, J= 7.6 Hz, 1H), 6.94 - 6.89 (m, 1H), 6.87 - 6.80 (m, 2H), 3.90 (s, 3H), 3.44 - 3.36 (m, 2H), 3.19 - 3.11 (m, 1H), 3.00 - 2.85 (m, 4H), 2.84 - 2.74 (m, 2H), 2.70 (s, 3H), 2.60 - 2.50 (m, 1H), 2.03 - 1.93 (m, 2H), 1.69 (s, 9H), 1.15 - 1.08 (m, 1H), 0.69 - 0.61 (m, 1H), 0.51 - 0.43 (m, 1H), 0.41 - 0.32 (m, 1H), 0.26 - 0.19 (m, 1H)
Example 95:
Synthetic Route:
[0523] Referring to the synthetic route of compound 91, methylamine hydrochloride was replaced with n-hexylamine to carry out the synthesis. The reaction mixture was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 95 (7 mg, yield: 19%) as a white solid. MS (ESI, m/z): 669.3 [M+H]+.
[0524] 1H NMR (400 MHz, CDCl3) δ 9.91 - 9.81 (m, 1H), 8.26 - 8.14 (m, 1H), 7.70 (d, J = 7.2 Hz, 2H), 7.49 (d, J = 8.0 Hz, 1H), 7.36 (s, 1H), 7.17 (d, J = 8.0 Hz, 1H), 6.82 - 6.70 (m, 2H), 3.86 (s, 3H), 3.60 - 3.46 (m, 2H), 3.36 - 3.24 (m, 2H), 3.18 - 3.05 (m, 1H), 2.98 - 2.75 (m, 4H), 2.60 - 2.44 (m, 1H), 2.36 - 2.13 (m, 2H), 1.83 - 1.74 (m, 2H), 1.69 (s, 9H), 1.54 - 1.33 (m, 8H), 1.14 - 1.07 (m, 1H), 0.92 (t, J = 7.2 Hz, 3H), 0.70 - 0.59 (m, 1H), 0.50 - 0.40 (m, 1H), 0.40 - 0.31 (m, 1H), 0.26 - 0.16 (m, 1H).
Example 96:
Synthetic Route:
[0526] Referring to the synthetic route of compound 38, compound 11-1 was replaced with compound 96-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 96 (68 mg, yield: 67%) as a white solid. MS (ESI, m/z): 592.3 [M+H]+.
[0527] 1H NMR (400 MHz, CDCl3) δ 7.68 (d, J = 8.0 Hz, 2H), 7.46 (d, J = 8.4 Hz, 1H), 7.35 (s, 1H), 7.13 (d, J= 8.0 Hz, 1H), 6.99 - 6.90 (m, 1H), 6.85 - 6.75 (m, 1H), 6.74 - 6.60 (m, 1H), 3.70 - 3.57 (m, 2H), 3.19 - 3.00 (m, 1H), 2.92 - 2.76 (m, 4H), 2.55 - 2.44 (m, 1H), 2.35 - 2.15 (m, 2H), 2.02 - 1.86 (m, 1H), 1.67 (s, 9H), 1.14 - 1.02 (m, 1H), 0.68 - 0.53 (m, 1H), 0.49 - 0.38 (m, 1H), 0.37 - 0.27 (m, 1H), 0.24 - 0.12 (m, 1H).
Example 97:
Synthetic Route:
[0529] Referring to the synthetic route of compound 38, compound 11-1 was replaced with compound 97-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 97 (17 mg, yield: 39%) as a white solid. MS (ESI, m/z): 556.3 [M+H]+.
[0530] 1H NMR (400 MHz, CDCl3) δ 7.68 (s, 2H), 7.46 (d, J = 8.0 Hz, 1H), 7.35 (s, 1H), 7.13 (d, J= 8.0 Hz, 1H), 6.78 - 6.68 (m, 1H), 6.66 - 6.56 (m, 1H), 6.48 - 6.36 (m, 1H), 5.91 (s, 2H), 3.67 - 3.53 (m, 2H), 3.11 - 2.97 (m, 1H), 2.92 - 2.69 (m, 4H), 2.55 - 2.41 (m, 1H), 2.34 - 2.14 (m, 2H), 2.00 - 1.86 (m, 2H), 1.67 (s, 9H), 1.15 - 1.03 (m, 1H), 0.68 - 0.53 (m, 1H), 0.49 - 0.39 (m, 1H), 0.38 - 0.27 (m, 1H), 0.25 - 0.13 (m, 1H).
Example 98:
Synthetic Route:
[0533] Referring to the synthetic route of compound 82, compound 11-1 was replaced with compound 89-1 and compound 82-4 was replaced with compound 98-3 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 98 (6 mg, yield: 19%) as a white solid. MS (ESI, m/z): 558.3 [M+H]+.
[0534] 1H NMR (400 MHz, MeOD) δ 7.97 (s, 1H), 7.69 (s, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.38 (s, 1H), 7.19 (d, J= 8.4 Hz, 1H), 6.99 - 6.91 (m, 1H), 6.64 - 6.58 (m, 1H), 6.51 - 6.45 (m, 1H), 3.76 (s, 3H), 3.58 - 3.51 (m, 2H), 3.14 - 3.05 (m, 1H), 2.85 - 2.77 (m, 2H), 2.71 - 2.58 (m, 2H), 2.55 - 2.46 (m, 1H), 2.29 - 2.17 (m, 2H), 1.90 - 1.98 (m, 2H), 1.67 (s, 3H), 1.35 - 1.30 (m, 2H), 1.13 - 0.99 (m, 3H), 0.62 - 0.53 (m, 1H), 0.42 - 0.33 (m, 2H), 0.15 - 0.10 (m, 1H).
Example 99:
Synthetic Route:
[0536] Referring to the synthetic route of compound 98, compound 98-3 was replaced with compound 99-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 99 (26 mg, yield: 87%) as a white solid. MS (ESI, m/z): 580.3 [M+H]+.
[0537] 1H NMR (400 MHz, CDCl3) δ 8.09 (s, 1H), 7.89 (s, 1H), 7.77 (d, J = 7.6 Hz, 2H), 7.54 - 7.47 (m, 3H), 7.40 - 7.31 (m, 2H), 7.16 (d, J= 7.2 Hz, 1H), 6.99 - 6.92 (m, 1H), 6.55 - 6.53 (m, 1H), 6.47 - 6.36 (m, 1H), 3.78 (s, 3H), 3.60 - 3.58 (m, 2H), 3.14 - 3.08 (m, 1H), 2.87 - 2.82 (m, 4H), 2.52 - 2.47 (m, 1H), 2.37 - 2.28 (m, 2H), 1.96 - 1.93 (m, 2H), 1.16 - 1.06 (m, 1H), 0.68 - 0.59 (m, 1H), 0.52 - 0.42 (m, 1H), 0.38 - 0.32 (m, 1H), 0.25 - 0.17 (m, 1H).
Example 100:
Synthetic Route:
[0539] Compound 100-1 (700 mg, 2.90 mmol), 3-bromophenol (502 mg, 2.90 mmol), and potassium carbonate (601 mg, 4.36 mmol) were added to N,N-dimethylformamide (10 mL), and the reaction mixture was heated to 80°C and stirred overnight. After the reaction was completed, 1 N dilute hydrochloric acid (50 mL) was added, and then ethyl acetate (100 mL) was added. The organic phase was washed with saturated brine, and the combined organic phases were concentrated to obtain a crude product. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 100-2 (529 mg, yield: 76%) as a yellow oil. MS (ESI, m/z): 241.8 [M+H]+.
[0540] Compound 100-2 (529 mg, 2.19 mmol), 1-octyne (289 mg, 2.62 mmol), copper(II) sulfate pentahydrate (109 mg, 0.44 mmol), and sodium ascorbate (173 mg, 0.87 mmol) were added to a mixture of tert-butanol (10 mL) and water (10 mL). The reaction mixture was heated to 45°C and stirred for 2 hours. After the reaction was completed, ethyl acetate (100 mL) was added. The organic phase was washed with saturated brine, and the combined organic phases were concentrated to obtain a crude product. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 100-3 (400 mg, yield: 52%) as a yellow oil. MS (ESI, m/z): 351.8 [M+H]+.
[0541] Referring to the synthetic route of compound 39, compound 39-4 was replaced with compound 100-3 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 100 (87 mg, yield: 37%) as a white solid. MS (ESI, m/z): 706.8 [M+H]+.
[0542] 1H NMR (400 MHz, CDCl3) δ 7.71 (s, 2H), 7.54 - 7.42 (m, 2H), 7.36 (s, 1H), 7.21 - 7.15 (m, 2H), 6.64 (d, J= 8.0 Hz, 1H), 6.50 (s, 1H), 6.38 (d, J= 8.0 Hz, 1H), 4.77 - 4.65 (m, 2H), 4.40 - 4.25 (m, 2H), 3.88 - 3.73 (m, 2H), 3.16 - 3.02 (m, 1H), 2.93 - 2.79 (m, 4H), 2.75 - 2.65 (m, 2H), 2.55 - 2.49 (m, 1H), 2.26 - 2.18 (m, 2H), 1.97 - 1.85 (m, 2H), 1.73 - 1.63 (m, 11H), 1.39 - 1.28 (m, 7H), 1.15 - 1.05 (m, 1H), 0.88 (t, J= 6.4 Hz, 3H), 0.67 - 0.58 (m, 1H), 0.49 - 0.32 (m, 2H), 0.24 - 0.18 (m, 1H).
Example 101:
Synthetic Route:
[0544] Referring to the synthetic route of compound 82, compound 82-4 was replaced with compound 101-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 101 (5 mg, yield: 24%) as a white solid. MS (ESI, m/z): 517.2 [M+H]+.
[0545] 1H NMR (400 MHz, DMSO-d6) δ 7.88 (s, 1H), 7.58 - 7.50 (m, 2H), 7.24 - 7.19 (m, 1H), 7.16 - 7.09 (m, 1H), 6.61 - 6.55 (m, 1H), 6.51 - 6.48 (m, 1H), 6.39 - 6.34 (m, 1H), 3.89 - 3.80 (m, 2H), 3.73 (s, 3H), 3.31 - 3.20 (m, 1H), 2.92 - 2.80 (m, 2H), 2.77 - 2.69 (m, 5H), 2.42 - 2.34 (m, 1H), 2.07 - 1.92 (m, 2H), 1.92 - 1.83 (m, 2H), 1.12 - 1.02 (m, 1H), 0.55 - 0.47 (m, 1H), 0.32 - 0.23 (m, 2H), 0.18 - 0.09 (m, 1H).
Example 102:
Synthetic Route:
[0547] Referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 102-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 102 (147 mg, yield: 82%) as a white solid. MS (ESI, m/z): 545.2 [M+H]+.
[0548] 1H NMR (400 MHz, CDCl3) δ 7.73 - 7.66 (m, 1H), 7.57 - 7.47 (m, 1H),7.38 (s, 1H), 7.25 - 7.13 (m, 2H), 6.99 - 6.26 (m, 3H), 3.86 - 3.74 (m, 5H), 3.44 - 3.33 (m, 1H), 3.30 - 3.15 (m, 1H), 3.07 - 2.76 (m, 4H), 2.56 - 2.45 (m, 1H), 2.42 - 2.16 (m, 2H), 2.10 - 1.84 (m, 2H), 1.47 (d, J= 6.8 Hz, 6H), 1.13 - 1.03 (m, 1H), 0.67 - 0.57 (m, 1H), 0.48 - 0.39 (m, 1H), 0.38 - 0.29 (m, 1H), 0.23 - 0.13 (m, 1H).
Example 103:
Synthetic Route:
[0550] Referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 103-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 103 (77 mg, yield: 78%) as a white solid. MS (ESI, m/z): 559.2 [M+H]+.
[0551] 1H NMR (400 MHz, CDCl3) δ 7.72 (s, 1H), 7.55 (d, J = 8.0 Hz, 1H), 7.37 (s, 1H), 7.24 - 7.11 (m, 2H), 6.62 - 6.45 (m, 3H), 3.87 - 3.75 (m, 5H), 3.24 - 3.17 (m, 1H), 2.94 - 2.76 (m, 4H), 2.54 - 2.46 (m, 1H), 2.32 - 2.19 (m, 2H), 2.06 - 1.90 (m, 2H), 1.51 (s, 9H), 1.15 - 1.06 (m, 1H), 0.67 - 0.57 (m, 1H), 0.51 - 0.42 (m, 1H), 0.39 - 0.30 (m, 1H), 0.23 - 0.14 (m, 1H).
Example 104:
Synthetic Route:
[0553] Referring to the synthetic route of compound 82, compound 82-4 was replaced with compound 104-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 104 (3 mg, yield: 17%) as a white solid. MS (ESI, m/z): 528.2 [M+H]+.
[0554] 1H NMR (400 MHz, MeOD) δ 7.69 (s, 1H), 7.56 (d, J = 8.0 Hz, 1H), 7.33 (s, 1H), 7.21 - 7.13 (m, 3H), 6.65 - 6.61 (m, 1H), 6.56 - 6.52 (m, 1H), 6.47 - 6.40 (m, 1H), 4.48 - 4.40 (m, 1H), 3.81 - 3.77 (m, 6H), 2.91 - 2.76 (m, 4H), 2.53 - 2.43 (m, 1H), 2.24 - 2.13 (m, 2H), 2.03 - 1.94 (m, 2H), 1.58 (d, J = 6.8 Hz, 6H), 1.10 - 1.04 (m, 1H), 0.67 - 0.57 (m, 1H), 0.45 - 0.39 (m, 1H), 0.35 - 0.29 (m, 1H), 0.21 - 0.14 (m, 1H).
Example 105:
Synthetic Route:
[0556] Referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 105-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 105 (64 mg, yield: 75%) as a white solid. MS (ESI, m/z): 532.9 [M+H]+.
[0557] 1H NMR (400 MHz, CDCl3) δ 7.70 (d, J= 8.0 Hz, 1H), 7.35 (s, 1H), 7.24 - 7.15 (m, 2H), 6.79 (s, 1H), 6.67 - 6.38 (m, 3H), 4.13 (s, 3H), 3.89 - 3.63 (m, 6H), 2.91 - 2.82 (m, 3H), 2.53 - 2.47 (m, 1H), 2.25 - 2.17 (m, 2H), 2.08 - 2.01 (m, 2H), 1.29 - 1.19 (m, 1H), 1.12 - 1.04 (m, 1H), 0.66 - 0.55 (m, 1H), 0.48 - 0.39 (m, 1H), 0.37 - 0.29 (m, 1H), 0.23 - 0.13 (m, 1H)
Example 106:
Synthetic Route:
[0559] Referring to the synthetic route of compound 82, compound 82-4 was replaced with compound 106-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 106 (54 mg, yield: 76%) as a white solid. MS (ESI, m/z): 545.2 [M+H]+.
[0560] 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 8.0 Hz, 1H), 7.38 - 7.33 (m, 1H), 7.27 - 7.24 (m, 1H), 7.23 - 7.12 (m, 2H), 6.63 (d, J = 8.0 Hz, 1H), 6.56 (s, 1H), 6.44 (d, J = 8.0 Hz, 1H), 3.89 - 3.77 (m, 5H), 3.76 - 3.64 (m, 1H), 3.43 - 3.34 (m, 1H), 2.92 - 2.79 (m, 4H), 2.58 - 2.46 (m, 1H), 2.28 - 2.15 (m, 2H), 2.10 - 1.96 (m, 2H), 1.47 (d, J = 6.8 Hz, 6H), 1.18 - 1.06 (m, 1H), 0.69 - 0.58 (m, 1H), 0.47 - 0.39 (m, 1H), 0.37 - 0.26 (m, 1H), 0.22 - 0.15 (m, 1H).
Example 107:
Synthetic Route:
[0562] Referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 106-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 107 (147 mg, yield: 82%) as a white solid. MS (ESI, m/z): 545.2 [M+H]+.
[0563] 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 8.0 Hz, 1H), 7.37 - 7.33 (m, 1H), 7.28 - 7.26 (m, 1H), 7.23 - 7.12 (m, 2H), 6.73 - 6.35 (m, 3H), 3.89 - 3.78 (m, 5H), 3.76 - 3.63 (m, 1H), 3.41 - 3.30 (m, 1H), 2.95 - 2.77 (m, 4H), 2.55 - 2.45 (m, 1H), 2.31 - 2.15 (m, 2H), 2.09 - 1.97 (m, 2H), 1.47 (d, J= 6.8 Hz, 6H), 1.16 - 1.03 (m, 1H), 0.66 - 0.55 (m, 1H), 0.48 - 0.39 (m, 1H), 0.37 - 0.27 (m, 1H), 0.24 - 0.13 (m, 1H).
Example 108:
Synthetic Route:
[0565] Referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 108-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 108 (89 mg, yield: 73%) as a white solid. MS (ESI, m/z): 559.2 [M+H]+.
[0566] 1H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 8.0 Hz, 1H), 7.35 (s, 1H), 7.28 (s, 1H), 7.23 - 7.13 (m, 2H), 6.68 - 6.60 (m, 1H), 6.56 (s, 1H), 6.48 - 6.38 (m, 1H), 3.91 - 3.77 (m, 5H), 3.75 - 3.64 (m, 1H), 2.93 - 2.76(m, 4H), 2.57 - 2.48 (m, 1H), 2.32 - 2.17 (m, 2H), 2.12 - 2.04 (m, 2H), 1.49 (s, 9H), 1.15 - 1.06 (m, 1H), 0.66 - 0.55 (m, 1H), 0.48 - 0.38 (m, 1H), 0.36 - 0.27 (m, 1H), 0.22 -0.12(m, 1H).
Example 109:
Synthetic Route:
[0568] Referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 109-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 109 (133 mg, yield: 77%) as a white solid. MS (ESI, m/z): 545.2 [M+H]+.
[0569] 1H NMR (400 MHz, CDCl3) δ 7.97 (d, J= 8.0 Hz, 1H), 7.38 (s, 1H), 7.25 - 7.21 (m, 2H), 6.91 (s, 1H), 6.78 - 6.33 (m, 3H), 3.90 - 3.74 (m, 6H), 3.24 - 3.09 (m, 1H), 3.01 - 2.76 (m, 4H), 2.57 - 2.43 (m, 1H), 2.35 - 2.00 (m, 4H), 1.38 (d, J = 6.8 Hz, 6H), 1.15 - 1.01 (m, 1H), 0.69 - 0.55 (m, 1H), 0.49 - 0.39 (m, 1H), 0.38 - 0.26 (m, 1H), 0.22 - 0.14 (m, 1H).
Example 110:
Synthetic Route:
[0571] Referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 110-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 110 (88 mg, yield: 73%) as a white solid. MS (ESI, m/z): 559.2 [M+H]+.
[0572] 1H NMR (400 MHz, CDCl3) δ 7.97 (d, J = 8.0 Hz, 1H), 7.38 (s, 1H), 7.22 (d, J= 8.0 Hz, 2H), 6.93 (s, 1H), 6.78 - 6.31 (m, 3H), 3.88 - 3.78 (m, 6H), 3.02 - 2.77 (m, 4H), 2.55 - 2.47 (m, 1H), 2.36 - 2.11 (m, 4H), 1.41 (s, 9H), 1.17 - 1.08 (m, 1H), 0.67 - 0.57 (m, 1H), 0.48 - 0.40 (m, 1H), 0.37 - 0.26 (m, 1H), 0.22 - 0.16 (m, 1H).
Example 111:
Synthetic Route:
[0574] Referring to the synthetic route of compound 82, compound 82-4 was replaced with compound 111-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 111 (69 mg, yield: 79%) as a white solid. MS (ESI, m/z): 545.2 [M+H]+.
[0575] 1H NMR (400 MHz, CDCl3) δ 7.94 (d, J = 8.0 Hz, 1H), 7.64 - 7.56 (m, 1H), 7.41 - 7.34 (m, 2H), 7.23 - 7.15 (m, 2H), 6.68 - 6.60 (m, 1H), 6.56 (s, 1H), 6.50 - 6.39 (m, 1H), 3.87 - 3.78 (m, 5H), 3.77 - 3.70 (m, 1H), 3.35 - 3.25 (m, 1H), 2.99 - 2.88 (m, 2H), 2.85 - 2.76 (m, 2H), 2.56 - 2.42 (m, 1H), 2.29 - 2.20 (m, 2H), 2.07 - 1.98 (m, 2H), 1.41 (d, J = 6.8 Hz, 6H), 1.13 - 1.04 (m, 1H), 0.65 - 0.55 (m, 1H), 0.47 - 0.39 (m, 1H), 0.35 - 0.24 (m, 1H), 0.21 - 0.14 (m, 1 H).
Example 112:
Synthetic Route:
[0577] Referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 111-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 112 (92 mg, yield: 89%) as a white solid. MS (ESI, m/z): 545.2 [M+H]+.
[0578] 1H NMR (400 MHz, CDCl3) δ 7.94 (d, J = 8.0 Hz, 1H), 7.62 - 7.57 (m, 1H), 7.40 - 7.35 (m, 1H), 7.25 - 7.15 (m, 3H), 6.74 - 6.35 (m, 2H), 3.90 - 3.70 (m, 6H), 3.34 - 3.22 (m, 1H), 3.04 - 2.76 (m, 4H), 2.55 - 2.45 (m, 1H), 2.36 - 2.13 (m, 2H), 2.12 - 1.97 (m, 2H), 1.41 (d, J = 6.8 Hz, 6H), 1.14 - 1.03 (m, 1H), 0.66 - 0.55 (m, 1H), 0.48 - 0.39 (m, 1H), 0.37 - 0.28 (m, 1H), 0.24 - 0.14 (m, 1H).
Example 113:
Synthetic Route:
[0580] Referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 113-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 113 (31 mg, yield: 33%) as a white solid. MS (ESI, m/z): 559.2 [M+H]+.
[0581] 1H NMR (400 MHz, CDCl3) δ 7.95 (d, J = 8.0 Hz, 1H), 7.63 - 7.57 (m, 1H), 7.42 - 7.35 (m, 1H), 7.24 - 7.16 (m, 2H), 6.70 - 6.40 (m, 3H), 3.90 - 3.70 (m, 6H), 3.04 - 2.87 (m, 2H), 2.85 - 2.62 (m, 2H), 2.55 - 2.46 (m, 1H), 2.36 - 2.22 (m, 2H), 2.12 - 1.98 (m, 2H), 1.46 (s, 9H), 1.14 - 1.04 (m, 1H), 0.66 - 0.56 (m, 1H), 0.49 - 0.41 (m, 1H), 0.38 - 0.27 (m, 1H), 0.23 - 0.14 (m, 1H).
Example 114:
Synthetic Route:
[0583] Referring to the synthetic route of compound 82, compound 82-4 was replaced with compound 114-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 114 (12 mg, yield: 28%) as a white solid. MS (ESI, m/z): 543.2 [M+H]+.
[0584] 1H NMR (400 MHz, CDCl3) δ 7.66 (d, J= 8.0 Hz, 1H), 7.38 (s, 1H), 7.24 - 7.15 (m, 2H), 6.68 - 6.58 (m, 1H), 6.57 - 6.50 (m, 1H), 6.49 - 6.41 (m, 1H), 6.40 (s, 1H), 3.89 - 3.76 (m, 5H), 3.66 - 3.50 (m, 1H), 3.00 - 2.76 (m, 4H), 2.56 - 2.44 (m, 1H), 2.30 - 2.12 (m, 2H), 2.07 - 1.95 (m, 2H), 1.44 (s, 9H), 1.13 - 1.01 (m, 1H), 0.68 - 0.56 (m, 1H), 0.50 - 0.39 (m, 1H), 0.38 - 0.28 (m, 1H), 0.24 - 0.14 (m, 1H).
Example 115:
Synthetic Route:
[0586] Referring to the synthetic route of compound 82, compound 82-4 was replaced with compound 115-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 115 (21 mg, yield: 64%) as a white solid. MS (ESI, m/z): 543.2 [M+H]+.
[0587] 1H NMR (400 MHz, CDCl3) δ 7.69 (d, J = 7.6 Hz, 1H), 7.42 - 7.35 (m, 1H), 7.23 - 7.12 (m, 2H), 6.67 - 6.58 (m, 1H), 6.58 - 6.49 (m, 1H), 6.48 - 6.39 (m, 1H), 6.31 - 6.24 (m, 1H), 3.86 - 3.80 (m, 5H), 3.55 - 3.41 (m, 1H), 3.00 - 2.76 (m, 5H), 2.30 - 2.16 (m, 2H), 2.05 - 1.97 (m, 2H), 1.45 (s, 9H), 1.16 - 1.01 (m, 1H), 0.68 - 0.57 (m, 1H), 0.51 - 0.39 (m, 1H), 0.38 - 0.28 (m, 1H), 0.26 - 0.13 (m, 1H).
Example 116:
Synthetic Route:
[0588]
Referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 115-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 116 (16 mg, yield: 31%) as a white solid. MS (ESI, m/z): 543.2 [M+H]+.
[0589] 1H NMR (400 MHz, CDCl3) δ 7.67 (d, J= 8.0 Hz, 1H), 7.38 (s, 1H), 7.23 - 7.14 (m, 2H), 6.67 - 6.60 (m, 1H), 6.55 (s, 1H), 6.48 - 6.40 (m, 1H), 6.26 (s, 1H), 3.86 - 3.77 (m, 5H), 3.54 - 3.42 (m, 1H), 3.01 - 2.76 (m, 4H), 2.55 - 2.44 (m, 1H), 2.32 - 2.14 (m, 2H), 2.08 - 1.93 (m, 2H), 1.46 (s, 9H), 1.12 - 1.04 (m, 1H), 0.66 - 0.56 (m, 1H), 0.49 - 0.39 (m, 1H), 0.37 - 0.28 (m, 1H), 0.23 - 0.14 (m, 1H).
Example 117:
Synthetic Route:
[0591] Referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 117-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 117 (39 mg, yield: 72%) as a white solid. MS (ESI, m/z): 543.2 [M+H]+.
[0592] 1H NMR (400 MHz, DMSO-d6) δ 11.97 (s, 1H), 7.97 (d, J = 8.0 Hz, 1H), 7.93 (s, 1H), 7.56 (s, 1H), 7.31 - 7.26 (m, 1H), 7.13 (t, J = 8.4 Hz, 1H), 6.62 - 6.57 (m, 1H), 6.54 - 6.50 (m, 1H), 6.40 - 6.34 (m, 1H), 3.93 - 3.85 (m, 2H), 3.84 - 3.76 (m, 1H), 3.73 (s, 3H), 2.92 - 2.81 (m, 2H), 2.76 - 2.67 (m, 2H), 2.45 - 2.39 (m, 1H), 2.08 - 1.95 (m, 4H), 1.30 (s, 9H), 1.12 - 1.04 (m, 1H), 0.58 - 0.48 (m, 1H), 0.38 - 0.25 (m, 2H), 0.21 - 0.10 (m, 1H).
Example 118:
Synthetic Route:
[0594] Referring to the synthetic route of compound 82, compound 82-4 was replaced with compound 118-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 118 (8 mg, yield: 9%) as a white solid. MS (ESI, m/z): 560.2 [M+H]+.
[0595] 1H NMR (400 MHz, CDCl3) δ 7.89 (d, J = 8.0 Hz, 1H), 7.42 (s, 1H), 7.27 - 7.17 (m, 2H), 6.69 - 6.61 (m, 1H), 6.57 (s, 1H), 6.49 - 6.40 (m, 1H), 3.96 - 3.73 (m, 6H), 3.82 - 3.75 (m, 1H), 3.04 - 2.92 (m, 2H), 2.92 - 2.80 (m, 2H), 2.58 - 2.44 (m, 1H), 2.31 - 2.17 (m, 2H), 2.10 - 2.03 (m, 2H), 1.59 (s, 9H), 1.16 - 1.04 (m, 1H), 0.70 - 0.55 (m, 1H), 0.52 - 0.40 (m, 1H), 0.39 - 0.29 (m, 1H), 0.26 - 0.12 (m, 1H).
Example 119:
Synthetic Route:
[0597] Referring to the synthetic route of compound 82, compound 82-4 was replaced with compound 119-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 119 (4 mg, yield: 4%) as a yellow solid. MS (ESI, m/z): 543.2 [M+H]+.
[0598] 1H NMR (400 MHz, CDCl3) δ 7.91 (d, J = 8.0 Hz, 1H), 7.49 - 7.43 (m, 2H), 7.22 (t, J = 8.0 Hz, 1H), 6.69 - 6.62 (m, 1H), 6.61 - 6.56 (m, 1H), 6.49 - 6.43 (m, 1H), 4.11 - 3.99 (m, 1H), 3.89 - 3.80 (m, 5H), 3.10 - 3.01 (m, 1H), 2.97 - 2.88 (m, 3H), 2.63 - 2.54 (m, 2H), 2.25 - 2.12 (m, 2H), 2.08 - 2.04 (m, 2H), 1.43 (s, 9H), 1.22 - 1.16 (m, 1H), 0.74 - 0.67 (m, 1H), 0.57 - 0.46 (m, 1H), 0.41 - 0.36 (m, 1H), 0.33 - 0.26 (m, 1H).
Example 120:
Synthetic Route:
[0600] Referring to the synthetic route of compound 82, compound 82-4 was replaced with compound 120-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 120 (19 mg, yield: 66%) as a white solid. MS (ESI, m/z): 501.2 [M+H]+.
[0601] 1H NMR (400 MHz, DMSO-d6) δ 8.57 (s, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.50 (s, 1H), 7.21 (d, J= 8.0 Hz, 1H), 7.12 - 7.08 (m, 1H), 6.64 - 6.55 (m, 1H), 6.54 - 6.46 (m, 1H), 6.41 - 6.32 (m, 1H), 4.15 (s, 3H), 3.90 - 3.81 (m, 2H), 3.73 (s, 3H), 3.65 - 3.55 (m, 1H), 2.94 - 2.84 (m, 2H), 2.76 - 2.64 (m, 2H), 2.44 - 2.35 (m, 1H), 2.07 - 1.87 (m, 4H), 1.12 - 1.03 (m, 1H), 0.57 - 0.47 (m, 1H), 0.35 - 0.22 (m, 2H), 0.19 - 0.10 (m, 1H).
Example 121:
Synthetic Route:
[0603] Referring to the synthetic route of compound 82, compound 82-4 was replaced with compound 121-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 121 (10 mg, yield: 34%) as a white solid. MS (ESI, m/z): 501.2 [M+H]+.
[0604] 1H NMR (400 MHz, DMSO-d6) δ 8.60 (s, 1H), 8.04 (d, J = 8.0 Hz, 1H), 7.49 (s, 1H), 7.21 (d, J= 8.0 Hz, 1H), 7.16 - 7.09 (m, 1H), 6.63 - 6.55 (m, 1H), 6.54 - 6.47 (m, 1H), 6.41 - 6.33 (m, 1H), 4.09 - 3.94 (m, 4H), 3.91 - 3.82 (m, 2H), 3.73 (s, 3H), 2.90 - 2.80 (m, 2H), 2.72 - 2.65 (m, 2H), 2.43 - 2.34 (m, 1H), 2.09 - 1.88 (m, 4H), 1.10 - 1.03 (m, 1H), 0.55 - 0.48 (m, 1H), 0.34 - 0.23 (m, 2H), 0.19 - 0.11 (m, 1H).
Example 122:
Synthetic Route:
[0606] Referring to the synthetic route of compound 82, compound 82-4 was replaced with compound 122-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 122 (8 mg, yield: 15%) as a white solid. MS (ESI, m/z): 544.2 [M+H]+.
[0607] 1H NMR (400 MHz, CDCl3) δ 8.08 (d, J = 8.0 Hz, 1H), 7.45 - 7.36 (m, 1H), 7.24 (d, J = 8.4 Hz, 2H), 6.82 - 6.31 (m, 3H), 4.01 - 3.69 (m, 6H), 3.06 - 2.77 (m, 4H), 2.59 - 2.45 (m, 1H), 2.39 - 2.13 (m, 2H), 2.14 - 1.97 (m, 2H), 1.53 (s, 9H), 1.14 - 1.06 (m, 1H), 0.68 - 0.57 (m, 1H), 0.51 - 0.41 (m, 1H), 0.38 - 0.30 (m, 1H), 0.27 - 0.15 (m, 1H).
Example 123:
Synthetic Route:
[0609] Referring to the synthetic route of compound 82, compound 82-4 was replaced with compound 123-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 123 (4 mg, yield: 11%) as a white solid. MS (ESI, m/z): 530.2 [M+H]+.
[0610] 1H NMR (400 MHz, CDCl3) δ 7.97 - 7.92 (m, 1H), 7.44 (s, 1H), 7.26 - 7.24 (m, 2H), 6.70 - 6.59 (m, 1H), 6.60 - 6.54 (m, 1H), 6.54 - 6.40 (m, 1H), 3.96 - 3.86 (m, 2H), 3.84 (s, 3H), 3.82 - 3.79 (m, 1H), 3.41 - 3.28 (m, 1H), 3.04 - 2.91 (m, 2H), 2.91 - 2.80 (m, 2H), 2.57 - 2.48 (m, 1H), 2.34 - 2.15 (m, 2H), 2.15 - 2.02 (m, 2H), 1.52 (s, 6H), 1.17 - 1.07 (m, 1H), 0.72 - 0.61 (m, 1H), 0.53 - 0.42 (m, 1H), 0.40 - 0.32 (m, 1H), 0.28 - 0.16 (m, 1H).
Example 124:
Synthetic Route:
[0612] Referring to the synthetic route of compound 82, compound 82-4 was replaced with compound 124-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 124 (10 mg, yield: 31%) as a white solid. MS (ESI, m/z): 544.3 [M+H]+.
[0613] 1H NMR (400 MHz, CDCl3) δ 7.94 (d, J= 8.0 Hz, 1H), 7.42 (s, 1H), 7.26 - 7.19 (m, 2H), 6.68 - 6.61 (m, 1H), 6.61 - 6.54 (m, 1H), 6.50 - 6.40 (m, 1H), 3.87 - 3.83 (m, 5H), 3.01 - 2.80 (m, 5H), 2.57 - 2.47 (m, 1H), 2.27 - 2.15 (m, 2H), 2.10 - 2.03 (m, 2H), 1.54 (s, 9H), 1.13 - 1.08 (m, 1H), 0.68 - 0.61 (m, 1H), 0.48 - 0.42 (m, 1H), 0.38 - 0.32 (m, 1H), 0.23 - 0.18 (m, 1H).
Example 125:
Synthetic Route:
[0615] Referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 124-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 125 (118 mg, yield: 68%) as a white solid. MS (ESI, m/z): 544.3 [M+H]+.
[0616] 1H NMR (400 MHz, CDCl3) δ 7.92 (d, J = 8.4 Hz, 1H), 7.40 (s, 1H), 7.26 - 7.14 (m, 2H), 6.66 - 6.58 (m, 1H), 6.55 (s, 1H), 6.48 - 6.38 (m, 1H), 3.91 - 3.71 (m, 6H), 2.98 - 2.79 (m, 4H), 2.56 - 2.47 (m, 1H), 2.31 - 2.13 (m, 2H), 2.12 - 1.99 (m, 2H), 1.52 (s, 9H), 1.14 - 1.05 (m, 1H), 0.69 - 0.57 (m, 1H), 0.49 - 0.39 (m, 1H), 0.36 - 0.28 (m, 1H), 0.21 - 0.16 (m, 1H).
Example 126:
Synthetic Route:
[0618] Referring to the synthetic route of compound 49, compound 49-2 was replaced with compound 82-2 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 126 (4 mg, yield: 9%) as a white solid. MS (ESI, m/z): 598.3 [M+H]+.
[0619] 1H NMR (400 MHz, CDCl3) δ 7.94 (d, J = 8.0 Hz, 1H), 7.41 (s, 1H), 7.30 - 7.19 (m, 2H), 6.68 - 6.59 (m, 1H), 6.59 - 6.50 (m, 1H), 6.49 - 6.38 (m, 1H), 3.90 - 3.83 (m, 2H), 3.80 (s, 3H), 3.77 - 3.75 (m, 1H), 2.98 - 2.82 (m, 4H), 2.58 - 2.43 (m, 1H), 2.30 - 2.16 (m, 2H), 2.10 - 2.03 (m, 2H), 1.78 (s, 6H), 1.11-1.07 (m, 1H), 0.67 - 0.60 (m, 1H), 0.49 - 0.41 (m, 1H), 0.37 - 0.32 (m, 1H), 0.25 - 0.16 (m, 1H).
Example 127:
Synthetic Route:
[0621] Referring to the synthetic route of compound 6, compound 6-1 was replaced with compound 127-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 127 (8 mg, yield: 14%) as a white solid. MS (ESI, m/z): 553.2 [M+H]+.
[0622] 1H NMR (400 MHz, CDCl3) δ 7.77 (s, 1H), 7.70 (s, 1H), 7.36 (d, J = 8.0 Hz, 1H), 7.25 - 7.00 (m, 3H), 6.59 - 6.49 (m, 1H), 6.47 - 6.39 (m, 1H), 6.38 - 6.27 (m, 1H), 3.85 - 3.65 (m, 5H), 3.05 - 2.91 (m, 1H), 2.82 - 2.72 (m, 4H), 2.49 - 2.32 (m, 1H), 2.25 - 2.10 (m, 2H), 2.02 (s, 6H), 1.87 - 1.76 (m, 2H), 1.11 - 0.93 (m, 1H), 0.57 - 0.52 (m, 1H), 0.39 - 0.33 (m, 1H), 0.28 - 0.25 (m, 1H), 0.14 - 0.10 (m, 1H).
Example 128:
Synthetic Route:
[0624] Referring to the synthetic route of compound 126, 3,3,3-trifluoro-2,2-dimethylpropionic acid was replaced with 2,2-dimethylbutyric acid to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 128 (5 mg, yield: 14%) as a white solid. MS (ESI, m/z): 558.3 [M+H]+.
[0625] 1H NMR (400 MHz, CDCl3) δ 7.94 (d, J = 8.0 Hz, 1H), 7.42 (s, 1H), 7.27 - 7.20 (m, 2H), 6.68 - 6.59 (m, 1H), 6.56 (s, 1H), 6.48 - 6.40 (m, 1H), 3.91 - 3.84 (m, 2H), 3.83 (s, 3H), 3.81 - 3.79 (m, 1H), 2.97 - 2.82 (m, 4H), 2.54 - 2.51 (m, 1H), 2.29 - 2.17 (m, 2H), 2.09 - 2.01 (m, 2H), 1.88 - 1.82 (m, 2H), 1.50 (s, 6H), 1.13 - 1.05 (m, 1H), 0.95 - 0.88 (m, 3H), 0.69 - 0.57 (m, 1H), 0.52 - 0.40 (m, 1H), 0.37 - 0.30 (m, 1H), 0.24 - 0.15 (m, 1H).
Example 129:
Synthetic Route:
[0627] Referring to the synthetic route of compound 126, 3,3,3-trifluoro-2,2-dimethylpropionic acid was replaced with 2,2-dimethylpentanoic acid to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 129 (15 mg, yield: 37%) as a white solid. MS (ESI, m/z): 572.3 [M+H]+.
[0628] 1H NMR (400 MHz, CDCl3) δ 7.95 (d, J= 8.0 Hz, 1H), 7.44 (s, 1H), 7.33 - 7.30 (m, 1H), 7.29 - 7.20 (m, 1H), 6.91 - 6.40 (m, 3H), 3.94 - 3.79 (m, 6H), 3.06 - 2.83 (m, 4H), 2.54 (q, J= 8.0 Hz, 1H), 2.32 - 2.19 (m, 2H), 2.13 - 2.06 (m, 2H), 1.82 - 1.78 (m, 2H), 1.53 (s, 6H), 1.39 - 1.33 (m, 2H), 1.17 - 1.07 (m, 1H), 0.94 (t, J= 7.2 Hz, 3H), 0.70 - 0.63 (m, 1H), 0.54 - 0.44 (m, 1H), 0.41 - 0.34 (m, 1H), 0.25 - 0.21 (m, 1H).
Example 130:
Synthetic Route:
[0630] Referring to the synthetic route of compound 126, 3,3,3-trifluoro-2,2-dimethylpropionic acid was replaced with 2,2-dimethylhexanoic acid to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 130 (29 mg, yield: 36%) as a white solid. MS (ESI, m/z): 586.3 [M+H]+.
[0631] 1H NMR (400 MHz, CDCl3) δ 7.94 (d, J = 8.0 Hz, 1H), 7.41 (s, 1H), 7.27 - 7.13 (m, 2H), 6.68 - 6.60 (m, 1H), 6.56 (s, 1H), 6.50 - 6.41 (m, 1H), 3.93 - 3.72 (m, 6H), 3.01 - 2.78 (m, 4H), 2.51 (q, J = 8.0 Hz, 1H), 2.30 - 2.14 (m, 2H), 2.12 - 2.00 (m, 2H), 1.85 - 1.73 (m, 2H), 1.50 (s, 6H), 1.37 - 1.27 (m, 4H), 1.13 - 1.05 (m, 1H), 0.89 (t, J = 6.8 Hz, 3H), 0.70 - 0.58 (m, 1H), 0.48- 0.41 (m, 1H), 0.38 - 0.30 (m, 1H), 0.23 - 0.14 (m, 1H).
Example 131:
Synthetic Route:
[0633] Referring to the synthetic route of compound 126, 3,3,3-trifluoro-2,2-dimethylpropionic acid was replaced with 2,2-dimethylheptanoic acid to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 131 (26 mg, yield: 32%) as a white solid. MS (ESI, m/z): 600.3 [M+H]+.
[0634] 1H NMR (400 MHz, CDCl3) δ 7.97 (d, J = 8.0 Hz, 1H), 7.44 (s, 1H), 7.33 - 7.28 (m, 1H), 7.24 (t, J = 8.0 Hz, 1H), 6.69 - 6.62 (m, 1H), 6.61 - 6.56 (m, 1H), 6.52 - 6.44 (m, 1H), 3.90 - 3.80 (m, 6H), 3.00 - 2.86 (m, 4H), 2.56 (q, J = 8.2 Hz, 1H), 2.29 - 2.20 (m, 2H), 2.11 - 2.06 (m, 2H), 1.83 - 1.79 (m, 2H), 1.53 (s, 6H), 1.32 - 1.30 (m, 6H), 1.14 - 1.10 (m, 1H), 0.94 - 0.88 (m, 3H), 0.69 - 0.62 (m, 1H), 0.51 - 0.44 (m, 1H), 0.41 - 0.35 (m, 1H), 0.25 - 0.19 (m, 1H).
Example 132:
Synthetic Route:
[0636] Referring to the synthetic route of compound 82, compound 82-4 was replaced with compound 132-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 132 (8 mg, yield: 40%) as a white solid. MS (ESI, m/z): 586.3 [M+H]+.
[0637] 1H NMR (400 MHz, CDCl3) δ 7.77 - 7.69 (m, 2H), 7.47 (d, J = 6.8 Hz, 1H), 7.35 (s, 1H), 7.23 - 7.16 (m, 1H), 7.14 (d, J = 7.2 Hz, 1H), 6.64 - 6.57 (m, 1H), 6.54 (s, 1H), 6.47 - 6.39 (m, 1H), 3.84 - 3.80 (m, 5H), 3.76 (s, 3H), 3.15 - 3.05 (m, 1H), 2.87 - 2.80 (m, 4H), 2.54 - 2.45 (m, 1H), 2.27 - 2.18 (m, 2H), 1.96 - 1.93 (m, 8H), 1.15 - 1.03 (m, 1H), 0.68 - 0.56 (m, 1H), 0.50 - 0.40 (m, 1H), 0.37 - 0.28 (m, 1H), 0.25 - 0.13 (m, 1H).
Example 133:
Synthetic Route:
[0639] Referring to the synthetic route of compound 126, 3,3,3-trifluoro-2,2-dimethylpropionic acid was replaced with benzoic acid to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 133 (4 mg, yield: 10%) as a white solid. MS (ESI, m/z): 564.3 [M+H]+.
[0640] 1H NMR (400 MHz, CDCl3) δ 8.22 - 8.13 (m, 2H), 8.09 (d, J= 8.0 Hz, 1H), 7.62 - 7.57 (m, 3H), 7.46 (s, 1H), 7.35 - 7.30 (m, 1H), 7.25 - 7.21 (m, 1H), 6.70 - 6.62 (m, 1H), 6.61 - 6.55 (m, 1H), 6.50 - 6.44 (m, 1H), 3.96 - 3.86 (m, 3H), 3.84 (s, 3H), 3.03 - 2.96 (m, 2H), 2.95 - 2.88 (m, 2H), 2.58 - 2.52 (m, 1H), 2.27 - 2.23 (m, 2H), 2.14 - 2.11 (m, 2H), 1.15 - 1.11 (m, 1H), 0.70 - 0.64 (m, 1H), 0.53 - 0.45 (m, 1H), 0.41 - 0.37 (m, 1H), 0.26 - 0.21 (m, 1H).
Example 134:
Synthetic Route:
[0642] Referring to the synthetic route of compound 126, 3,3,3-trifluoro-2,2-dimethylpropionic acid was replaced with 1-methylcyclopropane-1-carboxylic acid to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 134 (4 mg, yield: 9%) as a white solid. MS (ESI, m/z): 542.3 [M+H]+.
[0643] 1H NMR (400 MHz, CDCl3) δ 7.80 (d, J = 8.0 Hz, 1H), 7.32 (s, 1H), 7.25 -7.10 (m, 2H), 6.60 - 6.51 (m, 1H), 6.50 - 6.44 (m, 1H), 6.40 - 6.32 (m, 1H), 3.84 - 3.71 (m, 5H), 3.70 - 3.63 (m, 1H), 2.88 - 2.74 (m, 4H), 2.49 - 2.36 (m, 1H), 2.20 - 2.05 (m, 2H), 2.00 - 1.89 (m, 2H), 1.37 - 1.28 (m, 2H), 1.18 (s, 3H), 1.06 - 0.98 (m, 1H), 0.97- 0.95 (m, 2H), 0.63 - 0.49 (m, 1H), 0.44 - 0.33 (m, 1H), 0.28-0.24 (m, 1H), 0.17 - 0.07 (m, 1H).
Example 135:
Synthetic Route:
[0645] Referring to the synthetic route of compound 126, 3,3,3-trifluoro-2,2-dimethylpropionic acid was replaced with 1-cyclohexyl-2,2-dimethylpropanoic acid to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 135 (16 mg, yield: 80%) as a white solid. MS (ESI, m/z): 626.3 [M+H]+.
[0646] 1H NMR (400 MHz, CDCl3) δ 7.97 (d, J= 8.0 Hz, 1H), 7.45 (s, 1H), 7.32 - 7.30 (m, 1H), 7.28 - 7.23 (m, 1H), 6.83 - 6.42 (m, 3H), 3.91 - 3.84 (m, 6H), 3.09 - 2.87 (m, 4H), 2.60 - 2.52 (m, 1H), 2.39 - 2.21 (m, 2H), 2.14 - 2.06 (m, 2H), 1.77 - 1.73 (m, 2H), 1.64 - 1.57 (m, 4H), 1.53 (s, 6H), 1.50 - 1.42 (m, 3H), 1.20 - 1.14 (m, 2H), 1.11 - 1.07 (m, 1H), 0.93 - 0.87 (m, 2H), 0.70 - 0.64 (m, 1H), 0.51 - 0.46 (m, 1H), 0.41 - 0.36 (m, 1H), 0.26 - 0.20 (m, 1H).
Example 136:
Synthetic Route:
[0648] Referring to the synthetic route of compound 126, compound 126-5 (100 mg, 0.203 mmol) was synthesized. Compound 126-5 (100 mg, 0.203 mmol) and triethylamine (41 mg, 0.407 mmol) were dissolved in dichloromethane (5 mL). Compound 136-1 (41 mg, 0.264 mmol) was added, and the reaction was carried out at room temperature overnight. After concentration, the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 10%) to obtain compound 136-2 (110 mg, yield: 78%) as a white solid. MS (ESI, m/z): 792.2 [M+H]+.
[0649] Compound 136-2 (20 mg, 0.0253 mmol), sodium iodide (5.0 mg, 0.0339 mmol), potassium carbonate (5.6 mg, 0.0401 mmol), and piperidine (14 mg, 0.169 mmol) were dissolved in dimethyl sulfoxide (2 mL) and reacted at 85°C overnight. After concentration, the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 90% to 100%] to obtain compound 136-3 (18 mg, yield: 96%) as a white solid. MS (ESI, m/z): 741.2 [M+H]+.
[0650] To a reaction tube, compound 136-3 (18 mg, 0.0243 mmol), lithium hydroxide (4.1 mg, 0.171 mmol), tetrahydrofuran (3 mL), methanol (3 mL), and water (3 mL) were added. The reaction was carried out at 50°C for 2 hours. After concentration, the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 50% to 70%] to obtain compound 136 (3 mg, yield: 18%) as a white solid. MS (ESI, m/z): 727.2 [M+H]+.
[0651] 1H NMR (400 MHz, CDCl3) δ 7.42 (s, 1H), 7.32 -7.27 (m, 1H), 7.25 - 7.19 (m, 1H), 7.04 (d, J= 8.0 Hz, 1H), 6.68 - 6.40 (m, 3H), 4.09 - 3.93 (m, 4H), 3.86 - 3.82 (m, 5H), 3.56 - 3.51 (m, 4H), 3.50 - 3.43 (m, 1H), 2.97 - 2.82 (m, 3H), 2.70 - 2.61 (m, 1H), 2.46 - 2.40 (m, 1H), 2.28 - 2.03 (m, 4H), 1.69 - 1.63 (m, 2H), 1.62 - 1.54 (m, 4H), 1.40 (d, J= 10.4 Hz, 6H), 1.34 (d, J = 7.6 Hz, 6H), 1.26 - 1.21 (m, 1H), 0.71 - 0.64 (m, 1H), 0.56 - 0.48 (m, 1H), 0.40 - 0.33 (m, 1H), 0.28 - 0.20 (m, 1H).
Example 137:
Synthetic Route:
[0653] Compound 137-1 (250 mg, 1.19 mmol) was dissolved in dichloromethane (5 mL). Piperidine (121 mg, 1.43 mmol) and sodium triacetoxyborohydride (504 mg, 2.20 mmol) were added, and the reaction was carried out at room temperature overnight. After concentration, the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 40%) to obtain compound 137-2 (100 mg, yield: 30%) as a yellow oil. MS (ESI, m/z): 276.1 [M+H]+.
[0654] Compound 137-2 (45 mg, 0.163 mmol) was dissolved in tetrahydrofuran (3 mL), and 5% palladium on carbon (10 mg) was added. The reaction was carried out under a hydrogen atmosphere at room temperature overnight. The reaction mixture was rotary evaporated to dryness to remove the solvent to obtain compound 137-3 (42 mg, yield: 99%) as a yellow oil. MS (ESI, m/z): 186.1 [M+H]+.
[0655] Then, referring to the synthetic route of compound 126, 3,3,3-trifluoro-2,2-dimethylpropionic acid was replaced with compound 137-3 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 137 (16 mg, yield: 68%) as a white solid. MS (ESI, m/z): 627.3 [M+H]+.
[0656] 1H NMR (400 MHz, CDCl3) δ 7.91 (d, J = 8.0 Hz, 1H), 7.43 (s, 1H), 7.23 (t, J = 8.4 Hz, 1H), 6.98 (d, J = 8.0 Hz, 1H), 6.69 - 6.62 (m, 1H), 6.60 - 6.55 (m, 1H), 6.51 - 6.44 (m, 1H), 3.87 - 3.76 (m, 6H), 3.41 - 3.23 (m, 2H), 2.98 - 2.82 (m, 6H), 2.57 - 2.53 (m, 1H), 2.24 - 2.16 (m, 4H), 2.07 - 2.02 (m, 2H), 1.88 - 1.71 (m, 4H), 1.64 (s, 6H), 1.58 - 1.46 (m, 2H), 1.17 - 1.06 (m, 1H), 0.72 - 0.64 (m, 1H), 0.51 - 0.43 (m, 1H), 0.42 - 0.34 (m, 1H), 0.26 - 0.18 (m, 1H).
Example 138:
Synthetic Route:
[0658] Referring to the synthetic route of compound 126, 3,3,3-trifluoro-2,2-dimethylpropionic acid was replaced with trans-4-pentylcyclohexanecarboxylic acid to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 138 (3 mg, yield: 16%) as a white solid. MS (ESI, m/z): 640.3 [M+H]+.
[0659] 1H NMR (400 MHz, CDCl3) δ 7.95 (d, J = 8.0 Hz, 1H), 7.42 (s, 1H), 7.26 - 7.17 (m, 2H), 6.67 - 6.60 (m, 1H), 6.56 (s, 1H), 6.49 - 6.42 (m, 1H), 3.91 - 3.75 (m, 7H), 3.00 - 2.81 (m, 5H), 2.57 - 2.48 (m, 1H), 2.29 - 2.15 (m, 4H), 2.09 - 2.02 (m, 2H), 1.99 - 1.80 (m, 4H), 1.75 - 1.57(m, 4H), 1.22 - 1.00 (m, 5H), 0.97 - 0.84 (m, 5H), 0.65 - 0.63 (m, 1H), 0.50 - 0.43 (m, 1H), 0.44 - 0.32 (m, 1H), 0.23 - 0.19 (m, 1H).
Example 139:
Synthetic Route:
[0661] Referring to the synthetic route of compound 126, 3,3,3-trifluoro-2,2-dimethylpropionic acid was replaced with 1-adamantanecarboxylic acid to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 139 (20 mg, yield: 48%) as a white solid. MS (ESI, m/z): 622.3 [M+H]+.
[0662] 1H NMR (400 MHz, CDCl3) δ 7.85 (d, J = 8.0 Hz, 1H), 7.36 (s, 1H), 7.21 -7.10 (m, 2H), 6.58 - 6.52 (m, 1H), 6.49 (s, 1H), 6.45 - 6.37 (m, 1H), 3.79 (s, 3H), 3.77 - 3.68 (m, 2H), 3.68 - 3.55 (m, 1H), 2.89 - 2.69 (m, 2H), 2.70 - 2.52 (m, 2H), 2.49 - 2.43 (m, 1H), 2.28 - 2.03 (m, 11H), 1.98 - 1.92 (m, 2H), 1.83 - 1.72 (m, 6H), 0.94 - 0.89 (m, 1H), 0.49 - 0.38 (m, 1H), 0.33 - 0.17 (m, 2H), 0.08 - 0.05 (m, 1H).
Example 140:
Synthetic Route:
[0664] Referring to the synthetic route of compound 126, 3,3,3-trifluoro-2,2-dimethylpropionic acid was replaced with 1-methylcyclohexanecarboxylic acid to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 140 (17 mg, yield: 47%) as a white solid. MS (ESI, m/z): 584.3 [M+H]+.
[0665] 1H NMR (400 MHz, CDCl3) δ 7.94 (d, J = 8.0 Hz, 1H), 7.42 (s, 1H), 7.28 - 7.15 (m, 2H), 6.68 - 6.61 (m, 1H), 6.56 (s, 1H), 6.50 - 6.41 (m, 1H), 3.95 - 3.85 (m, 2H), 3.83 (s, 3H), 3.82 - 3.75 (m, 1H), 3.05 - 2.79 (m, 4H), 2.57 - 2.46 (m, 1H), 2.38 - 2.26 (m, 2H), 2.23 - 2.17 (m, 2H), 2.12 - 2.02 (m, 2H), 1.75 - 1.52 (m, 8H), 1.44 (s, 3H), 1.14 - 1.05 (m, 1H), 0.70 - 0.59 (m, 1H), 0.53 - 0.42 (m, 1H), 0.41 - 0.31 (m, 1H), 0.24 - 0.14 (m, 1H).
Example 141:
Synthetic Route:
[0667] Referring to the synthetic route of compound 81, compound 11-1 was replaced with compound 86-1 and compound 81-2 was replaced with compound 124-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 141 (24 mg, yield: 39%) as a white solid. MS (ESI, m/z): 562.3 [M+H]+.
[0668] 1H NMR (400 MHz, CDCl3) δ 7.93 (d, J= 8.0 Hz, 1H), 7.42 (s, 1H), 7.27 - 7.21 (m, 1H), 7.05 - 6.94 (m, 1H), 6.74 - 6.60 (m, 2H), 3.90 (s, 3H), 3.82 - 3.76 (m, 1H), 3.67 - 3.54 (m, 2H), 2.96 - 2.75 (m, 4H), 2.58 - 2.45 (m, 1H), 2.35 - 2.26 (m, 2H), 2.13 - 2.00 (m, 2H), 1.53 (s, 9H), 1.16 - 1.05 (m, 1H), 0.67 - 0.59 (m, 1H), 0.52 - 0.41 (m, 1H), 0.40 - 0.30 (m, 1H), 0.26 - 0.15 (m, 1H).
Example 142:
Synthetic Route:
[0670] Referring to the synthetic route of compound 141, compound 86-1 was replaced with compound 89-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 142 (91 mg, yield: 63%) as a white solid. MS (ESI, m/z): 562.3 [M+H]+.
[0671] 1H NMR (400 MHz, CDCl3) δ 7.92 (d, J= 8.0 Hz, 1H), 7.41 (s, 1H), 7.27 - 7.21 (m, 1H), 7.06 - 6.95 (m, 1H), 6.60 - 6.52 (m, 1H), 6.48 - 6.37 (m, 1H), 3.86 - 3.71 (m, 4H), 3.67 - 3.53 (m, 2H), 2.92 - 2.84 (m, 4H), 2.58 - 2.44 (m, 1H), 2.37 - 2.20 (m, 2H), 2.12 - 1.98 (m, 2H), 1.57 - 1.46 (m, 9H), 1.14 - 1.05 (m, 1H), 0.69 - 0.61 (m, 1H), 0.50 - 0.41 (m, 1H), 0.38 - 0.31 (m, 1H), 0.22 - 0.16 (m, 1H).
Example 143:
Synthetic Route:
[0673] Referring to the synthetic route of compound 141, compound 86-1 was replaced with compound 97-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 143 (97 mg, yield: 64%) as a white solid. MS (ESI, m/z): 558.3 [M+H]+.
[0674] 1H NMR (400 MHz, CDCl3) δ 7.92 (d, J = 8.0 Hz, 1H), 7.41 (s, 1H), 7.26 - 7.22 (m, 1H), 6.78 - 6.71 (m, 1H), 6.64 (s, 1H), 6.50 - 6.40 (m, 1H), 5.91 (s, 2H), 3.86 - 3.55 (m, 3H), 2.96 - 2.76 (m, 4H), 2.56 - 2.48 (m, 1H), 2.32 - 2.14 (m, 2H), 2.08 - 1.99 (m, 2H), 1.52 (s, 9H), 1.13 - 1.06 (m, 1H), 0.68 - 0.57 (m, 1H), 0.49 - 0.42 (m, 1H), 0.37 - 0.30 (m 1H), 0.23 - 0.18 (m, 1H).
Example 144:
Synthetic Route:
[0676] Referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 144-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 144 (226 mg, yield: 98%) as a white solid. MS (ESI, m/z): 511.2 [M+H]+.
[0677] 1H NMR (400 MHz, CDCl3) δ 8.46 (d, J = 8.0 Hz, 2H), 7.62 (s, 1H), 7.46 - 7.34 (m, 2H), 7.25 - 7.14 (m, 2H), 6.62 - 6.56 (m, 1H), 6.52 (s, 1H), 6.47 - 6.38 (m, 1H), 3.84 - 3.71 (m, 5H), 3.03 - 2.93 (m, 1H), 2.92 - 2.74 (m, 4H), 2.57 - 2.46 (m, 1H), 2.42 (s, 3H), 2.30 - 2.17 (m, 2H), 1.94 - 1.81 (m, 2H), 1.16 - 1.03 (m, 1H), 0.68 - 0.56 (m, 1H), 0.49 - 0.41 (m, 1H), 0.40 - 0.31 (m, 1H), 0.24 - 0.16 (m, 1H).
Example 145:
Synthetic Route:
[0679] Referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 145-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 145 (183 mg, yield: 92%) as a white solid. MS (ESI, m/z): 511.2 [M+H]+.
[0680] 1H NMR (400 MHz, CDCl3) δ 8.57 (d, J = 7.2 Hz, 1H), 7.47 - 7.37 (m, 2H), 7.26 (s, 1H), 7.22 - 7.13 (m, 3H), 6.62 - 6.56 (m, 1H), 6.54 - 6.48 (m, 1H), 6.47 - 6.38 (m, 1H), 3.86 - 3.71 (m, 5H), 3.11 - 2.96 (m, 1H), 2.93 - 2.74 (m, 4H), 2.63 (s, 3H), 2.57 - 2.48 (m, 1H), 2.29 - 2.17 (m, 2H), 1.96 - 1.80 (m, 2H), 1.17 - 1.06 (m, 1H), 0.69 - 0.58 (m, 1H), 0.49 - 0.42 (m, 1H), 0.40 - 0.31 (m, 1H), 0.26 - 0.13 (m, 1H).
Example 146:
Synthetic Route:
[0682] Referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 146-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 146 (51 mg, yield: 76%) as a white solid. MS (ESI, m/z): 511.2 [M+H]+.
[0683] 1H NMR (400 MHz, CDCl3) δ 7.76 - 7.61 (m, 2H), 7.42 - 7.35 (m, 2H), 7.23 - 7.05 (m, 3H), 6.65 - 6.50 (m, 2H), 6.47 - 6.38 (m, 1H), 3.87 - 3.77 (m, 5H), 3.55 - 3.41 (m, 1H), 2.90 - 2.77 (m, 4H), 2.61 (s, 3H), 2.54 - 2.43 (m, 1H), 2.29 - 2.16 (m, 2H), 2.08 - 1.98 (m, 2H), 1.12 - 1.02 (m, 1H), 0.66 - 0.54 (m, 1H), 0.46 - 0.38 (m, 1H), 0.36 - 0.27 (m, 1H), 0.21 - 0.14 (m, 1H).
Example 147:
Synthetic Route:
[0685] Referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 147-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 147 (59 mg, yield: 79%) as a white solid. MS (ESI, m/z): 511.2 [M+H]+.
[0686] 1H NMR (400 MHz, CDCl3) δ 8.59 (d, J = 8.0 Hz, 1H), 7.63 (d, J= 8.0 Hz, 1H), 7.36 (s, 2H), 7.21 - 7.11 (m, 2H), 7.07 (d, J= 8.4 Hz, 1H), 6.64 - 6.56 (m, 1H), 6.53 (s, 1H), 6.45 - 6.38 (m, 1H), 3.85 - 3.69 (m, 5H), 3.53 - 3.38 (m, 1H), 2.92 - 2.72 (m, 4H), 2.55 - 2.45 (m, 1H), 2.43 (s, 3H), 2.26 - 2.17 (m, 2H), 2.05 - 1.94 (m, 2H), 1.14 - 1.03 (m, 1H), 0.65 - 0.54 (m, 1H), 0.48 - 0.40 (m, 1H), 0.36 - 0.27 (m, 1H), 0.21 - 0.13 (m, 1H).
Example 148:
Synthetic Route:
[0688] Compound 148-1 (2 g, 11.6 mmol) was dissolved in dichloromethane (20 mL). Compound 148-2 (994 mg, 11.6 mmol), acetic acid (0.02 mL), and sodium triacetoxyborohydride (3.2 g, 15.1 mmol) were added, and the reaction was carried out at room temperature for 4 hours. After concentration, the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 40%) to obtain compound 148-3 (1.6 g, yield: 57%) as a colorless oil. MS (ESI, m/z): 243.1 [M+H]+.
[0689] Compound 148-3 (1.6 g, 6.6 mmol) was dissolved in dichloromethane (10 mL), and compound 148-4 (779 mg, 9.9 mmol) and triethylamine (1.33 g, 13.2 mmol) were added. The reaction was carried out at room temperature for 4 hours. After concentration, the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 40%) to obtain compound 148-5 (938 mg, yield: 50%) as a yellow oil. MS (ESI, m/z): 285.1 [M+H]+.
[0690] Then, referring to the synthetic route of compound 82, compound 82-4 was replaced with compound 148-5 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 148 (21 mg, yield: 84%) as a white solid. MS (ESI, m/z): 624.2 [M+H]+.
[0691] 1H NMR (400 MHz, CDCl3) δ 7.86 (t, J = 7.6 Hz, 1H), 7.73 (d, J = 7.6 Hz, 1H), 7.56 (d, J= 7.6 Hz, 1H), 7.41 (s, 1H), 7.28 - 7.27 (m, 1H), 7.25 - 7.13 (m, 3H), 6.69 - 6.38 (m, 2H), 3.94 (s, 2H), 3.88 - 3.78 (m, 5H), 3.72 - 3.57 (m, 1H), 2.98 - 2.75 (m, 4H), 2.58 - 2.47 (m, 1H), 2.38 - 2.16 (m, 2H), 2.09 (s, 3H), 2.06 - 1.97 (m, 2H), 1.18 - 1.05 (m, 1H), 0.88 (s, 9H), 0.68 - 0.59 (m, 1H), 0.52 - 0.41 (m, 1H), 0.40 - 0.30 (m, 1H), 0.26 - 0.16 (m, 1H).
Example 149:
Synthetic Route:
[0693] Referring to the synthetic route of compound 148, compound 148-3 was replaced with compound 148-1 and compound 148-4 was replaced with compound 149-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 149 (14 mg, yield: 23%) as a white solid. MS (ESI, m/z): 610.2 [M+H]+.
[0694] 1H NMR (400 MHz, CDCl3) δ 8.96 - 8.75 (m, 1H), 8.30 - 8.13 (m, 1H), 7.86 - 7.78 (m, 1H), 7.58 (d, J= 8.0 Hz, 1H), 7.37 (s, 1H), 7.25 - 7.16 (m, 2H), 7.14 - 7.08 (m, 1H), 6.66 - 6.58 (m, 1H), 6.54 (s, 1H), 6.49 - 6.42 (m, 1H), 3.87 - 3.65 (m, 5H), 3.36 - 3.16 (m, 1H), 2.90 - 2.61 (m, 4H), 2.53 - 2.35 (m, 1H), 2.33 - 2.07 (m, 4H), 2.02 - 1.80 (m, 2H), 1.32 - 1.25 (m, 1H), 1.07 (s, 9H), 0.68 - 0.55 (m, 1H), 0.49 - 0.38 (m, 1H), 0.37 - 0.25 (m, 1H), 0.22 - 0.05 (m, 1H).
Example 150:
Synthetic Route:
[0696] Referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 150-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 150 (30 mg, yield: 58%) as a white solid. MS (ESI, m/z): 535.2 [M+H]+.
[0697] 1H NMR (400 MHz, CDCl3) δ 8.27 (s, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.58 (d,J = 8.0 Hz, 1H), 7.43 (d, J= 8.0 Hz, 1H), 7.39 (s, 1H), 7.22 (d, J= 8.0 Hz, 1H), 7.26 - 7.13 (m, 3H), 6.64 - 6.58 (m, 2H), 6.54 (s, 1H), 6.48 - 6.40 (m, 1H), 3.90 - 3.76 (m, 5H), 3.31 - 3.23 (m, 1H), 2.94 - 2.78 (m, 4H), 2.55 - 2.44 (m, 1H), 2.29 - 2.18 (m, 2H), 1.97 - 1.86 (m, 2H), 1.15 - 1.05 (m, 1H), 0.69 - 0.58 (m, 1H), 0.51 - 0.42 (m, 1H), 0.39 - 0.28 (m, 1H), 0.22 - 0.13 (m, 1H).
Example 151:
Synthetic Route:
[0699] Referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 151-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 151 (103 mg, yield: 84%) as a white solid. MS (ESI, m/z): 553.2 [M+H]+.
[0700] 1H NMR (400 MHz, CDCl3) δ 8.46 (s, 1H), 7.58 (d, J = 8.0 Hz, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.40 (s, 1H), 7.24 - 7.15 (m, 2H), 7.17 - 7.04 (m, 1H), 6.99 - 6.90 (m, 1H), 6.76 - 6.33 (m, 4H), 3.88 - 3.76 (m, 5H), 3.34 - 3.25 (m, 1H), 2.95 - 2.79 (m, 4H), 2.53 - 2.45 (m, 1H), 2.33 - 2.16 (m, 2H), 2.02 - 1.89 (m, 2H), 1.15 - 1.03 (m, 1H), 0.68 - 0.57 (m, 1H), 0.51 - 0.40 (m, 1H), 0.38 - 0.29 (m, 1H), 0.24 - 0.16 (m, 1H).
Example 152
Synthetic Route:
[0702] Referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 152-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 152 (2 mg, yield: 11%) as a white solid. MS (ESI, m/z): 553.2 [M+H]+.
[0703] 1H NMR (400 MHz, MeOD) δ 8.15 - 7.99 (m, 3H), 7.58 - 7.52 (m, 1H), 7.49 - 7.42 (m, 2H), 7.35 - 7.30 (m, 1H), 7.16 (t, J= 8.0 Hz, 1H), 6.68 - 6.63 (m, 1H), 6.59 - 6.58 (m, 1H), 6.46 - 6.44 (m, 1H), 3.99 - 3.91 (m, 1H), 3.86 (m, 2H), 3.78 (s, 3H), 2.99 - 2.89 (m, 2H), 2.79 - 2.74 (m, 2H), 2.54 - 2.48 (m, 1H), 2.30 - 2.20 (m, 2H), 2.11 (m, 2H),1.17 - 1.09 (m, 1H), 0.62 - 0.60 (m, 1H), 0.43 - 0.33 (m, 2H), 0.20 - 0.16 (m, 1H).
Example 153:
Synthetic Route:
[0705] Referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 153-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 153 (4 mg, yield: 20%) as a white solid. MS (ESI, m/z): 537.2 [M+H]+.
[0706] 1H NMR (400 MHz, MeOD) δ 8.84 (d, J = 6.8 Hz, 1H), 8.18 (d, J = 8.0 Hz, 1H), 7.81 (d, J= 8.8 Hz, 1H), 7.72 - 7.65 (m, 1H), 7.45 (s, 1H), 7.30 - 7.28 (m, 1H), 7.21 - 7.13 (m, 2H), 6.67 - 6.65 (m, 1H), 6.60 - 6.59 (m, 1H), 6.46 - 6.44 (m, 1H), 4.18 - 4.12 (m, 1H), 3.86 - 3.83 (m, 2H), 3.78 (s, 3H), 2.96 - 2.93 (m, 2H), 2.74 - 2.63 (m, 2H), 2.57 - 2.51 (m, 1H), 2.26 - 2.18 (m, 2H), 2.09 - 2.03 (m, 2H), 1.14 - 1.07 (m, 1H), 0.62 - 0.55 (m, 1H), 0.42 - 0.36 (m, 2H), 0.18 - 0.12 (m, 1H).
Example 154:
Synthetic Route:
[0708] Referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 154-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 154 (27 mg, yield: 38%) as a white solid. MS (ESI, m/z): 547.2 [M+H]+.
[0709] 1H NMR (400 MHz, CDCl3) δ 8.25 (d, J = 8.4 Hz, 1H), 8.11 (d, J = 8.4 Hz, 1H), 7.88 - 7.79 (m, 2H), 7.77 - 7.70 (m, 2H), 7.55 (t, J= 8.0 Hz, 1H), 7.46 - 7.39 (m, 1H), 7.23 - 7.15 (m, 2H), 6.79 - 6.27 (m, 3H), 3.90 - 3.76 (m, 5H), 3.72 - 3.64 (m, 1H), 2.96 - 2.80 (m, 4H), 2.56 - 2.47 (m, 1H), 2.40 - 2.23 (m, 2H), 2.17 - 2.08 (m, 2H), 1.18 - 1.05 (m, 1H), 0.68 - 0.57 (m, 1H), 0.51 - 0.43 (m, 1H), 0.39 - 0.29 (m, 1H), 0.23 - 0.15 (m, 1H).
Example 155:
Synthetic Route:
[0711] Referring to the synthetic route of compound 81, compound 81-2 was replaced with compound 155-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% ammonia) = 0% to 100%] to obtain compound 155 (36 mg, yield: 53%) as a white solid. MS (ESI, m/z): 565.2 [M+H]+.
[0712] 1H NMR (400 MHz, CDCl3) δ 8.26 (d, J = 8.4 Hz, 1H), 7.86 (t, J= 8.4 Hz, 2H), 7.63 (d, J = 7.6 Hz, 1H), 7.50 - 7.37 (m, 3H), 7.23 - 7.15 (m, 2H), 6.67 - 6.60 (m, 1H), 6.56 (s, 1H), 6.46 - 6.39 (m, 1H), 3.90 - 3.73 (m, 6H), 2.98 - 2.80 (m, 4H), 2.58 - 2.47 (m, 1H), 2.35 - 2.21 (m, 2H), 2.19 - 2.10 (m, 2H), 1.18 - 1.08 (m, 1H), 0.69 - 0.57 (m, 1H), 0.50 - 0.39 (m, 1H), 0.37 - 0.29 (m, 1H), 0.22 - 0.13 (m, 1H).
Example 156:
Synthetic Route:
[0714] Referring to the synthetic route of compound 6, compound 6-1 was replaced with compound 156-1 and compound 6-4 was replaced with compound 156-4 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 156 (7 mg, yield: 5%) as a white solid. MS (ESI, m/z): 514.3 [M+H]+.
[0715] 1H NMR (400 MHz, CDCl3) δ 7.59 - 7.42 (m, 5H), 7.42 - 7.32 (m, 2H), 7.13 (d, J= 8.0 Hz, 1H), 7.00 - 6.91 (m, 1H), 6.61 - 6.50 (m, 1H), 6.48 - 6.41 (m, 1H), 3.82 - 3.76 (m, 3H), 3.64 - 3.52 (m, 2H), 3.16 - 3.01 (m, 1H), 2.94 - 2.69 (m, 4H), 2.59 - 2.47 (m, 1H), 2.43 - 2.26 (m, 2H), 1.99 - 1.90 (m, 2H), 1.16 - 1.06 (m, 1H), 0.70 - 0.58 (m, 1H), 0.52 - 0.41 (m, 1H), 0.40 - 0.30 (m, 1H), 0.27 - 0.15 (m, 1H).
Example 157:
Synthetic Route:
[0717] Referring to the synthetic route of compound 156, compound 156-1 was replaced with compound 157-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 157 (10 mg, yield: 40%) as a white solid. MS (ESI, m/z): 528.2 [M+H]+.
[0718] 1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 8.0 Hz, 1H), 7.42 - 7.37 (m, 2H), 7.33 - 7.28 (m, 1H), 7.27 - 7.19 (m, 1H), 7.13 (d, J = 8.0 Hz, 1H), 7.01 - 6.91 (m, 1H), 6.58 - 6.51 (m, 1H), 6.48 - 6.39 (m, 1H), 3.79 (s, 3H), 3.62 - 3.54 (m, 2H), 3.13 - 3.03 (m, 1H), 2.92 - 2.83 (m, 2H), 2.80 - 2.70 (m, 2H), 2.57 - 2.48 (m, 1H), 2.46 (s, 3H), 2.39 - 2.28 (m, 2H), 1.98 - 1.88 (m, 2H), 1.15 - 1.03 (m, 1H), 0.68 - 0.57 (m, 1H), 0.49 - 0.42 (m, 1H), 0.39 - 0.29 (m, 1H), 0.25 - 0.17 (m, 1H).
Example 158:
Synthetic Route:
[0720] Referring to the synthetic route of compound 157, compound 1-1 was replaced with compound 12-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 158 (20 mg, yield: 42%) as a white solid. MS (ESI, m/z): 528.2 [M+H]+.
[0721] 1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 8.0 Hz, 1H), 7.41 - 7.36 (m, 2H), 7.30 (s, 1H), 7.27 - 7.20 (m, 2H), 7.13 (d, J = 7.6 Hz, 1H), 7.01 - 6.91 (m, 1H), 6.59 - 6.50 (m, 1H), 6.48 - 6.39 (m, 1H), 3.79 (s, 3H), 3.64 - 3.53 (m, 2H), 3.13 - 3.00 (m, 1H), 2.92 - 2.84 (m, 2H), 2.81 - 2.69 (m, 2H), 2.55 - 2.48 (m, 1H), 2.45 (s, 3H), 2.40 - 2.28 (m, 2H), 1.96 - 1.90 (m, 2H), 1.18 - 1.06 (m, 1H), 0.68 - 0.57 (m, 1H), 0.49 - 0.41 (m, 1H), 0.39 - 0.26 (m, 1H), 0.26 - 0.15 (m, 1H).
Example 159:
Synthetic Route:
[0723] Referring to the synthetic route of compound 156, compound 156-1 was replaced with compound 159-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 159 (2 mg, yield: 23%) as a white solid. MS (ESI, m/z): 528.2 [M+H]+.
[0724] 1H NMR (400 MHz, CDCl3) δ 7.39 (s, 1H), 7.37 - 7.33 (m, 2H), 7.28 - 7.21 (m, 2H), 7.14 - 7.05 (m, 2H), 6.99 - 6.90 (m, 1H), 6.55 - 6.46 (m, 1H), 6.45 - 6.37 (m, 1H), 3.77 (s, 3H), 3.58 - 3.49 (m, 2H), 2.92 - 2.84 (m, 2H), 2.84 - 2.62 (m, 3H), 2.55 - 2.46 (m, 1H), 2.31 - 2.18 (m, 5H), 1.94 - 1.83 (m, 2H), 1.15 - 1.05 (m, 1H), 0.68 - 0.57 (m, 1H), 0.52 - 0.42 (m, 1H), 0.39 - 0.31 (m, 1H), 0.27 - 0.19 (m, 1H).
Example 160:
Synthetic Route:
[0726] Referring to the synthetic route of compound 156, compound 156-1 was replaced with compound 160-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 160 (15 mg, yield: 73%) as a white solid. MS (ESI, m/z): 528.2 [M+H]+.
[0727] 1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 8.0 Hz, 1H), 7.40 -7.36 (m, 3H), 7.34 - 7.30 (m, 2H), 7.12 (d, J = 8.0 Hz, 1H), 7.01 - 6.91 (m, 1H), 6.58 - 6.49 (m, 1H), 6.47 - 6.36 (m, 1H), 3.79 (s, 3H), 3.63 - 3.55 (m, 2H), 3.13 - 3.00 (m, 1H), 2.91 - 2.84 (m, 2H), 2.79 - 2.70 (m, 2H), 2.56 - 2.47 (m, 1H), 2.45 (s, 3H), 2.41 - 2.30 (m, 2H), 1.95 - 1.88 (m, 2H), 1.17 - 1.03 (m, 1H), 0.68 - 0.58 (m, 1H), 0.52 - 0.41 (m, 1H), 0.41 - 0.32 (m, 1H), 0.28 - 0.18 (m, 1H).
Example 161:
Synthetic Route:
[0729] Referring to the synthetic route of compound 160, compound 1-1 was replaced with compound 12-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 161 (9 mg, yield: 28%) as a white solid. MS (ESI, m/z): 528.2 [M+H]+.
[0730] 1H NMR (400 MHz, CDCl3) δ 7.46 (d, J= 7.6 Hz, 1H), 7.41 - 7.35 (m, 3H), 7.34 - 7.30 (m, 2H), 7.12 (d, J = 8.8 Hz, 1H), 6.99 - 6.93 (m, 1H), 6.61 - 6.48 (m, 1H), 6.49 - 6.39 (m, 1H), 3.79 (s, 3H), 3.66 - 3.53 (m, 2H), 3.13 - 3.02 (m, 1H), 2.95 - 2.71 (m, 4H), 2.57 - 2.49 (m, 1H), 2.45 (s, 3H), 2.41 - 2.29 (m, 2H), 1.99 - 1.90 (m, 2H), 1.17 - 1.06 (m, 1H), 0.68 - 0.59 (m, 1H), 0.50 - 0.43 (m, 1H), 0.39 - 0.31 (m, 1H), 0.27 - 0.19 (m, 1H).
Example 162:
Synthetic Route:
[0732] Referring to the synthetic route of compound 156, compound 156-1 was replaced with compound 162-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 162 (9 mg, yield: 49%) as a white solid. MS (ESI, m/z): 542.2 [M+H]+.
[0733] 1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 7.2 Hz, 1H), 7.42 - 7.37 (m, 3H), 7.36 - 7.31 (m, 2H), 7.12 (d, J= 8.0 Hz, 1H), 7.01 - 6.91 (m, 1H), 6.59 - 6.49 (m, 1H), 6.47 - 6.39 (m, 1H), 3.79 (s, 3H), 3.62 - 3.54 (m, 2H), 3.14 - 3.02 (m, 1H), 2.91 - 2.83 (m, 2H), 2.80 - 2.70 (m, 4H), 2.56 - 2.46 (m, 1H), 2.42 - 2.25 (m, 2H), 1.97 - 1.89 (m, 2H), 1.33 (t, J = 7.2 Hz, 3H), 1.16 - 1.06 (m, 1H), 0.68 - 0.60 (m, 1H), 0.52 - 0.39 (m, 1H), 0.39 - 0.29 (m, 1H), 0.27 - 0.17 (m, 1H).
Example 163:
Synthetic Route:
[0735] Referring to the synthetic route of compound 156, compound 156-1 was replaced with compound 163-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 163 (9 mg, yield: 47%) as a white solid. MS (ESI, m/z): 556.3 [M+H]+.
[0736] 1H NMR (400 MHz, DMSO-d6) δ 7.51 (s, 1H), 7.47 - 7.39 (m, 2H), 7.36 (s, 1H), 7.32 - 7.28 (m, 2H), 7.18 (d, J = 8.0 Hz, 1H), 7.07 - 7.02(m, 1H), 6.57 - 6.55 (m, 1H), 6.51 - 6.47 (m, 1H), 3.72 (s, 3H), 3.49 - 3.46 (m, 2H), 3.03 - 2.97 (m, 2H), 2.79 - 2.65 (m, 4H), 2.43 - 2.37 (m, 1H), 2.15 - 2.05 (m, 2H), 1.95 - 1.92 (m, 2H), 1.27 (d, J= 7.2 Hz, 6H), 1.09 - 1.06 (m, 1H), 0.53 - 0.51 (m, 1H), 0.32 - 0.28 (m, 2H), 0.16 - 0.14 (m, 1H).
Example 164:
Synthetic Route:
[0738] Referring to the synthetic route of compound 98, compound 98-2 was replaced with compound 164-1 and compound 98-3 was replaced with compound 98-1. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 164 (21 mg, yield: 61%) as a white solid. MS (ESI, m/z): 554.3 [M+H]+.
[0739] 1H NMR (400 MHz, MeOD) δ 7.41 (s, 1H), 7.39 -7.31 (m, 2H), 7.23 (d, J= 7.6 Hz, 1H), 7.20 - 7.14 (m, 2H), 7.09 (d, J = 7.6 Hz, 1H), 6.98 - 6.88 (m, 1H), 6.62 - 6.56 (m, 1H), 6.56 - 6.44 (m, 1H), 3.75 (s, 3H), 3.57 - 3.49 (m, 2H), 3.10 - 3.01 (m, 1H), 2.77 - 2.69 (m, 2H), 2.69 - 2.50 (m, 3H), 2.33 - 2.19 (m, 2H), 2.04 - 1.88 (m, 3H), 1.14 - 1.06 (m, 1H), 1.05 - 0.98 (m, 2H), 0.76 - 0.69 (m, 2H), 0.63 - 0.54 (m, 1H), 0.44 - 0.33 (m, 2H), 0.18 - 0.10 (m, 1H).
Example 165:
Synthetic Route:
[0741] Referring to the synthetic route of compound 156, compound 156-3 was replaced with compound 1-4 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 165 (7 mg, yield: 5%) as a white solid. MS (ESI, m/z): 570.3 [M+H]+.
[0742] 1H NMR (400 MHz, CDCl3) δ 7.59 - 7.47 (m, 2H), 7.47 - 7.36 (m, 3H), 7.36 - 7.30 (m, 1H), 7.16 (d, J= 8.0 Hz, 1H), 6.99 - 6.89 (m, 1H), 6.62 - 6.51 (m, 1H), 6.49 - 6.38 (m, 1H), 3.79 (s, 3H), 3.61 (d, J = 11.2 Hz, 2H), 3.18 - 3.05 (m, 1H), 2.97 - 2.82 (m, 2H), 2.81 - 2.66 (m, 2H), 2.59 - 2.47 (m, 1H), 2.45 - 2.31 (m, 2H), 2.01 - 1.92 (m, 2H), 1.40 (s, 9H), 1.18 - 1.03 (m, 1H), 0.70 - 0.59 (m, 1H), 0.55 - 0.43 (m, 1H), 0.41 - 0.32 (m, 1H), 0.28 - 0.17 (m, 1H).
Example 166:
Synthetic Route:
[0744] Referring to the synthetic route of compound 165, compound 1-4 was replaced with compound 12-3 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 166 (30 mg, yield: 18%) as a white solid. MS (ESI, m/z): 570.3 [M+H]+.
[0745] 1H NMR (400 MHz, CDCl3) δ 7.54 - 7.47 (m, 2H), 7.45 - 7.41 (m, 2H), 7.39 (s, 1H), 7.33 - 7.28 (m, 1H), 7.14 (d, J= 8.0 Hz, 1H), 7.00 - 6.91 (m, 1H), 6.61 - 6.50 (m, 1H), 6.48 - 6.38 (m, 1H), 3.78 (s, 3H), 3.60 (d, J = 11.6 Hz, 2H), 3.16 - 3.03 (m, 1H), 2.94 - 2.82 (m, 2H), 2.80 - 2.67 (m, 2H), 2.57 - 2.46 (m, 1H), 2.45 - 2.28 (m, 2H), 2.00 - 1.89 (m, 2H), 1.39 (s, 9H), 1.15 - 1.06 (m, 1H), 0.69 - 0.56 (m, 1H), 0.52 - 0.40 (m, 1H), 0.40 - 0.29 (m, 1H), 0.26 - 0.16 (m, 1H).
Example 167:
Synthetic Route:
[0747] The synthesis of intermediate M1 was referred to obtain intermediate M8. Then, referring to the synthetic route of compound 165, compound 1-1 was replaced with compound 167-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 167 (26 mg, yield: 16%) as a white solid. MS (ESI, m/z): 570.3 [M+H]+.
[0748] 1H NMR (400 MHz, DMSO-d6) δ 7.53 - 7.41 (m, 5H), 7.33 (d, J = 6.4 Hz, 1H), 7.18 (d, J = 8.0 Hz, 1H), 7.09 - 7.00 (m, 1H), 6.58 - 6.47 (m, 2H), 3.72 (s, 3H), 3.54 - 3.43 (m, 2H), 3.11 - 2.98 (m, 1H), 2.78 - 2.67 (m, 4H), 2.42 - 2.38 (m, 1H), 2.12 - 2.08 (m, 2H), 1.94 - 1.92 (m, 2H), 1.35 (s, 9H), 1.11 - 1.03 (m, 1H), 0.52 - 0.48 (m, 1H), 0.35 - 0.24 (m, 2H), 0.19 - 0.12 (m, 1H).
Example 168:
Synthetic Route:
[0750] Referring to the synthetic route of compound 156, compound 156-3 was replaced with compound 6-3 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 168 (40 mg, yield: 7%) as a white solid. MS (ESI, m/z): 570.3 [M+H]+.
[0751] 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 8.4 Hz, 2H), 7.48 -7.39 (m, 4H), 7.15 (d, J = 8.4 Hz, 1H), 7.08-7.02 (m, 1H), 6.58-6.55 (m, 1H), 6.52 - 6.45 (m, 1H), 3.72 (s, 3H), 3.50 - 3.42 (m, 2H), 3.28 - 3.13 (m, 1H), 2.82 - 2.72 (m, 2H), 2.61 - 2.36 (m, 3H), 2.18 - 2.05 (m, 2H), 1.95 - 1.87 (m, 2H), 1.35 (s, 9H), 1.10 - 0.98 (m, 1H), 0.53 - 0.45 (m, 1H), 0.33 - 0.20 (m, 2H), 0.16 - 0.08 (m, 1H).
Example 169:
Synthetic Route:
[0753] Referring to the synthetic route of compound 168, compound 6-3 was replaced with compound 14-2 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 169 (30 mg, yield: 27%) as a white solid. MS (ESI, m/z): 570.3 [M+H]+.
[0754] 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J= 8.4 Hz, 2H), 7.51 (s, 1H), 7.48 - 7.40 (m, 3H), 7.16 (d, J = 8.4 Hz, 1H), 7.08 - 7.02 (m, 1H), 6.58 - 6.55 (m, 1H), 6.52 - 6.47 (m, 1H), 3.72 (s, 3H), 3.48 - 3.45 (m, 2H), 3.10 - 3.03 (m, 1H), 2.89 - 2.59 (m, 4H), 2.45 - 2.29 (m, 1H), 2.16 - 2.07 (m, 2H), 1.94 - 1.91 (m, 2H), 1.35 (s, 9H), 1.12 - 1.04 (m, 1H), 0.59 - 0.48 (m, 1H), 0.35 - 0.25 (m, 2H), 0.20 - 0.11 (m, 1H).
Example 170:
Synthetic Route:
[0756] Referring to the synthetic route of compound 167, compound 1-2 was replaced with compound 6-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 170 (28 mg, yield: 25%) as a white solid. MS (ESI, m/z): 570.3 [M+H]+.
[0757] 1H NMR (400 MHz, DMSO-d6) δ 7.56 (d, J = 8.4 Hz, 2H), 7.51 (s, 1H), 7.46 - 7.42 (m, 3H), 7.17 (d, J = 8.4 Hz, 1H), 7.08 - 7.02 (m, 1H), 6.58 - 6.55 (m, 1H), 6.51 - 6.47 (m, 1H), 3.72 (s, 3H), 3.51 - 3.42 (m, 2H), 3.12 - 3.02 (m, 1H), 2.81 - 2.70 (m, 4H), 2.42 - 2.35 (m, 1H), 2.13 - 2.09 (m, 2H), 1.94 - 1.90 (m, 2H), 1.35 (s, 9H), 1.11 - 1.06 (m, 1H), 0.56 - 0.50 (m, 1H), 0.33 - 0.26 (m, 2H), 0.16 - 0.14 (m, 1H).
Example 171:
Synthetic Route:
[0759] Referring to the synthetic route of compound 164, compound 164-1 was replaced with compound 171-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 171 (15 mg, yield: 34%) as a white solid. MS (ESI, m/z): 548.2 [M+H]+.
[0760] 1H NMR (400 MHz, MeOD) δ 7.53 - 7.48 (m, 2H), 7.45 - 7.34 (m, 4H), 7.18 (d, J= 8.0 Hz, 1H), 6.94 (dd, J = 12.4, 8.8 Hz, 1H), 6.59 (dd, J = 7.2, 2.8 Hz, 1H), 6.51 - 6.45 (m, 1H), 3.75 (s, 3H), 3.53 - 3.48 (m, 2H), 3.12 - 2.99 (m, 1H), 2.87 - 2.70 (m, 4H), 2.55 - 2.42 (m, 1H), 2.39 - 2.18 (m, 2H), 1.95 - 1.90 (m, 2H), 1.19 - 1.06 (m, 1H), 0.68 - 0.54 (m, 1H), 0.48 - 0.28 (m, 2H), 0.24 - 0.12 (m, 1H).
Example 172:
Synthetic Route:
[0762] Referring to the synthetic route of compound 164, compound 164-1 was replaced with compound 172-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 172 (18 mg, yield: 36%) as a white solid. MS (ESI, m/z): 582.2 [M+H]+.
[0763] 1H NMR (400 MHz, CDCl3) δ 7.72 (s, 1H), 7.65 - 7.60 (m, 3H), 7.46 - 7.37 (m, 2H), 7.14 (d, J= 7.6 Hz, 1H), 6.96 - 6.91 (m, 1H), 6.55 - 6.48 (m, 1H), 6.44 - 6.40 (m, 1H), 3.77 (s, 3H), 3.59 - 3.56 (m, 2H), 2.98 - 2.96 (m, 1H), 2.90 - 2.84 (m, 2H), 2.75 - 2.67 (m, 2H), 2.54 - 2.44 (m, 1H), 2.40 - 2.26 (m, 2H), 1.96 - 1.85 (m, 2H), 1.15 - 1.04 (m, 1H), 0.67 - 0.58 (m, 1H), 0.50 - 0.41 (m, 1H), 0.38 - 0.30 (m, 1H), 0.24 - 0.16 (m, 1H).
Example 173:
Synthetic Route:
[0765] Referring to the synthetic route of compound 164, compound 98-1 was replaced with compound 142-1 and compound 164-1 was replaced with compound 173-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 173 (14 mg, yield: 48%) as a white solid. MS (ESI, m/z): 598.1 [M+H]+.
[0766] 1H NMR (400 MHz, MeOD) δ 7.65 - 7.59 (m, 1H), 7.51 (d, J = 7.6 Hz, 1H), 7.46 - 7.36 (m, 3H), 7.35 - 7.28 (m, 1H), 7.22 - 7.16 (m, 1H), 6.94 (dd, J = 12.4, 8.8 Hz, 1H), 6.59 (dd, J = 7.2, 3.2 Hz, 1H), 6.52 - 6.46 (m, 1H), 3.75 (s, 3H), 3.59 - 3.49 (m, 2H), 3.12 - 3.02 (m, 1H), 2.87 - 2.68 (m, 4H), 2.52 - 2.44 (m, 1H), 2.34 - 2.21 (m, 2H), 2.00 - 1.90 (m, 2H), 1.18 - 1.07 (m, 1H), 0.66 - 0.51 (m, 1H), 0.46 - 0.29 (m, 2H), 0.21- 0.15 (m, 1H).
Example 174:
Synthetic Route:
[0768] Referring to the synthetic route of compound 164, compound 164-1 was replaced with compound 174-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 174 (7 mg, yield: 32%) as a white solid. MS (ESI, m/z): 539.2 [M+H]+.
[0769] 1H NMR (400 MHz, DMSO-d6) δ 7.96 (s, 1H), 7.90 - 7.81 (m, 2H), 7.78 - 7.71 (m, 1H), 7.46 (s, 1H), 7.37 (d, J = 8.0 Hz, 1H), 7.16 (d, J = 8.0 Hz, 1H), 7.04 (dd, J = 12.4, 8.8 Hz, 1H), 6.56 (dd, J = 7.6, 2.8 Hz, 1H), 6.52 - 6.46 (m, 1H), 3.72 (s, 3H), 3.49 - 3.40 (m, 2H), 3.09 - 2.98 (m, 1H), 2.82 - 2.72 (m, 2H), 2.50 - 2.28 (m, 3H), 2.15 - 2.02 (m, 2H), 1.99 - 1.88 (m, 2H), 1.06 - 0.94 (m, 1H), 0.49 - 0.39 (m, 1H), 0.32 - 0.22 (m, 2H), 0.12 - 0.03 (m, 1H).
Example 175:
Synthetic Route:
[0771] Referring to the synthetic route of compound 173, compound 173-1 was replaced with compound 175-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 175 (25 mg, yield: 61%) as a white solid. MS (ESI, m/z): 558.3 [M+H]+.
[0772] 1H NMR (400 MHz, DMSO-d6) δ 7.51 - 7.42 (m, 5H), 7.36 (d, J = 8.0 Hz, 1H), 7.14 (d, J = 8.0 Hz, 1H), 7.08 - 7.01 (m, 1H), 6.57 - 6.54 (m, 1H), 6.51 - 6.47 (m, 1H), 5.24 (s, br, 1H), 4.80 - 4.77 (m, 1H), 3.71 (s, 3H), 3.47 - 3.42 (m, 2H), 3.04 - 3.01 (m, 1H), 2.75 - 2.70 (m, 2H), 2.49 - 2.37 (m, 3H), 2.12 - 2.08 (m, 2H), 1.90 - 1.87 (m, 2H), 1.39 (d, J = 6.8 Hz, 3H), 1.02 - 0.99 (m, 1H), 0.48 - 0.43 (m, 1H), 0.33 - 0.17 (m, 2H), 0.11 - 0.07 (m, 1H).
Example 176:
Synthetic Route:
[0774] Referring to the synthetic route of compound 173, compound 173-1 was replaced with compound 176-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 176 (12 mg, yield: 37%) as a white solid. MS (ESI, m/z): 572.2 [M+H]+.
[0775] 1H NMR (400 MHz, DMSO-d6) δ 7.56 - 7.35 (m, 6H), 7.16 (d, J = 8.0 Hz, 1H), 7.07 - 7.01 (m, 1H), 6.58 - 6.54 (m, 1H), 6.52 - 6.46 (m, 1H), 4.42 - 4.36 (m, 1H), 3.71 (s, 3H), 3.46 - 3.44 (m, 2H), 3.19 (s, 3H), 3.09 - 3.05 (m, 1H), 2.80 - 2.74 (m, 2H), 2.47 - 2.41 (m, 3H), 2.13 - 2.08 (m, 2H), 1.95 - 1.89 (m, 2H), 1.40 (d, J = 6.4 Hz, 3H), 1.01 - 0.99 (m, 1H), 0.49 - 0.44 (m, 1H), 0.33 - 0.21 (m, 2H), 0.16 - 0.06 (m, 1H).
Example 177:
Synthetic Route:
[0777] Referring to the synthetic route of compound 173, compound 173-1 was replaced with compound 177-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 177 (41 mg, yield: 35%) as a white solid. MS (ESI, m/z): 572.3 [M+H]+.
[0778] 1H NMR (400 MHz, DMSO-d6) δ 7.62 (d, J = 8.4 Hz, 2H), 7.48 - 7.40 (m, 3H), 7.36 (d, J= 8.0 Hz, 1H), 7.17 - 7.11 (m, 1H), 7.04 (dd, J= 12.4, 8.8 Hz, 1H), 6.56 (dd, J = 7.6, 2.8 Hz, 1H), 6.52 - 6.45 (m, 1H), 5.07 (s, br, 1H), 3.72 (s, 3H), 3.50 - 3.42 (m, 2H), 3.11 - 2.99 (m, 1H), 2.83 - 2.70 (m, 2H), 2.48 - 2.29 (m, 3H), 2.20 - 2.03 (m, 2H), 1.95 - 1.87 (m, 2H), 1.49 (s, 6H), 1.05 - 0.94 (m, 1H), 0.50 - 0.38 (m, 1H), 0.32 - 0.20 (m, 2H), 0.12 - 0.04 (m, 1H).
Example 178:
Synthetic Route:
[0780] Referring to the synthetic route of compound 164, compound 164-1 was replaced with compound 178-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 178 (11 mg, yield: 54%) as a white solid. MS (ESI, m/z): 532.2 [M+H]+.
[0781] 1H NMR (400 MHz, DMSO-d6) δ 7.62 - 7.54 (m, 1H), 7.45 (s, 1H), 7.39 - 7.29 (m, 3H), 7.29 - 7.22 (m, 1H), 7.16 (d, J = 8.0 Hz, 1H), 7.04 (dd, J = 12.4, 8.8 Hz, 1H), 6.56 (dd, J = 7.6, 2.8 Hz, 1H), 6.52 - 6.46 (m, 1H), 3.72 (s, 3H), 3.50 - 3.41 (m, 2H), 3.10 - 3.00 (m, 1H), 2.82 - 2.72 (m, 2H), 2.47 - 2.37 (m, 3H), 2.16 - 2.02 (m, 2H), 1.98 - 1.87 (m, 2H), 1.05 - 0.94 (m, 1H), 0.49 - 0.41 (m, 1H), 0.30 - 0.21 (m, 2H), 0.11 - 0.04 (m, 1H).
Example 179:
Synthetic Route:
[0783] Referring to the synthetic route of compound 173, compound 173-1 was replaced with compound 179-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 179 (10 mg, yield: 48%) as a white solid. MS (ESI, m/z): 544.2 [M+H]+.
[0784] 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 8.0 Hz, 1H), 7.41 - 7.37 (m, 3H), 7.12 (d, J = 8.0 Hz, 1H), 7.08 - 7.01 (m, 2H), 7.00 - 6.90 (m, 1H), 6.57 - 6.50 (m, 1H), 6.48 - 6.38 (m, 1H), 3.89 (s, 3H), 3.78 (s, 3H), 3.61 - 3.55 (m, 2H), 3.08 - 3.00 (m, 1H), 2.90 - 2.83 (m, 2H), 2.79 - 2.71 (m, 2H), 2.53 - 2.46 (m, 1H), 2.39 - 2.29 (m, 2H), 1.95 - 1.89 (m, 2H), 1.15 - 1.01 (m, 1H), 0.69 - 0.58 (m, 1H), 0.51 - 0.41 (m, 1H), 0.37 - 0.29 (m, 1H), 0.26 - 0.16 (m, 1H).
Example 180:
Synthetic Route:
[0786] Referring to the synthetic route of compound 173, compound 173-1 was replaced with compound 180-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 180 (43 mg, yield: 23%) as a white solid. MS (ESI, m/z): 543.3 [M+H]+.
[0787] 1H NMR (400 MHz, MeOD) δ 7.45 - 7.36 (m, 3H), 7.15 - 6.89 (m, 5H), 6.57 - 6.49 (m, 1H), 6.51 - 6.45 (m, 1H), 3.85 (s, 3H), 3.74 (s, 3H), 3.59 - 3.47 (m, 2H), 3.15 - 3.06 (m, 1H), 2.86 - 2.69 (m, 4H), 2.45 - 2.43 (m, 1H), 2.32 - 2.20 (m, 2H), 1.99 - 1.89 (m, 2H), 1.17 - 1.07 (m, 1H), 0.65 - 0.56 (m, 1H), 0.46 - 0.29 (m, 2H), 0.21 - 0.13 (m, 1H).
Example 181:
Synthetic Route:
[0789] Referring to the synthetic route of compound 164, compound 164-1 was replaced with compound 181-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 181 (35 mg, yield: 62%) as a white solid. MS (ESI, m/z): 560.2 [M+H]+.
[0790] 1H NMR (400 MHz, MeOD) δ 7.45 - 7.38 (m, 5H), 7.36 (d, J = 8.0 Hz, 1H), 7.21 - 7.14 (m, 1H), 6.94 (dd, J = 12.4, 8.8 Hz, 1H), 6.58 (dd, J = 7.2, 3.2 Hz, 1H), 6.50 - 6.45 (m, 1H), 3.75 (s, 3H), 3.56 - 3.49 (m, 2H), 3.11 - 3.01 (m, 1H), 2.80 - 2.45 (m, 8H), 2.32 - 2.18 (m, 2H), 1.98 - 1.86 (m, 2H), 1.13 - 1.02 (m, 1H), 0.62 - 0.52 (m, 1H), 0.44 - 0.31 (m, 2H), 0.18 - 0.08 (m, 1H).
Example 182:
Synthetic Route:
[0792] Referring to the synthetic route of compound 164, compound 164-1 was replaced with compound 182-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 182 (23 mg, yield: 79%) as a white solid. MS (ESI, m/z): 592.2 [M+H]+.
[0793] 1H NMR (400 MHz, MeOD) δ 8.15 - 8.05 (m, 2H), 7.78 (d, J = 8.4 Hz, 2H), 7.50 - 7.40 (m, 2H), 7.25 - 7.19 (m, 1H), 6.94 (dd, J = 12.4, 8.8 Hz, 1H), 6.59 (dd, J = 7.2, 2.8 Hz, 1H), 6.52 - 6.45 (m, 1H), 3.75 (s, 3H), 3.59 - 3.50 (m, 2H), 3.19 (s, 3H), 3.15 - 3.06 (m, 1H), 2.82 - 2.63 (m, 4H), 2.56 - 2.45 (m, 1H), 2.34 - 2.21 (m, 2H), 2.01 - 1.92 (m, 2H), 1.15 - 1.03 (m, 1H), 0.64 - 0.53 (m, 1H), 0.43 - 0.33 (m, 2H), 0.19 - 0.11 (m, 1H).
Example 183:
Synthetic Route:
[0795] Referring to the synthetic route of compound 164, compound 164-1 was replaced with compound 183-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 183 (5 mg, yield: 12%) as a white solid. MS (ESI, m/z): 620.2 [M+H]+.
[0796] 1H NMR (400 MHz, DMSO-d6) δ 8.01 - 7.96 (m, 2H), 7.81 (d, J = 8.4 Hz, 2H), 7.47 - 7.40 (m, 2H), 7.17 (d, J = 8.0 Hz, 1H), 7.09 - 7.00 (m, 1H), 6.59 - 6.53 (m, 1H), 6.51 - 6.46 (m, 1H), 3.72 (s, 3H), 3.56 - 3.45 (m, 2H), 3.15 - 3.05 (m, 1H), 2.83 - 2.75 (m, 2H), 2.50 - 2.41 (m, 2H), 2.32 - 2.28 (m, 1H), 2.25 - 2.18 (m, 1H), 2.16 - 2.07 (m, 2H), 1.99 - 1.91 (m, 2H), 1.23 (d, J = 6.8 Hz, 6H), 1.04 - 0.93 (m, 1H), 0.46 - 0.39 (m, 1H), 0.30 - 0.20 (m, 2H), 0.10 - 0.03 (m, 1H).
Example 184:
Synthetic Route:
[0798] To a solution of compound 184-1 (1.0 g, 5.80 mmol) and sodium acetate (0.95 g, 11.60 mmol) in ethanol/acetic acid/water/acetone (5/8/5/14/ = 3.5 mL) at 0°C, sodium borohydride (1.65 g, 43.50 mmol) was added. The reaction was stirred at 0°C for 3 hours. LCMS monitoring confirmed the complete consumption of the starting material. The reaction mixture was added with saturated sodium bicarbonate solution (20 mL) and extracted with ethyl acetate (30 mL × 3). The combined organic phases were concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 184-2 (880 mg, yield: 70%) as a colorless oil. MS (ESI, m/z): 214.1 [M+H]+.
[0799] At room temperature, in a 25 mL three-necked flask under a nitrogen atmosphere, compound 184-2 (100 mg, 0.46 mmol), potassium acetate (137 mg, 1.40 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) chloride (68 mg, 0.09 mmol), and bis(pinacolato)diboron (130 mg, 0.51 mmol) were added. Then, 1,4-dioxane (3 mL) was added and stirred. The reaction mixture was placed in a 90°C oil bath and reacted for 16 hours. LCMS monitoring confirmed the complete consumption of the starting material. The reaction mixture was diluted with ethyl acetate (50 mL), filtered, and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 184-3 (130 mg, yield: 95%) as a yellow solid. MS (ESI, m/z): 262.3 [M+H]+.
[0800] Then, referring to the synthetic route of compound 164, compound 164-1 was replaced with compound 184-3 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 184 (7 mg, yield: 26%) as a white solid. MS (ESI, m/z): 571.3 [M+H]+.
[0801] 1H NMR (400 MHz, MeOD) δ 7.37 - 7.34 (m, 2H), 7.23 (d, J = 8.4 Hz, 2H), 7.14 (d, J = 8.0 Hz, 1H), 6.94 (dd, J = 12.4, 8.8 Hz, 1H), 6.77 (d, J = 8.4 Hz, 2H), 6.59 (dd, J = 7.2, 2.8 Hz, 1H), 6.49 - 6.46 (m, 1H), 3.75 (s, 3H), 3.70 - 3.62 (m, 1H), 3.58 - 3.44 (m, 2H), 3.15 - 3.01 (m, 2H), 2.77 - 2.65 (m, 4H), 2.54 - 2.47 (m, 1H), 2.29 - 2.20 (m, 2H), 1.94 - 1.91(m , 2H), 1.23 (d, J = 6.4 Hz, 6H), 1.10 - 1.06 (m, 1H), 0.58 - 0.54 (m, 1H), 0.39 - 0.35 (m, 2H), 0.15 - 0.11 (m, 1H).
Example 185:
Synthetic Route:
[0803] To a solution of compound 184-2 (200 mg, 0.93 mmol) in N,N-dimethylformamide (5 mL) at 0°C, sodium hydride (112 mg, 4.67 mmol) was added. The reaction was stirred at 0°C for 0.5 hours. Then, iodomethane (398 mg, 2.8 mmol) was added, and the reaction mixture was stirred at room temperature for an additional 1.5 hours. LCMS monitoring confirmed the complete consumption of the starting material. The reaction mixture was quenched with water (20 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic phases were concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 20%) to obtain compound 185-1 (100 mg, yield: 47%) as a yellow oil. MS (ESI, m/z): 228.1 [M+H]+.
[0804] Then, referring to the synthetic route of compound 184, compound 184-2 was replaced with compound 185-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 185 (32 mg, yield: 33%) as a white solid. MS (ESI, m/z): 585.2 [M+H]+.
[0805] 1H NMR (400 MHz, MeOD) δ 7.40 - 7.34 (m, 2H), 7.31 (d, J = 7.6 Hz, 2H), 7.15 (d, J = 8.0 Hz, 1H), 7.02 - 6.89 (m, 3H), 6.64 - 6.55 (m, 1H), 6.52 - 6.43 (m, 1H), 4.24 - 4.14 (m, 1H), 3.75 (s, 3H), 3.57 - 3.48 (m, 2H), 3.15 - 3.02 (m, 1H), 2.82 - 2.70 (m, 5H), 2.70 - 2.56 (m, 2H), 2.56 - 2.47 (m, 1H), 2.32 - 2.17 (m, 2H), 1.97 - 1.87 (m, 2H), 1.21 (d, J = 6.8 Hz, 6H), 1.11 - 1.01 (m, 1H), 0.62 - 0.53 (m, 1H), 0.44 - 0.33 (m, 2H), 0.17 - 0.09 (m, 1H).
Example 186:
Synthetic Route:
[0807] To a solution of compound 184-2 (200 mg, 0.93 mmol) in dichloromethane (5 mL) at 0°C, acetyl chloride (220 mg, 2.80 mol) was added. The reaction was stirred at room temperature for 1 hour. LCMS monitoring confirmed the complete consumption of the starting material. The reaction mixture was concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 186-1 (200 mg, yield: 83%) as a yellow solid. MS (ESI, m/z): 256.1 [M+H]+.
[0808] Then, referring to the synthetic route of compound 184, compound 184-2 was replaced with compound 186-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 186 (5 mg, yield: 19%) as a white solid. MS (ESI, m/z): 613.3 [M+H]+.
[0809] 1H NMR (400 MHz, MeOD) δ 7.63 (d, J = 8.0 Hz, 2H), 7.46 - 7.36 (m, 4H), 7.21 (d, J = 8.0 Hz, 1H), 6.97 - 6.92 (m, 1H), 6.61 - 6.58 (m, 1H), 6.49 - 6.47 (m, 1H), 4.98 - 4.92 (m, 1H), 3.75 (s, 3H), 3.55 - 3.48 (m, 2H), 3.14 - 3.10 (m, 1H), 2.80 - 2.61 (m, 4H), 2.56 - 2.58 (m, 1H), 2.30 - 2.28 (m, 2H), 2.00 - 1.93 (m, 2H), 1.83 (s, 3H), 1.14 (d, J = 6.8 Hz, 6H), 1.10 - 1.08 (m, 1H), 0.59 - 0.58 (m, 1H), 0.41 - 0.36 (m, 2H), 0.15 - 0.13 (m, 1H).
Example 187:
Synthetic Route:
[0811] Referring to the synthetic route of compound 184, compound 184-1 was replaced with compound 187-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 187 (13 mg, yield: 27%) as a white solid. MS (ESI, m/z): 571.3 [M+H]+.
[0812] 1H NMR (400 MHz, DMSO-d6) δ 7.46 (s, 1H), 7.40 (d, J = 8.0 Hz, 1H), 7.22 - 7.13 (m, 2H), 7.07 - 7.02 (m, 1H), 6.65 - 6.55 (m, 4H), 6.51 - 6.47 (m, 1H), 5.59 (d, J = 7.2 Hz, 1H), 3.72 (s, 3H), 3.60 - 3.43 (m, 3H), 3.11 - 3.09 (m, 1H), 2.79 - 2.71 (m, 2H), 2.54 - 2.37 (s, 3H), 2.16 - 2.04 (m, 2H), 1.93 - 1.88 (m, 2H), 1.17 (d, J = 6.4 Hz, 6H), 1.07 - 0.99 (m, 1H), 0.52 - 0.48 (m, 1H), 0.30 - 0.25 (m, 2H), 0.15 - 0.11 (m, 1H).
Example 188:
Synthetic Route:
[0814] To a solution of compound 187-1 (171 mg, 1 mmol) in 1,2-dichloroethane (2 mL) at 0°C, pivaldehyde (86 mg, 1 mmol), sodium triacetoxyborohydride (636 mg, 3 mmol), acetic acid (60 mg, 1 mmol), and anhydrous magnesium sulfate (120 mg, 1 mmol) were added. The reaction was stirred at room temperature for 2 hours. LCMS monitoring confirmed the complete consumption of the starting material. The reaction mixture was added with saturated sodium bicarbonate solution (5 mL) and extracted with ethyl acetate (10 mL × 3). The combined organic phases were concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 188-1 (213 mg, yield: 88%) as a colorless oil. MS (ESI, m/z): 242.2 [M+H]+.
[0815] Referring to the synthetic route of compound 184, compound 184-2 was replaced with compound 188-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 188 (5 mg, yield: 20%) as a white solid. MS (ESI, m/z): 599.4 [M+H]+.
[0816] 1H NMR (400 MHz, MeOD) δ 7.43 (d, J = 8.0 Hz, 1H), 7.37 (s, 1H), 7.22 - 7.18 (m, 1H), 7.13 (d, J = 8.0 Hz, 1H), 6.94 (dd, J = 12.4, 8.8 Hz, 1H), 6.77 - 6.74 (m, 1H), 6.71 - 6.64 (m, 2H), 6.61 - 6.56 (m, 1H), 6.51 - 6.46 (m, 1H), 3.75 (s, 3H), 3.54 - 3.48 (m, 2H), 3.18 - 3.13 (m, 1H), 2.94 (s, 2H), 2.84 - 2.70 (m, 4H), 2.51 - 2.45 (m, 1H), 2.31 - 2.22 (m, 2H),1.96 - 1.93 (m, 2H), 1.14 - 1.11 (m, 1H), 0.96 (s, 9H), 0.63 - 0.58 (m, 1H), 0.42 - 0.32 (m, 2H), 0.20 - 0.15 (m, 1H).
Example 189
Synthetic Route:
[0818] To a solution of compound 188-1 (300 mg, 1.24 mmol) in dichloromethane (5 mL), paraformaldehyde (37.2 mg, 1.24 mmol) and sodium triacetoxyborohydride (787.7 mg, 3.72 mmol) were added. The reaction was stirred at room temperature for 16 hours. LCMS monitoring confirmed the complete consumption of the starting material. The reaction mixture was added with saturated sodium bicarbonate solution (20 mL) and extracted with ethyl acetate (50 mL × 3). The combined organic phases were concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 189-1 (100 mg, yield: 32%) as a colorless oil. MS (ESI, m/z): 256.1 [M+H]+.
[0819] Then, referring to the synthetic route of compound 184, compound 184-2 was replaced with compound 189-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 189 (8 mg, yield: 24%) as a white solid. MS (ESI, m/z): 613.3 [M+H]+.
[0820] 1H NMR (400 MHz, DMSO-d6) δ 7.50 (s, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.31 - 7.27 (m, 1H), 7.15 (d, J = 8.0 Hz, 1H), 7.07 - 7.02 (m, 1H), 6.81 - 6.79 (m, 2H), 6.71 (d, J = 7.6 Hz, 1H), 6.56 - 6.54 (m, 1H), 6.52 - 6.45 (m, 1H), 3.71 (s, 3H), 3.49 - 3.46 (m, 2H), 3.19 (s, 2H), 3.13 - 3.08 (m, 1H), 2.99 (s, 3H), 2.77 - 2.70 (m, 4H), 2.46 - 2.41 (m, 1H), 2.15 - 2.05 (m, 2H), 1.93 - 1.90 (m, 2H), 1.11 - 1.07 (m, 1H), 0.97 (s, 9H), 0.55 - 0.50 (m, 1H), 0.32 - 0.27 (m, 2H), 0.18 - 0.15 (m, 1H).
Example 190:
Synthetic Route:
[0822] Referring to the synthetic route of compound 186, compound 184-2 was replaced with compound 188-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 190 (8 mg, yield: 24%) as a white solid. MS (ESI, m/z): 641.3 [M+H]+.
[0823] 1H NMR (400 MHz, DMSO-d6) δ 7.50 (s, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.31 - 7.27 (m, 1H), 7.15 (d, J = 8.0 Hz, 1H), 7.07 - 7.02 (m, 1H), 6.81 - 6.79 (m, 2H), 6.71 (d, J = 7.6 Hz, 1H), 6.56 - 6.54 (m, 1H), 6.52 - 6.45 (m, 1H), 3.71 (s, 3H), 3.49 - 3.46 (m, 2H), 3.19 (s, 2H), 3.13 - 3.08 (m, 1H), 2.99 (s, 3H), 2.77 - 2.70 (m, 4H), 2.46 - 2.41 (m, 1H), 2.15 - 2.05 (m, 2H), 1.93 - 1.90 (m, 2H), 1.11 - 1.07 (m, 1H), 0.97 (s, 9H), 0.55 - 0.50 (m, 1H), 0.32 - 0.27 (m, 2H), 0.18 - 0.15 (m, 1H).
Example 191:
Synthetic Route:
[0825] Referring to the synthetic route of compound 186, compound 184-2 was replaced with compound 187-2 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 191 (25 mg, yield: 51%) as a white solid. MS (ESI, m/z): 613.3 [M+H]+.
[0826] 1H NMR (400 MHz, MeOD) δ 7.69 - 7.58 (m, 2H), 7.45 - 7.37 (m, 2H), 7.32 (s, 1H), 7.27 (d, J = 7.6 Hz, 1H), 7.18 (d, J = 8.0 Hz, 1H), 6.94 (dd, J = 12.4, 8.8 Hz, 1H), 6.56 (dd, J = 7.2, 2.8 Hz, 1H), 6.52 - 6.45 (m, 1H), 5.04 - 4.92 (m, 1H), 3.75 (s, 3H), 3.59 - 3.49 (m, 2H), 3.13 - 3.04 (m, 1H), 2.85 - 2.65 (m, 4H), 2.52 - 2.44 (m, 1H), 2.32 - 2.20 (m, 2H), 2.07 - 1.88 (m, 2H), 1.83 (s, 3H), 1.18 - 1.06 (m, 7H), 0.67 - 0.56 (m, 1H), 0.44 - 0.32 (m, 2H), 0.21 - 0.14 (m, 1H).
Example 192:
Synthetic Route:
[0828] To a solution of compound 192-1 (200 mg, 0.91 mmol) in N,N-dimethylformamide (5 mL), compound 192-2 (90 mg, 0.91 mmol) and potassium carbonate (376 mg, 2.73 mmol) were added. The reaction was stirred at 80°C for 24 hours. LCMS monitoring confirmed the complete consumption of the starting material. The reaction mixture was directly concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 192-3 (150 mg, yield: 55%) as a yellow oil. MS (ESI, m/z): 299.0 [M+H]+.
[0829] To a solution of compound 192-3 (100 mg, 0.33 mmol) in ethanol/water = 1/1 (10 mL), iron powder (93 mg, 1.67 mmol) and ammonium chloride (178 mg, 3.34 mmol) were added. The reaction was stirred at 60°C for 2 hours. LCMS monitoring confirmed the complete consumption of the starting material. The reaction mixture was directly concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 192-4 (60 mg, yield: 67%) as a pale yellow oil. MS (ESI, m/z): 269.1 [M+H]+.
[0830] To a solution of compound 192-4 (50 mg, 0.185 mmol) in tetrahydrofuran (10 mL) at 0°C, a solution of 3 M hydrochloric acid (0.6 mL) and sodium nitrite (19 mg, 0.28 mmol) in water (1 mL) was added. The reaction was stirred at 0°C for 15 minutes. Then, a solution of potassium iodide (61.5 mg, 0.37 mmol) in water (0.5 mL) was added, and the reaction was stirred at room temperature for 48 hours. LCMS monitoring confirmed the complete consumption of the starting material. The reaction was quenched with saturated sodium sulfite aqueous solution (10 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic phases were concentrated, and the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 192-5 (25 mg, yield: 53%) as a pale yellow oil. MS (ESI, m/z): 254.1 [M+H]+.
[0831] Then, referring to the synthetic route of compound 184, compound 184-2 was replaced with compound 192-5 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 192 (14 mg, yield: 30%) as a white solid. MS (ESI, m/z): 611.2 [M+H]+.
[0832] 1H NMR (400 MHz, MeOD) δ 7.44 - 7.37 (m, 2H), 7.29 -7.22 (m, 1H), 7.19 - 7.13 (m, 1H), 6.94 (dd, J = 12.4, 8.8 Hz, 1H), 6.85 - 6.81 (m, 1H), 6.80 - 6.75 (m, 1H), 6.72 (d, J = 7.6 Hz, 1H), 6.58 (dd, J = 7.2, 2.8 Hz, 1H), 6.50 - 6.45 (m, 1H), 3.75 (s, 3H), 3.58 - 3.49 (m, 2H), 3.43 - 3.36 (m, 2H), 3.20 - 3.13 (m, 1H), 2.77 - 2.48 (m, 5H), 2.34 - 2.21 (m, 2H), 2.00 - 1.88 (m, 6H), 1.47 (s, 6H), 1.14 - 1.02 (m, 1H), 0.62 - 0.52 (m, 1H), 0.43 - 0.32 (m, 2H), 0.18 - 0.09 (m, 1H).
Example 193:
Synthetic Route:
[0834] Referring to the synthetic route of compound 164, compound 164-1 was replaced with compound 193-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 193 (60 mg, yield: 75%) as a white solid. MS (ESI, m/z): 580.3 [M+H]+.
[0835] 1H NMR (400 MHz, CDCl3) δ 8.02 - 7.94 (m, 1H), 7.87 - 7.81 (m, 1H), 7.80 - 7.77 (m, 1H), 7.77 - 7.70 (m, 1H), 7.58 (t, J = 8.0 Hz, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.44 - 7.40 (m, 1H), 7.39 - 7.32 (m, 1H), 7.18 - 7.12 (m, 1H), 7.03 - 6.90 (m, 1H), 6.60 - 6.49 (m, 2H), 6.47 - 6.39 (m, 1H), 3.79 (s, 3H), 3.67 - 3.53 (m, 2H), 3.15 - 3.07 (m, 1H), 2.91 - 2.84 (m, 2H), 2.84 - 2.71 (m, 2H), 2.57 - 2.47 (m, 1H), 2.45 - 2.30 (m, 2H), 2.02 - 1.90 (m, 2H), 1.18 - 1.04 (m, 1H), 0.70 - 0.59 (m, 1H), 0.52 - 0.42 (m, 1H), 0.40 - 0.31 (m, 1H), 0.27 - 0.16 (m, 1H).
Example 194:
Synthetic Route:
[0837] To a solution of 4-bromobenzoic acid 194-1 (500 mg, 2.48 mmol) in N,N-dimethylformamide (20 mL), 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.41 g, 3.73 mmol), methylamine hydrochloride 194-2 (839.7 mg, 12.4 mmol), and N,N-diisopropylethylamine (964 mg, 7.46 mmol) were added. The reaction was stirred at 25°C for 4 hours. LCMS monitoring confirmed the complete consumption of the starting material. The reaction mixture was diluted with ethyl acetate (50 mL) and washed with water (30 mL × 3). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 194-3 (500 mg, yield: 94%) as a white solid. MS (ESI, m/z): 213.9 [M+H]+.
[0838] Then, referring to the synthetic route of compound 184, compound 184-2 was replaced with compound 194-3 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 194 (14 mg, yield: 27%) as a white solid. MS (ESI, m/z): 571.2 [M+H]+.
[0839] 1H NMR (400 MHz, MeOD) δ 7.96 (d, J = 8.4 Hz, 2H), 7.60 (d, J = 8.4 Hz, 2H), 7.45 -7.40 (m, 2H), 7.18 (d, J = 8.4 Hz, 1H), 6.95 (dd, J = 12.4, 8.8 Hz, 1H), 6.58 (dd, J = 7.2, 2.8 Hz, 1H), 6.52 - 6.44 (m, 1H), 3.74 (s, 3H), 3.53 - 3.50 (m, 2H), 3.14 - 3.06 (m, 1H), 2.96 (s, 3H), 2.87 - 2.69 (m, 4H), 2.53 - 2.43 (m, 1H), 2.33 - 2.23 (m, 2H), 1.95 - 1.92 (m, 2H), 1.21 - 1.01 (m, 1H), 0.67 - 0.57 (m, 1H), 0.46 - 0.30 (m, 2H), 0.22 - 0.14 (m, 1H).
Example 195:
Synthetic Route:
[0841] Referring to the synthetic route of compound 194, compound 194-2 was replaced with compound 195-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 195 (12 mg, yield: 10%) as a white solid. MS (ESI, m/z): 585.3 [M+H]+.
[0842] 1H NMR (400 MHz, MeOD) δ 7.96 (d, J = 8.4 Hz, 2H), 7.59 (d, J = 8.4 Hz, 2H), 7.45 - 7.39 (m, 2H), 7.18 (d, J = 8.0 Hz, 1H), 6.95 (dd, J = 12.4, 8.8 Hz, 1H), 6.58 (dd, J = 7.2, 2.8 Hz, 1H), 6.51 - 6.46 (m, 1H), 3.75 (s, 3H), 3.58 - 3.49 (m, 2H), 3.49 - 3.41 (m, 2H), 3.15 - 3.16 (m, 1H), 2.89 - 2.67 (m, 4H), 2.54 - 2.42 (m, 1H), 2.39 - 2.18 (m, 2H), 2.01 - 1.89 (m, 2H), 1.26 (t, J = 7.2 Hz, 3H), 1.17 - 1.07 (m, 1H), 0.68 - 0.57 (m, 1H), 0.46 - 0.31 (m, 2H), 0.21 - 0.13 (m, 1H).
Example 196:
Synthetic Route:
[0844] Referring to the synthetic route of compound 194, compound 194-2 was replaced with compound 196-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 196 (24 mg, yield: 14%) as a white solid. MS (ESI, m/z): 599.3 [M+H]+.
[0845] 1H NMR (400 MHz, MeOD) δ 7.95 (d, J = 8.4 Hz, 2H), 7.59 (d, J = 8.4 Hz, 2H), 7.45 - 7.39 (m, 2H), 7.25 - 7.14 (m, 1H), 6.94 (dd, J = 12.4, 8.8 Hz, 1H), 6.58 (dd, J = 7.2, 3.2 Hz, 1H), 6.53 - 6.44 (m, 1H), 4.38 - 4.12 (m, 1H), 3.75 (s, 3H), 3.53 - 3.50 (m, 2H), 3.14 - 3.07 (m, 1H), 2.80 - 2.67 (m, 4H), 2.55 - 2.45 (m, 1H), 2.33 - 2.20 (m, 2H), 1.99 - 1.90 (m, 2H), 1.28 (d, J = 6.4 Hz, 6 H), 1.18 - 1.05 (m, 1H), 0.54 - 0.67 (m, 1H), 0.45 - 0.29 (m, 2H), 0.21 - 0.12 (m, 1H).
Example 197:
Synthetic Route:
[0847] Referring to the synthetic route of compound 194, compound 194-2 was replaced with compound 197-1 and compound 98-1 was replaced with compound 142-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 197 (10 mg, yield: 51%) as a white solid. MS (ESI, m/z): 613.3 [M+H]+.
[0848] 1H NMR (400 MHz, CDCl3) δ 7.80 (d, J = 7.6 Hz, 2H), 7.48 (d, J = 7.6 Hz, 2H), 7.42 - 7.31 (m, 2H), 7.11 (d, J = 8.0 Hz, 1H), 6.96 - 6.84 (m, 1H), 6.55 - 6.45 (m, 1H), 6.44 - 6.31 (m, 1H), 6.15 (s, br, 1H), 3.74 (s, 3H), 3.58 - 3.46 (m, 2H), 3.05 - 2.91 (m, 1H), 2.72 - 2.63 (m, 4H), 2.50 - 2.40 (m, 1H), 2.37 - 2.20 (m, 2H), 1.93 - 1.82 (m, 2H), 1.46 (s, 9H), 1.11 - 0.97 (m, 1H), 0.65 - 0.52 (m, 1H), 0.46 - 0.36 (m, 1H), 0.35 - 0.27 (m, 1H), 0.20 - 0.10 (m, 1H).
Example 198:
Synthetic Route:
[0850] Referring to the synthetic route of compound 197, compound 197-1 was replaced with compound 198-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 198 (60 mg, yield: 59%) as a white solid. MS (ESI, m/z): 627.3 [M+H]+.
[0851] 1H NMR (400 MHz, CDCl3) δ 7.90 (d, J = 7.2 Hz, 2H), 7.54 (d, J = 7.2 Hz, 2H), 7.48 - 7.37 (m, 2H), 7.18 - 7.10 (m, 1H), 7.02 - 6.89 (m, 1H), 6.54 (s, br, 1H), 6.49 - 6.39 (m, 1H), 6.36 - 6.26 (m, 1H), 3.78 (s, 3H), 3.68 - 3.51 (m, 2H), 3.42 - 3.28 (m, 2H), 3.14 - 2.98 (m, 1H), 2.95 - 2.82 (m, 2H), 2.81 - 2.67 (m, 2H), 2.60 - 2.45 (m, 1H), 2.42 - 2.26 (m, 2H), 1.98 - 1.84 (m, 2H), 1.16 - 1.07 (m, 1H), 1.03 (s, 9H), 0.70 - 0.57 (m, 1H), 0.52 - 0.41 (m, 1H), 0.41 - 0.29 (m, 1H), 0.26 - 0.17 (m, 1H).
Example 199:
Synthetic Route:
[0853] Referring to the synthetic route of compound 194, compound 194-2 was replaced with compound 199-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 199 (60 mg, yield: 62%) as a white solid. MS (ESI, m/z): 641.3 [M+H]+.
[0854] 1H NMR (400 MHz, CDCl3) δ 7.88 (d, J = 6.8 Hz, 1H), 7.52 (d, J = 6.8 Hz, 1H), 7.46 - 7.37 (m, 2H), 7.13 (d, J = 7.2 Hz, 1H), 7.02 - 6.90 (m, 1H), 6.55 - 6.45 (m, 2H), 6.24 - 6.18 (m, 1H), 3.79 (s, 3H), 3.65 - 3.45 (m, 4H), 3.14 - 2.97 (m, 1H), 2.94 - 2.83 (m, 2H), 2.82 - 2.66 (m, 2H), 2.56 - 2.45 (m, 1H), 2.44 - 2.24 (m, 2H), 1.98 - 1.84 (m, 2H), 1.65 - 1.53 (m, 2H), 1.16 - 1.06 (m, 1H), 1.02 (s, 9H), 0.70 - 0.57 (m, 1H), 0.52 - 0.41 (m, 1H), 0.40 - 0.28 (m, 1H), 0.28 - 0.16 (m, 1H).
Example 200:
Synthetic Route:
[0856] Referring to the synthetic route of compound 194, compound 194-2 was replaced with compound 200-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 200 (70 mg, yield: 58%) as a white solid. MS (ESI, m/z): 611.3 [M+H]+.
[0857] 1H NMR (400 MHz, CDCl3) δ 7.66 (d, J = 8.0 Hz, 2H), 7.53 - 7.44 (m, 3H), 7.41 (s, 1H), 7.15 (d, J = 8.0 Hz, 1H), 7.05 - 6.87 (m, 1H), 6.73 - 6.30 (m, 2H), 3.80 (s, 3H), 3.76 - 3.66 (m, 2H), 3.65 - 3.49 (m, 4H), 3.11 - 3.03 (m, 1H), 2.92 - 2.72 (m, 4H), 2.59 - 2.45 (m, 1H), 2.45 - 2.19 (m, 2H), 2.13 - 1.78 (m, 6H), 1.19 - 1.00 (m, 1H), 0.71 - 0.57 (m, 1H), 0.55 - 0.40 (m, 1H), 0.39 - 0.30 (m, 1H), 0.28 - 0.12 (m, 1H).
Example 201:
Synthetic Route:
[0859] Referring to the synthetic route of compound 194, compound 194-2 was replaced with compound 201-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 201 (21 mg, yield: 10%) as a white solid. MS (ESI, m/z): 625.3 [M+H]+.
[0860] 1H NMR (400 MHz, DMSO-d6) δ 8.40 - 8.31 (m, 1H), 7.97 (d, J = 8.4 Hz, 2H), 7.57 (d, J = 8.4 Hz, 2H), 7.47 (s, 1H), 7.41 - 7.34 (m, 1H), 7.17 (d, J = 8.4 Hz, 1H), 7.04 (dd, J = 12.4, 8.8 Hz, 1H), 6.58 - 6.44 (m, 2H), 4.26 - 4.23 (m, 1H), 4.33 - 4.19 (m, 1H), 3.73 (s, 3H), 3.47 - 3.44 (m, 2H), 3.05 - 3.01 (m, 1H), 2.76 - 2.70 (m, 2H), 2.56 - 2.39 (m, 2H), 2.10 - 2.08 (m, 2H), 1.93 - 1.88 (m, 4H), 1.78 - 1.64 (m, 2H), 1.61 - 1.50 (m, 4H), 1.00 - 0.97 (m, 1H), 0.50 - 0.43 (m, 1H), 0.33 - 0.22 (m, 2H), 0.09 - 0.07 (m, 1H).
Example 202:
Synthetic Route:
[0862] Referring to the synthetic route of compound 194, compound 194-2 was replaced with compound 202-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 202 (25 mg, yield: 63%) as a white solid. MS (ESI, m/z): 641.3 [M+H]+.
[0863] 1H NMR (400 MHz, CDCl3) δ 7.63 - 7.42 (m, 5H), 7.40 (s, 1H), 7.14 (d, J = 8.0 Hz, 1H), 7.03 - 6.88 (m, 1H), 6.62 - 6.49 (m, 1H), 6.48 - 6.39 (m, 1H), 3.79 (s, 3H), 3.64 - 3.52 (m, 2H), 3.50 - 3.34 (m, 2H), 3.26 - 3.13 (m, 3H), 3.12 - 2.99 (m, 1H), 2.95 - 2.82 (m, 2H), 2.81 - 2.67 (m, 2H), 2.58 - 2.46 (m, 1H), 2.43 - 2.21 (m, 2H), 1.97 - 1.85 (m, 2H), 1.18 - 0.81 (m, 10H), 0.70 - 0.56 (m, 1H), 0.54 - 0.40 (m, 1H), 0.39 - 0.30 (m, 1H), 0.25 - 0.15 (m, 1H).
Example 203:
Synthetic Route:
[0865] Referring to the synthetic route of compound 3, compound 3-1 was replaced with compound 90-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 203 (19 mg, yield: 50%) as a white solid. MS (ESI, m/z): 586.3 [M+H]+.
[0866] 1H NMR (400 MHz, CDCl3) δ 7.56 - 7.48 (m, 2H), 7.46 - 7.40 (m, 3H), 7.36 - 7.29 (m, 2H), 7.15 (d, J = 8.0 Hz, 1H), 6.66 - 6.60 (m, 1H), 6.56 - 6.50 (m, 1H), 3.80 (s, 3H), 3.59 - 3.50 (m, 2H), 3.17 - 3.04 (m, 1H), 2.94 - 2.81 (m, 2H), 2.75 - 2.65 (m, 2H), 2.59 - 2.47 (m, 1H), 2.46 - 2.32 (m, 2H), 1.99 - 1.92 (m, 2H), 1.40 (s, 9H), 1.17 - 1.05 (m, 1H), 0.70 - 0.65 (m, 1H), 0.49 - 0.44 (m, 1H), 0.38 - 0.34 (m, 1H), 0.25 - 0.21 (m, 1H).
Example 204:
Synthetic Route:
[0868] Referring to the synthetic route of compound 6, compound 6-4 was replaced with compound 204-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 204 (6 mg, yield: 31%) as a white solid. MS (ESI, m/z): 582.3 [M+H]+.
[0869] 1H NMR (400 MHz, MeOD) δ 7.55 (d, J = 8.0 Hz, 2H), 7.42 -7.37 (m, 4H), 7.14 (d, J = 8.0 Hz, 1H), 6.86 (d, J = 8.8 Hz, 1H), 6.72 (d, J = 2.4 Hz, 1H),6.60 - 6.56 (m, 1H), 3.82 (s, 3H), 3.78 (s, 3H), 3.64 - 3.60 (m, 2H), 3.11 - 3.05 (m, 1H), 2.79 - 2.69 (m, 4H), 2.48 - 2.46 (m, 1H), 2.26 - 2.21 (m, 2H),1.97 - 1.93 (m, 2H), 1.39 (s, 9H), 1.15 - 1.09 (m, 1H), 0.63 - 0.57 (m, 1H), 0.42 - 0.39 (m, 1H), 0.35 - 0.31 (m, 1H), 0.20 - 0.16 (m, 1H).
Example 205:
Synthetic Route:
[0871] Referring to the synthetic route of compound 6, compound 6-4 was replaced with compound 205-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 205 (12 mg, yield: 24%) as a white solid. MS (ESI, m/z): 582.3 [M+H]+.
[0872] 1H NMR (400 MHz, DMSO-d6) δ 7.55 (d, J = 8.2 Hz, 2H), 7.46 - 7.41 (m, 3H), 7.37 (d, J = 8.0 Hz, 1H), 7.11 (d, J = 8.0 Hz, 1H), 6.11 - 6.08 (m, 2H), 5.98 - 5.93 (m, 1H), 3.82 - 3.79 (m, 2H), 3.71 (s, 6H), 3.14 - 3.04 (m, 1H), 2.83 - 2.76 (m, 2H), 2.73 - 2.35 (m, 3H), 2.03 - 2.01 (m, 2H), 1.86 - 1.83 (m, 2H), 1.35 (s, 9H), 1.03 - 0.93 (m, 1H), 0.48 - 0.38 (m, 1H), 0.29 - 0.20 (m, 2H), 0.11 - 0.03 (m, 1H).
Example 206:
Synthetic Route:
[0874] Referring to the synthetic route of compound 6, compound 6-4 was replaced with compound 206-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 206 (29 mg, yield: 49%) as a white solid. MS (ESI, m/z): 570.2 [M+H]+.
[0875] 1H NMR (400 MHz, MeOD) δ 7.55 (d, J = 8.4 Hz, 2H), 7.43 -7.37 (m, 4H), 7.14 (d, J = 8.0 Hz, 1H), 6.97 - 6.92 (m, 1H), 6.76 - 6.73 (m, 1H), 6.55 - 6.51 (m, 1H), 3.85 (s, 3H), 3.69 - 3.66 (m, 2H), 3.13 - 3.09 (m, 1H), 2.78 - 2.65 (m, 4H), 2.47 - 2.45 (m, 1H), 2.28 - 2.19 (m, 2H),1.97 - 1.94 (m, 2H), 1.39 (s, 9H), 1.15 - 1.10 (m, 1H), 0.63 - 0.59 (m, 1H), 0.43 - 0.38 (m, 1H), 0.36 - 0.32 (m, 1H), 0.19 - 0.15 (m, 1H).
Example 207:
Synthetic Route:
[0877] Referring to the synthetic route of compound 6, compound 6-4 was replaced with compound 207-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 207 (13 mg, yield: 44%) as a white solid. MS (ESI, m/z): 562.2 [M+H]+.
[0878] 1H NMR (400 MHz, MeOD) δ 7.54 (d, J = 8.4 Hz, 2H), 7.43 - 7.37 (m, 4H), 7.15 (dd, J = 8.0, 1.2 Hz, 1H), 7.08 (d, J = 8.4 Hz, 1H), 6.93 (s, 1H), 6.85 - 6.78 (m, 1H), 3.68 - 3.65 (m, 2H), 3.12 - 3.03 (m, 1H), 2.86 - 2.67 (m, 8H), 2.53 - 2.43 (m, 1H), 2.31 - 2.49 (m, 2H), 2.07 - 2.02 (m, 2H), 1.94 - 1.92 (m, 2H), 1.39 (s, 9H), 1.15 - 1.03 (m, 1H), 0.64 - 0.52 (m, 1H), 0.45 - 0.33 (m, 2H), 0.19 - 0.13 (m, 1H).
Example 208:
Synthetic Route:
[0880] Referring to the synthetic route of compound 6, compound 6-4 was replaced with compound 208-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 208 (13 mg, yield: 42%) as a white solid. MS (ESI, m/z): 564.2 [M+H]+.
[0881] 1H NMR (400 MHz, MeOD) δ 7.55 (d, J = 8.4 Hz, 2H), 7.43 -7.34 (m, 4H), 7.14 (d, J = 8.0 Hz, 1H), 7.05 (d, J = 8.0 Hz, 1H), 6.52 - 6.50 (m, 1H),6.47 - 6.43 (m, 1H), 4.50 (t, J = 8.0 Hz, 2H), 3.71 - 3.68 (m, 2H), 3.15 - 3.05 (m, 3H), 2.78 - 2.65 (m, 4H), 2.51 - 2.45 (m, 1H), 2.25 - 2.17 (m, 2H),1.94 - 1.91 (m, 2H), 1.39 (s, 9H), 1.14 - 1.08 (m, 1H), 0.69 - 0.57 (m, 1H), 0.41 - 0.32 (m, 2H), 0.18 - 0.15 (m, 1H).
Example 209:
Synthetic Route:
[0883] Referring to the synthetic route of compound 6, compound 6-4 was replaced with compound 209-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 209 (11 mg, yield: 37%) as a white solid. MS (ESI, m/z): 562.2 [M+H]+.
[0884] 1H NMR (400 MHz, DMSO-d6) δ 7.08 - 7.77 (m, 1H), 7.55 (d, J = 8.0 Hz, 2H), 7.49 - 7.36 (m, 5H), 7.13 - 7.11 (m, 2H), 7.03 - 6.99 (m, 1H), 6.82 - 6.78 (m, 1H), 3.84 - 3.81 (m, 2H), 3.50 - 3.07 (m, 1H), 2.87 - 2.81 (m, 2H), 2.49 - 2.36 (m, 3H), 2.11 - 2.08 (m, 2H), 1.91 - 1.88 (m, 2H), 1.35 (s, 9H), 1.02 - 0.94 (m, 1H), 0.47 - 0.41 (m, 1H), 0.28 - 0.22 (m, 2H), 0.10 - 0.08 (m, 1H).
Example 210:
Synthetic Route:
[0886] Referring to the synthetic route of compound 157, compound 157-4 was replaced with compound 210-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 210 (17 mg, yield: 59%) as a white solid. MS (ESI, m/z): 524.2 [M+H]+.
[0887] 1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 8.0 Hz, 1H), 7.42 - 7.34 (m, 2H), 7.30 - 7.16 (m, 3H), 7.11 (d, J= 8.0 Hz, 1H), 6.76 - 6.69 (m, 1H), 6.62 (s, 1H), 6.49 - 6.35 (m, 1H), 5.91 (s, 2H), 3.65 - 3.52 (m, 2H), 3.10 - 2.97 (m, 1H), 2.92 - 2.64 (m, 4H), 2.54 - 2.39 (m, 4H), 2.35 - 2.15 (m, 2H), 1.98 - 1.85 (m, 2H), 1.15 -1.04 (m, 1H), 0.67 - 0.55 (m, 1H), 0.50 - 0.27 (m, 2H), 0.24 - 0.15 (m, 1H).
Example 211:
Synthetic Route:
[0889] Referring to the synthetic route of compound 6, compound 6-1 was replaced with compound 211-1, and compound 6-4 was replaced with compound 210-1 to synthesize compound 211 (3.9 mg, yield: 13%) as a white solid. MS (ESI, m/z): 540.2 [M+H]+.
[0890] 1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 8.0 Hz, 1H), 7.44 - 7.38 (m, 2H), 7.13 (d, J = 8.0 Hz, 1H), 7.08 - 6.99 (m, 2H), 6.96 - 6.89 (m, 1H), 6.76 - 6.69 (m, 1H), 6.63 (s, 1H), 6.47 - 6.35 (m, 1H), 5.92 (s, 2H), 3.87 (s, 3H), 3.64 - 3.54 (m, 2H), 3.13 - 3.01 (m, 1H), 2.91 - 2.84 (m, 2H), 2.77 - 2.68 (m, 2H), 2.56 - 2.47 (m, 1H), 2.34 - 2.23 (m, 2H), 1.96 - 1.89 (m, 2H), 1.18 - 1.05 (m, 1H), 0.70 - 0.58 (m, 1H), 0.52 - 0.41 (m, 1H), 0.39 - 0.28 (m, 1H), 0.25 - 0.16 (m, 1H).
Example 212:
Synthetic Route:
[0892] Referring to the synthetic route of compound 6, compound 6-4 was replaced with compound 210-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 212 (17 mg, yield: 59%) as a white solid. MS (ESI, m/z): 566.2 [M+H]+.
[0893] 1H NMR (400 MHz, CDCl3) δ 7.55 (d, J = 8.4 Hz, 2H), 7.44-7.35 (m, 4H), 7.14 (d, J = 8.0 Hz, 1H), 6.71 (d, J = 8.4 Hz, 1H), 6.67 (d, J= 2.4 Hz, 1H), 6.52 - 6.46 (m, 1H), 5.87(s, 2H), 3.60 - 3.52 (m, 2H), 3.10 - 3.00 (m, 1H), 2.81 - 2.69 (m, 4H), 2.51 - 2.42 (m, 1H), 2.28 - 2.19 (m, 2H), 1.98 - 1.90 (m, 2H), 1.39 (s, 9H), 1.15 - 1.10 (m, 1H), 0.63 - 0.58 (m, 1H), 0.43 - 0.31 (m, 2H), 0.20 - 0.15 (m, 1H).
Example 213:
Synthetic Route:
[0895] Referring to the synthetic route of compound 14, compound 11-1 was replaced with compound 210-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 213 (18 mg, yield: 60%) as a white solid. MS (ESI, m/z): 566.2 [M+H]+.
[0896] 1H NMR (400 MHz, CDCl3) δ 7.53 - 7.49 (m, 3H), 7.42 - 7.38 (m, 3H), 7.12 (d, J = 8.6 Hz, 1H), 6.75 (d, J= 8.0 Hz, 1H), 6.68 - 6.57 (m, 1H), 6.51 - 6.39 (m, 1H), 5.93 (s, 2H), 3.67 - 3.55 (m, 2H), 3.14 - 2.97 (m, 1H), 2.91 - 2.85 (m, 2H), 2.84 - 2.66 (m, 2H), 2.53 - 2.46 (m, 1H), 2.38 - 2.20 (m, 2H), 1.97 - 1.90 (m, 2H), 1.41 (s, 9H), 1.14 - 1.07 (m, 1H), 0.67 - 0.56 (m, 1H), 0.52 - 0.41 (m, 1H), 0.38 - 0.30 (m, 1H), 0.27 - 0.16 (m, 1H).
Example 214:
Synthetic Route:
[0898] Referring to the synthetic route of compound 6, compound 6-4 was replaced with compound 214-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 214 (1 mg, yield: 8%) as a white solid. MS (ESI, m/z): 563.2 [M+H]+.
[0899] 1H NMR (400 MHz, MeOD) δ 8.29 (s, 1H), 7.58 (d, J = 8.8 Hz, 1H), 7.54 (d, J = 8.0 Hz, 2H), 7.46 - 7.35 (m, 4H), 7.25 (d, J = 2.0 Hz, 1H), 7.20 - 7.14 (m, 2H), 3.89 - 3.81 (m, 2H), 3.18 - 3.09 (m, 1H), 2.92 - 2.81 (m, 2H), 2.70 - 2.56 (m, 2H), 2.55 - 2.45 (m, 1H), 2.31 - 2.20 (m, 2H), 2.02 - 1.92 (m, 2H), 1.39 (s, 9H), 1.11 - 1.01 (m, 1H), 0.60 - 0.52 (m, 1H), 0.41 - 0.32 (m, 2H), 0.15 - 0.10 (m, 1H).
Example 215:
Synthetic Route:
[0901] Referring to the synthetic route of compound 6, compound 6-4 was replaced with compound 215-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 215 (15 mg, yield: 37%) as a white solid. MS (ESI, m/z): 580.3 [M+H]+.
[0902] 1H NMR (400 MHz, CD3OD) δ 7.54 (d, J = 8.4 Hz, 2H), 7.43 - 7.35 (m, 4H), 7.16 (d, J = 8.8 Hz, 1H), 6.72 (d, J = 8.8 Hz, 1H), 6.61 - 6.49 (m, 2H), 4.24 - 4.11 (m, 4H), 3.62 - 3.52 (m, 2H), 3.11 - 3.01 (m, 1H), 2.71 - 2.60 (m, 4H), 2.56 - 2.45 (m, 1H), 2.29 - 2.16 (m, 2H), 1.97 - 1.87 (m, 2H), 1.39 (s, 9H), 1.14 - 0.99 (m, 1H), 0.63 - 0.51 (m, 1H), 0.42 - 0.32 (m, 2H), 0.20 - 0.11 (m, 1H).
Example 216:
Synthetic Route:
[0904] Under a nitrogen atmosphere, sodium hydride (67 mg, 1.68 mmol) was added to a solution of compound 216-1 (300 mg, 1.4 mmol) in N,N-dimethylformamide (5 mL) at 0°C, and the mixture was stirred for 0.5 hours. Then, 2-(trimethylsilyl)ethoxymethyl chloride (351 mg, 2.1 mmol) was added, and stirring was continued at room temperature for 1.5 hours. The resulting mixture was added to water (50 mL) and extracted with ethyl acetate (30 mL × 3). The combined organic phases were washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 216-2 (300 mg, yield: 62%) as a pale red solid.
[0905] Referring to the synthetic route of compound 6, compound 6-4 was replaced with compound 216-2 to synthesize compound 216-3 (50 mg, yield: 63%) as a yellow oil. MS (ESI, m/z): 723.4 [M+H]+.
[0906] At room temperature, trifluoroacetic acid (1 mL) was added to a solution of compound 216-3 (50 mg, 0.069 mmol) in dichloromethane (2 mL), and the reaction mixture was stirred for 2.5 hours. The solvent was then removed by concentration, followed by the addition of ammonia in methanol (7 M, 1 mL). The mixture was stirred at room temperature for 0.5 hours. After concentration, the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 216-4 (30 mg, yield: 73%) as a yellow solid. MS (ESI, m/z): 593.3 [M+H]+.
[0907] Referring to the synthetic route of compound 6, compound 6-5 was replaced with compound 216-4 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 216 (2 mg, yield: 8%) as a white solid. MS (ESI, m/z): 579.2 [M+H]+.
[0908] 1HNMR (400 MHz, CD3OD) δ 7.59 - 7.57 (m, 3H), 7.48 - 7.35 (m, 5H), 7.26 - 7.15 (m, 2H), 3.80 - 3.68 (m, 4H), 3.48 - 3.44 (m, 1H), 2.81 - 2.73(m, 2H), 2.66 - 2.42 (m, 3H), 2.27 - 2.24 (m, 2H), 1.39 (s, 9H), 1.14 - 1.10 (m,1H), 0.64 - 0.61(m, 1H), 0.46 - 0.30 (m, 2H), 0.22 - 0.14 (m, 1H). Example 217:
Synthetic Route:
[0910] Referring to the synthetic route of compound 12, compound 12-2 (160 mg, 0.29 mmol) was obtained and added to tetrahydrofuran (10 mL). Lithium bis(trimethylsilyl)amide (0.87 mL, 1 mol/L) was then slowly added to the reaction mixture at -78°C and stirred for 30 minutes, followed by warming to 0°C and stirring for 80 minutes. After cooling to -78°C, a solution of iodomethane (203 mg, 1.45 mmol) in tetrahydrofuran (5 mL) was slowly added to the reaction mixture and stirred at room temperature for 2 hours. After the reaction was completed, the reaction mixture was quenched with saturated ammonium chloride solution (10 mL). Ethyl acetate (100 mL) was added, and the organic phase was washed with saturated brine. The organic phase was concentrated to obtain a crude product. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 217-1 (162 mg, yield: 97%) as a yellow oil. MS (ESI, m/z): 574.3 [M+H]+.
[0911] Then, referring to the synthetic route of compound 89, compound 38-3 was replaced with compound 217-2 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 217 (153 mg, yield: 93%) as a white solid. MS (ESI, m/z): 584.3 [M+H]+.
[0912] 1H NMR (400 MHz, CDCl3) δ 7.54 - 7.34 (m, 5H), 7.33 - 7.27 (m, 1H), 7.17 - 7.09 (m, 1H), 6.98 - 6.88 (m, 1H), 6.57 - 6.48 (m, 1H), 6.45 - 6.38 (m, 1H), 3.77 (s, 3H), 3.65 - 3.51 (m, 2H), 3.14 - 3.01 (m, 1H), 2.84 - 2.63 (m, 3H), 2.35 - 2.24 (m, 2H), 2.06 - 1.98 (m, 1H), 1.98 - 1.85 (m, 2H), 1.40 - 1.36 (m, 12H), 1.15 - 1.06 (m, 1H), 0.74 - 0.66 (m, 1H), 0.55 - 0.46 (m, 1H), 0.44 - 0.37 (m, 1H), 0.34 - 0.25 (m, 1H).
Example 218:
Synthetic Route:
[0914] Referring to the synthetic route of compound 217, compound 12-2 was replaced with compound 14-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 218 (20 mg, yield: 18%) as a white solid. MS (ESI, m/z): 584.3 [M+H]+.
[0915] 1H NMR (400 MHz, DMSO-d6) δ .56 (d, J = 8.0 Hz, 2H), 7.45 - 7.39 (m, 4H), 7.12 (d, J = 8.0 Hz, 1H), 7.07 - 7.02 (m, 1H), 6.57 - 6.48 (m, 2H), 3.71 (s, 3H), 3.56 - 3.37 (m, 2H), 3.09 - 3.03 (m, 1H), 2.86 - 2.74 (m, 3H), 2.19 - 2.06 (m, 3H), 1.97-1.87 (m, 2H), 1.35 (s, 9H), 1.29 - 1.19 (m, 3H), 1.15 - 1.07 (m, 1H), 0.70 - 0.61 (m, 1H), 0.41 - 0.23 (m, 2H), -0.06 - -0.16 (m, 1H).
Example 219:
Synthetic Route:
[0917] Referring to the synthetic route of compound 217, iodomethane was replaced with N-fluorobenzenesulfonimide to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 219 (10 mg, yield: 48%) as a white solid. MS (ESI, m/z): 588.3 [M+H]+.
[0918] 1H NMR (400 MHz, CDCl3) δ 7.62 - 7.18 (m, 6H), 7.06 - 6.89 (m, 2H), 6.62 - 6.50 (m, 1H), 6.49 - 6.38 (m, 1H), 5.40 - 4.80 (m, 1H), 3.79 (s, 3H), 3.69 - 3.52 (m, 2H), 3.20 - 3.03 (m, 1H), 2.85 - 2.63 (m, 2H), 2.50 - 2.24 (m, 1H), 2.14 - 1.82 (m, 4H), 1.38 - 1.33 (m, 10H), 0.72- 0.20 (m, 3H), 0.14 - 0.00 (m, 1H).
Example 220:
Synthetic Route:
[0920] Referring to the synthetic route of compound 219, compound 12-2 was replaced with compound 14-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 220 (15 mg, yield: 43%) as a white solid. MS (ESI, m/z): 588.3 [M+H]+.
[0921] 1H NMR (400 MHz, DMSO-d6) δ 7.58 - 7.45 (m, 6H), 7.25 (d, J = 8.4 Hz, 1H), 7.08 - 7.03 (m, 1H), 6.59 - 6.54 (m, 1H), 6.52 - 6.47 (m, 1H), 5.18 (d, J = 48.0 Hz, 1H), 3.72 (s, 3H), 3.52 - 3.42 (m, 2H), 3.14 - 3.02 (m, 1H), 2.86 - 2.72 (m, 2H), 2.69 - 2.55 (m, 1H), 2.18 - 2.06 (m, 2H), 1.99 - 1.87 (m, 2H), 1.38 - 1.33 (m, 10H), 0.66 - 0.56 (m, 1H), 0.50 - 0.34 (m, 2H), 0.08 - 0.01 (m, 1H).
Example 221:
Synthetic Route:
[0923] Referring to the synthetic route of compound 60, compound 60-1 (12.5 g, 28.60 mmol) was synthesized and added to dichloromethane (100 mL) with stirring. Trifluoroacetic acid (12 mL) was then added, and the reaction was carried out at room temperature for 3 hours. After the reaction was completed, the reaction mixture was concentrated and diluted with ethyl acetate (200 mL). The organic phase was washed with water (80 mL) and then with saturated sodium bicarbonate solution (80 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated to obtain compound 221-1 (9.6 g, crude product) as a yellow solid. MS (ESI, m/z): 338.3 [M+H]+.
[0924] Compound 221-1 (9.6 g, 28.49 mmol), 3-bromo-4-fluoroanisole 156-4 (5.84 g, 28.49 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (2.97 g, 5.13 mmol), and cesium carbonate (24.07 g, 78.07 mmol) were added to anhydrous 1,4-dioxane (500 mL) and stirred. Under a nitrogen atmosphere, tris(dibenzylideneacetone)dipalladium (2.35 g, 2.56 mmol) was added, and the reaction was carried out at 100°C for 16 hours. After the reaction was completed, the reaction mixture was diluted with dichloromethane: methanol (5:1) (600 mL) and filtered. The filtrate was concentrated to obtain a crude product. The resulting crude product was then purified by column chromatography to obtain compound 221-2 (7.2 g, crude product) as a yellow oil. MS (ESI, m/z): 462.3 [M+H]+.
[0925] Compound 221-2 (7.2 g, 15.61 mmol) was added to anhydrous tetrahydrofuran (300 mL), followed by the portion-wise addition of lithium borohydride (7.5 g, 344.35 mmol). The reaction mixture was stirred at room temperature for 8 hours. After the reaction was completed, the system was slowly poured into an ice-cold sodium bicarbonate solution (400 mL) with stirring. The mixture was extracted with ethyl acetate (200 mL), and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The resulting crude product was then purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 221-3 (6.6 g, yield: 98%) as a yellow oil. MS (ESI, m/z): 434.3 [M+H]+.
[0926] Compound 221-3 (800 mg, 1.85 mmol), 4-tert-butylphenylboronic acid 12-2 (493 mg, 2.77 mmol), bis(triphenylphosphine)palladium(II) chloride (130 mg, 0.18 mmol), and potassium carbonate (765 mg, 5.54 mmol) were added to a mixture of N,N-dimethylformamide (6 mL) and water (2 mL) and stirred. Under a nitrogen atmosphere, the reaction mixture was stirred at 100°C for 16 hours. After the reaction was completed, the reaction mixture was diluted with ethyl acetate (50 mL) and filtered. The organic phase was washed with water (30 mL), dried over anhydrous sodium sulfate, and concentrated to obtain a crude product. The resulting crude product was then purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 221-4 (830 mg, yield: 92%) as a yellow oil. MS (ESI, m/z): 488.3 [M+H]+.
[0927] Compound 221-4 (820 mg, 1.68 mmol) was added to dichloromethane (20 mL) and stirred. At 0°C, Dess-Martin periodinane (857 mg, 2.02 mmol) was added, and the reaction mixture was stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was quenched with saturated sodium bicarbonate solution (10 mL) and concentrated to obtain a crude product. The resulting crude product was then purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 221-5 (760 mg, yield: 93%) as a yellow solid. MS (ESI, m/z): 486.3 [M+H]+.
[0928] To a reaction tube, under a nitrogen atmosphere, triphenylphosphine (164 mg, 0.46 mmol) and THF (2 mL) were added. After cooling to 0°C, a 1 mmol/L solution of potassium tert-butoxide (460 µL, 0.46 mmol) was slowly added dropwise. The reaction mixture was stirred for 1 hour, and then compound 221-5 (97 g, 0.2 mmol) was added. The reaction was heated to 60°C and stirred for 24 hours. After filtration and rotary evaporation to dryness, compound 221-6 (82 mg, crude product) was obtained as a white solid. MS (ESI, m/z): 484.3 [M+H]+.
[0929] To a reaction tube, under a nitrogen atmosphere, compound 221-6 (70 mg, 0.15 mmol), ethyl diazoacetate 221-7 (45 mg, 0.24 mmol), Pd(OAc)2 (7 mg, 0.03 mmol), and toluene (1 mL) were added. The reaction was carried out at 80°C for 4 hours. After cooling to room temperature, water (20 mL) was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The combined organic phases were dried over anhydrous sodium sulfate and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 221-8 (36 mg, yield: 42%) as a white solid. MS (ESI, m/z): 570.3 [M+H]+.
[0930] To a reaction tube, compound 221-8 (36 mg, 63 µmol) and methanol (2 mL) were added. A solution of NaOH (51 mg, 1.26 mmol) in water (0.5 mL) was then added dropwise to the reaction, and the mixture was stirred at room temperature overnight. The pH was adjusted to 3 with 1 N dilute hydrochloric acid, and the mixture was extracted with ethyl acetate (10 mL). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 221 (24 mg, yield: 70%) as a white solid. MS (ESI, m/z): 542.3 [M+H]+.
[0931] 1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 7.6 Hz, 2H), 7.45 -7.35 (m, 4H), 7.13 (d, J = 8.0 Hz, 1H), 7.00 - 6.89 (m, 1H), 6.57 - 6.49 (m, 1H), 6.45 - 6.37 (m, 1H), 3.77 (s, 3H), 3.61 - 3.52 (m, 2H), 3.12 - 3.02 (m, 1H), 2.79 - 2.71 (m, 3H), 2.39 - 2.26 (m, 2H), 2.15 - 2.06 (m, 1H), 1.96 - 1.87 (m, 2H), 1.78 - 1.69 (m, 1H), 1.47 - 1.36 (m, 10H).
Example 222:
Synthetic Route:
[0933] Referring to the synthetic route of compound 221, compound 221-5 (165 mg, 0.34 mmol) was synthesized and added to anhydrous tetrahydrofuran (20 mL) with stirring. At 0°C, cyclopropylmagnesium bromide M1-4 (1.0 M in THF, 0.51 mL, 0.51 mmol) was slowly added, and the reaction mixture was stirred at 0°C for 1 hour. After the reaction was completed, the reaction mixture was quenched with saturated sodium bicarbonate solution (20 mL) and concentrated to obtain a crude product. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 222-1 (168 mg, yield: 94%) as a yellow oil. MS (ESI, m/z): 528.3 [M+H]+.
[0934] Compound 222-1 (160 mg, 0.30 mmol) was added to anhydrous acetonitrile (20 mL) under a nitrogen atmosphere. Trichloroacetonitrile (87.2 mg, 0.60 mmol) was added, and then 1,8-diazabicyclo[5.4.0]undec-7-ene (4 mg, 0.03 mmol) was added. The reaction mixture was stirred at room temperature for 40 minutes. Then, 1-methoxy-1-(trimethylsiloxy)-2-methyl-1-propene 222-2 (156.4 mg, 0.90 mmol) was added, and then bis(trifluoromethanesulfonyl)imide (18 mg, 0.06 mmol) was added. The reaction was carried out at room temperature for 2 hours. After the reaction was completed, the reaction mixture was quenched with saturated ammonium chloride solution and concentrated to obtain a crude product. The resulting crude product was then purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 222-3 (80 mg, yield: 44%) as a colorless oil. MS (ESI, m/z): 612.3 [M+H]+.
[0935] Compound 222-3 (80 mg, 0.13 mmol) was added to methanol (2 mL) and tetrahydrofuran (2 mL) and stirred. A 4 M sodium hydroxide solution (2 mL) was added, and the reaction mixture was stirred at 85°C for 3 days. After the reaction was completed, the pH was adjusted to 3-4 with 1 N hydrochloric acid, and the mixture was extracted with ethyl acetate (10 mL). The organic phase was concentrated to obtain a crude product. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 222 (38 mg, yield: 49%) as a white solid. MS (ESI, m/z): 598.3 [M+H]+.
[0936] 1H NMR (400 MHz, DMSO-d6) δ 7.59 - 7.53 (m, 2H), 7.48 - 7.36 (m, 4H), 7.12 (d, J = 8.0 Hz, 1H), 7.07 - 7.02 (m, 1H), 6.64 - 6.53 (m, 1H), 6.50 - 6.47 (m, 1H), 3.72 (s, 3H), 3.51 - 3.43 (m, 2H), 3.13 - 3.02 (m, 1H), 2.83 - 2.73 (m, 2H), 2.28 (d, J = 10.8 Hz, 1H), 2.16 - 2.08 (m, 2H), 1.97 - 1.89 (m, 2H), 1.47 - 1.39 (m, 1H), 1.36 (s, 9H), 1.18 (s, 3H), 1.04 (s, 3H), 0.72 - 0.60 (m, 1H), 0.47 - 0.40 (m, 1H), 0.39 - 0.25 (m, 1H), -0.21 - -0.32 (m, 1H).
Example 223:
Synthetic Route:
[0938] Compound 223-1 (2 g, 11.8 mmol) and N-iodosuccinimide (2.9 g, 12.9 mmol) were added to acetic acid (20 mL) and stirred at room temperature for 2 hours. After the reaction was completed, most of the acetic acid was removed by concentration, and ethyl acetate (100 mL) was added. The organic phase was washed with saturated sodium bicarbonate solution (100 mL) and saturated brine (50 mL). The organic phase was concentrated to obtain a crude product, which was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 223-2 (1.95 g, yield: 56%) as a yellow solid. MS (ESI, m/z): 297.3 [M+H]+.
[0939] Under a nitrogen atmosphere, compound 223-2 (1.95 g, 6.59 mmol), compound M1-9 (1.38 g, 6.59 mmol), copper(I) iodide (125 mg, 0.66 mmol), bis(triphenylphosphine)palladium(II) chloride (231 mg, 0.33 mmol), and triethylamine (2 g, 19.8 mmol) were added to acetonitrile (240 mL). The reaction mixture was heated to 100°C and stirred overnight. After the reaction was completed, the reaction mixture was directly concentrated and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 223-3 (1.7 g, yield: 69%) as a yellow oil. MS (ESI, m/z): 378.3 [M+H]+.
[0940] Compound 223-3 (1.35 g, 3.58 mmol) was added to tetrahydrofuran (20 mL), followed by the slow addition of liquid bromine (3.6 mL, 1 M in acetic acid) under an ice-water bath. The reaction mixture was then stirred at room temperature for 1 hour. After the reaction was completed, ethyl acetate (100 mL) was added. The organic phase was washed with saturated sodium bicarbonate solution (100 mL) and saturated brine (50 mL), then concentrated to obtain a crude product. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 223-4 (729 mg, yield: 45%) as a yellow oil. MS (ESI, m/z): 456.3 [M+H]+.
[0941] Under a nitrogen atmosphere, compound 223-4 (729 mg, 1.6 mmol), compound 6-1 (341 mg, 1.92 mmol), tetrakis(triphenylphosphine)palladium (185 mg, 0.16 mmol), and sodium carbonate (508 mg, 4.8 mmol) were added to a mixture of 1,4-dioxane (8 mL) and water (1 mL). The reaction mixture was heated to 100°C and stirred overnight. After the reaction was completed, ethyl acetate (100 mL) was added, and the organic phase was washed with saturated brine (50 mL). The organic phase was concentrated to obtain a crude product, which was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 223-5 (784 mg, yield: 96%) as a yellow oil. MS (ESI, m/z): 510.3 [M+H]+.
[0942] Compound 223-5 (784 mg, 1.54 mmol) was added to dichloromethane (15 mL), followed by the addition of a 4 N hydrochloric acid/1,4-dioxane solution (5 mL) to the reaction mixture, which was then stirred at room temperature for 2 hours. After the reaction was completed, the organic phase was directly concentrated to obtain compound 223-6 (630 mg, crude product) as a yellow oil. MS (ESI, m/z): 410.3 [M+H]+.
[0943] Under a nitrogen atmosphere, compound 223-6 (630 mg, 1.54 mmol), 4-fluoro-3-iodoanisole 89-1 (504 mg, 2.0 mmol), tris(dibenzylideneacetone)dipalladium (141 mg, 0.15 mmol), 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl (144 mg, 0.31 mmol), and cesium carbonate (2 g, 6.16 mmol) were added to a solution of 1,4-dioxane (15 mL). The reaction mixture was heated to 100°C and stirred overnight. After the reaction was completed, ethyl acetate (100 mL) was added, and the organic phase was washed with saturated brine (50 mL). The organic phase was concentrated to obtain a crude product, which was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 223-7 (370 mg, yield: 45%) as a yellow oil. MS (ESI, m/z): 534.3 [M+H]+.
[0944] Under a nitrogen atmosphere, compound 223-7 (370 mg, 0.69 mmol) was added to a mixture of tetrahydrofuran (20 mL) and methanol (10 mL). Then, lithium aluminum hydride (40 mg, 1.04 mmol) was slowly added to the reaction mixture under an ice-water bath and stirred for 2 hours. After the reaction was completed, water (0.1 mL), 15% sodium hydroxide aqueous solution (0.1 mL), and water (0.3 mL) were added separately and stirred for 0.5 hours. After filtration, the reaction mixture was directly concentrated to obtain compound 223-8 (400 mg, crude product) as a yellow oil. MS (ESI, m/z): 506.3 [M+H]+.
[0945] Compound 223-8 (400 mg, 0.79 mmol) was added to a mixture of tetrahydrofuran (10 mL) and dichloromethane (10 mL). Then, Dess-Martin periodinane (671 mg, 1.58 mmol) was slowly added to the reaction mixture under an ice-water bath, and the reaction mixture was stirred at room temperature for 5 hours. After the reaction was completed, ethyl acetate (100 mL) was added. The organic phase was washed with saturated sodium bicarbonate solution (100 mL) and saturated brine (500 mL), then concentrated to obtain a crude product. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 223-9 (245 mg, yield: 62%) as a yellow oil. MS (ESI, m/z): 504.3 [M+H]+.
[0946] Under a nitrogen atmosphere, compound 223-9 (245 mg, 0.49 mmol) was added to a tetrahydrofuran (10 mL) solution. Then, cyclopropylmagnesium bromide M1-4 (1.9 mL, 0.97 mmol, 0.5 mol/L) was slowly added dropwise to the reaction mixture under an ice-water bath and stirred for half an hour. After the reaction was completed, the reaction mixture was quenched with saturated ammonium chloride solution (10 mL). Ethyl acetate (100 mL) was added, and the organic phase was washed with saturated brine (50 mL). The organic phase was concentrated to obtain a crude product, which was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 223-10 (185 mg, yield: 62%) as a yellow oil. MS (ESI, m/z): 546.3 [M+H]+.
[0947] Under a nitrogen atmosphere, compound 223-10 (185 mg, 0.34 mmol), 1-(tert-butyldimethylsilyloxy)-1-methoxyethene (128 mg, 0.68 mmol), and rhenium carbonyl bromide (14 mg, 0.034 mmol) were added to a toluene (10 mL) solution and heated to 120°C with stirring overnight. After the reaction was completed, ethyl acetate (100 mL) was added, and the organic phase was washed with saturated brine (50 mL). The organic phase was concentrated to obtain a crude product, which was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 223-11 (136 mg, yield: 67%) as a yellow oil. MS (ESI, m/z): 602.3 [M+H]+.
[0948] Compound 223-11 (136 mg, 0.23 mmol) was added to a mixture of tetrahydrofuran (6 mL) and methanol (4 mL). Then, a solution of lithium hydroxide (109 mg, 4.5 mmol) in water (1 mL) was added to the reaction mixture, which was heated to 60°C and stirred for 2 hours. After the reaction was completed, 1 N dilute hydrochloric acid (10 mL) and ethyl acetate (100 mL) were added. The organic phase was washed with saturated brine (50 mL), concentrated to obtain a crude product, and purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 223 (2 mg, yield: 2%) as a white solid. MS (ESI, m/z): 588.3 [M+H]+.
[0949] 1H NMR (400 MHz, CDCl3) δ 7.53 (d, J = 8.0 Hz, 2H), 7.41 - 7.35 (m, 3H), 7.21 (d, J = 10.4 Hz, 1H), 6.99 - 6.94 (m, 1H), 6.58 - 6.51 (m, 1H), 6.48 -6.40 (m, 1H), 3.79 (s, 3H), 3.64-3.53 (m, 2H), 3.13 -3.05 (m, 1H), 2.92 - 2.88 (m, 2H), 2.82 - 2.71 (m, 3H), 2.40 - 2.28 (m, 2H), 1.99-1.90 (m, 2H), 1.41 (s, 9H), 1.27 - 1.17 (m, 1H), 0.69 -0 .61 (m, 1H), 0.52 - 0.42 (m, 1H), 0.40 - 0.34 (m, 1H), 0.26 - 0.19 (m, 1H).
Example 224:
Synthetic Route:
[0952] Referring to the synthetic route of compound 223, compound 89-1 was replaced with compound 224-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 224 (4 mg, yield: 7%) as a white solid. MS (ESI, m/z): 622.3 [M+H]+.
[0953] 1H NMR (400 MHz, CDCl3) δ 7.53 (d, J = 7.2 Hz, 2H), 7.41 - 7.35 (m, 3H), 7.21 (d, J = 10.4 Hz, 1H), 7.10 (d, J = 11.2 Hz, 1H), 6.59 (s, 1H), 3.88 (s, 3H), 3.63 - 3.51 (m, 2H), 3.16 - 3.05 (m, 1H), 2.95 - 2.69 (m, 5H), 2.43 - 2.28 (m, 2H), 2.00 - 1.89 (m, 2H), 1.41 (s, 9H), 1.17 - 1.08 (m, 1H), 0.68 - 0.63 (m, 1H), 0.50 - 0.42 (m, 1H), 0.41 - 0.33 (m, 1H), 0.26 - 0.19 (m, 1H).
Example 225:
Synthetic Route:
[0955] Compound 225-1 (1.2 g, 8.57 mmol) and N-iodosuccinimide (1.93 g, 8.57 mmol) were added to dichloromethane (20 mL) and stirred at room temperature for 6 hours. After the reaction was completed, the reaction mixture was directly concentrated to obtain a crude product, which was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 225-2 (330 mg, yield: 15%) as a yellow solid. MS (ESI, m/z): 267.3 [M+H]+.
[0956] Compound 225-2 (322 mg, 1.21 mmol), iodomethane (206 mg, 1.45 mmol), and potassium carbonate (334 mg, 2.42 mmol) were added to N,N-dimethylformamide (5 mL) and stirred at room temperature for 3 hours. After the reaction was completed, saturated brine (20 mL) was added, and the reaction mixture was extracted with ethyl acetate (20 mL × 3). The combined organic phases were concentrated to obtain a crude product, which was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 225-3 (338 mg, yield: 99%) as a white solid. MS (ESI, m/z): 281.3 [M+H]+.
[0957] At -20°C, M1-4 (12 mL, 0.5 mmol/mL in THF) was slowly added dropwise to a mixture of compound 225-3 (339 mg, 1.21 mmol) and tetrahydrofuran (10 mL). After the addition was completed, the reaction mixture was stirred at -20°C for 2 hours. After the reaction was completed, the reaction mixture was quenched with saturated ammonium chloride aqueous solution (20 mL) and extracted with ethyl acetate (20 mL × 3). The combined organic phases were concentrated to obtain compound 225-4 (330 mg, crude product) as a colorless oil. MS (ESI, m/z): 323.3 [M+H]+.
[0958] Compound 225-4 (330 mg, 1.03 mmol), compound 225-5 (771 mg, 4.1 mmol), and rhenium pentacarbonyl bromide (83 mg, 0.205 mmol) were added to toluene (5 mL) and stirred at room temperature for 16 hours. After the reaction was completed, the reaction mixture was directly concentrated to obtain a crude product, which was purified by column chromatography to obtain compound 225-6 (310 mg, yield: 80%) as a yellow oil. MS (ESI, m/z): 379.3 [M+H]+.
[0959] Compound 225-6 (305 mg, 0.807 mmol) and boron tribromide (1 mL) were added to dichloromethane (5 mL) and stirred at room temperature for 16 hours. After the reaction was completed, the reaction mixture was directly concentrated to obtain a crude product, which was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 225-7 (140 mg, yield: 48%) as a yellow oil. MS (ESI, m/z): 365.3 [M+H]+.
[0960] Referring to the synthetic route of intermediate M1, compound M1-8 was replaced with compound 225-7 to synthesize intermediate 225-8. Referring to the synthetic route of compound 6, intermediate M1 was replaced with intermediate 225-8 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 225 (2 mg, yield: 9%) as a white solid. MS (ESI, m/z): 584.3 [M+H]+.
[0961] 1H NMR (400 MHz, CDCl3) δ 7.53 (d, J = 6.6 Hz, 2H), 7.40 (d, J = 6.6 Hz, 2H), 7.29 - 7.24 (m, 1H), 7.12 - 7.04 (m, 1H), 7.00 - 6.91 (m, 1H), 6.57 - 6.51 (m, 1H), 6.48 - 6.39 (m, 1H), 3.78 (s, 3H), 3.64 - 3.54 (m, 2H), 3.17 - 3.04 (m, 1H), 2.93 (d, J = 6.8 Hz, 2H), 2.84 - 2.71 (m, 3H), 2.47 - 2.32 (m, 2H), 2.00 - 1.91 (m, 2H), 1.41 (s, 9H), 1.21 - 1.17 (m, 1H), 0.68 - 0.58 (m, 1H), 0.49 - 0.32 (m, 2H), 0.29 - 0.19 (m, 1H).
Example 226:
Synthetic Route:
[0963] Referring to the synthetic route of intermediate M1, M1-9 was replaced with commercially available starting material M4-9 to synthesize compound 226-1. Referring to the synthetic route of compound 6, the synthesis was carried out, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 226 (18 mg, yield: 35%) as a white solid. MS (ESI, m/z): 584.3 [M+H]+.
[0964] 1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 8.0 Hz, 2H), 7.36 (s, 1H), 7.30 - 7.23 (m, 2H), 7.16 - 7.10 (m, 1H), 7.08 -7.00 (m, 1H), 6.85 (m, 1H), 6.43 - 6.28 (m, 2H), 3.72 (s, 3H), 3.15 - 3.02 (m, 2H), 2.90 - 2.79 (m, 2H), 2.77 - 2.65 (m, 2H), 2.51 -2.43 (m, 1H), 2.41 - 2.30 (m, 2H), 1.77 - 1.63 (m, 2H), 1.44 (s, 3H), 1.37 s, 9H), 1.15 - 1.04 (m, 1H), 0.65 - 0.55 (m, 1H), 0.50 - 0.41 (m, 1H), 0.38 - 0.29 (m, 1H), 0.24 - 0.16 (m, 1H).
Example 227:
Synthetic Route:
[0966] Compound 168 (300 mg, 0.53 mmol), ammonium chloride (42 mg, 0.79 mmol), 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (400 mg, 1.05 mmol), and N,N-diisopropylethylamine (170 mg, 1.32 mmol) were added to N,N-dimethylformamide (10 mL) and stirred at room temperature for 2 hours. After the reaction was completed, saturated brine (50 mL) was added, and the reaction mixture was extracted with ethyl acetate (20 mL × 3). The combined organic phases were concentrated to obtain a crude product, which was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 227-1 (280 mg, yield: 93%) as a yellow oil. MS (ESI, m/z): 569.3 [M+H]+.
[0967] To a reaction flask containing compound 227-1 (280 mg, 0.49 mmol), triethylamine (125 mg, 1.23 mmol), and 1,4-dioxane (15 mL), trifluoroacetic acid (207 mg, 0.98 mmol) was added dropwise, and the reaction mixture was stirred at room temperature for 16 hours. After the reaction was completed, the reaction mixture was directly concentrated to obtain a crude product, which was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 227-2 (220 mg, yield: 81%) as a yellow oil. MS (ESI, m/z): 551.2 [M+H]+.
[0968] To a reaction flask containing compound 227-2 (120 mg, 0.22 mmol) and toluene (15 mL), trimethylsilyl azide (88 mg, 0.76 mmol) and dibutyltin oxide (81 mg, 0.33 mmol) were added separately. The reaction mixture was stirred under a nitrogen atmosphere at 120°C for 16 hours. After the reaction was completed, the reaction mixture was directly concentrated to obtain a crude product, which was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 227 (18 mg, yield: 14%) as a yellow solid. MS (ESI, m/z): 594.3 [M+H]+.
[0969] 1H NMR (400 MHz, DMSO-d6) δ 7.56 (d, J = 8.4 Hz, 2H), 7.45 - 7.38 (m 3H), 7.35 (s, 1H), 7.16 (dd, J = 11.6, 9.2 Hz, 1H), 7.09 (d, J = 8.0 Hz, 1H), 6.94 (dd, J = 6.4, 2.8 Hz, 1H), 6.84 - 6.77(m, 1H), 3.80 (s, 3H), 3.74 - 3.64 (m, 2H), 3.50 - 3.40 (m, 2H), 3.36 - 3.18 (m, 3H), 2.50 - 2.35 (m, 3H), 2.15 - 2.05 (m, 2H), 1.35 (s, 9H), 1.27 - 1.17 (m, 1H), 0.54 - 0.44 (m, 1H), 0.38 - 0.29 (m, 1H), 0.14 - 0.07 (m, 2H).
Example 228:
Synthetic Route:
[0971] Referring to the synthetic route of compound 227, compound 227-2 (60 mg, 0.11 mmol) was synthesized. Compound 227-2 (60 mg, 0.11 mmol) and 50% hydroxylamine aqueous solution (18 mg, 0.55 mmol) were added to dimethyl sulfoxide (5 mL). The reaction mixture was stirred at 90°C under a nitrogen atmosphere for 4 hours. After the reaction was completed, saturated brine (30 mL) was added, and the reaction mixture was extracted with ethyl acetate (20 mL × 3). The combined organic phases were concentrated to obtain a crude product, which was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 228-1 (40 mg, yield: 62%) as a yellow oil. MS (ESI, m/z): 584.3 [M+H]+.
[0972] Compound 228-1 (40 mg, 0.069 mmol) and N,N'-carbonyldiimidazole (22 mg, 0.14 mmol) were added to 1,4-dioxane (5 mL) and stirred under a nitrogen atmosphere at 90°C for 4 hours. After the reaction was completed, the reaction mixture was directly concentrated and purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 228 (3 mg, yield: 5%) as a yellow solid. MS (ESI, m/z): 610.3 [M+H]+.
[0973] 1H NMR (400 MHz, CD3OD) δ 7.55 (d, J = 8.4 Hz, 2H), 7.45 - 7.38 (m, 4H), 7.11 (d, J = 8.0 Hz, 1H), 6.97 - 6.90 (m, 1H), 6.66 - 6.56 (m, 1H), 6.53 - 6.44 (m, 1H), 3.75 (s, 3H), 3.58 - 3.49 (m, 2H), 3.15 - 3.07 (m,1H), 3.05 - 2.91 (m, 2H), 2.81 - 2.69 (m, 2H), 2.42 - 2.20 (m, 3H), 2.00 - 1.87 (m, 2H), 1.39 (s, 9H), 1.23 - 1.11 (m, 1H), 0.70 - 0.59 (m, 1H), 0.48 - 0.38 (m, 1H), 0.33 - 0.23 (m, 1H), 0.20 - 0.13 (m, 1H).
Example 229:
Synthetic Route:
[0975] Compound 229-1 (10.0 g, 47.9 mmol) and carbon tetrabromide (17.5 g, 52.6 mmol) were added to dichloromethane (350 mL) and stirred. Triphenylphosphine (25.1 g, 95.7 mmol) was added in portions at 0°C, and the reaction was carried out at 0°C for 2 hours. After the reaction was completed, petroleum ether (350 mL) was added, and the mixture was filtered. The filtrate was concentrated to obtain a crude product. The resulting crude product was then purified by normal -phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 229-2 (14.5 g, yield: 83%) as a yellow solid. MS (ESI, m/z): 365.9 [M+H]+.
[0976] Compound 229-2 (14.5 g, 39.9 mmol) was added to anhydrous ethanol (160 mL) and stirred. Stannous chloride (30.2 g, 159.8 mmol) was added, and the reaction was carried out at 100°C for 1 hour. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product. The resulting crude product was diluted with ethyl acetate (400 mL) and water (100 mL), adjusted to pH = 9 with saturated sodium carbonate solution, extracted with ethyl acetate, and the combined organic phases were dried over anhydrous sodium sulfate and concentrated to obtain a crude product. The resulting crude product was then purified by normal -phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 229-3 (13.1 g, yield: 98%) as a yellow oil. MS (ESI, m/z): 335.9 [M+H]+.
[0977] Compound 229-3 (13.1 g, 39.3 mmol), N-Boc-1,2,5,6-tetrahydropyridine-4-boronic acid pinacol ester 229-4 (18.2 g, 59.0 mmol), potassium phosphate hydrate (45.2 g, 196.8 mmol), and 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (970 mg, 2.4 mmol) were added to toluene (300 mL) and stirred. Under a nitrogen atmosphere, palladium acetate (266 mg, 1.2 mmol) was added, and the reaction was carried out at 90°C for 24 hours. After the reaction was completed, the reaction mixture was diluted with ethyl acetate and filtered. The filtrate was concentrated to obtain a crude product. The resulting crude product was then purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 229-5 (7.6 g, yield: 54%) as a yellow oil. MS (ESI, m/z): 357.3 [M+H]+.
[0978] Compound 229-5 (7.6 g, 21.4 mmol) was added to methanol (50 mL) and tetrahydrofuran (50 mL) and stirred. 10% palladium on carbon (1.52 g) was added, and the reaction was carried out under hydrogen (1 atm) at room temperature for 24 hours. After the reaction was completed, the reaction mixture was filtered, and the filtrate was concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 229-6 (7.6 g, yield: 99%) as a yellow solid. MS (ESI, m/z): 359.3 [M+H]+.
[0979] Compound 229-6 (7.6 g, 21.2 mmol) was added to anhydrous tetrahydrofuran (80 mL). Sodium hydride (60%, 2.6 g, 63.7 mmol) was added in portions at 0°C, and the mixture was stirred at 0°C for 1 hour. Then, a solution of p-toluenesulfonyl chloride (6.1 g, 31.8 mmol) in anhydrous tetrahydrofuran (20 mL) was slowly added dropwise at 0°C, followed by stirring at room temperature for 16 hours. After the reaction was completed, the reaction mixture was quenched with saturated ammonium chloride solution and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The resulting crude product was then purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 229-7 (5.2 g, yield: 48%) as a yellow solid. MS (ESI, m/z): 513.3 [M+H]+.
[0980] Compound 229-7 (5.2 g, 10.2 mmol) was added to anhydrous dichloromethane (100 mL) and stirred. N-Bromosuccinimide (2.7 g, 15.2 mmol) was added in portions at 0°C, and the reaction was carried out at 0°C for 2 hours. After the reaction was completed, the reaction mixture was quenched with saturated sodium bicarbonate solution and concentrated to obtain a crude product. The resulting crude product was then purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 229-8 (4.1 g, yield: 68%) as a brown oil. MS (ESI, m/z): 591.2 [M+H]+.
[0981] Compound 229-8 (4.1 g, 7.0 mmol) was added to dichloromethane (40 mL) and stirred, followed by the addition of trifluoroacetic acid (4 mL). The reaction was carried out at room temperature for 2 hours. After the reaction was completed, the reaction mixture was concentrated, diluted with ethyl acetate, and the organic phase was washed with saturated sodium bicarbonate solution. The organic phase was dried over anhydrous sodium sulfate, concentrated, and then purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 229-9 (3.4 g, yield: 99%) as a yellow solid. MS (ESI, m/z): 491.2 [M+H]+.
[0982] Compound 229-9 (3.4 g, 7.0 mmol), 3-bromo-4-fluoroanisole 156-4 (4.3 g, 20.8 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (804 mg, 1.4 mmol), and cesium carbonate (6.8 g, 20.8 mmol) were added to anhydrous 1,4-dioxane (30 mL) and stirred. Under a nitrogen atmosphere, tris(dibenzylideneacetone)dipalladium (636 mg, 0.7 mmol) was added, and the reaction was carried out in a sealed tube and heated to 120°C for 36 hours. After the reaction was completed, the reaction mixture was diluted with dichloromethane: methanol (5:1) (200 mL), filtered, and the filtrate was concentrated. The resulting crude product was then purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%). The resulting crude product was then purified by column chromatography to obtain compound 229-11 (900 mg, crude product) as a yellow oil. MS (ESI, m/z): 615.2 [M+H]+.
[0983] Compound 229-11 (650 mg, 1.1 mmol) was added to anhydrous tetrahydrofuran (20 mL), followed by the portion-wise addition of lithium borohydride (312 mg, 5.3 mmol). The reaction mixture was stirred at room temperature for 16 hours. After the reaction was completed, the system was slowly poured into ice water with stirring. The mixture was extracted with ethyl acetate, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The resulting crude product was then purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 229-12 (320 mg, yield: 52%) as a yellow oil. MS (ESI, m/z): 587.2 [M+H]+.
[0984] Compound 229-12 (320 mg, 0.55 mmol) was added to dichloromethane (15 mL) and stirred. At 0°C, Dess-Martin periodinane (278 mg, 0.66 mmol) was added, and the reaction mixture was stirred at room temperature for 4 hours at 0°C. After the reaction was completed, the reaction mixture was quenched with saturated sodium bicarbonate solution and concentrated to obtain a crude product. The resulting crude product was then purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 229-13 (170 mg, yield: 53%) as a yellow oil. MS (ESI, m/z): 585.2 [M+H]+.
[0985] Compound 229-13 (170 mg, 0.29 mmol) was added to anhydrous tetrahydrofuran (10 mL) and stirred. At 0°C, cyclopropylmagnesium bromide M1-4 (1.0 M in tetrahydrofuran, 0.87 mL, 0.87 mmol) was slowly added, and the reaction mixture was stirred at room temperature for 2 hours. After the reaction was completed, the reaction mixture was quenched with saturated sodium bicarbonate solution and concentrated to obtain a crude product. The resulting crude product was then purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 229-15 (170 mg, yield: 93%) as a yellow oil. MS (ESI, m/z): 627.2 [M+H]+.
[0986] Compound 229-15 (170 mg, 0.27 mmol), 1-(tert-butyldimethylsilyloxy)-1-methoxyethene 225-5 (153 mg, 0.81 mmol), and rhenium pentacarbonyl bromide (22 mg, 0.05 mmol) were added to anhydrous toluene (5 mL). The reaction was carried out in a sealed tube under a nitrogen atmosphere and heated at 120°C for 24 hours. After the reaction was completed, the reaction mixture was concentrated and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 229-16 (110 mg, yield: 59%) as a yellow oil. MS (ESI, m/z): 683.3 [M+H]+.
[0987] Compound 229-16 (110 mg, 0.16 mmol), 4-tert-butylbenzeneboronic acid 6-1 (43 mg, 0.24 mmol), bis(triphenylphosphine)palladium(II) chloride (11 mg, 0.02 mmol), and potassium carbonate (67 mg, 0.48 mmol) were added to N,N-dimethylformamide (4 mL) and water (1 mL) and stirred. Under a nitrogen atmosphere, the reaction mixture was stirred at 100°C for 16 hours. After the reaction was completed, the reaction mixture was filtered, concentrated, and purified by normal -phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 229-17 (117 mg, yield: 99%) as a yellow oil. MS (ESI, m/z): 737.3 [M+H]+.
[0988] Compound 229-17 (118 mg, 0.16 mmol) was added to methanol (5 mL) and stirred. 4 M sodium hydroxide solution (5 mL) was added, and the reaction mixture was stirred at 100°C for 36 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product, which was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 229 (1.8 mg, yield: 2%) as a white solid. MS (ESI, m/z): 569.3 [M+H]+.
[0989] 1H NMR (400 MHz, DMSO-d6) δ 11.10 (s, 1H), 7.49 (d, J = 7.6 Hz, 2H), 7.37-7.35 (m, 3H), 7.17 (s, 1H), 7.07 - 7.02 (m, 1H), 6.90 (d, J = 7.6 Hz, 1H), 6.59 - 6.57 (m, 1H), 6.50 - 6.48 (m, 1H), 3.72 (s, 3H), 3.60 - 3.46 (m, 2H), 3.07 - 3.00 (m, 1H), 2.79 - 2.63 (m, 4H), 2.39 - 2.31 (m, 1H), 2.25 - 2.11 (m, 2H), 1.92 - 1.83 (m, 2H), 1.35 (s, 9H), 1.09 - 0.98 (m, 1H), 0.53 - 0.44 (m, 1H), 0.36 - 0.21 (m, 2H), 0.14 - 0.04 (m, 1H).
Example 230:
Synthetic Route:
[0991] Compound 229-12 (1 g, 1.7 mmol) was added to methanol (20 mL) and stirred. 4 M sodium hydroxide solution (20 mL) was added, and the reaction mixture was stirred at 100°C for 6 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product. The resulting crude product was then purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 230-2 (330 mg, yield: 45%) as a white solid. MS (ESI, m/z): 433.3 [M+H]+.
[0992] Compound 230-2 (330 mg, 0.76 mmol) was added to dichloromethane (10 mL) and stirred. At 0°C, Dess-Martin periodinane (389 mg, 0.92 mmol) was added, and the reaction mixture was stirred at room temperature for 4 hours. After the reaction was completed, the reaction mixture was quenched with saturated sodium bicarbonate solution and concentrated to obtain a crude product. The resulting crude product was then purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 230-3 (220 mg, yield: 67%) as a yellow oil. MS (ESI, m/z): 431.3 [M+H]+.
[0993] Compound 230-3 (200 mg, 0.47 mmol) was added to N,N-dimethylformamide (5 mL), and sodium hydride (60%, 37 mg, 0.93 mmol) was added at 0°C. The reaction mixture was stirred at 0°C for 0.5 hours, followed by the addition of iodomethane (201 mg, 1.40 mmol) at 0°C. The reaction mixture was then stirred at room temperature for 2 hours. After the reaction was completed, the reaction mixture was quenched with water and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product. The resulting crude product was then purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 230-4 (200 mg, yield: 97%) as a yellow oil. MS (ESI, m/z): 445.3 [M+H]+.
[0994] Then, referring to the synthetic route of compound 229, compound 229-13 was replaced with compound 230-4 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 230 (11 mg, yield: 6%) as a white solid. MS (ESI, m/z): 583.3 [M+H]+.
[0995] 1H NMR (400 MHz, DMSO-d6) δ 7.49 - 7.47 (m, 2H), 7.31 - 7.28 (m, 3H), 7.16 (d, J = 8.0 Hz, 1H), 7.09 - 6.97 (m, 1H), 6.95 - 6.85 (m, 1H), 6.61 - 6.44 (m, 2H), 3.85 (s, 3H), 3.71 (s, 3H), 3.47 - 3.38 (m, 2H), 3.20 - 3.16 (m, 1H), 2.78 - 2.63 (m, 4H), 2.44 - 2.38 (m, 1H), 2.18 - 2.02 (m, 2H), 1.90 - 1.76 (m, 2H), 1.35 (s, 9H), 1.13 - 1.02 (m, 1H), 0.58 - 0.45 (m, 1H), 0.37 - 0.20 (m, 2H), 0.18 - 0.03 (m, 1H).
Example 231:
Synthetic Route:
[0997] Referring to the synthetic route of intermediate M1, compound M1-6 was replaced with commercially available starting material M8-6 to synthesize intermediate M8. Then, referring to the synthetic route of compound 12, the synthesis was carried out, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 231 (10 mg, yield: 20%) as a white solid. MS (ESI, m/z): 530.3 [M+H]+.
[0998] 1H NMR (400 MHz, CDCl3) δ 7.52 - 7.49 (m, 2H), 7.47 - 7.42 (m, 2H), 7.36 (s, 1H), 7.33 - 7.30 (m, 1H), 7.12 (d, J = 8.4 Hz, 1H), 6.96 (dd, J = 12.0, 8.8 Hz, 1H), 6.57 - 6.51 (m, 1H), 6.47 - 6.41 (m, 1H), 3.79 (s, 3H), 3.65 - 3.56 (m, 2H), 3.14 - 3.08 (m, 3H), 2.79 - 2.70 (m, 4H), 2.42 - 2.32 (m, 2H), 2.00 - 1.92 (m, 2H), 1.40 (s, 9H).
Example 232:
Synthetic Route:
[1000] Referring to the synthetic route of compound 221, compound 6-1 was replaced with compound 1-2 to synthesize compound 232-2 (60 mg, 0.12 mmol), and compound 232-2 (60 mg, 0.12 mmol) was added to anhydrous tetrahydrofuran (10 mL) and stirred. Methylmagnesium bromide 232-3 (1.0 M in tetrahydrofuran, 0.37 mL, 0.37 mmol) was slowly added at 0°C, and the reaction mixture was stirred at 0°C for 1 hour. After the reaction was completed, the reaction mixture was quenched with saturated sodium bicarbonate solution (10 mL). The organic layer was concentrated to obtain a crude product, which was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 232-4 (60 mg, yield: 97%) as a yellow oil. MS (ESI, m/z): 502.3 [M+H]+.
[1001] Compound 232-4 (60 mg, 0.12 mmol), 1-(tert-butyldimethylsilyloxy)-1-methoxyethene 232-5 (68 mg, 0.36 mmol), and rhenium pentacarbonyl bromide (5 mg, 0.01 mmol) were added to anhydrous toluene (4 mL). The reaction was carried out in a sealed tube under a nitrogen atmosphere and heated at 120°C for 16 hours. After the reaction was completed, the reaction mixture was concentrated and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 232-5 (66 mg, yield: 59%) as a yellow oil. MS (ESI, m/z): 558.3 [M+H]+.
[1002] Compound 232-5 (66 mg, 0.12 mmol) was added to ethanol (3 mL) and stirred. 4 M sodium hydroxide solution (3 mL) was added, and the reaction mixture was stirred at 50°C for 16 hours. After the reaction was completed, the pH was adjusted to 3-4 with 1 N hydrochloric acid, and the mixture was extracted with ethyl acetate (10 mL). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to obtain a crude product, which was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 232 (26 mg, yield: 40%) as a white solid. MS (ESI, m/z): 544.3 [M+H]+.
[1003] 1H NMR (400 MHz, DMSO-d6) δ 7.56 - 7.38 (m, 5H), 7.33 (d, J = 6.8 Hz, 1H), 7.19 (d, J = 8.0 Hz, 1H), 7.07 - 7.02 (m, 1H), 6.57 - 6.55 (m, 1H), 6.53 - 6.44 (m, 1H), 3.72 (s, 3H), 3.53-3.44 (m, 2H), 3.27 - 3.26 (m, 1H), 3.11 - 3.02 (m, 1H), 2.77 - 2.71 (m, 2H), 2.58 (d, J = 7.6 Hz, 2H), 2.16 - 2.07 (m, 2H), 1.92 - 1.90 (m, 2H), 1.35 (s, 9H), 1.28 (d, J = 6.8 Hz, 3H).
Example 233:
Synthetic Route:
[1005] Referring to the synthetic route of compound 232, compound 232-3 was replaced with compound 233-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 233 (7 mg, yield: 15%) as a white solid. MS (ESI, m/z): 558.3 [M+H]+.
[1006] 1H NMR (400 MHz, DMSO-d6) δ 7.50 - 7.43 (m, 5H), 7.36 - 7.31 (m, 1H), 7.17 - 7.12 (m, 1H), 7.08 - 7.01 (m, 1H), 6.58 - 6.54 (m, 1H), 6.52 - 6.47 (m, 1H), 3.72 (s, 3H), 3.53 - 3.46 (m, 2H), 3.07 - 3.01 (m, 1H), 2.78 - 2.64 (m, 2H), 2.63 - 2.53 (m, 3H), 2.21 - 2.05 (m, 2H), 2.01 - 1.92 (m, 2H), 1.78 - 1.54 (m, 2H), 1.36 (s, 9H), 0.74 (t, J = 7.2 Hz, 3H).
Example 234:
Synthetic Route:
[1008] Compound 49-6 (710 mg, 1.49 mmol) and N,N-dimethylformamide (0.2 mL) were added to dichloromethane (30 mL) and stirred. Under a nitrogen atmosphere, oxalyl chloride (283 mg, 2.23 mmol) was added dropwise at 0°C, and the reaction was carried out for 4 hours. After the reaction was completed (monitored with methanol), the reaction mixture was directly used in the next step. MS (ESI, m/z): 491.2 [M-4]+.
[1009] The reaction mixture containing compound 234-1 (366 mg, 0.74 mmol) obtained from the previous step was slowly added dropwise under a nitrogen atmosphere at 0°C to a mixture of o-toluidine 234-2 (159 mg, 1.48 mmol) and triethylamine (375 mg, 3.71 mmol) in dichloromethane (40 mL). The reaction mixture was stirred at room temperature for 16 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product. The resulting crude product was purified by normal-phase column chromatography (petroleum ether: ethyl acetate = 8:2) to obtain compound 234-3 (410 mg, yield: 97%) as a yellow oil. MS (ESI, m/z): 571.3 [M+H]+.
[1010] Compound 234-3 (400 mg, 0.7 mmol) was added to methanol (20 mL) and stirred. 4 M sodium hydroxide solution (20 mL) was added, and the reaction mixture was stirred at 60°C for 16 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product, which was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 234 (350 mg, yield: 90%) as a white solid. MS (ESI, m/z): 557.2 [M+H]+.
[1011] 1H NMR (400 MHz, CDCl3) δ 8.51- 8.47 (m, 1H), 8.02 - 7.97 (m, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.45 (s, 1H), 7.30 - 7.24 (m, 1H), 7.26 - 7.08 (m, 4H), 6.63 (dd, J = 8.0 Hz, 1H), 6.58 - 6.52 (m, 1H), 6.45 (dd, J = 8.0 Hz, 1H), 3.96- 3.76 (m, 6H), 3.05 - 2.75 (m, 4H), 2.54 - 2.45 (m, 1H), 2.30 - 2.12 (m, 2H), 2.08 - 1.99 (m, 2H), 1.18 - 1.03 (m, 1H), 0.68- 0.62 (m, 1H), 0.51- 0.44 (m, 1H), 0.38- 0.33 (m, 1H), 0.23- 0.18 (m, 1H).
Example 235:
Synthetic Route:
[1013] Referring to the synthetic route of compound 234, compound 49-6 was replaced with compound 126-3, and compound 234-2 was replaced with compound 235-2. The synthesis was carried out, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 235 (35 mg, yield: 69%) as a white solid. MS (ESI, m/z): 553.2 [M+H]+.
[1014] 1H NMR (400 MHz, DMSO-d6) δ 9.71 (s, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.82 - 7.76 (m, 1H), 7.74 (dd, J = 8.0, 1.2 Hz, 1H), 7.57 (s, 1H), 7.48 - 7.41 (m, 1H), 7.28 (d, J = 8.1 Hz, 1H), 7.26 - 7.20 (m, 1H), 7.15 - 7.09 (m, 1H), 6.62 - 6.56 (m, 1H), 6.52 - 6.48 (m, 1H), 6.37 (dd, J = 8.0, 2.0 Hz, 1H), 3.91 - 3.81 (m, 2H), 3.73 (s, 3H), 3.69 - 3.60 (m, 1H), 2.87 - 2.79 (m, 2H), 2.75 - 2.65 (m, 2H), 2.43 - 2.35 (m, 1H), 2.02 - 1.94 (m, 4H), 1.11 - 1.04 (m, 1H), 0.56 - 0.48 (m, 1H), 0.34 - 0.24 (m, 2H), 0.19 - 0.12 (m, 1H).
Example 236:
Synthetic Route:
[1016] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 236-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 236 (1 mg, yield: 5%) as a white solid. MS (ESI, m/z): 564.2 [M+H]+.
[1017] 1H NMR (400 MHz, DMSO-d6) δ 10.50 (s, 1H), 8.49 (s, 1H), 7.92 (d, J = 7.7 Hz, 1H), 7.85 - 7.73 (m, 3H), 7.57 (s, 1H), 7.49 - 7.42 (m, 1H), 7.30 (d, J = 8.1 Hz, 1H), 7.19 - 7.12 (m, 1H), 6.61 (dd, J = 8.2, 1.9 Hz, 1H), 6.56 - 6.51 (m, 1H), 6.40 (dd, J = 8.1, 2.1 Hz, 1H), 3.92 - 3.85 (m, 2H), 3.76 (s, 3H), 3.70 - 3.60 (s, 1H), 2.91 - 2.82 (m, 2H), 2.72 - 2.60 (m, 2H), 2.52 - 2.41 (m, 1H), 2.08 - 1.93 (m, 4H), 1.15 - 1.03 (m, 1H), 0.58 - 0.48 (m, 1H), 0.38 - 0.25 (m, 2H), 0.20 - 0.10 (m, 1H).
Example 237:
Synthetic Route:
[1019] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 237-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 237 (3 mg, yield: 9%) as a white solid. MS (ESI, m/z): 607.2 [M+H]+.
[1020] 1H NMR (400 MHz, DMSO-d6) δ 9.92 (s, 1H), 8.39 (s, 1H), 7.82 (d, J = 7.6 Hz, 1H), 7.79 - 7.73 (m, 1H), 7.71 (d, J = 8.0 Hz, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.59 - 7.50 (m, 2H), 7.27 (d, J = 8.2 Hz, 1H), 7.17 - 7.08 (m, 1H), 6.59 (dd, J = 8.2, 2.0 Hz, 1H), 6.54 - 6.46 (m, 1H), 6.37 (dd, J = 8.0, 2.0 Hz, 1H), 3.91 - 3.84 (m, 2H), 3.73 (s, 3H), 3.64 - 3.54 (m, 1H), 2.86 - 2.75 (m, 2H), 2.74 - 2.63 (m, 2H), 2.45 - 2.35 (m, 1H), 2.06 - 1.89 (m, 4H), 1.12 - 1.02 (m, 1H), 0.56 - 0.47 (m, 1H), 0.34 - 0.24 (m, 2H), 0.18 - 0.10 (m, 1H).
Example 238:
Synthetic Route:
[1022] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 237-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 237 (18 mg, yield: 64%) as a white solid. MS (ESI, m/z): 607.2 [M+H]+.
[1023] 1H NMR (400 MHz, CDCl3) δ 8.43 (d, J = 8.4 Hz, 1H), 8.09 (s, 1H), 7.72 - 7.66 (m, 3H), 7.47 (s, 1H), 7.34 - 7.30 (m, 2H), 7.24 - 7.19 (m, 1H), 6.69 - 6.42 (m, 3H), 3.86 - 3.83 (m, 6H), 2.99 - 2.86 (m, 4H), 2.57 - 2.50 (m, 1H), 2.31 - 2.19 (m, 2H), 2.09 - 2.04 (m, 2H), 1.14 - 1.09 (m, 1H), 0.69 - 0.61 (m, 1H), 0.53 - 0.46 (m, 1H), 0.41 - 0.35 (m, 1H), 0.26 - 0.20 (m, 1H).
Example 239:
Synthetic Route:
[1025] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 239-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 239 (35 mg, yield: 69%) as a white solid. MS (ESI, m/z): 553.2 [M+H]+.
[1026] 1H NMR (400 MHz, CDCl3) δ 8.00 (d, J = 8.0 Hz, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.60 (s, 1H), 7.45 (s, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.28 - 7.24 (m, 2H), 7.23 -7.12 (m, 2H), 6.62 (dd, J = 8.4, 2.4 Hz, 1H), 6.56 - 6.53 (m, 1H), 6.44 (dd, J = 8.4, 2.4 Hz, 1H), 3.93 - 3.78 (m, 6H), 2.97 - 2.78 (m, 4H), 2.57 - 2.45 (m, 1H), 2.38 (s, 3H), 2.29 - 2.12 (m, 2H), 2.10 - 1.95 (m, 2H), 1.16 - 1.03 (m, 1H), 0.69 - 0.62 (m, 1H), 0.51 - 0.44 (m, 1H), 0.39 - 0.33 (m, 1H), 0.24 -0.18 (m, 1H).
Example 240:
Synthetic Route:
[1028] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 240-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 240 (2 mg, yield: 5%) as a white solid. MS (ESI, m/z): 623.2 [M+H]+.
[1029] 1H NMR (400 MHz, MeOD) δ 8.03 (d, J = 7.0 Hz, 1H), 7.78 (d, J = 8.2 Hz, 1H), 7.55 - 7.40 (m, 5H), 7.39 - 7.32 (m, 2H), 7.25 - 7.19 (m, 2H), 7.13 - 7.04 (m, 1H), 4.00 - 3.74 (m 6H), 2.92 - 2.74 (m, 4H), 2.60 - 2.44 (m, 3H), 2.44 - 2.34 (m, 2H), 1.16 - 1.10 (m, 1H), 0.68 - 0.58 (m, 1H), 0.47 - 0.31 (m, 2H), 0.23 - 0.12 (m, 1H).
Example 241:
Synthetic Route:
[1031] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 241-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 241 (39 mg, yield: 48%) as a white solid. MS (ESI, m/z): 615.2 [M+H]+.
[1032] 1H NMR (400 MHz, CDCl3) δ 8.64 (d, J = 8.4 Hz, 1H), 7.86 (s, 1H), 7.58 - 7.39 (m, 6H), 7.34 - 7.27 (m, 2H), 7.27 - 7.15 (m, 2H), 6.87 (d, J = 8.4 Hz, 1H), 6.62 (d, J = 8.4 Hz, 1H), 6.58 - 6.49 (m, 2H), 6.45 (d, J = 8.4 Hz, 1H), 3.94 - 3.66 (m, 6H), 2.92 - 2.76 (m, 4H), 2.52 - 2.40 (m, 1H), 2.17 - 2.07 (m, 2H), 1.98 - 1.86 (m, 2H), 1.08 - 1.02 (m, 1H), 0.66 - 0.60 (m, 1H), 0.52 - 0.38 (m, 1H), 0.35 - 0.30 (m, 1H), 0.21 - 0.10 (m, 1H).
Example 242:
Synthetic Route:
[1034] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 242-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 242 (10 mg, yield: 51%) as a white solid. MS (ESI, m/z): 553.2 [M+H]+.
[1035] 1H NMR (400 MHz, CDCl3) δ 7.56 (d, J = 8.0 Hz, 1H), 7.42 (s, 1H), 7.38 - 7.31 (m, 2H), 7.24 - 7.16 (m, 4H), 6.96 - 6.90 (m, 1H), 6.79 - 6.50 (m, 3H), 3.82 - 3.60 (m, 6H), 3.16 - 3.03 (m, 2H), 2.81 - 2.68 (m, 2H), 2.45 - 2.38 (m, 1H), 2.32 (s, 3H), 2.29 - 2.18 (m, 2H), 2.12 - 2.01 (m, 2H), 1.07 - 0.96 (m, 1H), 0.62 - 0.51 (m, 1H), 0.43 - 0.35 (m, 1H), 0.32 - 0.24 (m, 1H), 0.16 - 0.09 (m, 1H).
Example 243:
Synthetic Route:
[1037] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 243-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 243 (12 mg, yield: 42%) as a white solid. MS (ESI, m/z): 567.2 [M+H]+.
[1038] 1H NMR (400 MHz, DMSO-d6) δ 10.13 (s, 1H), 7.65 (s, 1H), 7.60 - 7.51 (m, 3H), 7.28 - 7.14 (m, 4H), 6.97 - 6.92 (m, 1H), 6.79 - 6.60 (m, 2H), 6.57 - 6.47 (m, 1H), 3.85 - 3.75 (m, 2H), 3.74 (s, 3H), 3.19 - 3.11 (m, 2H), 3.11 - 3.00 (m, 1H), 2.75 - 2.72 (m, 2H), 2.63 - 2.56 (m, 2H), 2.40 - 2.35 (m, 1H), 2.05 - 1.96 (m, 4H), 1.19 - 1.15 (m, 3H), 1.09 - 1.03 (m, 1H), 0.56 - 0.48 (m, 1H), 0.31 - 0.25 (m, 2H), 0.18 - 0.11 (m, 1H).
Example 244:
Synthetic Route:
[1040] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 244-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 244 (18 mg, yield: 56%) as a white solid. MS (ESI, m/z): 507.2 [M+H]+.
[1041] 1H NMR (400 MHz, DMSO-d6) δ 10.52 (s, 1H), 8.25 (s, 1H), 7.98 - 7.94 (m, 1H), 7.63 - 7.55 (m, 3H), 7.49 - 7.42 (m, 1H), 7.30 - 7.22 (m, 1H), 7.15 - 7.06 (m, 1H), 6.60 - 6.52 (m, 1H), 6.50 - 6.46 (m, 1H), 6.39 - 6.32 (m, 1H), 3.85 - 3.80 (m, 2H), 3.72 - 3.70 (m, 3H), 3.60 - 3.35 (m, 1H), 2.85 - 2.77 (m, 2H), 2.74 - 2.70 (m, 2H), 2.40 - 2.35 (m, 1H), 2.00 - 1.93 (m, 4H), 1.10 - 1.03 (m, 1H), 0.56 - 0.48 (m, 1H), 0.31 - 0.22 (m, 2H), 0.18 - 0.10 (m, 1H).
Example 245:
Synthetic Route:
[1043] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 245-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 245 (11 mg, yield: 30%) as a white solid. MS (ESI, m/z): 569.2 [M+H]+.
[1044] 1H NMR (400 MHz, MeOD) δ 7.47 (d, J = 8.2 Hz, 1H), 7.36 - 7.26 (m, 2H), 7.19 - 7.07 (m, 3H), 7.03 - 6.99 (m, 1H), 6.63 - 6.57 (m, 1H), 6.51 - 6.48 (m, 1H), 6.44 - 6.42 (m, 1H), 6.31 - 6.29 (m, 1H), 3.73 - 3.62 (m, 8H), 3.43 - 3.35 (m, 1H), 2.74 - 2.71 (m, 2H), 2.60 - 2.35 (m, 3H), 2.09 - 1.98 (m, 2H), 1.93 - 1.90 (m, 2H), 0.96 - 0.93 (m, 1H), 0.50 - 0.41 (m, 1H), 0.30 - 0.18 (m, 2H), 0.03 - 0.05 (m, 1H).
Example 246:
Synthetic Route:
[1046] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 246-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 246 (16 mg, yield: 46%) as a white solid. MS (ESI, m/z): 582.2 [M+H]+.
[1047] 1H NMR (400 MHz, CDCl3) δ 7.72 - 7.58 (m, 2H), 7.43 (s, 1H), 7.26 - 7.15 (m, 4H), 6.94 - 6.84 (m, 1H), 6.71 - 6.44 (m, 4H), 3.85 - 3.76 (m, 6H), 3.00 (s, 6H), 2.97 - 2.85 (m, 4H), 2.55 - 2.45 (m, 1H), 2.34 - 2.15 (m, 2H), 2.06 - 1.95 (m, 2H), 1.12 - 1.04 (m, 1H), 0.67 - 0.59 (m, 1H), 0.51 - 0.40 (m, 1H), 0.38 - 0.30 (m, 1H), 0.25 - 0.17 (m, 1H).
Example 247:
Synthetic Route:
[1049] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 247-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 247 (23 mg, yield: 53%) as a white solid. MS (ESI, m/z): 617.2 [M+H]+.
[1050] 1H NMR (400 MHz, CDCl3) δ 7.97 (s, 1H), 7.59 - 7.51 (m, 2H), 7.44 (s, 1H), 7.34 - 7.30 (m, 1H), 7.27 - 7.22 (m, 4H), 6.83 - 6.42 (m, 3H), 3.84 - 3.75 (m, 6H), 3.13 - 2.74 (m, 4H), 2.53 - 2.46 (m, 1H), 2.33 - 2.17 (m, 2H), 2.04 - 1.98 (m, 2H), 1.11 - 1.04 (m, 1H), 0.70 - 0.62 (m, 1H), 0.49 - 0.42 (m, 1H), 0.38 - 0.32 (m, 1H), 0.22 - 0.16 (m, 1H).
Example 248:
Synthetic Route:
[1052] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 248-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 248 (2 mg, yield: 3%) as a white solid. MS (ESI, m/z): 573.2 [M+H]+.
[1053] 1H NMR (400 MHz, DMSO-d6) δ 10.39 (s, 1H), 7.98 - 7.92 (m, 1H), 7.69 - 7.63 (m, 1H), 7.61 - 7.55 (m, 2H), 7.41 - 7.35 (m, 1H), 7.29 - 7.23 (m, 1H), 7.20 - 7.14 (m, 1H), 7.14 - 7.09 (m, 1H), 6.60 - 6.55 (m, 1H), 6.51 - 6.47 (m, 1H), 6.39 - 6.33 (m, 1H), 3.90 - 3.77 (m, 2H), 3.72 (s, 3H), 3.49 - 3.46 (m, 1H), 2.86 - 2.78 (m, 2H), 2.77 - 2.69 (m, 2H), 2.42 - 2.35 (m, 1H), 2.00 - 1.91 (m, 4H), 1.11 - 1.03 (m, 1H), 0.56 - 0.48 (m, 1H), 0.32 - 0.24 (m, 2H), 0.18 - 0.11 (m, 1H).
Example 249:
Synthetic Route:
[1055] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 249-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 249 (1 mg, yield: 5%) as a white solid. MS (ESI, m/z): 564.2 [M+H]+.
[1056] 1H NMR (400 MHz, DMSO-d6) δ 10.53 (s, 1H), 8.23 (s, 1H), 8.06 - 7.97 (m, 1H), 7.66 - 7.53 (m, 4H), 7.26 (d, J = 8.0 Hz, 1H), 7.15 - 7.08 (m, 1H), 6.61 - 6.53 (m, 1H), 6.51 - 6.46 (m, 1H), 6.40 - 6.32 (m, 1H), 3.89 - 3.79 (m, 2H), 3.72 (s, 3H), 3.54 - 3.40 (m, 1H), 2.87 - 2.78 (m, 2H), 2.77 - 2.70 (m, 2H), 2.42 - 2.34 (m, 1H), 2.03 - 1.89 (m, 4H), 1.11 - 1.02 (m, 1H), 0.57 - 0.48 (m, 1H), 0.34 - 0.23 (m, 2H), 0.19 - 0.09 (m, 1H).
Example 250:
Synthetic Route:
[1058] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 250-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 250 (124 mg, yield: 85%) as a white solid. MS (ESI, m/z): 571.2 [M+H]+.
[1059] 1H NMR (400 MHz, CDCl3) δ 8.32-8.25 (m, 1H), 8.02-7.97 (m, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.43 (s, 1H), 7.29-7.25 (m, 1H), 7.23-7.16 (m, 1H), 7.11-7.05 (m, 1H), 6.93-6.99 (m, 1H), 6.73 - 6.35 (m, 3H), 3.93 - 3.75 (m, 6H), 3.02 - 2.77 (m, 4H), 2.58 - 2.47 (m, 1H), 2.33 (s, 3H), 2.28 - 2.12 (m, 2H), 2.08 - 1.95 (m, 2H), 1.14 - 1.04 (m, 1H), 0.68 - 0.57 (m, 1H), 0.53 - 0.45 (m, 1H), 0.40 - 0.30 (m, 1H), 0.26 - 0.16 (m, 1H).
Example 251:
Synthetic Route:
[1061] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 251-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 251 (126 mg, yield: 92%) as a white solid. MS (ESI, m/z): 571.2 [M+H]+.
[1062] 1H NMR (400 MHz, CDCl3) δ 8.33 - 8.26 (m, 1H), 7.91 (s, 1H), 7.68 (d, J = 8.4 Hz, 1H), 7.43 (s, 1H), 7.29 - 7.24 (m, 1H), 7.23 - 7.16 (m, 1H), 7.08 - 6.95 (m, 2H), 6.77 - 6.33 (m, 3H), 3.96 - 3.77 (m, 6H), 3.08 - 2.76 (m, 4H), 2.57 - 2.46 (m, 1H), 2.35 (s, 3H), 2.28 - 2.12 (m, 2H), 2.08 - 1.96 (m, 2H), 1.15 - 1.07 (m, 1H), 0.70 - 0.59 (m, 1H), 0.54 - 0.43 (m, 1H), 0.38 - 0.29 (m, 1H), 0.24 - 0.15 (m, 1H).
Example 252:
Synthetic Route:
[1064] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 252-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 252 (1 mg, yield: 4%) as a white solid. MS (ESI, m/z): 571.2 [M+H]+.
[1065] 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 8.0 Hz, 1H), 7.48 (s, 1H), 7.38 - 7.30 (m, 2H), 7.28 - 7.18 (m, 2H), 7.13 (d, J = 7.6 Hz, 1H), 7.09 - 7.01 (m, 1H), 6.63 (dd, J= 8.0, 2.4 Hz, 1H), 6.58 - 6.53 (m, 1H), 6.45 (dd, J = 8.0, 2.4 Hz, 1H), 3.84 - 3.82 (m, 6H), 3.01 - 2.82 (m, 4H), 2.58 - 2.50 (m, 1H), 2.41 (s, 3H), 2.25 - 2.13 (m, 2H), 2.11 - 2.04 (m, 2H), 1.18 - 1.08 (m, 1H), 0.73 - 0.63 (m, 1H), 0.53 - 0.46 (m, 1H), 0.42 - 0.36 (m, 1H), 0.26 - 0.21 (m, 1H).
Example 253:
Synthetic Route:
[1067] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 253-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 253 (32 mg, yield: 63%) as a white solid. MS (ESI, m/z): 571.2 [M+H]+.
[1068] 1H NMR (400 MHz, CDCl3) δ 8.30 (d, J = 7.6 Hz, 1H), 7.98 - 7.92 (m, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.43 (s, 1H), 7.29 - 7.25 (m, 1H), 7.26 - 7.23 (m, 1H), 7.03 (dd, J = 8.0, 7.6 Hz, 1H), 6.93 - 6.85 (m, 1H), 6.73 - 6.35 (m, 3H), 3.93 - 3.76 (m, 6H), 3.02 - 2.77 (m, 4H), 2.53 - 2.46 (m, 1H), 2.37 (s, 3H), 2.28 - 2.12 (m, 2H), 2.08 - 2.00 (m, 2H), 1.15 - 1.04 (m, 1H), 0.68 - 0.59 (m, 1H), 0.51 - 0.41 (m, 1H), 0.39 - 0.30 (m, 1H), 0.23 - 0.15 (m, 1H).
Example 254:
Synthetic Route:
[1070] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 254-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 254 (109 mg, yield: 83%) as a white solid. MS (ESI, m/z): 574.9 [M+H]+.
[1071] 1H NMR (400 MHz, CDCl3) δ 8.30 - 8.19 (m, 1H), 7.98 (s, 1H), 7.67 (d, J = 8.0 Hz, 1H), 7.44 (s, 1H), 7.28 (d, J = 8.0 Hz, 1H), 7.23 - 7.09 (m, 2H), 7.01 - 6.91 (m, 1H), 6.73 - 6.36 (m, 3H), 3.92 - 3.78 (m, 6H), 3.02 - 2.78 (m, 4H), 2.54 - 2.46 (m, 1H), 2.27 - 2.13 (s, 2H), 2.08 - 1.98 (m, 2H), 1.15 - 1.06 (m, 1H), 0.67 - 0.59 (m, 1H), 0.51 - 0.43 (m, 1H), 0.39 - 0.30 (m, 1H), 0.25 - 0.16 (m, 1H).
Example 255:
Synthetic Route:
[1073] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 255-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 255 (118 mg, yield: 93%) as a white solid. MS (ESI, m/z): 574.9 [M+H]+.
[1074] 1H NMR (400 MHz, CDCl3) δ 8.46 - 8.38 (m, 1H), 7.86 (s, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.44 (s, 1H), 7.30 - 7.26 (m, 1H), 7.24 - 7.16 (m, 1H), 7.00 - 6.89 (m, 2H), 6.76 - 6.35 (m, 3H), 3.90 - 3.76 (m, 6H), 3.02 - 2.76 (m, 4H), 2.55 - 2.57 (m, 1H), 2.28 - 2.13 (m, 2H), 2.08 - 1.97 (m, 2H), 1.14 - 1.06 (m, 1H), 0.69 - 0.60 (m, 1H), 0.50 - 0.39 (m, 1H), 0.37 - 0.29 (m, 1H), 0.25 - 0.14 (m, 1H).
Example 256:
Synthetic Route:
[1076] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 256-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 256 (2 mg, yield: 4%) as a white solid. MS (ESI, m/z): 574.9 [M+H]+.
[1077] 1H NMR (400 MHz, CDCl3) δ 7.73 (d, J = 8.0 Hz, 1H), 7.49 - 7.45 (m, 1H), 7.35 - 7.26 (m, 3H), 7.24 - 7.18 (m, 1H), 7.10 - 7.02 (m, 2H), 6.63 (dd, J = 8.0, 2.4 Hz, 1H), 6.58 - 6.53 (m, 1H), 6.45 (dd, J = 8.0, 2.4 Hz, 1H), 3.84 - 3.81 (m, 6H), 3.01 - 2.83 (m, 4H), 2.58 - 2.49 (m, 1H), 2.25 - 2.17 (m, 2H), 2.08 - 2.06 (m, 2H), 1.16 - 1.08 (m, 1H), 0.71 - 0.65 (m, 1H), 0.53 - 0.46 (m, 1H), 0.43 - 0.34 (m, 1H), 0.26 - 0.20 (m, 1H).
Example 257:
Synthetic Route:
[1079] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 257-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 257 (13 mg, yield: 41%) as a white solid. MS (ESI, m/z): 574.9 [M+H]+.
[1080] 1H NMR (400 MHz, CDCl3) δ 8.37 - 8.31 (m, 1H), 8.02 (s, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.44 (s, 1H), 7.28 (d, J = 8.2 Hz, 1H), 7.23 - 7.16 (m, 1H), 7.15 - 7.06 (m, 1H), 6.82 - 6.75 (m, 1H), 6.74 - 6.34 (m, 3H), 3.93 - 3.78 (m, 6H), 3.05 - 2.79 (m, 4H), 2.54 - 2.45 (m, 1H), 2.30 - 2.14 (m, 2H), 2.09 - 1.98 (m, 2H), 1.14 - 1.03 (m, 1H), 0.69 - 0.60 (m, 1H), 0.51 - 0.42 (m, 1H), 0.38 - 0.30 (m, 1H), 0.23 - 0.15 (m, 1H).
Example 258:
Synthetic Route:
[1082] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 258-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 258 (107 mg, yield: 87%) as a white solid. MS (ESI, m/z): 587.2 [M+H]+.
[1083] 1H NMR (400 MHz, CDCl3) δ 8.09 - 8.03 (m, 1H), 8.00 - 7.97 (m, 1H), 7.75 - 7.64 (d, J = 8.0 Hz, 1H), 7.43 (s, 1H), 7.28 - 7.24 (m, 2H), 7.23 - 7.17 (m, 1H), 7.15 - 7.08 m, 1H), 6.8 - 6.75 (m, 1H), 6.72 - 6.38 (m, 3H), 3.92 (s, 3H), 3.87 - 3.75 (m, 6H), 3.01 - 2.78 (m, 4H), 2.54 - 2.47 (m, 1H), 2.28 - 2.12 (m, 2H), 2.09 - 1.99 (m, 2H), 1.14 - 1.04 (m, 1H), 0.67 - 0.58 (m, 1H), 0.48 - 0.43 (m, 1H), 0.39 - 0.27 (m, 1H), 0.23 - 0.15 (m, 1H).
Example 259:
Synthetic Route:
[1085] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 259-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 259 (10 mg, yield: 25%) as a white solid. MS (ESI, m/z): 587.2 [M+H]+.
[1086] 1H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 8.0 Hz, 1H), 7.46 (s, 1H), 7.36 (s, 1H), 7.30 - 7.15 (m, 3H), 6.92 - 6.84 (m, 1H), 6.79 (d, J = 8.4 Hz, 1H), 6.63 (d, J = 8.6 Hz, 1H), 6.56 (s, 1H), 6.49 - 6.43 (m, 1H), 3.90 (s, 3H), 3.89 - 3.75 (m, 6H), 2.98 - 2.81 (m, 4H), 2.57 - 2.49 (m, 1H), 2.27 - 2.14 (m, 2H), 2.11 - 2.03 (m, 2H), 1.17 - 1.08 (m, 1H), 0.71 - 0.64 (m, 1H), 0.52 - 0.46 (m, 1H), 0.43 - 0.33 (m, 1H), 0.28 - 0.19 (m, 1H).
Example 260:
Synthetic Route:
[1088] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 260-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 260 (24 mg, yield: 57%) as a white solid. MS (ESI, m/z): 587.2 [M+H]+.
[1089] 1H NMR (400 MHz, CDCl3) δ 8.17 - 8.12 (m, 1H), 8.00 - 7.96 (m, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.43 (s, 1H), 7.29 - 7.25 (m, 1H), 7.23 - 7.17 (m, 1H), 7.10 - 7.01 (m, 1H), 6.72 - 6.34 (m, 4H), 3.88 - 3.76 (m, 9H), 3.03 - 2.78 (m, 4H), 2.54 - 2.46 (m, 1H), 2.29 - 2.14 (m, 2H), 2.07 - 1.99 (m, 2H), 1.14 - 1.04 (m, 1H), 0.68 - 0.59 (m, 1H), 0.50 - 0.42 (m, 1H), 0.38 - 0.30 (m, 1H), 0.23 - 0.15 (m, 1H).
Example 261:
Synthetic Route:
[1091] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 261-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 261 (15 mg, yield: 47%) as a white solid. MS (ESI, m/z): 624.9 [M+H]+.
[1092] 1H NMR (400 MHz, CDCl3) δ 8.94 - 8.86 (m, 1H), 8.11 - 8.02 (m, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.45 (s, 1H), 7.42 - 7.37 (m, 1H), 7.32 - 7.27 (m, 2H), 7.23 - 7.16 (m, 1H), 6.74 - 6.37 (m, 3H), 3.89 - 3.78 (m, 6H), 3.04 - 2.79 (m, 4H), 2.53 - 2.46 (m, 1H), 2.28 - 2.14 (m, 2H), 2.08 - 1.99 (m, 2H), 1.14 - 1.04 (m, 1H), 0.68 - 0.60 (m, 1H), 0.51 - 0.42 (m, 1H), 0.39 - 0.31 (m, 1H), 0.23 - 0.15 (m, 1H).
Example 262:
Synthetic Route:
[1094] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 262-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 262 (12 mg, yield: 27%) as a white solid. MS (ESI, m/z): 640.9 [M+H]+.
[1095] 1H NMR (400 MHz, CDCl3) δ 8.57 - 8.48 (m, 1H), 8.03 (s, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.45 (s, 1H), 7.28 (d, J = 8.2 Hz, 1H), 7.24 - 7.12 (m, 2H), 7.00 - 6.93 (m, 1H), 6.76 - 6.36 (m, 3H), 3.90 - 3.78 (m, 6H), 3.04 - 2.77 (m, 4H), 2.54 - 2.45 (m, 1H), 2.29 - 2.14 (m, 2H), 2.08 - 1.97 (m, 2H), 1.15 - 1.14 (m 1H), 0.69 - 0.60 (m, 1H), 0.51 - 0.42 (m, 1H), 0.39 - 0.31 (m, 1H), 0.23 - 0.15 (m, 1H).
Example 263:
Synthetic Route:
[1097] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 263-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 263 (40 mg, yield: 60%) as a white solid. MS (ESI, m/z): 624.9 [M+H]+.
[1098] 1H NMR (400 MHz, CDCl3) δ 7.71 (d, J = 8.0 Hz, 1H), 7.61 - 7.55 (m, 1H), 7.50 - 7.42 (m, 4H), 7.32 - 7.30 (m, 1H), 7.24 - 7.19 (m, 1H), 6.68 - 6.62 (m, 1H), 6.60 - 6.55 (m, 1H), 6.49 - 6.44 (m, 1H), 3.87 - 3.77 (m, 6H), 3.00 - 2.84 (m, 4H), 2.58 - 2.48 (m, 1H), 2.28 - 2.14 (m, 2H), 2.09 - 2.04 (m, 2H), 1.17 - 1.09 (m, 1H), 0.73 - 0.63 (m, 1H), 0.55 - 0.47 (m, 1H), 0.42 - 0.34 (m, 1H), 0.26 - 0.17 (m, 1H).
Example 264:
Synthetic Route:
[1100] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 264-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 264 (16 mg, yield: 73%) as a white solid. MS (ESI, m/z): 635.2 [M+H]+.
[1101] 1H NMR (400 MHz, CDCl3) δ 7.80 (d, J = 8.0 Hz, 1H), 7.54 - 7.45 (m, 3H), 7.33 - 7.30 (m, 1H), 7.28 - 7.19 (m, 3H), 6.88 - 6.42 (m, 3H), 3.93 - 3.79 (m, 6H), 3.04 - 2.84 (m, 4H), 2.57 - 2.53 (m, 1H), 2.43 - 2.25 (m, 2H), 2.14 - 2.07 (m, 2H), 1.18 - 1.09 (m, 1H), 0.72 - 0.64 (m, 1H), 0.53 - 0.47 (m, 1H), 0.42 - 0.35 (m, 1H), 0.26 - 0.19 (m, 1H).
Example 265:
Synthetic Route:
[1103] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 265-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 265 (21 mg, yield: 44%) as a white solid. MS (ESI, m/z): 586.9 [M+H]+.
[1104] 1H NMR (400 MHz, CDCl3) δ 8.46 (s, 1H), 8.33 (s, 1H), 7.82 (d, J = 8.2 Hz, 1H), 7.48 (s, 1H), 7.36 - 7.29 (m, 2H), 7.27 - 7.22 (m, 1H), 6.91 (d, J = 8.4 Hz, 1H), 6.66 - 6. -59 (m, 1H), 6.55 (s, 1H), 6.47 - 6.41 (m, 1H), 3.96 - 3.81 (m, 6H), 3.10 - 2.82 (m, 4H), 2.58 - 2.50 (m, 1H), 2.42 (s, 3H), 2.37 - 2.16 (m, 2H), 2.14 - 2.15 (m, 2H), 1.17 - 1.08 (m, 1H), 0.71 - 0.63 (m, 1H), 0.53 - 0.47 (m, 1H), 0.41 - 0.34 (m, 1H), 0.26 - 0.18 (m, 1H).
Example 266:
Synthetic Route:
[1106] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 266-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 266 (15 mg, yield: 43%) as a white solid. MS (ESI, m/z): 590.9 [M+H]+.
[1107] 1H NMR (400 MHz, CDCl3) δ 8.50 (dd, J = 8.8, 3.2 Hz, 1H), 8.37 (s, 1H), 7.81 (d, J = 8.4 Hz, 1H), 7.45 (s, 1H), 7.39 (dd, J = 8.4, 3.2 Hz, 1H), 7.28 (d, J = 8.0 Hz, 1H), 7.24-6.15 (m, 1H), 6.86-6.78 (m, 1H), 6.78 - 6.29 (m, 3H), 3.91 - 3.77 (m, 6H), 3.04 - 2.78 (m, 4H), 2.54 - 2.46 (m, 1H), 2.29 - 2.15 (m, 2H), 2.09 - 2.0 (m, 2H), 1.15 - 1.03 (m, 1H), 0.69 - 0.60 (m, 1H), 0.53 - 0.42 (m, 1H), 0.39 - 0.31 (m, 1H), 0.24 - 0.16 (m, 1H).
Example 267:
Synthetic Route:
[1109] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 267-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 267 (12 mg, yield: 33%) as a white solid. MS (ESI, m/z): 606.9 [M+H]+.
[1110] 1H NMR (400 MHz, CDCl3) δ 8.75 - 8.71 (m, 1H), 8.32 (s, 1H), 7.79 (d, J = 8.0 Hz, 1H), 7.44 (s, 1H), 7.36 (d, J= 9.2 Hz, 1H), 7.28 (d, J= 9.2 Hz, 1H), 7.23 - 7.16 (m, 1H), 7.08 (dd, J= 8.0, 2.4 Hz, 1H), 6.72 - 6.35 (m, 3H), 3.91 - 2.78 (m, 6H), 3.02 - 2.78 (m, 4H), 2.54 - 2.47 (m, 1H), 2.28 - 2.14 (m, 2H), 2.08 - 1.98 (m, 2H), 1.14 - 1.04 (m, 1H), 0.69 - 0.59 (m, 1H), 0.51 - 0.42 (m, 1H), 0.38 - 0.31 (m, 1H), 0.24 - 0.15 (m, 1H).
Example 268:
Synthetic Route:
[1112] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 268-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 268 (27 mg, yield: 45%) as a white solid. MS (ESI, m/z): 602.9 [M+H]+.
[1113] 1H NMR (400 MHz, CDCl3) δ 8.35 - 8.27 (m, 2H), 7.83 (d, J = 8.4 Hz, 1H), 7.43 (s, 1H), 7.30 (d, J = 8.4 Hz, 1H), 7.29 - 7.26 (m, 1H), 7.23 - 7.16 (m, 1H), 6.72 - 6.38 (m, 4H), 3.90 - 3.76 (m, 9H), 3.01 - 2.79 (m, 4H), 2.54 - 2.46 (m, 1H), 2.29 - 2.13 (m, 2H), 2.08 - 2.00 (m, 2H), 1.15 - 1.04 (m, 1H), 0.69 - 0.59 (m, 1H), 0.51 - 0.42 (m, 1H), 0.39 - 0.30 (m, 1H), 0.24 - 0.15 (m, 1H).
Example 269:
Synthetic Route:
[1115] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 269-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 269 (66 mg, yield: 79%) as a white solid. MS (ESI, m/z): 567.3 [M+H]+.
[1116] 1H NMR (400 MHz, CDCl3) δ 7.84 (s, 1H), 7.65 (d, J = 8.0 Hz, 1H), 7.54 (s, 1H), 7.44 (s, 1H), 7.25 - 7.22 (m, 1H), 7.22 - 7.16 (m, 1H), 7.13 (d, J = 7.6 Hz, 1H), 6.95 (d, J = 7.6 Hz, 1H), 6.72 - 6.34 (m, 3H), 3.94 - 3.77 (m, 6H), 3.02 - 3.80 (m, 4H), 2.55 - 2.45 (m, 1H), 2.37 (s, 3H), 2.31 (s, 3H), 2.27 - 2.10 (m, 2H), 2.08 - 1.97 (m, 2H), 1.15 - 1.02 (m, 1H), 0.71 - 0.58 (m, 1H), 0.51 - 0.42 (m, 1H), 0.39 - 0.31 (m, 1H), 0.23 - 0.15 (m, 1H).
Example 270:
Synthetic Route:
[1118] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 270-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 270 (43 mg, yield: 59%) as a white solid. MS (ESI, m/z): 591.1 [M+H]+.
[1119] 1H NMR (400 MHz, CDCl3) δ 8.63 - 8.57 (m, 1H), 8.00 - 7.95 (m, 1H), 7.64 (d, J = 8.0 Hz, 1H), 7.46 (s, 1H), 7.30 - 7.25 (m, 1H), 7.25 - 7.18 (m, 1H), 7.13 - 7.04 (m, 2H), 6.74 - 6.35 (m, 3H), 3.91 - 3.77 (m, 6H), 3.11 - 2.79 (m, 4H), 2.58 - 2.45 (m, 1H), 2.36 - 2.14 (m, 2H), 2.12 - 2.02 (m, 2H), 1.17 - 1.03 (m, 1H), 0.72 - 0.59 (m, 1H), 0.54 - 0.42 (m, 1H), 0.40 - 0.31 (m, 1H), 0.27 - 0.15 (m, 1H).
Example 271:
Synthetic Route:
[1121] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 271-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 271 (34 mg, yield: 55%) as a white solid. MS (ESI, m/z): 635.1 [M+H]+.
[1122] 1H NMR (400 MHz, CDCl3) δ 8.52 - 8.46 (m, 1H), 8.37 (s, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.69 - 7.52 (m, 1H), 7.46 (s, 1H), 7.33 - 7.18 (m, 2H), 6.81 - 6.75 (m, 1H), 6.72 - 6.36 (m, 3H), 3.96 - 3.78 (m, 6H), 3.04 - 2.78 (m, 4H), 2.56 - 2.46 (m, 1H), 2.28 - 2.12 (m, 2H), 2.09 - 1.99 (m, 2H), 1.14 - 1.05 (m, 1H), 0.69 - 0.60 (m 1H), 0.51 - 0.42 (m, 1H), 0.39 - 0.31 (m, 1H), 0.24 - 0.15 (m, 1H).
Example 272:
Synthetic Route:
[1124] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 272-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 272 (86 mg, yield: 87%) as a white solid. MS (ESI, m/z): 583.3 [M+H]+.
[1125] 1H NMR (400 MHz, CDCl3) δ 8.46 (s, 1H), 8.37 (s, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.42 (s, 1H), 7.25 (d, J = 6.4 Hz, 1H), 7.22 - 7.16 (m, 1H), 6.89 (d, J = 6.4 Hz, 1H), 6.83 (d, J = 8.0 Hz, 1H), 6.72 - 6.36 (m, 3H), 3.95 - 3.76 (m, 9H), 3.04 - 2.78 (m, 4H), 2.54 - 2.46 (m, 1H), 2.35 (s, 3H), 2.28 - 2.12 (m, 2H), 2.08 - 1.98 (m, 2H), 1.14 - 1.05 (m, 1H), 0.68 - 0.59 (m, 1H), 0.51 - 0.42 (m, 1H), 0.38 - 0.30 (m, 1H), 0.23 - 0.16 (m, 1H).
Example 273:
Synthetic Route:
[1127] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 273-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 273 (15 mg, yield: 45%) as a white solid. MS (ESI, m/z): 631.1 [M+H]+.
[1128] 1H NMR (400 MHz, CDCl3) δ 8.42 (s, 1H), 8.27 (s, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.52 - 7.40 (m, 2H), 7.29 - 7.25 (m, 1H), 7.22 - 7.16 (m, 1H), 6.85 (d, J = 8.0 Hz, 1H), 6.67 - 6.37 (m, 3H), 3.89 - 3.77 (m, 6H), 3.01 - 2.79 (m, 4H), 2.55 - 2.46 (m, 1H), 2.38 (s, 3H), 2.27 - 2.13 (m, 2H), 2.09 - 1.98 (m, 2H), 1.15 - 1.04 (m, 1H), 0.70 - 0.59 (m, 1H), 0.53 - 0.44 (m, 1H), 0.38 - 0.30 (m, 1H), 0.24 - 0.15 (m, 1H).
Example 274:
Synthetic Route:
[1130] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 274-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 274 (3 mg, yield: 8%) as a white solid. MS (ESI, m/z): 632.2 [M+H]+.
[1131] 1H NMR (400 MHz, CDCl3) δ 7.80 - 7.75 (m, 1H), 7.54 - 7.49 (m, 2H), 7.36 (d, J = 8.4 Hz, 1H), 7.31 (s, 1H), 7.24 - 7.18 (m, 1H), 7.13 (d, J= 8.4 Hz, 1H), 6.61 - 6.57 (m, 1H), 6.53 - 6.50 (m, 1H), 6.49 - 6.44 (m, 1H), 4.15 (s, 3H), 3.91 - 3.80 (m, 4H), 3.79 - 3.70 (m, 2H), 2.88 - 2.77 (m, 2H), 2.77 - 2.70 (m, 2H), 2.50 - 2.43 (m, 1H), 2.05 - 1.99 (m, 2H), 1.46 - 1.37 (m, 2H), 1.11 - 1.04 (m, 1H), 0.66 - 0.64 (m, 1H), 0.49 - 0.45 (m, 1H), 0.37 - 0.33 (m, 1H), 0.21 - 0.17 (m, 1H).
Example 275:
Synthetic Route:
[1133] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 275-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 275 (5 mg, yield: 11%) as a white solid. MS (ESI, m/z): 640.9 [M+H]+.
[1134] 1H NMR (400 MHz, CDCl3) δ 9.04 (s, 1H), 8.45 (s, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.60 (d, J= 8.4 Hz, 1H), 7.49 (s, 1H), 7.39 (d, J= 8.4 Hz, 1H), 7.33 (d, J= 8.0 Hz, 1H), 7.26 - 7.19 (m, 1H), 6.68 - 6.62 (m, 1H), 6.57 (s, 1H), 6.47 (d, J = 8.0 Hz, 1H), 3.88 - 3.84 (m, 6H), 3.03 - 2.84 (m, 4H), 2.59 - 2.50 (m, 1H), 2.27 - 2.18 (m, 2H), 2.09 - 2.05 (m, 2H), 1.16 - 1.10 (m, 1H), 0.72 - 0.64 (m, 1H), 0.56 - 0.47 (m, 1H), 0.43 - 0.35 (m, 1H), 0.27 - 0.21 (m, 1H).
Example 276:
Synthetic Route:
[1136] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 276-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 276 (1 mg, yield: 4%) as a white solid. MS (ESI, m/z): 618.2 [M+H]+.
[1137] 1H NMR (400 MHz, CDCl3) δ 9.64 - 9.60 (m, 1H), 8.47 (s, 1H), 8.01 (dd, J = 8.8, 2.4 Hz, 1H), 7.83 (d, J = 8.4 Hz, 1H), 7.65 (d, J = 8.8 Hz, 1H), 7.50 (s, 1H), 7.34 (d, J = 8.4 Hz, 1H), 7.25 - 7.20 (m, 1H), 6.65 (d, J = 8.4 Hz, 1H), 6.58 (s, 1H), 6.51 - 6.45 (m, 1H), 3.92 - 3.83 (m, 6H), 3.01 - 2.87 (m, 4H), 2.60 - 2.54 (m, 1H), 2.27 - 2.19 (m, 2H), 2.10 - 2.05 (m, 2H), 1.19 - 1.09 (m, 1H), 0.73 - 0.61 (m, 1H), 0.55 - 0.48 (m, 1H), 0.45 - 0.35 (m, 1H), 0.28 - 0.21 (m, 1H).
Example 277:
Synthetic Route:
[1139] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 277-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 277 (5 mg, yield: 12%) as a white solid. MS (ESI, m/z): 657.2 [M+H]+.
[1140] 1H NMR (400 MHz, CDCl3) δ 8.72 - 8.68 (m, 1H), 8.41 (s, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.51 - 7.45 (m, 2H), 7.34 - 7.29 (m, 1H), 7.26 - 7.19 (m, 1H), 7.01 (d, J = 8.8 Hz, 1H), 6.65 (d, J = 8.4 Hz, 1H), 6.58 (s, 1H), 6.47 (d, J = 8.4 Hz, 1H), 3.87 -3.84 (m, 6H), 3.00 - 2.85 (m, 4H), 2.58 - 2.50 (m, 1H), 2.27 -2.18 (m, 2H), 2.08 - 2.05 (m, 2H), 1.16 - 1.06 (m, 1H), 0.72 - 0.63 (m, 1H), 0.53 - 0.47 (m, 1H), 0.41 - 0.35 (m, 1H), 0.26 - 0.20 (m, 1H).
Example 278:
Synthetic Route:
[1142] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 278-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 278 (9 mg, yield: 30%) as a white solid. MS (ESI, m/z): 601.2 [M+H]+.
[1143] 1H NMR (400 MHz, CDCl3) δ 8.52 - 8.49 (m, 1H), 8.33 (s, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.46 (s, 1H), 7.37 (d, J = 8.4 Hz, 1H), 7.33 - 7.27 (m, 1H), 7.25 - 7.19 (m, 1H), 6.97 (dd, J = 8.4, 2.4 Hz, 1H), 6.65 (dd, J = 8.4, 2.4 Hz, 1H), 6.59 - 6.55 (m, 1H), 6.46 (dd, J = 8.4, 2.4 Hz, 1H), 3.91 - 3.79 (m, 6H), 3.01 - 2.85 (m, 4H), 2.73 (q, J = 7.6 Hz, 2H), 2.57 - 2.51 (m, 1H), 2.27 - 2.19 (m, 2H), 2.12 - 2.02 (m, 2H), 1.30 (t, J = 7.2 Hz, 3H), 1.17 - 1.08 (m, 1H), 0.72 - 0.62 (m, 1H), 0.53 - 0.46 (m, 1H), 0.41 - 0.35 (m, 1H), 0.26 - 0.20 (m, 1H).
Example 279:
Synthetic Route:
[1145] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 279-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 279 (8 mg, yield: 18%) as a white solid. MS (ESI, m/z): 613.2 [M+H]+.
[1146] 1H NMR (400 MHz, CDCl3) δ 8.43 (s, 1H), 8.31 (s, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.46 (s, 1H), 7.35 - 7.29 (m, 2H), 7.26 - 7.19 (m, 1H), 6.81 (d, J = 8.4 Hz, 1H), 6.67 - 6.62 (m, 1H), 6.57 (s, 1H), 6.47 (d, J = 8.4 Hz, 1H), 3.91 - 3.83 (m, 6H), 3.00 - 2.83 (m, 4H), 2.58 - 2.51 (m, 1H), 2.30 - 2.16 (m, 2H), 2.11 - 2.03 (m, 2H), 2.02 - 1.94 (m, 1H), 1.17 - 1.08 (m, 1H), 1.06 - 0.99 (m, 2H), 0.81 - 0.75 (m, 2H), 0.72 - 0.61 (m, 1H), 0.53 - 0.46 (m, 1H), 0.44 - 0.34 (m, 1H), 0.25 - 0.20 (m, 1H).
Example 280:
Synthetic Route:
[1148] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 280-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 280 (6 mg, yield: 14%) as a white solid. MS (ESI, m/z): 649.2 [M+H]+.
[1149] 1H NMR (400 MHz, CDCl3) δ 8.95 - 8.92 (m, 1H), 8.40 (s, 1H), 7.89 (d, J= 8.4 Hz, 1H), 7.68 (d, J = 7.6 Hz, 2H), 7.56 - 7.45 (m, 4H), 7.45 - 7.32 (m, 3H), 7.25 - 7.19 (m, 1H), 6.64 (d, J = 8.4 Hz, 1H), 6.56 (s, 1H), 6.46 (d, J = 9.6 Hz, 1H), 3.91 - 3.80 (m, 6H), 3.01 - 2.85 (m, 4H), 2.59 - 2.49 (m, 1H), 2.27 - 2.19 (m, 2H), 2.09 - 2.05 (m, 2H), 1.16 - 1.08 (m, 1H), 0.73 - 0.64 (m, 1H), 0.55 - 0.45 (m, 1H), 0.44 - 0.35 (m, 1H), 0.30 - 0.19 (m, 1H).
Example 281:
Synthetic Route:
[1151] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 281-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 281 (5 mg, yield: 8%) as a white solid. MS (ESI, m/z): 655.2 [M+H]+.
[1152] 1H NMR (400 MHz, CDCl3) δ 7.46 (d, J = 8.0 Hz, 1H), 7.41 (d, J = 8.0 Hz, 1H), 7.32 - 7.29 (m, 1H), 7.26 - 7.19 (m, 1H), 7.19 - 7.12 (m, 2H), 6.97 (s, 1H), 6.69 - 6.61 (m, 1H), 6.61 - 6.56 (m, 1H), 6.56 - 6.48 (m, 1H), 4.13 (s, 3H), 3.83 (s, 3H), 3.73 - 3.64 (m, 2H), 3.60 - 3.45 (m, 1H), 2.85 - 2.70 (m, 4H), 2.52 - 2.46 (m, 1H), 2.29 - 2.20 (m, 2H), 2.10 - 2.04 (m, 2H), 1.11 - 1.02 (m, 1H), 0.68 - 0.59 (m, 1H), 0.50 - 0.42 (m, 1H), 0.36 - 0.31 (m, 1H), 0.24 - 0.16 (m, 1H).
Example 282:
Synthetic Route:
[1154] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 282-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 282 (8 mg, yield: 22%) as a white solid. MS (ESI, m/z): 598.2 [M+H]+.
[1155] 1H NMR (400 MHz, CDCl3) δ 9.09 (d, J = 2.0 Hz, 1H), 8.44 (s, 1H), 7.81 (d, J = 8.4 Hz, 1H), 7.59 (d, J = 8.4 Hz, 1H), 7.49 (s, 1H), 7.41 (dd, J = 8.4, 2.0 Hz, 1H), 7.33 (d, J = 7.6 Hz, 1H), 7.26 - 7.20 (m, 1H), 6.65 (d, J = 7.2 Hz, 1H), 6.58 (s, 1H), 6.48 (d, J = 8.4 Hz, 1H), 3.88 - 3.80 (m, 6H), 3.01 - 2.88 (m, 4H), 2.58 - 2.49 (m, 1H), 2.27 - 2.18 (m, 2H), 2.08 - 2.05 (m, 2H), 1.15 - 1.10 (m, 1H), 0.71 - 0.64 (m, 1H), 0.54 - 0.46 (m, 1H), 0.43 - 0.36 (m, 1H), 0.26 - 0.20 (m, 1H).
Example 283:
Synthetic Route:
[1157] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 283-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 283 (8 mg, yield: 28%) as a white solid. MS (ESI, m/z): 615.2 [M+H]+.
[1158] 1H NMR (400 MHz, CDCl3) δ 9.27 (s, 1H), 8.40 (s, 1H), 7.85 (d, J = 8.4 Hz, 1H), 7.79 - 7.69 (m, 1H), 7.58 (d, J = 8.4 Hz, 1H), 7.49 (s, 1H), 7.39 - 7.31 (m, 1H), 7.27 - 7.19 (m, 1H), 6.65 (d, J = 8.4 Hz, 1H), 6.58 (s, 1H), 6.47 (d, J = 8.4 Hz, 1H), 3.97 - 3.73 (m, 6H), 3.05 - 2.82 (m, 4H), 2.71 (s, 3H), 2.57 - 2.51(m, 1H), 2.30 - 2.17 (m, 2H), 2.13 - 2.03 (m, 2H), 1.17 - 1.07 (m, 1H), 0.71 - 0.65 (m, 1H), 0.54 - 0.47 (m, 1H), 0.42 - 0.36 (m, 1H), 0.32 - 0.19 (m, 1H).
Example 284:
Synthetic Route:
[1160] Compound 284-1 (400 mg, 1.93 mmol), piperidine (493 mg, 5.80 mmol), sodium tert-butoxide (557 mg, 5.80 mmol), and 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (241 mg, 0.39 mmol) were added to toluene (15 mL) and stirred. Tris(dibenzylideneacetone)dipalladium (177 mg, 0.19 mmol) was added, and the reaction was carried out at 100°C under a nitrogen atmosphere for 16 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product. The resulting crude product was then purified by normal-phase column chromatography (petroleum ether: ethyl acetate = 8:2) to obtain another crude product. Another crude product was then purified by reverse-phase column chromatography (water (0.1% formic acid): acetonitrile = 7:3) to obtain compound 284-2 (45 mg, yield: 11%) as a yellow solid. MS (ESI, m/z): 211.2 [M+H]+.
[1161] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 284-2 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 284 (5 mg, yield: 14%) as a white solid. MS (ESI, m/z): 656.2 [M+H]+.
[1162] 1H NMR (400 MHz, CDCl3) δ 8.34 - 8.30 (m, 1H), 8.29 (s, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.45 (s, 1H), 7.28 - 7.20 (m, 3H), 6.69 (dd, J = 8.8, 2.8 Hz, 1H), 6.64 (d, J= 8.4 Hz, 1H), 6.58 - 6.55 (m, 1H), 6.48 - 6.43 (m, 1H), 3.90 - 3.84 (m, 6H), 3.29 - 3.22 (m, 4H), 3.02 - 2.84 (m, 4H), 2.56 - 2.50 (m, 1H), 2.28 - 2.17 (m, 2H), 2.12 - 2.01 (m, 2H), 1.77- 1.72 (m, 4H), 1.64 - 1.60 (m, 2H), 1.15 - 1.05 (m, 1H), 0.71 - 0.62 (m, 1H), 0.52 - 0.46 (m, 1H), 0.40 - 0.35 (m, 1H), 0.26 - 0.20 (m, 1H).
Example 285:
Synthetic Route:
[1164] Referring to the synthetic route of compound 284, piperidine was replaced with morpholine to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 285 (6 mg, yield: 17%) as a white solid. MS (ESI, m/z): 658.2 [M+H]+.
[1165] 1H NMR (400 MHz, CDCl3) δ 8.37 - 8.34 (m, 1H), 8.33 (s, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.46 (s, 1H), 7.30 - 7.34 (m, 2H), 7.25 - 7.19 (m, 1H), 6.67 - 6.64 (m, 2H), 6.59 - 6.54 (m, 1H), 6.49 - 6.44 (m, 1H), 3.95 - 3.82 (m, 10H), 3.29 - 3.22 (m, 4H), 3.03 - 2.86 (m, 4H), 2.57 - 2.51 (m, 1H), 2.27 - 2.17 (m, 2H), 2.10 - 2.01 (m, 2H), 1.18 - 1.08 (m, 1H), 0.71 - 0.62 (m, 1H), 0.53 - 0.46 (m, 1H), 0.41 - 0.35 (m, 1H), 0.28 - 0.19 (m, 1H).
Example 286:
Synthetic Route:
[1167] Referring to the synthetic route of compound 284, compound 284-2 was replaced with compound 286-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 286 (6 mg, yield: 17%) as a white solid. MS (ESI, m/z): 630.2 [M+H]+.
[1168] 1H NMR (400 MHz, CDCl3) δ 8.50 - 8.44 (m, 1H), 8.33 (s, 1H), 7.87 - 7.70 (m, 2H), 7.53 (s, 1H), 7.44 (s, 1H), 7.37 (d, J = 8.0 Hz, 1H), 7.30 - 7.25 (m, 1H), 7.23 - 7.17 (m, 1H), 6.76 - 6.36 (m, 3H), 3.87 - 3.73 (m, 6H), 3.00 - 2.77 (m, 4H), 2.55 - 2.43 (m, 1H), 2.30 - 2.20 (m, 2H), 2.17 (s, 3H), 2.09 - 1.98 (m, 2H), 1.14 - 1.04 (m, 1H), 0.68 - 0.59 (m, 1H), 0.51 - 0.41 (m, 1H), 0.39 - 0.30 (m, 1H), 0.25 - 0.15 (m, 1H).
Example 287:
Synthetic Route:
[1170] To a reaction tube, compound 234 (36 mg, 65 µmol), compound 287-1 (10 mg, 78 µmol), HATU (30 mg, 78 µmol), and DCM (2 mL) were added. The reaction was carried out at room temperature overnight. After the reaction mixture was rotary evaporated to dryness to remove the solvent, the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 287 (31 mg, yield: 69%) as a white solid. MS (ESI, m/z): 663.9 [M+H]+.
[1171] 1H NMR (400 MHz, CDCl3) δ 8.29 (m, 2H), 7.61 (d, J = 8.0 Hz, 1H), 7.51 (s, 1H), 7.42 - 7.26 (m, 4H), 7.17 - 7.15 (m, 4H), 6.91 (d, J = 8.0 Hz, 1H), 4.07 - 3.97 (m, 1H), 3.85 (s, 3H), 3.82 - 3.63 (m, 4H), 3.48 - 3.32 (m, 2H), 3.16 - 2.47 (m, 7H), 2.31 - 2.16 (m, 2H), 1.13 - 1.01 (m, 1H), 0.62 - 0.52 (m, 1H), 0.42 - 0.26 (m, 2H), 0.19 - 0.09 (m, 1H).
Example 288:
Synthetic Route:
[1173] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 288-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 288 (5 mg, yield: 43%) as a white solid. MS (ESI, m/z): 592.9 [M+H]+.
[1174] 1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 8.0 Hz, 1H), 7.48 (s, 1H), 7.29 - 7.19 (m, 3H), 6.88 - 6.81 (m, 2H), 6.76 - 6.40 (m, 3H), 3.87 - 3.78 (m, 6H), 2.98 - 2.83 (m, 4H), 2.56 - 2.49 (m, 1H), 2.30 - 2.17 (m, 2H), 2.10 - 2.04 (m, 2H), 1.16 - 1.06 (m, 1H), 0.72 - 0.63 (m, 1H), 0.55 - 0.46 (m, 1H), 0.42 - 0.35 (m, 1H), 0.25 - 0.19 (m, 1H).
Example 289:
Synthetic Route:
[1176] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 289-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 289 (3 mg, yield: 8%) as a white solid. MS (ESI, m/z): 546.2 [M+H]+.
[1177] 1H NMR (400 MHz, CDCl3) δ 8.49 (s, 1H), 7.85 -7.70 (m, 1H), 7.55 - 7.30 (m, 2H), 7.22 - 7.07 (m, 2H), 6.57 (d, J = 6.2 Hz, 1H), 6.50 (s, 1H), 6.42 (d, J = 7.6 Hz, 1H), 3.84 - 3.62 (m, 6H), 3.00 - 2.60 (m, 4H), 2.50 - 2.35 (m, 1H), 2.04 - 1.86 (m, 4H), 1.10 - 1.00 (m, 1H), 0.67 - 0.55 (m, 1H), 0.50 - 0.37 (m, 1H), 0.35 - 0.22 (m, 1H), 0.20 - 0.10 (m, 1H).
Example 290:
Synthetic Route:
[1179] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 290-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 290 (3 mg, yield: 13%) as a white solid. MS (ESI, m/z): 546.2 [M+H]+.
[1180] 1H NMR (400 MHz, CD3OD) δ 8.46 (s, 1H), 7.77 (d, J = 8.0 Hz, 1H), 7.50 (d, J = 3.8 Hz, 1H), 7.47 (s, 1H), 7.30 (dd, J = 8.2, 1.2 Hz, 1H), 7.20 - 7.11 (m, 2H), 6.64 (dd, J = 8.2, 2.0 Hz, 1H), 6.58 - 6.54 (m, 1H), 6.44 (dd, J = 8.0, 2.2 Hz, 1H), 3.87 - 3.74 (m, 5H), 3.72 - 3.60 (m, 1H), 2.93 - 2.70 (m, 4H), 2.53 - 2.44 (m, 1H), 2.24 - 2.10 (m, 2H), 2.10 - 2.04 (m, 2H), 1.16 - 1.07 (m, 1H), 0.65 - 0.56 (m, 1H), 0.45 - 0.32 (m, 2H), 0.21 - 0.13 (m, 1H).
Example 291:
Synthetic Route:
[1182] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 291-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 291 (2 mg, yield: 2%) as a white solid. MS (ESI, m/z): 529.2 [M+H]+.
[1183] 1H NMR (400 MHz, CDCl3) δ 7.66 (d, J = 7.6 Hz, 1H), 7.49 (s, 1H), 7.25 - 7.17 (m, 2H), 6.85 (s, 2H), 6.62 (d, J = 7.8 Hz, 1H), 6.54 (s, 1H), 6.44 (d, J= 8.4 Hz, 1H), 3.86 - 3.80 (m, 5H), 3.71 - 3.62 (m, 1H), 2.92 - 2.85 (m, 3H), 2.78 - 2.70 (m, 1H), 2.58 - 2.50 (m, 1H), 2.24 -2.10 (m, 2H), 2.04 - 1.94 (m, 2H), 1.17 - 1.10 (m, 1H), 0.67 - 0.57 (m, 1H), 0.54 - 0.45 (m, 1H), 0.38 - 0.29 (m, 1H), 0.24 - 0.14 (m, 1H).
Example 292:
Synthetic Route:
[1185] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 292-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 292 (2 mg, yield: 11%) as a white solid. MS (ESI, m/z): 530.2 [M+H]+.
[1186] 1H NMR (400 MHz, MeOD) δ 7.66 - 7.52 (m, 2H), 7.35 (s, 1H), 7.18 (d, J = 8.2 Hz, 1H), 7.08 - 7.02 (m, 2H), 6.53 (dd, J = 8.2, 2.0 Hz, 1H), 6.48 - 6.44 (m, 1H), 6.34 (dd, J = 8.0, 2.2 Hz, 1H), 3.75 - 3.65 (m, 5H), 3.57 - 3.49 (m, 1H), 2.78 - 2.70 (m, 2H), 2.65 - 2.50 (m, 2H), 2.43 - 2.35 (m, 1H), 2.10 - 2.00 (m, 2H), 1.97 - 1.91 (m, 2H), 1.02 - 0.95(m, 1H), 0.52 - 0.46 (m, 1H), 0.31 - 0.25 (m, 2H), 0.07 - 0.02 (m, 1H).
Example 293:
Synthetic Route:
[1188] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 293-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 293 (2 mg, yield: 6%) as a white solid. MS (ESI, m/z): 547.2 [M+H]+.
[1189] 1H NMR (400 MHz, CD3OD) δ 8.34 (s, 1H), 7.82 (d, J = 7.8 Hz, 1H), 7.44 (s, 1H), 7.28 (d, J = 7.0 Hz, 1H), 7.16 - 7.09 (m, 1H), 6.62 (dd, J = 8.0, 2.0 Hz, 1H), 6.57 - 6.53 (m, 1H), 6.42 (dd, J = 8.2, 2.0 Hz, 1H), 4.58 (s, 1H), 3.87 - 3.70 (m, 6H), 2.94 - 2.81 (m, 2H), 2.69 (dd, J = 13.8, 6.6 Hz, 1H), 2.63 - 2.57 (m, 1H), 2.52 - 2.45 (m, 1H), 2.21 - 2.07 (m, 2H), 2.07 - 1.98 (m, 2H), 1.10 - 1.03 (m, 1H), 0.61 - 0.53 (m, 1H), 0.40 - 0.31 (m, 2H), 0.15 - 0.08 (m, 1H).
Example 294:
Synthetic Route:
[1191] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 294-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 294 (2 mg, yield: 10%) as a white solid. MS (ESI, m/z): 530.2 [M+H]+.
[1192] 1H NMR (400 MHz, DMSO-d6) δ 8.16 (s, 1H), 7.55 - 7.46 (m, 1H), 7.30 (s, 1H), 7.15 - 7.06 (m, 2H), 6.59 (dd, J = 8.0, 2.0 Hz, 1H), 6.52 - 6.49 (m, 1H), 6.35 (dd, J = 8.0, 2.0 Hz, 1H), 3.89 - 3.80 (m, 2H), 3.73 (s, 3H), 3.30 - 3.16 (m, 1H), 2.88 - 2.79 (m, 2H), 2.55 - 2.35 (m, 3H), 2.02 - 1.95 (m, 2H), 1.95 - 1.88 (m, 2H), 0.87 - 0.84 (m, 1H), 0.45 - 0.41 (m, 1H), 0.29 - 0.21 (m, 2H), 0.10 - 0.07 (m, 1H).
Example 295:
Synthetic Route:
[1194] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 295-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 295 (4 mg, yield: 10%) as a white solid. MS (ESI, m/z): 531.2 [M+H]+.
[1195] 1H NMR (400 MHz, MeOD) δ 7.73 (d, J = 8.0 Hz, 1H), 7.45 (s, 1H), 7.29 (d, J = 8.2 Hz, 1H), 7.17 - 7.11 (m, 1H), 6.62 (dd, J = 8.0, 1.8 Hz, 1H), 6.58 - 6.53 (m, 1H), 6.43 (dd, J = 8.2, 2.0 Hz, 1H), 3.86 - 3.73 (m, 5H), 3.68 - 3.55 (m, 1H), 2.87 - 2.80 (m, 2H), 2.71 - 2.47 (m, 3H), 2.20 - 1.99 (m, 2H), 2.08 - 2.00 (m, 2H), 1.12 - 1.02 (m, 1H), 0.61 - 0.54 (m, 1H), 0.42 - 0.33 (m, 2H), 0.15 - 0.08 (m, 1H).
Example 296:
Synthetic Route:
[1197] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 296-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 296 (3 mg, yield: 21%) as a white solid. MS (ESI, m/z): 580.2 [M+H]+.
[1198] 1H NMR (400 MHz, MeOD) δ 8.11 (dd, J = 7.8, 1.6 Hz, 1H), 8.07 (d, J= 8.0 Hz, 1H), 7.55 (s, 1H), 7.47 - 7.42 (m, 1H), 7.39 (dd, J = 8.2, 1.2 Hz, 1H), 7.19 - 7.13 (m, 1H), 7.08 - 7.02 (m, 2H), 6.66 (dd, J= 8.0, 2.0 Hz, 1H), 6.61 - 6.57 (m, 1H), 6.46 (dd, J = 7.8, 2.2 Hz, 1H), 4.02 - 3.93 (m, 1H), 3.92 - 3.84 (m, 2H), 3.78 (s, 3H), 2.95 - 2.90 (m, 2H), 2.89 - 2.62 (m, 2H), 2.55 - 2.47 (m, 1H), 2.27 - 2.18 (m, 2H), 2.18 - 2.12 (m, 2H), 1.18 - 1.10 (m, 1H), 0.66 - 0.59 (m, 1H), 0.46 - 0.33 (m, 2H), 0.22 - 0.15 (m, 1H).
Example 297:
Synthetic Route:
[1200] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 297-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 297 (5 mg, yield: 21%) as a white solid. MS (ESI, m/z): 596.2 [M+H]+.
[1201] 1H NMR (400 MHz, MeOD) δ 7.89 (d, J = 8.0 Hz, 1H), 7.86 - 7.78 (m, 1H), 7.75 (d, J = 7.8 Hz, 1H), 7.50 - 7.43 (m, 2H), 7.37 - 7.30 (m, 2H), 7.18 - 7.12 (m, 1H), 6.64 (dd, J = 8.2, 2.0 Hz, 1H), 6.60 - 6.56 (m, 1H), 6.44 (dd, J= 8.0, 2.0 Hz, 1H), 3.86 - 3.79 (m, 2H), 3.79 - 3.70 (m, 4H), 2.97 - 2.84 (m, 2H), 2.76 - 2.59 (m, 2H), 2.55 - 2.48 (m, 1H), 2.24 - 2.12 (m, 2H), 2.11 - 2.04 (m, 2H), 1.14 - 1.04 (m, 1H), 0.64 - 0.55 (m, 1H), 0.42 - 0.35 (m, 2H), 0.17 - 0.11 (m, 1H).
Example 298:
Synthetic Route:
[1203] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 298-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 298 (10 mg, yield: 14%) as a white solid. MS (ESI, m/z): 602.2 [M+H]+.
[1204] 1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 8.4 Hz, 1H), 7.50 (s, 1H), 7.30 - 7.21 (m, 2H), 7.06 (d, J = 8.4 Hz, 1H), 6.88 - 6.42 (m, 3H), 4.02 - 3.66 (m, 6H), 3.20 - 2.95 (m, 2H), 2.91 - 2.82 (m, 1H), 2.79 - 2.66 (m, 1H), 2.60 - 2.50 (m, 1H), 2.46 - 2.22 (m, 2H), 2.17 - 2.02 (m, 2H), 1.41 (s, 9H), 1.18 - 1.06 (m, 1H), 0.68 - 0.55 (m, 1H), 0.52 - 0.42 (m, 1H), 0.42 - 0.31 (m, 1H), 0.16 - 0.13 (m, 1H).
Example 299:
Synthetic Route:
[1206] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 299-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 299 (12 mg, yield: 19%) as a white solid. MS (ESI, m/z): 602.2 [M+H]+.
[1207] 1H NMR (400 MHz, CDCl3) δ 7.67 (d, J = 8.4 Hz, 1H), 7.51 (s, 1H), 7.27 - 7.18 (m, 2H), 7.15 (s, 1H), 6.68 - 6.62 (m, 1H), 6.59 - 6.55 (m, 1H), 6.50 - 6.44 (m, 1H), 3.92 - 3.73 (m, 6H), 3.01 - 2.75 (m, 4H), 2.62 - 2.52 (m, 1H), 2.29 - 2.15 (m, 2H), 2.13 - 2.03 (m, 2H), 1.44 (s, 9H), 1.21 - 1.10 (m, 1H), 0.73 - 0.60 (m, 1H), 0.54 -0.48 (m, 1H), 0.39 -0.34 (m, 1H), 0.26 - 0.17 (m, 1H).
Example 300:
Synthetic Route:
[1209] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 300-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 299 (13 mg, yield: 18%) as a white solid. MS (ESI, m/z): 586.2 [M+H]+.
[1210] 1H NMR (400 MHz, CDCl3) δ 8.84 (s, 1H), 7.67 (d, J = 8.4 Hz, 1H), 7.47 (s, 1H), 7.29 - 7.20 (m, 2H), 6.87 (s, 1H), 6.65 (d, J = 8.4 Hz, 1H), 6.60 - 6.55 (m, 1H), 6.47 (dd, J = 8.4, 2.4 Hz, 1H), 3.84 - 3.74 (m, 6H), 3.02 - 2.79 (m, 4H), 2.58 - 2.48 (m, 1H), 2.25 - 2.17 (m, 2H), 2.08 - 2.02 (m, 2H), 1.41 (s, 9H), 1.18 - 1.08 (m, 1H), 0.71 - 0.64 (m, 1H), 0.54 - 0.46 (m, 1H), 0.43 - 0.33 (m, 1H), 0.25 - 0.16 (m, 1H).
Example 301:
Synthetic Route:
[1212] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 301-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 301 (36 mg, yield: 53%) as a white solid. MS (ESI, m/z): 586.2 [M+H]+.
[1213] 1H NMR (400 MHz, CDCl3) δ 8.54 (s, 1H), 7.63 (d, J = 8.4 Hz, 1H), 7.47 (s, 1H), 7.32 (d, J = 8.4 Hz, 1H), 7.25 - 7.19 (m, 1H), 6.64 (dd, J = 8.4, 2.4 Hz, 1H), 6.58 - 6.54 (m, 1H), 6.50 (s, 1H), 6.47 (dd, J = 8.4, 2.4 Hz, 1H), 3.90 - 3.69 (m, 6H), 2.99 - 2.81 (m, 4H), 2.56 - 2.47 (m, 1H), 2.26 - 2.13 (m, 2H), 2.04 - 2.00 (m, 2H), 1.39 (s, 9H), 1.16 - 1.06 (m, 1H), 0.71- 0.64 (m, 1H), 0.56 - 0.43 (m, 1H), 0.40 - 0.34 (m, 1H), 0.24 - 0.18 (m, 1H).
Example 302:
Synthetic Route:
[1215] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 302-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 302 (1 mg, yield: 9%) as a white solid. MS (ESI, m/z): 619.2 [M+H]+.
[1216] 1H NMR (400 MHz, cd3od) δ 7.88 - 7.78 (m, 3H), 7.53 (s, 1H), 7.48 - 7.41 (m, 2H), 7.41 - 7.34 (m, 2H), 7.23 - 7.17 (m, 1H), 6.78 (s, 1H), 6.68 (dd, J = 8.2, 2.0 Hz, 1H), 6.63 - 6.59 (m, 1H), 6.49 (dd, J = 8.1, 2.1 Hz, 1H), 3.94 (s, 3H), 3.91 - 3.83 (m, 2H), 3.82 (s, 3H), 3.73 - 3.62 (m, 1H), 2.95 - 2.73 (m, 4H), 2.60 - 2.51 (m, 1H), 2.28 - 2.06 (m, 4H), 1.21 - 1.14 (m, 1H), 0.71 - 0.61 (m, 1H), 0.50 - 0.37 (m, 2H), 0.27 - 0.17 (m, 1H).
Example 303:
Synthetic Route:
[1218] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 303-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 303 (1 mg, yield: 7%) as a white solid. MS (ESI, m/z): 619.2 [M+H]+.
[1219] 1H NMR (400 MHz, CD3OD) δ 7.57 - 7.50 (m, 4H), 7.48 - 7.45 (m, 1H), 7.42 - 7.40 (m, 2H), 7.19 - 7.13 (m, 2H), 6.61 (dd, J = 8.2, 2.2 Hz, 1H), 6.55 - 6.53 (m, 1H), 6.45 - 6.43 (m, 2H), 3.79 - 3.70 (m, 5H), 3.35 - 3.33 (m, 1H), 2.76 - 2.72 (m, 2H), 2.71 - 2.63 (m, 2H), 2.49 - 2.43 (m, 1H), 2.34 (s, 3H), 2.08 - 2.04 (m, 2H), 1.90 - 1.87 (m, 2H), 1.12 - 1.03 (m, 1H), 0.62 - 0.57 (m, 1H), 0.39 - 0.30 (m, 2H), 0.15 - 0.12 (m, 1H).
Example 304:
Synthetic Route:
[1221] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 304-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 304 (2 mg, yield: 10%) as a white solid. MS (ESI, m/z): 543.2 [M+H]+.
[1222] 1H NMR (400 MHz, DMSO-d6) δ 12.27 (s, 1H), 8.26-8.18 (m, 1H), 7.42 (s, 1H), 7.19 - 7.10 (m, 2H), 7.01 (d, J = 2.0 Hz, 1H), 6.80 (d, J = 2.0 Hz, 1H), 6.62 - 6.57 (m, 1H), 6.53 - 6.49 (m, 1H), 6.39 - 6.34 (m, 1H), 4.41 - 4.23 (m, 1H), 3.94 - 3.84 (m, 2H), 3.73 (s, 3H), 3.57 (s, 3H), 2.85 - 2.77 (m, 2H), 2.72 - 2.66 (m, 2H), 2.39 - 2.33 (m, 1H), 2.02 - 1.90 (m, 4H), 1.11 - 1.03 (m, 1H), 0.55 - 0.48 (m, 1H), 0.34 - 0.24 (m, 2H), 0.18 - 0.11 (m, 1H).
Example 305:
Synthetic Route:
[1224] Referring to the synthetic route of compound 49, compound 49-2 was replaced with compound 98-1 to synthesize compound 305-3. Then, referring to the synthetic route of compound 235, compound 126-3 was replaced with compound 305-3, and compound 235-2 was replaced with compound 305-5. The synthesis was carried out, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 305 (10 mg, yield: 62%) as a white solid. MS (ESI, m/z): 537.2 [M+H]+.
[1225] 1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 8.0 Hz, 1H), 7.39 (s, 1H), 7.21 (d, J = 8.0 Hz, 1H), 7.03 - 6.88 (m, 1H), 6.61 - 6.51 (m, 1H), 6.45 - 6.43 (m, 1H), 5.84 (s, 1H), 3.80 (s, 3H), 3.77 - 3.69 (m, 1H), 3.62 - 3.52 (m, 2H), 2.95 - 2.76 (m, 4H), 2.55 - 2.43 (m, 1H), 2.32 - 2.16 (m, 2H), 2.07 - 1.96 (m, 2H), 1.52 (s, 9H), 1.15 - 1.02 (m, 1H), 0.70 - 0.58 (m, 1H), 0.51 - 0.40 (m, 1H), 0.39 - 0.28 (m, 1H), 0.24 - 0.14 (m, 1H).
Example 306:
Synthetic Route:
[1227] Referring to the synthetic route of compound 305, compound 305-5 was replaced with compound 306-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 306 (15 mg, yield: 72%) as a white solid. MS (ESI, m/z): 551.2 [M+H]+.
[1228] 1H NMR (400 MHz, CDCl3) δ 7.55 (d, J = 8.0 Hz, 1H), 7.41 (s, 1H), 7.24 (d, J = 8.0 Hz, 1H), 6.96 (dd, J = 12.0, 8.8 Hz, 1H), 6.60 - 6.51 (m, 1H), 6.48 - 6.40 (m, 1H), 6.05 (t, J = 6.4 Hz, 1H), 3.81 - 3.74 (m, 4H), 3.63 - 3.54 (m, 2H), 3.33 (d, J = 6.4 Hz, 2H), 2.97 - 2.78 (m, 4H), 2.55 - 2.44 (m, 1H), 2.32 - 2.17 (m, 2H), 2.05 - 1.97 (m, 2H), 1.15 - 1.07 (m, 1H), 1.05 (s, 9H), 0.69 - 0.60 (m, 1H), 0.52 - 0.41 (m, 1H), 0.39 - 0.30 (m, 1H), 0.25 - 0.14 (m, 1H).
Example 307:
Synthetic Route:
[1230] Referring to the synthetic route of compound 305, compound 305-5 was replaced with compound 307-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 307 (15 mg, yield: 63%) as a white solid. MS (ESI, m/z): 565.2 [M+H]+.
[1231] 1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 8.0 Hz, 1H), 7.40 (s, 1H), 7.21 (d, J = 8.0 Hz, 1H), 6.96 (dd, J = 12.0, 8.8 Hz, 1H), 6.60 - 6.52 (m, 1H), 6.47 - 6.39 (m, 1H), 5.92 (t, J = 6.0 Hz, 1H), 3.81 - 3.73 (m, 4H), 3.63 - 3.48 (m, 4H), 2.90 - 2.78 (m, 4H), 2.56 - 2.46 (m, 1H), 2.28 - 2.19 (m, 2H), 2.05 - 1.96 (m, 2H), 1.63 - 1.54 (m, 2H), 1.16 - 1.05 (m, 1H), 1.01 (s, 9H), 0.69 - 0.59 (m, 1H), 0.51 - 0.41 (m, 1H), 0.39 - 0.29 (m, 1H), 0.25 - 0.14 (m, 1H).
Example 308:
Synthetic Route:
[1233] Referring to the synthetic route of compound 305, compound 305-5 was replaced with compound 308-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 308 (24 mg, yield: 60%) as a white solid. MS (ESI, m/z): 521.2 [M+H]+.
[1234] 1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 8.0 Hz, 1H), 7.38 (s, 1H), 7.18 (d, J = 6.8 Hz, 1H), 6.99 - 6.90 (m, 1H), 6.57 - 6.51 (m, 1H), 6.45 - 6.37 (m, 1H), 6.15 - 6.06 (m, 1H), 3.90 - 3.73 (m, 4H), 3.61 - 3.51 (m, 2H), 2.95 - 2.75 (m, 5H), 2.53 - 2.43 (m, 1H), 2.29 - 2.14 (m, 2H), 2.07 - 1.95 (m, 2H), 1.13 - 1.00 (m, 1H), 0.95 - 0.85 (m, 2H), 0.69 - 0.58 (m, 3H), 0.48 - 0.40 (m, 1H), 0.36 - 0.36 (m, 1H), 0.23 - 0.12 (m, 1H).
Example 309:
Synthetic Route:
[1236] Referring to the synthetic route of compound 305, compound 305-5 was replaced with compound 309-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 309 (17 mg, yield: 38%) as a white solid. MS (ESI, m/z): 535.2 [M+H]+.
[1237] 1H NMR (400 MHz, CDCl3) δ 7.55 (d, J = 8.0 Hz, 1H), 7.39 (s, 1H), 7.21 (d, J = 8.0 Hz, 1H), 6.98 - 6.89 (m, 1H), 6.55 - 6.51 (m, 1H), 6.45 - 6.38 (m, 1H), 6.12 - 6.03 (m, 1H), 3.82 - 3.70 (m, 4H), 3.61 - 3.51 (m, 2H), 3.41 - 3.31 (m, 2H), 2.90 - 2.80 (m, 4H), 2.54 - 2.43 (m, 1H), 2.30 - 2.16 (m, 2H), 2.05 - 1.94 (m, 2H), 1.17 - 1.01 (m, 2H), 0.68 - 0.53 (m, 3H), 0.51 - 0.39 (m, 1H), 0.39 - 0.27 (m, 3H), 0.22 - 0.09 (m, 1H).
Example 310:
Synthetic Route:
[1239] Referring to the synthetic route of compound 305, compound 305-5 was replaced with compound 310-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 310 (20 mg, yield: 38%) as a white solid. MS (ESI, m/z): 537.2 [M+H]+.
[1240] 1H NMR (400 MHz, CDCl3) δ 7.56 - 7.46 (m, 1H), 7.39 (s, 1H), 7.21 (d, J = 8.0 Hz, 1H), 6.98 - 6.90 (m, 1H), 6.57 - 6.51 (m, 1H), 6.45 - 6.38 (m, 1H), 6.07 - 5.98 (m, 1H), 3.83 - 3.70 (m, 4H), 3.62 - 3.51 (m, 2H), 3.38 - 3.29 (m, 2H), 2.93 - 2.76 (m, 4H), 2.52 - 2.42 (m, 1H), 2.28 - 2.15 (m, 2H), 2.05 - 1.88 (m, 3H), 1.13 - 0.97 (d, J= 5.6 Hz, 7H), 0.66 - 0.57 (m, 1H), 0.49 - 0.40 (m, 1H), 0.37 - 0.29 (m, 1H), 0.22 - 0.14 (m, 1H).
Example 311:
Synthetic Route:
[1242] Referring to the synthetic route of compound 305, compound 305-5 was replaced with compound 311-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 311 (26 mg, yield: 57%) as a white solid. MS (ESI, m/z): 523.2 [M+H]+.
[1243] 1H NMR (400 MHz, CDCl3) δ 7.33 (s, 1H), 7.30 (d, J = 7.6 Hz, 1H), 7.12 (d,J = 7.6 Hz, 1H), 6.98 - 6.89 (m, 1H), 6.56 - 6.49 (m, 1H), 6.45 - 6.38 (m, 1H), 3.77 (s, 3H), 3.70 - 3.31 (m, 4H), 3.22 - 2.91 (m, 4H), 2.85 - 2.75 (m, 4H), 2.50 - 2.43 (m, 1H), 2.25 - 2.11 (m, 2H), 2.08 - 1.98 (m, 2H), 1.28 - 1.02 (m, 4H), 0.64 - 0.57 (m, 1H), 0.47 - 0.38 (m, 1H), 0.36 - 0.28 (m, 1H), 0.21 - 0.14 (m, 1H).
Example 312:
Synthetic Route:
[1246] Referring to the synthetic route of compound 305, compound 305-5 was replaced with compound 312-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 312 (17 mg, yield: 55%) as a white solid. MS (ESI, m/z): 509.2 [M+H]+.
[1247] 1H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 8.0 Hz, 1H), 7.38 (s, 1H), 7.19 (d, J = 8.0 Hz, 1H), 7.02 - 6.85 (m, 1H), 6.57 - 6.51 (m, 1H), 6.45 - 6.38 (m, 1H), 5.98 - 5.91 (m, 1H), 3.83 - 3.70 (m, 4H), 3.60 - 3.47 (m, 4H), 2.91 - 2.73 (m, 4H), 2.53 - 2.42 (m, 1H), 2.27 - 2.15 (m, 2H), 2.03 - 1.95 (m, 2H), 1.31 - 1.25 (m, 3H), 1.12 - 1.02 (m, 1H), 0.66 - 0.57 (m, 1H), 0.46 - 0.40 (m, 1H), 0.37 - 0.27 (m, 1H), 0.21 - 0.13 (m, 1H).
Example 313:
Synthetic Route:
[1249] Referring to the synthetic route of compound 305, compound 305-5 was replaced with compound 313-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 313 (13 mg, yield: 54%) as a white solid. MS (ESI, m/z): 523.2 [M+H]+.
[1250] 1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 6.8 Hz, 1H), 7.38 (s, 1H), 7.19 (d, J = 6.8 Hz, 1H), 7.01 - 6.87 (m, 1H), 6.58 - 6.50 (m, 1H), 6.46 - 6.36 (m, 1H), 6.00 (s, 1H), 3.80 - 3.70 (m, 4H), 3.61 - 3.40 (m, 4H), 2.92 - 2.71 (m, 4H), 2.53 - 2.41 (m, 1H), 2.26 - 2.13 (m, 2H), 2.03 - 1.92 (m, 2H), 1.73 - 1.61 (m, 2H), 1.11 - 0.97 (m, 4H), 0.65 - 0.56 (m, 1H), 0.47 - 0.39 (m, 1H), 0.35 - 0.27 (m, 1H), 0.20 - 0.11 (m, 1H).
Example 314:
Synthetic Route:
[1252] Referring to the synthetic route of compound 305, compound 305-5 was replaced with compound 314-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 314 (10 mg, yield: 66%) as a white solid. MS (ESI, m/z): 557.2 [M+H]+.
[1253] 1H NMR (400 MHz, CDCl3) δ 7.72 (s, 1H), 7.67 - 7.60 (m, 3H), 7.49 - 7.36 (m, 3H), 7.29 - 7.24 (m, 1H), 7.22 - 7.15 (m, 1H), 7.02 - 6.91 (m, 1H), 6.61 - 6.51 (m, 1H), 6.45 - 6.43 (m, 1H), 3.85 - 3.72 (m, 4H), 3.63 - 3.54 (m, 2H), 3.00 - 2.74 (m, 4H), 2.59 - 2.43 (m, 1H), 2.34 - 2.18 (m, 2H), 2.08 - 1.98 (m, 2H), 1.17 - 1.04 (m, 1H), 0.72 - 0.60 (m, 1H), 0.54 - 0.43 (m, 1H), 0.41 - 0.31 (m, 1H), 0.27 - 0.15 (m, 1H).
Example 315:
Synthetic Route:
[1255] Referring to the synthetic route of compound 305, compound 305-5 was replaced with compound 315-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 315 (10 mg, yield: 62%) as a white solid. MS (ESI, m/z): 613.2 [M+H]+.
[1256] 1H NMR (400 MHz, CDCl3) δ 7.69 - 7.60 (m, 2H), 7.55 (d, J = 8.4 Hz, 2H), 7.46 - 7.41 (m, 3H), 7.28 - 7.24 (m, 1H), 7.02 - 6.89 (m, 1H), 6.61 - 6.51 (m, 1H), 6.47 - 6.39 (m, 1H), 3.83 - 3.74 (m, 4H), 3.63 - 3.55 (m, 2H), 2.95 - 2.80 (m, 4H), 2.57 - 2.44 (m, 1H), 2.35 - 2.17 (m, 2H), 2.07 - 1.99 (m, 2H), 1.35 (s, 9H), 1.18 - 1.03 (m, 1H), 0.72 - 0.61 (m, 1H), 0.54 - 0.44 (m, 1H), 0.42 - 0.32 (m, 1H), 0.27 - 0.17 (m, 1H).
Example 316:
Synthetic Route:
[1258] Referring to the synthetic route of compound 305, compound 305-5 was replaced with compound 316-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 316 (15 mg, yield: 66%) as a white solid. MS (ESI, m/z): 613.2 [M+H]+.
[1259] 1H NMR (400 MHz, CDCl3) δ 7.72 - 7.62 (m, 2H), 7.57 (s, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.45 (s, 1H), 7.38 - 7.32 (m, 1H), 7.27 - 7.20 (m, 2H), 7.01 - 6.90 (m, 1H), 6.60 - 6.50 (m, 1H), 6.49 - 6.38 (m, 1H), 3.79 (m, 4H), 3.63 - 3.54 (m, 2H), 3.00 - 2.75 (m, 4H), 2.57 - 2.44 (m, 1H), 2.37 - 2.17 (m, 2H), 2.07 - 1.98 (m, 2H), 1.37 (s, 9H), 1.18 - 1.04 (m, 1H), 0.72 - 0.61 (m, 1H), 0.53 - 0.43 (m, 1H), 0.42 - 0.32 (m, 1H), 0.27 - 0.17 (m, 1H).
Example 317:
Synthetic Route:
[1261] Referring to the synthetic route of compound 305, compound 305-5 was replaced with compound 317-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 317 (6 mg, yield: 11%) as a white solid. MS (ESI, m/z): 575.2 [M+H]+.
[1262] 1H NMR (400 MHz, DMSO-d6) δ 10.26 (s, 1H), 8.45 (s, 1H), 7.78 - 7.76 (m, 2H), 7.59 (d, J = 7.6 Hz, 1H), 7.55 (s, 1H), 7.26 (d, J = 8.4 Hz, 1H), 7.21 - 7.17 (m, 2H), 7.09 - 7.00 (m, 1H), 6.59 - 6.57 (m, 1H), 6.51 - 6.48 (m, 1H), 3.73 (s, 3H), 3.60 - 3.30 (m, 3H), 2.81 - 2.76 (m, 2H), 2.69 - 2.67 (m, 2H), 2.44 - 2.40 (m, 1H), 2.04 - 1.99 (m, 4H), 1.12 - 1.05 (m, 1H), 0.55 - 0.49 (m, 1H), 0.32 - 0.27 (m, 2H), 0.17 - 0.12 (m, 1H).
Example 318:
Synthetic Route:
[1264] Referring to the synthetic route of compound 305, compound 305-5 was replaced with compound 318-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 318 (4 mg, yield: 7%) as a white solid. MS (ESI, m/z): 575.2 [M+H]+.
[1265] 1H NMR (400 MHz, CDCl3) δ 7.75 (s, 1H), 7.66 - 7.58 (m, 2H), 7.46 (s, 1H), 7.40 - 7.31 (m, 1H), 7.30 - 7.24 (m, 2H), 6.98 - 6.93 (m, 1H), 6.89 - 6.87 (m, 1H), 6.57 - 6.55 (m, 1H), 6.46 -6.42 (m, 1H), 3.79 (s, 3H), 3.77 - 3.73 (m, 1H), 3.61 - 3.58 (m, 2H), 2.89 - 2.82 (m, 4H), 2.58 - 2.48 (m, 1H), 2.32 - 2.21 (m, 2H), 2.05 - 2.00 (m, 2H), 1.14 - 1.08 (m, 1H), 0.70 - 0.63 (m, 1H), 0.52 - 0.45 (m, 1H), 0.39 - 0.33 (m, 1H), 0.24 - 0.18 (m, 1H).
Example 319:
Synthetic Route:
[1267] Referring to the synthetic route of compound 305, compound 305-5 was replaced with compound 319-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 319 (9 mg, yield: 42%) as a white solid. MS (ESI, m/z): 571.2 [M+H]+.
[1268] 1H NMR (400 MHz, CDCl3) δ 8.03 - 7.95 (m, 1H), 7.64 - 7.59 (m, 1H), 7.57 (s, 1H), 7.46 (s, 1H), 7.31 - 7.23 (m, 2H), 7.18 - 7.08 (m, 1H), 6.99 - 6.88 (m, 1H), 6.57 - 6.49 (m, 1H), 6.46 - 6.37 (m, 1H), 3.84 - 3.69 (m, 4H), 3.61 - 3.50 (m, 2H), 2.90 - 2.74 (m, 4H), 2.56 - 2.46 (m, 1H), 2.36 (s, 3H), 2.33 - 2.16 (m, 2H), 2.07 - 1.98 (m, 2H), 1.15 - 1.06 (m, 1H), 0.68 - 0.61 (m, 1H), 0.49 - 0.42 (m, 1H), 0.39 - 0.30 (m, 1H), 0.23 - 0.17 (m, 1H).
Example 320:
Synthetic Route:
[1270] Referring to the synthetic route of compound 305, compound 305-5 was replaced with compound 320-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 320 (18 mg, yield: 70%) as a white solid. MS (ESI, m/z): 571.2 [M+H]+.
[1271] 1H NMR (400 MHz, CDCl3) δ 7.68 - 7.57 (m, 1H), 7.51 (s, 1H), 7.43 (s, 1H), 7.40 - 7.33 (m, 1H), 7.31 - 7.20 (m, 2H), 7.02 - 6.90 (m, 2H), 6.61 - 6.51 (m, 1H), 6.48 - 6.39 (m, 1H), 3.84 - 3.70 (m, 4H), 3.62 - 3.49 (m, 2H), 2.96 - 2.76 (m, 4H), 2.52 - 2.45 (m, 1H), 2.39 (s, 3H), 2.34 - 2.19 (m, 2H), 2.07 - 1.97 (m, 2H), 1.13 - 1.00 (m, 1H), 0.70 - 0.57 (m, 1H), 0.51 - 0.41 (m, 1H), 0.38 - 0.28 (m, 1H), 0.23 - 0.14 (m, 1H).
Example 321:
Synthetic Route:
[1273] Referring to the synthetic route of compound 305, compound 305-5 was replaced with compound 321-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 321 (23 mg, yield: 74%) as a white solid. MS (ESI, m/z): 571.2 [M+H]+.
[1274] 1H NMR (400 MHz, CDCl3) δ 7.68 - 7.57 (m, 2H), 7.50 (d, J= 7.6 Hz, 2H), 7.43 (s, 1H), 7.27 - 7.22 (m, 1H), 7.19 (d, J = 7.6 Hz, 2H), 7.00 - 6.88 (m, 1H), 6.64 - 6.51 (m, 1H), 6.47-6.39 (m, 1H), 3.83 - 3.71 (m, 4H), 3.62 - 3.49 (m, 2H), 2.96-2.73 (m, 4H), 2.54 - 2.44 (m, 1H), 2.35 (s, 3H), 2.31 - 2.15 (m, 2H), 2.06 - 1.95 (m, 2H), 1.12 - 1.01 (m, 1H), 0.68 - 0.56 (m, 1H), 0.52 - 0.40 (m, 1H), 0.38 - 0.29 (m, 1H), 0.22 - 0.14 (m, 1H).
Example 322:
Synthetic Route:
[1276] Referring to the synthetic route of compound 305, compound 98-1 was replaced with compound 141-2, and compound 305-5 was replaced with compound 322-5. The synthesis was carried out, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 322 (1 mg, yield: 4%) as a white solid. MS (ESI, m/z): 591.2 [M+H]+.
[1277] 1H NMR (400 MHz, CDCl3) δ 8.63 (d, J = 8.0 Hz, 1H), 8.35 (s, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.50 - 7.43 (m, 2H), 7.38 - 7.34 (m, 1H), 7.33 - 7.27 (m, 1H), 7.13 - 7.08 (m, 1H), 7.03 - 6.99 (m, 1H), 6.69 - 6.61 (m, 2H), 3.90 (s, 3H), 3.88 - 3.80 (m, 1H), 3.66 - 3.54 (m, 2H), 2.98 - 2.84 (m, 4H), 2.59 - 2.49 (m, 1H), 2.34 - 2.27 (m, 2H), 2.08 - 2.04 (m, 2H), 1.15 - 1.11 (m, 1H), 0.73 - 0.62 (m, 1H), 0.53 - 0.44 (m, 1H), 0.43 - 0.33 (m, 1H), 0.28 - 0.19 (m, 1H).
Example 323:
Synthetic Route:
[1279] Referring to the synthetic route of compound 322, compound 322-5 was replaced with compound 323-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 323 (3 mg, yield: 9%) as a white solid. MS (ESI, m/z): 575.2 [M+H]+.
[1280] 1H NMR (400 MHz, CDCl3) δ 8.55 - 8.47 (m, 1H), 8.01 (s, 1H), 7.71 (d, J= 8.0 Hz, 1H), 7.47 (s, 1H), 7.34 - 7.29 (m, 1H), 7.24 -7.08 (m, 3H), 7.04 - 6.98 (m, 1H), 6.68 - 6.63 (m, 2H), 3.90 (s, 3H), 3.87 - 3.77 (m, 1H), 3.66 - 2.55 (m, 2H), 3.05 - 2.80 (m, 4H), 2.59 - 2.49 (m, 1H), 2.34 - 2.25 (m, 2H), 2.11 - 2.01 (m, 2H), 1.15 - 1.08 (m, 1H), 0.72 - 0.60 (m, 1H), 0.53 - 0.42 (m, 1H), 0.41 - 0.31 (m, 1H), 0.24 - 0.18 (m, 1H).
Example 324:
Synthetic Route:
[1282] Referring to the synthetic route of compound 322, compound 322-5 was replaced with compound 324-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 324 (2 mg, yield: 6%) as a white solid. MS (ESI, m/z): 571.2 [M+H]+.
[1283] 1H NMR (400 MHz, CDCl3) δ 8.02 - 7.95 (m, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.60 (s, 1H), 7.47 (s, 1H), 7.33 - 7.22 (m, 3H), 7.19 - 7.11 (m, 1H), 7.02 -6.97 (m, 1H), 6.68 - 6.62 (m, 2H), 3.90 (s, 3H), 3.87 - 3.74 (m, 1H), 3.63 - 3.52 (m, 2H), 2.97 - 2.80 (m, 4H), 2.54 - 2.49 (m, 1H), 2.38 (s, 3H), 2.29 -2.24 (m, 2H), 2.08 - 1.97 (m, 2H), 1.15 - 1.08 (m, 1H), 0.73 - 0.60 (m, 1H), 0.51 - 0.45 (m, 1H), 0.40 - 0.32 (m, 1H), 0.24 - 0.18 (m, 1H).
Example 325:
Synthetic Route:
[1285] Referring to the synthetic route of compound 322, compound 322-5 was replaced with compound 325-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 325 (10 mg, yield: 51%) as a white solid. MS (ESI, m/z): 571.2 [M+H]+.
[1286] 1H NMR (400 MHz, CDCl3) δ 7.69 - 7.60 (m, 2H), 7.54 - 7.49 (m, 1H), 7.48 - 7.42 (m, 1H), 7.41 - 7.34 (m, 1H), 7.27 - 7.24 (m, 2H), 7.04 - 6.95 (m, 2H), 6.69 - 6.60 (m, 2H), 3.89 (s, 3H), 3.85 - 3.74 (m, 1H), 3.62 - 3.49 (m, 2H), 2.93 - 2.81 (m, 4H), 2.56 - 2.45 (m, 1H), 2.40 (s, 3H), 2.30 - 2.20 (m, 2H), 2.07 - 1.99 (m, 2H), 1.15 - 1.07 (m, 1H), 0.70 - 0.60 (m, 1H), 0.51 - 0.43 (m, 1H), 0.40 - 0.30 (m, 1H), 0.26 - 0.17 (m, 1H).
Example 326:
Synthetic Route:
[1288] Compound 82-1 (45 mg, 0.11 mmol), compound 326-1 (100 mg, 0.61 mmol), and sodium cyanoborohydride (17 mg, 0.27 mmol) were dissolved in a mixture of methanol (10 mL) and acetic acid (1 mL). The reaction was carried out at 60°C for 48 hours. After the reaction was completed, saturated sodium bicarbonate solution (20 mL) was added, and the mixture was extracted with ethyl acetate (20 mL × 3). The combined organic phases were concentrated and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 326-2 (40 mg, yield: 66%). MS (ESI, m/z): 554.3 [M+H]+.
[1289] Referring to the synthetic route of compound 323, compound 322-4 was replaced with compound 326-2 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 326 (1 mg, yield: 0.5%) as a white solid. MS (ESI, m/z): 599.3 [M+H]+.
[1290] 1H NMR (400 MHz, MeOD) δ 7.77 - 7.70 (m, 1H), 7.58 (d, J = 8.2 Hz, 1H), 7.37 - 7.31 (m, 1H), 7.30 - 7.22 (m, 2H), 7.15 (d, J = 8.2 Hz, 1H), 7.10 - 6.99 (m, 4H), 6.97 - 6.92 (m, 1H), 4.50 - 4.37 (m, 1H), 3.85 - 3.74 (m, 4H), 3.60 - 3.45 (m, 1H), 3.32 - 3.22 (m, 1H), 3.00 - 2.76 (m, 2H), 2.73 - 2.54 (m, 2H), 2.37 - 2.25 (m, 1H), 2.25 - 1.96 (m, 6H), 0.99 - 0.91 (m, 1H), 0.61 (t, J = 7.2 Hz, 3H), 0.50 - 0.40 (m, 1H), 0.29 - 0.13 (m, 2H), 0.04 - -0.06 (m, 1H).
Example 327:
Synthetic Route:
[1292] Referring to the synthetic route of compound 326, compound 326-1 was replaced with compound 327-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 327 (4 mg, yield: 14%) as a white solid. MS (ESI, m/z): 639.2 [M+H]+.
[1293] 1H NMR (400 MHz, MeOD) δ 7.95 - 7.90 (m, 1H), 7.70 - 7.69 (m, 2H), 7.44 - 7.33 (m, 3H), 7.38 - 7.32 (m, 1H), 7.29 (d, J = 8.0 Hz, 1H), 7.27 - 7.17 (m, 3H), 4.24 - 4.15 (m, 1H), 3.56 - 3.45 (m, 2H), 3.09 - 3.00 (m, 1H), 2.87 - 2.70 (m, 2H), 2.52 - 2.27 (m, 3H), 2.25 - 1.92 (m, 4H), 1.51 (d, J = 6.8 Hz, 3H), 1.18 - 1.04 (m, 1H), 0.69 - 0.53 (m, 1H), 0.46 - 0.29 (m, 2H), 0.20 - 0.14 (m, 1H).
Example 328:
Synthetic Route:
[1295] Referring to the synthetic route of compound 326, compound 326-1 was replaced with compound 328-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 328 (2 mg, yield: 3%) as a white solid. MS (ESI, m/z): 585.2 [M+H]+.
[1296] 1H NMR (400 MHz, MeOD) δ 7.94 - 7.88 (m, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.48 - 7.41 (m, 3H), 7.33 (d, J = 8.2 Hz, 1H), 7.28 - 7.18 (m, 3H), 7.12 (d, J = 8.0 Hz, 1H), 7.10 - 7.04 (m, 1H), 4.79 - 4.65 (m, 1H), 3.93 (s, 3H), 3.80 - 3.61 (m, 2H), 3.43 - 3.31 (m, 1H), 3.02 - 2.82 (m, 2H), 2.78 - 2.60 (m, 2H), 2.55 - 2.43 (m, 1H), 2.38 - 2.08 (m, 4H), 1.68 (d, J = 6.8 Hz, 3H), 1.16 - 1.04 (m, 1H), 0.64 - 0.56 (m, 1H), 0.42 - 0.32 (m, 2H), 0.18 - 0.08 (m, 1H).
Example 329:
Synthetic Route:
[1298] Referring to the synthetic route of compound 60, compound 329-4 was synthesized. Then, referring to the synthetic route of compound 328 and replacing compound 82-1 with compound 329-5, the synthesis was carried out, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 329 (20 mg, yield: 41%) as a white solid. MS (ESI, m/z): 557.2 [M+H]+.
[1299] 1H NMR (400 MHz, CDCl3) δ 8.33 - 8.24 (m, 1H), 8.18 - 8.03 (m, 1H), 7.41 - 7.32 (m, 2H), 7.19 - 7.00 (m, 6H), 6.94 - 6.88 (m, 1H), 6.82 - 6.75 (m, 1H), 4.37 - 4.25 (m, 1H), 3.88 - 3.81 (m, 1H), 3.75 (s, 3H), 3.69 - 3.63 (m, 1H), 3.59 - 3.53 (m, 1H), 3.43 - 3.33 (m, 2H), 2.61 - 2.44 (m, 3H), 1.24 - 1.16 (m, 3H), 0.93 - 0.79 (m, 1H), 0.48 - 0.34 (m, 1H), 0.33 - 0.20 (m, 2H) 0.10 - 0.00 (m, 1H).
Example 330:
Synthetic Route:
[1301] Referring to the synthetic route of compound 49, compound 11-1 was replaced with compound 210-1 to synthesize compound 330-4. Then, referring to the synthetic route of compound 319, compound 305-4 was replaced with compound 330-4 to carry out the synthesis, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 330 (24 mg, yield: 54%) as a white solid. MS (ESI, m/z): 567.2 [M+H]+.
[1302] 1H NMR (400 MHz, CDCl3) δ 8.04 - 7.94 (m, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.61 (s, 1H), 7.47 (s, 1H), 7.33 - 7.25 (m, 3H), 7.17 - 7.13 (m, 1H), 6.74 (d, J = 8.4 Hz, 1H), 6.64 (d, J = 2.4 Hz, 1H), 6.45 (dd, J = 8.4, 2.4 Hz, 1H), 5.92 (s, 2H), 3.78 - 3.73 (m, 1H), 3.64 - 3.56 (m, 2H), 3.05 - 2.69 (m, 4H), 2.55 - 2.47 (m, 1H), 2.37 (s, 3H), 2.29 - 2.13 (m, 2H), 2.08 - 1.98 (m, 2H), 1.27- 1.06 (m, 1H), 0.69 - 0.62 (m, 1H), 0.51- 0.45 (m, 1H), 0.39 - 0.33 (m, 1H), 0.24 - 0.18 (m, 1H).
Example 331:
Synthetic Route:
[1304] Referring to the synthetic route of compound 330, compound 319-1 was replaced with compound 323-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 331 (15 mg, yield: 54%) as a white solid. MS (ESI, m/z): 571.2 [M+H]+.
[1305] 1H NMR (400 MHz, CDCl3) δ 8.52 - 8.44 (m, 1H), 8.01 (s, 1H), 7.70 (d, J = 8.0 Hz, 1H), 7.46 (s, 1H), 7.33 - 7.27 (m, 1H), 7.24 - 7.11 (m, 3H), 6.75 (d, J = 8.8 Hz, 1H), 6.70 - 6.61 (m, 1H), 6.54 - 6.42 (m, 1H), 5.92 (s, 2H), 3.84 - 3.74 (m, 1H), 3.68 - 3.56 (m, 2H), 2.97 - 2.81 (m, 4H), 2.57 - 2.47 (m, 1H), 2.33 - 2.17 (m, 2H), 2.11 - 1.99 (m, 2H), 1.15 - 1.06 (m, 1H), 0.69 - 0.59 (m, 1H), 0.53 - 0.43 (m, 1H), 0.40 - 0.31 (m, 1H), 0.28 - 0.16 (m, 1H).
Example 332:
Synthetic Route:
[1307] Referring to the synthetic route of compound 330, compound 319-1 was replaced with compound 265-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 332 (22 mg, yield: 62%) as a white solid. MS (ESI, m/z): 601.2 [M+H]+.
[1308] 1H NMR (400 MHz, CDCl3) δ 8.48 (s, 1H), 8.33 (s, 1H), 7.86 (d, J = 8.0 Hz, 1H), 7.48 (s, 1H), 7.36 - 7.29 (m, 2H), 6.97 - 6.91 (m, 1H), 6.77 (d, J = 8.4 Hz, 1H), 6.67 (s, 1H), 6.52 - 6.45 (m, 1H), 5.95 (s, 2H), 3.89 - 3.75 (m, 1H), 3.70 - 3.58 (m, 2H), 2.95 - 2.81 (m, 4H), 2.60 - 2.51 (m, 1H), 2.43 (s, 3H), 2.34 - 2.21 (m, 2H), 2.10 - 2.03 (m, 2H), 1.18 - 1.08 (m, 1H), 0.73 - 0.64 (m, 1H), 0.55 - 0.46 (m, 1H), 0.44 - 0.34 (m, 1H), 0.28 - 0.18 (m, 1H).
Example 333:
Synthetic Route:
[1310] Referring to the synthetic route of compound 330, compound 319-1 was replaced with compound 266-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 333 (20 mg, yield: 71%) as a white solid. MS (ESI, m/z): 605.2 [M+H]+.
[1311] 1H NMR (400 MHz, CDCl3) δ 8.57-8.49 (m, 1H), 8.40 (s, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.48 (s, 1H), 7.42 (dd, J = 8.8, 5.6 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 6.91 - 6.81 (m, 1H), 6.77 (d, J = 8.4 Hz, 1H), 6.68-6.64 (m, 1H), 6.52 - 6.46 (m, 1H), 5.94 (s, 2H),3.86 - 3.73 (m, 1H), 3.70 - 3.60 (m, 2H), 2.97 - 2.84 (m, 4H), 2.58 - 2.49 (m, 1H), 2.31 - 2.17 (m, 2H), 2.12 - 2.03 (m, 2H), 1.16 - 1.08 (m, 1H), 0.72 - 0.64 (m, 1H), 0.55 - 0.46 (m, 1H), 0.42 - 0.33 (m, 1H), 0.28 - 0.16 (m, 1H).
Example 334:
Synthetic Route:
[1313] Referring to the synthetic route of compound 330, compound 319-1 was replaced with compound 271-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 334 (18 mg, yield: 55%) as a white solid. MS (ESI, m/z): 649.1 [M+H]+.
[1314] 1H NMR (400 MHz, CDCl3) δ 8.56 - 8.49 (m, 1H), 8.39 (s, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.58 (dd, J = 8.8, 5.6 Hz, 1H), 7.49 (s, 1H), 7.34 - 7.30 (m, 1H), 6.85 - 6.75 (m, 2H), 6.67 (d, J = 2.0 Hz, 1H), 6.51 - 6.45 (m, 1H), 5.94 (s, 2H), 3.87 - 3.74 (m, 1H), 3.69 - 3.60 (m, 2H), 2.94 - 2.83 (m, 4H), 2.58 - 2.50 (m, 1H), 2.33 - 2.18 (m, 2H), 2.12 - 2.03 (m, 2H), 1.18 - 1.07 (m, 1H), 0.71 - 0.61 (m, 1H), 0.56 - 0.45 (m, 1H), 0.43 - 0.34 (m, 1H), 0.29 - 0.18 (m, 1H).
Example 335:
Synthetic Route:
[1316] Referring to the synthetic route of compound 330, compound 319-1 was replaced with compound 275-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 335 (34 mg, yield: 83%) as a white solid. MS (ESI, m/z): 655.2 [M+H]+.
[1317] 1H NMR (400 MHz, CDCl3) δ 9.06 - 9.02 (m, 1H), 8.45 (s, 1H), 7.83 (d, J = 8.0 Hz, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.50 (s, 1H), 7.42 - 7.37 (m, 1H), 7.33 (d, J = 8.0 Hz, 1H), 6.77 (d, J = 8.4 Hz, 1H), 6.72 - 6.65 (m, 1H), 6.54 - 6.44 (m, 1H), 5.95 (s, 2H), 3.89 - 3.78 (m, 1H), 3.69 - 3.60 (m, 2H), 2.94 - 2.83 (m, 4H), 2.59 - 2.49 (m, 1H), 2.34 - 2.22 (m, 2H), 2.11 - 2.03 (m, 2H), 1.18 - 1.07 (m, 1H), 0.74 - 0.63 (m, 1H), 0.56 - 0.46 (m, 1H), 0.43 - 0.34 (m, 1H), 0.31 - 0.20 (m, 1H).
Example 336:
Synthetic Route:
[1319] Referring to the synthetic route of compound 330, compound 319-1 was replaced with compound 270-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 336 (25 mg, yield: 60%) as a white solid. MS (ESI, m/z): 655.2 [M+H]+.
[1320] 1H NMR (400 MHz, CDCl3) δ 8.66 - 8.61 (m, 1H), 8.05 - 7.99 (m, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.49 (s, 1H), 7.34 - 7.30 (m, 1H), 7.14 - 7.08 (m, 2H), 6.77 (d, J = 8.4 Hz, 1H), 6.68 (s, 1H), 6.56 - 6.45 (m, 1H), 5.95 (s, 2H), 3.84 - 3.73 (m, 1H), 3.68 - 3.59 (m, 2H), 2.97 - 2.82 (m, 4H), 2.59 - 2.48 (m, 1H), 2.32 - 2.17 (m, 2H), 2.09 - 2.02 (m, 2H), 1.17 - 1.07 (m, 1H), 0.75 - 0.63 (m, 1H), 0.54 - 0.45 (m, 1H), 0.43 - 0.34 (m, 1H), 0.27 - 0.19 (m, 1H).
Example 337:
Synthetic Route:
[1322] Referring to the synthetic route of compound 330, compound 319-1 was replaced with compound 276-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 337 (18 mg, yield: 53%) as a white solid. MS (ESI, m/z): 615.2 [M+H]+.
[1323] 1H NMR (400 MHz, CDCl3) δ 8.53 - 8.48 (m, 1H), 8.34 (s, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.48 (s, 1H), 7.37 (d, J = 8.4 Hz, 1H), 7.32 - 7.29 (m, 1H), 6.97 (dd, J = 8.4, 2.0 Hz, 1H), 6.77 (d, J = 8.4 Hz, 1H), 6.71 - 6.66 (m, 1H), 6.53 - 6.44 (m, 1H), 5.95 (s, 2H), 3.88 - 3.78 (m, 1H), 3.68 - 3.60 (m, 2H), 2.94 - 2.83 (m, 4H), 2.72 (q, J = 7.6 Hz, 2H), 2.58 - 2.50 (m, 1H), 2.33 - 2.20 (m, 2H), 2.12 - 2.02 (m, 2H), 1.30 (t, J = 7.6 Hz, 3H), 1.18 - 1.08 (m, 1H), 0.71 - 0.61 (m, 1H), 0.55 - 0.46 (m, 1H), 0.42 - 0.34 (m, 1H), 0.29 - 0.20 (m, 1H).
Example 338:
Synthetic Route:
[1325] Referring to the synthetic route of compound 305, compound 98-1 was replaced with compound 142-1 to synthesize compound 338-4. Then, referring to the synthetic route of compound 270, compound 234-1 was replaced with compound 338-4 to carry out the synthesis, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 338 (32 mg, yield: 68%) as a white solid. MS (ESI, m/z): 609.2 [M+H]+.
[1326] 1H NMR (400 MHz, CDCl3) δ 8.66 - 8.62 (m, 1H), 8.03 (d, J = 3.2 Hz, 1H), 7.69 (d, J = 8.0 Hz, 1H), 7.48 (s, 1H), 7.32 (d, J = 8.4 Hz, 1H), 7.17 - 7.08 (m, 2H), 6.99 (dd, J = 12.0, 8.8 Hz, 1H), 6.63 - 6.54 (m, 1H), 6.51 - 6.43 (m, 1H), 3.87 - 3.78 (m, 4H), 3.67 - 3.58 (m, 2H), 2.96 - 2.84 (m, 4H), 2.58 - 2.50 (m, 1H), 2.35 - 2.22 (m, 2H), 2.09 - 2.04 (m, 2H), 1.15 - 1.09 (m, 1H), 0.72 - 0.64 (m, 1H), 0.53 - 0.46 (m, 1H), 0.42 - 0.34 (m, 1H), 0.29 - 0.19 (m, 1H).
Example 339:
Synthetic Route:
[1328] Referring to the synthetic route of compound 338, compound 270-1 was replaced with compound 276-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 339 (22 mg, yield: 58%) as a white solid. MS (ESI, m/z): 619.2 [M+H]+.
[1329] 1H NMR (400 MHz, CDCl3) δ 8.54 - 6.48 (m, 1H), 8.34 (s, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.47 (s, 1H), 7.37 (d, J = 8.4 Hz, 1H), 7.32 - 7.30 (m, 1H), 7.04 - 6.94 (m, 2H), 6.59 (dd, J = 7.2, 2.8 Hz, 1H), 6.50-6.43 (m, 1H), 3.90 - 3.78 (m, 4H), 3.66 - 3.59 (m, 2H), 2.95 - 2.85 (m, 4H), 2.72 (q, J = 7.6 Hz, 2H), 2.59 - 2.49 (m, 1H), 2.36 - 2.25 (m, 2H), 2.14 - 2.03 (m, 2H), 1.31 (t, J = 7.6 Hz, 3H), 1.18 - 1.08 (m, 1H), 0.72 - 0.63 (m, 1H), 0.52 - 0.45 (m, 1H), 0.41 - 0.33 (m, 1H), 0.29 - 0.20 (m, 1H).
Example 340:
Synthetic Route:
[1331] Referring to the synthetic route of compound 338, compound 270-1 was replaced with compound 275-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 340 (17 mg, yield: 53%) as a white solid. MS (ESI, m/z): 659.2 [M+H]+.
[1332] 1H NMR (400 MHz, CDCl3) δ 9.06 - 9.03 (m, 1H), 8.46 (s, 1H), 7.84 (d, J = 8.4 Hz, 1H), 7.60 (d, J = 8.4 Hz, 1H), 7.49 (s, 1H), 7.39 (dd, J = 6.8, 2.4 Hz, 1H), 7.33 (dd, J = 8.4, 1.2 Hz, 1H), 6.99 (dd, J = 12.0, 8.8 Hz, 1H), 6.69 - 6.62 (m, 1H), 6.52 - 6.43 (m, 1H), 3.90 - 3.79 (m, 4H), 3.66 - 3.60 (m, 2H), 2.99 - 2.83 (m, 4H), 2.61 - 2.50 (m, 1H), 2.41 - 2.25 (m, 2H), 2.15 - 2.05 (m, 2H), 1.18 - 1.10 (m, 1H), 0.75 - 0.65 (m, 1H), 0.56 - 0.45 (m, 1H), 0.42 - 0.33 (m, 1H), 0.27 - 0.20 (m, 1H).
Example 341:
Synthetic Route:
[1334] Referring to the synthetic route of compound 338, compound 270-1 was replaced with compound 266-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 341 (15 mg, yield: 50%) as a white solid. MS (ESI, m/z): 609.2 [M+H]+.
[1335] 1H NMR (400 MHz, CDCl3) δ 8.54 (dd, J = 10.8, 3.2 Hz, 1H), 8.41 (s, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.49 (s, 1H), 7.42 (dd, J = 8.8, 5.6 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 6.99 (dd, J = 12.0, 8.8 Hz, 1H), 6.89-6.82 (m, 1H), 6.63-6.57 (m, 1H), 6.51-6.44 (m, 1H), 3.89 - 3.80 (m, 4H), 3.68 - 3.59 (m, 2H), 2.99 - 2.86 (m, 4H), 2.60 - 2.48 (m, 1H), 2.40 - 2.27 (m, 2H), 2.10 - 2.03 (m, 2H), 1.18 - 1.09 (m, 1H), 0.76 - 0.64 (m, 1H), 0.58 - 0.48 (m, 1H), 0.43 - 0.31 (m, 1H), 0.27 - 0.19 (m, 1H).
Example 342:
Synthetic Route:
[1337] Referring to the synthetic route of compound 338, compound 270-1 was replaced with compound 271-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 342 (15 mg, yield: 54%) as a white solid. MS (ESI, m/z): 653.1 [M+H]+.
[1338] 1H NMR (400 MHz, CDCl3) δ 8.54 (dd, J = 10.8, 3.2 Hz, 1H), 8.41 (s, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.49 (s, 1H), 7.42 (dd, J = 8.8, 5.6 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 6.99 (dd, J = 12.0, 8.8 Hz, 1H), 6.88 - 6.83 (m, 1H), 6.63 - 6.57 (m, 1H), 6.51 - 6.44 (m, 1H), 3.88 - 3.79 (m, 4H), 3.69 - 3.60 (m, 2H), 2.97 - 2.86 (m, 4H), 2.60 - 2.50 (m, 1H), 2.37 - 2.26 (m, 2H), 2.10 - 2.04 (m, 2H), 1.19 - 1.11 (m, 1H), 0.72 - 0.63 (m, 1H), 0.57 - 0.48 (m, 1H), 0.45 - 0.35 (m, 1H), 0.30 - 0.20 (m, 1H).
Example 343:
Synthetic Route:
[1340] Referring to the synthetic route of compound 338, compound 270-1 was replaced with compound 265-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 343 (17 mg, yield: 50%) as a white solid. MS (ESI, m/z): 605.1 [M+H]+.
[1341] 1H NMR (400 MHz, CDCl3) δ 8.49 (s, 1H), 8.34 (s, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.48 (s, 1H), 7.37 - 7.31 (m, 2H), 7.03 - 6.92 (m, 2H), 6.65 - 6.55 (m, 1H), 6.51 - 6.42 (m, 1H), 3.91 - 3.80 (m, 4H), 3.66 - 3.58 (m, 2H), 2.97 - 2.85 (m, 4H), 2.59 - 2.51 (m, 1H), 2.43 (s, 3H), 2.37 - 2.26 (m, 2H), 2.13 - 2.06 (m, 2H), 1.18 - 1.08 (m, 1H), 0.72 - 0.61 (m, 1H), 0.57 - 0.46 (m, 1H), 0.43 - 0.35 (m, 1H), 0.31 - 0.19 (m, 1H).
Example 344:
Synthetic Route:
[1343] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 344-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 344 (12 mg, yield: 50%) as a white solid. MS (ESI, m/z): 545.3 [M+H]+.
[1344] 1H NMR (400 MHz, DMSO-d6) δ 7.91 (d, J = 8.0 Hz, 1H), 7.51 - 7.37 (m, 2H), 7.18 (d, J = 8.0 Hz, 1H), 7.14 - 7.06 (m, 1H), 6.56 (dd, J = 8.2, 2.0 Hz, 1H), 6.51 - 6.45 (m, 1H), 6.35 (dd, J = 8.0, 2.1 Hz, 1H), 3.87 - 3.74 (m, 3H), 3.71 (s, 3H), 3.47 - 3.39 (m, 1H), 2.82 - 2.72 (m, 2H), 2.61 - 2.50 (m, 2H), 2.42 - 2.36 (m, 1H), 2.03 - 1.64 (m, 8H), 1.61 - 1.54 (m, 1H), 1.40 - 1.24 (m, 4H), 1.19 - 1.08 (m, 1H), 1.04 - 0.95 (m, 1H), 0.51 - 0.42 (m, 1H), 0.29 - 0.21 (m, 2H), 0.11 - 0.04 (m, 1H).
Example 345:
Synthetic Route:
[1346] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 345-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 345 (4 mg, yield: 8%) as a white solid. MS (ESI, m/z): 529.3 [M+H]+.
[1347] 1H NMR (400 MHz, DMSO-d6) δ 8.55 (s, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.39 (s, 1H), 7.18 (d, J = 8.2 Hz, 1H), 7.15 - 7.08 (m, 1H), 6.57 (dd, J = 8.2, 2.0 Hz, 1H), 6.52 - 6.46 (m, 1H), 6.36 (dd, J = 8.0, 2.0 Hz, 1H), 3.88 - 3.77 (m, 2H), 3.73 (s, 3H), 3.52 - 3.44 (m, 1H), 2.86 - 2.75 (m, 2H), 2.48 - 2.42 (m, 2H), 2.40 - 2.22 (m, 2H), 2.10 (s, 6H), 2.00 - 1.84 (m, 4H), 1.01 - 0.91 (m, 1H), 0.47 - 0.38 (m, 1H), 0.29 - 0.19 (m, 2H), 0.10 - 0.02 (m, 1H).
Example 346:
Synthetic Route:
[1349] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 346-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 346 (9 mg, yield: 31%) as a white solid. MS (ESI, m/z): 557.3 [M+H]+.
[1350] 1H NMR (400 MHz, DMSO-d6) δ 8.09 (d, J = 6.4 Hz, 1H), 7.52 - 7.45 (m, 2H), 7.22 (d, J = 8.4 Hz, 1H), 7.15 - 7.08 (m, 1H), 6.57 (dd, J = 8.4, 2.0 Hz, 1H), 6.52 - 6.47 (m, 1H), 6.36 (dd, J = 8.0, 2.0 Hz, 1H), 4.19 - 4.09 (m, 1H), 3.87-3.78 (m, 2H), 3.73 (s, 3H), 3.46 - 3.38 (m, 1H), 2.84 - 2.62 (m, 4H), 2.48 - 2.44 (m, 1H), 2.42 - 2.34 (m, 1H), 2.20 - 2.15 (m, 1H), 2.01 - 1.82 (m, 5H), 1.74 - 1.66 (m, 1H), 1.56 - 1.25 (m, 5H), 1.15 - 0.99 (m, 2H), 0.55 - 0.47 (m, 1H), 0.33 - 0.22 (m, 2H), 0.18 - 0.09 (m, 1H).
Example 347:
Synthetic Route:
[1352] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 347-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 347 (2 mg, yield: 5%) as a white solid. MS (ESI, m/z): 599.4 [M+H]+.
[1353] 1H NMR (400 MHz, DMSO-d6) δ 11.97 (s, 1H), 8.10 (d, J = 8.6 Hz, 1H), 7.54 - 7.46 (m, 2H), 7.24 (d, J = 8.2 Hz, 1H), 7.20 - 7.10 (m, 1H), 6.81 - 6.26 (m, 3H), 4.48 - 4.35 (m, 1H), 3.88 - 3.76 (m, 2H), 3.73 (s, 3H), 2.97 - 2.65 (m, 4H), 2.42 - 2.33 (m, 1H), 2.24 - 2.12 (m, 1H), 2.03 - 1.97 (m, 2H), 1.92 - 1.77 (m, 2H), 1.72 - 1.60 (m, 2H), 1.41 - 1.29 (m, 2H), 1.26 - 1.19 (m, 2H), 1.15 - 1.02 (m, 2H), 0.96 (s, 3H), 0.88 (s, 3H), 0.83 (s, 3H), 0.57 - 0.47 (m, 1H), 0.32 - 0.23 (m, 2H), 0.18 - 0.09 (m, 1H).
Example 348:
Synthetic Route:
[1355] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 348-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 348 (5 mg, yield: 10%) as a white solid. MS (ESI, m/z): 573.2 [M+H]+.
[1356] 1H NMR (400 MHz, DMSO-d6) δ 7.92 (d, J = 8.0 Hz, 1H), 7.56 - 7.45 (m, 2H), 7.21 (d, J = 8.4 Hz, 1H), 7.15 - 7.08 (m, 1H), 6.61 - 6.55 (m, 1H), 6.51 - 6.47 (m, 1H), 6.36 (dd, J = 8.0, 2.0 Hz, 1H), 3.88 - 3.78 (m, 2H), 3.78 - 3.67 (m, 4H), 3.41 - 3.52 (m, 1H), 2.86 - 2.74 (m, 2H), 2.74 - 2.64 (m, 2H), 2.39 - 2.33 (m, 1H), 2.01 - 1.85 (m, 4H), 1.74 - 1.63 (m, 2H), 1.63 - 1.58 (m, 2H), 1.46 - 1.36 (m, 2H), 1.31 - 1.20 (m, 2H), 1.09 - 1.00 (m, 1H), 0.93 (s, 6H), 0.55 - 0.48 (m, 1H), 0.32 - 0.21 (m, 2H), 0.16 - 0.09 (m, 1H).
Example 349:
Synthetic Route:
[1358] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 349-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 349 (9 mg, yield: 10%) as a white solid. MS (ESI, m/z): 597.4 [M+H]+.
[1359] 1H NMR (400 MHz, DMSO-d6) δ 12.14 (s, 1H), 7.50 - 7.40 (m, 3H), 7.16 (d, J = 8.6 Hz, 1H), 7.12 - 7.04 (m, 1H), 6.54 (dd, J = 8.2, 2.0 Hz, 1H), 6.48 - 6.43 (m, 1H), 6.33 (dd, J = 8.0, 2.0 Hz, 1H), 3.84 - 3.75 (m, 2H), 3.69 (s, 3H), 3.43 - 3.28 (m, 3H), 2.85 - 2.73 (m, 2H), 2.71 - 2.59 (m, 2H), 2.38 - 2.28 (m, 1H), 2.07 - 2.01 (m, 8H), 1.93 - 1.85 (m, 3H), 1.64 (s, 6H), 1.09 - 0.96 (m, 1H), 0.52 - 0.43 (m, 1H), 0.28 - 0.19 (m, 2H), 0.14 - 0.04 (m, 1H).
Example 350:
Synthetic Route:
[1361] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 350-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 350 (6 mg, yield: 20%) as a white solid. MS (ESI, m/z): 613.3 [M+H]+.
[1362] 1H NMR (400 MHz, DMSO-d6) δ 7.56 (s, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.42 (s, 1H), 7.21 (d, J = 8.0 Hz, 1H), 7.19 - 7.13 (m, 1H), 6.62 (dd, J = 8.2, 2.0 Hz, 1H), 6.56 - 6.52 (m, 1H), 6.40 (dd, J = 8.0, 2.0 Hz, 1H), 4.57 (s, 1H), 3.92 - 3.81 (s, 2H), 3.77 (s, 3H), 3.48 - 3.40 (m, 1H), 2.90 - 2.79 (m, 2H), 2.53 - 2.47 (m, 1H), 2.41 - 2.25 (m, 2H), 2.25 - 2.18 (m, 2H), 2.08 - 1.88 (m, 10H), 1.61 (d, J = 8.6 Hz, 6H), 1.06 - 0.96 (m, 1H), 0.51 - 0.42 (m, 1H), 0.32 - 0.23 (m, 2H), 0.11 - 0.06 (m, 1H).
Example 351:
Synthetic Route:
[1364] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 351-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 351 (3 mg, yield: 6%) as a white solid. MS (ESI, m/z): 625.3 [M+H]+.
[1365] 1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 8.0 Hz, 1H), 7.36 (s, 1H), 7.22 - 7.15 (m, 2H), 6.60 (dd, J = 8.2, 2.0 Hz, 1H), 6.54 - 6.50 (m, 1H), 6.41 (dd, J = 8.2, 2.2 Hz, 1H), 5.72 (s, 1H), 3.82 - 3.71 (m, 6H), 2.98 - 2.88 (m, 2H), 2.88 - 2.76 (m, 2H), 2.54 - 2.44 (m, 1H), 2.18 - 2.06 (m, 2H), 2.01 - 1.94 (m, 4H), 1.85 - 1.76 (m, 4H), 1.48 - 1.43 (m, 2H), 1.38 - 1.25 (m, 5H), 1.09 - 1.03 (m, 1H), 0.90 (s, 6H), 0.66 - 0.58 (m, 1H), 0.48 - 0.39 (m, 1H), 0.37 - 0.29 (m, 1H), 0.22 - 0.12 (m, 1H).
Example 352:
Synthetic Route:
[1367] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 352-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 352 (8 mg, yield: 28%) as a white solid. MS (ESI, m/z): 597.3 [M+H]+.
[1368] 1H NMR (400 MHz, CD3OD) δ 7.51 (d, J = 8.2 Hz, 1H), 7.40 (s, 1H), 7.24 (dd, J = 8.2, 1.2 Hz, 1H), 7.14 - 7.07 (m, 1H), 6.58 (dd, J= 8.0, 2.0 Hz, 1H), 6.54 - 6.50 (m, 1H), 6.40 (dd, J = 8.0, 2.0 Hz, 1H), 4.20 - 4.14 (m, 1H), 3.81 - 3.70 (m, 5H), 3.53 - 3.44 (m, 1H), 2.83 - 2.72 (m, 2H), 2.64 (dd, J = 13.4, 6.8 Hz, 1H), 2.57 - 2.44 (m, 2H), 2.17 - 1.77 (m, 16H), 1.75 - 1.66 (m, 2H), 1.10 - 0.98 (m, 1H), 0.57 - 0.47 (m, 1H), 0.38 - 0.27 (m, 2H), 0.10 - 0.05 (m, 1H).
Example 353:
Synthetic Route:
[1370] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 353-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 353 (8 mg, yield: 38%) as a white solid. MS (ESI, m/z): 611.3 [M+H]+.
[1371] 1H NMR (400 MHz, DMSO-d6) δ 7.53 - 7.43 (m, 3H), 7.19 (d, J = 8.4 Hz, 1H), 7.14 - 7.09 (m, 1H), 6.57 (d, J = 8.4 Hz, 1H), 6.51 - 6.47 (m, 1H), 6.36 (dd, J = 8.0, 2.0 Hz, 1H), 3.86 - 3.80 (m, 2H), 3.73 (s, 3H), 3.45 - 3.33 (m, 1H), 2.86 - 2.76 (m, 2H), 2.72 - 2.63 (m, 2H), 2.11 - 1.88 (m, 10H), 1.84 - 1.79 (m, 2H), 1.65 - 1.49 (m, 2H), 1.46 - 1.36 (m, 4H), 1.08 - 0.99 (m, 1H), 0.84 (s, 3H), 0.58 - 0.47 (m, 1H), 0.30 - 0.22 (m, 2H), 0.15 - 0.07 (m, 1H).
Example 354:
Synthetic Route:
[1373] Referring to the synthetic route of compound 234, compound 234-2 was replaced with compound 351-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 354 (4 mg, yield: 13%) as a white solid. MS (ESI, m/z): 625.3 [M+H]+.
[1374] 1H NMR (400 MHz, CDCl3) δ 7.49 (d, J = 8.4 Hz, 1H), 7.37 (s, 1H), 7.23 - 7.16 (m, 2H), 6.70 - 6.58 (m, 1H), 6.57 - 6.51 (m, 1H), 6.48 - 6.38 (m, 1H), 5.74 (s, 1H), 3.89 - 3.69 (m, 6H), 3.05 - 2.75 (m, 4H), 2.53 - 2.43 (m, 1H), 2.25 - 2.20 (m, 1H), 2.19 - 2.08 (m, 2H), 2.03 - 1.96 (m, 4H), 1.85 - 1.78 (m, 4H), 1.48 - 1.46 (m, 2H), 1.37 - 1.33 (m, 2H), 1.23 - 1.17 (m, 2H), 1.10 - 1.05 (m, 1H), 0.92 (s, 6H), 0.65 - 0.60 (m, 1H), 0.50 - 0.42 (m, 1H), 0.37 - 0.30 (m, 1H), 0.21 - 0.15 (m, 1H).
Example 355:
Synthetic Route:
[1376] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 355-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 355 (6 mg, yield: 23%) as a white solid. MS (ESI, m/z): 553.3 [M+H]+.
[1377] 1H NMR (400 MHz, DMSO-d6) δ 12.22 - 11.51 (m, 1H), 8.61 (t, J = 5.6 Hz, 1H), 7.62 (d, J = 8.0 Hz, 1H), 7.51 (s, 1H), 7.39 - 7.34 (m, 4H), 7.28 - 7.21 (m, 2H), 7.15 - 7.09 (m, 1H), 6.60 - 6.54 (m, 1H), 6.50 - 6.47 (m, 1H), 6.38 - 6.36 (m, 1H), 4.51 (d, J = 6.0 Hz, 2H), 3.84 - 3.81 (m, 2H), 3.73 (s, 3H), 3.57 - 3.52 (m, 1H), 2.82 - 2.69 (m, 4H), 2.41 - 2.34 (m, 1H), 1.96 - 1.87 (m, 4H), 1.06 - 1.03 (m, 1H), 0.54 - 0.49 (m, 1H), 0.31 - 0.25(m, 2H), 0.16 - 0.11 (m, 1H).
Example 356:
Synthetic Route:
[1379] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 356-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 356 (20 mg, yield: 34%) as a white solid. MS (ESI, m/z): 583.3 [M+H]+.
[1380] 1H NMR (400 MHz, CDCl3) δ 7.58 (d, J = 8.0 Hz, 1H), 7.45 (s, 1H), 7.32 - 7.29 (m, 1H), 7.25 - 7.20 (m, 1H), 6.79 - 6.39 (m, 3H), 3.85 - 3.80 (m, 6H), 2.98 - 2.81 (m, 4H), 2.52 - 2.45 (m, 1H), 2.32 - 2.11 (m, 2H), 2.07 - 2.02 (m, 2H), 1.61 (s, 9H), 1.12 - 1.07 (m, 1H), 0.68 - 0.64 (m, 1H), 0.49 - 0.44 (m, 1H), 0.38 - 0.33 (m, 1H), 0.22 - 0.17 (m, 1H).
Example 357:
Synthetic Route:
[1382] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 357-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 357 (2 mg, yield: 11%) as a white solid. MS (ESI, m/z): 530.2 [M+H]+.
[1383] 1H NMR (400 MHz, DMSO-d6) δ 8.16 (s, 1H), 7.55 - 7.46 (m, 1H), 7.30 (s, 1H), 7.15 - 7.06 (m, 2H), 6.59 (dd, J = 8.2, 2.0 Hz, 1H), 6.52 - 6.49 (m, 1H), 6.35 (dd, J = 8.0, 2.0 Hz, 1H), 3.89 - 3.80 (m, 2H), 3.73 (s, 3H), 3.30 - 3.16 (m, 1H), 2.88 - 2.79 (m, 2H), 2.55 - 2.35 (m, 3H), 2.02 - 1.95 (m, 2H), 1.95 - 1.88 (m, 2H), 0.87 - 0.84 (m, 1H), 0.45 - 0.41 (m, 1H), 0.29 - 0.21 (m, 2H), 0.10 - 0.07 (m, 1H).
Example 358:
Synthetic Route:
[1385] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 200-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 358 (31 mg, yield: 41%) as a white solid. MS (ESI, m/z): 517.2 [M+H]+.
[1386] 1H NMR (400 MHz, CDCl3) δ 7.37 - 7.32 (m, 2H), 7.24 - 7.17 (m, 1H), 7.16-7.12 (m, 1H), 6.62 (dd, J = 8.0, 2.4 Hz, 1H), 6.57 - 6.52 (m, 1H), 6.45 (dd, J = 8.0, 2.4 Hz, 1H), 3.83 - 3.78 (m, 5H), 3.77 - 3.67 (m, 2H), 3.45 - 3.35 (m, 2H), 3.19 - 3.11 (m, 1H), 2.94 - 2.74 (m, 4H), 2.55 - 2.45 (m, 1H), 2.22 - 1.84 (m, 8H), 1.13 - 1.04 (m, 1H), 0.66 - 0.59 (m, 1H), 0.48 - 0.42 (m, 1H), 0.37 - 0.31 (m, 1H), 0.22 - 0.16 (m, 1H).
Example 359:
Synthetic Route:
[1388] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 359-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 359 (55 mg, yield: 73%) as a white solid. MS (ESI, m/z): 531.2 [M+H]+.
[1389] 1H NMR (400 MHz, CDCl3) δ 7.38 - 7.31 (m, 2H), 7.25 - 7.18 (m, 1H), 7.15 (d, J = 8.0 Hz, 1H), 6.62 (dd, J = 8.0, 2.4 Hz, 1H), 6.58 - 6.53 (m, 1H), 6.45 (dd, J = 8.0, 2.4 Hz, 1H), 4.50 - 4.35 (m, 1H), 3.83 - 3.79 (m, 5H), 3.55 - 3.28 (m, 2H), 3.23 - 3.09 (m, 1H), 2.96 - 2.78 (m, 4H), 2.56 - 2.46 (m, 1H), 2.28 - 2.10 (m, 4H), 2.08 - 1.92 (m, 2H), 1.87 - 1.73 (m, 1H), 1.71 - 1.65 (m, 1H), 1.53 - 1.27 (m, 3H), 1.17 - 1.06 (m, 1H), 0.66 - 0.60 (m, 1H), 0.49 - 0.42 (m, 1H), 0.37 - 0.31 (m, 1H), 0.22 - 0.16 (m, 1H).
Example 360:
Synthetic Route:
[1391] Referring to the synthetic route of compound 235, compound 235-2 was replaced with compound 360-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 360 (15 mg, yield: 36%) as a white solid. MS (ESI, m/z): 543.2 [M+H]+.
[1392] 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 8.0 Hz, 1H), 7.36 (s, 1H), 7.25 - 7.16 (m, 2H), 6.63 (dd, J = 8.0, 2.4 Hz, 1H), 6.58 - 6.54 (m, 1H), 6.46 (dd, J = 8.0, 2.4 Hz, 1H), 4.20 - 4.02 (m, 4H), 3.86 - 3.80 (m, 5H), 3.36 - 3.29 (m, 1H), 2.97 - 2.81 (m, 4H), 2.56 - 2.46 (m, 1H), 2.31 - 2.13 (m, 6H), 2.07 - 1.96 (m, 2H), 1.93 - 1.80 (m, 2H), 1.16 - 1.03 (m, 1H), 0.70 - 0.59 (m, 1H), 0.52 - 0.42 (m, 1H), 0.39 - 0.35 (m, 1H), 0.24 - 0.19 (m, 1H).
Example 361:
Synthetic Route:
[1394] Referring to the synthetic route of compound 49, compound 49-3 was replaced with compound 361-1, and compound 49-10 was replaced with compound 361-2. The synthesis was carried out, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 361 (48 mg, yield: 56%) as a white solid. MS (ESI, m/z): 502.2 [M+H]+.
[1395] 1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 8.0 Hz, 1H), 7.31 (s, 1H), 7.24 - 7.18 (m, 1H), 7.14 (d, J = 8.0 Hz, 1H), 6.63 (d, J = 7.6 Hz, 1H), 6.56 (s, 1H), 6.45 (d, J = 7.6 Hz, 1H), 6.33 - 6.31 (m, 2H), 3.86 - 3.82 (m, 5H), 3.10 - 3.02 (m, 1H), 2.93 - 2.83 (m, 4H), 2.54 - 2.45 (m, 1H), 2.26 - 2.12 (m, 2H), 1.96 - 1.90 (m, 2H), 1.18 (s, 9H), 1.12 - 1.06 (m, 1H), 0.66 - 0.56 (m, 1H), 0.46 - 0.40 (m, 1H), 0.35 - 0.30 (m, 1H), 0.20 - 0.16 (m, 1H).
Example 362:
Synthetic Route:
[1397] Referring to the synthetic route of compound 361, compound 49-2 was replaced with compound 82-2, and compound 361-1 was replaced with compound 362-1. The synthesis was carried out, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 362 (45 mg, yield: 45%) as a white solid. MS (ESI, m/z): 588.2 [M+H]+.
[1398] 1H NMR (400 MHz, CDCl3) δ 7.73 - 7.30 (m, 2H), 7.24 - 7.17 (m, 1H), 7.16 - 7.06 (m, 1H), 6.73 - 6.39 (m, 3H), 6.39 - 5.66 (m, 2H), 3.93 - 3.74 (m, 6H), 3.01 - 2.79 (m, 4H), 2.59 - 2.43 (m, 2H), 2.30 - 2.08 (m, 2H), 1.99 - 1.84 (m, 2H), 1.17 - 1.11 (m, 3H), 1.12 - 1.06 (m, 1H), 1.02 - 0.97 (m, 3H), 0.67 - 0.58 (m, 1H), 0.49 - 0.42 (m, 1H), 0.38 - 0.30 (m, 1H), 0.24 - 0.18 (m, 1H).
Example 363:
Synthetic Route:
[1400] Referring to the synthetic route of compound 362, compound 362-1 was replaced with compound 363-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 363 (8 mg, yield: 39%) as a white solid. MS (ESI, m/z): 574.2 [M+H]+.
[1401] 1H NMR (400 MHz, CDCl3) δ 7.71 - 7.30 (m, 2H), 7.24 - 7.17 (m, 1H), 7.15 - 7.08 (m, 1H), 6.65 - 6.58 (m, 1H), 6.58 - 6.52 (m, 1H), 6.47- 5.79 (m, 3H), 3.86 - 3.78 (m, 5H), 3.09 - 2.81 (m, 5H), 2.57 - 2.44 (m, 1H), 2.35 - 2.26 (m, 1H), 2.21 - 2.10 (m, 3H), 1.95 - 1.88 (m, 2H), 1.19 - 0.98 (m, 4H), 0.66 - 0.57 (m, 1H), 0.49 - 0.39 (m, 1H), 0.38 - 0.29 (m, 1H), 0.24 - 0.14 (m, 1H).
Synthetic Route:
[1404] Referring to the synthetic route of compound 362, compound 362-1 was replaced with compound 364-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 364 (40 mg, yield: 80%) as a white solid. MS (ESI, m/z): 486.2 [M+H]+.
[1405] 1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 8.0 Hz, 1H), 7.31 (s, 1H), 7.25 - 7.18 (m, 1H), 7.11 (d, J = 7.6 Hz, 1H), 6.68 - 6.59 (m, 1H), 6.58 - 6.50 (m, 2H), 6.48 - 6.40 (m, 1H), 5.82 - 5.73 (m, 1H), 3.87 - 3.80 (m, 5H), 3.15 - 2.73 (m, 5H), 2.54 - 2.43 (m, 1H), 2.26 - 2.06 (m, 2H), 1.96 - 1.87 (m, 2H), 1.64 - 1.59 (m, 1H), 1.11 - 1.04 (m, 1H), 0.91 - 0.84 (m, 2H), 0.65 - 0.59 (m, 1H), 0.57 - 0.52 (m, 2H), 0.47 - 0.40 (m, 1H), 0.37 - 0.31 (m, 1H), 0.23 - 0.16 (m, 1H).
Example 365:
Synthetic Route:
[1407] Referring to the synthetic route of compound 361, compound 49-2 was replaced with compound 330-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 365 (90 mg, yield: 39%) as a white solid. MS (ESI, m/z): 530.2 [M+H]+.
[1408] 1H NMR (400 MHz, CDCl3) δ 7.70 (d, J = 8.4 Hz, 1H), 7.32 (s, 1H), 7.14 (d, J = 7.6 Hz, 1H), 6.76 (d, J = 8.8 Hz, 1H), 6.65 (s, 1H), 6.51 - 6.42 (m, 1H), 6.34 - 6.31 (m, 2H), 5.93 (s, 2H), 3.68 - 3.57 (m, 2H), 3.05 - 2.95 (m, 1H), 2.92 - 2.77 (m, 4H), 2.57 - 2.44 (m, 1H), 2.29 - 2.14 (m, 2H), 2.01 - 1.88 (m, 2H), 1.18 (s, 9H), 1.12 - 1.06 (m, 1H), 0.66 - 0.57 (m, 1H), 0.48 - 0.39 (m, 1H), 0.35 - 0.30 (m, 1H), 0.24 - 0.16 (m, 1H).
Example 366:
Synthetic Route:
[1410] Referring to the synthetic route of compound 361, compound 49-2 was replaced with compound 98-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 366 (2 mg, yield: 8%) as a white solid. MS (ESI, m/z): 520.2 [M+H]+.
[1411] 1H NMR (400 MHz, DMSO-d6) δ 7.72 (d, J = 8.0 Hz, 1H), 7.44 (s, 1H), 7.17 (d, J = 8.0 Hz, 1H), 7.05 (dd, J = 12.4, 8.8 Hz, 1H), 6.61 - 6.57 (m, 1H), 6.51- 6.49 (m, 1H), 6.47 - 6.34 (m, 2H),
3.73 (s, 3H), 3.50 - 3.47 (m, 2H), 3.25 - 3.14 (m, 1H), 2.92 - 2.80 (m, 2H), 2.79 - 2.59 (m, 2H), 2.43 - 2.33 (m, 1H), 2.12 - 1.87 (m, 2H), 1.87 - 1.85 (m, 2H), 1.16 (s, 9H), 1.12 - 1.04 (m, 1H), 0.55-0.48 (m, 1H), 0.35 - 0.24 (m, 2H), 0.19 - 0.10 (m, 1H).
Example 367:
Synthetic Route:
[1413] Referring to the synthetic route of compound 361, compound 49-2 was replaced with compound 142-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 367 (3 mg, yield: 21%) as a white solid. MS (ESI, m/z): 520.2 [M+H]+.
[1414] 1H NMR (400 MHz, DMSO-d6) δ 7.72 (d, J = 8.4 Hz, 1H), 7.43 (s, 1H), 7.16 (d, J = 8.4 Hz, 1H), 7.05 (dd, J = 12.4, 8.8 Hz, 1H), 6.59 - 6.57 (m, 1H), 6.52 - 6.47 (m, 1H), 6.47 - 6.32 (m, 2H), 3.73 (s, 3H), 3.52 - 3.48 (m, 2H), 3.19 - 3.15 (m, 1H), 2.88 - 2.82 (m, 2H), 2.71 - 2.62 (m, 2H), 2.41 - 2.33 (m, 1H), 2.06 - 1.96 (m, 2H), 1.87 - 1.84 (m, 2H), 1.15 (s, 9H), 1.09 - 1.01 (m, 1H), 0.53 - 0.43 (m, 1H), 0.31 - 0.25 (m, 2H), 0.16 - 0.09 (m, 1H).
Example 368:
Synthetic Route:
[1416] Referring to the synthetic route of compound 366, compound 361-1 was replaced with compound 368-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 368 (8 mg, yield: 13%) as a white solid. MS (ESI, m/z): 522.2 [M+H]+.
[1417] 1H NMR (400 MHz, DMSO-d6) δ 7.76-7.69 (m, 1H), 7.47-7.43 (m, 1H), 7.19 - 7.16 (m, 1H), 7.08 - 7.03 (m, 1H), 6.67 - 6.24 (m, 4H), 3.73 (s, 3H), 3.50 - 3.47 (m,2H), 3.19 - 3.17 (m, 1H), 2.88 - 2.82 (m, 2H), 2.70 - 2.63 (m, 2H), 2.44 - 2.35 (m, 1H), 2.08 - 1.98 (m, 2H), 1.88 - 1.82 (m, 2H), 1.32 (s, 6H), 1.07 - 1.02 (m, 1H), 0.55 - 0.48 (m, 1H), 0.33 - 0.25 (m, 2H), 0.17 - 0.11 (m, 1H).
Example 369:
Synthetic Route:
[1419] Referring to the synthetic route of compound 368, compound 98-1 was replaced with compound 142-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 369 (6 mg, yield: 11%) as a white solid. MS (ESI, m/z): 522.2 [M+H]+.
[1420] 1H NMR (400 MHz, DMSO-d6) δ 12.8-11.76 (m, 1H), 7.80 - 7.70 (m, 1H), 7.48 - 7.40 (m, 1H), 7.21 - 7.13 (m, 1H), 7.10 - 7.01 (m, 1H), 6.66 - 6.55 (m, 2H), 6.54 - 6.44 (m, 2H), 4.73 (s, 1H), 3.73 (s, 3H), 3.55 - 3.44 (m, 2H), 3.21 - 3.13 (m, 1H), 2.86 - 2.80 (m, 2H), 2.77 - 2.66 (m, 2H), 2.41 - 2.36 (m, 1H), 2.06 - 1.94 (m, 2H), 1.90 - 1.81 (m, 2H), 1.32 (s, 6H), 1.12 - 1.02 (m, 1H), 0.55 - 0.43 (m, 1H), 0.34 - 0.23 (m, 2H), 0.18 - 0.09 (m, 1H).
Example 370:
Synthetic Route:
[1422] Referring to the synthetic route of compound 366, compound 361-1 was replaced with compound 370-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 370 (1 mg, yield: 3%) as a white solid. MS (ESI, m/z): 492.2 [M+H]+.
[1423] 1H NMR (400 MHz, MeOD) δ 7.31 (s, 1H), 7.23 (d, J = 8.0 Hz, 1H), 7.10 (d, J = 8.0 Hz, 1H), 6.95 (dd, J= 12.2, 8.8 Hz, 1H), 6.60 (dd, J = 7.2, 2.8 Hz, 1H), 6.52 - 6.46 (m, 1H), 6.11 - 6.08 (m, 1H), 3.76 (s, 3H), 3.55 - 3.48 (m, 2H), 2.93 - 2.70 (m, 5H), 2.50 - 2.40 (m, 1H), 2.21 - 2.10 (m, 2H), 1.97 (s, 3H), 1.95 - 1.85 (m, 2H), 1.68 (s, 3H), 1.14 - 1.07 (m, 1H), 0.64 - 0.55 (m, 1H), 0.43 - 0.29 (m, 2H), 0.19 - 0.11 (m, 1H).
Example 371:
Synthetic Route:
[1425] Referring to the synthetic route of compound 366, compound 361-1 was replaced with compound 371-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 371 (5 mg, yield: 45%) as a white solid. MS (ESI, m/z): 520.2 [M+H]+.
[1426] 1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 8.0 Hz, 1H), 7.31 (s, 1H), 7.10 (d, J= 7.6 Hz, 1H), 6.96 (dd, J = 12.0, 8.4 Hz, 1H), 6.59 - 6.54 (m, 1H), 6.48 - 6.40 (m, 1H), 5.40 - 5.27 (m, 2H), 3.80 (s, 3H), 3.63 - 3.57 (m, 2H), 3.42 (d, J = 5.6 Hz, 2H), 3.02 - 2.77 (m, 6H), 2.51 - 2.45 (m, 1H), 2.27 - 2.21 (m, 2H), 1.90 - 1.86 (m, 2H), 1.11 - 1.04 (m, 7H), 0.63 - 0.59 (m, 1H), 0.46 - 0.41 (m, 1H), 0.38 - 0.31 (m, 1H), 0.22 - 0.17 (m, 1H).
Example 372:
Synthetic Route:
[1428] Referring to the synthetic route of compound 367, compound 361-1 was replaced with compound 372-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 372 (40 mg, yield: 57%) as a white solid. MS (ESI, m/z): 506.3 [M+H]+.
[1429] 1H NMR (400 MHz, CDCl3) δ 7.36 (d, J = 8.4 Hz, 1H), 7.29 (s, 1H), 7.07 (d, J = 8.4 Hz, 1H), 6.99 - 6.91 (m, 1H), 6.58 - 6.53 (m, 1H), 6.46 - 6.39 (m, 1H), 5.29 - 5.20 (m, 1H), 3.79 (s, 3H), 3.64 - 3.54 (m, 2H), 3.33 (d, J = 6.0 Hz, 2H), 2.98 - 2.89 (m, 1H), 2.86 - 2.76 (m, 4H), 2.51 - 2.42 (m, 1H), 2.33 - 2.19 (m, 2H), 1.90 - 1.84 (m, 2H), 1.81 (s, 3H), 1.72 (s, 3H), 1.13 - 1.02 (m, 1H), 0.64 - 0.57 (m, 1H), 0.47 - 0.39 (m, 1H), 0.35 - 0.28 (m, 1H), 0.23 - 0.14 (m, 1H).
Example 373:
Synthetic Route:
[1431] Referring to the synthetic route of compound 367, compound 361-1 was replaced with compound 373-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 373 (15 mg, yield: 76%) as a white solid. MS (ESI, m/z): 518.2 [M+H]+.
[1432] 1H NMR (400 MHz, CDCl3) δ 7.50 - 7.37 (m, 1H), 7.33 - 7.29 (m, 1H), 7.14 - 7.06 (m, 1H), 7.01 - 6.92 (m, 1H), 6.61 - 6.54 (m, 1H), 6.49 - 6.41 (m, 1H), 5.69 - 5.36 (m, 1H), 5.17 - 4.80 (m, 1H), 3.80 (s, 3H), 3.64 - 3.57 (m, 2H), 3.55 - 3.32 (m, 2H), 3.07 - 2.92 (m, 1H), 2.89 - 2.74 (m, 4H), 2.53 - 2.42 (m, 1H), 2.35 - 2.19 (m, 2H), 1.96 - 1.84 (m, 2H), 1.85 - 1.77 (m, 1H), 1.16 - 1.03 (m, 1H), 0.94 - 0.66 (m, 2H), 0.63 - 0.57 (m, 1H), 0.49 - 0.26 (m, 4H), 0.24 - 0.15 (m, 1H).
Example 374:
Synthetic Route:
[1434] Referring to the synthetic route of compound 372, compound 142-1 was replaced with compound 49-2 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 374 (12 mg, yield: 57%) as a white solid. MS (ESI, m/z): 488.3 [M+H]+.
[1435] 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.34 (m, 1H), 7.29 - 7.27 (m, 1H), 7.22 - 7.17 (m, 1H), 7.07 (d, J = 7.6 Hz, 1H), 6.64 - 6.58 (m, 1H), 6.55 - 6.51 (m, 1H), 6.48 - 6.39 (m, 1H), 5.29 - 5.19 (m, 1H), 3.85 - 3.79 (m, 5H), 3.36 - 3.30 (m, 2H), 3.01 - 2.90 (m, 1H), 2.88 - 2.80 (m, 4H), 2.51 - 2.39 (m, 1H), 2.24 - 2.10 (m, 2H), 1.91 - 1.84 (m, 2H), 1.81 (s, 3H), 1.72 (s, 3H), 1.12 - 1.03 (m, 1H), 0.66 - 0.53 (m, 1H), 0.46 - 0.37 (m, 1H), 0.35 - 0.28 (m, 1H), 0.22 - 0.15 (m, 1H).
Example 375:
Synthetic Route:
[1437] Referring to the synthetic route of compound 373, compound 142-1 was replaced with compound 49-2 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 375 (4 mg, yield: 18%) as a white solid. MS (ESI, m/z): 500.2 [M+H]+.
[1438] 1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 7.4 Hz, 1H), 7.31 (s, 1H), 7.23 - 7.18 (m, 1H), 7.10 (d, J = 7.4 Hz, 1H), 6.66 - 6.59 (m, 1H), 6.57 - 6.51 (m, 1H), 6.49 - 6.39 (m, 1H), 5.68 - 5.34 (m, 1H), 5.18 - 4.80 (m, 1H), 3.86 - 3.81 (m, 5H), 3.53 (d, J = 7.0 Hz, 2H), 3.06 - 2.98 (m, 1H), 2.88 - 2.81 (m, 4H), 2.50 - 2.45 (m, 1H), 2.22 - 2.14 (m, 2H), 1.93 - 1.88 (m, 2H), 1.83 - 1.78 (m, 1H), 1.12 - 1.06 (m, 1H), 0.89 - 0.82 (m, 2H), 0.65 - 0.59 (m, 1H), 0.47 - 0.40 (m, 3H), 0.35 - 0.30 (m, 1H), 0.22 - 0.17 (m, 1H).
Example 376:
Synthetic Route:
[1440] Referring to the synthetic route of compound 330, compound 330-2 was replaced with compound 372-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 376 (3 mg, yield: 20%) as a white solid. MS (ESI, m/z): 502.3 [M+H]+.
[1441] 1H NMR (400 MHz, CDCl3) δ 7.39 - 7.33 (m, 1H), 7.32 - 7.28 (m, 1H), 7.10 - 7.06 (m, 1H), 6.77 - 6.70 (m, 1H), 6.68 - 6.60 (m, 1H), 6.48 - 6.38 (m, 1H), 5.92 (s, 2H), 5.28 - 5.20 (m, 1H), 3.69 - 3.52 (m, 2H), 3.34 - 3.30 (m, 2H), 2.90 - 2.72 (m, 5H), 2.50 - 2.43 (m, 1H), 2.31 - 2.04 (m, 2H), 1.90 - 1.82 (m, 2H), 1.81 (s, 3H), 1.72 (s, 3H), 1.11 - 1.04 (m, 1H), 0.64 - 0.59 (m, 1H), 0.45 - 0.39 (m, 1H), 0.35 - 0.30 (m, 1H), 0.21 - 0.16 (m, 1H).
Example 377:
Synthetic Route:
[1443] Compound 49-6 (1100 mg, 2.31 mmol) and compound 377-1 (339 mg, 3.46 mmol) were dissolved in dichloromethane (20 mL). 2-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (1100 mg, 3.0 mmol) and triethylamine (698 mg, 6.92 mmol) were added, and the reaction was carried out at room temperature overnight. After concentration, the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 30%) to obtain compound 377-2 (1250 mg, yield: 99%) as a white solid. MS (ESI, m/z): 521.3 [M+H]+.
[1444] Compound 377-2 (500 mg, 0.96 mmol) was dissolved in tetrahydrofuran (5 mL), and compound 377-3 (1.0 M, 1.5 mL) was added at 0°C. The reaction was carried out at 0°C for 1 hour, then quenched with saturated ammonium chloride solution (1 mL). After concentration, the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 10%) to obtain compound 377-4 (350 mg, yield: 68%) as a white solid. MS (ESI, m/z): 532.3 [M+H]+.
[1445] Compound 377-4 (130 mg, 0.244 mmol) was dissolved in tetrahydrofuran (5 mL). Phenyl Grignard reagent (1.0 M, 0.32 mL) was added at 0°C, and the reaction was carried out at 0°C for 1 hour. The reaction mixture was quenched with saturated ammonium chloride solution (1 mL), concentrated, and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 10%) to obtain compound 377-6 (70 mg, yield: 47%) as a white solid. MS (ESI, m/z): 610.3 [M+H]+.
[1446] Compound 377-6 (70 mg, 0.114 mmol) was dissolved in dichloromethane (3 mL), and trifluoroacetic acid (3 mL) was added. The reaction was carried out at room temperature for 2 hours, and after concentration, the resulting crude product was directly used in the next step. MS (ESI, m/z): 592.3 [M+H]+.
[1447] To a reaction tube, compound 377-7 (35 mg, 0.0589 mmol), lithium hydroxide (8.2 mg, 0.341 mmol), tetrahydrofuran (3 mL), methanol (3 mL), and water (3 mL) were added. The reaction was carried out at 50°C for 2 hours. After concentration, the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 50% to 70%] to obtain compound 377 (18 mg, yield: 51%) as a white solid. MS (ESI, m/z): 578.4 [M+H]+.
[1448] 1H NMR (400 MHz, CDCl3) δ 7.35 - 7.26 (m, 4H), 7.25 - 7.12 (m, 4H), 7.08 - 6.97 (m, 1H), 6.60 - 6.54 (m, 1H), 6.51 - 6.45 (m, 1H), 6.44 - 6.39 (m, 1H), 5.95 (t, J = 7.6 Hz, 1H), 3.81- 3.68 (m, 5H), 2.83 - 2.55 (m, 5H), 2.49 - 2.39 (m, 1H), 2.27 - 2.19 (m, 2H), 2.17 - 2.06 (m, 2H), 1.80 - 1.68 (m, 3H), 1.12 - 1.02 (m, 1H), 0.96 - 0.88 (m, 6H), 0.67 - 0.52 (m, 1H), 0.52 - 0.37 (m, 1H), 0.35 - 0.27 (m, 1H), 0.24 - 0.12 (m, 1H).
Example 378:
Synthetic Route:
[1450] Referring to the synthetic route of compound 362, compound 362-1 was replaced with compound 378-1 to obtain synthesize compound 378-2 (100 mg, 0.188 mmol), and compound 378-2 (100 mg, 0.188 mmol) was added to a mixture of dichloromethane (3 mL) and trifluoroacetic acid (1 mL). The reaction was carried out at room temperature for 2 hours, and after concentration, the resulting crude product was directly used in the next step. LCMS: [M+H]+ = 555.0.
[1451] Then, referring to the synthetic route of compound 362, compound 362-2 was replaced with compound 378-3 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 378 (60 mg, yield: 63%) as a white solid. MS (ESI, m/z): 541.2 [M+H]+.
[1452] 1H NMR (400 MHz, DMSO-d6) δ 7.38 - 7.32 (m, 2H), 7.15 - 7.08 (m, 2H), 6.61 - 6.54 (m, 1H), 6.52 - 6.48 (m, 1H), 6.40 - 6.33 (m, 1H), 5.90 - 5.84 (m, 1H), 3.86 - 3.81 (m, 2H), 3.74 (s, 3H), 3.57 - 3.46 (m, 1H), 3.31 - 3.24 (m, 1H), 3.14 - 3.03 (m, 1H), 2.84 - 2.68 (m, 4H), 2.48 - 2.42 (m, 1H), 2.40 - 2.24 (m, 2H), 2.09 - 1.95 (m, 4H), 1.83 - 1.72 (m, 4H), 1.67 - 1.46 (m, 2H), 1.02 - 0.90 (m, 1H), 0.47 - 0.38 (m, 1H), 0.30 - 0.20 (m, 2H), 0.10 - 0.01 (m, 1H).
Example 379:
Synthetic Route:
[1454] Referring to the synthetic route of compound 366, compound 361-1 was replaced with compound 379-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 379 (13 mg, yield: 44%) as a white solid. MS (ESI, m/z): 518.2 [M+H]+.
[1455] 1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 8.0 Hz, 1H), 7.29 (s, 1H), 7.07 (dd, J = 8.0, 1.2 Hz, 1H), 6.94 (dd, J = 12.0, 8.8 Hz, 1H), 6.57 - 6.52 (m, 1H), 6.45 - 6.38 (m, 1H), 5.80 - 5.75 (m, 1H), 3.78 (s, 3H), 3.61 - 3.53 (m, 2H), 3.03 - 2.92 (m, 1H), 2.91 - 2.73 (m, 4H), 2.51 - 2.42 (m, 1H), 2.36 - 2.19 (m, 6H), 1.91 - 1.83 (m, 2H), 1.83 - 1.69 (m, 4H), 1.13 - 1.03 (m, 1H), 0.67 - 0.55 (m, 1H), 0.47 - 0.38 (m, 1H), 0.37 - 0.28 (m, 1H), 0.22 - 0.14 (m, 1H).
Example 380:
Synthetic Route:
[1457] Referring to the synthetic route of compound 366, compound 361-1 was replaced with compound 380-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 380 (3 mg, yield: 18%) as a white solid. MS (ESI, m/z): 574.2 [M+H]+.
[1458] 1H NMR (400 MHz, DMSO-d6) δ 7.41 (d, J = 8.0 Hz, 1H), 7.30 (s, 1H), 7.08 (d, J = 8.4 Hz, 1H), 6.98 - 6.93 (m, 1H), 6.58 - 6.54 (m, 1H), 6.45 - 6.40 (m, 1H), 5.82 - 5.77 (m, 1H), 3.79 (s, 3H), 3.63 - 3.53 (m, 2H), 3.04 - 2.93 (m, 1H), 2.90 - 2.77 (m, 4H), 2.53 - 2.44 (m, 1H), 2.43 - 2.39 (m, 2H), 2.28 - 2.23 (m, 4H), 2.07 - 1.94 (m, 4H), 1.93 - 1.84 (m, 2H), 1.11 - 1.05 (m, 1H), 0.95 (s, 9H), 0.65 - 0.56 (m, 1H), 0.47 - 0.40 (m, 1H), 0.38 - 0.30 (m, 1H), 0.22 - 0.16 (m, 1H).
Example 381:
Synthetic Route:
[1460] Referring to the synthetic route of compound 366, compound 361-1 was replaced with compound 381-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 381 (8 mg, yield: 13%) as a white solid. MS (ESI, m/z): 561.2 [M+H]+.
[1461] 1H NMR (400 MHz, CDCl3) δ 7.41 - 7.39 (m, 2H), 7.10 - 7.00 (m, 2H), 6.56 (dd, J = 7.6 Hz, 3.2 Hz, 1H), 6.50 - 6.44 (m, 1H), 5.82 - 5.77 (m, 1H), 3.71 (s, 3H), 3.49 - 3.40 (m, 2H), 3.19 - 3.17 (m, 2H), 3.06 - 3.00 (m, 1H), 2.82 - 2.74 (m, 3H), 2.71 - 2.64 (m, 4H), 2.46 - 2.40 (m, 2H), 2.37 - 2.30 (m, 1H), 2.07 - 1.95 (m, 2H), 1.88 - 1.79 (m, 2H), 1.10 - 0.98 (m, 7H), 0.54 - 0.45 (m, 1H), 0.31 - 0.22 (m, 2H), 0.15 - 0.07 (m, 1H).
Example 382:
Synthetic Route:
[1463] Referring to the synthetic route of compound 366, compound 361-1 was replaced with compound 382-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 382 (8 mg, yield: 15%) as a white solid. MS (ESI, m/z): 504.2 [M+H]+.
[1464] 1HNMR (400 MHz, MeOD) δ 7.50 (d, J = 8.0 Hz, 1H), 7.32 (s, 1H), 7.13 (dd, J = 8.0, 1.2 Hz, 1H), 6.95 (dd, J = 12.2, 8.8 Hz, 1H), 6.61 (dd, J = 7.2, 2.8 Hz, 1H), 6.53 - 6.46 (m, 1H), 6.03 - 5.98 (m, 1H), 3.76 (s, 3H), 3.59 - 3.50 (m, 2H), 3.21 - 3.13 (m, 1H), 2.84 - 2.70 (m, 6H), 2.60 - 2.52 (m, 2H), 2.50 - 2.41 (m, 1H), 2.28 - 2.14 (m, 2H), 2.11 - 2.02 (m, 2H), 1.96 - 1.86 (m, 2H), 1.15 - 1.05 (m, 1H), 0.63 - 0.55 (m, 1H), 0.44 - 0.29 (m, 2H), 0.19 - 0.10 (m, 1H).
Example 383:
Synthetic Route:
[1466] Referring to the synthetic route of compound 366, compound 361-1 was replaced with compound 383-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 383 (12 mg, yield: 45%) as a white solid. MS (ESI, m/z): 518.2 [M+H]+.
[1467] 1H NMR (400 MHz, CDCl3) δ 7.40 (d, J = 7.6 Hz, 1H), 7.30 (s, 1H), 7.09 (d, J = 7.6 Hz, 1H), 7.00 - 6.93 (m, 1H), 6.62 - 6.53 (m, 1H), 6.48 - 6.40 (m, 1H), 5.59 - 5.36 (m, 1H), 3.80 (s, 3H), 3.66 - 3.56 (m, 2H), 2.98 - 2.76 (m, 5H), 2.74 - 2.60 (m, 2H), 2.53 - 2.43 (m, 1H), 2.36 - 2.18 (m, 3H), 2.12 - 1.96 (m, 2H), 1.92 - 1.83 (m, 2H), 1.76 - 1.71 (m, 1H), 1.13 - 1.04 (m, 1H), 0.99 - 0.94 (m, 1H), 0.92 - 0.85 (m, 1H), 0.65 - 0.56 (m, 1H), 0.47 - 0.40 (m, 1H), 0.41 - 0.29 (m, 1H), 0.25 - 0.15 (m, 1H).
Example 384:
Synthetic Route:
[1469] Referring to the synthetic route of compound 373, compound 142-1 was replaced with compound 49-2 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 375 (5 mg, yield: 26%) as a white solid. MS (ESI, m/z): 504.2 [M+H]+.
[1470] 1H NMR (400 MHz, CDCl3) δ 7.53 (d, J = 8.0 Hz, 1H), 7.32 (s, 1H), 7.26 - 7.20 (m, 1H), 7.07 (d, J = 7.6 Hz, 1H), 6.65 (d, J = 6.8 Hz, 1H), 6.57 (s, 1H), 6.47 (d, J = 8.0 Hz, 1H), 3.89 - 3.82 (m, 5H), 2.97 - 2.81 (m, 6H), 2.56 - 2.46 (m, 1H), 2.32 - 2.17 (m, 2H), 1.92 - 1.81 (m, 3H), 1.79 - 1.71 (m, 1H), 1.40 (d, J = 7.0 Hz, 3H), 1.32 - 1.23 (m, 4H), 1.16 - 1.09 (m, 1H), 0.89 (t, J = 7.2 Hz, 3H), 0.69 - 0.60 (m, 1H), 0.53 - 0.44 (m, 1H), 0.41 - 0.31 (m, 1H), 0.28 - 0.18 (m, 1H).
Example 385:
Synthetic Route:
[1472] Compound 377-4 (130 mg, 0.244 mmol) was dissolved in tetrahydrofuran (5 mL). Methyl Grignard reagent 385-1 (1.0 M, 0.32 mL) was added at 0°C, and the reaction was carried out at 0°C for 1 hour. The reaction mixture was quenched with saturated ammonium chloride solution (1 mL), concentrated, and purified by normal -phase column chromatography (ethyl acetate: petroleum ether = 10%) to obtain compound 385-2 (20 mg, yield: 15%) as a white solid. LCMS: [M+H]+ = 548.3.
[1473] Compound 385-2 (20 mg, 0.0376 mmol) was dissolved in methanol (3 mL), and one drop of concentrated hydrochloric acid was added as a catalyst along with palladium on carbon (10 mg). The reaction was carried out under a hydrogen atmosphere at 50°C overnight, followed by filtration and concentration. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 10%) to obtain compound 385-3 (10 mg, yield: 50%) as a white solid. LCMS: [M+H]+ = 532.3.
[1474] To a reaction tube, compound 385-3 (10 mg, 0.0187 mmol), lithium hydroxide (8.2 mg, 0.341 mmol), methanol (1 mL), water (1 mL), and tetrahydrofuran (1 mL) were added. The reaction was carried out at 50°C for 2 hours. After the reaction mixture was rotary evaporated to remove the solvent, the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 50% to 70%] to obtain compound 385 (4.2 mg, yield: 42%) as a white solid. LCMS: [M+H]+ = 518.3.
[1475] 1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 8.0 Hz, 1H), 7.32 (s, 1H), 7.26 - 7.19 (m, 1H), 7.07 (d, J = 8.4 Hz, 1H), 6.65 (d, J = 7.6 Hz, 1H), 6.57 (s, 1H), 6.47 (d, J = 7.6 Hz, 1H), 3.89 - 3.83 (m, 5H), 2.98 - 2.84 (m, 6H), 2.54 - 2.45 (m, 1H), 2.28 - 2.16 (m, 2H), 1.91 - 1.83 (m, 2H), 1.82 - 1.71 (m, 2H), 1.60 - 1.52 (m, 1H), 1.40 (d, J = 7.2 Hz, 3H), 1.23 - 1.07 (m, 3H), 0.92 - 0.85 (m, 6H), 0.70 - 0.60 (m, 1H), 0.52 - 0.43 (m, 1H), 0.40 - 0.31 (m, 1H), 0.27 - 0.19 (m, 1H).
Example 386:
Synthetic Route:
[1477] Referring to the synthetic route of compound 377, compound 377-3 was replaced with compound 386-1 to synthesize compound 386-3. Then, referring to the synthetic route of compound 385, compound 385-2 was replaced with compound 386-3, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 386 (12 mg, yield: 37%) as a white solid. MS (ESI, m/z): 566.2 [M+H]+.
[1478] 1H NMR (400 MHz, CDCl3) δ 7.40 - 7.30 (m, 3H), 7.28 - 7.26 (m, 2H), 7.21 - 7.13 (m, 3H), 6.99 (d, J = 8.0 Hz, 1H), 6.59 (dd, J = 8.0, 2.0 Hz, 1H), 6.54 - 6.49 (m, 1H), 6.42 (dd, J = 8.0, 2.0 Hz, 1H), 4.13 - 4.05 (m, 1H), 3.84 - 3.75 (m, 5H), 3.00 - 2.90 (m, 1H), 2.87 - 2.76 (m, 4H), 2.49 - 2.41 (m, 1H), 2.26 - 2.11 (m, 4H), 1.82 - 1.73 (m, 2H), 1.34 - 1.26 (m, 4H), 1.10 - 1.01 (m, 1H), 0.87 (t, J = 7.2 Hz, 3H), 0.64 - 0.57 (m, 1H), 0.48 - 0.40 (m, 1H), 0.34 - 0.29 (m, 1H), 0.23 - 0.14 (m, 1H).
Example 387:
Synthetic Route:
[1480] Referring to the synthetic route of compound 385, compound 385-2 was replaced with compound 377-6. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 387 (20 mg, yield: 57%) as a white solid. MS (ESI, m/z): 580.2 [M+H]+.
[1481] 1H NMR (400 MHz, CDCl3) δ 7.39 (d, J = 8.0 Hz, 1H), 7.35 - 7.30 (m, 2H), 7.29 - 7.26 (m, 3H), 7.21 - 7.13 (m, 2H), 6.99 (d, J = 8.4 Hz, 1H), 6.59 (d, J = 8.0 Hz, 1H), 6.52 (s, 1H), 6.42 (d, J = 7.6 Hz, 1H), 4.11 - 4.03 (m, 1H), 3.85 - 3.74 (m, 5H), 3.01 - 2.89 (m, 1H), 2.85 - 2.73 (m, 4H), 2.47 - 2.39 (m, 1H), 2.28 - 2.08 (m, 4H), 1.81 - 1.71 (m, 2H), 1.62 - 1.53 (m, 1H), 1.25 - 1.15 (m, 2H), 1.09 - 1.01 (m, 1H), 0.90 - 0.82 (m, 6H), 0.63 - 0.54 (m, 1H), 0.48 - 0.38 (m, 1H), 0.38 - 0.27 (m, 1H), 0.23 - 0.12 (m, 1H).
Example 388:
Synthetic Route:
[1483] Referring to the synthetic route of compound 366, compound 361-1 was replaced with compound 388-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 388 (3 mg, yield: 6%) as a white solid. MS (ESI, m/z): 522.2 [M+H]+.
[1484] 1H NMR (400 MHz, DMSO-d6) δ 7.37 - 7.35 (m, 2H), 7.10 (d, J = 7.6 Hz, 1H), 7.05 (dd, J = 12.4, 8.8 Hz, 1H), 6.58 (dd, J = 7.2, 2.8 Hz, 1H), 6.52 - 6.46 (m, 1H), 3.73 (s, 3H), 3.53 - 3.44 (m, 2H), 3.04 - 2.96 (m, 1H), 2.86 - 2.76 (m, 2H), 2.75 - 2.63 (m, 2H), 2.59 - 2.55 (m, 2H), 2.39 - 2.31 (m, 1H), 2.08 - 1.94 (m, 2H), 1.85 - 1.82 (m, 2H), 1.48 - 1.39 (m, 2H), 1.08 - 1.03 (m, 1H), 1.00 (s, 9H), 0.55 - 0.46 (m, 1H), 0.31 - 0.24 (m, 2H), 0.15 - 0.10 (m, 1H).
Example 389:
Synthetic Route:
[1486] Referring to the synthetic route of compound 389, compound 98-1 was replaced with compound 142-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 389 (3 mg, yield: 9%) as a white solid. MS (ESI, m/z): 522.3 [M+H]+.
[1487] 1H NMR (400 MHz, CDCl3) δ 7.39 (d, J = 8.0 Hz, 1H), 7.30 (s, 1H), 7.10 (d, J = 8.0 Hz, 1H), 7.01 - 6.90 (m, 1H), 6.62 - 6.43 (m, 2H), 3.80 (s, 3H), 3.65 - 3.56 (m, 2H), 2.93 - 2.77 (m, 5H), 2.64 - 2.55 (m, 2H), 2.51 - 2.45 (m, 1H), 2.27 - 2.24 (m, 2H), 1.94 - 1.84 (m, 2H), 1.54 - 1.49 (m, 2H), 1.03 (s, 9H), 0.91 - 0.88 (m, 1H), 0.62 - 0.58 (m, 1H), 0.45 - 0.43 (m, 1H), 0.35 - 0.33 (m, 1H), 0.21 - 0.18 (m, 1H).
Example 390:
Synthetic Route:
[1489] Compound 368-2 (80 mg, 0.15 mmol) was added to methanol (4 mL) and tetrahydrofuran (4 mL) and stirred. Palladium on carbon (20 mg) was then added, and the reaction mixture was stirred under hydrogen (1 atm) at room temperature for 40 minutes. After the reaction was completed, the reaction mixture was filtered, concentrated, and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 390-1 (80 mg, yield: 99%) as a yellow solid. MS (ESI, m/z): 538.2 [M+H]+.
[1490] Compound 390-1 (80 mg, 0.15 mmol) was added to methanol (1 mL), water (1 mL), and tetrahydrofuran (1 mL) and stirred. 4 M sodium hydroxide solution (3 mL) was added, and the reaction mixture was stirred at 70°C for 16 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 390 (41 mg, yield: 52%) as a white solid. MS (ESI, m/z): 524.2 [M+H]+.
[1491] 1H NMR (400 MHz, DMSO-d6) δ 7.43 - 7.38 (m, 2H), 7.14 - 7.03 (m, 2H), 6.62 - 6.54 (m, 1H), 6.52 - 6.45 (m, 1H), 4.34 (s, 1H), 3.73 (s, 3H), 3.53 - 3.44 (m, 2H), 3.04 - 2.98 (m, 1H), 2.87 - 2.76 (m, 2H), 2.72 - 2.64 (m, 4H), 2.37 - 2.31 (m, 1H), 2.06 - 1.97 (m, 2H), 1.90 - 1.81 (m, 2H), 1.64 - 1.60 (m, 2H), 1.19 (s, 6H), 1.09 - 1.01 (m, 1H), 0.54 - 0.51 (m, 1H), 0.32 - 0.22 (m, 2H), 0.14 - 0.11 (m, 1H).
Example 391:
Synthetic Route:
[1493] Referring to the synthetic route of compound 390, compound 368-2 was replaced with compound 373-2 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 391 (3 mg, yield: 23%) as a white solid. MS (ESI, m/z): 520.3 [M+H]+.
[1494] 1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 8.0 Hz, 1H), 7.30 (s, 1H), 7.10 (d, J = 8.0 Hz, 1H), 6.96 (dd, J = 12.0, 9.2 Hz, 1H), 6.59 - 6.54 (m, 1H), 6.47 - 641 (m, 1H), 3.80 (s, 3H), 3.66 - 3.56 (m, 2H), 2.96 - 2.78 (m, 5H), 2.70 - 2.63 (m, 2H), 2.53 - 2.44 (m, 1H), 2.31 - 2.25 (m, 2H), 1.89 - 1.84 (m, 2H), 1.78 - 1.74 (m, 1H), 1.32 - 1.26 (m, 4H), 1.14 - 1.07 (m, 1H), 0.78 - 0.70 (m, 1H), 0.65 - 0.57 (m, 1H), 0.45 - 0.42 (m, 2H), 0.37 - 0.32 (m, 1H), 0.25 - 0.17 (m, 1H), 0.05 - 0.00 (m, 2H).
Example 392:
Synthetic Route:
[1496] Compound 98-1 (200 mg, 0.37 mmol), compound 392-1 (373 mg, 1.88 mmol), [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) chloride dichloromethane complex (26 mg, 0.04 mmol), and potassium carbonate (156 mg, 1.13 mmol) were added to a mixture of 1,4-dioxane: water = 5:1 (25 mL). The reaction mixture was stirred at 80°C for 16 hours. LCMS monitoring confirmed the complete consumption of the starting material. The reaction mixture was extracted with ethyl acetate (50 mL) and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 20%) to obtain compound 392-2 (100 mg, yield: 51%) as a yellow oil. MS (ESI, m/z): 522.2 [M+H]+.
[1497] Compound 392-2 (41 mg, 0.07 mmol) was added to a mixture of trifluoroacetic acid (4.48 mg, 0.04 mmol) and dichloromethane (4 mL) with stirring. The reaction mixture was stirred at 0°C for 40 minutes. After the reaction was completed, the reaction mixture was filtered, concentrated, and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 392-3 (30 mg, yield: 77%) as a yellow oil. MS (ESI, m/z): 494.2 [M+H]+.
[1498] Compound 392-3 (30 mg, 0.06 mmol) was dissolved in tetrahydrofuran (5 mL). Methyl Grignard reagent 385-1 (1.0 M, 0.07 mL) was added at 0°C, and the reaction was carried out at 0°C for 2 hours. The reaction mixture was quenched with saturated ammonium chloride solution (1 mL), concentrated, and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 10%) to obtain compound 392-4 (30 mg, yield: 96%) as a white solid. LCMS: [M+H]+ = 510.3.
[1499] Compound 392-4 (20 mg, 0.04 mmol) was added to methanol (1 mL), water (1 mL), and tetrahydrofuran (1 mL) and stirred. 4 M sodium hydroxide solution (3 mL) was added, and the reaction mixture was stirred at 70°C for 16 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 392 (18 mg, yield: 54%) as a white solid. MS (ESI, m/z): 496.2 [M+H]+.
[1500] 1H NMR (400 MHz, MeOD) δ 7.38 (d, J = 8.0 Hz, 1H), 7.32 (s, 1H), 7.13 (d, J = 8.0 Hz, 1H), 6.95 (dd, J = 12.2, 8.8 Hz, 1H), 6.61 (dd, J = 7.2, 3.0 Hz, 1H), 6.52 - 6.46 (m, 1H), 4.09 - 4.02 (m, 1H), 3.76 (s, 3H), 3.58 - 3.50 (m, 2H), 3.08 - 2.97 (m, 1H), 2.87 - 2.76 (m, 3H), 2.76 - 2.55 (m, 3H), 2.52 - 2.43 (m, 1H), 2.26 - 2.15 (m, 2H), 1.94 - 1.84 (m, 2H), 1.18 (d, J= 6.2 Hz, 3H), 1.10 - 1.02 (m, 1H), 0.60 - 0.52 (m, 1H), 0.41 - 0.30 (m, 2H), 0.14 - 0.06 (m, 1H).
Example 393:
Synthetic Route:
[1503] Compound 392-3 (30 mg, 0.06 mmol) was dissolved in tetrahydrofuran (2 mL) and methanol (2 mL). Sodium borohydride (6 mg, 0.16 mmol) was added at 0°C, and the reaction was carried out at 25°C for 2 hours. The reaction mixture was quenched with saturated ammonium chloride solution (1 mL), concentrated, and purified by normal - phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 393-1 (20 mg, yield: 67%) as a yellow solid. MS (ESI, m/z): 496.2 [M+H]+.
[1504] Compound 393-1 (20 mg, 0.04 mmol) was dissolved in N,N-dimethylformamide (3 mL). Sodium hydride (2 mg, 0.06 mmol) was added at 0°C, and the reaction was carried out at 25°C for 1 hour. Compound 393-2 (55 mg, 0.32 mmol) was then added, followed by quenching with saturated sodium bicarbonate solution (1 mL). The reaction mixture was concentrated and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 393-3 (15 mg, yield: 62%) as a yellow solid. MS (ESI, m/z): 538.3 [M+H]+.
[1505] Compound 393-3 (15 mg, 0.03 mmol) was added to methanol (1 mL), water (1 mL), and tetrahydrofuran (1 mL) and stirred. Lithium hydroxide (4 mg, 0.14 mmol) was added, and the reaction mixture was stirred at 25°C for 16 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 393 (2 mg, yield: 11%) as a white solid. MS (ESI, m/z): 524.2 [M+H]+.
[1506] 1H NMR (400 MHz, MeOD) δ 7.45 (d, J = 8.0 Hz, 1H), 7.31 (s, 1H), 7.20 (dd, J = 11.6, 9.0 Hz, 1H), 7.13 (dd, J = 8.0, 1.2 Hz, 1H), 7.07 - 6.98 (m, 1H), 6.89 - 6.83 (m, 1H), 3.83 (s, 3H), 3.78 - 3.70 (m, 2H), 3.66 (t, J = 6.6 Hz, 2H), 3.63 - 3.55 (m, 1H), 3.46 - 3.35 (m, 2H), 3.31 - 3.23 (m, 1H), 2.92 (t, J = 6.6 Hz, 2H), 2.84 - 2.70 (m, 2H), 2.48 - 2.32 (m, 3H), 2.16 - 2.08 (m, 2H), 1.14 - 1.06 (m, 7H), 0.65 - 0.57 (m, 1H), 0.43 - 0.29 (m, 2H), 0.19 - 0.11 (m, 1H).
Example 394:
Synthetic Route:
[1508] Compound 392-4 (20 mg, 0.04 mmol) was dissolved in N,N-dimethylformamide (3 mL). Sodium hydride (2 mg, 0.06 mmol) was added at 0°C, and the reaction was carried out at 25°C for 1 hour. Iodomethane (45 mg, 0.31 mmol) was then added, followed by quenching with saturated sodium bicarbonate solution (1 mL). The reaction mixture was concentrated and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 394-1 (15 mg, yield: 73%) as a yellow solid. MS (ESI, m/z): 524.3 [M+H]+.
[1509] Compound 394-1 (15 mg, 0.02 mmol) was added to methanol (1 mL), water (1 mL), and tetrahydrofuran (1 mL) and stirred. Lithium hydroxide (4 mg, 0.14 mmol) was added, and the reaction mixture was stirred at 25°C for 4 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 394 (3 mg, yield: 18%) as a white solid. MS (ESI, m/z): 510.2 [M+H]+.
[1510] 1H NMR (400 MHz, DMSO-d6) δ 7.36 (d, J = 8.0 Hz, 1H), 7.28 (s, 1H), 7.09 - 7.00 (m, 2H), 6.58 (dd, J = 7.6, 2.8 Hz, 1H), 6.52 - 6.45 (m, 1H), 3.73 (s, 3H), 3.58 - 3.43 (m, 3H), 3.25 (s, 3H), 3.05 - 2.96 (m, 1H), 2.88 - 2.76 (m, 3H), 2.68 - 2.62 (m, 1H), 2.51 - 2.40 (m, 3H), 2.08 - 1.96 (m, 2H), 1.87 - 1.77 (m, 2H), 1.08 (d, J = 6.0 Hz, 3H), 0.99 - 0.90(m, 1H), 0.45 - 0.37 (m, 1H), 0.28 - 0.19 (m, 2H), 0.08 - 0.03 (m, 1H).
Example 395:
Synthetic Route:
[1512] Compound 392-4 (25 mg, 0.05 mmol) was dissolved in N,N-dimethylformamide (3 mL). Dess-Martin periodinane (31 mg, 0.07 mmol) was added at 0°C, and the reaction was carried out at 25°C for 1 hour. The reaction was quenched with water (10 mL) and extracted with ethyl acetate (10 mL × 3). The organic phase was concentrated and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 395-1 (15 mg, yield: 60%) as a yellow solid. MS (ESI, m/z): 508.3 [M+H]+.
[1513] Compound 395-1 (15 mg, 0.03 mmol) was added to methanol (1 mL), water (1 mL), and tetrahydrofuran (1 mL) and stirred. Lithium hydroxide (4 mg, 0.14 mmol) was added, and the reaction mixture was stirred at 25°C for 16 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 395 (1 mg, yield: 8%) as a white solid. MS (ESI, m/z): 494.2 [M+H]+.
[1514] 1H NMR (400 MHz, MeOD) δ 7.37 - 7.29 (m, 2H), 7.13 (d, J = 8.0 Hz, 1H), 6.95 (dd, J = 12.2, 8.8 Hz, 1H), 6.61 (dd, J = 7.2, 3.0 Hz, 1H), 6.52 - 6.47 (m, 1H), 3.83 (s, 2H), 3.76 (s, 3H), 3.58 - 3.50 (m, 2H), 3.06 - 2.95 (m, 1H), 2.86 - 2.69 (m, 4H), 2.50 - 2.41 (m, 1H), 2.24 - 2.12 (m, 5H), 1.94 - 1.83 (m, 2H), 1.12 - 1.04 (m, 1H), 0.62 - 0.54 (m, 1H), 0.42 - 0.29 (m, 2H), 0.18 - 0.11 (m, 1H).
Example 396:
Synthetic Route:
[1516] Compound 395-1 (20 mg, 0.04 mmol) was dissolved in dichloromethane (5 mL), followed by the addition of 1,2-ethanediol (25 mg, 0.39 mmol), triethyl orthoformate (8 mg, 0.06 mmol), and D-camphorsulfonic acid (0.9 mg, 0.01 mmol). The reaction was carried out at 25°C for 24 hours, then quenched with saturated sodium bicarbonate (10 mL) and extracted with ethyl acetate (10 mL × 3). The organic phase was concentrated and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 396-1 (15 mg, yield: 55%) as a yellow solid. MS (ESI, m/z): 552.3 [M+H]+.
[1517] Compound 396-1 (15 mg, 0.03 mmol) was added to methanol (1 mL), water (1 mL), and tetrahydrofuran (1 mL) and stirred. Lithium hydroxide (4 mg, 0.14 mmol) was added, and the reaction mixture was stirred at 25°C for 16 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 396 (1 mg, yield: 3%) as a white solid. MS (ESI, m/z): 538.2 [M+H]+.
[1518] 1H NMR (400 MHz, MeOD) δ 7.44 (d, J = 8.0 Hz, 1H), 7.30 (s, 1H), 7.12 (d, J = 7.4 Hz, 1H), 6.95 (dd, J = 12.2, 9.0 Hz, 1H), 6.62 (dd, J = 7.4, 2.8 Hz, 1H), 6.51 - 6.46 (m, 1H), 3.88 - 3.83 (m, 2H), 3.78 - 3.73 (m, 5H), 3.58 - 3.50 (m, 2H), 3.07 - 2.98 (m, 1H), 2.97 (s, 2H), 2.84 - 2.76 (m, 2H), 2.68 - 2.44 (m, 3H), 2.24 - 2.12 (m, 2H), 1.93 - 1.88 (m, 2H), 1.34 (s, 3H), 1.09 - 1.02 (m, 1H), 0.58 - 0.51 (m, 1H), 0.40 - 0.33 (m, 2H), 0.14 - 0.09 (m, 1H).
Example 397:
Synthetic Route:
[1519]
Compound 392-3 (90 mg, 0.15 mmol) was added to methanol (4 mL) and tetrahydrofuran (4 mL) and stirred. Platinum dioxide (10 mg, 0.044 mmol) was then added, and the reaction mixture was stirred under hydrogen (1 atm) at room temperature for 2 hours. After the reaction was completed, the reaction mixture was filtered, concentrated, and purified by normal-phase column chromatography (methanol: dichloromethane = 0% to 20%) to obtain compound 397-1 (78 mg, yield: 99%) as a white solid. MS (ESI, m/z): 510.2 [M+H]+.
[1520] Referring to the synthetic route of compound 308, compound 305-3 was replaced with compound 397-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 397 (12 mg, yield: 20%) as a white solid. MS (ESI, m/z): 535.2 [M+H]+.
[1521] 1H NMR (400 MHz, CDCl3) δ 7.36 (s, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.13 (d, J = 8.0 Hz, 1H), 6.97 (dd, J = 12.0, 8.8 Hz, 1H), 6.60 - 6.54 (m, 1H), 6.50 - 6.42 (m, 1H), 5.82 - 5.74 (m, 1H), 3.80 (s, 3H), 3.60 - 3.55 (m, 2H), 3.53 (s, 2H), 2.92 - 2.88 (m, 1H), 2.88 - 2.77 (m, 4H), 2.68 - 2.61 (m, 1H), 2.53 - 2.45 (m, 1H), 2.30 - 2.17 (m, 2H), 1.89 - 1.79 (m, 2H), 1.15 - 1.03 (m, 1H), 0.76 - 0.69 (m, 2H), 0.67 - 0.60 (m, 1H), 0.48 - 0.42 (m, 1H), 0.41 - 0.37 (m, 2H), 0.37 - 0.32 (m, 1H), 0.25 - 0.16 (m, 1H).
Example 398:
Synthetic Route:
[1523] Compound 49-5 (168 mg, 0.364 mmol) was dissolved in methanol (4 mL) and tetrahydrofuran (4 mL). Sodium borohydride (15 mg, 0.4 mmol) was added at 0°C, and the reaction was carried out at 0°C for 3 hours. After concentration, the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 398-1 (136 mg, yield: 81%) as a yellow oil. MS (ESI, m/z): 464.3 [M+H]+.
[1524] Compound 398-1 (68 mg, 0.147 mmol), compound 398-2 (100 µL, 0.2 mmol, 2 M), and triethylamine (100 µL) were dissolved in dichloromethane (4 mL). The reaction was carried out at 25°C for 24 hours. After concentration, the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 398-3 (71 mg, yield: 88%) as a yellow oil. MS (ESI, m/z): 548.3 [M+H]+.
[1525] Compound 398-3 (71 mg, 0.13 mmol) and compound 398-4 (47 mg, 0.26 mmol) were dissolved in dichloroethane (5 mL) and reacted at 25°C for 24 hours. After concentration, the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 398 (14 mg, yield: 20%) as a white solid. MS (ESI, m/z): 534.2 [M+H]+.
[1526] 1H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 8.0 Hz, 1H), 7.35 (s, 1H), 7.25 - 7.19 (m, 1H), 7.15 (d, J = 8.0 Hz, 1H), 6.66 - 6.62 (m, 1H), 6.58 - 6.55 (m, 1H), 6.49 - 6.44 (m, 1H), 5.24 (s, 2H), 3.91 - 3.78 (m, 5H), 3.19 - 3.04 (m, 1H), 2.97 - 2.80 (m, 4H), 2.57 - 2.45 (m, 1H), 2.30 - 2.12 (m, 2H), 1.99 - 1.88 (m, 2H), 1.22 (s, 9H), 1.17 - 1.06 (m, 1H), 0.72 - 0.58 (m, 1H), 0.53 - 0.42 (m, 1H), 0.41 - 0.31 (m, 1H), 0.27 - 0.16 (m, 1H).
Example 399:
Synthetic Route:
[1528] Compound 49-5 (138 mg, 0.3 mmol), compound 399-1 (312 mg, 3.0 mmol), and p-toluenesulfonic acid monohydrate (8 mg, 0.03 mmol) were dissolved in toluene (2 mL) and refluxed for 2 hours. After concentration, the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 399-2 (148 mg, yield: 90%) as a white solid. MS (ESI, m/z): 548.3 [M+H]+.
[1529] Compound 399-2 (148 mg, 0.27 mmol) was added to methanol (5 mL). Then, 1 mL of an aqueous solution of NaOH (108 mg, 2.7 mmol) was added dropwise to the reaction, and the reaction mixture was stirred at room temperature overnight. Dilute hydrochloric acid was added to adjust the pH to 3, followed by extraction with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 399 (122 mg, yield: 85%) as a white solid. MS (ESI, m/z): 534.2 [M+H]+.
[1530] 1H NMR (400 MHz, CDCl3) δ 7.72 (d, J = 8.0 Hz, 1H), 7.26 (s, 1H), 7.26 - 7.22 (m, 1H), 7.09 (d, J = 8.4 Hz, 1H), 6.62 (d, J = 8.0 Hz, 1H), 6.54 (s, 1H), 6.43 (d, J = 8.4 Hz, 1H), 5.68 (s, 1H), 3.87 - 3.75 (m, 7H), 3.71 - 3.64 (m, 2H), 3.22 - 3.08 (m, 1H), 2.91 - 2.73 (m, 4H), 2.52 - 2.42 (m, 1H), 2.24 - 2.09 (m, 2H), 2.00 - 1.91 (m, 2H), 1.39 (s, 3H), 1.09 - 0.99 (m, 1H), 0.83 (s, 3H), 0.62 - 0.53 (m, 1H), 0.42 - 0.34 (m, 1H), 0.32 - 0.25 (m, 1H), 0.16 - 0.08 (m, 1H).
Example 400:
Synthetic Route:
[1532] Referring to the synthetic route of compound 399, compound 399-1 was replaced with compound 400-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 400 (116 mg, yield: 97%) as a white solid. MS (ESI, m/z): 520.2 [M+H]+.
[1533] 1H NMR (400 MHz, CDCl3) δ 7.58 (d, J = 8.0 Hz, 1H), 7.29 (s, 1H), 7.24 - 7.16 (m, 1H), 7.09 (d, J = 8.0 Hz, 1H), 6.75 - 6.36 (m, 3H), 6.22 (s, 1H), 3.97 - 3.72 (m, 7H), 3.21-3.05 (m, 1H), 2.99 - 2.73 (m, 4H), 2.52 - 2.46 (m, 1H), 2.25 - 2.08 (m, 2H), 2,02 - 1.93 (m, 2H), 1.44 (d, J = 5.6 Hz, 3H), 1.36 (d, J = 5.6 Hz, 3H), 1.09 - 1.01 (m 1H), 0.65 - 0.53 (m, 1H), 0.44 - 0.36 (m, 1H), 0.34 - 0.27 (m, 1H), 0.18 - 0.11 (m, 1H).
Example 401:
Synthetic Route:
[1535] Compound 398-1 (30 mg, 0.0650 mmol) was dissolved in dichloromethane (1 mL), and trichloroacetonitrile (10 mg, 0.0679 mmol) and 1,8-diazabicyclo[5,4,0]undec-7-ene (0.1 mL) were added. The reaction was carried out at room temperature for 2 hours, then concentrated and dissolved in dichloromethane (2 mL). 2-Methyl-2-butanol (0.5 mL) and trifluoromethanesulfonic acid (0.05 mL) were added, and the reaction was carried out at room temperature overnight. After concentration, the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 10%) to obtain compound 401-2 (28 mg, yield: 82%) as a white solid. MS (ESI, m/z): 634.3 [M+H]+.
[1536] Compound 401-2 (28 mg, 0.044 mmol), lithium hydroxide (8.2 mg, 0.341 mmol), tetrahydrofuran (1 mL), methanol (1 mL), and water (1 mL) were reacted at 50°C for 2 hours. After concentration, the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 401 (19 mg, yield: 68%) as a white solid. MS (ESI, m/z): 620.2 [M+H]+.
[1537] 1H NMR (400 MHz, CDCl3) δ 7.53 (d, J = 8.0 Hz, 1H), 7.33 (s, 1H), 7.25 - 7.20 (m, 1H), 7.13 (d, J = 8.0 Hz, 1H), 6.65 (d, J = 8.4 Hz, 1H), 6.58 (s, 1H), 6.47 (d, J = 7.6 Hz, 1H), 4.64 (s, 2H), 3.87 - 3.82 (m, 5H), 3.18 (s, 2H), 3.13 - 3.05 (m, 1H), 2.94 - 2.82 (m, 4H), 2.55 - 2.47 (m, 1H), 2.26 - 2.15 (m, 2H), 1.99 - 1.91 (m, 2H), 1.16 - 1.07 (m, 1H), 0.95 (s, 9H), 0.68 - 0.60 (m, 1H), 0.53 - 0.43 (m, 1H), 0.39 - 0.33 (m, 1H), 0.24 - 0.17 (m, 1H).
Example 402:
Synthetic Route:
[1539] Referring to the synthetic route of compound 393, compound 392-3 was replaced with compound 126-2, and compound 393-2 was replaced with compound 402-3. The synthesis was carried out, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 400 (60 mg, yield: 50%) as a white solid. MS (ESI, m/z): 555.2 [M+H]+.
[1540] 1H NMR (400 MHz, CDCl3) δ 8.15 (d, J= 5.2 Hz, 1H), 7.60 - 7.54 (m, 1H), 7.50 (d, J = 8.0 Hz, 1H), 7.31 (s, 1H), 7.25 - 7.17 (m, 1H), 7.12 (d, J = 8.0 Hz, 1H), 6.90 - 6.83 (m, 1H), 6.69 (d, J = 8.4 Hz, 1H), 6.66 - 6.59 (m, 1H), 6.59 - 6.51 (m, 1H), 6.49 - 6.39 (m, 1H), 4.52 (t, J = 6.8 Hz, 2H), 3.90 - 3.75 (m, 5H), 3.13 (t, J = 6.8 Hz, 2H), 3.06 - 2.94 (m, 1H), 2.93 - 2.75 (m, 4H), 2.56 - 2.41 (m, 1H), 2.31 - 2.07 (m, 2H), 1.96 - 1.85 (m, 2H), 1.15 - 1.01 (m, 1H), 0.68 - 0.56 (m, 1H), 0.48 - 0.38 (m, 1H), 0.37 - 0.30 (m, 1H), 0.26 - 0.10 (m, 1H).
Example 403:
Synthetic Route:
[1542] Referring to the synthetic route of compound 398, compound 398-2 was replaced with compound 403-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 403 (3 mg, yield: 3%) as a white solid. MS (ESI, m/z): 554.2 [M+H]+.
[1543] 1H NMR (400 MHz, CDCl3) δ 8.07 (d, J = 8.0 Hz, 2H), 7.63 - 7.54 (m, 2H), 7.48 - 7.42 (m, 2H), 7.36 (s, 1H), 7.25 - 7.20 (m, 1H), 7.17 (d, J = 8.0 Hz, 1H), 6.67 - 6.61 (m, 1H), 6.60 - 6.54 (m, 1H), 6.50 - 6.43 (m, 1H), 5.52 (s, 2H), 3.90 - 3.81 (m, 5H), 3.27 - 3.16 (m, 1H), 2.98 - 2.79 (m, 4H), 2.55 - 2.46 (m, 1H), 2.30 - 2.17 (m, 2H), 2.02 - 1.92 (m, 2H), 1.16 - 1.04 (m, 1H), 0.69 - 0.59 (m, 1H), 0.50 - 0.41 (m, 1H), 0.40 - 0.30 (m, 1H), 0.25 - 0.16 (m, 1H).
Example 404:
Synthetic Route:
[1545] Referring to the synthetic route of compound 401, compound 401-1 was replaced with compound 404-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 404 (8 mg, yield: 40%) as a white solid. MS (ESI, m/z): 526.2 [M+H]+.
[1546] 1H NMR (400 MHz, CDCl3) δ 7.55 (d, J = 8.0 Hz, 1H), 7.38 - 7.31 (m, 4H), 7.17 (d, J = 8.0 Hz, 1H), 7.07 - 7.00 (m, 3H), 6.79 - 6.38 (m, 3H), 5.18 (s, 2H), 3.89 - 3.77 (m, 6H), 2.95 - 2.83 (m, 4H), 2.56 - 2.49 (m, 1H), 2.28 - 2.20 (m, 2H), 1.96 - 1.90 (m, 2H), 1.15 - 1.10 (m, 1H), 0.69 - 0.63 (m, 1H), 0.50 - 0.45 (m, 1H), 0.39 - 0.32 (m, 1H), 0.26 - 0.19 (m, 1H).
Example 405:
Synthetic Route:
[1548] Compound 126-2 (20 mg, 0.04 mmol) was dissolved in 1,2-dichloroethane (5 mL), followed by the addition of pyrrolidine (15.4 mg, 0.21 mmol) and anhydrous magnesium sulfate (15.59 mg, 0.13 mmol). The reaction was carried out at room temperature for 4 hours. Sodium triacetoxyborohydride (27.53 mg, 0.13 mmol) and acetic acid (0.1 mL) were then added, and the reaction was carried out at room temperature overnight. The reaction mixture was quenched with saturated sodium bicarbonate (10 mL) and extracted with dichloromethane (10 mL × 3). The combined organic phases were concentrated and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 405-1 (20 mg, yield: 71%) as a colorless oil. MS (ESI, m/z): 517.3 [M+H]+.
[1549] Compound 405-1 (20 mg, 0.03 mmol) was added to methanol (1 mL), water (1 mL), and tetrahydrofuran (1 mL) and stirred. Lithium hydroxide (5.56 mg, 0.23 mmol) was added, and the reaction mixture was stirred at 25°C for 16 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 405 (13 mg, yield: 27%) as a white solid. MS (ESI, m/z): 515.2 [M+H]+.
[1550] 1H NMR (400 MHz, MeOD) δ 7.57 (d, J = 8.0 Hz, 1H), 7.40 (s, 1H), 7.23 (d, J = 8.0 Hz, 1H), 7.19 - 7.12 (m, 1H), 6.63 (dd, J = 8.2, 2.0 Hz, 1H), 6.58 - 6.53 (m, 1H), 6.45 (dd, J = 8.0, 2.1 Hz, 1H), 4.39 (s, 2H), 3.87 - 3.72 (m, 5H), 3.27 - 3.14 (m, 4H), 2.92 - 2.82 (m, 2H), 2.78 - 2.58 (m, 2H), 2.52 - 2.40 (m, 1H), 2.24 - 2.11 (m, 2H), 2.09 - 1.98 (m, 4H), 1.95 - 1.83 (m, 2H), 1.13 - 0.99 (m, 1H), 0.66 - 0.51 (m, 1H), 0.42 - 0.29 (m, 2H), 0.17 - 0.07 (m, 1H).
Example 406:
Synthetic Route:
[1552] Compound 49-5 (1000 mg, 2.2 mmol) was dissolved in tetrahydrofuran (10 mL), and methyl Grignard reagent (1.0 M, 4.3 mL) was added dropwise. The reaction was carried out at room temperature overnight, then quenched with saturated ammonium chloride solution (1 mL). After concentration, the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 406-1 (620 mg, yield = 62%) as a white solid. MS (ESI, m/z): 478.3 [M+H]+.
[1553] Referring to the synthetic route of compound 401, compound 398-1 was replaced with compound 406-1, and compound 401-1 was replaced with compound 406-2. The synthesis was carried out, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 406 (38 mg, yield: 65%) as a white solid. MS (ESI, m/z): 478.3 [M+H]+.
[1554] 1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 8.0 Hz, 1H), 7.11 (s, 1H), 7.05 - 6.96 (m, 1H), 6.89 (dd, J = 8.0, 1.2 Hz, 1H), 6.42 (d, J = 8.0 Hz, 1H), 6.34 (s, 1H), 6.25 (d, J = 7.2 Hz, 1H), 4.49 - 4.37 (m, 1H), 3.65 - 3.58 (m, 5H), 3.06 (s, 3H), 2.85 - 2.75 (m, 1H), 2.72 - 2.58 (m, 4H), 2.33 - 2.23 (m, 1H), 2.07 - 1.94 (m, 2H), 1.76 - 1.61 (m, 2H), 1.39 (d, J = 6.4 Hz, 3H), 0.92 - 0.85 (m, 1H), 0.47 - 0.35 (m, 1H), 0.28 - 0.18 (m, 1H), 0.15 - 0.08 (m, 1H), 0.03 - 0.03 (m, 1H).
Example 407:
Synthetic Route:
[1556] Referring to the synthetic route of compound 406, compound 406-2 was replaced with compound 407-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 407 (27 mg, yield: 66%) as a white solid. MS (ESI, m/z): 492.3 [M+H]+.
[1557] 1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 8.0 Hz, 1H), 7.29 (s, 1H), 7.22 - 7.16 (m, 1H), 7.07 (d, J = 8.0 Hz, 1H), 6.61 (d, J = 8.4 Hz, 1H), 6.53 (s, 1H), 6.44 (d, J = 6.4 Hz, 1H), 4.72 (q, J = 6.4 Hz, 1H), 3.81 (m, 5H), 3.46 - 3.32 (m, 2H), 3.06 - 2.95 (m, 1H), 2.91 - 2.76 (m, 4H), 2.51 - 2.42 (m, 1H), 2.27 - 2.12 (m, 2H), 1.94 - 1.77 (m, 2H), 1.58 (d, J = 6.8 Hz, 3H), 1.18 (t, J = 6.8 Hz, 3H), 1.12 - 1.01 (m, 1H), 0.65 - 0.56 (m, 1H), 0.48 - 0.39 (m, 1H), 0.36 - 0.28 (m, 1H), 0.23 - 0.14 (m, 1H).
Example 408:
Synthetic Route:
[1559] Referring to the synthetic route of compound 406, compound 406-2 was replaced with compound 408-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 408 (58 mg, yield: 71%) as a white solid. MS (ESI, m/z): 506.3 [M+H]+.
[1560] 1H NMR (400 MHz, CDCl3) δ 7.41 (d, J = 8.0 Hz, 1H), 7.10 (s, 1H), 7.03 - 6.95 (m, 1H), 6.88 (dd, J = 8.0, 1.2 Hz, 1H), 6.41 (d, J = 8.0 Hz, 1H), 6.34 (s, 1H), 6.24 (d, J = 8.0 Hz, 1H), 4.51 (q, J = 6.4 Hz, 1H), 3.68 - 3.53 (m, 5H), 3.14 - 3.03 (m, 2H), 2.88 - 2.76 (m, 1H), 2.70 - 2.59 (m, 4H), 2.31 - 2.19 (m, 1H), 2.09 - 1.90 (m, 2H), 1.72 - 1.58 (m, 2H), 1.45 - 1.32 (m, 5H), 0.94 - 0.82 (m, 1H), 0.68 (t, J = 7.6 Hz, 3H), 0.46 - 0.46 (m, 1H), 0.29 - 0.21 (m, 1H), 0.16 - 0.09 (m, 1H), 0.03 - -0.07 (m, 1H).
Example 409:
Synthetic Route:
[1562] Referring to the synthetic route of compound 406, compound 406-2 was replaced with compound 409-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 409 (32 mg, yield: 64%) as a white solid. MS (ESI, m/z): 520.3 [M+H]+.
[1563] 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 8.0 Hz, 1H), 7.32 (s, 1H), 7.26 - 7.20 (m, 1H), 7.10 (d, J = 8.0 Hz, 1H), 6.69 - 6.60 (m, 1H), 6.59 - 6.53 (m, 1H), 6.51 - 6.43 (m, 1H), 4.71 (q, J = 6.4 Hz, 1H), 3.89 - 3.81 (m, 5H), 3.13 (d, J = 8.0 Hz, 2H), 3.08 - 3.00 (m, 1H), 2.94 - 2.83 (m, 4H), 2.55 - 2.46 (m, 1H), 2.28 - 2.15 (m, 2H), 1.95 - 1.83 (m, 3H), 1.60 (d, J = 6.4 Hz, 3H), 1.15 - 1.06 (m, 1H), 0.93 - 0.87 (m, 6H), 0.67 - 0.60 (m, 1H), 0.51 - 0.42 (m, 1H), 0.40 - 0.32 (m, 1H), 0.27 - 0.19 (m, 1H).
Example 410:
Synthetic Route:
[1565] Referring to the synthetic route of compound 406, compound 406-2 was replaced with compound 410-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 410 (32 mg, yield: 57%) as a white solid. MS (ESI, m/z): 520.3 [M+H]+.
[1566] 1H NMR (400 MHz, CDCl3) δ 7.63 (d, J = 8.0 Hz, 1H), 7.32 (s, 1H), 7.27 - 7.20 (m, 1H), 7.11 (dd, J = 8.0, 1.2 Hz, 1H), 6.65 (d, J = 7.6 Hz, 1H), 6.57 (s, 1H), 6.47 (d, J = 7.6 Hz, 1H), 4.73 (q, J = 6.8 Hz, 1H), 3.91 - 3.81 (m, 5H), 3.40 - 3.30 (m, 2H), 3.09 - 3.01 (m, 1H), 2.94 - 2.81 (m, 4H), 2.55 - 2.45 (m, 1H), 2.29 - 2.15 (m, 2H), 1.97 - 1.81 (m, 2H), 1.62 - 1.51 (m, 5H), 1.44 - 1.29 (m, 2H), 1.16 - 1.05 (m, 1H), 0.89 (t, J = 7.2 Hz, 3H), 0.69 - 0.57 (m, 1H), 0.53 - 0.43 (m, 1H), 0.38 - 0.31 (m, 1H), 0.29 - 0.17 (m, 1H).
Example 411:
Synthetic Route:
[1568] Referring to the synthetic route of compound 406, compound 406-2 was replaced with compound 401-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 411 (7 mg, yield: 28%) as a white solid. MS (ESI, m/z): 534.3 [M+H]+.
[1569] 1H NMR (400 MHz, CDCl3) δ 7.61 (d, J = 8.0 Hz, 1H), 7.32 (s, 1H), 7.26 - 7.20 (m, 1H), 7.11 - 7.07 (m, 1H), 6.65 (d, J = 8.0 Hz, 1H), 6.61 - 6.54 (m, 1H), 6.47 (d, J = 8.0 Hz, 1H), 4.72 - 4.64 (m, 1H), 3.87 - 3.82 (m, 5H), 3.13 - 2.96 (m, 3H), 2.91 - 2.82 (m, 4H), 2.54 - 2.46 (m, 1H), 2.28 - 2.16 (m, 2H), 1.97 - 1.84 (m, 2H), 1.58 (d, J= 6.4 Hz, 3H), 1.15 - 1.07 (m, 1H), 0.92 (s, 9H), 0.69 - 0.59 (m, 1H), 0.52 - 0.42 (m, 1H), 0.41 - 0.31 (m, 1H), 0.27 - 0.18 (m, 1H).
Example 412:
Synthetic Route:
[1571] Referring to the synthetic route of compound 406, compound 406-2 was replaced with compound 412-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 412 (34 mg, yield: 65%) as a white solid. MS (ESI, m/z): 548.3 [M+H]+.
[1572] 1H NMR (400 MHz, CDCl3) δ 7.62 (d, J = 8.0 Hz, 1H), 7.33 (s, 1H), 7.27-7.20 (m, 1H), 7.11 (dd, J = 8.0, 1.2 Hz, 1H), 6.66 (d, J = 7.6 Hz, 1H), 6.58 (s, 1H), 6.48 (d, J = 8.0 Hz, 1H), 4.74 (q, J = 6.4 Hz, 1H), 3.90 - 3.81 (m, 5H), 3.48 - 3.36 (m, 2H), 3.15 - 3.02 (m, 1H), 2.95 - 2.83 (m, 4H), 2.58 - 2.46 (m, 1H), 2.31 - 2.13 (m, 2H), 1.96 - 1.77 (m, 2H), 1.66 - 1.48 (m, 5H), 1.16 - 1.06 (m, 1H), 0.89 (s, 9H), 0.68 - 0.60 (m, 1H), 0.53 - 0.42 (m, 1H), 0.41 - 0.34 (m, 1H), 0.27 - 0.18 (m, 1H).
Example 413:
Synthetic Route:
[1574] Referring to the synthetic route of compound 406, compound 406-2 was replaced with compound 413-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 413 (28 mg, yield: 66%) as a white solid. MS (ESI, m/z): 534.3 [M+H]+.
[1575] 1H NMR (400 MHz, CDCl3) δ 7.66 - 7.60 (m, 1H), 7.33 (s, 1H), 7.27 - 7.20 (m, 1H), 7.11 (d, J = 8.0 Hz, 1H), 6.65 (d, J = 7.6 Hz, 1H), 6.57 (s, 1H), 6.47 (d, J = 7.6 Hz, 1H), 4.71 (q, J = 6.4 Hz, 1H), 3.92 - 3.80 (m, 5H), 3.29 - 3.19 (m, 1H), 3.17 - 3.11 (m, 1H), 3.09 - 3.00 (m, 1H), 2.95 - 2.79 (m, 4H), 2.58 - 2.46 (m, 1H), 2.30 - 2.15 (m, 2H), 1.99 - 1.83 (m, 2H), 1.70 - 1.63 (m, 1H), 1.60 (d, J = 6.4 Hz, 3H), 1.55 - 1.44 (m, 1H), 1.18 - 1.06 (m, 2H), 0.94 - 0.82 (m, 6H), 0.68 - 0.59 (m, 1H), 0.54 - 0.41 (m, 1H), 0.40 - 0.32 (m, 1H), 0.29 - 0.17 (m, 1H).
Example 414:
Synthetic Route:
[1577] Referring to the synthetic route of compound 406, compound 406-2 was replaced with compound 414-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 414 (18 mg, yield: 50%) as a white solid. MS (ESI, m/z): 604.3 [M+H]+.
[1578] 1H NMR (400 MHz, CDCl3) δ 7.63 (dd, J = 8.0, 1.6 Hz, 1H), 7.33 (s, 1H), 7.27 - 7.19 (m, 1H), 7.11 (d, J = 8.0 Hz, 1H), 6.65 (d, J = 8.0 Hz, 1H), 6.57 (s, 1H), 6.48 (d, J = 7.6 Hz, 1H), 4.73 (q, J = 6.4 Hz, 1H), 3.91 - 3.81 (m, 5H), 3.48 - 3.32 (m, 2H), 3.11 - 3.01 (m, 1H), 2.94 - 2.81 (m, 4H), 2.57 - 2.47 (m, 1H), 2.31 - 2.12 (m, 2H), 1.98 - 1.80 (m, 2H), 1.65 - 1.58 (m, 4H), 1.58 - 1.50 (m, 2H), 1.43 - 1.35 (m, 1H), 1.31 - 1.21 (m, 3H), 1.17 - 1.03 (m, 4H), 0.90 - 0.77 (m, 9H), 0.70 - 0.60 (m, 1H), 0.53 - 0.42 (m, 1H), 0.41 - 0.32 (m, 1H), 0.27 - 0.19 (m, 1H).
Example 415:
Synthetic Route:
[1580] Referring to the synthetic route of compound 406, compound 406-2 was replaced with compound 415-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 415 (28 mg, yield: 54%) as a white solid. MS (ESI, m/z): 602.3 [M+H]+.
[1581] 1H NMR (400 MHz, CDCl3) δ 7.64 (d, J = 8.0 Hz, 1H), 7.33 (s, 1H), 7.27 - 7.20 (m, 1H), 7.11 (d, J = 8.0 Hz, 1H), 6.66 (d, J = 8.0 Hz, 1H), 6.58 (s, 1H), 6.48 (d, J = 8.0 Hz, 1H), 5.17 - 5.04 (m, 1H), 4.78 - 4.69 (m, 1H), 3.91 - 3.82 (m, 5H), 3.47 - 3.33 (m, 2H), 3.11 - 3.01 (m, 1H), 2.98 - 2.82 (m, 4H), 2.56 - 2.48 (m, 1H), 2.34 - 2.14 (m, 2H), 2.07 - 1.82 (m, 4H), 1.71 (d, J = 5.6 Hz, 3H), 1.65 - 1.59 (m, 7H), 1.58 - 1.50 (m, 1H), 1.47 - 1.36 (m, 1H), 1.35 - 1.25 (m, 1H), 1.18 - 1.06 (m, 2H), 0.91 - 0.77 (m, 3H), 0.70 - 0.57 (m, 1H), 0.53 - 0.43 (m, 1H), 0.40 - 0.33 (m, 1H), 0.27 - 0.18 (m, 1H).
Example 416:
Synthetic Route:
[1583] Referring to the synthetic route of compound 401, methyl Grignard reagent was replaced with ethyl Grignard reagent to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 416 (31 mg, yield: 35%) as a white solid. MS (ESI, m/z): 548.3 [M+H]+.
[1584] 1H NMR (400 MHz, CDCl3) δ 7.58 (d, J = 8.0 Hz, 1H), 7.31 (s, 1H), 7.26 - 7.19 (m, 1H), 7.07 (dd, J = 8.0, 1.6 Hz, 1H), 6.64 (dd, J = 8.0, 2.4 Hz, 1H), 6.59 - 6.55 (m, 1H), 6.47 (dd, J = 8.0, 2.4 Hz, 1H), 4.38 (t, J = 6.8 Hz, 1H), 3.84 (s, 5H), 3.07 - 3.01 (m, 2H), 2.95 - 2.82 (m, 5H), 2.54 - 2.46 (m, 1H), 2.27 - 2.18 (m, 2H), 2.09 - 2.02 (m, 1H), 1.95 - 1.76 (m, 3H), 1.13 - 1.09 (m, 1H), 0.99 (t, J = 7.6 Hz, 3H), 0.92 (s, 9H), 0.67 - 0.60 (m, 1H), 0.50 - 0.44 (m, 1H), 0.39 - 0.33 (m, 1H), 0.25 - 0.20 (m, 1H).
Example 417:
Synthetic Route:
[1586] Referring to the synthetic route of compound 406, compound 406-2 was replaced with compound 417-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 417 (20 mg, yield: 48%) as a white solid. MS (ESI, m/z): 518.3 [M+H]+.
[1587] 1H NMR (400 MHz, CDCl3) δ 7.51 (d, J = 8.0 Hz, 1H), 7.16 (s, 1H), 7.10 - 7.03 (m, 1H), 6.95 (dd, J = 8.0, 1.2 Hz, 1H), 6.49 (d, J = 8.0 Hz, 1H), 6.41 (s, 1H), 6.32 (d, J = 7.6 Hz, 1H), 4.63 (q, J = 6.4 Hz, 1H), 3.76 - 3.62 (m, 5H), 3.14 - 2.96 (m, 2H), 2.93 - 2.84 (m, 1H), 2.77 - 2.68 (m, 4H), 2.39 - 2.27 (m, 1H), 2.14 - 1.97 (m, 2H), 1.80 - 1.65 (m, 2H), 1.47 (d, J = 6.4 Hz, 3H), 1.01 - 0.87 (m, 2H), 0.52 - 0.44 (m, 1H), 0.39 - 0.26 (m, 3H), 0.24 - 0.15 (m, 1H), 0.12 - 0.05 (m, 3H).
Example 418:
Synthetic Route:
[1589] Referring to the synthetic route of compound 406, compound 406-2 was replaced with compound 418-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 418 (19 mg, yield: 51%) as a white solid. MS (ESI, m/z): 532.4 [M+H]+.
[1590] 1H NMR (400 MHz, CDCl3) δ 7.62 - 7.55 (m, 1H), 7.29 (s, 1H), 7.22 - 7.16 (m, 1H), 7.09 - 7.04 (m, 1H), 6.61 (d, J = 8.0 Hz, 1H), 6.53 (s, 1H), 6.43 (d, J = 6.4 Hz, 1H), 4.69 (q, J = 6.4 Hz, 1H), 3.87 - 3.76 (m, 5H), 3.36 - 3.24 (m, 2H), 3.06 - 2.95 (m, 1H), 2.90 - 2.77 (m, 4H), 2.59 - 2.43 (m, 2H), 2.26 - 2.11 (m, 2H), 2.07 - 1.95 (m, 2H), 1.94 - 1.77 (m, 4H), 1.72 - 1.61 (m, 2H), 1.56 (d, J = 6.4 Hz, 3H), 1.14 - 1.02 (m, 1H), 0.65 - 0.56 (m, 1H), 0.47 - 0.39 (m, 1H), 0.36 - 0.28 (m, 1H), 0.23 - 0.14 (m, 1H).
Example 419:
Synthetic Route:
[1592] Referring to the synthetic route of compound 406, compound 406-2 was replaced with compound 419-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 419 (19 mg, yield: 32%) as a white solid. MS (ESI, m/z): 546.3 [M+H]+.
1H NMR (400 MHz, CDCl3) δ 7.60 (d, J = 8.0 Hz, 1H), 7.29 (s, 1H), 7.23 - 7.15 (m, 1H), 7.07 (d, J = 8.0 Hz, 1H), 6.61 (d, J = 8.0 Hz, 1H), 6.54 (s, 1H), 6.44 (d, J = 8.0 Hz, 1H), 4.71 - 4.62 (m, 1H), 3.85 - 3.72 (m, 6H), 3.20 (d, J = 6.8 Hz, 2H), 3.05 - 2.92 (m, 1H), 2.90 - 2.77 (m, 4H), 2.51 - 2.38 (m, 1H), 2.24 - 2.04 (m, 3H), 1.90 - 1.78 (m, 2H), 1.73 - 1.65 (m, 2H), 1.57 - 1.45 (m, 8H), 1.20 - 1.11 (m, 1H), 0.62 - 0.53 (m, 1H), 0.45 - 0.41 (m, 1H), 0.34 - 0.30 (m, 1H), 0.23 - 0.12 (m, 1H).
Example 420:
Synthetic Route:
[1594] Referring to the synthetic route of compound 406, compound 406-2 was replaced with compound 420-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 420 (16 mg, yield: 27%) as a white solid. MS (ESI, m/z): 544.3 [M+H]+.
[1595] 1H NMR (400 MHz, CDCl3) δ 7.63 (d, J = 8.0 Hz, 1H), 7.42 - 7.36 (m, 1H), 7.31 (s, 1H), 7.24 - 7.16 (m, 1H), 7.13 - 7.06 (m, 1H), 6.61 (d, J = 8.0 Hz, 1H), 6.57 - 6.51 (m, 1H), 6.47 - 6.41 (m, 1H), 6.35 - 6.30 (m, 1H), 6.25 - 6.20 (m, 1H), 4.81 (q, J = 6.4 Hz, 1H), 4.43 (d, J = 12.8 Hz, 1H), 4.27 (d, J = 12.8 Hz, 1H), 3.84 - 3.78 (m, 5H), 3.04 - 2.89 (m, 1H), 2.89 - 2.80 (m, 4H), 2.53 - 2.43 (m, 1H), 2.27 -2.14 (m, 2H), 1.97 - 1.77 (m, 1H), 1.59 (d, J= 6.4 Hz, 3H), 1.10 - 1.05 (m, 1H), 0.64 - 0.59 (m, 1H), 0.47 - 0.41 (m, 1H), 0.35 - 0.31 (m, 1H), 0.22 - 0.17 (m, 1H).
Example 421:
Synthetic Route:
[1597] Referring to the synthetic route of compound 406, compound 406-2 was replaced with compound 421-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 421 (18 mg, yield: 42%) as a white solid. MS (ESI, m/z): 560.3 [M+H]+.
[1598] 1H NMR (400 MHz, CDCl3) δ 7.65 (d, J = 8.0 Hz, 1H), 7.31 (s, 1H), 7.29 - 7.25 (m, 1H), 7.23 - 7.17 (m, 1H), 7.12 - 7.07 (m, 1H), 6.98 - 6.89 (m, 2H), 6.60 (dd, J = 8.0, 4.4 Hz, 1H), 6.54 - 6.50 (m, 1H), 6.43 (dd, J = 8.0, 4.4 Hz, 1H), 4.88 - 4.78 (m, 1H), 4.65 (d, J = 12.8, 1H), 4.48 (d, J = 12.8 Hz, 1H), 3.86 - 3.72 (m, 5H), 2.96 - 2.75 (m, 5H), 2.54 - 2.42 (m, 1H), 2.29 - 2.07 (m, 2H), 1.97 - 1.72 (m, 1H), 1.60 (d, J = 6.4 Hz, 3H), 1.14 - 1.02 (m, 1H), 0.66 - 0.56 (m, 1H), 0.49 - 0.40 (m, 1H), 0.38 - 0.28 (m, 1H), 0.24 - 0.14 (m, 1H).
Example 422:
Synthetic Route:
[1600] Referring to the synthetic route of compound 406, compound 406-2 was replaced with compound 422-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 422 (16 mg, yield: 27%) as a white solid. MS (ESI, m/z): 571.3 [M+H]+.
[1601] 1H NMR (400 MHz, CDCl3) δ 7.83 (d, J = 8.0 Hz, 1H), 7.38 (s, 1H), 7.27 (d, J = 5.6 Hz, 1H), 7.19 (t, J = 8.0 Hz, 1H), 7.02 (d, J = 6.8 Hz, 1H), 6.88 - 6.84 (m, 1H), 6.76 - 6.64 (m, 1H), 6.56 (dd, J = 8.0, 3.2 Hz, 1H), 6.43 (t, J = 8.0 Hz, 1H), 5.73 (d, J = 6.8 Hz, 1H), 4.73 - 4.64 (m, 1H), 3.81 (s, 3H), 3.59 (s, 3H), 2.91 - 2.75 (m, 5H), 2.56 - 2.41 (m, 1H), 2.32 - 2.17 (m, 2H), 1.93 (d, J = 12.8 Hz, 1H), 1.75 (d, J = 12.8 Hz, 1H), 1.62 (d, J = 6.4 Hz, 4H), 1.49 (s, 3H), 1.12 - 1.02 (m, 1H), 0.66 - 0.57 (m, 1H), 0.48 - 0.40 (m, 1H), 0.38 - 0.29 (m, 1H), 0.26 - 0.14 (m, 1H).
Example 423:
Synthetic Route:
[1603] Referring to the synthetic route of compound 401, methyl Grignard reagent was replaced with tert-butyl Grignard reagent to obtain compound 423-1 (31 mg, yield: 35%) as a white solid. MS (ESI, m/z): 520.3 [M+H]+.
[1604] Then, referring to the synthetic route of compound 401, compound 401-2 was replaced with compound 423-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 423 (30 mg, yield: 48%) as a white solid. MS (ESI, m/z): 506.3 [M+H]+.
[1605] 1H NMR (400 MHz, CDCl3) δ 7.63 (d, J = 8.0 Hz, 1H), 7.31 (s, 1H), 7.25 - 7.19 (m, 1H), 7.09 (d, J = 8.0 Hz, 1H), 6.67 - 6.61 (m, 1H), 6.59 - 6.55 (m, 1H), 6.49 - 6.44 (m, 1H), 4.71 (s, 1H), 3.89 - 3.78 (m, 5H), 3.08 - 2.98 (m, 1H), 2.92 - 2.78 (m, 4H), 2.54 - 2.44 (m, 1H), 2.31 - 2.15 (m, 2H), 1.91 - 1.82 (m, 2H), 1.15 - 1.04 (m, 10H), 0.68 - 0.59 (m, 1H), 0.51 - 0.41 (m, 1H), 0.39 - 0.31 (m, 1H), 0.25 - 0.17 (m, 1H).
Example 424:
Synthetic Route:
[1607] Referring to the synthetic route of compound 423, methyl Grignard reagent was replaced with phenyl Grignard reagent to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 424 (14 mg, yield: 35%) as a white solid. MS (ESI, m/z): 526.3 [M+H]+.
[1608] 1H NMR (400 MHz, CDCl3) δ 7.54 - 7.49 (m, 2H), 7.42 - 7.35 (m, 2H), 7.34 - 7.31 (m, 3H), 7.25 - 7.19 (m, 1H), 7.05 - 6.99 (m, 1H), 6.66 - 6.61 (m, 1H), 6.57 - 6.54 (m, 1H), 6.49 - 6.45 (m, 1H), 6.18 (s, 1H), 3.87 - 3.77 (m, 5H), 3.09 - 2.98 (m, 1H), 2.90 - 2.74 (m, 4H), 2.50 - 2.42 (m, 1H), 2.27 - 2.16 (m, 2H), 1.94 - 1.83 (m, 2H), 1.13 - 1.02 (m, 1H), 0.68 - 0.56 (m, 1H), 0.49 - 0.39 (m, 1H), 0.37 - 0.28 (m, 1H), 0.22 - 0.13 (m, 1H).
Example 425:
Synthetic Route:
[1610] Compound 424-1 (54 mg, 0.1 mmol) was dissolved in N,N-dimethylformamide (5 mL). Sodium hydride (6 mg, 0.15 mmol) was added at 0°C, and the reaction was carried out at 25°C for 1 hour. Iodomethane (43 mg, 0.30 mmol) was then added, followed by quenching with saturated sodium bicarbonate solution (1 mL). The reaction mixture was concentrated and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 425-1 (32 mg, yield: 61%) as a yellow oil. MS (ESI, m/z): 554.3 [M+H]+.
[1611] Compound 425-1 (32 mg, 0.06 mmol) was added to methanol (1 mL), water (1 mL), and tetrahydrofuran (1 mL) and stirred. Lithium hydroxide (4 mg, 0.14 mmol) was added, and the reaction mixture was stirred at 25°C for 4 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 425 (3 mg, yield: 23%) as a white solid. MS (ESI, m/z): 540.2 [M+H]+.
[1612] 1H NMR (400 MHz, CDCl3) δ 7.49 - 7.41 (m, 3H), 7.36 (t, J = 7.6 Hz, 2H), 7.32 -7.26 (m, 2H), 7.25 - 7.18 (m, 1H), 7.04 (d, J = 8.4 Hz, 1H), 6.65 - 6.59 (m, 1H), 6.55 - 6.52 (m, 1H), 6.48 - 6.43 (m, 1H), 5.58 (s, 1H), 3.88 - 3.78 (m, 5H), 3.46 (s, 3H), 3.08 - 2.96 (m, 1H), 2.91 - 2.77 (m, 4H), 2.53 - 2.44 (m, 1H), 2.26 - 2.16 (m, 2H), 1.91-1.81 (m, 2H), 1.14 - 1.03 (m, 1H), 0.67 - 0.59 (m, 1H), 0.50 - 0.41 (m, 1H), 0.39 - 0.31 (m, 1H), 0.25 - 0.16 (m, 1H).
Example 426:
Synthetic Route:
[1614] Referring to the synthetic route of compound 425, iodomethane was replaced with isobutyl iodide to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 426 (12 mg, yield: 24%) as a white solid. MS (ESI, m/z): 582.3 [M+H]+.
[1615] 1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 7.6 Hz, 2H), 7.42 (d, J = 8.0 Hz, 1H), 7.38 - 7.22 (m, 5H), 7.03 (d, J = 8.0 Hz, 1H), 6.67 - 6.59 (m, 1H), 6.59 - 6.53 (m, 1H), 6.50 - 6.42 (m, 1H), 5.65 (s, 1H), 3.85 - 3.80 (m, 5H), 3.34 - 3.25 (m, 2H), 3.13 - 3.02 (m, 1H), 2.90 - 2.76 (m, 4H), 2.53 - 2.43 (m, 1H), 2.28 - 2.14 (m, 2H), 2.02 - 1.95 (m, 1H), 1.88 - 1.82 (m, 2H), 1.13 - 0.94 (m, 7H), 0.67 - 0.57 (m, 1H), 0.50 - 0.40 (m, 1H), 0.39 - 0.30 (m, 1H), 0.26 - 0.15 (m, 1H).
Example 427:
Synthetic Route:
[1617] Referring to the synthetic route of compound 426, phenyl Grignard reagent was replaced with 4-methyl-phenyl Grignard reagent to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 427 (27 mg, yield: 34%) as a white solid. MS (ESI, m/z): 596.3 [M+H]+.
[1618] 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 8.0 Hz, 1H), 7.37 (d, J = 8.0 Hz, 2H), 7.31 - 7.21 (m, 2H), 7.17 (d, J = 8.0 Hz, 2H), 7.03 (d, J = 8.0 Hz, 1H), 6.68 - 6.42 (m, 3H), 5.63 (s, 1H), 3.85 - 3.81 (m, 5H), 3.35 - 3.22 (m, 2H), 3.13 - 3.07 (m, 1H), 2.91 - 2.75 (m, 4H), 2.51 - 2.45 (m, 1H), 2.37 (s, 3H), 2.29 - 2.15 (m, 2H), 2.02 - 1.96 (m, 1H), 1.93-1.81 (m, 2H), 1.15 - 0.93 (m, 7H), 0.65 - 0.58 (m, 1H), 0.48 - 0.41 (m, 1H), 0.37 - 0.31 (m, 1H), 0.22 - 0.16 (m, 1H).
Example 428:
Synthetic Route:
[1620] Referring to the synthetic route of compound 426, phenyl Grignard reagent was replaced with 3-methyl-phenyl Grignard reagent to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 428 (31 mg, yield: 45%) as a white solid. MS (ESI, m/z): 596.3 [M+H]+.
[1621] 1H NMR (400 MHz, CDCl3) δ 7.44 (d, J = 8.0 Hz, 1H), 7.35 - 7.15 (m, 5H), 7.10 (d, J = 7.2 Hz, 1H), 7.04 (d, J = 8.0 Hz, 1H), 6.67-6.42 (m, 3H), 5.62 (s, 1H), 3.84 - 3.81 (m, 5H), 3.34 - 3.16 (m, 2H), 3.09 - 3.03 (m, 1H), 2.91 - 2.72 (m, 4H), 2.53 - 2.42 (m, 1H), 2.37 (s, 3H), 2.30 - 2.14 (m, 2H), 2.04 - 1.94 (m, 1H), 1.88 - 1.82 (m, 2H), 1.11 - 0.94 (m, 7H), 0.67 - 0.57 (m, 1H), 0.48 - 0.41 (m, 1H), 0.37 - 0.31 (m, 1H), 0.22 - 0.16 (m, 1H).
Example 429:
Synthetic Route:
[1623] Referring to the synthetic route of compound 426, phenyl Grignard reagent was replaced with 2-methyl-phenyl Grignard reagent to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 429 (37 mg, yield: 48%) as a white solid. MS (ESI, m/z): 596.3 [M+H]+.
[1624] 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.27 (m, 1H), 7.13 - 6.94 (m, 5H), 6.86 - 6.69 (m, 1H), 6.60 - 6.31 (m, 3H), 6.27 - 6.22 (m, 1H), 5.54 (s, 1H), 3.68 - 3.45 (m, 5H), 3.17 - 2.97 (m, 2H), 2.68 - 2.44 (m, 5H), 2.34 - 2.16 (m, 1H), 2.20 - 1.35 (m, 8H), 0.97 - 0.82 (m, 1H), 0.82 - 0.73 (m, 6H), 0.48 - 0.37 (m, 1H), 0.31 -0.24 (m, 1H), 0.17 - 0.09 (m, 1H), 0.06 - -0.02 (m, 1H).
Example 430:
Synthetic Route:
[1626] Referring to the synthetic route of compound 426, phenyl Grignard reagent was replaced with 3-fluoro-phenyl Grignard reagent to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 430 (31 mg, yield: 52%) as a white solid. MS (ESI, m/z): 600.3 [M+H]+.
[1627] 1H NMR (400 MHz, CDCl3) δ 7.42 - 7.25 (m, 2H), 7.24 - 7.11 (m, 3H), 7.04 - 6.81 (m, 2H), 6.78 - 6.34 (m, 4H), 5.60 (s, 1H), 3.86 - 3.70 (m, 5H), 3.34 - 3.12 (m, 2H), 3.13 - 2.91 (m, 1H), 2.89 - 2.60 (m, 4H), 2.49 - 2.27 (m, 1H), 2.27 - 2.08 (m, 2H), 2.01 - 1.75 (m, 3H), 1.08 - 0.85 (m, 7H), 0.63 - 0.52 (m, 1H), 0.51 - 0.36 (m, 1H), 0.36 - 0.23 (m, 1H), 0.21 - 0.11 (m, 1H).
Example 431:
Synthetic Route:
[1629] Referring to the synthetic route of compound 426, phenyl Grignard reagent was replaced with 4-fluoro-phenyl Grignard reagent to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 431 (34 mg, yield: 61%) as a white solid. MS (ESI, m/z): 600.3 [M+H]+.
[1630] 1H NMR (400 MHz, CDCl3) δ 7.46 - 7.38 (m, 2H), 7.36 - 6.95 (m, 5H), 6.80 - 6.36 (m, 4H), 5.59 (s, 1H), 3.87 - 3.74 (m, 5H), 3.33 - 3.12 (m, 2H), 3.12 - 2.91 (m, 1H), 2.93 - 2.29 (m, 5H), 2.29 - 2.07 (m, 2H), 1.98 - 1.79 (m, 3H), 1.10 - 0.89 (m, 7H), 0.65 - 0.51 (m, 1H), 0.48 - 0.38 (m, 1H), 0.37 - 0.23 (m, 1H), 0.20 -0.10 (m, 1H).
Example 432:
Synthetic Route:
[1632] Referring to the synthetic route of compound 426, phenyl Grignard reagent was replaced with 2-fluoro-phenyl Grignard reagent to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 432 (43 mg, yield: 51%) as a white solid. MS (ESI, m/z): 600.3 [M+H]+.
[1633] 1H NMR (400 MHz, CDCl3) δ 7.78 - 7.28 (m, 2H), 7.25 - 6.92 (m, 5H), 6.78 - 5.86 (m, 5H), 3.89 - 3.56 (m, 6H), 3.29 - 3.13 (m, 2H), 2.92 - 2.59 (m, 4H), 2.38 - 2.25 (m, 1H), 1.97 - 1.79 (m, 3H), 1.78 - 1.50 (m, 2H), 1.03 - 0.88 (m, 7H), 0.64 - 0.53 (m, 1H), 0.48 - 0.37 (m, 1H), 0.34 - 0.25 (m, 1H), 0.20 - 0.10 (m, 1H).
Example 433:
Synthetic Route:
[1635] Referring to the synthetic route of compound 405, compound 126-2 was replaced with compound 392-3, and compound 200-1 was replaced with compound 305-5. The synthesis was carried out, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 433 (5 mg, yield: 17%) as a white solid. MS (ESI, m/z): 537.3 [M+H]+.
[1636] 1H NMR (400 MHz, MeOD) δ 7.39 (d, J = 8.0 Hz, 1H), 7.34 (s, 1H), 7.15 (dd, J = 8.0 Hz, 1.4, 1H), 6.95 (dd, J = 12.4, 8.8 Hz, 1H), 6.61 (dd, J = 7.2, 3.2 Hz, 1H), 6.52 - 6.46 (m, 1H), 3.76 (s, 3H), 3.58 - 3.51 (m, 2H), 3.08 - 2.98 (m, 1H), 2.87 - 2.78 (m, 6H), 2.70 - 2.54 (m, 2H), 2.52 - 2.44 (m, 1H), 2.24 - 2.14 (m, 2H), 1.90 - 1.84 (m, 2H), 1.10 (s, 9H), 1.07 - 1.02 (m, 1H), 0.60 - 0.51 (m, 1H), 0.40 - 0.33 (m, 2H), 0.14 - 0.08 (m, 1H).
Example 434:
Synthetic Route:
[1638] Referring to the synthetic route of compound 433, compound 305-5 was replaced with compound 434-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 434 (2 mg, yield: 14%) as a white solid. MS (ESI, m/z): 551.3 [M+H]+.
[1639] 1H NMR (400 MHz, DMSO-d6) δ 8.38 (s, 1H), 7.41 - 7.36 (m, 2H), 7.11 (d, J = 7.6 Hz, 1H), 7.05 (dd, J = 12.4, 8.8 Hz, 1H), 6.60 - 6.55 (m, 1H), 6.52 - 6.46 (m, 1H), 3.73 (s, 3H), 3.52 - 3.49 (m, 2H), 3.08 - 2.99 (m, 1H), 2.86 - 2.75 (m, 2H), 2.72 - 2.66 (m, 4H), 2.55 - 2.48 (m, 2H), 2.37 - 2.32 (m, 1H), 2.26 (s, 3H), 2.07 - 1.98 (m, 2H), 1.89 - 1.82 (m, 2H), 1.09 - 1.02 (m, 1H), 0.95 (s, 9H), 0.55 - 0.45 (m, 1H), 0.32 - 0.21 (m, 2H), 0.17 - 0.11 (m, 1H).
Example 435:
Synthetic Route:
[1641] Referring to the synthetic route of compound 405, compound 126-2 was replaced with compound 49-5, and compound 200-1 was replaced with compound 435-1. The synthesis was carried out, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 435 (38 mg, yield: 53%) as a white solid. MS (ESI, m/z): 519.3 [M+H]+.
[1642] 1H NMR (400 MHz, CDCl3) δ 7.39 (d, J = 7.6 Hz, 1H), 7.32 (s, 1H), 7.22 - 7.15 (m, 2H), 6.60-6.55 (m, 1H), 6.53-6.49 (m, 1H), 6.45-6.39 (m, 1H), 3.85 - 3.72 (m, 5H), 3.55 (s, 2H), 2.86 - 2.73 (m, 6H), 2.54 - 2.45 (m, 1H), 2.36 (s, 2H), 2.15 - 2.01 (m, 2H), 1.76 - 1.66 (m, 2H), 1.09 - 1.00 (m, 1H), 0.82 (s, 9H), 0.62 - 0.55 (m, 1H), 0.45 - 0.37 (m, 1H), 0.36 - 0.27 (m, 1H), 0.25 - 0.17 (m, 1H).
Example 436:
Synthetic Route:
[1644] Compound 49-5 (330 mg, 0.72 mmol) was dissolved in ethanol (5 mL), and 50% hydroxylamine hydrochloride aqueous solution (2 mL) was added. The reaction was carried out at 80°C for 2 hours. After concentration, the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 436-1 (330 mg, yield: 97%) as a white solid. MS (ESI, m/z): 477.3 [M+H]+.
[1645] Compound 436-1 (330 mg, 0.69 mmol) and 5% Pd/C (100 mg) were added to concentrated hydrochloric acid (2 mL) and methanol (15 mL), and the reaction was stirred under hydrogen at 60°C overnight. After concentration, the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 436-2 (150 mg, yield: 47%) as a yellow oil. MS (ESI, m/z): 463.3 [M+H]+.
[1646] Compound 436-2 (150 mg, 0.33 mmol) was added to triethylamine (0.1 mL) and dichloromethane (5 mL). At 0°C, compound 436-3 (0.1 mL) was added, and the reaction mixture was stirred at 25°C for 4 hours. After the reaction was completed, the reaction mixture was concentrated and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 436-4 (116 mg, yield: 64%) as a yellow oil. MS (ESI, m/z): 547.3 [M+H]+.
[1647] Compound 436-4 (116 mg, 0.21 mmol) was added to methanol (2 mL), water (2 mL), and tetrahydrofuran (2 mL) and stirred. Lithium hydroxide (8 mg, 0.32 mmol) was added, and the reaction mixture was stirred at 60°C for 4 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 436 (31 mg, yield: 27%) as a white solid. MS (ESI, m/z): 533.2 [M+H]+.
[1648] 1H NMR (400 MHz, CDCl3) δ 7.42 (d, J = 8.0 Hz, 1H), 7.36 (s, 1H), 7.25 - 7.18 (m, 1H), 7.14 (d, J = 8.0 Hz, 1H), 6.63 (dd, J = 8.0, 2.0 Hz, 1H), 6.58 - 6.55 (m, 1H), 6.47 (dd, J = 8.0, 2.0 Hz, 1H), 5.80 - 5.74 (m, 1H), 4.52 (d, J = 4.8 Hz, 2H), 3.87 - 3.78 (m, 5H), 3.13 - 3.01 (m, 1H), 2.95 - 2.77 (m, 4H), 2.55 - 2.45 (m, 1H), 2.26 - 2.13 (m, 2H), 1.93 - 1.84 (m, 2H), 1.23 (s, 9H), 1.15 - 1.05 (m, 1H), 0.69 - 0.60 (m, 1H), 0.51 - 0.42 (m, 1H), 0.40 - 0.32 (m, 1H), 0.25 - 0.17 (m, 1H).
Example 437:
Synthetic Route:
[1650] Referring to the synthetic route of compound 434, compound 436-3 was replaced with compound 437-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 437 (16 mg, yield: 29%) as a white solid. MS (ESI, m/z): 553.3 [M+H]+.
[1651] 1H NMR (400 MHz, CDCl3) δ 7.74 (d, J = 7.6 Hz, 2H), 7.51 -7.44 (m, 2H), 7.43 - 7.36 (m, 2H), 7.32 (s, 1H), 7.26 - 7.19 (m, 1H), 7.10 (d, J = 8.0 Hz, 1H), 6.64 - 6.57 (m, 1H), 6.55 - 6.50 (m, 1H), 6.46 - 6.41 (m, 1H), 6.34 - 6.26 (m, 1H), 4.70 (d, J = 4.8 Hz, 2H), 3.82 - 3.76 (m, 5H), 3.18 - 3.03 (m, 1H), 2.94 - 2.71 (m, 4H), 2.52 - 2.40 (m, 1H), 2.26 - 2.09 (m, 2H), 1.99 - 1.86 (m, 2H), 1.14 - 1.01 (m, 1H), 0.68 - 0.55 (m, 1H), 0.49 - 0.36 (m, 1H), 0.36 - 0.25 (m, 1H), 0.21 - 0.12 (m, 1H).
Example 438:
Synthetic Route:
[1653] Referring to the synthetic route of compound 405, compound 126-2 was replaced with compound 49-5, and compound 200-1 was replaced with compound 438-1. The synthesis was carried out, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 438 (36 mg, yield: 62%) as a white solid. MS (ESI, m/z): 533.3 [M+H]+.
[1654] 1H NMR (400 MHz, CDCl3) δ 7.59 (d, J = 8.4 Hz, 1H), 7.29 (s, 1H), 7.21 - 7.16 (m, 1H), 7.10 (d, J = 8.0 Hz, 1H), 6.61 (d, J = 8.4 Hz, 1H), 6.51 - 6.55 (m, 1H), 6.43 (d, J = 8.0 Hz, 1H), 3.85 - 3.77 (m, 5H), 3.71 - 3.52 (m, 2H), 3.22 - 3.04 (m, 1H), 2.90 - 2.76 (m, 4H), 2.50 - 2.45 (m, 1H), 2.28 - 2.15 (m, 7H), 1.90 - 1.81 (m, 2H), 1.13 - 1.04 (m, 1H), 0.95 (s, 9H), 0.65 - 0.55 (m, 1H), 0.47 - 0.39 (m, 1H), 0.38 - 0.28 (m, 1H), 0.25 - 0.13 (m, 1H).
Example 439:
Synthetic Route:
[1656] Compound 406-1 (114 mg, 0.239 mmol), diphenylphosphoryl azide (131 mg, 0.478 mmol), and 1,8-diazabicyclo[5.4.0]undec-7-ene (73 mg, 0.478 mmol) were dissolved in dichloromethane (5 mL). The reaction was carried out at 25°C for 24 hours. After concentration, the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 439-1 (67 mg, yield: 56%) as a white solid. MS (ESI, m/z): 503.3 [M+H]+.
[1657] Compound 439-1 (67 mg, 0.133 mmol) and triphenylphosphine (70 mg, 0.267 mmol) were added to a mixture of tetrahydrofuran (5 mL) and water (5 mL), and the reaction was stirred at 60°C overnight. After concentration, the resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 439-2 (51 mg, yield: 83%) as a yellow oil. MS (ESI, m/z): 477.3 [M+H]+.
[1658] Compound 439-2 (51 mg, 0.107 mmol) and compound 439-3 (13 mg, 0.161 mmol) were added to a mixture of acetic acid (0.05 mL) and dichloromethane (5 mL). Sodium triacetoxyborohydride (32 mg, 0.15 mmol) was added at 0°C, and the reaction mixture was stirred at 25°C for 24 hours. After the reaction was completed, the reaction mixture was concentrated and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 439-4 (55 mg, yield: 94%) as a yellow oil. MS (ESI, m/z): 547.3 [M+H]+.
[1659] Compound 439-4 (55 mg, 0.1 mmol) and 40% formaldehyde (0.1 mL) were added to a mixture of acetic acid (0.05 mL) and dichloromethane (5 mL). Sodium triacetoxyborohydride (32 mg, 0.15 mmol) was added at 0°C, and the reaction mixture was stirred at 25°C for 24 hours. After the reaction was completed, the reaction mixture was concentrated and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 439-5 (38 mg, yield: 68%) as a yellow oil. MS (ESI, m/z): 561.3 [M+H]+.
[1660] Compound 439-5 (36 mg, 0.0643 mmol) was added to methanol (1 mL), water (1 mL), and tetrahydrofuran (1 mL) and stirred. Lithium hydroxide (31 mg, 1.29 mmol) was added, and the reaction mixture was stirred at 60°C for 4 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 439 (5 mg, yield: 14%) as a white solid. MS (ESI, m/z): 547.3 [M+H]+.
[1661] 1H NMR (400 MHz, CDCl3) δ 7.64 - 7.55 (m, 1H), 7.32 - 7.28 (m, 1H), 7.22 - 7.15 (m, 1H), 7.11 - 7.05 (m, 1H), 6.60 (d, J= 8.4 Hz, 1H), 6.55 - 6.51 (m, 1H), 6.43 (dd, J = 8.0, 2.0 Hz, 1H), 4.14 - 3.94 (m, 1H), 3.86 - 3.73 (m, 5H), 3.17 - 3.04 (m, 1H), 2.92 - 2.73 (m, 4H), 2.53 - 1.98 (m, 8H), 1.90 - 1.65 (m, 2H), 1.59 - 1.42 (m, 3H), 1.13 - 1.04 (m, 1H), 0.96 (s, 9H), 0.66 - 0.55 (m, 1H), 0.49 - 0.39 (m, 1H), 0.37 - 0.28 (m, 1H), 0.24 - 0.14 (m, 1H).
Example 440:
Synthetic Route:
[1663] Referring to the synthetic route of compound 439, compound 406-2 was replaced with compound 424-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 440 (7 mg, yield: 15%) as a white solid. MS (ESI, m/z): 613.3 [M+H]+.
[1664] 1H NMR (400 MHz, CDCl3) δ 7.53 (d, J = 7.2 Hz, 2H), 7.42 (d, J = 8.0 Hz, 1H), 7.35 - 7.30 (m, 3H), 7.28 - 7.18 (m, 2H), 7.01 (d, J = 8.0 Hz, 1H), 6.68 - 6.60 (m, 1H), 6.58 - 6.54 (m, 1H), 6.50 - 6.41 (m, 1H), 4.92 (s, 1H), 3.93 - 3.75 (m, 5H), 3.12 - 3.01 (m, 1H), 2.93 - 2.73 (m, 4H), 2.57 - 2.03 (m, 8H), 1.97 -1.69 (m, 2H), 1.13 - 1.07 (m, 1H), 0.97 (s, 9H), 0.69 - 0.58 (m, 1H), 0.54 - 0.42 (m, 1H), 0.41 - 0.31 (m, 1H), 0.28 - 0.15 (m, 1H).
Example 441:
Synthetic Route:
[1666] Referring to the synthetic route of compound 439, compound 406-2 was replaced with compound 398-1, and compound 439-3 was replaced with compound 441-3. The synthesis was carried out, and the resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 441 (7 mg, yield: 15%) as a white solid. MS (ESI, m/z): 613.3 [M+H]+.
[1667] 1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 7.6 Hz, 1H), 7.37 - 7.28 (m, 6H), 7.26 - 7.19 (m, 1H), 7.16 (d, J = 8.0 Hz, 1H), 6.64 (d, J = 8.4 Hz, 1H), 6.59 - 6.55 (m, 1H), 6.48 (dd, J= 8.0 Hz, 2.0 Hz, 1H), 3.87 - 3.64 (m, 9H), 3.04 - 2.95 (m, 1H), 2.93 - 2.77 (m, 4H), 2.56 - 2.47 (m, 1H), 2.28 - 2.09 (m, 5H), 1.85 - 1.75 (m, 2H), 1.14 - 1.04 (m, 1H), 0.68 - 0.57 (m, 1H), 0.48 - 0.31 (m, 2H), 0.25 - 0.17 (m, 1H).
Example 442:
Synthetic Route:
[1669] Compound 435-2 (75 mg, 0.14 mmol), diisopropylethylamine (54 mg, 0.42 mmol), and acetic anhydride (54 mg, 0.42 mmol) were added to dichloromethane (2 mL) and stirred at 25°C for 24 hours. After the reaction was completed, the reaction mixture was concentrated and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 442-1 (68 mg, yield: 84%) as a yellow oil. MS (ESI, m/z): 575.3 [M+H]+.
[1670] Referring to the synthetic route of compound 439, compound 439-5 was replaced with compound 442-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 435 (56 mg, yield: 83%) as a white solid. MS (ESI, m/z): 561.3 [M+H]+.
[1671] 1H NMR (400 MHz, CDCl3) δ 7.45 - 7.28 (m, 2H), 7.24 - 7.17 (m, 1H), 7.11 - 7.05 (m, 1H), 6.74 - 6.36 (m, 3H), 4.86 - 4.66 (m, 2H), 3.88 - 3.75 (m, 5H), 3.33 - 2.98 (m, 3H), 2.95 - 2.74 (m, 4H), 2.55 - 2.46 (m, 1H), 2.31 - 2.10 (m, 5H), 1.90 - 1.79 (m, 2H), 1.12 - 0.95 (m, 10H), 0.66 - 0.57 (m, 1H), 0.47 - 0.39 (m, 1H), 0.36 - 0.28 (m, 1H), 0.21 - 0.14 (m, 1H).
Example 443:
Synthetic Route:
[1673] Compound 49-5 (78 mg, 0.17 mmol), compound 314-1 (24 mg, 0.26 mmol), and acetic acid (0.5 mL) were added to dichloromethane (15 mL) and stirred. The reaction was carried out at room temperature for 3 hours, followed by the addition of sodium triacetoxyborohydride (110 mg, 0.52 mmol). The reaction was then carried out at room temperature for 16 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product. The resulting crude product was purified by normal-phase column chromatography (petroleum ether: ethyl acetate = 8:2) to obtain compound 443-1 (90 mg, yield: 98%) as a yellow oil. MS (ESI, m/z): 539.3 [M+H]+.
[1674] Compound 443-1 (90 mg, 0.167 mmol) and trimethylacetic anhydride 443-2 (2 mL) were added to pyridine (1 mL) and stirred. The reaction was carried out at 120°C for 48 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product. The resulting crude product was purified by normal-phase column chromatography (petroleum ether: ethyl acetate = 7:3) to obtain compound 443-3 (100 mg, yield: 96%) as a yellow oil. MS (ESI, m/z): 623.3 [M+H]+.
[1675] Compound 443-3 (100 mg, 0.16 mmol) was added to tetrahydrofuran (10 mL) and stirred. Borane dimethyl sulfide complex (2.0 M, 1.0 mL, 2.0 mmol) was added, and the reaction was carried out at 60°C for 16 hours. After the reaction was completed, the reaction mixture was slowly quenched with methanol (1 mL) at 0°C and concentrated to obtain a crude product. The resulting crude product was then purified by reverse-phase column chromatography (water (0.1% formic acid): acetonitrile = 2:8) to obtain compound 443-4 (45 mg, yield: 48%) as a white solid. MS (ESI, m/z): 581.3 [M+H]+.
[1676] Compound 443-4 (45 mg, 0.078 mmol), 1-hydroxycyclohexyl phenyl ketone (160 mg, 0.78 mmol), and sodium hydroxide (31 mg, 0.78 mmol) were added to ethylene glycol dimethyl ether (10 mL) and stirred. The reaction was carried out at 110°C under a nitrogen atmosphere for 16 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product. The resulting crude product was then purified by reverse-phase column chromatography (water (0.1% formic acid): acetonitrile = 1:9) to obtain compound 443 (4 mg, yield: 9%) as an off-white solid. MS (ESI, m/z): 595.3 [M+H]+.
[1677] 1H NMR (400 MHz, CDCl3) δ 7.54 - 7.32 (m, 2H), 7.25 (t, J = 8.4 Hz, 2H), 7.18 -7.12 (m, 1H), 7.09 (d, J = 8.4 Hz, 1H), 6.83 (s, 1H), 6.76 (dd, J = 8.4, 2.8 Hz, 1H), 6.65 (dd, J = 17.2, 8.0 Hz, 2H), 6.58 (s, 1H), 6.49 (d, J = 8.4 Hz, 1H), 4.72 (s, 2H), 3.83 (s, 3H), 3.77 (d, J = 12.8 Hz, 2H), 3.31 (s, 2H), 2.92 -2.78 (m, 4H), 2.74 - 2.66 (m, 1H), 2.55 - 2.43 (m, 1H), 2.17 (t, J = 13.2 Hz, 2H), 1.69 (d, J = 13.2 Hz, 2H), 1.14 - 1.05 (m, 10H), 0.71 - 0.59 (m, 1H), 0.52 - 0.44 (m, 1H), 0.39 - 0.32 (m, 1H), 0.23 - 0.19 (m, 1H).
Example 444:
Synthetic Route:
[1679] Referring to the synthetic route of compound 443, compound 314-1 was replaced with compound 323-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 444 (56 mg, yield: 83%) as a white solid. MS (ESI, m/z): 613.3 [M+H]+.
Example 445:
Synthetic Route:
[1681] Referring to the synthetic route of compound 443, compound 314-1 was replaced with compound 318-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 445 (56 mg, yield: 83%) as a white solid. MS (ESI, m/z): 613.3 [M+H]+.
Example 446:
Synthetic Route:
[1683] Referring to the synthetic route of compound 443, compound 314-1 was replaced with compound 323-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 444 (56 mg, yield: 83%) as a white solid. MS (ESI, m/z): 629.3 [M+H]+.
Example 447:
Synthetic Route:
[1685] Referring to the synthetic route of compound 443, compound 314-1 was replaced with compound 248-1 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 447 (4 mg, yield: 9%) as a white solid. MS (ESI, m/z): 629.3 [M+H]+.
[1686] 1H NMR (400 MHz, CDCl3) δ 7.17 - 7.29 (m, 3H), 7.11 - 7.04 (m, 2H), 6.85 (s, 1H), 6.75 (dd, J = 8.4, 2.8 Hz, 1H), 6.69 - 6.58 (m, 2H), 6.58 - 6.51 (m, 1H), 6.46 (d, J = 8.4 Hz, 1H), 4.70 (s, 2H), 3.85 (s, 3H), 3.84 - 3.74 (m, 2H), 3.32 (s, 2H), 2.91 -2.79 (m, 3H), 2.76 - 2.67 (m, 2H), 2.54 - 2.45 (m, 1H), 2.21 - 2.08 (m, 2H), 1.72 - 1.63 (m, 2H), 1.13 - 1.05 (m, 10H), 0.70 - 0.59 (m, 1H), 0.50 - 0.43 (m, 1H), 0.39 - 0.31 (m, 1H), 0.22 - 0.19 (m, 1H).
Example 448:
Synthetic Route:
[1688] Referring to the synthetic route of compound 443, compound 443-4 was replaced with compound 447-2 to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 448 (3 mg, yield: 8%) as a white solid. MS (ESI, m/z): 643.3 [M+H]+.
[1689] 1H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 8.0 Hz, 1H), 7.34 - 7.29 (m, 2H), 7.25 - 7.16 (m, 2H), 7.10 (dd, J = 8.0, 1.6 Hz, 1H), 7.07 - 7.04 (m, 1H), 6.88 - 6.81 (m, 1H), 6.58 (dd, J = 8.4, 1.1 Hz, 1H), 6.52 - 6.48 (m, 1H), 6.44 (dd, J = 8.4, 2.4 Hz, 1H), 5.00 (s, 2H), 3.83 (s, 3H), 3.74 - 3.64 (m, 2H), 2.93 - 2.81 (m, 2H), 2.67 - 2.57 (m, 2H), 2.55 - 2.47 (m, 1H), 2.44 - 2.34 (m, 1H), 2.03 - 1.89 (m, 2H), 1.37 - 1.31 (m, 2H), 1.13 - 1.10 (m, 1H), 1.07 (s, 9H), 0.68 - 0.59 (m, 1H), 0.51 - 0.44 (m, 1H), 0.39 - 0.33 (m, 1H), 0.25 - 0.19 (m, 1H).
Example 449:
Synthetic Route:
[1691] Referring to the synthetic route of compound 398, compound 49-5 was replaced with compound 126-2 to synthesize compound 449-1 (20 mg, yield: 98%). MS (ESI, m/z): 464.3 [M+H]+.
[1692] Compound 449-1 (20 mg, 0.04 mmol) and triethylamine (13.08 mg, 0.13 mmol) were added to dichloromethane (10 mL). Methanesulfonyl chloride (7.4 mg, 0.06 mmol) was added at 0°C, and the reaction mixture was stirred at 25°C for 4 hours. After the reaction was completed, the reaction mixture was concentrated and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 449-2 (20 mg, yield: 96%) as a yellow oil. MS (ESI, m/z): 482.3 [M+H]+.
[1693] Compound 449-2 (20 mg, 0.04 mmol) was added to N,N-dimethylformamide (5 mL), followed by the addition of sodium hydride (1.2 mg, 0.05 mmol) at 0°C. The reaction mixture was stirred at 0°C for 0.5 hours, and then compound 449-3 (6.2 mg, 0.05 mmol) was added. The reaction mixture was stirred at 80°C for 4 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 449 (2 mg, yield: 7%) as a white solid. MS (ESI, m/z): 556.3 [M+H]+.
[1694] 1H NMR (400 MHz, MeOD) δ 7.49 (s, 1H), 7.39 (s, 1H), 7.33 (s, 1H), 7.27 (d, J = 8.0 Hz, 1H), 7.18 - 7.12 (m, 1H), 7.09 (dd, J= 8.1, 1.1 Hz, 1H), 6.65 - 6.60 (m, 1H), 6.56 - 6.53 (m, 1H), 6.44 (dd, J = 8.0, 2.1 Hz, 1H), 5.40 (s, 2H), 3.81 - 3.74 (m, 5H), 3.06 - 2.95 (m, 1H), 2.87 - 2.68 (m, 4H), 2.47 - 2.36 (m, 1H), 2.18 - 2.07 (m, 2H), 1.91 - 1.80 (m, 2H), 1.23 (s, 9H), 1.13 - 1.05 (m, 1H), 0.64 - 0.55 (m, 1H), 0.42 - 0.26 (m, 2H), 0.18 - 0.10 (m, 1H).
Example 450:
Synthetic Route:
[1696] Referring to the synthetic route of compound 397, compound 98-1 was replaced with compound 82-2 to synthesize compound 450-3 (550 mg, yield: 37%). MS (ESI, m/z): 492.3 [M+H]+.
[1697] Compound 450-3 (492 mg, 1 mmol), 2,2-dimethylpropionic acid hydrazide 450-4 (128 mg, 1.1 mmol), 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (418 mg, 1.1 mmol), and triethylamine (303 mg, 3 mmol) were added to dichloromethane (6 mL), and the reaction mixture was stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was concentrated and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 450-5 (367 mg, yield: 62%) as a yellow solid. MS (ESI, m/z): 590.3 [M+H]+.
[1698] To a mixture of compound 450-5 (367 mg, 0.62 mmol), p-toluenesulfonyl chloride (288 mg, 1.51 mmol), and dichloromethane (4 mL), triethylamine (382 mg, 3.78 mmol) was added dropwise at 0°C. The reaction mixture was stirred at room temperature for 3 hours. After the reaction was completed, the reaction mixture was concentrated and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 450-6 (290 mg, yield: 82%) as a yellow solid. MS (ESI, m/z): 572.3 [M+H]+.
[1699] Compound 450-6 (290 mg, 0.51 mmol) was added to methanol (2 mL), water (2 mL), and tetrahydrofuran (2 mL) and stirred. Lithium hydroxide (41 mg, 1.7 mmol) was added, and the reaction mixture was stirred at 60°C for 2 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 450 (120 mg, yield: 42%) as a white solid. MS (ESI, m/z): 558.3 [M+H]+.
[1700] 1H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 8.0 Hz, 1H), 7.32 (s, 1H), 7.24 - 7.17 (m, 1H), 7.12 (d, J = 8.0 Hz, 1H), 6.66 - 6.58 (m, 1H), 6.58 - 6.50 (m, 1H), 6.49 - 6.39 (m, 1H), 4.20 (s, 2H), 3.87 - 3.74 (m, 5H), 3.11 - 2.98 (m, 1H), 2.95 - 2.71 (m, 4H), 2.55 - 2.38 (m, 1H), 2.31 - 2.12 (m, 2H), 1.97 - 1.87 (m, 2H), 1.37 (s, 9H), 1.15 - 0.98 (m, 1H), 0.69 - 0.53 (m, 1H), 0.48 - 0.38 (m, 1H), 0.39 - 0.25 (m, 1H), 0.23 - 0.04 (m, 1H).
Example 451:
Synthetic Route:
[1702] Referring to the synthetic route of compound 126, 3,3,3-trifluoro-2,2-dimethylpropionic acid was replaced with 2,2-dimethylnonanoic acid to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 451 (20 mg, yield: 25%) as a white solid. MS (ESI, m/z): 628.3 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 7.93 (d, J = 8.0 Hz, 1H), 7.41 (s, 1H), 7.27 - 7.16 (m, 2H), 6.71 - 6.42 (m, 3H), 3.91 - 3.79 (m, 6H), 3.05 - 2.76 (m, 4H), 2.56 - 2.46 (m, 1H), 2.35 - 2.11 (m, 2H), 2.12 - 2.02 (m, 2H), 1.86 - 1.73 (m, 2H), 1.50 (s, 6H), 1.36 - 1.16 (m, 10H), 1.11 - 1.06 (m, 1H), 0.89 - 0.82 (m, 3H), 0.66 - 0.59 (m, 1H), 0.49 - 0.42 (m, 1H), 0.36 - 0.32 (m, 1H), 0.21 - 0.16 (m, 1H).
Example 452:
Synthetic Route:
[1704] Referring to the synthetic route of compound 126, 3,3,3-trifluoro-2,2-dimethylpropionic acid was replaced with 2,2-dimethyloctanoic acid to carry out the synthesis. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 452 (15 mg, yield: 36%) as a white solid. MS (ESI, m/z): 614.3 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 7.96 (d, J = 8.0 Hz, 1H), 7.43 (s, 1H), 7.31 - 7.26 (m, 1H), 7.26 - 7.19 (m, 1H), 6.65 (dd, J = 8.0, 2.4 Hz, 1H), 6.59 - 6.56 (m, 1H), 6.47 (dd, J = 8.0, 2.4 Hz, 1H), 3.89 - 3.79 (m, 6H), 3.02 - 2.82 (m, 4H), 2.60 - 2.50 (m, 1H), 2.28 - 2.19 (m, 2H), 2.15 - 2.02 (m, 2H), 1.86 - 1.77 (m, 2H), 1.53 (s, 6H), 1.35 - 1.25 (m, 8H), 1.17 - 1.07 (m, 1H), 0.88 (t, J = 6.8 Hz, 1H 3H), 0.69 - 0.63 (m, 1H), 0.51 - 0.44 (m, 1H), 0.39 - 0.34 (m, 1H), 0.24 - 0.18 (m, 1H).
Example 453:
Synthetic Route:
[1706] Compound 453-1 (900 mg, 4.5 mmol), compound 453-2 (450 mg, 4.5 mmol), and anhydrous potassium carbonate (621 mg, 4.5 mmol) were added to tetrahydrofuran (20 mL) and stirred at room temperature for 16 hours. After the reaction was completed, the reaction mixture was concentrated and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 453-3 (983 mg, yield: 78%) as a brick-red solid. MS (ESI, m/z): 281.3 [M+H]+.
[1707] Compound 453-3 (983 mg, 3.5 mmol) and 5% platinum on carbon (200 mg) were added to tetrahydrofuran (5 mL) and methanol (5 mL). The reaction mixture was stirred under a hydrogen atmosphere at room temperature for 16 hours. After the reaction was completed, the reaction mixture was concentrated and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 453-4 (812 mg, yield: 92%) as a white solid. MS (ESI, m/z): 251.3 [M+H]+.
[1708] Compound 453-4 (812 mg, 3.25 mmol) and compound 453-5 (692 mg, 3.25 mmol) were added to N,N-dimethylformamide (10 mL) and water (10 mL), and stirred at 110°C for 48 hours. After the reaction was completed, the reaction mixture was concentrated and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 453-6 (1170 mg, yield: 81%) as a white solid. MS (ESI, m/z): 444.3 [M+H]+.
[1709] Compound 453-6 (1.17 g, 2.6 mmol) and trifluoroacetic acid (3 mL) were added to dichloromethane (10 mL) and stirred at room temperature for 16 hours. After the reaction was completed, saturated sodium bicarbonate solution was added to adjust the pH to 8. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 453-7 (724 mg, yield: 63%) as a white solid. MS (ESI, m/z): 344.3 [M+H]+.
[1710] To a sealed tube, compound 453-7 (724 mg, 2.1 mmol), compound 156-4 (1.3 g, 6.3 mmol), tris(dibenzylideneacetone)dipalladium (92 mg, 0.1 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (116 mg, 0.2 mmol), cesium carbonate (1.31 g, 4.2 mmol), and dioxane (8 mL) were added under a nitrogen atmosphere. The reaction mixture was stirred at 120°C for 48 hours. After the reaction was completed, water (50 mL) was added, and the reaction mixture was extracted with ethyl acetate (30 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 453-8 (822 mg, yield: 84%) as a white solid. MS (ESI, m/z): 468.3 [M+H]+.
[1711] Compound 453-8 (822 mg, 1.76 mmol) was added to tetrahydrofuran (10 mL), followed by the addition of 1.5 M diisobutylaluminum hydride (2.6 mL, 3.9 mmol) at 0°C. The reaction mixture was stirred at 25°C for 24 hours. After the reaction was completed, 1 N hydrochloric acid (5 mL) was added to quench the reaction. The reaction mixture was extracted with ethyl acetate (30 mL × 3), and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 453-9 (731 mg, yield: 92%) as a white solid. MS (ESI, m/z): 440.3 [M+H]+.
[1712] Dess-Martin periodinane (1.06 g, 2.5 mmol) and sodium bicarbonate (630 mg, 7.5 mmol) were added to dichloromethane (20 mL). A solution of compound 453-9 (731 mg, 1.66 mmol) in dichloromethane (5 mL) was added at 0°C, and the reaction mixture was stirred at 25°C for 4 hours. After the reaction was completed, the reaction mixture was concentrated to obtain a crude product. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 453-10 (362 mg, yield: 50%) as a white solid. MS (ESI, m/z): 438.3 [M+H]+.
[1713] Compound 453-10 (362 mg, 0.83 mmol) was added to tetrahydrofuran (10 mL). At 0°C, 1.0 M cyclopropylmagnesium bromide (1.25 mL, 1.25 mmol) was added, and the reaction mixture was stirred at 0°C for 2 hours. After the reaction was completed, the reaction mixture was quenched with 1 N hydrochloric acid (5 mL) and extracted with ethyl acetate (10 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 453-11 (327 mg, yield: 82%) as a white solid. MS (ESI, m/z): 480.3 [M+H]+.
[1714] To a sealed tube, compound 453-11 (160 mg, 0.34 mmol), compound 225-5 (94 mg, 0.5 mmol), rhenium pentacarbonyl bromide (14 mg, 0.034 mmol), and toluene (2 mL) were added under a nitrogen atmosphere. The reaction mixture was reacted at 120°C for 8 hours, cooled to room temperature, added with water (10 mL), and extracted with ethyl acetate (10 mL × 3). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting crude product was purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound 453-12 (34 mg, yield: 29%) as a white solid. MS (ESI, m/z): 536.3 [M+H]+.
[1715] Compound 453-12 (34 mg, 0.058 mmol) was added to methanol (2 mL), followed by the dropwise addition of 0.5 mL of 1.0 M sodium hydroxide aqueous solution to the reaction system. The reaction was carried out at 50°C overnight. After cooling to room temperature, water (10 mL) was added, and the pH was adjusted to 3 with dilute hydrochloric acid. The mixture was extracted with ethyl acetate (10 mL × 3), and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The resulting crude product was purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain compound 453 (18 mg, yield: 55%) as a white solid. MS (ESI, m/z): 522.3 [M+H]+. 1H NMR (400 MHz, CDCl3) δ 7.69 (s, 1H), 7.25 - 7.21 (m, 2H), 7.00 - 6.86 (m, 1H), 6.58 - 6.48 (m, 1H), 6.46-6.36 (m, 1H), 4.11 (t, J = 8.5 Hz, 2H), 3.77 (s, 3H), 3.68 - 3.57 (m, 2H), 2.98 - 2.74 (m, 5H), 2.0 - 2.49 (m, 1H), 2.41 - 2.26 (m, 2H), 2.06 - 1.94 (m, 2H), 1.68 (t, J = 8.0 Hz, 2H), 1.15 - 0.99 (m, 10H), 0.66 - 0.56 (m, 1H), 0.46 - 0.31 (m, 2H), 0.27 - 0.16 (m, 1H).
Comparative Example 1
Synthetic Route:
[1717] Compound M1 (100 mg, 0.23 mmol) was added to dichloromethane (5 mL), and then trifluoroacetic acid (0.1 mL) was slowly added to the reaction mixture and stirred at room temperature for 1 hour. After the reaction was completed, the reaction mixture was directly concentrated and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound D-1 (13 mg, yield: 17%) as a yellow oil. MS (ESI, m/z): 328.3 [M+H]+.
[1718] Under a nitrogen atmosphere, compound D-1 (13 mg, 0.048 mmol), compound 156-4 (10 mg, 0.048 mmol), tris(dibenzylideneacetone)dipalladium (3.6 mg, 0.0048 mmol), 2-dicyclohexylphosphino-2',6'-diisopropoxybiphenyl (4.5 mg, 0.008 mmol), and cesium carbonate (26 mg, 0.08 mmol) were added to 1,4-dioxane (3 mL). The reaction mixture was heated to 100°C and stirred overnight. After the reaction was completed, the reaction mixture was directly concentrated and purified by normal-phase column chromatography (ethyl acetate: petroleum ether = 0% to 100%) to obtain compound D-2 (10 mg, yield: 46%) as a yellow oil. MS (ESI, m/z): 452.3 [M+H]+.
[1719] Compound D-2 (10 mg, 0.022 mmol) was added to tetrahydrofuran (2 mL) and methanol (2 mL). Then, a solution of lithium hydroxide (11 mg, 0.44 mmol) in water (1 mL) was added to the reaction mixture, which was heated to 60°C and stirred for 2 hours. After the reaction was completed, the reaction mixture was cooled to room temperature, and the pH was adjusted to 3 with 1 N hydrochloric acid. The reaction mixture was extracted with ethyl acetate (10 mL), and the organic phase was concentrated and purified by reverse-phase column chromatography [acetonitrile/water (0.05% formic acid) = 0% to 100%] to obtain comparative example 1 (2 mg, yield: 22%) as a white solid. MS (ESI, m/z): 438.3 [M+H]+.
[1720] 1H NMR (400 MHz, CDCl3) δ 7.43 (d, J = 8.4 Hz, 1H), 7.33 (s, 1H), 7.09 (d, J = 8.0 Hz, 1H), 6.98 - 6.93 (m, 1H), 6.58 - 6.53 (m, 1H), 6.46 - 6.41 (m, 1H), 6.39 (s, 1H), 3.79 (s, 3H), 3.56 (d, J = 11.6 Hz, 2H), 2.88 - 2.80 (m, 4H), 2.51 - 2.45 (m, 1H), 2.25 - 2.13 (m, 2H), 2.06 - 1.96 (m, 3H), 1.13 - 1.05 (m, 1H), 0.66 - 0.57 (m, 1H), 0.47 - 0.40 (m, 1H), 0.37 - 0.29 (m, 1H), 0.22 - 0.16 (m, 1H).
I. In Vitro Activity Assay Experimental Section:
Efficacy Test Example 1:
Detection of GPR40 Agonistic Activity of Compounds Using NFAT-RE-Based Reporter Gene Activity Assay
1. Method
1.1 Construction and preparation of plasmid pcDNA3.0-flag-FFAR1 (GPR40)
[1721] The pcDNA3.0-flag-FFAR1 (GPR40) plasmid was constructed using conventional molecular cloning methods. The main steps were as follows: The full-length cDNA sequence of human FFAR1 (GPR40) (NM_005303.3) was inserted into the HindIII and XbaI restriction sites of the pcDNA3.0 vector via PCR technology, resulting in the pcDNA3.0-flag-FFAR1 (GPR40) plasmid; pGL4.30 [luc2P NFAT-RE] (# E8481) and pRL-TK (#E2241) plasmids were both purchased from Promega; the plasmids were transformed into DH5α E. coli using the CaCl2 method, further cultured and amplified, and then purified using a plasmid extraction kit (TIANGEN, # DP117) to obtain the corresponding plasmid DNA.
1.2 Co-transfection of HEK293T cells with plasmids and compound treatment
[1722] HEK293T cells were seeded in a 96-well plate at a density of 1 × 104/well one day prior to plasmid transfection. Cell transfection was performed according to the instructions of the transfection reagent FuGENE® HD (Promega, # E2311). The main steps were as follows: Taking one well as an example, plasmids pcDNA3.0-flag-FFAR1 (GPR40), pGL4.30 [luc2P NFAT-RE], and pRL-TK were added at ratios of 50 ng, 50 ng, and 5 ng, respectively, into 10 µL of Opti-MEM™ I medium (Gibco, #11058021) and mixed thoroughly; then, 0.2 µL of FuGENE® HD was added, mixed thoroughly, and allowed to stand at room temperature for 5 minutes; finally, this 10 µL mixture was added to the cell well containing 100 µL of culture medium. 24 hours after co-transfection, the compounds were serially diluted at half-logarithmic intervals with 1 µM as the highest concentration, resulting in 10 concentration gradients, which were added to the cell culture medium for a 4-hour treatment. Two replicate wells were set up for each condition, with compounds TAK875 (previously entered Phase III clinical trials) and SCO267 (previously entered Phase I clinical trials) serving as positive controls.
1.3 Dual-Glo Luciferase assay
[1723] After 4 hours of compound treatment, the cells were assayed according to the instructions of the Dual-Glo® Luciferase Assay System (Promega, # E2940). The main steps were as follows: 50 µL of culture medium was aspirated from each well and discarded, followed by the addition of 50 µL of Dual-Glo® Luciferase Reagent, and the mixture was shaken at room temperature for 10 minutes. Then, 80 µL of the lysate reaction solution was transferred to a white opaque optiPlate-96 well plate, and the luminescence signal of Firefly luciferase (Firefly-Luc) was measured using an MD i3x multifunctional microplate reader. Subsequently, 40 µL of Dual-Glo® Stop & Glo® Reagent was added, and the mixture was shaken at room temperature for 10 minutes. Finally, the luminescence signal of Renilla luciferase (Renilla-Luc) was measured using the MD i3x multifunctional microplate reader. The ratio of Firefly-Luc/Renilla-Luc was used as the compound's agonistic activity toward GPR40, and normalization was performed using the ratio of the solvent DMSO group. A dose-response curve was fitted using a four-parameter model with GraphPad Prism 8.0 software to calculate the EC50 value.
2. Results
[1724] The experimental data are shown in Table 1 below. Table 1
| Cpd ID | Nuclear Factor of Activated T-Cells Reporter Gene Activity Assay (NFAT reporter assay) | |
| EC50 (µM) | Efficacy (%) | |
| TAK875 | * | 65 |
| SCO-267 | *** | 100 |
| Comparative Example 1 | NA | NA |
| Compound 1 | NA | † |
| Compound 2 | * | †† |
| Compound 3 | ** | †† |
| Compound 4 | ** | † |
| Compound 5 | ** | ††† |
| Compound 6 | * | †† |
| Compound 7 | ** | †† |
| Compound 8 | * | †† |
| Compound 9 | ** | †† |
| Compound 10 | ** | †† |
| Compound 11 | *** | ††† |
| Compound 12 | *** | †† |
| Compound 13 | ** | ††† |
| Compound 14 | *** | ††† |
| Compound 15 | ** | ††† |
| Compound 20 | ** | †† |
| Compound 21 | ** | †† |
| Compound 22 | ** | †† |
| Compound 23 | ** | †† |
| Compound 24 | ** | † |
| Compound 26 | ** | †† |
| Compound 27 | ** | † |
| Compound 28 | ** | ††† |
| Compound 29 | ** | †† |
| Compound 30 | ** | †† |
| Compound 31 | ** | †† |
| Compound 32 | ** | †† |
| Compound 33 | *** | †† |
| Compound 34 | *** | †† |
| Compound 35 | ** | †† |
| Compound 36 | ** | †† |
| Compound 37 | ** | †† |
| Compound 38 | *** | ††† |
| Compound 39 | ** | ††† |
| Compound 41 | ** | †† |
| Compound 43 | ** | †† |
| Compound 44 | ** | †† |
| Compound 45 | ** | †† |
| Compound 47 | ** | †† |
| Compound 48 | ** | †† |
| Compound 49 | **** | †† |
| Compound 52 | ** | † |
| Compound 53 | ** | †† |
| Compound 54 | *** | †† |
| Compound 55 | **** | †† |
| Compound 56 | ** | † |
| Compound 60 | ** | †† |
| Compound 61 | ** | †† |
| Compound 65 | ** | †† |
| Compound 66 | ** | †† |
| Compound 70 | * | †† |
| Compound 71 | ** | †† |
| Compound 79 | ** | †† |
| Compound 81 | ** | † |
| Compound 82 | ** | † |
| Compound 83 | ** | † |
| Compound 85 | ** | †† |
| Compound 86 | *** | ††† |
| Compound 87 | *** | †† |
| Compound 88 | ** | †† |
| Compound 89 | ** | †† |
| Compound 90 | ** | † |
| Compound 91 | ** | † |
| Compound 92 | ** | ††† |
| Compound 93 | ** | ††† |
| Compound 94 | ** | † |
| Compound 95 | ** | †† |
| Compound 96 | ** | ††† |
| Compound 97 | *** | †† |
| Compound 99 | ** | †† |
| Compound 101 | ** | †† |
| Compound 102 | *** | †† |
| Compound 103 | *** | †† |
| Compound 104 | * | †† |
| Compound 105 | *** | †† |
| Compound 106 | *** | †† |
| Compound 107 | ** | ††† |
| Compound 108 | *** | ††† |
| Compound 109 | ** | †† |
| Compound 110 | *** | †† |
| Compound 111 | *** | ††† |
| Compound 112 | *** | †† |
| Compound 113 | **** | †† |
| Compound 114 | *** | †† |
| Compound 115 | **** | †† |
| Compound 116 | **** | †† |
| Compound 117 | *** | †† |
| Compound 118 | *** | †† |
| Compound 120 | * | †† |
| Compound 121 | * | †† |
| Compound 122 | *** | †† |
| Compound 123 | ** | †† |
| Compound 124 | *** | †† |
| Compound 125 | *** | †† |
| Compound 126 | *** | †† |
| Compound 127 | ** | ††† |
| Compound 128 | *** | †† |
| Compound 129 | *** | †† |
| Compound 130 | *** | †† |
| Compound 131 | *** | †† |
| Compound 132 | ** | ††† |
| Compound 133 | ** | † |
| Compound 134 | ** | † |
| Compound 135 | *** | †† |
| Compound 137 | *** | ††† |
| Compound 138 | ** | †† |
| Compound 139 | ** | †† |
| Compound 140 | ** | ††† |
| Compound 141 | **** | ††† |
| Compound 142 | ** | †† |
| Compound 143 | *** | †† |
| Compound 144 | * | †† |
| Compound 145 | *** | †† |
| Compound 146 | ** | ††† |
| Compound 147 | *** | ††† |
| Compound 148 | ** | †† |
| Compound 149 | ** | †† |
| Compound 150 | ** | †† |
| Compound 151 | ** | †† |
| Compound 152 | ** | †† |
| Compound 153 | ** | ††† |
| Compound 154 | ** | ††† |
| Compound 155 | *** | ††† |
| Compound 156 | ** | †† |
| Compound 157 | ** | ††† |
| Compound 158 | ** | †† |
| Compound 159 | ** | †† |
| Compound 160 | ** | †† |
| Compound 161 | ** | † |
| Compound 162 | ** | ††† |
| Compound 163 | ** | †† |
| Compound 164 | ** | †† |
| Compound 165 | ** | ††† |
| Compound 166 | *** | †† |
| Compound 167 | ** | †† |
| Compound 168 | ** | ††† |
| Compound 169 | ** | ††† |
| Compound 170 | ** | †† |
| Compound 171 | ** | †† |
| Compound 172 | ** | † |
| Compound 173 | ** | ††† |
| Compound 174 | ** | †† |
| Compound 175 | * | †† |
| Compound 176 | ** | †† |
| Compound 177 | ** | †† |
| Compound 178 | ** | †† |
| Compound 179 | ** | ††† |
| Compound 180 | ** | †† |
| Compound 181 | ** | †† |
| Compound 183 | ** | †† |
| Compound 184 | ** | † |
| Compound 185 | ** | †† |
| Compound 186 | ** | † |
| Compound 187 | ** | †† |
| Compound 188 | ** | †† |
| Compound 190 | ** | †† |
| Compound 191 | ** | †† |
| Compound 192 | ** | †† |
| Compound 193 | ** | †† |
| Compound 198 | ** | †† |
| Compound 200 | ** | †† |
| Compound 202 | ** | †† |
| Compound 203 | ** | † |
| Compound 205 | ** | † |
| Compound 206 | ** | †† |
| Compound 208 | ** | ††† |
| Compound 209 | ** | †† |
| Compound 210 | ** | †† |
| Compound 211 | ** | ††† |
| Compound 212 | ** | †† |
| Compound 213 | *** | †† |
| Compound 214 | ** | † |
| Compound 215 | ** | †† |
| Compound 217 | *** | †† |
| Compound 218 | ** | ††† |
| Compound 219 | *** | † |
| Compound 220 | ** | †††† |
| Compound 222 | ** | ††† |
| Compound 223 | ** | † |
| Compound 231 | ** | † |
| Compound 232 | ** | † |
| Compound 233 | ** | †† |
| Compound 234 | **** | †† |
| Compound 235 | **** | †† |
| Compound 236 | *** | ††† |
| Compound 237 | *** | †† |
| Compound 238 | *** | ††† |
| Compound 239 | *** | ††† |
| Compound 240 | ** | †† |
| Compound 241 | ** | †† |
| Compound 242 | ** | †† |
| Compound 243 | * | †† |
| Compound 244 | * | †† |
| Compound 245 | ** | †† |
| Compound 246 | ** | †† |
| Compound 247 | ** | ††† |
| Compound 248 | ** | †† |
| Compound 249 | ** | †† |
| Compound 250 | ** | †† |
| Compound 251 | ** | †† |
| Compound 252 | ** | †† |
| Compound 253 | **** | ††† |
| Compound 254 | ** | ††† |
| Compound 255 | ** | †† |
| Compound 256 | ** | ††† |
| Compound 257 | **** | ††† |
| Compound 258 | ** | ††† |
| Compound 259 | * | †† |
| Compound 260 | *** | ††† |
| Compound 261 | **** | ††† |
| Compound 262 | ***** | †† |
| Compound 263 | ** | †† |
| Compound 264 | ** | †† |
| Compound 265 | **** | ††† |
| Compound 266 | ***** | †††† |
| Compound 267 | **** | ††† |
| Compound 268 | **** | †† |
| Compound 269 | *** | ††† |
| Compound 270 | *** | †††† |
| Compound 271 | **** | ††† |
| Compound 272 | *** | ††† |
| Compound 273 | **** | †† |
| Compound 274 | ** | †† |
| Compound 275 | *** | ††† |
| Compound 276 | *** | †† |
| Compound 277 | * | †††† |
| Compound 278 | ***** | †††† |
| Compound 279 | * | †† |
| Compound 280 | ** | †† |
| Compound 281 | ** | †† |
| Compound 282 | *** | †† |
| Compound 283 | *** | ††† |
| Compound 284 | **** | †† |
| Compound 285 | **** | †† |
| Compound 286 | ** | †† |
| Compound 288 | ** | †† |
| Compound 290 | ** | †† |
| Compound 293 | ** | †† |
| Compound 296 | ** | ††† |
| Compound 297 | ** | †† |
| Compound 298 | ** | †† |
| Compound 299 | ** | †† |
| Compound 300 | ** | †† |
| Compound 301 | ** | †† |
| Compound 302 | ** | † |
| Compound 304 | ** | ††† |
| Compound 305 | ** | †† |
| Compound 306 | ** | †† |
| Compound 307 | ** | †† |
| Compound 308 | * | †† |
| Compound 309 | ** | †† |
| Compound 310 | ** | †† |
| Compound 312 | ** | † |
| Compound 314 | ** | †† |
| Compound 315 | ** | †† |
| Compound 316 | ** | †† |
| Compound 317 | ** | † |
| Compound 319 | ** | †† |
| Compound 320 | *** | †† |
| Compound 321 | ** | †† |
| Compound 322 | **** | †† |
| Compound 323 | **** | †† |
| Compound 324 | **** | †† |
| Compound 325 | ** | †† |
| Compound 326 | ** | †† |
| Compound 327 | ** | †† |
| Compound 328 | * | †† |
| Compound 330 | *** | †† |
| Compound 331 | ** | †† |
| Compound 332 | **** | †† |
| Compound 333 | **** | †† |
| Compound 334 | **** | †† |
| Compound 335 | **** | †† |
| Compound 336 | **** | †† |
| Compound 337 | **** | †† |
| Compound 338 | *** | †† |
| Compound 339 | **** | †† |
| Compound 340 | ***** | ††† |
| Compound 341 | **** | †† |
| Compound 342 | **** | †† |
| Compound 343 | **** | ††† |
| Compound 344 | ** | †† |
| Compound 345 | ** | †† |
| Compound 346 | ** | †† |
| Compound 347 | *** | †† |
| Compound 348 | ** | †† |
| Compound 349 | ** | †† |
| Compound 351 | *** | †† |
| Compound 352 | *** | †† |
| Compound 353 | ** | ††† |
| Compound 354 | ** | †† |
| Compound 355 | ** | †† |
| Compound 358 | ** | † |
| Compound 359 | ** | † |
| Compound 360 | * | ††† |
| Compound 361 | *** | †† |
| Compound 362 | ** | †† |
| Compound 363 | ** | †† |
| Compound 364 | ** | †† |
| Compound 365 | *** | ††† |
| Compound 366 | *** | †† |
| Compound 367 | **** | †† |
| Compound 368 | ** | ††† |
| Compound 369 | ** | † |
| Compound 370 | ** | †† |
| Compound 371 | ** | †† |
| Compound 372 | ** | †† |
| Compound 373 | *** | †† |
| Compound 374 | *** | †† |
| Compound 375 | ** | †† |
| Compound 376 | *** | †† |
| Compound 377 | *** | †† |
| Compound 379 | ** | †† |
| Compound 380 | * | †† |
| Compound 383 | ** | ††† |
| Compound 384 | ** | †† |
| Compound 385 | *** | †† |
| Compound 386 | *** | †† |
| Compound 387 | *** | †† |
| Compound 388 | ** | †† |
| Compound 389 | ** | †† |
| Compound 390 | ** | †† |
| Compound 391 | ** | †† |
| Compound 393 | ** | †† |
| Compound 394 | * | †† |
| Compound 395 | ** | † |
| Compound 398 | ** | ††† |
| Compound 399 | ** | †† |
| Compound 400 | ** | † |
| Compound 401 | ** | ††† |
| Compound 402 | ** | † |
| Compound 404 | ** | †† |
| Compound 405 | ** | † |
| Compound 406 | ** | ††† |
| Compound 407 | ** | ††† |
| Compound 408 | ** | ††† |
| Compound 409 | *** | ††† |
| Compound 410 | ** | ††† |
| Compound 411 | *** | †† |
| Compound 412 | ** | ††† |
| Compound 413 | ** | ††† |
| Compound 414 | * | ††† |
| Compound 415 | * | ††† |
| Compound 416 | *** | †† |
| Compound 417 | ** | ††† |
| Compound 418 | *** | ††† |
| Compound 419 | *** | †††† |
| Compound 420 | ** | †† |
| Compound 421 | ** | ††† |
| Compound 423 | ** | † |
| Compound 424 | * | †† |
| Compound 425 | ** | †† |
| Compound 426 | *** | ††† |
| Compound 427 | ** | ††† |
| Compound 428 | ** | †† |
| Compound 429 | ** | ††† |
| Compound 430 | ** | ††† |
| Compound 431 | ** | †† |
| Compound 432 | *** | ††† |
| Compound 435 | *** | †† |
| Compound 436 | * | †† |
| Compound 438 | *** | †† |
| Compound 439 | ** | †† |
| Compound 440 | *** | ††† |
| Compound 441 | ** | †† |
| Compound 442 | ** | †† |
| Compound 447 | ** | †† |
| Compound 448 | ** | †† |
| Compound 450 | ** | † |
| Compound 451 | *** | †† |
| Compound 452 | *** | †† |
| *: EC50 > 0.5 µM; **: 0.5 µM ≥ EC50 > 0.1 µM; ***: 0.1 µM ≥ EC50 > 0.01 µM; ****:
0.01 µM ≥ EC50; NA indicates no activity. †: 100 ≥ Efficacy (%) > 50; ††: 150 ≥ Efficacy (%) > 100; ††† : Efficacy (%) > 150. Conclusion: The compounds of the present disclosure generally have good GPR40 activity. |
II. In Vivo Pharmacodynamic Assay Section:
Efficacy Test Example 1: Effect of Compounds of the Present Disclosure on Oral Glucose Tolerance Test (OGTT) in Normal C57BL6/J Mice
1. Experimental method
[1725] Eighteen normal male C57BL6/J mice (8-9 weeks old) were selected and randomly divided into 3 groups based on body weight and blood glucose levels, with 6 mice in each group. On the day of the OGTT, fasting was initiated at 8:30 AM. At 11:30 AM, drug interventions were administered via gavage (vehicle control, compound 14, 1 mg/kg, and compound 169, 1 mg/kg). At 1:30 PM, glucose (2 g/kg) was administered via gavage, while the blank control group received the vehicle control orally (2% DMSO + 15% solutol + 83% DDW solution) at a dosing volume of 10 mL/kg. Blood glucose measurements during the OGTT were taken at the following time points: 0, 15, 30, 60, 90, and 120 minutes after glucose administration.
2. Observation indicators and calculations
2.1 Blood glucose measurement
[1726] Blood glucose levels were measured at 0, 15, 30, 60, and 120 minutes after glucose administration. The area under the curve (AUC) for blood glucose over 120 minutes was calculated.
AUC (mmol/L·h) = (BG0 + BG15) × 0.25/2 + (BG15 + BG30) × 0.25/2 + (BG30 + BG60) ×
0.5/2 + (BG60 + BG90) × 0.5/2 + (BG90 + BG120) × 0.5/2
[1727] Note: BG0, BG15, BG30, BG60, BG90, and BG120 represent the blood glucose levels at 0, 15, 30, 60, 90, and 120 minutes after glucose administration, respectively.
3. Data processing and statistical analysis
[1728] Data were expressed as mean ± standard deviation. One-way ANOVA was employed for statistical analysis, with p < 0.05 considered statistically significant.
4. The experimental results are shown in Table 2.
[1729]
Table 2: Blood Glucose Levels at Each Time Point and AUC0-120 minutes
| Group | Blank Control Group | Compound 14 | Compound 169 | ||
| Blood Glucose (mmol/L) | 0 | 7.58±0.59* | 8.92±1.32 | 7.58±0.59* | 7.88±0.62 |
| 15 | 11.08±2.04**** | 21.03±2.44 | 11.08±2.04**** | 12.78±1.65**** | |
| 30 | 9.17±1.37**** | 14.33±1.54 | 9.17±1.37**** | 9.28±1.32**** | |
| 60 | 7.6±1.34**** | 15.17±1.4 | 7.6±1.34**** | 9.28±1.32**** | |
| 90 | 6.52±2* | 10.08±2.53 | 6.52±2* | 7.67±2.31 | |
| 120 | 5.87±1.13** | 10.67±2.9 | 5.87±1.13** | 7.13±1.25* | |
| AUC | 0-120 minutes | 941±62.00**** | 1622±84.00 | 941±62.00**** | 1075±66.01 **** |
| Note: One-way ANOVA, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. |
[1730] The effect of a single administration of the compound 14 and compound 169 of the present disclosure on oral glucose tolerance in normal C57BL6/J mice was investigated. As shown in Table 2, compound 14 and compound 169 significantly reduced the AUC0-120 minutes after a single administration at the dose of 1 mg/kg. Compared with the blank control, compound 14 and compound 169 at the dose of 1 mg/kg were observed to lower blood glucose levels and AUC0-120 minutes at all time points.
[1731] In summary, compound 14 and compound 169 of the present disclosure can significantly reduce oral glucose tolerance in normal C57BL6/J mice after a single administration at the dose of 1 mg/kg, demonstrating good hypoglycemic effects.
Efficacy Test Example 2: Effect of Compounds of the Present Disclosure on Oral Glucose Tolerance Test (OGTT) in High-Fat Diet-Induced DIO Mice
1. Experimental method
[1732] Normal male C57BL6/J mice (8-9 weeks old) were housed 3-4 per cage and fed a high-fat, high-cholesterol, high-fructose diet (D09100310, Research Diets) for 13 weeks with unrestricted access to water. After 13 weeks of high-fat, high-cholesterol, high-fructose diet feeding, the mice were randomly divided into 5 groups based on body weight and blood glucose levels, with age-matched mice fed a normal diet serving as the normal blank control group, with 6 mice in each group. Under fasting conditions (16 hours), the test compound 169 was administered via oral gavage at different concentrations of 0.03, 0.1, 0.6, and 3 mg/kg, while the normal blank control and model control groups were given the vehicle (15% solutol + 85% DDW solution), with a dosing volume of 10 mL/kg. On the day of administration, blood glucose levels in mice were measured. 2 hours after oral gavage administration, each group was given 2 g/kg of glucose orally. Blood glucose levels were measured at 0, 15, 30, 60, 90, 120, and 150 minutes after glucose administration.
2. Observation indicators and calculations
2.1 Blood glucose measurement
[1733] Blood glucose levels were measured at 0, 15, 30, 60, and 120 minutes after glucose administration. The area under the curve (AUC) for blood glucose over 120 minutes was calculated.
AUC (mmol/L·h) = (BG0 + BG15) × 0.25/2 + (BG15 + BG30) × 0.25/2 + (BG30 + BG60) ×
0.5/2 + (BG60 + BG90) × 0.5/2 + (BG90 + BG120) × 0.5/2
[1734] Note: BG0, BG15, BG30, BG60, BG90, and BG120 represent the blood glucose levels at 0, 15, 30, 60, 90, and 120 minutes after glucose administration, respectively.
3. Data processing and statistical analysis
[1735] Data were expressed as mean ± standard deviation. One-way ANOVA was employed for statistical analysis, with p < 0.05 considered statistically significant.
4. The experimental results are shown in Table 3.
[1736]
Table 3: Blood Glucose Levels at Each Time Point and AUC0-150 minutes
| Group | Normal Blank Control Group | Model Control Group | 0.03 mg/kg | 0.1 mg/kg | 0.6 mg/kg | 3 mg/kg | |
| 0 minutes | 8.68±1.15 | 10.2±1.23 | 10.78± 0.81 | 9.28±2.89 | 9.57± 2.06 | 13.02±2.46 | |
| 15 minutes | 21.9±2.22 | 22.2±2.39 | 20.08± 2.94 | 17.65±2.09 ** | 16.48± 2.15** * | 17.22±2.02 ** | |
| Blood Glucose (mmol/L) | 30 minutes | 17.77±1.78 | 16.63±2.38 | 16.63± 3.66 | 18.67±4.11 | 12.97± 3.71 | 14±3.49 |
| 60 minutes | 12.23±0.78 | 12.97±2.76 | 14.62± 3.62 | 13.53±3.03 | 11.98± 2.95 | 10.52±2.23 | |
| 90 minutes | 10.42±1.22 * | 13.92±3.41 | 14.92± 2.34 | 10.27±1.68 * | 11.27± 2.66 | 9.88±0.85* | |
| 120 minutes | 8.38±0.49 | 11.181±3.48 | 13±3.0 5 | 10.05±1.47 | 9.12± 2.14 | 8.3±1.63 | |
| 150 minutes | 8.08±0.82* | 10.67±2.26 | 10.75± 1.1 | 10.17±1.68 | 9.52± 1.62 | 7.37±1.44* * | |
| AUC0-150 min (mmol*min) | 1846±52.00 ** | 2094±133.0 0 | 2194± 132.70 | 1922±113.0 0* | 1725± 119.90 **** | 1642±91.83 **** | |
| One-way ANOVA, compared with the model control group, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. |
[1737] The effect of a single administration of the compound 169 of the present disclosure at doses of 0.03, 0.1, 0.6, and 3 mg/kg on oral glucose tolerance in a high-fat diet-induced DIO mouse model was investigated. As shown in Table 3, compound 169 significantly reduced the AUC0-150 minutes at doses of 0.1, 0.6, and 3 mg/kg, exhibiting a dose-dependent effect.
[1738] In summary, a single administration of compound 169 of the present disclosure can significantly reduce the oral glucose tolerance of DIO mice, showing a good hypoglycemic effect.
Efficacy Test Example 3: In Vivo Hypoglycemia Risk Assay
1. Experimental method
[1739] Twenty-four normal male C57BL6/J mice (8-9 weeks old) were selected and randomly divided into 4 groups based on body weight and blood glucose levels, with 6 mice in each group. Under fasting conditions (16 hours), compound 169 was orally administered at doses of 3 and 10 mg/kg, while the positive control drug Glibenclamide was given at 10 mg/kg. The blank control group was orally administered with the vehicle control (2% DMO + 15% solutol + 83% DDW solution), with a dosing volume of 10 mL/kg. Blood glucose levels were measured at 0, 30, 60, 120, and 180 minutes after administration on the day of dosing.
2. Observation indicators and calculations
2.1 Blood glucose measurement
[1740] Blood glucose levels were measured at 0, 30, 60, 120, and 180 minutes after administration. The area under the blood glucose curve (AUC) over 180 minutes was calculated.
[1741] Note: BG0, BG30, BG60, BG120, and BG180 represent blood glucose levels at 0, 30, 60, 120, and 180 minutes after administration, respectively.
3. Data processing and statistical analysis
[1742] Data were expressed as mean ± standard deviation. One-way ANOVA was employed for statistical analysis, with p < 0.05 considered statistically significant.
4. The experimental results are shown in Table 4.
[1743]
Table 4: Blood Glucose Levels at Each Time Point and AUC0-120 minutes
| Group | Blood Glucose (mmol/L) | AUC0-120 minutes (mmol*min) | |||
| 0 minutes | 30 minutes | 60 minutes | 120 minutes | ||
| Blank Control Group | 4.181±1.13 | 5.48±0.77 | 5.13±0.97 | 4.22±0.88 | 589±48.00 |
| Glibenclamide, 10 mg/kg | 4.47±0.85 | 4.57±0.92 | 4.18±0.94 | 3.32±1.05 | 492±50.30** |
| Compound 169, 3 mg/kg | 4.3±0.59 | 5.42±0.56 | 4.73±0.82 | 4.1±0.51 | 563±34.91 |
| Compound 169, 10 mg/kg | 4.65±0.75 | 6.1±1.01 | 4.92±1.01 | 4±0.87 | 594±49.00 |
[1745] As shown in Table 4, compared to the blank control, the AUC0-120 min data of Glibenclamide at 10 mg/kg indicated a risk of hypoglycemia; the compound of the present disclosure 169 at both 3 mg/kg and 10 mg/kg did not exhibit hypoglycemia, demonstrating no risk of hypoglycemia.
Efficacy Test Example 4: In Vivo Pharmacodynamic Assay for Non-Alcoholic Fatty Liver Disease
1. Experimental method
[1746] Normal male C57BL6/J mice (7-5 weeks old) were fed a high-fat, high-cholesterol, high-fructose diet (D09100310, Research Diets) for 20 weeks. Based on body weight and biochemical data, the mice were randomly divided into groups, with 6 mice per group. The compound 169 (0.03, 0.1, and 0.6 mg/kg) was administered via oral gavage. The positive control was MGL3196 (1 mg/kg), and the blank control group consisted of mice of the same strain and age fed a normal diet for the same duration. The blank control and model control groups were given the vehicle (15% solutol + 85% DDW), totaling 6 groups. Administration was performed once daily for 28 days. After overnight fasting, on day 29 at the experimental endpoint, blood was collected from the heart after CO2 euthanasia. Serum ALT and AST biochemical indicators were measured, and liver tissue was harvested for hepatic hydroxyproline content determination.
2. Measurement of blood biochemical ALT, AST, and hepatic hydroxyproline content
[1747] Blood was collected using anticoagulant-free tubes, allowed to stand at room temperature for 30 minutes, and then centrifuged at 4000 rpm for 10 minutes to separate serum, which was tested by Dian Diagnostics. Approximately 50 mg of liver tissue was taken from each mouse and tested according to the hydroxyproline assay kit method (Nanjing Jiancheng, Cat. No.: A030-2-1).
3. Data processing and statistical analysis
[1748] Data were expressed as mean ± standard deviation. One-way ANOVA was employed for statistical analysis, with p < 0.05 considered statistically significant.
4. The experimental results are shown in Table 5.
[1749]
Table 5: Blood Biochemistry and Hepatic Hydroxyproline Content
| Group | ALT (U/L) | AST (U/L) | Hepatic Hydroxyproline (µg/g) | Total Liver Hydroxyproline (µg/liver) |
| Blank Control | 34±19.32 | 84±32.42 | 91.95±27.41 | 101.97±28.92 |
| Model Control | 259.5±137.71 | 308±170.34 | 236.37±87.34 | 559.7±260.05 |
| MGL3196, 1 mpk | 140±63.06 | 242±67.42 | 173.63±32.06 | 313.58±98.24* |
| Compound 169, 0.03 mpk | 148±81.95 | 204.5±79.09 | 128.06±55.18** | 308.56±121.44* |
| Compound 169, 0.1 mpk | 110±37.12* | 156±30.59* | 119.16±39.65** | 266.4±80.67** |
| Compound 169, 0.6 mpk | 103.8±35.53* | 163.2±42.98 | 85.24±47.63*** | 187.94±110.56*** |
| Note: One-way ANOVA, *p < 0.05, **p < 0.01. |
[1750] As shown in Table 5, compared with the model control, compound 169 at doses of 0.03, 0.1, and 0.6 mg/kg reduced ALT, AST, and liver hydroxyproline levels, indicating that compound 169 has liver protection and liver fibrosis inhibition effects.
III. Pharmacokinetic Evaluation
[1751] The bioavailability and pharmacokinetic behavior of the compounds were evaluated in mice. 6 male ICR mice with similar body weights were selected, among which 3 mice were administered a single gavage dose of 10 mg/kg, and the other 3 mice were intravenously administered a single dose of 5 mg/kg. Blood samples were collected at 5 minutes (intravenous administration), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, and 7 hours after administration. The plasma samples were analyzed for concentration by LCMS/MS, and the pharmacokinetic parameters of the compounds were analyzed using the PKSolver free tool and non-compartmental analysis (NCA) software.
Experimental protocol:
[1752] Experimental animals: Each compound test group included 6 healthy male ICR mice, weighing 18-25 g, purchased from Charles River, which were randomly divided into 2 groups with 3 mice each.
[1753] Preparation of formulations: A certain amount of the compound was weighed and added to 2% DMSO + 15% Solutol + 83% physiological saline to form a clear solution.
[1754] Dosage: ICR mice were fasted overnight and administered the compound at a dose of 10 mg/kg via gavage or 5 mg/kg via intravenous injection. The dosing volumes for gavage and intravenous administration were 10 mL/kg and 5 mL/kg, respectively. Uniform feeding was conducted 2 hours after administration.
[1755] Sample collection: Approximately 30 µL of blood was collected from the great saphenous vein at 5 minutes (intravenous administration), 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, and 7 hours after administration. The blood was placed into commercially available tubes containing K2-EDTA. The blood samples were then centrifuged at 4°C and 4600 rpm for 5 minutes to obtain plasma samples. All plasma samples were rapidly frozen on dry ice and maintained at -70°C until LCMS/MS analysis was performed.
[1756] Sample preparation: 10 µL of plasma sample was aspirated and precipitated with a methanol solution containing 50 nmol/L of α-naphthoflavone (internal standard). The mixture was thoroughly mixed and centrifuged at 4°C and 14000 rpm for 5 minutes. Then, 75 µL of the supernatant was mixed with 75 µL of methanol for LCMS/MS analysis.
[1757] The pharmacokinetic parameter results are shown in Table 6.
Table 6
| Pharmacokinetic Parameters of Mice | |||||||
| Intravenous Administration (5 mg/kg) | Gavage Administration (10 mg/kg) | ||||||
| Compound | F (%) | T1/2 (h) | CL_obs (mL/min/kg) | Vss_obs (mL/kg) | Tmax (h) | Cmax (ng/mL ) | AUC0-7 h (h*ng/mL ) |
| Compound 12 | 44.6 | 5.02 | 1.9 | 520 | 2 | 6575 | 38020 |
| Compound 38 | 77.4 | 2.41 | 2.3 | 405 | 2 | 8596 | 55433 |
| Compound 89 | 73.7 | 5.46 | 1.3 | 546 | 2 | 11059 | 92234 |
| Compound 166 | 48.0 | 6.7 | 1.6 | 668 | 4 | 4948 | 48126 |
| Compound 168 | 24.0 | 3.9 | 2.1 | 494 | 3 | 3470 | 15359 |
[1758] Conclusion: These compounds are well absorbed in mice, with slow elimination, high exposure, and relatively high bioavailability, which can be used for further study.
IV. Tissue Distribution Evaluation
[1759] Experimental protocol: The tissue distribution characteristics of the compounds were evaluated in mice. 2 male ICR mice with similar body weights were selected, and the compound was administered via oral gavage at a dose of 5 mg/kg. The animals were sacrificed at 1 hour, and blood, liver, and heart were collected. After sample processing, the concentration of the compounds in each matrix was analyzed by LCMS/MS, and the average values of each group were calculated to evaluate the tissue/plasma ratio of the compounds.
[1761] Preparation of formulations: A certain amount of the compound was weighed and added to 2% DMSO + 15% Solutol + 83% distilled water to form a clear solution.
[1762] Dosage: ICR mice were fasted overnight and administered the compound via oral gavage at a dose of 5 mg/kg. The volume of oral gavage administration was 10 mL/kg. Uniform feeding was conducted 2 hours after administration.
[1763] Sample collection: Animals were sacrificed 1 hour after administration, and blood, liver, and heart tissues were collected. The blood was placed into commercially available tubes containing K2-EDTA. The blood samples were then centrifuged at 4°C and 4600 rpm for 5 minutes to obtain plasma samples. All plasma and tissue samples were rapidly frozen on dry ice and maintained at -70°C until LCMS/MS analysis was performed.
[1764] Sample preparation: 50 µL of the plasma sample was aspirated, precipitated with methanol, thoroughly mixed, and centrifuged at 4°C and 14000 rpm for 5 minutes. Then, 75 µL of the supernatant was mixed with 75 µL of methanol for LCMS/MS analysis. Tissue samples were homogenized using methanol. After homogenization, the mixture was centrifuged at 14,000 rpm for 5 minutes at 4°C. Subsequently, 75 µL of the supernatant was mixed with 75 µL of methanol for LCMS/MS analysis.
1. A compound of formula I or a pharmaceutically acceptable salt thereof:
wherein X is O or NR3, and R3 is H or C1-C6 alkyl; Q is C or N;
Z and Y are independently C or N;
G1 is H, C1-C6 alkyl, C1-C6 alkyl substituted by one or more G1-1, C6-C14 aryl, C6-C14 aryl substituted by one or more G1-2, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryl substituted by one or more G1-3, C1-C6 alkoxy, C1-C6 alkoxy substituted by one or more G1-4, C2-C6 alkenyl, C2-C6 alkenyl substituted by one or more G1-5, C2-C6 alkynyl, C2-C6 alkynyl substituted by one or more G1-6, C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by one or more G1-7, C3-C8 cycloalkenyl, C3-C8 cycloalkenyl substituted by one or more G1-8, 3- to 8-membered heterocycloalkyl, 3- to 8-membered heterocycloalkyl substituted by one or more G1-9, 3- to 8-membered heterocycloalkenyl, or 3- to 8-membered heterocycloalkenyl substituted by one or more G1-10;
the 5- to 10-membered heteroaryl, the 5- to 10-membered heteroaryl substituted by one or more G1-3, the 3- to 8-membered heterocycloalkyl, the 3- to 8-membered heterocycloalkyl substituted by one or more G1-9, the 3- to 8-membered heterocycloalkenyl, and the 3- to 8-membered heterocycloalkenyl substituted by one or more G1-10 have 1, 2, 3, or 4 heteroatoms selected from one or more types of N, S, and O;
each G1-1 , each G1-2 , each G1-3, each G1-4, each G1-5, each G1-6, each G1-7, each G1-8, each G1-9, and each G1-10 is independently deuterium, halogen, cyano, -NG1-1-1G1-1-2, -NC(=O)G1-1-3G1-1-4, hydroxyl, -S(=O)2-C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkyl substituted by one or more G1-1-5, C1-C6 alkoxy, C1-C6 alkoxy substituted by one or more G1-1-6, -S-C1-C6 alkyl, -S-C1-C6 alkyl substituted by one or more G1-1-7, C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by one or more G1-1-8, -O-C3-C8 cycloalkyl, -O-C3-C8 cycloalkyl substituted by one or more G1-1-9, or - C(=O)NG1-1-11G1-1-12;
alternatively, any two adjacent G1-2, together with the carbon atom to which they are attached, form a 3- to 8-membered heterocycloalkyl, a 3- to 8-membered heterocycloalkyl substituted by one or more G1-1-9, a C3-C8 cycloalkyl, or a C3-C8 cycloalkyl substituted by one or more G1-1-10;
G1-1-1, G1-1-2, G1-1-3, G1-1-4, G1-1-11, and G1-1-12 are independently H, C1-C6 alkyl, C3-C8 cycloalkyl, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryl substituted by one or more G1-1-10-1, C6-C14 aryl, or C6-C14 aryl substituted by one or more G1-1-10-2;
each G1-1-10-1 and each G1-1-10-2 is independently C1-C6 alkyl;
each G1-1-5, each G1-1-6, each G1-1-7, each G1-1-8, each G1-1-9, and each G1-1-10 is independently halogen, oxo, C1-C6 alkyl, C3-C8 cycloalkyl, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl substituted by one or more C1-C6 alkyl groups;
the 3- to 8-membered heterocycloalkyl, the 3- to 8-membered heterocycloalkyl substituted by one or more G1-1-9, the 5- to 10-membered heteroaryl, the 5- to 10-membered heteroaryl substituted by one or more G1-1-10-1, and the 5- to 10-membered heteroaryl substituted by one or more C1-C6 alkyl groups have 1, 2, 3, or 4 heteroatoms independently selected from one or more types of N, S, and O;
L1 is a bond or C1-C6 alkylene;
ring A is C4-C6 cycloalkyl, C4-C6 cycloalkyl substituted by one or more A1, C4-C6 cycloalkenyl, C4-C6 cycloalkenyl substituted by one or more A2, 4- to 8-membered heterocycloalkyl, 4- to 8-membered heterocycloalkyl substituted by one or more A3, 4- to 6-membered heterocycloalkenyl, or 4- to 6-membered heterocycloalkenyl substituted by one or more A4;
the 4- to 8-membered heterocycloalkyl, the 4- to 8-membered heterocycloalkyl substituted by one or more A3, the 4- to 6-membered heterocycloalkenyl, and the 4- to 6-membered heterocycloalkenyl substituted by one or more A4 have 1 or 2 heteroatoms independently selected from one or more types of N, S, and O;
each A1, each A2, each A3, and each A4 is independently deuterium, halogen, cyano, -NA1-1A1-2, -NC(=O)A1-3A1-4, hydroxyl, C1-C6 alkyl, C1-C6 alkyl substituted by one or more A1-5, C1-C6 alkoxy, or C1-C6 alkoxy substituted by one or more A1-6.
A1-1, A1-2, A1-3 , and A1-4 are independently deuterium, halogen, cyano, C1-C6 alkyl, or C1-C6 alkoxy;
each A1-5 and each A1-6 is independently hydrogen, deuterium, halogen, cyano, C1-C6 alkyl, or C1-C6 alkoxy;
R1 is -C(=O)NR1-1R1-2, C1-C6 alkyl, C1-C6 alkyl substituted by one or more R1-3, C2-C6 alkenyl, C2-C6 alkenyl substituted by one or more R1-10, -C(=O)R1-11, or ring B;
R1-1, R1-2, and R1-11 are independently H, -S(=O)2C1-C12 alkyl, C1-C12 alkyl, C1-C12 alkyl substituted by one or more R1-1-1, C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-1-2, C6-C14 aryl, C6-C14 aryl substituted by one or more R1-1-3, 5- to 14-membered heteroaryl, or 5- to 14-membered heteroaryl substituted by one or more R1-1-4,
alternatively, R1-1 and R1-2, together with the N atom to which they are attached, form a 3-to 14-membered heterocycloalkyl or a 3- to 14-membered heterocycloalkyl substituted by one or more R1-1-5;
each R1-1-1, each R1-1-2, each R1-1-3, R1-1-4, and each R1-1-5 is independently halogen, cyano, nitro, hydroxyl, amino, -NH(C1-C12 alkyl), -N(C1-C12 alkyl)2, -C(=O)-C1-C12 alkyl, - NHC(=O)-C1-C12 alkyl, C1-C12 alkyl, C1-C12 alkyl substituted by one or more R1-1-1-1, C1-C12 alkoxy, C1-C12 alkoxy substituted by one or more R1-1-1-2, C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-1-1-3, C6-C14 aryl, 3- to 12-membered heterocycloalkyl, or 5- to 14-membered heteroaryl;
each R1-1-1-1, each R1-1-1-2, and each R1-1-1-3 is independently halogen, C1-C12 alkyl, C3-C12 cycloalkyl, or C1-C12 alkoxy;
each R1-3 and each R1-10 is independently deuterium, halogen, cyano, hydroxyl, -NR1-3-1R1-3-2, -C(-O)NR1-3-3R1-3-4, -C(=O)R1-3-5, -S(=O)2-C1-C12 alkyl, -S-C1-C12 alkyl, C1-C12 alkyl, C1-C12 alkyl substituted by one or more R1-3-6, C1-C12 alkoxy, C1-C12 alkoxy substituted by one or more R1-3-7, 5- to 14-membered heteroaryl, 5- to 14-membered heteroaryl substituted by one or more R1-3-8, C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-3-9, C2-C6 alkenyl, C2-C6 alkenyl substituted by one or more R1-3-10, C6-C14 aryl, C6-C14 aryl substituted by one or more R1-3-11, -O-C6-C14 aryl, -O-C(=O)C6-C14 aryl, -O-5- to 14-membered heteroaryl, C3-C8 cycloalkenyl, C3-C8 cycloalkenyl substituted by one or more R1-3-12, 3- to 12-membered heterocycloalkyl, or 3- to 12-membered heterocycloalkyl substituted by one or more R1 -3-13;
R1-3-1, R1-3-2, R1-3-3, and R1-3-4 are independently H, hydroxyl, C1-C6 alkyl, -C1-C6 alkyl-C6-C14 aryl, C1-C6 alkoxy, -C(=O)R1-3-1-1, C3-C8 cycloalkyl, C6-C14 aryl, or C6-C14 aryl substituted by one or more R1-3-1-4,
alternatively, R1-3-1 and R1-3-2, together with the N atom to which they are attached, form a 3- to 8-membered heterocycloalkyl or a 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-1-2,
alternatively, R1-3-3 and R1-3-4, together with the N atom to which they are attached, form a 3- to 8-membered heterocycloalkyl or a 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-3-1,
each R1-3-1-1, each R1-3-1-2, each R1-3-1-4, and each R1-3-3-1 is independently halogen or C1-C6 alkyl;
R1-3-5 is independently H, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, or C3-C8 cycloalkyl; each R1-3-6, each R1-3-7, each R1-3-8, each R1-3-9, each R1-3-10, each R1-3-11, each R1-3-12, and each R1-3-13 is independently halogen, hydroxyl, carboxyl, cyano, -C(=O)-O-C1-C6 alkyl, - C(=O)-N(C1-C6 alkyl)2, -C(=O)-N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C2-C6 alkenyl, C6-C14 aryl, C6-C14 aryl substituted by one or more C1-C6 alkyl groups, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl substituted by one or more C1-C6 alkyl groups;
each R1-3-8 and each R1-3-11 is independently halogen, hydroxyl, carboxyl, cyano, -C(=O)-O-C1-C6 alkyl, -C(=O)-N(C1-C6 alkyl)2, -C(=O)-N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, or C2-C6 alkenyl;
the 5- to 14-membered heteroaryl, the 5- to 14-membered heteroaryl substituted by one or more R1-1-4, the 3- to 14-membered heterocycloalkyl, the 3- to 14-membered heterocycloalkyl substituted by one or more R1-1-5, the 3- to 12-membered heterocycloalkyl, the 3- to 8-membered heterocycloalkyl, the 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-1-2, the 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-3-1, the 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-3-1, and the 5- to 10-membered heteroaryl substituted by one or more C1-C6 alkyl groups have 1, 2, 3, or 4 heteroatoms independently selected from one or more types of N, S, and O;
ring B is C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-4, C3-C12 cycloalkenyl, C3-C12 cycloalkenyl substituted by one or more R1-5, 3- to 12-membered heterocycloalkyl, 3- to 12-membered heterocycloalkyl substituted by one or more R1-6, 3- to 12-membered heterocycloalkenyl, 3- to 12-membered heterocycloalkenyl substituted by one or more R1-7, C6-C14 aryl, C6-C14 aryl substituted by one or more R1-8, 5- to 14-membered heteroaryl, or 5- to 14-membered heteroaryl substituted by one or more R1-9;
each R1-4, each R1-5, each R1-6, each R1-7, each R1-8, and each R1-9 is independently deuterium, halogen, cyano, hydroxyl, -NR1-3-1aR1-3-2a, -C(=o)NR1-3-3aR1-3-4a, -C(-O)R1-3-5a, - S(=O)2-C1-C12 alkyl, -S-C1-C12 alkyl, C1-C12 alkyl, C1-C12 alkyl substituted by one or more R1-3-6a, C1-C12 alkoxy, C1-C12 alkoxy substituted by one or more R1-3-7a, 5- to 14-membered heteroaryl, 5- to 14-membered heteroaryl substituted by one or more R1-3-8a, C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-3-9a, C2-C6 alkenyl, C2-C6 alkenyl substituted by one or more R1-3-10a, C6-C14 aryl, C6-C14 aryl substituted by one or more R1-3-11a, -O-C6-C14 aryl, -O-C(=O)C6-C14 aryl, -O-5- to 10-membered heteroaryl, C3-C8 cycloalkenyl, C3-C8 cycloalkenyl substituted by one or more R1-3-12a, 3- to 12-membered heterocycloalkyl, or 3- to 12-membered heterocycloalkyl substituted by one or more R1-3-13a;
alternatively, any two adjacent R1-8, together with the carbon atom to which they are attached, form a 3- to 8-membered heterocycloalkyl, a 3- to 8-membered heterocycloalkyl substituted by one or more R1-8-1, or a C3-C14 cycloalkyl;
R1-3-1a, R1-3-2a, R1-3-3a, and R1-3-4a are independently H, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, -C(=O)R1-3-1-1a, or C3-C8 cycloalkyl,
alternatively, R1-3-1a and R1-3-2a, together with the N atom to which they are attached, form a 3- to 8-membered heterocycloalkyl or a 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-1-2a,
alternatively, R1-3-3a and R1-3-4a, together with the N atom to which they are attached, form a 3- to 8-membered heterocycloalkyl or a 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-3-1a,
each R1-3-1-1a, each R1-3-1-2a, and each R1-3-3-1a is independently halogen or C1-C6 alkyl;
R1-3-5a is independently H, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or 3- to 8-membered heterocycloalkyl;
each R1-3-6a , each R1-3-7a, each R1-3-8a, each R1-3-9a, each R1-3-10a, each R1-3-11a , each R1-3-12a, each R1-3-13a, and each R1-8-1 is independently halogen, hydroxyl, carboxyl, cyano, -C(=O)-O-C1-C6 alkyl, -C(=O)-NH-C1-C6 alkyl, -C(=O)-N(C1-C6 alkyl)2, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, 3- to 12-membered heterocycloalkyl, C2-C6 alkenyl, or -O-C(=O)-C1-C6 alkyl-3- to 12-membered heterocycloalkyl;
the 3- to 8-membered heterocycloalkyl, the 3- to 12-membered heterocycloalkyl, the 3- to 12-membered heterocycloalkenyl, the 5- to 10-membered heteroaryl, the 5- to 14-membered heteroaryl, the 3- to 12-membered heterocycloalkyl substituted by one or more R1-6, the 3- to 12-membered heterocycloalkenyl substituted by one or more R1-7, the 5- to 14-membered heteroaryl substituted by one or more R1-9, the 5- to 14-membered heteroaryl substituted by one or more R1-3-8a, the 3- to 12-membered heterocycloalkyl substituted by one or more R1-3-13a, the 3- to 8-membered heterocycloalkyl substituted by one or more R1-8-1, the 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-1-2a, the 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-3-1a, the 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-3-1a, the -O-5- to 10-membered heteroaryl, and the -O-C(=O)-C1-C6 alkyl-3- to 12-membered heterocycloalkyl have 1, 2, 3, or 4 heteroatoms independently selected from one or more types of N, S, and O;
R2 is hydrogen, deuterium, halogen, cyano, C1-C6 alkyl, or C1-C6 alkoxy;
L2 is a bond, C1-C6 alkylene, C1-C6 alkylene substituted by one or more L2-1, C3-C8 cycloalkylene, C3-C8 cycloalkylene substituted by one or more L2-2, -O-C1-C6 alkylene, -NH-C1-C6 alkylene, or -N(C1-C6 alkyl)-C1-C6 alkylene;
each L2-1 and each L2-2 is independently halogen, C1-C6 alkyl, C1-C6 alkyl substituted by one or more L2-1-1, C1-C6 alkoxy, C1-C6 alkoxy substituted by one or more L2-1-2, C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by one or more L2-1-3, C2-C6 alkynyl, or C2-C6 alkynyl substituted by one or more L2-1-4;
each L2-1-1, each L2-1-2, each L2-1-3, and each L2-1-4 is independently C3-C8 cycloalkyl or C3-C8 cycloalkyl substituted by one or more L2-1-1-1;
each L2-1-1-1 is independently halogen or C1-C6 alkyl;
G2 is H, -C(=O)G2-1, -C(=O)NG2-2G2-3, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryl substituted by one or more G2-4, -S(=O)2-OH, -P(=O)-(OH)2, -P(=O)-(OC1-C6 alkyl)(OH), 3- to 8-membered heterocycloalkenyl, or 3- to 8-membered heterocycloalkenyl substituted by one or more G2-5;
G2-1 is hydroxyl, C1-C6 alkyl, or -O-NH2;
G2-2 and G2-3 are independently H, -S(=O)2-C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkyl, C1-C6 alkyl substituted by one or more G2-2-1, or -NH(=O)-5- to 10-membered heteroaryl;
each G2-2-1 is independently carboxyl or -S(=O)2OH;
each G2-4 and each G2-5 is independently hydroxyl or oxo;
the 5- to 10-membered heteroaryl, the 5- to 10-membered heteroaryl substituted by one or more G2-4, the 3- to 8-membered heterocycloalkenyl, the 3- to 8-membered heterocycloalkenyl substituted by one or more G2-5, and the -NH(=O)-5- to 10-membered heteroaryl have 1, 2, 3, or 4 heteroatoms independently selected from one or more types of N, S, and O.
2. The compound of formula I or the pharmaceutically acceptable salt thereof according
to claim 1, wherein the compound of formula I is a compound of formula Ia
wherein X is O or NR3, and R3 is H or C1-C6 alkyl;
Z and Y are independently C or N;
G1 is H, C1-C6 alkyl, C1-C6 alkyl substituted by one or more G1-1, C6-C14 aryl, C6-C14 aryl substituted by one or more G1-2, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryl substituted by one or more G1-3, C1-C6 alkoxy, C1-C6 alkoxy substituted by one or more G1-4, C2-C6 alkenyl, C2-C6 alkenyl substituted by one or more G1-5, C2-C6 alkynyl, C2-C6 alkynyl substituted by one or more G1-6, C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by one or more G1-7, C3-C8 cycloalkenyl, C3-C8 cycloalkenyl substituted by one or more G1-8, 3- to 8-membered heterocycloalkyl, 3- to 8-membered heterocycloalkyl substituted by one or more G1-9, 3- to 8-membered heterocycloalkenyl, or 3- to 8-membered heterocycloalkenyl substituted by one or more G1-10;
each G1-1, each G1-2, each G1-3, each G1-4, each G1-5, each G1-6 , each G1-7, each G1-8, each G1-9, and each G1-10 is independently deuterium, halogen, cyano, -NG1-1-1G1-1-2, -NC(=O)G1-1-3G1-1-4, hydroxyl, -S(=O)2-C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkyl substituted by one or more G1-1-5, C1-C6 alkoxy, C1-C6 alkoxy substituted by one or more G1-1-6, -S-C1-C6 alkyl, -S-C1-C6 alkyl substituted by one or more G1-1-7, C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by one or more G1-1-8, -O-C3-C8 cycloalkyl, -O-C3-C8 cycloalkyl substituted by one or more G1-1-9, or - C(=O)NG1-1-11G1-1-12;
alternatively, any two adjacent G1-2, together with the carbon atom to which they are attached, form a 3- to 8-membered heterocycloalkyl, a 3- to 8-membered heterocycloalkyl substituted by one or more G1-1-9, a C3-C8 cycloalkyl, or a C3-C8 cycloalkyl substituted by one or more G1-1-10;
G1-1-1, G1-1-2, G1-1-3, G1-1-4, G1-1-11, and G1-1-12 are independently H, C1-C6 alkyl, C3-C8 cycloalkyl, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl substituted by one or more G1-1-10-1;
each G1-1-10-1 is independently C1-C6 alkyl;
each G1-1-5, each G1-1-6, each G1-1-7, each G1-1-8, each G1-1-9, and each G1-1-10 is independently halogen, oxo, C1-C6 alkyl, or C3-C8 cycloalkyl;
L1 is a bond or C1-C6 alkylene;
ring A is C4-C6 cycloalkyl, C4-C6 cycloalkyl substituted by one or more A1, C4-C6 cycloalkenyl, C4-C6 cycloalkenyl substituted by one or more A2, 4- to 6-membered heterocycloalkyl, 4- to 6-membered heterocycloalkyl substituted by one or more A1, 4- to 6-membered heterocycloalkenyl, or 4- to 6-membered heterocycloalkenyl substituted by one or more A4; the 4- to 6-membered heterocycloalkyl, the 4- to 6-membered heterocycloalkyl substituted by one or more A1, the 4- to 6-membered heterocycloalkenyl, and the 4- to 6-membered heterocycloalkenyl substituted by one or more A4 have 1 or 2 heteroatoms independently selected from one or more types of N, S, and O;
each A1, each A2, each A3, and each A4 is independently deuterium, halogen, cyano, -NA1-1A1-2, -NC(=O)A1-3A1-4, hydroxyl, C1-C6 alkyl, C1-C6 alkyl substituted by one or more A1-5, C1-C6 alkoxy, or C1-C6 alkoxy substituted by one or more A1-6;
A1-1, A1-2, A1-3, and A1-4 are independently deuterium, halogen, cyano, C1-C6 alkyl, or C1-C6 alkoxy;
each A1-5 and each A1-6 is independently hydrogen, deuterium, halogen, cyano, C1-C6 alkyl, or C1-C6 alkoxy;
R1 is -C(=O)NR1-1R1-2, C1-C6 alkyl substituted by one or more R1-3, or ring B;
R1-1 and R1-2 are independently H, C1-C6 alkyl, C1-C6 alkyl substituted by one or more R1-1-1, C3-C10 cycloalkyl, C3-C10 cycloalkyl substituted by one or more R1-1-2, C6-C14 aryl, C6-C14 aryl substituted by one or more R1-1-3, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl substituted by one or more R1-1-4;
each R1-1-1, each R1-1-2, each R1-1-3, and R1-1-4 is independently halogen, C1-C6 alkyl, or C3-C8 cycloalkyl;
ring B is C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by one or more R1-4, C3-C8 cycloalkenyl, C3-C8 cycloalkenyl substituted by one or more R1-5, 3- to 8-membered heterocycloalkyl, 3- to 8-membered heterocycloalkyl substituted by one or more R1-6, 3- to 8-membered heterocycloalkenyl, 3- to 8-membered heterocycloalkenyl substituted by one or more R1-7, C6-C14 aryl, C6-C14 aryl substituted by one or more R1-8, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl substituted by one or more R1-9;
each R1-3, each R1-4, each R1-5, each R1-6 , each R1-7, each R1-8, and each R1-9 is independently deuterium, halogen, cyano, hydroxyl, -NR1-3-1R1-3-2, -C(-O)NR1-3-3R1-3-4, - C(=O)R1-3-5, -S(=O)2-C1-C6 alkyl, -S-C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkyl substituted by one or more R1-3-6, C1-C6 alkoxy, C1-C6 alkoxy substituted by one or more R1-3-7, 5- to 10-membered heteroaryl, 5- to 10-membered heteroaryl substituted by one or more R1-3-8, C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by one or more R1-3-9, C2-C6 alkenyl, or C2-C6 alkenyl substituted by one or more R1-3-10,
alternatively, any two adjacent R1-8, together with the carbon atom to which they are attached, form a 3- to 8-membered heterocycloalkyl or a 3- to 8-membered heterocycloalkyl substituted by one or more R1-8-1;
R1-3-1, R1-3-2, R1-3-3, and R1-3-4 are independently H, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, - C(=O)R1-3-1-1, or C3-C8 cycloalkyl,
alternatively, R1-3-1 and R1-3-2, together with the N atom to which they are attached, form a 3- to 8-membered heterocycloalkyl or a 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-1-2,
alternatively, R1-3-3 and R1-3-4, together with the N atom to which they are attached, form a 3- to 8-membered heterocycloalkyl or a 3- to 8-membered heterocycloalkyl substituted by one or more R1-3-3-1,
R1-3-1-1 and each R1-3-1-1 is independently C1-C6 alkyl or 5- to 10-membered heteroaryl; R1-3-5 is independently H, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, or C3-C8 cycloalkyl;
each R1-3-6, each R1-3-7, each R1-3-8, each R1-3-9, and each R1-3-10 is independently halogen, hydroxyl, carboxyl, -C(=O)-O-C1-C6 alkyl, -C(=O)-NH-C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkoxy, C3-C8 cycloalkyl, or 3- to 8-membered heterocycloalkyl;
R2 is hydrogen, deuterium, halogen, cyano, C1-C6 alkyl, or C1-C6 alkoxy;
L2 is C1-C6 alkylene, C1-C6 alkylene substituted by one or more L2-1, C3-C8 cycloalkylene, or C3-C8 cycloalkylene substituted by one or more L2-2;
each L2-1 and each L2-2 is independently halogen, C1-C6 alkyl, C1-C6 alkyl substituted by one or more L2-1-1, C1-C6 alkoxy, C1-C6 alkoxy substituted by one or more L2-1-2, C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by one or more L2-1-3, C2-C6 alkynyl, or C2-C6 alkynyl substituted by one or more L2-1-4;
each L2-1-1, each L2-1-2, each L2-1-3, and each L2-1-4 is independently C3-C8 cycloalkyl or C3-C8 cycloalkyl substituted by one or more L2-1-1-1;
G2 is -C(=O)G2-1, -C(=O)NG2-2G2-3, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl substituted by one or more G2-4;
G2-1 is hydroxyl, C1-C6 alkyl, or -O-NH2;
G2-2 and G2-3 are independently H, -S(=O)2-C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 alkyl, or C1-C6 alkyl substituted by one or more G2-2-1;
each G2-2-1 is independently carboxyl or -S(=O)2OH;
each 5- to 10-membered heteroaryl, each 3- to 8-membered heterocycloalkenyl, and each 3- to 8-membered heterocycloalkyl has 1, 2, 3, or 4 heteroatoms independently selected from one or more types of N, S, and O.
3. The compound of formula I or the pharmaceutically acceptable salt thereof according
to claim 1, wherein the compound of formula I or the pharmaceutically acceptable salt
thereof satisfies one or more of the following conditions:
(1) in R3 and G1, the "C1-C6 alkyl" in the C1-C6 alkyl and the C1-C6 alkyl substituted by one or more G1-1 is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as methyl;
(2) in G1, the "C6-C14 aryl" in the C6-C14 aryl and the C6-C14 aryl substituted by one or more G1-2 is independently phenyl or naphthyl;
(3) in G1, the "5- to 10-membered heteroaryl" in the 5- to 10-membered heteroaryl and the 5-
to 10-membered heteroaryl substituted by one or more G1-3 is independently 5-, 6-, 9-, or 10-membered monocyclic or bicyclic heteroaryl with
1 or 2 heteroatoms independently selected from one or more types of N, S, and O, and
may further be pyridyl, thiazolyl, furanophenyl, or oxazolophenyl, such as
(4) in each G1-1, each G1-2, each G1-3, each G1-4, each G1-5, each G1-6, each G1-7, each G1-8, each G1-9, each G1-10, and each G1-11, the halogen is independently fluorine, chlorine, or bromine, such as fluorine or chlorine;
(5) in each G1-1, each G1-2, each G1-3, each G1-4, each G1-5, each G1-6, each G1-7, each G1-8, each G1-9, and each G1-10, the "C1-C6 alkyl" in the -S(=O)2-C1-C6 alkyl, the C1-C6 alkyl, the C1-C6 alkyl substituted by one or more G1-1-5, the -S-C1-C6 alkyl, and the -S-C1-C6 alkyl substituted by one or more G1-1-7 may independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as methyl or ethyl;
(6) in each G1-1, each G2, each G1-3, each G1-4, each G1-5, each G1-6 , each G1-7, each G1-8, each G1-9, and each G1-10, the "C1-C6 alkoxy" in the C1-C6 alkoxy and the C1-C6 alkoxy substituted by one or more G1-1-6 is independently methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, or tert-butoxy, such as methoxy or ethoxy;
(7) in each G1-1, each G1-2, each G1-3, each G1-4, each G1-5, each G1-6 , each G1-7, each G1-8, each G1-9, and each G1-10, the "C3-C8 cycloalkyl" in the C3-C8 cycloalkyl, the C3-C8 cycloalkyl substituted by one or more G1-1-8, the -O-C3-C8 cycloalkyl, and the -O-C3-C8 cycloalkyl substituted by one or more G1-1-9 is independently cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, such as cyclopropyl;
(8) the "3- to 8-membered heterocycloalkyl" formed by any two adjacent G1-2 together with the carbon atom to which they are attached and the "3- to 8-membered
heterocycloalkyl" in the 3- to 8-membered heterocycloalkyl substituted by one or more
G1-1-9 are independently 5- to 6-membered heterocycloalkyl with 1 or 2 heteroatoms independently
being N and/or O, such as
(9) the "C3-C8 cycloalkyl" formed by any two adjacent G1-2 together with the carbon atom to which they are attached and the "C3-C8 cycloalkyl" in the C3-C8 cycloalkyl substituted by one or more G1-1-10 are independently C3-C6 cycloalkyl, such as
(10) in G1-1-1, G1-1-2, G1-1-3, G1-1-4, G1-1-11, and G1-1-12, the C1-C6 alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as methyl;
(11) in G1-1-1, G1-1-2, G1-1-3, G1-1-4, G1-1-11, and G1-1-12, the C1-C6 alkyl may independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, or n-hexyl, such as methyl, tert-butyl, or n-hexyl;
(12) in G1-1-1, G1-1-2, G1-1-3 , G1-1-4, G1-1-11, and G1-1-12 , the "5- to 10-membered heteroaryl" in the 5- to 10-membered heteroaryl and the 5- to 10-membered heteroaryl substituted by one or more G1-1-10-1 is independently 5- to 6-membered heteroaryl with 1 or 2 heteroatoms being N, such as pyridyl;
(13) in each G1-1-10-1 and each G1-1-10-2, the "C1-C6 alkyl" in the C1-C6 alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as methyl;
(14) in each G1-1-5, each G1, each G1-1-7, each G1-1-8, each G1-1-9, and each G1-1-10, the halogen is independently fluorine, chlorine, or bromine, such as fluorine;
(15) in each G1-1-5, each G1-1-6, each G1-1-7, each G1-1-8, each G1-1-9, and each G1-1-10, the C3-C8 cycloalkyl is independently cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, such as cyclopropyl;
(16) in each G1-1-5, each G1, each G1-1-7, each G1-1-8, each G1-1-9, and each G1-1-10, the "5- to 10-membered heteroaryl" in the 5- to 10-membered heteroaryl and the 5-
to 10-membered heteroaryl substituted by one or more C1-C6 alkyl groups may be 5-, 6-, 9-, or 10-membered monocyclic or bicyclic heteroaryl
with 1, 2, or 3 heteroatoms being N, and may be triazolyl, such as
(17) in L1, the C1-C6 alkylene is methylene, ethylene, or propylene, such as methylene,
(18) in ring A, the "C4-C6 cycloalkyl" in the C4-C6 cycloalkyl and the C4-C6 cycloalkyl substituted by one or more A1 is independently cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, such as cyclohexyl;
preferably, the cyclohexyl is
(19) in ring A, the "C4-C6 cycloalkenyl" in the C4-C6 cycloalkenyl and the C4-C6 cycloalkenyl substituted by one or more A2 is cyclohexenyl containing one double bond, such as
(20) in ring A, the "4- to 8-membered heterocycloalkyl" in the 4- to 8-membered heterocycloalkyl and the 4- to 8-membered heterocycloalkyl substituted by one or more A3 may independently be 4- to 6-membered heterocycloalkyl with 1 or 2 heteroatoms being N or 7- to 8-membered bridged heterocycloalkyl with 1 or 2 heteroatoms being N;
the 4- to 6-membered heterocycloalkyl may be azetidinyl, pyrrolidinyl, or piperidinyl,
such as
the 7- to 8-membered bridged heterocycloalkyl may be azabicyclo[3.2.1]octanyl, such
as
ring A is connected to L via N at the left end and to
via C at the right end;
(21) in ring A, the "4- to 6-membered heterocycloalkenyl" in the 4- to 6-membered heterocycloalkenyl and the 4- to 6-membered heterocycloalkenyl substituted by one or more A4 is independently 6-membered heterocycloalkenyl with 1 heteroatom being N, containing 1 double bond;
(22) in each A1, each A2, each A3, and each A4, the halogen is independently fluorine, chlorine, or bromine, such as fluorine;
(23) in each A1, each A2, each A3, and each A4, the "C1-C6 alkyl" in the C1-C6 alkyl and the C1-C6 alkyl substituted by one or more A1-5 is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as methyl;
(24) in R1, the "C1-C6 alkyl" in the C1-C6 alkyl and the C1-C6 alkyl substituted by one or more R1-3 may be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl,
(25) in R1, the "C2-C6 alkenyl" in the C2-C6 alkenyl and the C2-C6 alkenyl substituted by one or more R1-10 may be vinyl, propenyl, pentenyl, or hexenyl, such as
(26) in R1-1, R1-2, and R1-11, the "C1-C12 alkyl" in the C1-C12 alkyl, the C1-C12 alkyl substituted by one or more R1-1-1, and the -S(=O)2C1-C12 alkyl may independently be C1-C6 alkyl or C7-C12 alkyl; the "C1-C6 alkyl" in the C1-C6 alkyl, the C1-C6 alkyl substituted by one or more R1-1-1, and the -S(=O)2C1-C6 alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, or
such as methyl, ethyl, or isopropyl;
(27) in R1-1, R1-2, and R1-11, the "C3-C12 cycloalkyl" in the C3-C12 cycloalkyl and the C3-C12 cycloalkyl substituted by one or more R1-1-2 may independently be C3-C10 cycloalkyl or C11-C12 cycloalkyl; the "C3-C10 cycloalkyl" in the C3-C10 cycloalkyl and the C3-C10 cycloalkyl substituted by one or more R1-1-2 may independently be C3-C6 monocyclic cycloalkyl, C5-C7 bridged cycloalkyl, or adamantyl, and may further be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[1.1.1]pentyl, bicyclo[2.2.1]heptyl, or adamantyl;
(28) R1-1 and R1-2, together with the N atom to which they are attached, form a 3- to 14-membered heterocycloalkyl, wherein the 3- to 14-membered heterocycloalkyl may be 4- to 6-membered monocyclic heterocycloalkyl with 1 or 2 heteroatoms being N or 6- to 14-membered bicyclic spirocycloalkyl with 1 or 2 heteroatoms being N, and may further be pyrrolidinyl or 2-azaspiro[3.3]heptyl;
(29) in R1-1, R1-2, and R1-11, the "C6-C14 aryl" in the C6-C14 aryl and the C6-C14 aryl substituted by one or more R1-1-3 is independently phenyl or naphthyl;
(30) in R1-1, R1-2, and R1-11, the "5- to 14-membered heteroaryl" in the 5- to 14-membered heteroaryl and the 5-
to 14-membered heteroaryl substituted by one or more G1-1-10-1 may independently be 5- to 10-membered heteroaryl or 11- to 14-membered heteroaryl,
wherein the "5- to 10-membered heteroaryl" in the 5- to 10-membered heteroaryl and
the 5- to 10-membered heteroaryl substituted by one or more G1-1-10-1 may independently be 5- to 6-membered heteroaryl or 8- to 10-membered bicyclic heteroaryl,
and may further be thiazolyl, oxazolyl, imidazolyl, pyrazolyl, thiadiazolyl, triazolyl,
tetrazolyl, pyridyl, benzo[d]isoxazolyl, or benzo[d]thiazolyl, such as
(31) in each R1-1-1, each R1-1-2, each R1-1-3, R1-1-4, and each R1-1-5, the halogen is independently fluorine, chlorine, or bromine, such as fluorine;
(32) in each R1-1-1, each R1-1-2, each R1-1-3, R1-1-4, and each R1-1-5, the "C1-C12 alkyl" in the -NH(C1-C12 alkyl), the -N(C1-C12 alkyl)2, the -C(=O)-C1-C12 alkyl, the -NHC(=O)-C1-C12 alkyl, the C1-C12 alkyl, and the C1-C12 alkyl substituted by one or more R1-1-1-1 may independently be C1-C6 alkyl or C7-C12 alkyl; the C1-C6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as methyl;
(33) in each R1-1-1, each R1-1-2, each R1-1-3, R1-1-4, and each R1-1-5, the "C3-C12 cycloalkyl" in the C3-C12 cycloalkyl and the C3-C12 cycloalkyl substituted by one or more R1-1-1-3 is independently C3-C8 cycloalkyl or C9-C10 cycloalkyl; the C3-C8 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, such as cyclopropyl;
(34) in each R1-1-1, each R1-1-2, each R1-1-3, R1-1-4, and each R1-1-5, the C6-C14 aryl is phenyl or naphthyl;
(35) in each R1-1-1, each R1-1-2, each R1-1-3, R1-1-4, and each R1-1-5, the 3- to 12-membered heterocycloalkyl may be 3- to 6-membered heterocycloalkyl with 1 or 2 heteroatoms being N and/or O, and may be piperidinyl or morpholinyl;
(36) in each R1-3 and each R1-10, the halogen is independently fluorine, chlorine, or bromine, such as fluorine or chlorine;
(37) in each R1-3 and each R1-10, the "C1-C12 alkyl" in the -S(=O)2-C1-C12 alkyl, the -S-C1-C12 alkyl, the C1-C12 alkyl, and the C1-C12 alkyl substituted by one or more R1-3-6 is independently C1-C6 alkyl or C7-C12 alkyl;
the "C1-C6 alkyl" in the -S(=O)2-C1-C6 alkyl, the -S-C1-C6 alkyl, the C1-C6 alkyl, and the C1-C6 alkyl substituted by one or more R1-3-6 may independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as isopropyl; the C7-C12 alkyl may be pentyl, hexyl, or heptyl;
(38) in each R1-3 and each R1-10, the "C1-C12 alkoxy" in the C1-C12 alkoxy and the C1-C12 alkoxy substituted by one or more R1-3-7 is independently C1-C6 alkoxy; the "C1-C6 alkoxy" in the C1-C6 alkoxy and the C1-C6 alkoxy substituted by one or more R1-3-7 may independently be methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, or tert-butoxy;
(39) in each R1-3 and each R1-10, the "5- to 14-membered heteroaryl" in the 5- to 14-membered heteroaryl, the 5- to 14-membered heteroaryl substituted by one or more R1-3-8, and the -O-5- to 14-membered heteroaryl is independently 5- to 10-membered heteroaryl; the "5-to 10-membered heteroaryl" in the 5- to 10-membered heteroaryl and the 5- to 10-membered heteroaryl substituted by one or more R1-3-8 may independently be 5- to 6-membered monocyclic heteroaryl with 1, 2, or 3 heteroatoms independently selected from one or two types of N, S, and O, and may further be 1H-pyrazolyl, pyridyl, or oxadiazolyl;
(40) in each R1-3 and each R1-10, the "C2-C6 alkenyl" in the C2-C6 alkenyl and the C2-C6 alkenyl substituted by one or more R1-3-10 is independently vinyl or propenyl, such as
(41) in each R1-3 and each R1-10, the "C6-C14 aryl" in the C6-C14 aryl, the C6-C14 aryl substituted by one or more R1-3-11, the -O-C6-C14 aryl, and the -O-C(=O)C6-C14 aryl is independently phenyl;
(42) in each R1-3 and each R1-10, the "3- to 12-membered heterocycloalkyl" in the 3- to 12-membered heterocycloalkyl
and the 3- to 12-membered heterocycloalkyl substituted by one or more R1-3-13 is 3- to 6-membered monocyclic heterocycloalkyl with 1 or 2 heteroatoms being O,
such as
(43) in R1-3-1, R1-3-2, R1-3-3, R1-3-4, R1-3-1a, R1-3-2a, R1-3-3a, and R1-3-4a, the C1-C6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl;
(44) in each R1-3 and each R1-10, the "C6-C14 aryl" in the C6-C14 aryl and the C6-C14 aryl substituted by one or more R1-3-1-4 is independently phenyl;
(45) in each R1-3-1-1, each R1-3-1-2, each R1-3-1-4, and each R1-3-3-1, the C1-C6 alkyl is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl;
(46) in each R1-3-6 , each R1-3-7 , each R1-3-8, each R1-3-9, each R1-3-10, each R1-3-11, each R1-3-12, and each R1-3-13, the "C1-C6 alkyl" in the -C(=O)-O-C1-C6 alkyl, the -C(=O)-N(C1-C6 alkyl)2, the -C(=O)-N(C1-C6 alkyl)2, and the C1-C6 alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl;
(47) in each R1-3-6, R1-3-7, R1-3-8, R1-3-9, R1-3-10, R1-3-11, R1-3-12, and R1-3-13, the C3-C8 cycloalkyl is cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl;
(48) in each R1-3-6, each R1-3-7, each R1-3-9, each R1-3-10, each R1-3-12, and each R1-3-13, the "5- to 10-membered heteroaryl" in the 5- to 10-membered heteroaryl and the 5- to 10-membered heteroaryl substituted by one or more C1-C6 alkyl groups is 5- to 6-membered heteroaryl with 1 or 2 heteroatoms selected from one or two types of N, S, and O, and may further be furanyl or thienyl;
(49) in ring B, the "C3-C12 cycloalkyl" in the C3-C12 cycloalkyl and the C3-C12 cycloalkyl substituted by one or more R1-4 is independently C3-C8 cycloalkyl or C9-C12 cycloalkyl; the "C3-C8 cycloalkyl" in the C3-C8 cycloalkyl and the C3-C8 cycloalkyl substituted by one or more R1-4 is independently cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, such as cyclohexyl;
(50) in ring B, the "C3-C12 cycloalkenyl" in the C3-C12 cycloalkenyl and the C3-C12 cycloalkenyl substituted by one or more R1-5 is independently C3-C8 cycloalkenyl or C9-C12 cycloalkenyl; the "C3-C8 cycloalkenyl" in the C3-C8 cycloalkenyl and the C3-C8 cycloalkenyl substituted by one or more R1-5 is cyclopropenyl containing one double bond, cyclobutenyl containing one double bond, cyclopentenyl containing one double bond, or cyclohexenyl containing one double bond, such as cyclopentenyl or cyclohexenyl;
(51) in ring B, the "3- to 12-membered heterocycloalkyl" in the 3- to 12-membered heterocycloalkyl and the 3- to 12-membered heterocycloalkyl substituted by one or more R1-6 is independently 3- to 8-membered heterocycloalkyl or 9- to 12-membered heterocycloalkyl; the "3- to 8-membered heterocycloalkyl" in the 3- to 8-membered heterocycloalkyl and the 3-to 8-membered heterocycloalkyl substituted by one or more R1-6 is independently 5- to 6-membered heterocycloalkyl with 1 or 2 heteroatoms independently being O and/or N, and the number is 1 or 2, such as piperidinyl, dioxolanyl, or dioxanyl;
(52) in ring B, the "3- to 12-membered heterocycloalkenyl" in the 3- to 12-membered heterocycloalkenyl and the 3- to 12-membered heterocycloalkenyl substituted by one or more R1-7 is independently 3- to 8-membered heterocycloalkenyl or 9- to 12-membered heterocycloalkenyl; the "3- to 8-membered heterocycloalkenyl" in the 3- to 8-membered heterocycloalkenyl and the 3- to 8-membered heterocycloalkenyl substituted by one or more R1-7 is independently 5- to 6-membered heterocycloalkenyl with 1 or 2 heteroatoms independently being N and containing one double bond, such as 1,2,3,6-tetrahydropyridyl;
(53) in ring B, the "C6-C14 aryl" in the C6-C14 aryl and the C6-C14 aryl substituted by one or more R1-8 is independently phenyl or naphthyl; preferably, when the "C6-C14 aryl" in the C6-C14 aryl substituted by one or more R1-8 is phenyl, the number of is 1, and the substitution position is at the ortho, meta, or para position of the phenyl, such as the para position;
(54) in ring B, the "5- to 14-membered heteroaryl" in the the 5- to 14-membered heteroaryl and the 5- to 14-membered heteroaryl substituted by one or more R1-9 is independently 5- to 10-membered heteroaryl or 11- to 14-membered heteroaryl; the "5- to 10-membered heteroaryl" in the the 5- to 10-membered heteroaryl and the 5- to 10-membered heteroaryl substituted by one or more R1-9 may independently be 5-, 6-, or 9-membered monocyclic or bicyclic heteroaryl with 1, 2, 3, or 4 heteroatoms selected from one or more types of N, S, and O, and may further be pyrrolyl, imidazolyl, 1H-pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, 1,3,4-oxadiazolyl, 1,3,4-oxadiazolyl, 1,2,4-oxadiazolyl, thienyl, thiazolyl, pyridyl, pyrimidinyl, indolyl, indazolyl, thiazolophenyl, or triazolopyridyl; or may further be 1H-pyrazolyl, 1,3,4-oxadiazolyl, thienyl, thiazolyl, pyridyl, pyrimidinyl, indolyl, indazolyl, thiazolophenyl, or triazolopyridyl;
(55) in each R1-4, each R1-5, each R1-6, each R1-7, each R1-8, and each R1-9, the halogen is independently fluorine, chlorine, or bromine, such as fluorine or chlorine;
(56) in each R1-4, each R1-5, each R1-6, each R1-7, each R1-8, and each R1-9, the "C1-C12 alkyl" in the -S(=O)2-C1-C12 alkyl, the -S-C1-C12 alkyl, the C1-C12 alkyl, and the C1-C12 alkyl substituted by one or more R1-3-6a is independently C1-C6 alkyl or C7-C12 alkyl; the "C1-C6 alkyl" in the -S(=O)2-C1-C6 alkyl, the -S-C1-C6 alkyl, the C1-C6 alkyl, and the C1-C6 alkyl substituted by one or more R1-3-6a may independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as isopropyl; the C7-C12 alkyl may be pentyl, hexyl, or heptyl;
(57) in each R1-4, each R1-5, each R1-6, each R1-7, each R1-8, and each R1-9, the "C1-C12 alkoxy" in the C1-C12 alkoxy and the C1-C12 alkoxy substituted by one or more R1-3-7a is independently C1-C6 alkoxy; the "C1-C6 alkoxy" in the C1-C6 alkoxy and the C1-C6 alkoxy substituted by one or more R1-3-7a may independently be methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, or tert-butoxy;
(58) in each R1-4, each R1-5, each R1-6, each R1-7, each R1-8, and each R1-9, the "5- to 14-membered heteroaryl" in the 5- to 14-membered heteroaryl and the 5- to 14-membered heteroaryl substituted by one or more R1-3-8a is independently 5- to 10-membered heteroaryl; the "5- to 10-membered heteroaryl" in the 5- to 10-membered heteroaryl and the 5- to 10-membered heteroaryl substituted by one or more R1-3-8a may independently be 5- to 6-membered monocyclic heteroaryl with 1 or 2 heteroatoms independently being N, and may further be 1H-pyrazolyl or pyridyl;
(59) in each R1-4, each R1-5, each R1-6, each R1-7, each R1-8, and each R1-9, the "C3-C12 cycloalkyl" in the C3-C12 cycloalkyl and the C3-C12 cycloalkyl substituted by one or more R1-3-9a is independently C3-C8 cycloalkyl or C9-C12 cycloalkyl; the "C3-C8 cycloalkyl" in the C3-C8 cycloalkyl and the C3-C8 cycloalkyl substituted by one or more R1-3-9a may independently be cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, such as cyclopropyl or cyclobutyl; the C9-C12 cycloalkyl may be adamantyl;
(60) in each R1-4, each R1-5, each R1-6, each R1-7, each R1-8, and each R1-9, the "C2-C6 alkenyl" in the C2-C6 alkenyl and the C2-C6 alkenyl substituted by one or more R1-3-10a may independently be vinyl or propenyl, such as
(61) the "3- to 8-membered heterocycloalkyl" formed by any two adjacent R1-8 together with the carbon atom to which they are attached and the "3- to 8-membered
heterocycloalkyl" in the 3- to 8-membered heterocycloalkyl substituted by one or more
R1-8-1 are independently 5- to 6-membered heterocycloalkyl with 1 or 2 heteroatoms independently
being N and/or O, such as
(62) any two adjacent R1-8, together with the carbon atom to which they are attached, form a C1-C14 cycloalkyl, and the C1-C14 cycloalkyl is C11-C14 tricyclic cycloalkyl, such as
(63) in R1-3-1a, R1-3-2a, R1-3-3a, R1-3-4a, and R1-3-5a, the C1-C6 alkyl may independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl,
or
(64) in R1-3-1a, R1-3-2a, R1-3-3a, R1-3-4a, and R1-3-5a, the C1-C6 alkoxy may independently be methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, or tert-butoxy;
(65) in R1-3-1a, R1-3-2a, R1-3-3a, R1-3-4a, and R1-3-5a, the C3-C8 cycloalkyl is independently cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, such as cyclopropyl or cyclopentyl;
(66) the "3- to 8-membered heterocycloalkyl" formed by R1-3-1a and R1-3-2a together with the N atom to which they are attached and the "3- to 8-membered heterocycloalkyl" in the 3-to 8-membered heterocycloalkyl substituted by one or more R1-3-1-2a are independently 5- to 6-membered heterocycloalkyl with 1 or 2 heteroatoms independently being N, and may further be pyrrolidinyl;
(67) the "3- to 8-membered heterocycloalkyl" formed by R1-3-3a and R1-3-4a together with the N atom to which they are attached and the "3- to 8-membered heterocycloalkyl" in the 3-to 8-membered heterocycloalkyl substituted by one or more R1-3-3-1a may independently be 5-to 6-membered heterocycloalkyl with 1 or 2 heteroatoms independently being N or 6- to 7-membered dispiro heterocycloalkyl with 1 or 2 heteroatoms independently being N, and may further be pyrrolidinyl or 2-azaspiro[3.3]heptyl;
(68) in each R1-3-1-1a, each R1-3-1-2a, and each R1-3-3-1a, the C1-C6 alkyl is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as methyl;
(69) in each R1-3-6a, each R1-3-7a, each R1-3-8a, each R1-3-8a, each R1-3-10a, each R1-3-11a, each R1-3-12a, and each R1-8-1, the "C1-C6 alkyl" in the C1-C6 alkyl, the -C(=O)-O-C1-C6 alkyl, the - C(=O)-NH-C1-C6 alkyl, and the -C(=O)-N(C1-C6 alkyl)2 may independently be methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as methyl or tert-butyl;
(70) in each R1-3-6a, each R1-3-7a, each R1-3-8a, each R1-3-8a, each R1-3-10a, each R1-3-11a, each R1-3-12a, and each R1-8-1, the "3- to 12-membered heterocycloalkyl" in the 3- to 12-membered heterocycloalkyl and the -O-C(=O)-C1-C6 alkyl-3- to 12-membered heterocycloalkyl is independently 5- to 6-membered monocyclic heterocycloalkyl with 1 or 2 heteroatoms being N, such as pyrrolidinyl;
(71) in L2, the "C1-C6 alkylene" in the C1-C6 alkylene, the C1-C6 alkylene substituted by one or more L2-1, the -O-C1-C6 alkylene, and the -N-C1-C6 alkylene may independently be methylene, ethylene, n-propylene, isopropylene, n-butylene, isobutylene, sec-butylene, or tert-butylene, such as methyl, ethyl, n-propyl, or isopropyl, for example, methylene or ethylene; preferably, when L2 is C1-C6 alkylene, then the C atom in the C1-C6 alkylene connected to
may be a non-chiral C, an S-configuration C, or an R-configuration C, and may further be an S-configuration C;
(72) in L2, the "C3-C8 cycloalkylene" in the C3-C8 cycloalkylene and the C3-C8 cycloalkylene substituted by one or more L2-2 is independently cyclopropylene, cyclobutylene, cyclopentylene, or cyclohexylene, such as cyclopropylene;
(73) in each L2-1, each L2-2, and each L2-1-1-1, the halogen is independently fluorine, chlorine, or bromine, such as fluorine;
(74) in each L2-1, each L2-2, and each L2-1-1-1, the "C1-C6 alkyl" in the C1-C6 alkyl and the C1-C6 alkyl substituted by one or more L2-1-1 is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as methyl, ethyl, n-propyl, or isopropyl;
(75) in each L2-1 and each L2-2, the "C1-C6 alkoxy" in the C1-C6 alkoxy and the C1-C6 alkoxy substituted by one or more L2-1-2 is independently methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, or tert-butoxy, such as methoxy or ethoxy;
(76) in each L2-1 and each L2-2, the "C3-C8 cycloalkyl" in the C3-C8 cycloalkyl and the C3-C8 cycloalkyl substituted by one or more L2-1-3 is independently cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, such as cyclopropyl or cyclobutyl;
(77) in each L2-1 and each L2-2, the "C2-C6 alkynyl" in the C2-C6 alkynyl and the C2-C6 alkynyl substituted by one or more L2-1-4 is independently ethynyl;
(78) in G2, the "5- to 10-membered heteroaryl" in the 5- to 10-membered heteroaryl and the 5-
to 10-membered heteroaryl substituted by one or more G2-4 is independently 5- to 6-membered heteroaryl with 2, 3, or 4 heteroatoms selected
from one or more types of N, O, and S, and may further be 5- to 6-membered heteroaryl
with 3 or 4 heteroatoms being N and/or O, such as tetrazolyl,
oxazolyl, or
(79) in G2, the "3- to 8-membered heterocycloalkenyl" in the 3- to 8-membered heterocycloalkenyl
and the 3- to 8-membered heterocycloalkenyl substituted by one or more G2-5 is independently 3- to 5-membered heterocycloalkenyl with 2 or 3 heteroatoms being
N and/or S, such as
(80) in G2-1, G2-2, and G2-3, the "C1-C6 alkyl" in the -S(=O)2-C1-C6 alkyl, C3-C8 cycloalkyl, the C1-C6 alkyl, and the C1-C6 alkyl substituted by one or more G2-2-1 is independently methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, or tert-butyl, such as methyl or ethyl;
(81) in G2-1, G2-2, and G2-3, the C3-C8 cycloalkyl is independently cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, such as cyclopropyl;
(82) in G2-2 and G2-3, the "5- to 10-membered heteroaryl" in the -NH(=O)-5- to 10-membered heteroaryl is 5- to 6-membered heteroaryl with 1 or 2 heteroatoms being N, such as pyridyl.
4. The compound of formula I or the pharmaceutically acceptable salt thereof according
to claim 3, wherein the compound of formula I or the pharmaceutically acceptable salt
thereof satisfies one or more of the following conditions:
(1) in G1, the C1-C6 alkyl substituted by one or more G1-1 is
(2) in G1, the C6-C14 aryl substituted by one or more G1-2 is phenyl substituted by 1 or 2 G1-2, and may further be any one of the following groups:
such as
(3) in G1, the 5- to 10-membered heteroaryl substituted by one or more G1-3 is 5- to 6-membered monocyclic heterocycloalkyl substituted by 1 or 2 G1-3, and may further be
(4) in R1-1, R1-2, and R1-11, the C1-C12 alkyl substituted by one or more R1-1-1 is C1-C6 alkyl substituted by one or more R1-1-1, and may further be
such as
(5) in R1-1, R1-2, and R1-11, the C6-C14 aryl substituted by one or more R1-1-3 is phenyl substituted by 1, 2, or 3 R1-1-3, and may further be
or
such as
(6) in R1-1, R1-2, and R1-11, the 5- to 14-membered heteroaryl substituted by one or more R1-1-4 is 5- to 6-membered monocyclic heteroaryl substituted by 1 or 2 R1-1-3 or 9- to 10-membered fused heteroaryl substituted by 1 or 2 R1-1-3, and may further be
(7) in ring A, the 4- to 8-membered heterocycloalkyl substituted by one or more A3 is 4-to 6-membered heterocycloalkyl substituted by one or more A1 or 7- to 8-membered bridged heterocycloalkyl substituted by one or more A1; the 4- to 6-membered heterocycloalkyl substituted by one or more A1 may be
the 7- to 8-membered bridged heterocycloalkyl substituted by one or more A1 or
5. The compound of formula I or the pharmaceutically acceptable salt thereof according
to claim 1, wherein the compound of formula I or the pharmaceutically acceptable salt
thereof satisfies one or more of the following conditions:
(1) ring A is
or
(2) in R1, in -C(=O)NR1-1R1-2, one of R1-1 and R1-2 may be H or C1-C12 alkyl, and the other may be -S(=O)2C1-C12 alkyl, C1-C12 alkyl, C1-C12 alkyl substituted by one or more R1-1-1, C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-1-2, C6-C14 aryl, C6-C14 aryl substituted by one or more R1-1-3, 5- to 14-membered heteroaryl, or 5- to 14-membered heteroaryl substituted by one
or more R1-1-4;
-C(=O)NR1-1R1-2 may further be the following group:
such as
(3) in R1, the C1-C6 alkyl substituted by one or more R1-3 is any one of the following groups:
(4) in R1, the C2-C6 alkenyl substituted by one or more R1-10 is
or
(5) in R1,-C(=O)R1-11 is
(7) in ring B, the C3-C12 cycloalkyl substituted by one or more R1-4 is C3-C8 cycloalkyl substituted by one or more R1-4, and may further be
(8) in ring B, the C3-C12 cycloalkenyl substituted by one or more R1-5 is C3-C8 cycloalkenyl substituted by one or more R1-5, and may be
(9) in ring B, the 3- to 12-membered heterocycloalkyl substituted by one or more R1-6 is 3- to 8-membered heterocycloalkyl substituted by one or more R1-6, and may be
(10) in ring B, the C3-C12 cycloalkenyl substituted by one or more R1-5 is 3- to 8-membered heterocycloalkenyl substituted by one or more R1-7, and may be
(11) in ring B, the C6-C14 aryl substituted by one or more R1-8 is any one of the following groups:
such as
(12) in ring B, the 5- to 10-membered heteroaryl substituted by one or more R1-9 is any one of the following groups:
such as
(13)
is any one of the following groups:
such as
or
preferably,
is
6. The compound of formula I or the pharmaceutically acceptable salt thereof according
to claim 1, wherein the compound of formula I or the pharmaceutically acceptable salt
thereof satisfies one or more of the following conditions:
(1) X is O;
(2) Z and Y are C;
(3) R2 is hydrogen;
(4) G1 is C1-C6 alkyl, C6-C14 aryl, C6-C14 aryl substituted by one or more G1-2 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl substituted by one or more G1-3;
(5) each G1-2 is independently halogen, cyano, -NG1-1-1G1-1-2, -S(=O)2-C1-C6 alkyl, C1-C6 alkyl, C1-C6 alkyl substituted by one or more G1-1-5 C1-C6 alkoxy, C1-C6 alkoxy substituted by one or more G1-1-6, -S-C1-C6 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl substituted by one or more G1-1-8, or -O-C3-C8 cycloalkyl;
(6) each G1-3 is independently halogen or C1-C6 alkoxy;
(7) ring A is 4- to 6-membered heterocycloalkyl or 4- to 6-membered heterocycloalkyl substituted by one or more A1; the 4- to 6-membered heterocycloalkyl and the 4- to 6-membered heterocycloalkyl substituted by one or more A1 have 1 heteroatom being N; preferably, when ring A is 4- to 6-membered heterocycloalkyl or 4- to 6-membered heterocycloalkyl substituted by one or more A3, then L1 is a bond, and G1 is connected to ring A via a heteroatom;
(8) each A1 is independently halogen or C1-C6 alkyl;
(9)
is
may be
7. The compound of formula I or the pharmaceutically acceptable salt thereof according
to claim 1, wherein the compound of formula I is selected from the following general
formulas I-1 to I-14:
in formula I-3, n1 is 0, 1, or 2;
in formula I-11, R1 is C1-C6 alkyl, C1-C6 alkyl substituted by one or more R1-3, C2-C6 alkenyl, or C2-C6 alkenyl substituted by one or more R1-10;
in formula I-12, n2 is 0, 1, or 2; R4 is C1-C6 alkyl, or R4 and G1-2 together form -(CH2)n3-, wherein n3 is 1, 2, or 3, and 1 or 2 of the -(CH2)n3- in -(CH2)n3- are optionally replaced by a group selected from: -CHR4a-, -CR4bR4c-, -NH-, -O-, and -C(=O)-; R4a, R4b, and R4c are independently C1-C6 alkyl or halogen;
in formula I-13, n2 is 0, 1, or 2;
in formula I-14, n2 is 0, 1, or 2.
8. The compound of formula I or the pharmaceutically acceptable salt thereof according
to claim 7, wherein
in formula I-1,
ring A is azetidinyl, pyrrolidinyl, or piperidinyl;
X is O; Z and Y are C;
more preferably, L2 is C1-C6 alkylene substituted by one or more L2-1, at least one L2-1 is C3-C8 cycloalkyl, and L2-1 is substituted at the terminal group of L2;
in formula I-9,
ring B is C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-4, C3-C12 cycloalkenyl, C3-C12 cycloalkenyl substituted by one or more R1-5, 3- to 12-membered heterocycloalkyl, 3- to 12-membered heterocycloalkyl substituted by one or more R1-6, 3- to 12-membered heterocycloalkenyl, 3- to 12-membered heterocycloalkenyl substituted by one or more R1-7, C6-C14 aryl, C6-C14 aryl substituted by one or more R1-8, 5- to 14-membered heteroaryl, or 5- to 14-membered heteroaryl substituted by one or more R1-9;
each R1-4, each R1-5, each R1-6, each R1-7, each R1-8, and each R1-9 is independently halogen, cyano, hydroxyl, -NR1-3-1aR1-3-2a, -C(=O)NR1-3-3aR1-3-4a, -C(=O)R1-3-5a, -S(=O)2-C1-C12 alkyl, - S-C1-C12 alkyl, C1-C12 alkyl, C1-C12 alkyl substituted by one or more R1-3-6a, C1-C12 alkoxy, C1-C12 alkoxy substituted by one or more R1-3-7a, 5- to 14-membered heteroaryl, 5- to 14-membered heteroaryl substituted by one or more R1-3-8a, C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-3-9a, C2-C6 alkenyl, C2-C6 alkenyl substituted by one or more R1-3-10a, C6-C14 aryl, C6-C14 aryl substituted by one or more R1-3-11a, -O-C6-C14 aryl, -O-C(=O)C6-C14 aryl, -O-5- to 10-membered heteroaryl, 3- to 12-membered heterocycloalkyl, or 3- to 12-membered heterocycloalkyl substituted by one or more R1-3-13a; alternatively, any two adjacent R1-8, together with the carbon atom to which they are attached, form a C3-C14 cycloalkyl;
R1-3-1a, R1-3-2a, R1-3-3a, and R1-3-4a are independently H, C1-C6 alkyl, -C(=O)R1-3-1-1a or C3-C8 cycloalkyl;
R1-3-1-1a is C1-C6 alkyl;
R1-3-5a is C3-C8 cycloalkyl;
each R1-3-6a and each R1-3-7a is independently halogen, hydroxyl, carboxyl, cyano, C1-C6 alkoxy, C3-C8 cycloalkyl, 3- to 12-membered heterocycloalkyl, or -O-C(=O)-C1-C6 alkyl-3- to 12-membered heterocycloalkyl;
each R1-3-8a, each R1-3-9a, each R1-3-10a, each R1-3-11a, and each R1-3-12a is independently C1-C6 alkyl;
in formula I-10, R1-1 and R1-2 are independently H, -S(=O)2C1-C12 alkyl, C1-C12 alkyl, C1-C12 alkyl substituted by one or more R1-1-1, C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-1-2, C6-C14 aryl, C6-C14 aryl substituted by one or more R1-1-3, 5- to 14-membered heteroaryl, or 5- to 14-membered heteroaryl substituted by one or more R1-1-4,
alternatively, R1-1 and R1-2, together with the N atom to which they are attached, form a 3-to 14-membered heterocycloalkyl or a 3- to 14-membered heterocycloalkyl substituted by one or more R1-1-5;
each R1-1-1 and each R1-1-2 is independently halogen, cyano, nitro, hydroxyl, amino, - NH(C1-C12 alkyl), -N(C1-C12 alkyl)2, C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-1-1-3, C6-C14 aryl, 3- to 12-membered heterocycloalkyl, or 5- to 14-membered heteroaryl;
each R1-1-3, R1-1-4, and each R1-1-5 is independently halogen, cyano, nitro, hydroxyl, amino, -NH(C1-C12 alkyl), -N(C1-C12 alkyl)2, -C(=O)-C1-C12 alkyl, -NHC(=O)-C1-C12 alkyl, C1-C12 alkyl, C1-C12 alkyl substituted by one or more R1-1-1-1, C1-C12 alkoxy, C1-C12 alkoxy substituted by one or more R1-1-1-2, C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-1-1-3, C6-C14 aryl, 3- to 12-membered heterocycloalkyl, or 5- to 14-membered heteroaryl;
each R1-1-1-1, each R1-1-1-2, and each R1-1-1-3 is independently halogen, C1-C12 alkyl, or C3-C12 cycloalkyl;
in formula I-11,
each R1-3 and each R1-10 is independently deuterium, halogen, cyano, hydroxyl, -NR1-3-1R1-3-2 -C(=O)NR1-3-3R1-3-4, -C(=O)R1-3-5, -S(=O)2-C1-C12 alkyl, -S-C1-C12 alkyl, C1-C12 alkyl, C1-C12 alkyl substituted by one or more R1-3-6, C1-C12 alkoxy, C1-C12 alkoxy substituted by one or more R1-3-7, 5- to 14-membered heteroaryl, 5- to 14-membered heteroaryl substituted by one or more R1-3-8, C3-C12 cycloalkyl, C3-C12 cycloalkyl substituted by one or more R1-3-9, C2-C6 alkenyl, C6-C14 aryl, C6-C14 aryl substituted by one or more R1-3-11, -O-C6-C14 aryl, -O-C(=O)C6-C14 aryl, -O-5- to 14-membered heteroaryl, C3-C8 cycloalkenyl, C3-C8 cycloalkenyl substituted by one or more R1-3-12, 3- to 12-membered heterocycloalkyl, or 3- to 12-membered heterocycloalkyl substituted by one or more R1-3-13;
R1-3-1, R1-3-2, R1-3-3, and R1-3-4 are independently H, C1-C6 alkyl, -C1-C6 alkyl-C6-C14 aryl, -C(=O)R1-3-1-1, C6-C14 aryl, or C6-C14 aryl substituted by one or more R1-3-1-4
each R1-3-6 and each R1-3-7 is independently C3-C8 cycloalkyl, 3- to 8-membered heterocycloalkyl, C2-C6 alkenyl, 5- to 10-membered heteroaryl, or 5- to 10-membered heteroaryl substituted by one or more C1-C6 alkyl groups;
each R1-3-8, each R1-3-9, each R1-3-10, each R1-3-11, each R1-3-12, and each R1-3-13 is independently halogen, hydroxyl, carboxyl, cyano, C1-C6 alkyl, or C1-C6 alkoxy;
in formula I-13, R4 is C1-C6 alkyl; G1-2 is halogen; R4 is C1-C6 alkyl;
in formula I-14, R2 is hydrogen or halogen.
9. The compound of formula I or the pharmaceutically acceptable salt thereof according
to claim 1, wherein the compound of formula I is any one of the following compounds:
10. A preparation method for the compound of formula I according to any one of claims
1 to 9, wherein the method is method 1 or 2:
when G2 is -C(=O)OH, the method is method 1; method 1 comprises the following step: subjecting
compound -1 to a hydrolysis reaction in a solvent in the presence of a base to obtain
the compound of formula I;
wherein R4 is C1-C6 alkyl; Q, X, Y, Z, R1, R2, L, G1, G2, and ring A are as defined in any one of claims 1 to 6;
when G2 is 5- to 10-membered heteroaryl, the method is method 2; method 2 comprises the following step: subjecting compound II-2 and trimethylsilyl azide to a cyclization reaction in a solvent in the presence of a catalyst to obtain the compound of formula I;
alternatively, subjecting compound II-2 and N,N'-carbonyldiimidazole to a cyclization reaction in a solvent in the presence of a
catalyst to obtain the compound of formula I;
wherein R5 is
or cyano; Q, X, Y, Z, R1, R2, L, G1, G2, and ring A are as defined in any one of claims 1 to 8.
11. A compound II-1, II-2, II-1a, or II-2a:
wherein Q, X, Y, Z, R1, R2, R3, R4, R5, L1, L2, G1, and ring A are as defined in any one of claims 1 to 9;
the compound II-1a or II-2a is preferably any one of the following compounds:
12. A pharmaceutical composition comprising the compound of formula I or the pharmaceutically
acceptable salt thereof according to any one of claims 1 to 9, and a pharmaceutically
acceptable excipient.
13. A use of the compound of formula I or the pharmaceutically acceptable salt thereof
according to any one of claims 1 to 9 in the manufacture of a GPR40 agonist or in
the manufacture of a medicament;
the medicament is used for treating or preventing diabetes or a GPR40-related disease;
the GPR40-related disease is preferably diabetes.
14. A method for treating or preventing a disease, comprising administering to a patient
an effective amount of the compound of formula I or the pharmaceutically acceptable
salt thereof according to any one of claims 1 to 9;
wherein the disease is diabetes or a GPR40-related disease;
the GPR40-related disease is preferably diabetes.
REFERENCES CITED IN THE DESCRIPTION
This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.
Patent documents cited in the description